<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39306468</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>404</Volume><Issue>10458</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1118</EndPage><MedlinePgn>1107-1118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(24)01595-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(24)01595-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival.</AbstractText><AbstractText Label="METHODS">TransMet was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe. Patients aged 18-65 years, with Eastern Cooperative Oncology Group performance score 0-1, permanently unresectable colorectal liver metastases from resected BRAF-non-mutated colorectal cancer responsive to systemic chemotherapy (&#x2265;3 months, &#x2264;3 lines), and no extrahepatic disease, were eligible for enrolment. Patients were randomised (1:1) to liver transplantation plus chemotherapy or chemotherapy alone, using block randomisation. The liver transplantation plus chemotherapy group underwent liver transplantation for 2 months or less after the last chemotherapy cycle. At randomisation, the liver transplantation plus chemotherapy group received a median of 21&#xb7;0 chemotherapy cycles (IQR 18&#xb7;0-29&#xb7;0) versus 17&#xb7;0 cycles (12&#xb7;0-24&#xb7;0) in the chemotherapy alone group, in up to three lines of chemotherapy. During first-line chemotherapy, 64 (68%) of 94 patients had received doublet chemotherapy and 30 (32%) of 94 patients had received triplet regimens; 76 (80%) of 94 patients had targeted therapy. Transplanted patients received tailored immunosuppression (methylprednisolone 10 mg/kg intravenously on day 0; tacrolimus 0&#xb7;1 mg/kg via gastric tube on day 0, 6-10 ng/mL days 1-14; mycophenolate mofetil 10 mg/kg intravenously day 0 to &lt;2 months and switch to everolimus 5-8 ng/mL), and postoperative chemotherapy, and the chemotherapy group had continued chemotherapy. The primary endpoint was 5-year overall survival analysed in the intention to treat and per-protocol population. Safety events were assessed in the as-treated population. The study is registered with ClinicalTrials.gov (NCT02597348), and accrual is complete.</AbstractText><AbstractText Label="FINDINGS">Between Feb 18, 2016, and July 5, 2021, 94 patients were randomly assigned and included in the intention-to-treat population, with 47 in the liver transplantation plus chemotherapy group and 47 in the chemotherapy alone group. 11 patients in the liver transplantation plus chemotherapy group and nine patients in the chemotherapy alone group did not receive the assigned treatment; 36 patients and 38 patients in each group, respectively, were included in the per-protocol analysis. Patients had a median age of 54&#xb7;0 years (IQR 47&#xb7;0-59&#xb7;0), and 55 (59%) of 94 patients were male and 39 (41%) were female. Median follow-up was 59&#xb7;3 months (IQR 42&#xb7;4-60&#xb7;2). In the intention-to-treat population, 5-year overall survival was 56&#xb7;6% (95% CI 43&#xb7;2-74&#xb7;1) for liver transplantation plus chemotherapy and 12&#xb7;6% (5&#xb7;2-30&#xb7;1) for chemotherapy alone (HR 0&#xb7;37 [95% CI 0&#xb7;21-0&#xb7;65]; p=0&#xb7;0003) and 73&#xb7;3% (95% CI 59&#xb7;6-90&#xb7;0) and 9&#xb7;3% (3&#xb7;2-26&#xb7;8), respectively, for the per-protocol population. Serious adverse events occurred in 32 (80%) of 40 patients who underwent liver transplantation (from either group), and 69 serious adverse events were observed in 45 (83%) of 54 patients treated with chemotherapy alone. Three patients in the liver transplantation plus chemotherapy group were retransplanted, one of whom died postoperatively of multi-organ failure.</AbstractText><AbstractText Label="INTERPRETATION">In selected patients with permanently unresectable colorectal liver metastases, liver transplantation plus chemotherapy with organ allocation priority significantly improved survival versus chemotherapy alone. These results support the validation of liver transplantation as a new standard option for patients with permanently unresectable liver-only metastases.</AbstractText><AbstractText Label="FUNDING">French National Cancer Institute and Assistance Publique-H&#xf4;pitaux de Paris.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, AP-HP H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France; Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France. Electronic address: rene.adam@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piedvache</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, AP-HP H&#xf4;pital Kremlin Bic&#xea;tre, University of Paris-Saclay, Le Kremlin Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, H&#xf4;pital Haut-L&#xe9;v&#xea;que, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Jean Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, H&#xf4;pital Haut-L&#xe9;v&#xea;que, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salam&#xe9;</LastName><ForeName>Ephrem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Pancreatic Surgery, Regional University Hospital, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucur</LastName><ForeName>Petru</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Pancreatic Surgery, Regional University Hospital, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherqui</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Transplantation, AP-HP H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scatton</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, AP-HP H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Victoire</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Digestive Oncology, University Hospital Grenoble, Universit&#xe9; Grenoble Alpes Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducreux</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cillo</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery and Liver Transplant Unit, University Hospital Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery Unit, AP-HP H&#xf4;pital Beaujon, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery and Liver Transplantation, H&#xf4;pital de la Croix-Rousse, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verslype</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coubeau</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Abdominal Surgery and Transplantation, University Hospital Saint Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardwigsen</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Digestive, Hepatobiliary and Transplantation Surgery, Marseille University Hospital Timone, Marseilles, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boleslawski</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplantation, University Hospital Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muscari</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, H&#xf4;pital Rangueil, University Hospitals Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeddou</LastName><ForeName>Heithem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pezet</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Surgery, University Hospital Clermont-Ferrand, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyd</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Digestive and Oncological Surgery, Regional University Hospital Besan&#xe7;on, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucidi</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery and Transplantation, H&#xf4;pital Universitaire de Bruxelles, Universit&#xe9; Libre de Bruxelles, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geboes</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology/Digestive Oncology, University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerut</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Experimental and Clinical Research, Catholic University of Louvain, Louvain, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majno</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, University of Italian Switzerland, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimaldi</LastName><ForeName>Lamiae</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, AP-HP H&#xf4;pital Kremlin Bic&#xea;tre, University of Paris-Saclay, Le Kremlin Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewin</LastName><ForeName>Ma&#xef;t&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, UPR Chronotherapy, Cancers and Transplantation, Faculty of Medicine, University of Paris-Saclay, Villejuif, France; Department of Radiology, H&#xf4;pital Paul-Brousse, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelli</LastName><ForeName>Maximiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Surgery and Interventional Radiology, Gustave Roussy Hospital, University of Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaborative TransMet group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02597348</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2024 Sep 21;404(10458):1078-1079. doi: 10.1016/S0140-6736(24)01926-3.</RefSource><PMID Version="1">39306454</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):271-274. doi: 10.21037/hbsn-2025-51.</RefSource><PMID Version="1">40342761</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests We declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Adam</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piedvache</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiche</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adam</LastName><ForeName>Jean Philippe</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salam&#xe9;</LastName><ForeName>Ephrem</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bucur</LastName><ForeName>Petru</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherqui</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scatton</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granger</LastName><ForeName>Victoire</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducreux</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cillo</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchy</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mabrut</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verslype</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coubeau</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardwigsen</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boleslawski</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muscari</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeddou</LastName><ForeName>Heithem</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pezet</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyd</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucidi</LastName><ForeName>Valerio</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geboes</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerut</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majno</LastName><ForeName>Pietro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimaldi</LastName><ForeName>Lamiae</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levi</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewin</LastName><ForeName>Ma&#xef;t&#xe9;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gelli</LastName><ForeName>Maximiliano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soubrane</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesurtel</LastName><ForeName>Mickael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachet</LastName><ForeName>Jean Baptsite</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesourd</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jary</LastName><ForeName>Marine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonardi</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hebbar</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boudjema</LastName><ForeName>Karim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chirica</LastName><ForeName>Mircea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lecomte</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borg</LastName><ForeName>Chirstophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guimbaud</LastName><ForeName>Rosine</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taieb</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burra</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rougier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueras</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>22</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>22</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39306468</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)01595-2</ArticleId><ArticleId IdType="pii">S0140-6736(24)01595-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39798579</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>405</Volume><Issue>10474</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>232</EndPage><MedlinePgn>216-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(24)02551-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(24)02551-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.</AbstractText><AbstractText Label="METHODS">In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries. Eligible patients were randomly assigned (1:1:1), stratified by TACE method, region, and portal vein invasion, using an interactive voice response or web response system, to TACE plus either durvalumab plus bevacizumab (1500 mg intravenous durvalumab once every 4 weeks, then 1120 mg durvalumab plus 15 mg/kg intravenous bevacizumab once every 3 weeks), durvalumab plus placebo (same regimen using placebo instead of bevacizumab), or placebo alone (same regimen using placebo instead of durvalumab and instead of bevacizumab). Participants, investigators, and those assessing outcomes were masked to treatment assignment until data analysis. The primary endpoint was progression-free survival, by blinded independent central review (BICR), and per RECIST version 1.1, with durvalumab plus bevacizumab versus placebo alone in the intention-to-treat population (ITT; ie, all participants assigned to treatment). Key secondary endpoints were progression-free survival by BICR per RECIST version 1.1 with durvalumab plus placebo versus placebo alone, overall survival, and time to deterioration in select patient-reported outcomes. Participants continue to be followed up for overall survival, and overall survival and patient-reported outcomes will be reported in a later publication. Safety was assessed in the safety analysis set, which included all participants assigned to treatment who received any study treatment (ie, any durvalumab, bevacizumab, or placebo) by treatment received. This study is registered with ClinicalTrials.gov, NCT03778957, and is closed to accrual.</AbstractText><AbstractText Label="FINDINGS">Between Nov 30, 2018, and July 19, 2021, 887 patients were screened, of whom 616 were randomly assigned to durvalumab plus bevacizumab (n=204), durvalumab plus placebo (n=207), or placebo alone (n=205; ITT population). Median age was 65&#xb7;0 years (IQR 59&#xb7;0-72&#xb7;0), 135 (22%) of 616 participants were female, 481 (78%) were male, 375 (61%) were Asian, 176 (29%) were White, 22 (4%) were American Indian or Alaska Native, nine (1%) were Black or African American, one (&lt;1%) was native Hawaiian or other Pacific Islander, and 33 (5%) were other races. As of data cutoff (Sept 11, 2023) median follow-up for progression-free survival was 27&#xb7;9 months (95% CI 27&#xb7;4-30&#xb7;4), median progression-free survival was 15&#xb7;0 months (95% CI 11&#xb7;1-18&#xb7;9) with durvalumab plus bevacizumab, 10&#xb7;0 months (9&#xb7;0-12&#xb7;7) with durvalumab, and 8&#xb7;2 months (6&#xb7;9-11&#xb7;1) with placebo. Progression-free survival hazard ratio was 0&#xb7;77 (95% CI 0&#xb7;61-0&#xb7;98; two-sided p=0&#xb7;032) for durvalumab plus bevacizumab versus placebo, and 0&#xb7;94 (0&#xb7;75-1&#xb7;19; two-sided p=0&#xb7;64) for durvalumab plus placebo versus placebo. The most common maximum grade 3-4 adverse events were hypertension in participants who received durvalumab and bevacizumab (nine [6%] of 154 participants), anaemia in participants who received durvalumab and placebo (ten [4%] of 232 participants), and post-embolisation syndrome in participants who received placebo alone (eight [4%] of 200 participants). Study treatment-related adverse events that led to death occurred in none of 154 participants who received durvalumab and bevacizumab, three (1%) of 232 who received durvalumab and placebo (n=1 for arterial haemorrhage, liver injury, and multiple organ dysfunction syndrome), and three (2%) of 200 who received placebo alone (n=1 for oesophageal varices haemorrhage, upper gastrointestinal haemorrhage, and dermatomyositis).</AbstractText><AbstractText Label="INTERPRETATION">Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including the final overall survival data and patient-reported outcomes, will help to further characterise the potential clinical benefits of durvalumab plus bevacizumab plus TACE in hepatocellular carcinoma amenable to embolisation.</AbstractText><AbstractText Label="FUNDING">AstraZeneca.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sangro</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Liver Unit and HPB Oncology Area, Cl&#xed;nica Universidad de Navarra and CIBEREHD, Pamplona, Spain. Electronic address: bsangro@unav.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erinjeri</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Center of Nanjing, Jinling Hospital, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Clinical Oncology, Prince of Wales Hospital, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Yasuaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, National Cancer Center, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Anh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>General Surgery Department, Nhan Dan Gia Dinh Hospital, Ho Chi Minh City, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escobar</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital San Lucas Cardiol&#xf3;gica del Sureste, Chiapas, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Chuken</LastName><ForeName>Yamil Alonso</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>I Can Oncology Centre, New Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jung-Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tak</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breder</LastName><ForeName>Valeriy V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, N N Blokhin National Medical Research Center of Oncology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suttichaimongkol</LastName><ForeName>Tanita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Cancer and Innovative Therapy, AP-HP H&#xf4;pital Beaujon, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shi-Ming</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peron</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hepatology Unit, Rangueil University Hospital, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Quang T</ForeName><Initials>QT</Initials><AffiliationInfo><Affiliation>Friendship Hospital, Hanoi, Viet Nam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Lunan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chang-Fang</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Cancer Center and Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Florinda A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veluvolu</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Willis-Knighton Hematology/Oncology, A Department of Willis-Knighton Medical Center, Shreveport, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thungappa</LastName><ForeName>Satheesh Chiradoni</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, HCG Oncology, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matos</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology, Pindara Private Hospital, Benowa, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x17b;otkiewicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udoye</LastName><ForeName>Stephanie I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurland</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Gordon J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lencioni</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EMERALD-1 Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03778957</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber><NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>28X28X9OKV</RegistryNumber><NameOfSubstance UI="C000613593">durvalumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2025 Jan 18;405(10474):174-176. doi: 10.1016/S0140-6736(24)02680-1.</RefSource><PMID Version="1">39798580</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="Y">Bevacizumab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016461" MajorTopicYN="Y">Chemoembolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="Y">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests BS reports consultancy fees from AstraZeneca, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Merck Sharp &amp; Dohme, Roche, and Sanofi; payment or honoraria from AstraZeneca, Eisai, Roche, and Sirtex Medical; and support for travel or attending meetings from AstraZeneca and Roche. MK reports grants or contracts from AbbVie, Chugai Pharmaceutical, Eisai, GE HealthCare Japan, Otsuka Pharmaceutical, and Taiho Pharmaceutical; consultancy fees from AstraZeneca, Chugai Pharmaceutical, Eisai, and Roche; and payment or honoraria from AstraZeneca, Chugai Pharmaceutical, Eisai, Eli Lilly, and Takeda. JPE reports consultancy fees from AstraZeneca and fees for participation on a data safety monitoring board or advisory board from AstraZeneca. ZR reports consultancy fees from AstraZeneca, Merck Sharp &amp; Dohme, and Roche; and fees for participation on a data safety monitoring board or advisory board from AstraZeneca, Merck Sharp &amp; Dohme, and Roche. SLC reports grants or contracts from Celleron, Genorbio, Ipsen, Merck Sharp &amp; Dohme, Novartis, and Sirtex Medical; consultancy fees from AstraZeneca, Autem Therapeutics, Eisai, and Merck Sharp &amp; Dohme; payment or honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Hutchison MediPharma, Ipsen, Merck Sharp &amp; Dohme, and Roche; and support for travel or attending meetings from AstraZeneca, Eisai, Ipsen, and Roche. YA reports payment or honoraria from AstraZeneca and fees for participation on a data safety monitoring board or advisory board from AstraZeneca. JH reports grants or contracts from Roche; consultancy fees from AbbVie Korea, GlaxoSmithKline, and Immunocore; payment or honoraria from AstraZeneca, Gilead Sciences, Oncolys BioPharma, Roche, and Yuhan Korea; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from AstraZeneca. JE reports grants or contracts from AstraZeneca, Bristol Myers Squibb, and Merck Sharp &amp; Dohme; payment or honoraria from Asofarma Pharma; support for travel or attending meetings from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Janssen, Merck Sharp &amp; Dohme and Roche; and being a board member for Sociedad Mexicana de Oncolog&#xed;a. J-HY reports grants or contracts from Dicerna Pharmaceuticals, GlaxoSmithKline, Mediver, Merck Sharp &amp; Dohme, NewG-Lab Pharma, Pharmicell, Roche, and Vir Biotechnology. VVB reports consultancy fees, payment or honoraria, and fees for participation on a data safety monitoring board or advisory board from AstraZeneca, Bayer, Eisai, and Roche. TS reports payment or honoraria from American Taiwan Biopharm, AstraZeneca (Thailand), Berlin Pharmaceutical Industry, DKSH (Thailand), Janssen, Reckitt Benckiser (Thailand), Roche Thailand, Roche Diagnostics (Thailand), Sandoz (Thailand), Takeda (Thailand), and Thai Otsuka Pharmaceutical; and support for travel or attending meetings from American Taiwan Biopharm, AstraZeneca (Thailand), Berlin Pharmaceutical Industry, DKSH (Thailand), Ferring Pharmaceuticals, Reckitt Benckiser (Thailand), Roche Thailand, Roche Diagnostics (Thailand), Takeda (Thailand), and Thai Meiji. MB reports consultancy fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Merck Sharp &amp; Dohme, Roche, Sirtex Medical, and Taiho Pharmaceutical; and payment or honoraria from Bayer and Sirtex Medical. S-ML reports honoraria from Roche; support for travel or attending meetings from AstraZeneca and Roche; fees for participation on an advisory board from AstraZeneca; and an unpaid position as President and Honoured President of the Taiwan Liver Cancer Association. J-MP reports grants or contracts, consultancy fees, payment or honoraria, and support for travel or attending meetings from AbbVie, Bayer, Gilead Sciences, Ipsen, and Roche. C-FC reports grants or contracts from AbbVie, Aceta Pharma, AstraZeneca, Bayer, Bristol Meyers Squibb, Genentech, Translational Research In Oncology, and Roche; payment or honoraria from Roche; fees for participation on a data safety monitoring board or advisory board from Roche; and a role as an expert on the Committee of National Health Insurance Administration (Taiwan). MM reports support for travel or attending meetings from AstraZeneca. M&#x17b; is an employee of AstraZeneca. SIU and GJC are employees of AstraZeneca and hold stock in AstraZeneca. JFK is an employee of AstraZeneca; holds stock in AstraZeneca; reports support for travel or attending meetings from ASCO Breakthrough; and is listed as co-inventor with MedImmune as the applicant on patents PCT/US2018/018513 (WO2018/152415), filed Feb 16, 2018, and with AstraZeneca as the applicant on patents PCT/EP2021/062695 (WO2021/228978), filed May 12, 2021, and PCT/EP2022/079828 (2023/174569), filed Oct 25, 2022. RL reports consultancy fees from AstraZeneca. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Abdalla</LastName><ForeName>Kathia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allaire</LastName><ForeName>Manon</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antunes</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assenat</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barreto</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beg</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertollo</LastName><ForeName>Glaucio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanc</LastName><ForeName>Jean-Frederic</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouattour</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boya</LastName><ForeName>Rakesh Reddy</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breder</LastName><ForeName>Valery</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronowicki</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buranachokphaisan</LastName><ForeName>Manoch</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgoyne</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Ting-Tsung</ForeName><Initials>TT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao</LastName><ForeName>Yee</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chang-Fang</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Minsig</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Sunghee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coburn</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Contreras</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dayyani</LastName><ForeName>Farshid</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decaens</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dechaphunkul</LastName><ForeName>Arunee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Consuelo Diaz</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dev</LastName><ForeName>Anouk</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutra</LastName><ForeName>Jamille</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eastgate</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escobar</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estfan</LastName><ForeName>Bassam</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frin</LastName><ForeName>Anne-Claire</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganguly</LastName><ForeName>Sandip</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ganta</LastName><ForeName>Ranga Raman</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Shanzhi</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guo</LastName><ForeName>Yabing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagihara</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsu</LastName><ForeName>Chih-Hung</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Inaba</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jain</LastName><ForeName>Shikha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonker</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>K</LastName><ForeName>Rajeev L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kate</LastName><ForeName>Shruti</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Naoya</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawaoka</LastName><ForeName>Tomokazu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kee</LastName><ForeName>Kwong-Ming</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung Up</ForeName><Initials>SU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kioka</LastName><ForeName>Kiyohide</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koga</LastName><ForeName>Hironori</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kudo</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Hidekatsu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le</LastName><ForeName>Phuong</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Han-Chu</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Joon Hyeok</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Teng-Yu</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Dongliang</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Hailiang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Cheng-Yao</ForeName><Initials>CY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Shi-Ming</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Yamil</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Ligong</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mai</LastName><ForeName>Anh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mamontov</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maneenil</LastName><ForeName>Kunlatida</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manikhas</LastName><ForeName>Aleksei</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masi</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matilla</LastName><ForeName>Ana Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matos</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzaferro</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meng</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohapatra</LastName><ForeName>Prabrajya Narayan</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moiseyenko</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molina</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montero</LastName><ForeName>Jose Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Manabu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motola</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukhametshina</LastName><ForeName>Guzel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Hayato</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nault</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Quang</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicoll</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noriega</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okusaka</LastName><ForeName>Takuji</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onishi</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostwal</LastName><ForeName>Vikas Sureshchand</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pan</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Joong-Won</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Ankit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peron</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qin</LastName><ForeName>Shukui</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Zhenggang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Stuart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Runglodvatana</LastName><ForeName>Yotsawaj</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sangro</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>Florinda</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxena</LastName><ForeName>Ravi Kumar</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shao</LastName><ForeName>Guoliang</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shields</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shirokova</LastName><ForeName>Oksana</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shreenivas</LastName><ForeName>Aditya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sisani</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skoropad</LastName><ForeName>Vitalii</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strasser</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suksombooncharoen</LastName><ForeName>Thatthan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suttichaimongkol</LastName><ForeName>Tanita</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tai</LastName><ForeName>Wai Meng</ForeName><Initials>WM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tak</LastName><ForeName>Won Young</ForeName><Initials>WY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teng</LastName><ForeName>Gaojun</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thungappa</LastName><ForeName>Satheesh Chiradoni</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>Nguyen</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trinh</LastName><ForeName>Son</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuchiya</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Kunihiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ugarteburu</LastName><ForeName>Idoia</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ungtrakul</LastName><ForeName>Teerapat</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaccaro</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veluvolu</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vo</LastName><ForeName>Truc</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wada</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weir</LastName><ForeName>Alva</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Aibing</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>Lvnan</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jung-Hwan</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarubenkov</LastName><ForeName>Oleg</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yongyi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yonghong</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xu</ForeName><Initials>X</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>20</Day><Hour>22</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>12</Day><Hour>15</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39798579</ArticleId><ArticleId IdType="mid">NIHMS2089825</ArticleId><ArticleId IdType="pmc">PMC12282661</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(24)02551-0</ArticleId><ArticleId IdType="pii">S0140-6736(24)02551-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (suppl 4): iv238&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">30285213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison. Clin Mol Hepatol 2023; 29: 252&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10121305</ArticleId><ArticleId IdType="pubmed">36907570</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12540794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong B-Y, Jin Z-C, Chen J-J, Zhu H-D, Zhu X-L. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol 2023; 11: 480&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9817054</ArticleId><ArticleId IdType="pubmed">36643046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">23397536</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35: 2155&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691343</ArticleId><ArticleId IdType="pubmed">25752327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 2014; 60: 1697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">24996197</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21664811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 2016; 64: 1090&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26809111</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 2021; 73 (suppl 1): 158&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">32430997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020; 69: 1492&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398460</ArticleId><ArticleId IdType="pubmed">31801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2017; 2: 565&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28648803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilagan CH, Goldman DA, G&#xf6;nen M, et al. Recurrence of hepatocellular carcinoma after complete radiologic response to trans-arterial embolization: a retrospective study on patterns, treatments, and prognoses. Ann Surg Oncol 2022; 29: 6815&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9509465</ArticleId><ArticleId IdType="pubmed">35838903</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Lee D, Shim JH, et al. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. PLoS One 2020; 15: e0229696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055892</ArticleId><ArticleId IdType="pubmed">32130270</ArticleId></ArticleIdList></Reference><Reference><Citation>Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019; 19: 795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693268</ArticleId><ArticleId IdType="pubmed">31409405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo M, Cheng A-L, Park J-W, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3: 37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568538</ArticleId></ArticleIdList></Reference><Reference><Citation>Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer 2012; 12: 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292503</ArticleId><ArticleId IdType="pubmed">22244160</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter M, Ulbrich G, Sieghart W, et al. Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology 2015; 277: 903&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26131911</ArticleId></ArticleIdList></Reference><Reference><Citation>Montasser A, Beaufr&#xe8;re A, Cauchy F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021; 79: 36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">33326644</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1: EVIDoa2100070.</Citation><ArticleIdList><ArticleId IdType="pubmed">38319892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21: 808&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">32502443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022; 23: 77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">34914889</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021; 22: 977&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">34143971</ArticleId></ArticleIdList></Reference><Reference><Citation>Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J Clin Oncol 2024; 42 (suppl 17): LBA4008 (abstr).</Citation></Reference><Reference><Citation>Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 2025; published online Jan 8. 10.1016/S0140-6736(24)02575-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)02575-3</ArticleId><ArticleId IdType="pubmed">39798578</ArticleId></ArticleIdList></Reference><Reference><Citation>Peck-Radosavljevic M, Kudo M, Raoul J-L, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol 2018; 36 (suppl 15): 4018 (abstr).</Citation></Reference><Reference><Citation>Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA 2023; 329: 1589&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10843851</ArticleId><ArticleId IdType="pubmed">37159031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HY, Heo J, Kim T-Y, et al. 
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: results from the phase 2 study 22 (NCT02519348). J Clin Oncol
2022; 40: 436 (abstr).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32615109</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>956</EndPage><MedlinePgn>947-956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30224-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30224-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging.</AbstractText><AbstractText Label="METHODS">We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503.</AbstractText><AbstractText Label="FINDINGS">Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76&#xb7;8% (95% CI 60&#xb7;8-96&#xb7;9) in the transplantation group versus 18&#xb7;3% (7&#xb7;1-47&#xb7;0) in the control group (hazard ratio [HR] 0&#xb7;20, 95% CI 0&#xb7;07-0&#xb7;57; p=0&#xb7;003). 5-year overall survival was 77&#xb7;5% (95% CI 61&#xb7;9-97&#xb7;1) in the transplantation group versus 31&#xb7;2% (16&#xb7;6-58&#xb7;5) in the control group (HR 0&#xb7;32, 95% CI 0&#xb7;11-0&#xb7;92; p=0&#xb7;035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation).</AbstractText><AbstractText Label="INTERPRETATION">Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria.</AbstractText><AbstractText Label="FUNDING">Italian Ministry of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzaferro</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citterio</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhoori</LastName><ForeName>Sherrie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miceli</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colledan</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salizzoni</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romagnoli</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General and Liver Transplant Surgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivarelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisone</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruttadauria</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Sandro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luc&#xe0;</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Giorgio</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabella</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiuoli</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iavarone</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, CRC A M and A Migliavacca Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svegliati Baroni</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelico</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginanni Corradini</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpes</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regalia</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz Dit Busset</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sposito</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01387503</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2020 Jul;21(7):867-869. doi: 10.1016/S1470-2045(20)30333-8.</RefSource><PMID Version="1">32615100</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Oncol. 2020 Aug;21(8):e373. doi: 10.1016/S1470-2045(20)30387-9.</RefSource><PMID Version="1">32758474</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32615109</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(20)30224-2</ArticleId><ArticleId IdType="pii">S1470-2045(20)30224-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30442501</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.</ArticleTitle><Pagination><StartPage>1617</StartPage><EndPage>1629</EndPage><MedlinePgn>1617-1629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(18)30578-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(18)30578-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma.</AbstractText><AbstractText Label="METHODS">We did an international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma at 104 institutions in 12 countries. Eligible patients were aged 1-20 years and had MYCN-amplified neuroblastoma with stages 2, 3, or 4S, or stage 4 neuroblastoma of any MYCN status, according to the International Neuroblastoma Staging System. Patients were eligible if they had been enrolled at diagnosis in the HR-NBL1/SIOPEN trial, had completed the multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had received radiotherapy to the primary tumour site. In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m<sup>2</sup> per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6&#x2008;&#xd7;&#x2008;10<sup>6</sup> IU/m<sup>2</sup> per day on days 1-5 and days 8-12 of each cycle) with the minimisation method to balance randomisation for national groups and type of high-dose therapy. All participants received oral isotretinoin (160 mg/m<sup>2</sup> per day for 2 weeks) before the first immunotherapy cycle and after each immunotherapy cycle, for six cycles. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01704716, and EudraCT, number 2006-001489-17, and recruitment to this randomisation is closed.</AbstractText><AbstractText Label="FINDINGS">Between Oct 22, 2009, and Aug 12, 2013, 422 patients were eligible to participate in the immunotherapy randomisation, of whom 406 (96%) were randomly assigned to a treatment group (n=200 to dinutuximab beta and n=206 to dinutuximab beta with subcutaneous IL-2). Median follow-up was 4&#xb7;7 years (IQR 3&#xb7;9-5&#xb7;3). Because of toxicity, 117 (62%) of 188 patients assigned to dinutuximab beta and subcutaneous IL-2 received their allocated treatment, by contrast with 160 (87%) of 183 patients who received dinutuximab beta alone (p&lt;0&#xb7;0001). 3-year event-free survival was 56% (95% CI 49-63) with dinutuximab beta (83 patients had an event) and 60% (53-66) with dinutuximab beta and subcutaneous IL-2 (80 patients had an event; p=0&#xb7;76). Four patients died of toxicity (n=2 in each group); one patient in each group while receiving immunotherapy (n=1 congestive heart failure and pulmonary hypertension due to capillary leak syndrome; n=1 infection-related acute respiratory distress syndrome), and one patient in each group after five cycles of immunotherapy (n=1 fungal infection and multi-organ failure; n=1 pulmonary fibrosis). The most common grade 3-4 adverse events were hypersensitivity reactions (19 [10%] of 185 patients in the dinutuximab beta group vs 39 [20%] of 191 patients in the dinutuximab plus subcutaneous IL-2 group), capillary leak (five [4%] of 119 vs 19 [15%] of 125), fever (25 [14%] of 185 vs 76 [40%] of 190), infection (47 [25%] of 185 vs 64 [33%] of 191), immunotherapy-related pain (19 [16%] of 122 vs 32 [26%] of 124), and impaired general condition (30 [16%] of 185 vs 78 [41%] of 192).</AbstractText><AbstractText Label="INTERPRETATION">There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was associated with greater toxicity than dinutuximab beta alone. Dinutuximab beta and isotretinoin without subcutaneous IL-2 should thus be considered the standard of care until results of ongoing randomised trials using a modified schedule of dinutuximab beta and subcutaneous IL-2 are available.</AbstractText><AbstractText Label="FUNDING">European Commission 5th Frame Work Grant, St. Anna Kinderkrebsforschung, Fondation ARC pour la recherche sur le Cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladenstein</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St Anna Children's Hospital, Vienna, Austria; Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. Electronic address: ruth.ladenstein@ccri.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;tschger</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valteau-Couanet</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luksch</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castel</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaniv</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach Tikvah, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laureys</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology and Stem Cell Transplantation University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Penelope</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Great Ormond Street Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michon</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Children, Adolescent and Young Adults Department, Institut Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Cormac</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Haemato-Oncology, Our Lady's Children's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trahair</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Godfrey Chi Fung</ForeName><Initials>GCF</Initials><AffiliationInfo><Affiliation>Department of Paediatrics &amp; Adolescent Medicine, Queen Mary Hospital, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruud</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatric Medicine, Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Hospital of Aarhus, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck Popovic</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Paediatric Surgery, Paediatric Haematology Oncology Unit, University Hospital Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreier</LastName><ForeName>Guenter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibner</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Apeiron Biologics AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambros</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biology, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Paediatric Surgery, St George's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaze</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Oncology, University College London Hospitals NHS Foundation Trust, National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaventa</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology Unit, Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Andrew D J</ForeName><Initials>ADJ</Initials><AffiliationInfo><Affiliation>Paediatric and Adolescent Drug Development Team, Oak Centre for Children and Young People, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lode</LastName><ForeName>Holger N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Paediatric Haematology-Oncology Department, University Medicine Greifswald, Greifswald, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01704716</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>8177</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>7SQY4ZUD30</RegistryNumber><NameOfSubstance UI="C112746">dinutuximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EH28UP18IF</RegistryNumber><NameOfSubstance UI="D015474">Isotretinoin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2018 Dec;19(12):1549-1551. doi: 10.1016/S1470-2045(18)30627-2.</RefSource><PMID Version="1">30442498</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015474" MajorTopicYN="N">Isotretinoin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30442501</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(18)30578-3</ArticleId><ArticleId IdType="pii">S1470-2045(18)30578-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25698099</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1983</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical nutrition (Edinburgh, Scotland)</Title><ISOAbbreviation>Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Identifying critically-ill patients who will benefit most from nutritional therapy: Further validation of the "modified NUTRIC" nutritional risk assessment tool.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>162</EndPage><MedlinePgn>158-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2015.01.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0261-5614(15)00037-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Better tools are needed to assist in the identification of critically ill patients most likely to benefit from artificial nutrition therapy. Recently, the Nutrition Risk in Critically ill (NUTRIC) score has been developed for such purpose. The objective of this study was to externally validate a modified version of the NUTRIC score in a second database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a post hoc analysis of a database of a randomized control trial of intensive care unit (ICU) patients with multi-organ failure. Data for all variables of the NUTRIC score with the exception of IL-6 levels were collected. These included age, APACHE II score, SOFA score, number of co-morbidities, days from hospital admission to ICU admission. The NUTRIC score was calculated using the exact same thresholds and point system as developed previously except the IL-6 item was omitted. A logistic model including the NUTRIC score, the nutritional adequacy and their interaction was estimated to assess if the NUTRIC score modified the association between nutritional adequacy and 28-day mortality. We also examined the association of elevated NUTRIC scores and 6-month month mortality and the interaction between NUTRIC score and nutritional adequacy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1199 patients were analyzed. The mean total calories prescribed was 1817 cal (SD 312) with total mean protein prescribed of 98.3 g (SD 23.6). The number of patients who received PN was 9.5%. The overall 28-day mortality rate in this validation sample was 29% and the mean NUTRIC score was 5.5 (SD 1.6). Based on the logistic model, the odds of mortality at 28 days was multiplied by 1.4 (95% CI, 1.3-1.5) for every point increase on the NUTRIC score. The mean (SD) nutritional adequacy was 50.2 (29.5) with an interquartile range from 24.8 to 74.1. The test for interaction confirmed that the association between nutritional adequacy and 28-day mortality is significantly modified by the NUTRIC score (test for interaction p = 0.029). In particular, there is a strong positive association between nutritional adequacy and 28 day survival in patients with a high NUTRIC score but this association diminishes with decreasing NUTRIC score. Higher NUTRIC scores are also significantly associated with higher 6-month mortality (p &lt; 0.0001) and again the positive association between nutritional adequacy and 6 month survival was significantly stronger (and perhaps only present) in patients with higher NUTRIC score (test for interaction p = 0.038).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The NUTRIC scoring system is externally validated and may be useful in identifying critically ill patients most likely to benefit from optimal amounts of macronutrients when considering mortality as an outcome.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada; Gastroenterology, St. Joseph's Healthcare Centre/London Health Sciences Centre, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Rana M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwala</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Section of Critical Care Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Western Ontario, London, Ontario, Canada; Critical Care/Trauma Centre, London Health Sciences Centre, Victoria Campus, Canada; Lawson Health Research Institute, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyland</LastName><ForeName>Daren K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada; Department of Community Health and Epidemiology, Queen's University, Kingston, Ontario, Canada; Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: dkh2@queensu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr</MedlineTA><NlmUniqueID>8309603</NlmUniqueID><ISSNLinking>0261-5614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044342" MajorTopicYN="N">Malnutrition</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015596" MajorTopicYN="Y">Nutrition Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009752" MajorTopicYN="Y">Nutritional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Critically ill patients</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Nutrition</Keyword><Keyword MajorTopicYN="N">Nutritional risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25698099</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2015.01.015</ArticleId><ArticleId IdType="pii">S0261-5614(15)00037-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34970680</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1 Suppl 1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.</ArticleTitle><Pagination><StartPage>S53</StartPage><EndPage>S58</EndPage><MedlinePgn>S53-S58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2021-052888H</ELocationID><Abstract><AbstractText Label="CONTEXT">Prior criteria to define pediatric multiple organ dysfunction syndrome (MODS) did not include gastrointestinal dysfunction.</AbstractText><AbstractText Label="OBJECTIVES">Our objective was to evaluate current evidence and to develop consensus criteria for gastrointestinal dysfunction in critically ill children.</AbstractText><AbstractText Label="DATA SOURCES">Electronic searches of PubMed and EMBASE were conducted from January 1992 to January 2020, using medical subject heading terms and text words to define gastrointestinal dysfunction, pediatric critical illness, and outcomes.</AbstractText><AbstractText Label="STUDY SELECTION">Studies were included if they evaluated critically ill children with gastrointestinal dysfunction, performance characteristics of assessment/scoring tools to screen for gastrointestinal dysfunction, and assessed outcomes related to mortality, functional status, organ-specific outcomes, or other patient-centered outcomes. Studies of adults or premature infants, animal studies, reviews/commentaries, case series with sample size &#x2264;10, and non-English language studies with inability to determine eligibility criteria were excluded.</AbstractText><AbstractText Label="DATA EXTRACTION">Data were abstracted from each eligible study into a standard data extraction form along with risk of bias assessment by a task force member.</AbstractText><AbstractText Label="RESULTS">The systematic review supports the following criteria for severe gastrointestinal dysfunction: 1a) bowel perforation, 1b) pneumatosis intestinalis, or 1c) bowel ischemia, present on plain abdominal radiograph, computed tomography (CT) scan, magnetic resonance imaging (MRI), or gross surgical inspection, or 2) rectal sloughing of gut mucosa.</AbstractText><AbstractText Label="LIMITATIONS">The validity of the consensus criteria for gastrointestinal dysfunction are limited by the quantity and quality of current evidence.</AbstractText><AbstractText Label="CONCLUSIONS">Understanding the role of gastrointestinal dysfunction in the pathophysiology and outcomes of MODS is important in pediatric critical illness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and the Steele Children's Research Center, University of Arizona College of Medicine, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Sharon Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathan</LastName><ForeName>Nazima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University of Cambridge and Kings College, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Ann-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Healthcare of Atlanta, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK106462</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PG/09/084/27993</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>FINANCIAL DISCLOSURES: The authors have indicated they have no financial relationships relevant to this article to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bembea</LastName><ForeName>Melania M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agus</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akcan-Arikan</LastName><ForeName>Ayse</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Peta</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basu</LastName><ForeName>Rajit</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohn</LastName><ForeName>Desmond</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Leonardo R</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carcillo</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Checchia</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheifetz</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eckerle</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erickson</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farris</LastName><ForeName>Reid W D</ForeName><Initials>RWD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faustino</LastName><ForeName>E Vincent S</ForeName><Initials>EVS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuhrman</LastName><ForeName>Dana Y</ForeName><Initials>DY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giuliano</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Guilliams</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaies</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorga</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson</LastName><ForeName>Sheila J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassinger</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeffries</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kannan</LastName><ForeName>Sujatha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khemani</LastName><ForeName>Robinder G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kissoon</LastName><ForeName>Niranjan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laussen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jan Hau</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobner</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKiernan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monagle</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odetola</LastName><ForeName>Folafoluwa</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineda</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowan</LastName><ForeName>Courtney M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryerson</LastName><ForeName>Lindsay M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlapbach</LastName><ForeName>Luregn J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selewski</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekerdemian</LastName><ForeName>Lara S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lincoln S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spaeder</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasker</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiagarajan</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tissieres</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traube</LastName><ForeName>Chani</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Shan L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitney</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Doug</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wynn</LastName><ForeName>James L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yehya</LastName><ForeName>Nadir</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34970680</ArticleId><ArticleId IdType="mid">NIHMS1843068</ArticleId><ArticleId IdType="pmc">PMC9662164</ArticleId><ArticleId IdType="doi">10.1542/peds.2021-052888H</ArticleId><ArticleId IdType="pii">184292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klingensmith NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness. Crit Care Clin. 2016;32(2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808565</ArticleId><ArticleId IdType="pubmed">27016162</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JR. Intestinal mucosal barrier function in health and disease. NatRevImmunol. 2009;9(11):799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19855405</ArticleId></ArticleIdList></Reference><Reference><Citation>Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12(4):R90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575570</ArticleId><ArticleId IdType="pubmed">18625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrani VM, Brown A, Huang W, Bissett I, Windsor JA. Gastrointestinal Dysfunction in Critical Illness: A Review of Scoring Tools. JPEN J Parenter Enteral Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350771</ArticleId></ArticleIdList></Reference><Reference><Citation>Eveleens RD, Joosten KFM, de Koning BAE, Hulst JM, Verbruggen S. Definitions, predictors and outcomes of feeding intolerance in critically ill children: A systematic review. Clin Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30962102</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Larmonier CB, Deschenes J, Redford D, Kiela PR, Ghishan FK. Clinical characteristics associated with postoperative intestinal epithelial barrier dysfunction in children with congenital heart disease. Pediatr Crit Care Med. 2015;16(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286428</ArticleId><ArticleId IdType="pubmed">25162512</ArticleId></ArticleIdList></Reference><Reference><Citation>Derikx JP, Bijker EM, Vos GD, et al. Gut mucosal cell damage in meningococcal sepsis in children: relation with clinical outcome. Crit Care Med. 2010;38(1):133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tume LN, Bickerdike A, Latten L, et al. Routine gastric residual volume measurement and energy target achievement in the PICU: a comparison study. Eur J Pediatr. 2017;176(12):1637&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682857</ArticleId><ArticleId IdType="pubmed">28921175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, McAleer D, Hamilton S, et al. Challenges to optimal enteral nutrition in a multidisciplinary pediatric intensive care unit. JPEN JParenterEnteral Nutr. 2010;34(1):38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902117</ArticleId><ArticleId IdType="pubmed">19903872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurbegov AC, Sondheimer JM. Pneumatosis intestinalis in non-neonatal pediatric patients. Pediatrics. 2001;108(2):402&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg. 2017;52(3):414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Yan DC, Lai JY, et al. Strangulated small bowel obstruction in children. J Pediatr Surg. 2017;52(8):1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">28318600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghani SM, Nikeghbalian S, Kazemi K, et al. Outcome of bowel perforation after pediatric liver transplantation. Pediatr Transplant. 2008;12(2):146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanada Y, Mizuta K, Wakiya T, et al. Bowel perforation after pediatric living donor liver transplantation. Pediatr Surg Int. 2011;27(1):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848288</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked A, Vargas J, Csete ME, et al. Diagnosis and treatment of bowel perforation following pediatric orthotopic liver transplantation. Arch Surg. 1993;128(9):994&#x2013;998; discussion 998&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">8368937</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan B, Dasgupta M, Gajewski K, et al. Low near infrared spectroscopic somatic oxygen saturation at admission is associated with need for lifesaving interventions among unplanned admissions to the pediatric intensive care unit. J Clin Monit Comput. 2018;32(1):89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulueta JL, Vida VL, Perisinotto E, Pittarello D, Stellin G. Role of intraoperative regional oxygen saturation using near infrared spectroscopy in the prediction of low output syndrome after pediatric heart surgery. J Card Surg. 2013;28(4):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">23734582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailov TA, Kuhn EM, Manzi J, et al. Early enteral nutrition is associated with lower mortality in critically ill children. JPEN J Parenter Enteral Nutr. 2014;38(4):459&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">24403379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes in critically ill children--an international multicenter cohort study*. Crit Care Med. 2012;40(7):2204&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704225</ArticleId><ArticleId IdType="pubmed">22564954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017;41(5):706&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">28686844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisti MJ, Shahid AS, Shahunja KM, et al. Ileus in children presenting with diarrhea and severe acute malnutrition: A chart review. PLoS Negl Trop Dis. 2017;11(5):e0005603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441652</ArticleId><ArticleId IdType="pubmed">28493871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaibou M, Tucci M, Dugas MA, Farrell CA, Proulx F, Lacroix J. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics. 1998;102(4 Pt 1):933&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755268</ArticleId></ArticleIdList></Reference><Reference><Citation>Je BK, Kim HK, Horn PS. Abdominal Compartment Syndrome in Children: Clinical and Imaging Features. AJR Am J Roentgenol. 2019;212(3):655&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">30645165</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: A Prospective Epidemiological Study. J Intensive Care Med. 2016;31(6):403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39(7):1190&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horoz OO, Yildizdas D, Sari Y, Unal I, Ekinci F, Petmezci E. The relationship of abdominal perfusion pressure with mortality in critically ill pediatric patients. J Pediatr Surg. 2019;54(9):1731&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MB, Firek B, Shi M, et al. Disruption of the microbiota across multiple body sites in critically ill children. Microbiome. 2016;4(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5200963</ArticleId><ArticleId IdType="pubmed">28034303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeyesekera A, Wagner J, De Goffau M, et al. Multi-Compartment Profiling of Bacterial and Host Metabolites Identifies Intestinal Dysbiosis and Its Functional Consequences in the Critically Ill Child. Crit Care Med. 2019;47(9):e727&#x2013;e734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6699985</ArticleId><ArticleId IdType="pubmed">31169619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56(4):1171&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059822</ArticleId><ArticleId IdType="pubmed">20931284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoseph BP, Klingensmith NJ, Liang Z, et al. Mechanisms of Intestinal Barrier Dysfunction in Sepsis. Shock. 2016;46(1):52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910519</ArticleId><ArticleId IdType="pubmed">27299587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40375154</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-230X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC gastroenterology</Title><ISOAbbreviation>BMC Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.</ArticleTitle><Pagination><StartPage>374</StartPage><MedlinePgn>374</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">374</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12876-025-03954-4</ELocationID><Abstract><AbstractText>This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n&#x2009;=&#x2009;11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47&#x2009;&#xb1;&#x2009;4.32 vs. 50.25&#x2009;&#xb1;&#x2009;7.70&#xa0;years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P&#x2009;=&#x2009;0.1081). Regional analysis indicated relatively stable prevalence in North America (P&#x2009;=&#x2009;0.5787), Europe (P&#x2009;=&#x2009;0.0881), other regions (P&#x2009;=&#x2009;0.738), while prevalence in China showed a significant increase (P&#x2009;=&#x2009;0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG&#x2009;&gt;&#x2009;3.1&#xa0;mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Jiongdi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Wentong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Kaixin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kedong</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, 710061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zipeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pancreatic Center, Department of Gastroenterology, Yangzhou Key Laboratory of Pancreatic Disease, Institute of Digestive Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, 225100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Guotao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pancreatic Center, Department of Gastroenterology, Yangzhou Key Laboratory of Pancreatic Disease, Institute of Digestive Diseases, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, 225100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China. wenli7007@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex, Severe, and Rare Diseases, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, 100730, China. wenli7007@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cao</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. f.cao@xwhosp.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Center of Acute Pancreatitis, Capital Medical University, Beijing, 100053, China. f.cao@xwhosp.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Chinese Hypertriglyceridemia-Associated Pancreatitis Study Group (CHPSG)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PX20250806</GrantID><Agency>Research and Cultivation Project of Beijing Municipal Hospital Administration</Agency><Country/></Grant><Grant><GrantID>PX2023030</GrantID><Agency>Research and Cultivation Project of Beijing Municipal Hospital Administration</Agency><Country/></Grant><Grant><GrantID>2020-1-2012</GrantID><Agency>Capital Medical Development and Research Special Project</Agency><Country/></Grant><Grant><GrantID>7242069</GrantID><Agency>Natural Science Foundation of Beijing Municipality</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Gastroenterol</MedlineTA><NlmUniqueID>100968547</NlmUniqueID><ISSNLinking>1471-230X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015228" MajorTopicYN="Y">Hypertriglyceridemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypertriglyceridemia-induced Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Recurrence</Keyword><Keyword MajorTopicYN="N">Severity</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All data used for the secondary analysis in our manuscript are from published, ethically reviewed studies that have ensured patient privacy protection and data anonymization. Therefore, ethical statements are not applicable in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40375154</ArticleId><ArticleId IdType="pmc">PMC12082898</ArticleId><ArticleId IdType="doi">10.1186/s12876-025-03954-4</ArticleId><ArticleId IdType="pii">10.1186/s12876-025-03954-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>B&#xe1;lint ER, F&#x171;r G, Kiss L, et al. Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis. Sci Rep. 2020;10(1):17936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578029</ArticleId><ArticleId IdType="pubmed">33087766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021;325(4):382&#x2013;90.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pubmed">33496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkeg&#xe5;rd J, Cronin-Fenton D, Heide-J&#xf8;rgensen U, et al. Acute pancreatitis and pancreatic cancer risk: a nationwide matched-cohort study in Denmark. Gastroenterology. 2018;154(6):1729&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29432727</ArticleId></ArticleIdList></Reference><Reference><Citation>Munigala S, Almaskeen S, Subramaniam DS, et al. Acute pancreatitis recurrences augment long-term pancreatic cancer risk. Am J Gastroenterol. 2023;118(4):727&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045975</ArticleId><ArticleId IdType="pubmed">36473072</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuzzi JP, King JA, Leong JH, et al. Global incidence of acute pancreatitis is increasing over time: a systematic review and meta-analysis. Gastroenterology. 2022;162(1):122&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">34571026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosztbacher D, Han&#xe1;k L, Farkas N, et al. Hypertriglyceridemia-induced acute pancreatitis: a prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases. Pancreatology. 2020;20(4):608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">32402696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Deng L, Jin T, et al. Hypertriglyceridaemia-associated acute pancreatitis: diagnosis and impact on severity. HPB (Oxford). 2019;21(9):1240&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30885545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497&#x2013;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">26323188</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr RA, Rejowski BJ, Cote GA, et al. Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology. 2016;16(4):469&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">27012480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XL, Li F, Zhen YM, et al. Clinical study of 224 patients with hypertriglyceridemia pancreatitis. Chin Med J (Engl). 2015;128(15):2045&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717952</ArticleId><ArticleId IdType="pubmed">26228216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothoulakis I, Paragomi P, Archibugi L, et al. Clinical features of hypertriglyceridemia-induced acute pancreatitis in an international, multicenter, prospective cohort (APPRENTICE consortium). Pancreatology. 2020;20(3):325&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">32107193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, He J, Ma S, et al. The role of comorbid hypertriglyceridemia and abdominal obesity in the severity of acute pancreatitis: a retrospective study. Lipids Health Dis. 2021;20(1):171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627607</ArticleId><ArticleId IdType="pubmed">34838056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu W, Luo G, Chen T, et al. A 5-year retrospective cohort study: epidemiology, etiology, severity, and outcomes of acute pancreatitis. Pancreas. 2020;49(9):1161&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32897999</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Zhou Z, Li H, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. Pancreas. 2015;44(3):409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25438072</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Wang G, Yu B, et al. Elevated hypertriglyceridemia and decreased gallstones in the etiological composition ratio of acute pancreatitis as affected by seasons and festivals: a two-center real-world study from China. Front Cell Infect Microbiol. 2022;12:976816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9730824</ArticleId><ArticleId IdType="pubmed">36506025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S, Vege SS, Sheth SG, et al. American college of gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">38857482</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandra S, Virlos IT, King NK, et al. Hyperlipidaemia and outcome in acute pancreatitis. Int J Clin Pract. 2006;60(2):156&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16451286</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Wang S, Zhang Z. A 23-year, single-center, retrospective analysis of 36 cases of acute pancreatitis in pregnancy. Int J Gynaecol Obstet. 2015;130(2):123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25983209</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Liu J, Lu Y, et al. Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a retrospective study. J Clin Apher. 2016;31(6):571&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Dai CY, Hou NJ, et al. Etiology, severity and recurrence of acute pancreatitis in southern Taiwan. J Formos Med Assoc. 2006;105(7):550&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877234</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhoda S, Zimrin AB, Baer MR, et al. Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. Transfus Apher Sci. 2017;56(2):123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27789124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Fuentes HE, Attar BM, et al. Evaluation of the prognostic value of neutrophil to lymphocyte ratio in patients with hypertriglyceridemia-induced acute pancreatitis. Pancreatology. 2017;17(6):893&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29030078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual I, Sanahuja A, Garc&#xed;a N, et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: cohort analysis of 1457 patients. Pancreatology. 2019;19(5):623&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31229460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Kang H, Kim EJ, et al. Clinical features and outcomes of hypertriglyceridemia-induced acute pancreatitis: propensity score matching analysis from a prospective acute pancreatitis registry. Pancreatology. 2020;20(4):617&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">32265135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Huang Y, Yu H, et al. The association of parameters of body composition and laboratory markers with the severity of hypertriglyceridemia-induced pancreatitis. Lipids Health Dis. 2021;20(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879630</ArticleId><ArticleId IdType="pubmed">33573658</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothoulakis I, Paragomi P, Tuft M, et al. Association of serum triglyceride levels with severity in acute pancreatitis: results from an international, multicenter cohort study. Digestion. 2021;102(5):809&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9191264</ArticleId><ArticleId IdType="pubmed">33477149</ArticleId></ArticleIdList></Reference><Reference><Citation>Dancu G, Bende F, Danila M, et al. Hypertriglyceridaemia-induced acute pancreatitis: a different disease phenotype. Diagnostics (Basel). 2022;12(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9028994</ArticleId><ArticleId IdType="pubmed">35453916</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Pan S, Zhang D, et al. Hyperlipemia pancreatitis onset time affects the association between elevated serum triglyceride levels and disease severity. Lipids Health Dis. 2022;21(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9153118</ArticleId><ArticleId IdType="pubmed">35637538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin XY, Zeng Y, Zhang ZC, et al. Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: a retrospective single-center study. World J Gastroenterol. 2022;28(29):3946&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9367230</ArticleId><ArticleId IdType="pubmed">36157550</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K, Guo C, He L, et al. Different clinical characteristics between recurrent and non-recurrent acute pancreatitis: a retrospective cohort study from a tertiary hospital. Saudi J Gastroenterol. 2022;28(4):282&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9408740</ArticleId><ArticleId IdType="pubmed">35259860</ArticleId></ArticleIdList></Reference><Reference><Citation>Song K, Wu Z, Meng J, et al. Hypertriglyceridemia as a risk factor for complications of acute pancreatitis and the development of a severity prediction model. HPB (Oxford). 2023;25(9):1065&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">37211462</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang JX, Hu LS, Liu P, et al. Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis. World J Gastroenterol. 2017;23(47):8387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743509</ArticleId><ArticleId IdType="pubmed">29307998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Niu X, Zhang W, et al. Comparison of the development and prognosis in patients of hypertriglyceridemic pancreatitis with and without diabetes. Gastroenterol Res Pract. 2021;2021:8895268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677390</ArticleId><ArticleId IdType="pubmed">34925505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L, Guan L, Li X, et al. Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: a prospective cohort study. J Clin Lipidol. 2023;17(1).</Citation><ArticleIdList><ArticleId IdType="pubmed">36697323</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan L, Ding L, Wan J, et al. Serum triglyceride levels are associated with recurrence in patients with acute hypertriglyceridemic pancreatitis. Front Med. 2023;10:1079637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10050706</ArticleId><ArticleId IdType="pubmed">37007797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Jia Q, Liu N, et al. Lipid metabolism for predicting the recurrence of hypertriglyceridemic acute pancreatitis. Heliyon. 2023;9(6):e17443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10333607</ArticleId><ArticleId IdType="pubmed">37441413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo SI, Chang JH, Kim TH, et al. Subsets associated with developing acute pancreatitis in patients with severe hypertriglyceridemia and the severity of pancreatitis. Pancreatology. 2019;19(6):795&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">31421975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for diagnosis and treatment of acute pancreatitis in China (2021). Zhonghua Wai Ke Za Zhi. 2021;59(7):578&#x2013;587. Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">34256457</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M, Zhou X, Zippi M, et al. Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis. Ann Med. 2023;55(2):2265939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10563627</ArticleId><ArticleId IdType="pubmed">37813108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen SEJ, Varbo A, Nordestgaard BG, et al. Hypertriglyceridemia-associated pancreatitis: new concepts and potential mechanisms. Clin Chem. 2023;69(10):1132&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">37530032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu BU, Batech M, Dong EY, et al. Influence of ambulatory triglyceride levels on risk of recurrence in patients with hypertriglyceridemic pancreatitis. Dig Dis Sci. 2019;64(3):890&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30094622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanloo J, B&#xe9;land-Bonenfant S, Paquette M, et al. Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; a 7-year retrospective cohort study at Canadian quaternary care hospitals. J Clin Lipidol. 2022;16(4):455&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">35659855</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Bai X, Chen X, et al. A 16-year trend of etiology in acute pancreatitis: the increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis. J Clin Lipidol. 2019;13(6).</Citation><ArticleIdList><ArticleId IdType="pubmed">31735687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Chen Y, Liu S, et al. Early plasmapheresis among patients with hypertriglyceridemia-associated acute pancreatitis. JAMA Netw Open. 2023;6(6):e2320802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10308255</ArticleId><ArticleId IdType="pubmed">37378979</ArticleId></ArticleIdList></Reference><Reference><Citation>Opoku S, Gan Y, Fu W, et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019;19(1):1500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849283</ArticleId><ArticleId IdType="pubmed">31711454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis. 2016;248:2&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26978581</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer J, Singh VP, Pitchumoni CS, et al. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939000</ArticleId><ArticleId IdType="pubmed">24172179</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Xu P, Li F, et al. Internal migration and regional differences of population aging: an empirical study of 287 cities in China. Biosci Trends. 2018;12(2):132&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">29607873</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2).</Citation><ArticleIdList><ArticleId IdType="pubmed">28437620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YC, Hsiao FC, Lin CP, et al. High triglyceride variability increases the risk of first attack of acute pancreatitis. Am J Gastroenterol. 2023;118(6):1080&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226468</ArticleId><ArticleId IdType="pubmed">36716230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss L, F&#x171;r G, Pisipati S, et al. Mechanisms linking hypertriglyceridemia to acute pancreatitis. Acta Physiol (Oxf). 2023;237(3):e13916.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599412</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto K, Horibe M, Sanui M, et al. Plasmapheresis therapy has no triglyceride-lowering effect in patients with hypertriglyceridemic pancreatitis. Intensive Care Med. 2017;43(6):949&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28233051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">32571534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafrir B, Saliba W, Jubran A, et al. Severe hypertriglyceridemia-related pancreatitis: characteristics and predictors of recurrence. Pancreas. 2019;48(2):182&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30629026</ArticleId></ArticleIdList></Reference><Reference><Citation>Aune D, Mahamat-Saleh Y, Norat T, et al. Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies. Pancreatology. 2020;20(4):602&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409279</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson A, Park WG. Acute pancreatitis and diabetes mellitus: a review. Korean J Intern Med. 2021Jan;36(1):15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820652</ArticleId><ArticleId IdType="pubmed">33147904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32242947</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1449</StartPage><EndPage>1459</EndPage><MedlinePgn>1449-1459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25822</ELocationID><Abstract><AbstractText Label="BACKGROUND">Currently, the epidemic of coronavirus disease 2019 (COVID-19) has begun to spread worldwide. We aim to explore reliable evidence for the diagnosis and treatment of the COVID-19 by analyzing all the published studies by Chinese scholars on the clinical and imaging features in novel coronavirus pneumonia caused by SARS-CoV-2.</AbstractText><AbstractText Label="METHODS">We searched five medical databases including two Chinese and three English databases for all published articles on COVID-19 since the outbreak. A random-effects model was designed, and the imaging and clinical data from all studies were collected for meta-analysis.</AbstractText><AbstractText Label="RESULTS">Overall, 31 articles and 46&#x2009;959 patients were included, including 10 English articles and 21 Chinese articles. The results of meta-analysis showed that the most common clinical manifestations were fever (87.3%; 0.838-0.909), cough (58.1%; 0.502-0.660), dyspnea (38.3%; 0.246-0.520), muscle soreness or fatigue (35.5%; 0.253-0.456), and chest distress (31.2%; -0.024 to 0.648). The main imaging findings were bilateral pneumonia (75.7%; 0.639-0.871) and ground-glass opacification (69.9%; 0.602-0.796). Among the patients, the incidence that required intensive care unit (ICU) was (29.3%; 0.190-0.395), the incidence with acute respiratory distress syndrome was (28.8%; 0.147-0.429), the incidence with multiple organ dysfunction syndrome was (8.5%; -0.008 to 0.179), and the case fatality rate of patients with COVID-19 was (6.8%; 0.044-0.093).</AbstractText><AbstractText Label="CONCLUSION">COVID-19 is a new clinical infectious disease that mainly causes bilateral pneumonia and lung function deteriorates rapidly. Nearly a third of patients need to be admitted to the ICU, and patients are likely to present respiratory failure or even death.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yinghao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Liyuan Hospital, Tongji Medical College, Huazhong University of Since and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nosocomial Infection Management, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Kailin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2572-0907</Identifier><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/N013468/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>02.03.2019-111</GrantID><Agency>Free Innovation Pre-research Fund and Platform Scientific Research Fund in 2019</Agency><Country>International</Country></Grant><Grant><GrantID>2018CFC884</GrantID><Agency>Science and Technology Department of Hubei Province</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019 novel coronavirus pneumonia</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">imaging finding</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32242947</ArticleId><ArticleId IdType="pmc">PMC7228215</ArticleId><ArticleId IdType="doi">10.1002/jmv.25822</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457&#x2010;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089049</ArticleId><ArticleId IdType="pubmed">32009228</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus&#x2010;infected pneumonia. N Engl J Med. 2020;382(13):1199&#x2010;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2010;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID&#x2010;19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Health Economics . Quality Appraisal of Case Series Studies Checklist; 2014.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507&#x2010;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019&#x2010;nCoV). Radiology. 2020;295(1):202&#x2010;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194022</ArticleId><ArticleId IdType="pubmed">32017661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x2010;infected pneumonia in Wuhan, China. JAMA. 2020;233(3):104&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Fang Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;3(4):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147277</ArticleId><ArticleId IdType="pubmed">32044814</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323(11):1092&#x2010;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042871</ArticleId><ArticleId IdType="pubmed">32031568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma X, Wang HY, et al. Computed tomography features of patients with novel coronavirus pneumonia. Shanghai Med J. 2020;43(2):1&#x2010;10.</Citation></Reference><Reference><Citation>Liu YX, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019&#x2010;nCoV infected patients linked to viral loads and lung injury (Chinese). Sci China Life Sci. 2020;50(3):258&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088566</ArticleId><ArticleId IdType="pubmed">32048163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhang JP, Du YH, et al. CT features of patients with imported 2019&#x2010;nCoV&#x2010;pneumonia. J Xi'an Jiaotong Univ (Med Sci) 2020;41(2):187.</Citation></Reference><Reference><Citation>Gong XM, Li H, Song L, et al. Preliminary explore on CT characteristics of coronavirus disease 2019 (COVID&#x2010;19). Radiol Prac. 2020;35(3):261&#x2010;265.</Citation></Reference><Reference><Citation>Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019&#x2010;nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;133(21):146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087663</ArticleId><ArticleId IdType="pubmed">32055945</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang D, Tang S, et al. The epidemiological and clinical characteristics of 2019 novel coronavirus infection in Changsha, China. Preprint Lancet. 2020;50(2):342&#x2010;346.</Citation></Reference><Reference><Citation>Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID&#x2010;19) pneumonia. Radiology. 2020;35(1):200370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang MQ, Wang XH, Chen YL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jiehe He Huxi Zazhi. 2020;43(0):E013.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061066</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng K, Yun YX, Wang XF, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. Chin J Pediatr. 2020;58(3):E007.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XF, Yuan J, Zheng YJ, et al. Retracted: Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen. Chin J Pediatr. 2020;58(1):E008.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062875</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel Coronavirus Pneumonia Emergency Response Epidemiology Team . The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID&#x2010;19) in China. J. Chin Epi. 2020;41(2):145&#x2010;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu FM, Ding HL, Gong XM, et al. Chest CT performance and clinical characteristics of coronavirus disease 2019 (COVID&#x2010;19). Radiol Prac. 2020;35(3):266&#x2010;268.</Citation></Reference><Reference><Citation>Zhuang YJ, Chen Z, Li J. Clinical and epidemiological characteristics of 26 patients dia gnosed with novel coronavirus pneumonia. Chin J Nosocomiology. 2020;23(6):826&#x2010;829.</Citation></Reference><Reference><Citation>Wang K, Kang SR, Tian RH, et al. CT characteristic appearances of patients with novel coronavirus pneumonia. J Clin Med. 2020;1(27):27&#x2010;31.</Citation></Reference><Reference><Citation>Chen M, An W, Xia F, et al. Retrospective analysis of COVID&#x2010;19 patients with different clinical subtypes. Herald Med. 2020;41(5):1&#x2010;12.</Citation></Reference><Reference><Citation>Zhong FY, Zhang HF, Wang BC, et al. CT findings in 2019 novel coronavirus disease (COVID&#x2010;19) patients. Med J Wuhan Univ. 2020;31(1):1&#x2010;5.</Citation></Reference><Reference><Citation>Fu GZ, Xu CY, Sun HC, et al. Application of chest CT examination in screening of patients with novel coronavirus pneumonia. Med J Wenzhou Univ. 2020;20(2):1&#x2010;9.</Citation></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS&#x2010;CoV&#x2010;2 pneumonia in Wuhan, China: a single&#x2010;centered, retrospective, observational study. Lancet Respir Med. 2020;8(4):E26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji GH, Huang MH, Zhang Q, et al. CT manifestations and dynamic changes of coronavirus disease 2019. Chin J Med Imaging Technol. 2020;36(2):242&#x2010;247.</Citation></Reference><Reference><Citation>Chen L, Feng SY, Wang FX, et al. Clinical diagnosis and treatment of critical patients with novel coronavirus pneumonia (report of 12 cases). J Clin Med. 2020;27(1):32&#x2010;35.</Citation></Reference><Reference><Citation>Zeng GF, Yang HP, Zhang XY, et al. Analysis of clinical and imaging features of novel coronavirus pneumonia in Chongqing traditional Chinese medicine system. J Emerg Tradit Chin Med. 2020;29(3):377&#x2010;380.</Citation></Reference><Reference><Citation>Cao J, Zhou J, Liao XN, et al. Clinical characteristics and CT signs of coronavirus disease 2019 (COVID&#x2010;19) in the elderly. Med J Wuhan Univ. 2020;4(2):1&#x2010;4.</Citation></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;213(42):543&#x2010;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XT, Ye H, Yang SF, et al. Chest CT features of COVID&#x2010;19. J Pract Med. 2020;2(3):1&#x2010;3.</Citation></Reference><Reference><Citation>Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020;43(0):E005.</Citation><ArticleIdList><ArticleId IdType="pubmed">32026671</ArticleId></ArticleIdList></Reference><Reference><Citation>Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine . An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID&#x2010;19). J. Chin Epi. 2020;41(2):139.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Wang RS, Qu GQ, et al. Systematic solution of new coronavirus pneumonia in dead cadavers. J Forensic Sci. 2020;36(1):19&#x2010;21.</Citation></Reference><Reference><Citation>Guan GW, Gao L, Wang JW, et al. Study on the mechanism of liver enzyme abnormality in pneumonia infected by novel coronavirus. J Hepatol. 2020;28(2):E002.</Citation><ArticleIdList><ArticleId IdType="pubmed">32077659</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457962</ArticleId><ArticleId IdType="pubmed">27578435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj B, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801&#x2010;8811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC167208</ArticleId><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727&#x2010;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019&#x2010;nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66(4):549&#x2010;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108203</ArticleId><ArticleId IdType="pubmed">32031583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT&#x2010;PCR testing in coronavirus disease 2019 (COVID&#x2010;19) in China: a report of 1014 cases. Radiology. 2020;24(3):200642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233399</ArticleId><ArticleId IdType="pubmed">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldog P, Tekeli T, Vizi Z, D&#xe9;nes A, Bartha FA, R&#xf6;st G. Risk assessment of novel coronavirus COVID&#x2010;19 outbreaks outside China. J Clin Med. 2020;9(2):571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073711</ArticleId><ArticleId IdType="pubmed">32093043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019&#x2010;nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020;395(10225):689&#x2010;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159271</ArticleId><ArticleId IdType="pubmed">32014114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands P, Mundaca&#x2010;Shah C, Dzau VJ. The neglected dimension of global security&#x2014;a framework for countering infectious&#x2010;disease crises. N Engl J Med. 2016;374(13):1281&#x2010;1287.</Citation><ArticleIdList><ArticleId IdType="pubmed">26761419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25444751</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3492</ISSN><JournalIssue CitedMedium="Internet"><Volume>440</Volume><PubDate><Year>2015</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Clinica chimica acta; international journal of clinical chemistry</Title><ISOAbbreviation>Clin Chim Acta</ISOAbbreviation></Journal><ArticleTitle>Novel markers predict death and organ failure following hemorrhagic shock.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>92</EndPage><MedlinePgn>87-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cca.2014.10.045</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0009-8981(14)00492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ADAMTS 13, sP-Selectin and HSP27 have been investigated as potential prognostic markers in patients with hemorrhagic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was part of a double-blind, randomized, parallel-group, controlled trial and included seventeen trauma patients presented to ED with severe hemorrhagic. The sera for testing were collected from these patients at the time of admission. Investigators and laboratory personnel performing testing were blinded to the patients' identity and clinical course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prognostic value of ADAMTS13, sP-Selectin, and HSP27 was compared to prognostic value of systolic blood pressure (SBP), base deficit estimation (BD), heart rate (HR), shock index (SI) and tissue oxygen saturation (StO2) by constructing the receiver operation characteristics (ROC). The area under the curve (AUC) of the ROC for HSP27 (0.92) was greater than for SBP (0.45), BD (0.89), HR (0.61), SI (0.45) and StO2 (0.46). AUC for sP-Selectin (0.86) and for ADAMTS13 antigen (0.74) were comparable with BD one, but greater than for the rest of currently used tests.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Serum concentrations of ADAMTS13, HSP27 and sP-Selectin measured during the admission, appear to be comparable to or better than SBP, BD, SI, HR and StO2 in predicting MODS and death after hemorrhage from trauma. These potential new markers deserve further investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furmaga</LastName><ForeName>Wieslaw</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States. Electronic address: furmaga@uthscsa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prihoda</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Valery</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arar</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Chim Acta</MedlineTA><NlmUniqueID>1302422</NlmUniqueID><ISSNLinking>0009-8981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C057725">HSPB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="C099604">ADAMTS13 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADAMTS13</Keyword><Keyword MajorTopicYN="N">HSP27</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock markers</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">sP-Selectin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25444751</ArticleId><ArticleId IdType="doi">10.1016/j.cca.2014.10.045</ArticleId><ArticleId IdType="pii">S0009-8981(14)00492-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26438223</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Effects of packed red blood cell storage duration on post-transfusion clinical outcomes: a meta-analysis and systematic review.</ArticleTitle><Pagination><StartPage>2087</StartPage><EndPage>2097</EndPage><MedlinePgn>2087-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-015-4078-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There is substantial conjecture regarding the clinical significance of packed red blood cell (PRBC) changes that occur during in vitro storage. Here, we present a meta- and systematic analysis of adult studies published between 1994 and 2015 with the aim of updating existing quantitative reviews and providing a comprehensive cover of the six most commonly studied outcomes-mortality, infection, renal dysfunction, multiple organ dysfunction syndrome (MODS), thrombotic complications and prolonged hospital length of stay.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Computerised searches of Pubmed and EMBASE identified publications that reported target outcomes and PRBC storage duration prior to transfusion. Bibliographies of relevant literature were manually searched to incorporate missed studies. Randomised controlled trial (RCT) data was meta-analysed using a random effects model with Cochrane Collaboration Review Manager (RevMan) version 5.1 software. Observational investigations were systematically reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-four papers were selected covering 462,581 patients with the majority of studies being observational in nature. Meta-analysis of eight RCTs demonstrated a trend towards decreased mortality with stored PRBC transfusion; albeit this effect was not statistically significant (OR 0.91, 95 % CI 0.78-1.05, p = 0.20). In a small subset of intensive care unit (ICU), cardiac surgery and trauma patients; observational studies suggested that prolonged storage may be correlated with increased mortality. Trauma and cardiac surgery patients appeared to be most susceptible to the potential infectious complications of stored PRBCs. Stored PRBCs were unlikely to affect thrombotic complications or hospital length of stay. There were inadequate data to determine whether stored PRBCs had clinically relevant effects on renal dysfunction and MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although literature presents a concerning picture of potential storage complications, current findings are too inconsistent to drive changes in clinical practice. Results from current RCTs will likely play a role in PRBC age guidelines for cardiac surgery and ICU patients. However, these studies may be less efficacious at detecting small effects that are limited to specific subpopulations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Monica Suet Ying</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-0431-9110</Identifier><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Brisbane, QLD, Australia. monica.ng91@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Angela Suet Yeung</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. angela.ng1@uqconnect.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. angela.ng1@uqconnect.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. jessica.chan4@uqconnect.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tung</LastName><ForeName>John-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, Australian Red Cross Blood Service, Kelvin Grove, Brisbane, QLD, Australia. JTung@redcrossblood.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>John Francis</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD, Australia. TPCH-CCRG@health.qld.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Brisbane, QLD, Australia. TPCH-CCRG@health.qld.gov.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="Y">Erythrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood storage</Keyword><Keyword MajorTopicYN="N">Erythrocyte transfusion</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Red blood cells</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26438223</ArticleId><ArticleId IdType="doi">10.1007/s00134-015-4078-5</ArticleId><ArticleId IdType="pii">10.1007/s00134-015-4078-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Thromb Haemost. 2011 Mar;9(3):574-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21166993</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Hemother. 2008 Oct;35(5):359-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21512625</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2012 Apr 15;185(8):842-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22281833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Dec;65(6):1411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1196-202</Citation><ArticleIdList><ArticleId IdType="pubmed">22082281</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Apr 9;372(15):1419-29</Citation><ArticleIdList><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Aug;65(2):279-82; discussion 282-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18695462</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Dec;51(12):2695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">21645005</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2012 Feb;203(2):198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">21924400</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Nov;51(11):2286-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21564106</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2010 May;159(5):737-743.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">20435180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Burn Care Res. 2014 Mar-Apr;35(2):186-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23799480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2002 Nov;53(5):1023-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12435963</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2004 Oct;44(10):1468-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15383020</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2013 Oct 04;17(5):R222</Citation><ArticleIdList><ArticleId IdType="pubmed">24093554</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2010 May;159(5):876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20435199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thorac Cardiovasc Surg. 2011 Jan;141(1):231-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20621313</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2011 May;106(5):643-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21414977</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2014 May;41 Suppl 1:98-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24662781</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2012 Oct;36(10):2436-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22714578</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 16;8(7):e68820</Citation><ArticleIdList><ArticleId IdType="pubmed">23874777</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2008 Mar 20;358(12):1229-39</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cardiothorac Surg. 2011 Mar;39(3):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20702101</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Transfus. 2012 May;10 Suppl 2:s7-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22890271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2011 Jan;35(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20823694</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2009;13(5):R151</Citation><ArticleIdList><ArticleId IdType="pubmed">19772604</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2013 Jan;118(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23154297</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Transpl. 2013 Nov;19(11):1181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23813754</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Jul;49(7):1375-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2011 Apr;35(4):355-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21192282</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1203-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22257314</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Anesthesiol. 2014 Oct 21;14:95</Citation><ArticleIdList><ArticleId IdType="pubmed">25352766</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Dec;49(12):2599-603</Citation><ArticleIdList><ArticleId IdType="pubmed">20163690</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Jan;53(1):34-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22519710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hematol. 2013 Dec;92(12):1701-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23832235</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jun;52(6):1184-95</Citation><ArticleIdList><ArticleId IdType="pubmed">22188419</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Cardiothorac Vasc Anesth. 2012 Sep;16(3):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22556036</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Rev. 2013 Jan;27(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22902231</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver Transpl. 2012 Apr;18(4):475-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22238247</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Jul;49(7):1384-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19453985</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 Nov;51(11):2488-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21569047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2010 Aug;69(2):330-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20699741</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Hemother. 2012 Aug;39(4):271-276</Citation><ArticleIdList><ArticleId IdType="pubmed">22969697</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2010 Mar;50(3):600-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2005 Sep;71(9):781-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16468518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Am. 2014 Feb 19;96(4):272-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24553882</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Apr 9;372(15):1410-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25853745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2002 Jun;52(6):1224-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12045660</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2014 Jun 17;5:214</Citation><ArticleIdList><ArticleId IdType="pubmed">24987374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intensive Care. 2013 Jan 15;3(1):2</Citation><ArticleIdList><ArticleId IdType="pubmed">23316800</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(2):R116</Citation><ArticleIdList><ArticleId IdType="pubmed">21496231</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2010 Feb;98(2):124-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19754522</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Apher Sci. 2010 Aug;43(1):95-106</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2013 Apr 08;17(2):R66</Citation><ArticleIdList><ArticleId IdType="pubmed">23566599</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2012 Feb 01;16(1):R19</Citation><ArticleIdList><ArticleId IdType="pubmed">22297161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2001 Jul;44(7):955-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11496075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Exp Toxicol. 2012 Jul;31(7):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22249389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2008 Oct;65(4):794-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18849793</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Transfus. 2012 Jul;10(3):290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22395349</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 Jan;100(1):36-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21175654</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Jul;52(7):1410-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22233290</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2002 Jun;137(6):711-6; discussion 716-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12049543</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2006 Oct;46(10):1712-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 May;100(4):418-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21488881</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2011 May;51(5):1122-3</Citation><ArticleIdList><ArticleId IdType="pubmed">21545596</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2008 Apr;36(4):1290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18379257</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2013 Jun;44(6):747-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2010 Jun;50(6):1185-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20158690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematology Am Soc Hematol Educ Program. 2011;2011:475-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22160077</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2011;15(6):R263</Citation><ArticleIdList><ArticleId IdType="pubmed">22044745</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21371695</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-229X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical radiology</Title><ISOAbbreviation>Clin Radiol</ISOAbbreviation></Journal><ArticleTitle>Embolization for non-variceal upper gastrointestinal tract haemorrhage: a systematic review.</ArticleTitle><Pagination><StartPage>500</StartPage><EndPage>509</EndPage><MedlinePgn>500-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.crad.2010.11.016</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the published evidence on the endovascular treatment of non-variceal upper gastrointestinal haemorrhage.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An Ovid Medline search of published literature was performed (1966-2009). Non-English literature, experimental studies, variceal haemorrhage and case series with fewer than five patients were excluded. The search yielded 1888 abstracts. Thirty-five articles were selected for final analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total number of pooled patients was 927. The technical and clinical success of embolization ranged from 52-100% and 44-100%, respectively. The pooled mean technical/clinical success rate in primary upper gastrointestinal tract haemorrhage (PUGITH) only, trans-papillary haemorrhage (TPH) only, and mixed studies were 84%/67%, 93%/89%, and 93%/64%, respectively. Clinical outcome was adversely affected by multi-organ failure, shock, corticosteroids, transfusion, and coagulopathy. The anatomical source of haemorrhage and procedural variables did not affect the outcome. A successful embolization improved survival by 13.3 times. Retrospective comparison with surgery demonstrated equivalent mortality and clinical success, despite embolization being applied to a more elderly population with a higher prevalence of co-morbidities.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Embolization is effective in this very difficult cohort of patients with outcomes similar to surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirsadraee</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leeds General Infirmary, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirukonda</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Everett</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Radiol</MedlineTA><NlmUniqueID>1306016</NlmUniqueID><ISSNLinking>0009-9260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016099" MajorTopicYN="N">Endoscopy, Gastrointestinal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016558" MajorTopicYN="N">Hemostasis, Endoscopic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21371695</ArticleId><ArticleId IdType="doi">10.1016/j.crad.2010.11.016</ArticleId><ArticleId IdType="pii">S0009-9260(11)00033-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27762438</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2044</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Anaesthesia</Title><ISOAbbreviation>Anaesthesia</ISOAbbreviation></Journal><ArticleTitle>The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>117</EndPage><MedlinePgn>106-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/anae.13628</ELocationID><Abstract><AbstractText>Acute respiratory distress syndrome is associated with high mortality and morbidity. Inhaled nitric oxide has been used to improve oxygenation but its role remains controversial. Our primary objective in this systematic review was to examine the effects of inhaled nitric oxide administration on mortality in adults and children with acute respiratory distress syndrome. We included all randomised, controlled trials, irrespective of date of publication, blinding status, outcomes reported or language. Our primary outcome measure was all-cause mortality. We performed several subgroup and sensitivity analyses to assess the effect of inhaled nitric oxide. There was no statistically significant effect of inhaled nitric oxide on longest follow-up mortality (inhaled nitric oxide group 250/654 deaths (38.2%) vs. control group 221/589 deaths (37.5%; relative risk (95% CI) 1.04 (0.9-1.19)). We found a significant improvement in PaO<sub>2</sub> /F<sub>I</sub> O<sub>2</sub> ratio at 24 h (mean difference (95% CI) 15.91 (8.25-23.56)), but not at 48 h or 72 h, while four trials indicated improved oxygenation in the inhaled nitric oxide group at 96 h (mean difference (95% CI) 14.51 (3.64-25.38)). There were no statistically significant differences in ventilator-free days, duration of mechanical ventilation, resolution of multi-organ failure, quality of life, length of stay in intensive care unit or hospital, cost-benefit analysis and methaemoglobin and nitrogen dioxide levels. There was an increased risk of renal impairment (risk ratio (95% CI) 1.59 (1.17-2.16)) with inhaled nitric oxide. In conclusion, there is insufficient evidence to support inhaled nitric oxide in any category of critically ill patients with acute respiratory distress syndrome despite a transient improvement in oxygenation, since mortality is not reduced and it may induce renal impairment.</AbstractText><CopyrightInformation>&#xa9; 2016 The Association of Anaesthetists of Great Britain and Ireland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>O</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6606-1736</Identifier><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebistorf</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group and Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anaesthesia</MedlineTA><NlmUniqueID>0370524</NlmUniqueID><ISSNLinking>0003-2409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27762438</ArticleId><ArticleId IdType="doi">10.1111/anae.13628</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28331537</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1749-7922</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>World journal of emergency surgery : WJES</Title><ISOAbbreviation>World J Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Combined totally mini-invasive approach in necrotizing pancreatitis: a case report and systematic literature review.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13017-017-0126-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Currently, both the step-up approach, combining percutaneous drainage (PD) and video-assisted retroperitoneal debridement (VARD), and endoscopic transgastric necrosectomy (ETN) are mini-invasive techniques for infected necrosis in severe acute pancreatitis. A combination of these approaches could maximize the management of necrotizing pancreatitis, conjugating the benefits from both the experiences. However, reporting of this combined strategy is anecdotal. This is the first reported case of severe necrotizing pancreatitis complicated by biliary fistula treated by a combination of ETN, PD, VARD, and endoscopic biliary stenting. Moreover, a systematic literature review of comparative studies on minimally invasive techniques in necrotizing pancreatitis has been provided.</AbstractText><AbstractText Label="CASE PRESENTATION">A 59-year-old patient was referred to our center for acute necrotizing pancreatitis associated with multi-organ failure. No invasive procedures were attempted in the first month from the onset: enteral feeding by a naso-duodenal tube was started, and antibiotics were administered to control sepsis. After 4&#xa0;weeks, CT scans showed a central walled-off pancreatic necrosis (WOPN) of pancreatic head communicating bilateral retroperitoneal collections. ETN was performed, and bile leakage was found at the right margin of the WOPN. Endoscopic retrograde cholangiopancreatography confirmed the presence of a choledocal fistula within the WOPN, and a biliary stent was placed. An ultrasound-guided PD was performed on the left retroperitoneal collection. Due to the subsequent repeated onset of septic shocks and the evidence of size increase of the right retroperitoneal collection, a VARD was decided. The CT scans documented the resolution of all the collections, and the patient promptly recovered from sepsis. After 6&#xa0;months, the patient is in good clinical condition.</AbstractText><AbstractText Label="CONCLUSIONS">No mini-invasive technique has demonstrated significantly better outcomes over the others, and each technique has specific indications, advantages, and pitfalls. Indeed, ETN could be suitable for central WOPNs, while VARD or PD could be suggested for lateral collections. A combination of different approaches is feasible and could significantly optimize the clinical management in critically ill patients affected by complicated necrotizing pancreatitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiara</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutignani</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digestive Endoscopy Service, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sammartano</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brioschi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimbanassi</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trauma Team and Emergency Surgery, Niguarda Trauma Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, Milan, 20162 Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Emerg Surg</MedlineTA><NlmUniqueID>101266603</NlmUniqueID><ISSNLinking>1749-7922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002760" MajorTopicYN="N">Cholangiopancreatography, Endoscopic Retrograde</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003646" MajorTopicYN="N">Debridement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020535" MajorTopicYN="N">Video-Assisted Surgery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endoscopic transgastric necrosectomy</Keyword><Keyword MajorTopicYN="N">Percutaneous drainage</Keyword><Keyword MajorTopicYN="N">Severe pancreatitis</Keyword><Keyword MajorTopicYN="N">Step-up approach</Keyword><Keyword MajorTopicYN="N">Video-assisted retroperitoneal debridement</Keyword><Keyword MajorTopicYN="N">Walled-off pancreatic necrosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28331537</ArticleId><ArticleId IdType="pmc">PMC5356234</ArticleId><ArticleId IdType="doi">10.1186/s13017-017-0126-5</ArticleId><ArticleId IdType="pii">126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trikudanathan G, Attam R, Arain MA, Mallery S, Freeman ML. Endoscopic interventions for necrotizing pancreatitis. Am J Gastroenterol. 2014;109(7):969&#x2013;81. doi: 10.1038/ajg.2014.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.130</ArticleId><ArticleId IdType="pubmed">24957157</ArticleId></ArticleIdList></Reference><Reference><Citation>Werge M, Novovic S, Schmidt PN, Gluud LL. Infection increases mortality in necrotizing pancreatitis: a systematic review and meta-analysis. Pancreatology. 2016; Jul 9 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">27449605</ArticleId></ArticleIdList></Reference><Reference><Citation>Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;2(8656):201&#x2013;5. doi: 10.1016/S0140-6736(89)90381-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)90381-4</ArticleId><ArticleId IdType="pubmed">2568529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagniez PL, Panis Y. Surgical treatment of acute pancreatitis. Rev Prat. 1996;46(6):704&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8731737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackert T, B&#xfc;chler MW. Decision making in necrotizing pancreatitis. Dig Dis. 2016;34(5):517&#x2013;24. doi: 10.1159/000445232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445232</ArticleId><ArticleId IdType="pubmed">27332898</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JA, Carter CR. Minimally invasive necrosectomy techniques in severe acute pancreatitis: role of percutaneous necrosectomy and video-assisted retroperitoneal debridement. Gastroenterol Res Pract. 2015;2015:693040. doi: 10.1155/2015/693040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/693040</ArticleId><ArticleId IdType="pmc">PMC4637484</ArticleId><ArticleId IdType="pubmed">26587018</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, van Ramshorst B, Nieuwenhuijs VB, Timmer R, Lam&#xe9;ris JS, Kruyt PM, Manusama ER, van der Harst E, van der Schelling GP, Karsten T, Hesselink EJ, van Laarhoven CJ, Rosman C, Bosscha K, de Wit RJ, Houdijk AP, van Leeuwen MS, Buskens E, Gooszen HG, Dutch Pancreatitis Study Group A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362(16):1491&#x2013;502. doi: 10.1056/NEJMoa0908821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908821</ArticleId><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagenholz PJ, Thabet A, Mueller PR, Forcione DG. Combined endoscopic trangastric drainage and video assisted retroperitoneal pancreatic debridement&#x2014;the best of both worlds for extensive pancreatic necrosis with enteric fistulae. Pancreatology 2016; Jun 19 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pubmed">27344627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary A, Sachdev A, Negi S. Biliary complications of pancreatic necrosis. Int J Pancreatol. 2001;29(3):129&#x2013;31. doi: 10.1385/IJGC:29:3:129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IJGC:29:3:129</ArticleId><ArticleId IdType="pubmed">12067215</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CR, McKay CJ, Imrie CW. Percutaneous necrosectomy and sinus tract endoscopy in the management of infected pancreatic necrosis: an initial experience. Ann Surg. 2000;232(2):175&#x2013;80. doi: 10.1097/00000658-200008000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-200008000-00004</ArticleId><ArticleId IdType="pmc">PMC1421126</ArticleId><ArticleId IdType="pubmed">10903593</ArticleId></ArticleIdList></Reference><Reference><Citation>van Santvoort HC, Besselink MG, Bollen TL, Buskens E, van Ramshorst B, Gooszen HG, Dutch Acute Pancreatitis Study Group Case-matched comparison of the retroperitoneal approach with laparotomy for necrotizing pancreatitis. World J Surg. 2007;31(8):1635&#x2013;42. doi: 10.1007/s00268-007-9083-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-007-9083-6</ArticleId><ArticleId IdType="pubmed">17572838</ArticleId></ArticleIdList></Reference><Reference><Citation>Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, Sutton R, Neoptolemos JP. Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. Ann Surg. 2010;251(5):787&#x2013;93. doi: 10.1097/SLA.0b013e3181d96c53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181d96c53</ArticleId><ArticleId IdType="pubmed">20395850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y, Jiao H, Tan X, Sun L, Zhang W. Laparotomy versus retroperitoneal laparoscopy in debridement and drainage of retroperitoneal infected necrosis in severe acute pancreatitis. Surg Endosc. 2013;27(11):4217&#x2013;23. doi: 10.1007/s00464-013-3026-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-013-3026-0</ArticleId><ArticleId IdType="pubmed">23793802</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lu H, Hu W, Zhang Z. A retroperitoneal approach for infected pancreatic necrosis. Scand J Gastroenterol. 2013;48(2):225&#x2013;30. doi: 10.3109/00365521.2012.749514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2012.749514</ArticleId><ArticleId IdType="pubmed">23215866</ArticleId></ArticleIdList></Reference><Reference><Citation>Senthil Kumar P, Ravichandran P, Jeswanth S. Case matched comparison study of the necrosectomy by retroperitoneal approach with transperitoneal approach for necrotizing pancreatitis in patients with CT severity score of 7 and above. Int J Surg. 2012;10(10):587&#x2013;92. doi: 10.1016/j.ijsu.2012.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2012.09.027</ArticleId><ArticleId IdType="pubmed">23022952</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupelis G, Fokin V, Zeiza K, Plaudis H, Suhova A, Drozdova N, Boka V. Focused open necrosectomy in necrotizing pancreatitis. HPB (Oxford) 2013;15(7):535&#x2013;40. doi: 10.1111/hpb.12004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hpb.12004</ArticleId><ArticleId IdType="pmc">PMC3692024</ArticleId><ArticleId IdType="pubmed">23458703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluck M, Ross A, Irani S, Lin O, Gan SI, Fotoohi M, Hauptmann E, Crane R, Siegal J, Robinson DH, Traverso LW, Kozarek RA. Dual modality drainage for symptomatic walled-off pancreatic necrosis reduces length of hospitalization, radiological procedures, and number of endoscopies compared to standard percutaneous drainage. J Gastrointest Surg. 2012;16(2):248&#x2013;56. doi: 10.1007/s11605-011-1759-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-011-1759-4</ArticleId><ArticleId IdType="pubmed">22125167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner TB, Chahal P, Papachristou GI, Vege SS, Petersen BT, Gostout CJ, Topazian MD, Takahashi N, Sarr MG, Baron TH. A comparison of direct endoscopic necrosectomy with transmural endoscopic drainage for the treatment of walled-off pancreatic necrosis. Gastrointest Endosc. 2009;69(6):1085&#x2013;94. doi: 10.1016/j.gie.2008.06.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2008.06.061</ArticleId><ArticleId IdType="pubmed">19243764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Conwell DL, Thompson CC. Direct endoscopic necrosectomy versus step-up approach for walled-off pancreatic necrosis: comparison of clinical outcome and health care utilization. Pancreas. 2014;43(8):1334&#x2013;9. doi: 10.1097/MPA.0000000000000213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0000000000000213</ArticleId><ArticleId IdType="pmc">PMC5019103</ArticleId><ArticleId IdType="pubmed">25083997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan V, Charachon A, Lescot T, Chafa&#xef; N, Le Baleur Y, Delchier JC, Paye F. Endoscopic transgastric versus surgical necrosectomy in infected pancreatic necrosis. Clin Res Hepatol Gastroenterol. 2014;38(6):770&#x2013;6. doi: 10.1016/j.clinre.2014.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2014.06.016</ArticleId><ArticleId IdType="pubmed">25153999</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo S, Walklin R, Wewelwala C, Berry R, Devonshire D, Croagh D. Interventional management of necrotizing pancreatitis: an Australian experience. ANZ J Surg. 2015 Nov 24 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">26603130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker OJ, van Santvoort HC, van Brunschot S, Geskus RB, Besselink MG, Bollen TL, van Eijck CH, Fockens P, Hazebroek EJ, Nijmeijer RM, Poley JW, van Ramshorst B, Vleggaar FP, Boermeester MA, Gooszen HG, Weusten BL, Timmer R, Dutch Pancreatitis Study Group Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012;307(10):1053&#x2013;61. doi: 10.1001/jama.2012.276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.276</ArticleId><ArticleId IdType="pubmed">22416101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bausch D, Wellner U, Kahl S, Kuesters S, Richter-Schrag HJ, Utzolino S, Hopt UT, Keck T, Fischer A. Minimally invasive operations for acute necrotizing pancreatitis: comparison of minimally invasive retroperitoneal necrosectomy with ETN. Surgery. 2012;152(3):S128&#x2013;34. doi: 10.1016/j.surg.2012.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.05.021</ArticleId><ArticleId IdType="pubmed">22770962</ArticleId></ArticleIdList></Reference><Reference><Citation>van Brunschot S, van Grinsven J, Voermans RP, Bakker OJ, Besselink MG, Boermeester MA, Bollen TL, Bosscha K, Bouwense SA, Bruno MJ, Cappendijk VC, Consten EC, Dejong CH, Dijkgraaf MG, van Eijck CH, Erkelens GW, van Goor H, Hadithi M, Haveman JW, Hofker SH, Jansen JJ, Lam&#xe9;ris JS, van Lienden KP, Manusama ER, Meijssen MA, Mulder CJ, Nieuwenhuis VB, Poley JW, de Ridder RJ, Rosman C, Schaapherder AF, Scheepers JJ, Schoon EJ, Seerden T, Spanier BW, Straathof JW, Timmer R, Venneman NG, Vleggaar FP, Witteman BJ, Gooszen HG, van Santvoort HC, Fockens P, Dutch Pancreatitis Study Group Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial [ISRCTN09186711] BMC Gastroenterol. 2013;13:161. doi: 10.1186/1471-230X-13-161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-161</ArticleId><ArticleId IdType="pmc">PMC4222267</ArticleId><ArticleId IdType="pubmed">24274589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasch S, Phillip V, Reichel S, Rau B, Zapf C, Rosendahl J, Halm U, Zach&#xe4;us M, M&#xfc;ller M, Kleger A, Neesse A, Hampe J, Ellrichmann M, R&#xfc;ckert F, Strau&#xdf; P, Arlt A, Ellenrieder V, Gress TM, Hartwig W, Klar E, M&#xf6;ssner J, Post S, Schmid RM, Seufferlein T, Siech M, Werner J, Will U, Alg&#xfc;l H. Open surgical versus minimal invasive necrosectomy of the pancreas&#x2014;a retrospective multicenter analysis of the German Pancreatitis Study Group. PLoS One. 2016;11(9):e0163651. doi: 10.1371/journal.pone.0163651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0163651</ArticleId><ArticleId IdType="pmc">PMC5036800</ArticleId><ArticleId IdType="pubmed">27668746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang JY, Holt BA, Hawes RH, Hasan MK, Arnoletti JP, Christein JD, Wilcox CM, Varadarajulu S. Outcomes after implementing a tailored endoscopic step-up approach to walled-off necrosis in acute pancreatitis. Br J Surg. 2014;101(13):1729&#x2013;38. doi: 10.1002/bjs.9664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9664</ArticleId><ArticleId IdType="pubmed">25333872</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MG. The &#x2018;step-up approach&#x201d; to infected necrotizing pancreatitis: delay, drain, debride. Dig Liver Dis. 2011;43(6):421&#x2013;2. doi: 10.1016/j.dld.2011.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2011.04.001</ArticleId><ArticleId IdType="pubmed">21531639</ArticleId></ArticleIdList></Reference><Reference><Citation>Doctor N, Philip S, Gandhi V, Hussain M, Barreto SG. Analysis of the delayed approach to the management of infected pancreatic necrosis. World J Gastroenterol. 2011;17(3):366&#x2013;71. doi: 10.3748/wjg.v17.i3.366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i3.366</ArticleId><ArticleId IdType="pmc">PMC3022298</ArticleId><ArticleId IdType="pubmed">21253397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulagendra Perumal S, Pillai SA, Perumal S, Sathyanesan J, Palaniappan R. Outcome of video-assisted translumbar retroperitoneal necrosectomy and closed lavage for severe necrotizing pancreatitis. ANZ J Surg. 2014;84(4):270&#x2013;4. doi: 10.1111/ans.12107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12107</ArticleId><ArticleId IdType="pubmed">23458245</ArticleId></ArticleIdList></Reference><Reference><Citation>Besselink MG, van Santvoort HC, Nieuwenhuijs VB, Boermeester MA, Bollen TL, Buskens E, Dejong CH, van Eijck CH, van Goor H, Hofker SS, Lameris JS, van Leeuwen MS, Ploeg RJ, van Ramshorst B, Schaapherder AF, Cuesta MA, Consten EC, Gouma DJ, van der Harst E, Hesselink EJ, Houdijk LP, Karsten TM, van Laarhoven CJ, Pierie JP, Rosman C, Bilgen EJ, Timmer R, van der Tweel I, de Wit RJ, Witteman BJ, Gooszen HG, Dutch Acute Pancreatitis Study Group Minimally invasive &#x2018;step-up approach&#x2019; versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868] BMC Surg. 2006;6:6. doi: 10.1186/1471-2482-6-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2482-6-6</ArticleId><ArticleId IdType="pmc">PMC1508161</ArticleId><ArticleId IdType="pubmed">16606471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakorafas GH, Sarr MG, Farnell MB. Pancreaticobiliary fistula: an unusual complication of necrotising pancreatitis. Eur J Surg. 2001;167(2):151&#x2013;3. doi: 10.1080/110241501750070655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/110241501750070655</ArticleId><ArticleId IdType="pubmed">11266259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar R, Singh I, Brar P, Prasad A, Doley RP, Wig JD. Pancreatic choledochal fistula complicating acute pancreatitis. Am J Case Rep. 2012;13:47&#x2013;50. doi: 10.12659/AJCR.882600.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.882600</ArticleId><ArticleId IdType="pmc">PMC3616175</ArticleId><ArticleId IdType="pubmed">23569486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhall JC, Marwah S, Singh RB, Marwah N, Mathur SK. Extra-hepatic biliary-ductal necrosis in acute pancreatitis: a rare complication. Pediatr Surg Int. 2000;16(3):209&#x2013;10. doi: 10.1007/s003830050725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003830050725</ArticleId><ArticleId IdType="pubmed">10786984</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BM, Traverso LW, Freeny PC. Intrapancreatic communication of bile and pancreatic ducts secondary to pancreatic necrosis. Arch Surg. 1988;123(8):1000&#x2013;3. doi: 10.1001/archsurg.1988.01400320086017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1988.01400320086017</ArticleId><ArticleId IdType="pubmed">3395229</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Ali JA, Chung H, Munk PL, Byrne MF. Pancreatic pseudocyst with fistula to the common bile duct resolved by combined biliary and pancreatic stenting&#x2014;a case report and literature review. Can J Gastroenterol. 2009;23(8):557&#x2013;9. doi: 10.1155/2009/597208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2009/597208</ArticleId><ArticleId IdType="pmc">PMC2732178</ArticleId><ArticleId IdType="pubmed">19668801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki AP, McKay CJ, Carter CR. Infected pancreatic necrosis: minimizing the cut. ANZ J Surg. 2010;80(1-2):58&#x2013;70. doi: 10.1111/j.1445-2197.2009.05177.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2009.05177.x</ArticleId><ArticleId IdType="pubmed">20575882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33970455</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Resuscitative Effect of Centhaquine (Lyfaquin<sup>&#xae;</sup>) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.</ArticleTitle><Pagination><StartPage>3223</StartPage><EndPage>3265</EndPage><MedlinePgn>3223-3265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-021-01760-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Centhaquine (Lyfaquin<sup>&#xae;</sup>) showed significant efficacy as a resuscitative agent in animal models of haemorrhagic shock. Its safety and tolerability were confirmed in healthy human volunteers. In this study, our primary objective was to determine the safety, and the secondary objective was to assess the efficacy of centhaquine in patients with hypovolemic shock.</AbstractText><AbstractText Label="METHODS">A prospective, multicentre, randomized phase II study was conducted in male and female patients aged 18-70 years with hypovolemic shock having systolic BP&#x2009;&#x2264;&#x2009;90 mmHg. Patients were randomized in a 1:1 ratio to either the control or centhaquine group. The control group received 100 ml of normal saline infusion over 1 h, while the centhaquine group received 0.01 mg/kg of centhaquine in 100 ml normal saline infusion over 1 h. Every patient received standard of care (SOC) and was followed for 28 days.</AbstractText><AbstractText Label="RESULTS">Fifty patients were included, and 45 completed the trial: 22 in the control group and 23 in the centhaquine group. The demographics of patients in both groups were comparable. No adverse event related to centhaquine was recorded in the 28-day observation period. The baseline, Injury Scoring System score, haemoglobin, and haematocrit were similar in both groups. However, 91% of the patients in the centhaquine group needed major surgery, whereas only 68% in the control group (p&#x2009;=&#x2009;0.0526). Twenty-eight-day all-cause mortality was 0/23 in the centhaquine group and 2/22 in the control group. The percent time in ICU and ventilator support was less in the centhaquine group than in the control group. The total amount of vasopressors needed in the first 48 h of resuscitation was lower in the centhaquine group than in the control group (3.12&#x2009;&#xb1;&#x2009;2.18 vs. 9.39&#x2009;&#xb1;&#x2009;4.28 mg). An increase in systolic and diastolic BP from baseline through 48 h was more marked in the centhaquine group than in the control group. Compared with the control group, blood lactate level was lower by 1.75&#x2009;&#xb1;&#x2009;1.07 mmol/l in the centhaquine group on day 3 of resuscitation. Improvements in base deficit, multiple organ dysfunction syndrome (MODS) score and adult respiratory distress syndrome (ARDS) were greater in the centhaquine group than in the control group.</AbstractText><AbstractText Label="CONCLUSION">When added to SOC, centhaquine is a well-tolerated and effective resuscitative agent. It improves the clinical outcome of patients with hypovolemic shock.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov identifier number: NCT04056065.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gulati</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7420-4554</Identifier><AffiliationInfo><Affiliation>Professor Emeritus, Midwestern University, Downers Grove, IL, USA. agulati@midestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dayanand Medical College &amp; Hospital, Civil Lines, Tagore Nagar, Ludhiana, Punjab, 141001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Nilesh Radheshyam</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, New Era Hospital, Near Jalaram Mandir, Queta Colony, Telephone Exchange Chowk, Central Avenue Road, Nagpur, Maharashtra, 440008, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahate</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Seven Star Hospital Jagnade Square, KDK College Road, Nagpur, Maharashtra, 440009, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhuri</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Institute of Post-Graduate Medical Education and Research and SSKM Hospital, 244 A.J.C. Bose Road, Kolkata, West Bengal, 700020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Soumen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Institute of Post-Graduate Medical Education and Research and SSKM Hospital, 244 A.J.C. Bose Road, Kolkata, West Bengal, 700020, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhibar</LastName><ForeName>Deba Prasad</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nehru Hospital, Post-Graduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh, 160 012, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhu</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belgaum, Karnataka, 590010, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haveri</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belgaum, Karnataka, 590010, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, ORIANA Hospital, Plot No.: 6, 7, 8 Ravindrapuri Bhelpur, Varanasi, Uttar Pradesh, 221005, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavhale</LastName><ForeName>Manish S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Pharmazz India Private Limited, Greater Noida, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04056065</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>57961-90-7</RegistryNumber><NameOfSubstance UI="C045913">centhaquine</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="Y">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Centhaquine</Keyword><Keyword MajorTopicYN="N">Haemorrhage</Keyword><Keyword MajorTopicYN="N">Hypovolemia</Keyword><Keyword MajorTopicYN="N">Resuscitative agent</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>10</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33970455</ArticleId><ArticleId IdType="pmc">PMC8189997</ArticleId><ArticleId IdType="doi">10.1007/s12325-021-01760-4</ArticleId><ArticleId IdType="pii">10.1007/s12325-021-01760-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taghavi S, Jones G, Duchesne J, McGrew P, Guidry C, Schroll R, et al. Impact of trauma center volume on major vascular injury: an analysis of the National Trauma Data Bank (NTDB) Am J Surg. 2020;220(3):787&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">32061398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378(4):370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Haut ER, Kalish BT, Cotton BA, Efron DT, Haider AH, Stevens KA, et al. Prehospital intravenous fluid administration is associated with higher mortality in trauma patients: a National Trauma Data Bank analysis. Ann Surg. 2011;253(2):371&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">21178760</ArticleId></ArticleIdList></Reference><Reference><Citation>Haut ER, Kalish BT, Cotton BA, Efron DT, Haider AH, Stevens KA, et al. Reply to letter: "Prehospital intravenous fluid administration is associated with higher mortality in trauma patients". Ann Surg. 2014;259(2):e20&#x2013;e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24398926</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nederpelt CJ, El Hechi MW, Kongkaewpaisan N, Kokoroskos N, Mendoza AE, Saillant NN, et al. Fresh frozen plasma-to-packed red blood cell ratio and mortality in traumatic hemorrhage: nationwide analysis of 4,427 patients. J Am Coll Surg. 2020;230(6):893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31759164</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2011;11(5):003709.</Citation><ArticleIdList><ArticleId IdType="pubmed">21563137</ArticleId></ArticleIdList></Reference><Reference><Citation>Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med. 2000;28(4):947&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe T, Saitoh D, Hagiwara S, Oshima K. Use of vasopressor increases the risk of mortality in traumatic hemorrhagic shock: a nationwide cohort study in Japan. Crit Care Med. 2018;46(12):e1145&#x2013;e1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">30199392</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoff PE, Nikolian VC, Higgins G, Chtraklin K, Eidy H, Ghandour MH, et al. Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg. 2018;84(4):642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29251706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster F, Burban M, de la Bourdonnaye M, Fizanne L, Douay O, Loufrani L, et al. Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care. 2010;14(5):R165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219260</ArticleId><ArticleId IdType="pubmed">20836847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wepler M, Merz T, Wachter U, Vogt J, Calzia E, Scheuerle A, et al. The mitochondria-targeted H2S-Donor AP39 in a murine model of combined hemorrhagic shock and blunt chest trauma. Shock. 2019;52(2):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">29927788</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakral S, Wolf A, Beilman GJ, Suryanarayanan R. Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock. Int J Pharm. 2018;537(1&#x2013;2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">29274369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP. Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats. Shock. 1998;9(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am J Physiol. 1997;273(2 Pt 2):H827&#x2013;H836.</Citation><ArticleIdList><ArticleId IdType="pubmed">9277500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282(19):1857&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg MD, Philbin NB, Gao W, Group DCTHSS, European HI. Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010;68(5):1158&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20145575</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-Hellmann A, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX) Crit Care Med. 2015;43(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25083980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A. Vascular endothelium and hypovolemic shock. Curr Vasc Pharmacol. 2016;14(2):187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">26638794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Lavhale M, Giri R, Andurkar S, Xanthos T. Centhaquine citrate. Alpha2B-Adrenoceptor ligand, resuscitative agent for hypovolemic shock. Drugs Fut. 2020;45(3):153&#x2013;163.</Citation></Reference><Reference><Citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012;178(1):415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22487389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013;31(9):1315&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23871440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontouli Z, Staikou C, Iacovidou N, Mamais I, Kouskouni E, Papalois A, et al. Resuscitation with centhaquin and 6% hydroxyethyl starch 130/04 improves survival in a swine model of hemorrhagic shock: a randomized experimental study. Eur J Trauma Emerg Surg. 2019;45(6):1077&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">30006694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013;179(1):115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22964270</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapanagiotou P, Xanthos T, Gulati A, Chalkias A, Papalois A, Kontouli Z, et al. Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res. 2016;200(1):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216751</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds PS, Michael MJ, Cochran ED, Wegelin JA, Spiess BD. Prehospital use of plasma in traumatic hemorrhage (The PUPTH Trial): study protocol for a randomised controlled trial. Trials. 2015;30(16):321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518517</ArticleId><ArticleId IdType="pubmed">26220293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, Schreiber MA, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253(3):431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232054</ArticleId><ArticleId IdType="pubmed">21178763</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">2281232</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan NR, Eckert M, Martin MJ. Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg. 2014;149(9):904&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K. Aggressive fluid management in the critically ill: Pro. J Intensive Care. 2019;7:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6359791</ArticleId><ArticleId IdType="pubmed">30761213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi L, Costantini TW, Coimbra R. Hypovolemic shock resuscitation. Surg Clin N Am. 2012;92(6):1403&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Voshtina E, Zhang Z, Murphy A. Alpha adrenergic receptors mediate resuscitative effect of centhaquin in hemorrhaged rats. Crit Care Med. 2012;40(12):U162&#x2013;U163.</Citation></Reference><Reference><Citation>Berlin DA, Bakker J. Understanding venous return. Intensive Care Med. 2014;40(10):1564&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JR, Maas JJ, Pinsky MR. Bedside assessment of mean systemic filling pressure. Curr Opin Crit Care. 2010;16(3):231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">20168223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias A, Koutsovasilis A, Laou E, Papalois A, Xanthos T. Measurement of mean systemic filling pressure after severe hemorrhagic shock in swine anesthetized with propofol-based total intravenous anesthesia: implications for vasopressor-free resuscitation. Acute Crit Care. 2020;35(2):93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280792</ArticleId><ArticleId IdType="pubmed">32506874</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Baker K. Venous return and clinical hemodynamics: how the body works during acute hemorrhage. Adv Physiol Educ. 2015;39(4):267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">26628647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen AJ, leNoble PJ, Steegers EA, van Rhenen DJ, Duvekot JJ. Relationship between haemoglobin change and estimated blood loss after delivery. BJOG. 2007;114(5):657.</Citation><ArticleIdList><ArticleId IdType="pubmed">17439585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yefet E, Yossef A, Suleiman A, Hatokay A, Nachum Z. Hemoglobin drop following postpartum hemorrhage. Sci Rep. 2020;10(1):21546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725815</ArticleId><ArticleId IdType="pubmed">33298992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439620</ArticleId><ArticleId IdType="pubmed">30772908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla LS, Ostermann M, Forni L, Tidmarsh GF. Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care. 2019;23(1):124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469125</ArticleId><ArticleId IdType="pubmed">30992045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazmuri RJ, Whitehouse K, Whittinghill K, Baetiong A, Shah K, Radhakrishnan J. Early and sustained vasopressin infusion augments the hemodynamic efficacy of restrictive fluid resuscitation and improves survival in a liver laceration model of hemorrhagic shock. J Trauma Acute Care Surg. 2017;82(2):317&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">27906869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">27483065</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lat I, Coopersmith CM, De Backer D, Research Committee of the Surviving Sepsis C, Members of the Surviving Sepsis Campaign Research Committee contributing to this article are as f, Co-chair AGA, et al. The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Crit Care Med. 2021;49(4):623&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963440</ArticleId><ArticleId IdType="pubmed">33731607</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Arshad K. Centhaquin decreases the requirement of norepinephrine, maintains blood pressure and improves survival following resuscitation of hemorrhaged rats. Crit Care Med. 2011;39(12):114.</Citation></Reference><Reference><Citation>Odom SR, Howell MD, Silva GS, Nielsen VM, Gupta A, Shapiro NI, et al. Lactate clearance as a predictor of mortality in trauma patients. J Trauma Acute Care Surg. 2013;74(4):999&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511137</ArticleId></ArticleIdList></Reference><Reference><Citation>Doran CM, Doran CA, Woolley T, Carter A, Male K, Midwinter MJ, et al. Targeted resuscitation improves coagulation and outcome. J Trauma Acute Care Surg. 2012;72(4):835&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">22491594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37658072</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and mortality in patients hospitalized for burns in Catalonia, Spain.</ArticleTitle><Pagination><StartPage>14364</StartPage><MedlinePgn>14364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-40198-2</ELocationID><Abstract><AbstractText>Burn injuries are one of the leading causes of morbidity worldwide. Although the overall incidence of burns and burn-related mortality is declining, these factors have not been analysed in our population for 25 years. The aim of this study has been to determine whether the epidemiological profile of patients hospitalized for burns has changed over the past 25 years. We performed a retrospective cohort study of patients hospitalised between 1 January 2011 and 31 December 2018 with a primary diagnosis of burns. The incidence of burns in our setting was 3.68/10<sup>5</sup> population. Most patients admitted for burns were men (61%), aged between 35 and 45 years (16.8%), followed by children aged between 0 and 4 years (12.4%). Scalding was the most prevalent mechanism of injury, and the region most frequently affected was the hands. The mean burned total body surface (TBSA) area was 8.3%, and the proportion of severely burned patients was 9.7%. Obesity was the most prevalent comorbidity (39.5%). The median length of stay was 1.8 days. The most frequent in-hospital complications were sepsis (16.6%), acute kidney injury (7.9%), and cardiovascular complications (5.9%). Risk factors for mortality were advanced age, high abbreviated burn severity index score, smoke inhalation, existing cardiovascular disease full-thickness burn, and high percentage of burned TBSA. Overall mortality was 4.3%. Multi-organ failure was the most frequent cause of death, with an incidence of 49.5%. The population has aged over the 25 years since the previous study, and the number of comorbidities has increased. The incidence and severity of burns, and the percentage of burned TBSA have all decreased, with scalding being the most prevalent mechanism of injury. The clinical presentation and evolution of burns differs between children and adults. Risk factors for mortality were advanced age, smoke inhalation, existing cardiovascular disease, full-thickness burn, and high percentage of burned TBSA.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abarca</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain. labarcavilchez@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilabert</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Alicante, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Us&#xfa;a</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barret</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Plastic Surgery Department and Burn Centre, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colomina</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Clinic, Hospital Universitari de Bellvitge, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012906">Smoke</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012906" MajorTopicYN="N">Smoke</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>PG honorary for lectures from Baxter Spain. MJC fees for lectures from Baxter Spain.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37658072</ArticleId><ArticleId IdType="pmc">PMC10474035</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-40198-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-40198-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. Epidemiology of injuries from fire, heat and hot substances: Global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study. Inj. Prev. 2019 doi: 10.1136/injuryprev-2019-043299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/injuryprev-2019-043299</ArticleId><ArticleId IdType="pmc">PMC7571358</ArticleId><ArticleId IdType="pubmed">31857422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolle C, Cambiaso-Daniel J, Forbes AA, Wurzer P, Hundeshagen G, Branski LK, et al. Recent trends in burn epidemiology worldwide: A systematic review. Burns. 2017 doi: 10.1016/j.burns.2016.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5616188</ArticleId><ArticleId IdType="pubmed">27600982</ArticleId></ArticleIdList></Reference><Reference><Citation>Haikonen K, Lillsunde PM, Vuola J. Inpatient costs of fire-related injuries in Finland. Burns. 2014 doi: 10.1016/j.burns.2014.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.016</ArticleId><ArticleId IdType="pubmed">24742781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger E, Kowal S, Pinar Bilir S, Han E, Foster K. Relationship between patient characteristics and number of procedures as well as length of stay for patients surviving severe burn injuries: Analysis of the american burn association national burn repository. J. Burn Care Res. 2020;41:1037&#x2013;1044. doi: 10.1093/jbcr/iraa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa040</ArticleId><ArticleId IdType="pmc">PMC7510847</ArticleId><ArticleId IdType="pubmed">32221517</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilabert P, Us&#xfa;a G, Mart&#xed;n N, Abarca L, Barret JP, Colomina MJ. Fluid resuscitation management in patients with burns: Update. Br. J. Anaesth. 2016;117:284&#x2013;296. doi: 10.1093/bja/aew266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew266</ArticleId><ArticleId IdType="pubmed">27543523</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;kerlund E, Huss FRM, Sj&#xf6;berg F. Burns in Sweden: An analysis of 24 538 cases during the period 1987&#x2013;2004. Burns. 2007;33:31&#x2013;36. doi: 10.1016/j.burns.2006.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.002</ArticleId><ArticleId IdType="pubmed">17223486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dokter J, Vloemans AF, Beerthuizen GIJM, van der Vlies CH, Boxma H, Breederveld R, et al. Epidemiology and trends in severe burns in the Netherlands. Burns. 2014;40:1406&#x2013;1414. doi: 10.1016/j.burns.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.003</ArticleId><ArticleId IdType="pubmed">24703338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederer IA, Hacker S, Sternat N, Waldmann A, Salameh O, Radtke C, et al. Gender has no influence on mortality after burn injuries: A 20-year single center study with 839 patients. Burns. 2019;45:205&#x2013;212. doi: 10.1016/j.burns.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.08.012</ArticleId><ArticleId IdType="pubmed">30170774</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Moser EM, Pfortmueller CA, Olariu R, Lehmann B, Exadaktylos AK. Aetiology of adult burns treated from 2000 to 2012 in a Swiss University Hospital. Burns. 2016;42:919&#x2013;925. doi: 10.1016/j.burns.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.005</ArticleId><ArticleId IdType="pubmed">27061890</ArticleId></ArticleIdList></Reference><Reference><Citation>Onarheim H, Jensen SA, Rosenberg BE, Guttormsen AB. The epidemiology of patients with burn injuries admitted to Norwegian hospitals in 2007. Burns. 2009 doi: 10.1016/j.burns.2009.06.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.06.191</ArticleId><ArticleId IdType="pubmed">19748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieptu V, Moscalu R, Mihai A, Moscalu M, Pieptu D, Azoic&#x103;i D. Epidemiology of hospitalized burns in Romania: A 10-year study on 92,333 patients. Burns. 2021 doi: 10.1016/j.burns.2021.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.05.020</ArticleId><ArticleId IdType="pubmed">34670711</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiefer JL, Perbix W, Grigutsch D, Zinser M, Demir E, Fuchs PC, et al. Etiology, incidence and gender-specific patterns of severe burns in a German Burn Center&#x2014;Insights of 25 years. Burns. 2016;42:687&#x2013;696. doi: 10.1016/j.burns.2015.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.10.031</ArticleId><ArticleId IdType="pubmed">26708237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanttula K, Haikonen K, Vuola J. Hospitalized burns in Finland: 36 305 cases from 1980&#x2013;2010. Burns. 2018;44:651&#x2013;657. doi: 10.1016/j.burns.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.09.001</ArticleId><ArticleId IdType="pubmed">29029854</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodorou P, Xu W, Weinand C, Perbix W, Maegele M, Lefering R, et al. Incidence and treatment of burns: A twenty-year experience from a single center in Germany. Burns. 2013;39:49&#x2013;54. doi: 10.1016/j.burns.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.05.003</ArticleId><ArticleId IdType="pubmed">22673118</ArticleId></ArticleIdList></Reference><Reference><Citation>van Yperen DT, van Lieshout EMM, Verhofstad MHJ, van der Vlies CH. Epidemiology of burn patients admitted in the Netherlands: A nationwide registry study investigating incidence rates and hospital admission from 2014 to 2018. Eur. J. Trauma Emerg. Surg. 2021 doi: 10.1007/s00068-021-01777-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-021-01777-y</ArticleId><ArticleId IdType="pmc">PMC9192419</ArticleId><ArticleId IdType="pubmed">34463772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayakova Y, Vajarov I, Stanev A, Nenkova N, Hristov H. Epidemiological analysis of burn patients in East Bulgaria. Burns. 2014;40:683&#x2013;688. doi: 10.1016/j.burns.2013.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2013.08.016</ArticleId><ArticleId IdType="pubmed">24035580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. Crit. Care Med. 2015;43:808&#x2013;815. doi: 10.1097/CCM.0000000000000790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000790</ArticleId><ArticleId IdType="pmc">PMC4359665</ArticleId><ArticleId IdType="pubmed">25559438</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Stanford L, Moore D, Cairns B, Charles A. The measured effect magnitude of co-morbidities on burn injury mortality. Burns. 2016;42:1433&#x2013;1438. doi: 10.1016/j.burns.2016.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.007</ArticleId><ArticleId IdType="pmc">PMC5278667</ArticleId><ArticleId IdType="pubmed">27593340</ArticleId></ArticleIdList></Reference><Reference><Citation>Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, et al. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral centre in southeast Asia: A 3-year retrospective review. Burns. 2017;43:436&#x2013;444. doi: 10.1016/j.burns.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.06.004</ArticleId><ArticleId IdType="pubmed">28159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA. Systematic review and meta-analysis of complications and outcomes of obese patients with burns. Burns. 2016;42:1634&#x2013;1643. doi: 10.1016/j.burns.2016.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.008</ArticleId><ArticleId IdType="pubmed">27268011</ArticleId></ArticleIdList></Reference><Reference><Citation>Barret JP, Gomez P, Solano I, Gonzalez-Dorrego M, Crisol FJ. Epidemiology and mortality of adult burns in Catalonia 1999. Burns. 1999;25:325&#x2013;329. doi: 10.1016/S0305-4179(98)00190-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(98)00190-9</ArticleId><ArticleId IdType="pubmed">10431980</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RL, Palmieri TL, Horton JW, et al. American burn association consensus conference to define sepsis and infection in burns. J. Burn Care Res. 2007;28:776&#x2013;790. doi: 10.1097/BCR.0b013e3181599bc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Putra ON, Saputro ID, Diana D. Rifle criteria for acute kidney injury in burn patients: prevalence and risk factors. Ann. Burns Fire Disasters. 2021;34:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534303</ArticleId><ArticleId IdType="pubmed">34744541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartotto R, Li Z, Hanna S, Spano S, Wood D, Chung K, et al. The Acute Respiratory Distress Syndrome (ARDS) in mechanically ventilated burn patients: An analysis of risk factors, clinical features, and outcomes using the Berlin ARDS definition. Burns. 2016;42:1423&#x2013;1432. doi: 10.1016/j.burns.2016.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.01.031</ArticleId><ArticleId IdType="pubmed">27520712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JLA, Bastida JL, Mart&#xed;nez MM, Moreno JMM, Chamorro JJ. Socio-economic cost and health-related quality of life of burn victims in Spain. Burns. 2008;34:975&#x2013;981. doi: 10.1016/j.burns.2007.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2007.12.011</ArticleId><ArticleId IdType="pubmed">18472221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa D, Ceniceros A, Galeiras R, P&#xe9;rtega-D&#xed;az S, Guti&#xe9;rrez-Urb&#xf3;n JM, Rodr&#xed;guez-Mayo M, et al. Microbiology in burns patients with blood stream infections: Trends over time and during the course of hospitalization. Infect. Dis. 2018;50:289&#x2013;296. doi: 10.1080/23744235.2017.1397738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2017.1397738</ArticleId><ArticleId IdType="pubmed">29105600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: A systematic review of the incidence, etiology, morbidity, and mortality. Crit. Care. 2010 doi: 10.1186/cc9300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9300</ArticleId><ArticleId IdType="pmc">PMC3219295</ArticleId><ArticleId IdType="pubmed">20958968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Wood F, Semmens J, Edgar DW, Spilsbury K, Hendrie D, et al. A study of burn hospitalizations for children younger than 5 years of age: 1983&#x2013;2008. Pediatrics. 2011 doi: 10.1542/peds.2010-3136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-3136</ArticleId><ArticleId IdType="pubmed">21382945</ArticleId></ArticleIdList></Reference><Reference><Citation>Harats M, Peleg K, Givon A, Kornhaber R, Goder M, Jaeger M, et al. Burns in Israel, comparative study: Demographic, etiologic and clinical trends 1997&#x2013;2003 versus 2004&#x2013;2010. Burns. 2016;42:500&#x2013;507. doi: 10.1016/j.burns.2015.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.05.023</ArticleId><ArticleId IdType="pubmed">26410362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop MJ, Wijnen BFM, Nieuwenhuis MK, Dokter J, Middelkoop E, Polinder S, et al. Economic burden of burn injuries in the Netherlands: A 3 months follow-up study. Injury. 2016;47:203&#x2013;210. doi: 10.1016/j.injury.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2015.09.009</ArticleId><ArticleId IdType="pubmed">26454627</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios Garc&#xed;a P, Pacheco Compa&#xf1;a FJ, Rodr&#xed;guez P&#xe9;rez E, Bugallo Sanz JI, Fern&#xe1;ndez-Quinto A, Avellaneda-Oviedo EM. Trends in burn injuries in Galicia (Spain): An epidemiological study. Int. Wound J. 2020;17:1717&#x2013;1724. doi: 10.1111/iwj.13456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iwj.13456</ArticleId><ArticleId IdType="pmc">PMC7949175</ArticleId><ArticleId IdType="pubmed">32662941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Rea S, Boyd JH, Randall SM, Wood FM. Mortality after burn injury in children: A 33-year population-based study. Pediatrics. 2015;135:e903&#x2013;e910. doi: 10.1542/peds.2014-3140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-3140</ArticleId><ArticleId IdType="pubmed">25802351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavlin D, Chegireddy V, Boukovalas S, Nia AM, Branski LK, Friedman JD, et al. Multi-institutional analysis of independent predictors for burn mortality in the United States. Burns Trauma. 2018 doi: 10.1186/s41038-018-0127-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0127-y</ArticleId><ArticleId IdType="pmc">PMC6103989</ArticleId><ArticleId IdType="pubmed">30151396</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang S, Tan J, Zhou J, Wu J, Luo G. Epidemiology of pediatric burns in southwest China from 2011 to 2015. Burns. 2017;43:1306&#x2013;1317. doi: 10.1016/j.burns.2017.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.03.004</ArticleId><ArticleId IdType="pubmed">28372828</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M, Wheeler KK, Shi J, Thakkar RK, Fabia RB, Groner JI, et al. Epidemiology and trend of US pediatric burn hospitalizations, 2003&#x2013;2016. Burns. 2021;47:551&#x2013;559. doi: 10.1016/j.burns.2020.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.05.021</ArticleId><ArticleId IdType="pubmed">33781634</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EL, Maguire S, Holl&#xe9;n LI, Nuttall D, Rea D, Kemp AM. Agents, mechanisms and clinical features of non-scald burns in children: A prospective UK study. Burns. 2017;43:1218&#x2013;1226. doi: 10.1016/j.burns.2017.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.036</ArticleId><ArticleId IdType="pubmed">28645715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu L, Javed MU, Eales M, Hemington-Gorse S. A 10 year epidemiological study of paediatric burns at the Welsh Centre for burns and plastic surgery. Burns. 2017;43:632&#x2013;637. doi: 10.1016/j.burns.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.004</ArticleId><ArticleId IdType="pubmed">27816410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li D, Shen C, Chai J, Zhu H, Lin Y, et al. Epidemiology of burns in pediatric patients of Beijing City. BMC Pediatr. 2016 doi: 10.1186/s12887-016-0686-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-016-0686-7</ArticleId><ArticleId IdType="pmc">PMC5070381</ArticleId><ArticleId IdType="pubmed">27756257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendrick D, Young B, Mason-Jones AJ, Ilyas N, Achana FA, Cooper NJ, et al. Home safety education and provision of safety equipment for injury prevention. Cochrane Database of Syst. Rev. 2012 doi: 10.1002/14651858.CD005014.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005014.pub3</ArticleId><ArticleId IdType="pmc">PMC9758703</ArticleId><ArticleId IdType="pubmed">22972081</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopenko M, Reed AJM, Chicco M, Issa F. Preventable burns from domestic tap water. Eur. Burn J. 2022;3:362&#x2013;369. doi: 10.3390/ebj3020031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ebj3020031</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JV, Viana J, Oliveira A, Ramalho A, Sousa-Teixeira J, Duke J, et al. Hospitalisations with burns in children younger than five years in Portugal, 2011&#x2013;2015. Burns. 2019;45:1223&#x2013;1230. doi: 10.1016/j.burns.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.01.003</ArticleId><ArticleId IdType="pubmed">30686698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SH, Chen YC, Chen TJ, Ma H. Epidemiology of burns in Taiwan: A nationwide report including inpatients and outpatients. Burns. 2014;40:1397&#x2013;1405. doi: 10.1016/j.burns.2014.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.01.014</ArticleId><ArticleId IdType="pubmed">24518304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Shen C, Zhao D, Li D, Shang Y. Epidemiology of hospitalized burn patients in China: A systematic review. Burns Open. 2018;2:8&#x2013;16. doi: 10.1016/j.burnso.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burnso.2017.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Ma B, Zeng D, Fang X, Li H, Xiao S, et al. Burns in a major burns center in East China from 2005 to 2014: Incidence and outcome. Burns. 2017;43:1586&#x2013;1595. doi: 10.1016/j.burns.2017.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.033</ArticleId><ArticleId IdType="pubmed">28855061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasiak J, Spinks A, Ashby K, Clapperton A, Cleland H, Gabbe B. The epidemiology of burn injuries in an Australian setting, 2000&#x2013;2006. Burns. 2009;35:1124&#x2013;1132. doi: 10.1016/j.burns.2009.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.04.016</ArticleId><ArticleId IdType="pubmed">19482430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, He X, Xian J, Liao J, Chen X, Luo Y, et al. Development of a framework for managing severe burns through a 17-year retrospective analysis of burn epidemiology and outcomes. Sci. Rep. 2021 doi: 10.1038/s41598-021-88507-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88507-x</ArticleId><ArticleId IdType="pmc">PMC8087787</ArticleId><ArticleId IdType="pubmed">33931691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland H, Fernando DT, Gabbe BJ. Trends in Victorian burn injuries 2008&#x2013;2017. Burns. 2021 doi: 10.1016/j.burns.2021.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.06.007</ArticleId><ArticleId IdType="pubmed">34304930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura A, Tsurumi A, Que YA, Almpani M, Zheng H, Tompkins RG, et al. Associations between clinical characteristics and the development of multiple organ failure after severe burns in adult patients. Burns. 2019;45:1775&#x2013;1782. doi: 10.1016/j.burns.2019.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.02.014</ArticleId><ArticleId IdType="pubmed">31690472</ArticleId></ArticleIdList></Reference><Reference><Citation>Brink C, Isaacs Q, Scriba MF, Nathire MEH, Rode H, Martinez R. Infant burns: A single institution retrospective review. Burns. 2019;45:1518&#x2013;1527. doi: 10.1016/j.burns.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.11.005</ArticleId><ArticleId IdType="pubmed">30638666</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Reid T, Williams F, Cairns B, Charles A. Burn mortality in patients with preexisting cardiovascular disease. Burns. 2017;43:949&#x2013;955. doi: 10.1016/j.burns.2017.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.026</ArticleId><ArticleId IdType="pmc">PMC5912170</ArticleId><ArticleId IdType="pubmed">28189352</ArticleId></ArticleIdList></Reference><Reference><Citation>Observatorio Espa&#xf1;ol de las Drogas y las Adicciones. Informe 2021. Alcohol, tabaco y drogas ilegales en Espa&#xf1;a. Madrid: Ministerio de Sanidad. Delegaci&#xf3;n del Gobierno para el Plan Nacional sobre Drogas. 243 p. (2021).</Citation></Reference><Reference><Citation>Eiroa-Orosa FJ, Giannoni-Pastor A, Fidel-Kinori SG, Arg&#xfc;ello JM. Substance use and misuse in burn patients: Testing the classical hypotheses of the interaction between post-traumatic symptomatology and substance use. J. Addict. Dis. 2016;35:194&#x2013;204. doi: 10.1080/10550887.2015.1127717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10550887.2015.1127717</ArticleId><ArticleId IdType="pubmed">26670348</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Rodrigo C, Herv&#xe1;s B&#xe1;rbara G, Gianzo Citores M, Aranceta-Bartrina J. Prevalence of obesity and associated cardiovascular risk factors in the Spanish population: The ENPE study. Revista Espa&#xf1;ola de Cardiolog&#xed;a (English Edition) 2021 doi: 10.1016/j.rec.2020.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2020.12.020</ArticleId><ArticleId IdType="pubmed">33773941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018 Key findings Data from the National Health and Nutrition Examination Survey. 2017.</Citation></Reference><Reference><Citation>Mild Obesity Is Protective After Severe Burn Injury n.d.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963145</ArticleId><ArticleId IdType="pubmed">23877367</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A, Neyra JA, Madni T, Imran J, Phelan H, Arnoldo B, et al. Acute kidney injury after burn. Burns. 2017;43:898&#x2013;908. doi: 10.1016/j.burns.2017.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.023</ArticleId><ArticleId IdType="pubmed">28412129</ArticleId></ArticleIdList></Reference><Reference><Citation>Demsey D, Mordhorst A, Griesdale DEG, Papp A. Improved outcomes of renal injury following burn trauma. Burns. 2019;45:1024&#x2013;1030. doi: 10.1016/j.burns.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.001</ArticleId><ArticleId IdType="pubmed">31054958</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkestad T, Brurberg KG, Nordhuus KM, Tveiten CK, Guttormsen AB, Os I, et al. Acute kidney injury in burn patients admitted to the intensive care unit: A systematic review and meta-analysis. Crit. Care. 2020 doi: 10.1186/s13054-019-2710-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2710-4</ArticleId><ArticleId IdType="pmc">PMC6941386</ArticleId><ArticleId IdType="pubmed">31898523</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski W, Kawecki M, Surowiecka-Pastewka A, Klimm W, Szamotulska K, Niemczyk S. Early and late acute kidney injury in severely burned patients. Med. Sci. Monit. 2016;22:3755&#x2013;3763. doi: 10.12659/MSM.895875.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.895875</ArticleId><ArticleId IdType="pmc">PMC5070618</ArticleId><ArticleId IdType="pubmed">27746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Xiao Y, Wang C, Hong X, Sun Y, Ma B, et al. Risk factors for acute kidney injury in patients with burn injury: A meta-analysis and systematic review. J. Burn Care Res. 2017;38:271&#x2013;282. doi: 10.1097/BCR.0000000000000438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000438</ArticleId><ArticleId IdType="pubmed">27617407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo G, Yang SY, Chuang SS, Fan PC, Chang CH, Hsiao YC, et al. Using acute kidney injury severity and scoring systems to predict outcome in patients with burn injury. J. Formos. Med. Assoc. 2016;115:1046&#x2013;1052. doi: 10.1016/j.jfma.2016.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2016.10.012</ArticleId><ArticleId IdType="pubmed">27923537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Chor Lip H, Tan JH, Thomas M, Imran FH, Azmah Tuan Mat TN. Survival analysis and mortality predictors of hospitalized severe burn victims in a Malaysian burns intensive care unit. Burns Trauma. 2019 doi: 10.1186/s41038-018-0140-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0140-1</ArticleId><ArticleId IdType="pmc">PMC6348617</ArticleId><ArticleId IdType="pubmed">30705904</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Randall SM, Wood FM, Boyd JH, Fear MW. Burns and long-term infectious disease morbidity: A population-based study. Burns. 2017;43:273&#x2013;281. doi: 10.1016/j.burns.2016.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.020</ArticleId><ArticleId IdType="pubmed">28041752</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz-Pasteur A, Hussein K, Finkelstein R, Ullmann Y, Egozi D. Blood stream infections (BSI) in severe burn patients-early and late BSI: A 9-year study. Burns. 2013 doi: 10.1016/j.burns.2012.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.09.015</ArticleId><ArticleId IdType="pubmed">23159703</ArticleId></ArticleIdList></Reference><Reference><Citation>Costescu Strachinaru DI, Gallez JL, Fran&#xe7;ois PM, Baekelandt D, Paridaens MS, Pirnay JP, et al. Epidemiology and etiology of blood stream infections in a Belgian burn wound center. Acta Clin. Belg. Int. J. Clin. Lab. Med. 2021 doi: 10.1080/17843286.2021.1872309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2021.1872309</ArticleId><ArticleId IdType="pubmed">33432871</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand&#xe3;o C. The role of comorbidities on outcome prediction in acute burn patients place des comorbidit&#xe9;s dans les crit&#xe8;res pronostiques des patients br&#xfb;l&#xe9;s. Ann. Burns Fire Disasters. 2021;34:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717902</ArticleId><ArticleId IdType="pubmed">35035325</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster NA, Zingg M, Haile SR, K&#xfc;nzi W, Giovanoli P, Guggenheim M. 30 years later&#x2014;Does the ABSI need revision? Burns. 2011;37:958&#x2013;963. doi: 10.1016/j.burns.2011.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2011.03.009</ArticleId><ArticleId IdType="pubmed">21493008</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomar M, &#xc1;lvarez-Lerma F, Riera A, D&#xed;az MT, Torres F, Agra Y, et al. Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: The Spanish experience. Crit. Care Med. 2013;41:2364&#x2013;2372. doi: 10.1097/CCM.0b013e3182923622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182923622</ArticleId><ArticleId IdType="pubmed">23939352</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SF, Bessey PQ, Schurr MJ, Browning SM, Jeng JC, Caruso DM, et al. National burn repository 2005: A ten-year review. J. Burn Care Res. 2006;27:411&#x2013;436. doi: 10.1097/01.BCR.0000226260.17523.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000226260.17523.22</ArticleId><ArticleId IdType="pubmed">16819343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallinen O, Maisniemi K, B&#xf6;hling T, Tukiainen E, Koljonen V. Multiple organ failure as a cause of death in patients with severe burns. J. Burn Care Res. 2012;33:206&#x2013;211. doi: 10.1097/BCR.0b013e3182331e73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3182331e73</ArticleId><ArticleId IdType="pubmed">21979843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel KJ, Omeis T, Papp A. Demographics and clinical outcomes of adult burn patients admitted to a single provincial burn centre: A 40-year review. Burns. 2020;46:1958&#x2013;1967. doi: 10.1016/j.burns.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.06.020</ArticleId><ArticleId IdType="pubmed">32660831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Nie C, Zhang H, Zeng X, Yu H, Wei Z, et al. Epidemiological characteristics and factors affecting length of hospital stay for children and adults with burns in Zunyi, China: A retrospective study. PeerJ. 2018 doi: 10.7717/peerj.5740.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.5740</ArticleId><ArticleId IdType="pmc">PMC6173946</ArticleId><ArticleId IdType="pubmed">30310756</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom L, Klingberg A, Laflamme L, Wallis L, Hasselberg M. Gender differences in burns: A study from emergency centres in the Western Cape, South Africa. Burns. 2016;42:1600&#x2013;1608. doi: 10.1016/j.burns.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.003</ArticleId><ArticleId IdType="pubmed">27262931</ArticleId></ArticleIdList></Reference><Reference><Citation>Toppi J, Cleland H, Gabbe B. Severe burns in Australian and New Zealand adults: Epidemiology and burn centre care. Burns. 2019;45:1456&#x2013;1461. doi: 10.1016/j.burns.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.006</ArticleId><ArticleId IdType="pubmed">31053412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta K, Arega H, Smith NL, Li K, Gause E, Lee J, et al. Gender-based disparities in burn injuries, care and outcomes: A World Health Organization (WHO) Global Burn Registry cohort study. Am. J. Surg. 2021 doi: 10.1016/j.amjsurg.2021.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2021.07.041</ArticleId><ArticleId IdType="pmc">PMC8688305</ArticleId><ArticleId IdType="pubmed">34330521</ArticleId></ArticleIdList></Reference><Reference><Citation>Obed D, Schroeter A, Gruber L, Bucher F, Salim M, Bingoel AS, et al. Epidemiology and outcome analysis of 1359 intensive care burn patients: A 13-year retrospective study in a major burn center in Germany. Burns. 2022 doi: 10.1016/j.burns.2022.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2022.08.022</ArticleId><ArticleId IdType="pubmed">36195487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurczyk K, Chrisco LP, di Corpo M, Nizamani R, Sljivic S, Calvert CT, et al. Work-Related burn injuries in a tertiary care burn center, 2013 to 2018. J. Burn Care Res. 2020;41:1009&#x2013;1014. doi: 10.1093/jbcr/iraa105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa105</ArticleId><ArticleId IdType="pubmed">32598473</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes JA, Cleland H, Tracy LM, Darton A, Wood FM, Perrett T, et al. Epidemiology of work-related burn injuries presenting to burn centres in Australia and New Zealand. Burns. 2019;45:484&#x2013;493. doi: 10.1016/j.burns.2018.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.011</ArticleId><ArticleId IdType="pubmed">30274814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40414542</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>435</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Sex differences on the effect of hemoadsorption during cardiac surgery - A REMOVE trial post-hoc analysis.</ArticleTitle><Pagination><StartPage>133371</StartPage><MedlinePgn>133371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2025.133371</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(25)00414-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Multi-organ failure is one of the leading causes of mortality after cardiac surgery for infective endocarditis (IE). Although the randomized evidence does not support the use of hemoadsorption during cardiac surgery for IE, observational studies suggest a beneficial effect in selected patient groups. We aimed to analyze the effect of sex differences on hemoadsorption in patients with IE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a post-hoc analysis of the REMOVE-trial that randomized patients with IE who underwent cardiac surgery with hemoadsorption using CytoSorb&#xae; or control. The primary endpoint was variation of Sequential Organ Failure Assessment (&#x394;SOFA), defined as the difference between the mean total postoperative and baseline SOFA score within 24&#xa0;h of surgery. The secondary endpoints were 30-day mortality and other usual postoperative outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 282 patients, 73 (25.9&#xa0;%) were females (38 and 35 patients in the hemoadsorption and control group, respectively) and 209 (74.1&#xa0;%) were males (98 and 111 patients in the hemoadsorption and control group, respectively). The overall &#x394;SOFA did not differ significantly between the intervention groups in both female and male subgroups (MD: -2.13, 95&#xa0;% CI -5.20 to 0.93, p&#xa0;=&#xa0;0.163; MD: 0.31, 95&#xa0;% CI -0.91 to 1.53, p&#xa0;=&#xa0;0.612, respectively) and neither did 30-day mortality (HR&#xa0;=&#xa0;0.54, 95&#xa0;% CI 0.23 to 1.24, p&#xa0;=&#xa0;0.132; HR 1.17, 95&#xa0;% CI 0.61 to 2.21, p&#xa0;=&#xa0;0.634, respectively).&#xa0;No significant differences were observed concerning the other secondary outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The intraoperative use of hemoadsorption was not associated with reduction of postoperative organ dysfunction, 30-day mortality, or other major clinical endpoints in both sex subgroups.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caldonazo</LastName><ForeName>Tulio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany. Electronic address: tulio.caldonazo@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazzini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirov</LastName><ForeName>Hristo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Infection Control, Friedrich-Schiller-University Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Clinical Studies, UniversityHospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saha</LastName><ForeName>Shekhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boburg</LastName><ForeName>Rodrigo Sandoval</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freiburger</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rustenbach</LastName><ForeName>Christian J&#xf6;rg</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Eberhard Karls University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin-Cuartas</LastName><ForeName>Mateo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Helios-University-Wuppertal, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>REMOVE Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="Y">Endocarditis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart surgery</Keyword><Keyword MajorTopicYN="N">Hemoadsorption</Keyword><Keyword MajorTopicYN="N">Infective endocarditis</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>7</Day><Hour>16</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40414542</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2025.133371</ArticleId><ArticleId IdType="pii">S0167-5273(25)00414-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34061314</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin<sup>&#xae;</sup>) as a Resuscitative Agent in Hypovolemic Shock Patients.</ArticleTitle><Pagination><StartPage>1079</StartPage><EndPage>1100</EndPage><MedlinePgn>1079-1100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-021-01547-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Centhaquine (Lyfaquin<sup>&#xae;</sup>) showed significant safety and efficacy in preclinical and clinical phase I and II studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, multicentric, randomized phase III study was conducted in patients with hypovolemic shock, systolic blood pressure (SBP) &#x2264; 90 mmHg, and blood lactate levels &#x2265; 2 mmol/L. Patients were randomized in a 2:1 ratio to the centhaquine group (n = 71) or the control (saline) group (n = 34). Every patient received standard of care (SOC) and was followed for 28 days. The study drug (normal saline or centhaquine 0.01 mg/kg) was administered in 100 mL of normal saline infusion over 1 h. The primary objectives were to determine changes (mean through 48 h) in SBP, diastolic blood pressure (DBP), blood lactate levels, and base deficit. The secondary objectives included the amount of fluids, blood products, and vasopressors administered in the first 48 h, duration of hospital stay, time in intensive care units, time on ventilator support, change in acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), and the proportion of patients with 28-day all-cause mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The demographics of patients and baseline vitals in both groups were comparable. The cause of hypovolemic shock was trauma in 29.4 and 47.1% of control group and centhaquine group patients, respectively, and gastroenteritis in 44.1 and 29.4%, respectively. Shock index (SI) and quick sequential organ failure assessment at baseline were similar in the two groups. An equal amount of fluids and blood products were administered in both groups during the first 48 h of resuscitation. A lesser amount of vasopressors was needed in the first 48 h of resuscitation in the centhaquine group. An increase in SBP from baseline was consistently higher up to 48 h (12.9% increase in area under the curve from 0 to 48 h [AUC<sub>0-48</sub>]) in the centhaquine group than in the control group. A significant increase in pulse pressure (48.1% increase in AUC<sub>0-48</sub>) in the centhaquine group compared with the control group suggests improved stroke volume due to centhaquine. The SI was significantly lower in the centhaquine group from 1 h (p&#x2009;=&#x2009;0.032) to 4 h (p&#x2009;=&#x2009;0.049) of resuscitation. Resuscitation with centhaquine resulted in a significantly greater number of patients with improved blood lactate (control 46.9%; centhaquine 69.3%; p&#x2009;=&#x2009;0.03) and the base deficit (control 43.7%; centhaquine 69.8%; p&#x2009;=&#x2009;0.01) than in the control group. ARDS and MODS improved with centhaquine, and an 8.8% absolute reduction in 28-day all-cause mortality was observed in the centhaquine group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Centhaquine is an efficacious resuscitative agent for treating hypovolemic shock. The efficacy of centhaquine in distributive shock is being explored.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinical Trials Registry, India; ctri.icmr.org.in, CTRI/2019/01/017196; clinicaltrials.gov, NCT04045327.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gulati</LastName><ForeName>Anil</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7420-4554</Identifier><AffiliationInfo><Affiliation>Pharmazz, Inc., 50 West 75th Street, Suite 105, Willowbrook, IL, 60527, USA. anil.gulati@pharmazz.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhuri</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Postgraduate Medical Education and Research/SSKM Hospital, Kolkata, West Bengal, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chiranjeev Medical Centre, Jhansi, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>S K Noushad</ForeName><Initials>SKN</Initials><AffiliationInfo><Affiliation>ACSR Government Medical College and Hospital, Nellore, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidhu</LastName><ForeName>Gursaran Kaur</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Sidhu Hospital Pvt. Ltd., Ludhiana, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Parvez David</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Christian Medical College and Hospital, Ludhiana, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahate</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Seven Star Hospital, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bothra</LastName><ForeName>Aditya R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Rahate Surgical Hospital and ICU, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Gyan P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>King George's Medical University, Lucknow, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maheshwari</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jawahar Lal Nehru Medical College and Attached Hospital, Ajmer, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeswani</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Criticare Hospital and Research Institute, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haveri</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>KLE's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Apurva</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GSVM Medical College, Uttar Pradesh, Kanpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Nilesh Radheshyam</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>New Era Hospital, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04045327</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058647">Adrenergic alpha-2 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>57961-90-7</RegistryNumber><NameOfSubstance UI="C045913">centhaquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2021 May 09:2020.07.30.20068114. doi: 10.1101/2020.07.30.20068114.</RefSource><PMID Version="1">33173916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D058647" MajorTopicYN="N">Adrenergic alpha-2 Receptor Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Anil Gulati has issued and pending patents and is an employee and stockholder of Pharmazz, Inc. Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S.K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R. Bothra, Gyan P. Singh, Sanjiv Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, and Nilesh Radheshyam Agrawal have no conflicts of interest that are directly relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34061314</ArticleId><ArticleId IdType="pmc">PMC8167383</ArticleId><ArticleId IdType="doi">10.1007/s40265-021-01547-5</ArticleId><ArticleId IdType="pii">10.1007/s40265-021-01547-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gulati A. Vascular endothelium and hypovolemic shock. Curr Vasc Pharmacol. 2016;14(2):187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">26638794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi L, Costantini TW, Coimbra R. Hypovolemic shock resuscitation. Surg Clin North Am. 2012;92(6):1403&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23153876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JW. Hemorrhagic shock. N Engl J Med. 2018;378(4):370&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman EJ, Richmond TS, Wiebe DJ, Jacoby SF, Holena DN. Patient experiences of trauma resuscitation. JAMA Surg. 2017;152(9):843&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710455</ArticleId><ArticleId IdType="pubmed">28564706</ArticleId></ArticleIdList></Reference><Reference><Citation>Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;2:CD000567.</Citation><ArticleIdList><ArticleId IdType="pubmed">23450531</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoff PE, Nikolian VC, Higgins G, Chtraklin K, Eidy H, Ghandour MH, et al. Valproic acid induces prosurvival transcriptomic changes in swine subjected to traumatic injury and hemorrhagic shock. J Trauma Acute Care Surg. 2018;84(4):642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">29251706</ArticleId></ArticleIdList></Reference><Reference><Citation>Causey MW, Miller S, Hoffer Z, Hempel J, Stallings JD, Jin G, et al. Beneficial effects of histone deacetylase inhibition with severe hemorrhage and ischemia-reperfusion injury. J Surg Res. 2013;184(1):533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">23683808</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Dai X, Zhu D, Xu X, Gao C, Wu C. An exogenous hydrogen sulphide donor, NaHS, inhibits the apoptosis signaling pathway to exert cardio-protective effects in a rat hemorrhagic shock model. Int J Clin Exp Pathol. 2015;8(6):6245&#x2013;6254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525835</ArticleId><ArticleId IdType="pubmed">26261501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster F, Burban M, de la Bourdonnaye M, Fizanne L, Douay O, Loufrani L, et al. Effects of hydrogen sulfide on hemodynamics, inflammatory response and oxidative stress during resuscitated hemorrhagic shock in rats. Crit Care. 2010;14(5):R165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219260</ArticleId><ArticleId IdType="pubmed">20836847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wepler M, Merz T, Wachter U, Vogt J, Calzia E, Scheuerle A, et al. The mitochondria-targeted H2S-donor AP39 in a Murine model of combined hemorrhagic shock and blunt chest trauma. Shock. 2019;52(2):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">29927788</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakral S, Wolf A, Beilman GJ, Suryanarayanan R. Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock. Int J Pharm. 2018;537(1&#x2013;2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">29274369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Lusczek ER, Beilman GJ. Hibernation-based approaches in the treatment of hemorrhagic shock. Shock. 2018;50(1):14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29283978</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP. Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats. Shock. 1998;9(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am J Physiol. 1997;273(2 Pt 2):H827&#x2013;H836.</Citation><ArticleIdList><ArticleId IdType="pubmed">9277500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282(19):1857&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan EP, Koenigsberg MD, Philbin NB, Gao W, Group DCTHSS, European HI Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010;68(5):1158&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">20145575</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AT, Lucas A, Muller CR, Munoz C, Bolden-Rush C, Palmer AF, et al. Resuscitation from hemorrhagic shock with fresh and stored blood and polymerized hemoglobin. Shock. 2020;54:464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442586</ArticleId><ArticleId IdType="pubmed">32097242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould SA, Moore EE, Moore FA, Haenel JB, Burch JM, Sehgal H, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma. 1997;43(2):325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291380</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Privalle CT, Singer M, Lorente JA, Boehm E, Meier-Hellmann A, et al. Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX) Crit Care Med. 2015;43(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25083980</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy JH, Goodnough LT, Greilich PE, Parr GV, Stewart RW, Gratz I, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002;124(1):35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091806</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EE, Moore FA, Fabian TC, Bernard AC, Fulda GJ, Hoyt DB, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg. 2009;208(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">19228496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Barve A, Sen AP. Pharmacology of hemoglobin therapeutics. J Lab Clin Med. 1999;133(2):112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989762</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn DR, Kocian R. Artificial O2 carriers: status in 2005. Curr Pharm Des. 2005;11(31):4099&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16378514</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nederpelt CJ, El Hechi MW, Kongkaewpaisan N, Kokoroskos N, Mendoza AE, Saillant NN, et al. Fresh frozen plasma-to-packed red blood cell ratio and mortality in traumatic hemorrhage: nationwide analysis of 4,427 patients. J Am Coll Surg. 2020;230(6):893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">31759164</ArticleId></ArticleIdList></Reference><Reference><Citation>Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2011;5:CD003709.</Citation><ArticleIdList><ArticleId IdType="pubmed">21563137</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Hesayen A, Parker JD. The effects of dobutamine on renal sympathetic activity in human heart failure. J Cardiovasc Pharmacol. 2008;51(5):434&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398381</ArticleId></ArticleIdList></Reference><Reference><Citation>Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med. 2000;28(4):947&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Abe T, Saitoh D, Hagiwara S, Oshima K. Use of vasopressor increases the risk of mortality in traumatic hemorrhagic shock: a nationwide cohort study in Japan. Crit Care Med. 2018;46(12):e1145&#x2013;e1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">30199392</ArticleId></ArticleIdList></Reference><Reference><Citation>Santry HP, Alam HB. Fluid resuscitation: past, present, and the future. Shock. 2010;33(3):229&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988844</ArticleId><ArticleId IdType="pubmed">20160609</ArticleId></ArticleIdList></Reference><Reference><Citation>Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273(5276):803&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">8670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszkat M, Kurnik D, Solus J, Sofowora GG, Xie HG, Jiang L, et al. Variation in the alpha2B-adrenergic receptor gene (ADRA2B) and its relationship to vascular response in vivo. Pharmacogenet Genom. 2005;15(6):407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">15900214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. Resuscitative effect of centhaquine (Lyfaquin&#xae;) in hypovolemic shock patients: a randomized, multicentric, controlled trial. Adv Ther. 2021 doi: 10.1007/s12325-021-01760-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01760-4</ArticleId><ArticleId IdType="pmc">PMC8189997</ArticleId><ArticleId IdType="pubmed">33970455</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias A, Koutsovasilis A, Laou E, Papalois A, Xanthos T. Measurement of mean systemic filling pressure after severe hemorrhagic shock in swine anesthetized with propofol-based total intravenous anesthesia: implications for vasopressor-free resuscitation. Acute Crit Care. 2020;35(2):93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280792</ArticleId><ArticleId IdType="pubmed">32506874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Hussain G, Srimal RC. Effect of repeated administration of centhaquin, a centrally acting hypotensive drug, on adrenergic, cholinergic (Muscarinic), dopaminergic, and serotonergic receptors in brain-regions of rat. Drug Dev Res. 1991;23(4):307&#x2013;323.</Citation></Reference><Reference><Citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012;178(1):415&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22487389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013;31(9):1315&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">23871440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013;179(1):115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22964270</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapanagiotou P, Xanthos T, Gulati A, Chalkias A, Papalois A, Kontouli Z, et al. Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res. 2016;200(1):227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontouli Z, Staikou C, Iacovidou N, Mamais I, Kouskouni E, Papalois A, et al. Resuscitation with centhaquin and 6% hydroxyethyl starch 130/0.4 improves survival in a swine model of hemorrhagic shock: a randomized experimental study. Eur J Trauma Emerg Surg. 2019;45(6):1077&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">30006694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Lavhale M, Giri R, Andurkar S, Xanthos T. Centhaquine citrate. Alpha2B-adrenoceptor ligand, resuscitative agent for hypovolemic shock. Drugs Fut. 2020;45(3):153&#x2013;163.</Citation></Reference><Reference><Citation>Birkhahn RH, Gaeta TJ, Terry D, Bove JJ, Tloczkowski J. Shock index in diagnosing early acute hypovolemia. Am J Emerg Med. 2005;23(3):323&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15915406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rady MY, Rivers EP, Martin GB, Smithline H, Appelton T, Nowak RM. Continuous central venous oximetry and shock index in the emergency department: use in the evaluation of clinical shock. Am J Emerg Med. 1992;10(6):538&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">1388378</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YS, Chiu IM, Tsai MT, Lin CF, Lin CF. Delta shock index during emergency department stay is associated with in hospital mortality in critically ill patients. Front Med (Lausanne). 2021;8:648375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100221</ArticleId><ArticleId IdType="pubmed">33968957</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulden R, Hoyle MC, Monis J, Railton D, Riley V, Martin P, et al. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. Emerg Med J. 2018;35(6):345&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">29467173</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315(8):762&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138(3):720&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">3202424</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan NR, Eckert M, Martin MJ. Changing patterns of in-hospital deaths following implementation of damage control resuscitation practices in US forward military treatment facilities. JAMA Surg. 2014;149(9):904&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">25029432</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob M, Sahu S, Singh YP, Mehta Y, Yang KY, Kuo SW, et al. A prospective observational study of rational fluid therapy in Asian intensive care units: another puzzle piece in fluid therapy. Indian J Crit Care Med. 2020;24(11):1028&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751049</ArticleId><ArticleId IdType="pubmed">33384507</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin DA, Bakker J. Understanding venous return. Intensive Care Med. 2014;40(10):1564&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JR, Maas JJ, Pinsky MR. Bedside assessment of mean systemic filling pressure. Curr Opin Crit Care. 2010;16(3):231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">20168223</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Baker K. Venous return and clinical hemodynamics: how the body works during acute hemorrhage. Adv Physiol Educ. 2015;39(4):267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">26628647</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Menyar A, Goyal P, Tilley E, Latifi R. The clinical utility of shock index to predict the need for blood transfusion and outcomes in trauma. J Surg Res. 2018;227:52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">29804862</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenco CW, Lammers DT, Morte KR, Bingham JR, Martin MJ, Eckert MJ. Shock index as a predictor of massive transfusion and emergent surgery on the modern battlefield. J Surg Res. 2020;16(256):112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">32683051</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyette F, Suffoletto B, Castillo JL, Quintero J, Callaway C, Puyana JC. Prehospital serum lactate as a predictor of outcomes in trauma patients: a retrospective observational study. J Trauma. 2011;70(4):782&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">21610386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Peng M, Liao C, Hu X, Wang A, Li X. Relative efficacy and safety of early lactate clearance-guided therapy resuscitation in patients with sepsis: a meta-analysis. Medicine (Baltimore) 2019;98(8):e14453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408023</ArticleId><ArticleId IdType="pubmed">30813144</ArticleId></ArticleIdList></Reference><Reference><Citation>Giancarelli A, Birrer KL, Alban RF, Hobbs BP, Liu-DeRyke X. Hypocalcemia in trauma patients receiving massive transfusion. J Surg Res. 2016;202(1):182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditzel RM, Jr, Anderson JL, Eisenhart WJ, Rankin CJ, DeFeo DR, Oak S, et al. A review of transfusion- and trauma-induced hypocalcemia: Is it time to change the lethal triad to the lethal diamond? J Trauma Acute Care Surg. 2020;88(3):434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">31876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which multicenter randomized controlled trials in critical care medicine have shown reduced mortality? A systematic review. Crit Care Med. 2019;47(12):1680&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">31567349</ArticleId></ArticleIdList></Reference><Reference><Citation>Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, et al. Intensive care in India: the Indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20(4):216&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859158</ArticleId><ArticleId IdType="pubmed">27186054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandarkar P, Patil P, Soni KD, O'Reilly GM, Dharap S, Mathew J, et al. An analysis of 30-day in-hospital trauma mortality in four urban university hospitals using the Australia india trauma registry. World J Surg. 2021;45(2):380&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773616</ArticleId><ArticleId IdType="pubmed">33084947</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Wu M, Lu X, Zhong Y, Kang X, Song Y, et al. Is restrictive fluid resuscitation beneficial not only for hemorrhagic shock but also for septic shock?: a meta-analysis. Medicine (Baltimore) 2021;100(12):e25143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282070</ArticleId><ArticleId IdType="pubmed">33761680</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignon P, Laterre PF, Daix T, Francois B. New agents in development for sepsis: any reason for hope? Drugs. 2020;80(17):1751&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7502152</ArticleId><ArticleId IdType="pubmed">32951149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkwarf KJ, Cotton BA. Resuscitation for hypovolemic shock. Surg Clin N Am. 2017;97(6):1307&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">29132511</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SK, Choupoo NS, Ray S. Reducing vasopressor exposure in patients with vasodilatory hypotension. JAMA. 2020;324(9):897&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">32870290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26274754</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1478-7083</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of the Royal College of Surgeons of England</Title><ISOAbbreviation>Ann R Coll Surg Engl</ISOAbbreviation></Journal><ArticleTitle>A prospective cohort study of risk prediction in simultaneous pancreas and kidney transplantation.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>450</EndPage><MedlinePgn>445-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1308/rcsann.2015.0001</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Current risk prediction scoring systems in pancreas transplantation are limited to organ factors and are specific to predicting graft outcome. They do not consider recipient factors or inform regarding recipient morbidity. The aim of this study was to assess the utility of commonly used general surgical risk prediction models (P-POSSUM [Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity], MODS [multiple organ dysfunction score], Charlson co-morbidity index, revised cardiac risk index, ASA [American Society of Anesthesiologists] grade and Waterlow score), and to correlate them with total length of hospital stay (LOS) and critical care unit (CCU) LOS, important surrogate markers of patient outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All risk prediction scores were calculated prospectively for all simultaneous pancreas and kidney (SPK) transplant recipients from November 2011 to October 2013, and correlated with outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 57 SPK transplant recipients were analysed. The mean age was 42.0 years (standard deviation [SD]: 7.60 years), 27 (52%) were male and the mean body mass index was 25.43kg/m(2) (SD: 3.11kg/m(2)). The mean pancreas and kidney cold ischaemic times were 703 minutes (SD: 182 minutes) and 850 minutes (SD: 192 minutes) respectively. The median total LOS and mean CCU LOS was 17 days (range: 8-79 days) and 7 days (SD: 4.04 days) respectively. When correlated with risk prediction scores, Waterlow score was the only significant predictor of total LOS and CCU LOS (p&lt;0.001 [Spearman's correlation] and p=0.001 [Pearson's correlation] respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preoperative risk prediction plays an important part in planning perioperative care. To date, no validated risk prediction scoring system exists for SPK transplantation. This prospective study indicates that Waterlow score identifies high risk individuals and has value in the prediction of outcome following SPK transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khambalia</LastName><ForeName>H A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinuddin</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Summers</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pararajasingam</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhanda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forgacs</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dellen</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Central Manchester University Hospitals NHS Foundation Trust , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann R Coll Surg Engl</MedlineTA><NlmUniqueID>7506860</NlmUniqueID><ISSNLinking>0035-8843</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016035" MajorTopicYN="N">Pancreas Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Outcome assessment</Keyword><Keyword MajorTopicYN="N">Pancreas transplantation</Keyword><Keyword MajorTopicYN="N">Risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26274754</ArticleId><ArticleId IdType="pmc">PMC5126239</ArticleId><ArticleId IdType="doi">10.1308/rcsann.2015.0001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Charlson ME, Sax FL, MacKenzie CR, et al. . Morbidity during hospitalization: can we predict it?&#xa0;J Chronic Dis&#xa0;1987; : 705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">3110198</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg&#xa0;1991; : 355&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">2021856</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, et al. . Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med&#xa0;1995; : 1,638&#x2013;1,652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis&#xa0;1987; : 373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Marcantonio ER, Mangione CM, et al. . Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation&#xa0;1999; : 1,043&#x2013;1,049.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak PH, Campbell RC, Irwin MG. The ASA Physical Status Classification: inter-observer consistency. Anaesth Intensive Care&#xa0;2002; : 633&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413266</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RS, Kumar KS, Russo MW, et al. . Model for end-stage liver disease and Child&#x2013;Turcotte&#x2013;Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl&#xa0;2002; : 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910574</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat AE, Blok JJ, Putter H, et al. . The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant&#xa0;2012; : 2,789&#x2013;2,796.</Citation><ArticleIdList><ArticleId IdType="pubmed">22823098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorina P, La Rocca E, Astorri E, et al. . Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care&#xa0;2000; : 1,804&#x2013;1,810.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra S, Tavakoli M, Kallinikos PA, et al. . Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care&#xa0;2007; 30: ,608&#x2013;2,612.</Citation><ArticleIdList><ArticleId IdType="pubmed">17623821</ArticleId></ArticleIdList></Reference><Reference><Citation>Woeste G, Wullstein C, Prid&#xf6;hl O, et al. . Incidence of minor and major amputations after pancreas/kidney transplantation. Transpl Int&#xa0;2003; : 128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">12595975</ArticleId></ArticleIdList></Reference><Reference><Citation>Humar A, Ramcharan T, Kandaswamy R, et al. . Technical failures after pancreas transplants: why grafts fail and the risk factors &#x2013; a multivariate analysis. Transplantation&#xa0;2004; : 1,188&#x2013;1,192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502718</ArticleId></ArticleIdList></Reference><Reference><Citation>Troppmann C. Complications after pancreas transplantation. Curr Opin Organ Transplant&#xa0;2010; : 112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">20009931</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal HP, Garland L, Novak K, et al. . Risk factors for postimplantation pancreatitis and pancreatic thrombosis in pancreas transplant recipients. Transplantation&#xa0;1993; : 609&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8212156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall CG, Sandrasegaran K, Maglinte DT, Fridell JA. Bowel complications seen on CT after pancreas transplantation with enteric drainage. Am J Roentgenol2006; : 1,288&#x2013;1,295.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M, Salvalaggio PR, Topal J, et al. . Incidence, timing and site of infections among pancreas transplant recipients. J Hosp Infect&#xa0;2004; : 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003665</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinkers MT, Rahmel AO, Slot MC, et al. . How to recognize a suitable pancreas donor: a Eurotransplant study of preprocurement factors. Transplant Proc&#xa0;2008; : 1,275&#x2013;1,278.</Citation><ArticleIdList><ArticleId IdType="pubmed">18589086</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod DA, Sung RS, Meyer KH, et al. . Systematic evaluation of pancreas allograft quality, outcomes and geographic variation in utilization. Am J Transplant&#xa0;2010; : 837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">20121753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland DE, Gruessner RW, Dunn DL, et al. . Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg&#xa0;2001; : 463&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421277</ArticleId><ArticleId IdType="pubmed">11303130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant&#xa0;2004; : 2,018&#x2013;2,026.</Citation><ArticleIdList><ArticleId IdType="pubmed">15575904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio MS, Reddy PN, Kuo HT, et al. . Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation&#xa0;2010; : 1,117&#x2013;1,125.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablorsu E, Ghazanfar A, Mehra S, et al. . Outcome of pancreas transplantation in recipients older than 50 years: a single-centre experience. Transplantation&#xa0;2008; : 1,511&#x2013;1,514.</Citation><ArticleIdList><ArticleId IdType="pubmed">19077882</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterlow J. Pressure sores: a risk assessment card. Nurs Times&#xa0;1985; : 49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">3853163</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorn CC, Smith M, Aziz O, Holme TC. The Waterlow score for risk assessment in surgical patients. Ann R Coll Surg Engl&#xa0;2013; : 52&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964640</ArticleId><ArticleId IdType="pubmed">23317729</ArticleId></ArticleIdList></Reference><Reference><Citation>Khuri SF, Henderson WG, DePalma RG, et al. . Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg&#xa0;2005; : 326&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1357741</ArticleId><ArticleId IdType="pubmed">16135919</ArticleId></ArticleIdList></Reference><Reference><Citation>Noori N, Kopple JD. Effect of diabetes mellitus on protein-energy wasting and protein wasting in end-stage renal disease. Semin Dial&#xa0;2010; : 178&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasticci F, Fantuzzi AL, Pegoraro M, et al. . Nutritional management of stage 5 chronic kidney disease. J Ren Care&#xa0;2012; : 50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">22369595</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenvinkel P, Barany P, Chung SH, et al. . A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant&#xa0;2002; : 1,266&#x2013;1,274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105251</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimann A, Braga M, Harsanyi L, et al. . ESPEN guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr&#xa0;2006; : 224&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698152</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev&#xa0;2012; : CD008879.</Citation><ArticleIdList><ArticleId IdType="pubmed">23152265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31471407</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Predictive Value of Osteoprotegerin and Neutrophil Gelatinase-associated Lipocalin on Multiple Organ Failure in Multiple Trauma.</ArticleTitle><Pagination><StartPage>1573</StartPage><EndPage>1580</EndPage><MedlinePgn>1573-1580</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21873/invivo.11639</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Multiple organ dysfunction syndrome (MODS) is the leading cause of late posttraumatic mortality. This study analyzed the prognostic values of osteoprotegerin (OPG) and neutrophil gelatinase-associated lipocalin (NGAL/lipocalin 2) compared to interleukin-6 (IL-6) in multiply injured patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A retrospective observational cohort study on multiply injured patients with an injury severity score (ISS) of &#x2265;16 was performed. OPG, NGAL and IL-6 blood concentrations were measured. Statistical analysis comprised receiver-operating-characteristic (ROC) analysis with the corresponding area under the curve (AUC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine patients with a mean ISS of 34&#xb1;11 were included. Fourteen patients (36%) developed MODS and 8 patients (21%) died. Plasma levels of NGAL, OPG, and IL-6 were significantly elevated in the MODS+ group. Each biomarker positively correlated with MODS score and diagnosis of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NGAL and OPG might be indicative of MODS and could have the potential to be biomarkers in the early detection of patients at risk of posttraumatic MODS.</AbstractText><CopyrightInformation>Copyright&#xa9; 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macke</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mommsen</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeckey</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General, Trauma and Reconstructive Surgery, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clausen</LastName><ForeName>Jan-Dierk</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neunaber</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkelmann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Trauma Department, Hannover Medical School, Hannover, Germany winkelmann.marcel@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489506">LCN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071068">Lipocalin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506030">TNFRSF11B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071068" MajorTopicYN="N">Lipocalin-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Multiple organ failure</Keyword><Keyword MajorTopicYN="N">lipocalin</Keyword><Keyword MajorTopicYN="N">multiple injury</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">multiple trauma</Keyword></KeywordList><CoiStatement>The Authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31471407</ArticleId><ArticleId IdType="pmc">PMC6754992</ArticleId><ArticleId IdType="doi">10.21873/invivo.11639</ArticleId><ArticleId IdType="pii">33/5/1573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ciesla DJ, Moore EE, Johnson JL, Burch JM, Cothren CC, Sauaia A. A 12-year prospective study of postinjury multiple organ failure: Has anything changed. Arch Surg. 2005;140(5):432&#x2013;438. PMID: 15897438. DOI: 10.1001/archsurg.140.5.432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15897438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40(9):912&#x2013;918. PMID: 19541301. DOI: 10.1016/j.injury.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast-Kolb D, Aufmkolk M, Rucholtz S, Obertacke U, Waydhas C. Multiple organ failure still a major cause of morbidity but not mortality in blunt multiple trauma. J Trauma. 2001;51(5):835&#x2013;841. discussion 841-832 PMID: 11706328.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706328</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattstrom O, Granath F, Rossi P, Oldner A. Early predictors of morbidity and mortality in trauma patients treated in the intensive care unit. Acta Anaesthesiol Scand. 2010;54(8):1007&#x2013;1017. PMID: 20626360. DOI: 10.1111/j.1399-6576.2010. 02266.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626360</ArticleId></ArticleIdList></Reference><Reference><Citation>Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O&#x2019;Keefe GE, Cohen MJ, Moldawer LL, Tompkins RG, Maier RV, Inflammation and the Host Response to Injury Collaborative Research P The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock. Crit Care Med. 2012;40(4):1129&#x2013;1135. PMID: 22020243. DOI: 10.1097/CCM.0b013e3182376e9f.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343366</ArticleId><ArticleId IdType="pubmed">22020243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahl JE, Calvo RY, Sise MJ, Sise CB, Thorndike JF, Shackford SR. The changing nature of death on the trauma service. J Trauma Acute Care Surg. 2013;75(2):195&#x2013;201. PMID: 23823614. DOI: 10.1097/TA.0b013e3182997865.</Citation><ArticleIdList><ArticleId IdType="pubmed">23823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, Sakka SG, Bouillon B, Wafaisade A, Committee on Emergency Medicine IC , Trauma Management of the German Trauma Society Sektion NIS Epidemiology and risk factors of multiple-organ failure after multiple trauma: An analysis of 31,154 patients from the traumaregister dgu. J Trauma Acute Care Surg. 2014;76(4):921&#x2013;927. discussion 927-928 PMID: 24662853. DOI: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Chin TL, Banerjee A, Sperry JL, Maier RV, Burlew CC. Temporal trends of postinjury multiple-organ failure: Still resource intensive, morbid, and lethal. J Trauma Acute Care Surg. 2014;76(3):582&#x2013;592, discussion 592-583. PMID: 24553523. DOI: 10.1097/TA.0000000 000000147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4116088</ArticleId><ArticleId IdType="pubmed">24553523</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts CS, Pape HC, Jones AL, Malkani AL, Rodriguez JL, Giannoudis PV. Damage control orthopaedics: Evolving concepts in the treatment of patients who have sustained orthopaedic trauma. Instr Course Lect. 2005;54:447&#x2013;462. PMID: 15948472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sears BW, Stover MD, Callaci J. Pathoanatomy and clinical correlates of the immunoinflammatory response following orthopaedic trauma. J Am Acad Orthop Surg. 2009;17(4):255&#x2013;265. PMID: 19307674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675552</ArticleId><ArticleId IdType="pubmed">19307674</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpin G, Cohen M, Assaf M, Meir T, Katz R, Pollack S. Cytokine levels (il-4, il-6, il-8 and tgfbeta) as potential biomarkers of systemic inflammatory response in trauma patients. Int Orthop. 2014;38(6):1303&#x2013;1309. PMID: 24402554. DOI: 10.1007/s00264-013-2261-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037528</ArticleId><ArticleId IdType="pubmed">24402554</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;1652. PMID: 7587228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine. Intensive Care Med. 1996;22(7):707&#x2013;710. PMID: 8844239.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28(6):668&#x2013;674. PMID: 18092384.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between il-6 levels and the systemic inflammatory response score: Can an il-6 cutoff predict a sirs state. J Trauma. 2008;65(3):646&#x2013;652. PMID: 18784579. DOI: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51(2):97&#x2013;102. PMID: 18377749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jastrow KM 3rd, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg. 2009;209(3):320&#x2013;331. PMID: 19717036. DOI: 10.1016/j.jamcollsurg.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717036</ArticleId></ArticleIdList></Reference><Reference><Citation>Haasper C, Kalmbach M, Dikos GD, Meller R, Muller C, Krettek C, Hildebrand F, Frink M. Prognostic value of procalcitonin (pct) and/or interleukin-6 (il-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (mods) or sepsis. Technol Health Care. 2010;18(2):89&#x2013;100. PMID: 20495248. DOI: 10.3233/THC-2010-0571.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165&#x2013;176. PMID: 9568710.</Citation><ArticleIdList><ArticleId IdType="pubmed">9568710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (ocif) and osteoprotegerin (opg): A mechanism by which opg/ocif inhibits osteoclasto-genesis in vitro. Endocrinology. 1998;139(3):1329&#x2013;1337. PMID: 9492069. DOI: 10.1210/endo.139.3.5837.</Citation><ArticleIdList><ArticleId IdType="pubmed">9492069</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T. Osteoclast differentiation factor (odf) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246(1):199&#x2013;204. PMID: 9600092. DOI: 10.1006/bbrc.1998.8586.</Citation><ArticleIdList><ArticleId IdType="pubmed">9600092</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. Trance is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188(5):997&#x2013;1001. PMID: 9730902. DOI: 10.1084/jem.188.5.997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213394</ArticleId><ArticleId IdType="pubmed">9730902</ArticleId></ArticleIdList></Reference><Reference><Citation>Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand trail. J Biol Chem. 1998;273(23):14363&#x2013;14367. PMID: 9603945. DOI: 10.1074/jbc.273.23.14363.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603945</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid P, Holen I. Pathophysiological roles of osteoprotegerin (opg) Eur J Cell Biol. 2009;88(1):1&#x2013;17. PMID: 18707795. DOI: 10.1016/j.ejcb.2008.06.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">18707795</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the tnf receptor and its ligand enhance t-cell growth and dendritic-cell function. Nature. 1997;390(6656):175&#x2013;179. PMID: 9367155. DOI: 10.1038/ 36593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9367155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. Trance (tumor necrosis factor [tnf]-related activation-induced cytokine), a new tnf family member predominantly expressed in t cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(12):2075&#x2013;2080. PMID: 9396779. DOI: 10.1084/jem.186.12.2075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199171</ArticleId><ArticleId IdType="pubmed">9396779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, Pascual V, Hood LE, Clark EA. Opg/fdcr-1, a tnf receptor family member, is expressed in lymphoid cells and is up-regulated by ligating cd40. J Immunol. 1998;161(11):6113&#x2013;6121. PMID: 9834095.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834095</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoppet M, Henser S, Ruppert V, Stubig T, Al-Fakhri N, Maisch B, Hofbauer LC. Osteoprotegerin expression in dendritic cells increases with maturation and is nf-kappab-dependent. J Cell Biochem. 2007;100(6):1430&#x2013;1439. PMID: 17171649. DOI: 10.1002/jcb.21129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17171649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates b cell development and function. J Immunol. 2001;166(3):1482&#x2013;1491. PMID: 11160187. DOI: 10.4049/jimmunol. 166.3.1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">11160187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Lacraz S, Ferrari S. Do rankl inhibitors (denosumab) affect inflammation and immunity. Osteoporos Int. 2011;22(2):435&#x2013;446. PMID: 20571772. DOI: 10.1007/s00198-010-1326-y.</Citation><ArticleIdList><ArticleId IdType="pubmed">20571772</ArticleId></ArticleIdList></Reference><Reference><Citation>To M, Ito K, Ausin PM, Kharitonov SA, Barnes PJ. Osteoprotegerin in sputum is a potential biomarker in copd. Chest. 2011;140(1):76&#x2013;83. PMID: 21127170; DOI: 10.1378/ chest.10-1608.</Citation><ArticleIdList><ArticleId IdType="pubmed">21127170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C. N-gal: Diagnosing aki as soon as possible. Crit Care. 2007;11(6):173&#x2013;173. PMID: 18001501. DOI: 10.1186/cc6162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246201</ArticleId><ArticleId IdType="pubmed">18001501</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Swaminathan M, Garg AX, Consortium T-A. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748&#x2013;1757. PMID: 21836147. DOI: 10.1681/ASN.2010111163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171945</ArticleId><ArticleId IdType="pubmed">21836143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering JW, Endre ZH. The clinical utility of plasma neutrophil gelatinase-associated lipocalin in acute kidney injury. Blood Purif. 2013;35(4):295&#x2013;302. PMID: 23712081. DOI: 10.1159/000351542.</Citation><ArticleIdList><ArticleId IdType="pubmed">23712081</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: A critical evaluation of current status. Ann Clin Biochem. 2014;51(Pt 3):335&#x2013;351. PMID: 24518531. DOI: 10.1177/0004 563214521795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104776</ArticleId><ArticleId IdType="pubmed">24518531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C, Legrand M, Goldstein SL, Hur M, Tran N, Howell EC, Cantaluppi V, Cruz DN, Damman K, Bagshaw SM, Di Somma S, Lewington A. Neutrophil gelatinase-associated lipocalin: Ready for routine clinical use? An international perspective. Blood Purif. 2014;37(4):271&#x2013;285. PMID: 25012891. DOI: 10.1159/000360689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842016</ArticleId><ArticleId IdType="pubmed">25012891</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart IJ, Glass KR, Howard JT, Morrow BD, Sosnov JA, Siew ED, Wickersham N, Latack W, Kwan HK, Heegard KD, Diaz C, Henderson AT, Saenz KK, Ikizler TA, Chung KK. The potential utility of urinary biomarkers for risk prediction in combat casualties: A prospective observational cohort study. Crit Care. 2015;19:252&#x2013;252. PMID: 26077788. DOI: 10.1186/s13054-015-0965-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487799</ArticleId><ArticleId IdType="pubmed">26077788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli TA, Wodzin E, Medicine AftAoA Abbreviated injury scale 2005: Association for the Advancement of Automotive Medicine. Barrington. 2008; Update 2008 ISBN-13: 978-0000002020.</Citation></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr., Long WB. The injury severity score: A method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14(3):187&#x2013;196. PMID: 4814394.</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T, German Sepsis S , German Interdisciplinary Association of Intensive C and Emergency M Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of s-2k guidelines of the german sepsis society (deutsche sepsis-gesellschaft e.V. (dsg)) and the german interdisciplinary association of intensive care and emergency medicine (deutsche interdisziplinare vereinigung fur intensiv- und notfallmedizin (divi)). Ger Med Sci. 2010;8 DOI: 10.3205/000103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899863</ArticleId><ArticleId IdType="pubmed">20628653</ArticleId></ArticleIdList></Reference><Reference><Citation>Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: The berlin definition. JAMA. 2012;307(23):2526&#x2013;2533. PMID: 22797452. DOI: 10.1001/jama.2012.5669.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32&#x2013;35. PMID: 15405679. DOI: 10.1002/1097-0142(1950) 3:1&lt; 32::aid-cncr2820030106&gt;3.0.co;2-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, STARD Group Stard 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527&#x2013;h5527. PMID: 26511519. DOI: 10.1136/bmj.h5527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623764</ArticleId><ArticleId IdType="pubmed">26511519</ArticleId></ArticleIdList></Reference><Reference><Citation>Frink M, Pape HC, van Griensven M, Krettek C, Chaudry IH, Hildebrand F. Influence of sex and age on mods and cytokines after multiple injuries. Shock. 2007;27(2):151&#x2013;156. PMID: 17224789. DOI: 10.1097/01.shk.0000239767.64786.de.</Citation><ArticleIdList><ArticleId IdType="pubmed">17224789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38(12):1336&#x2013;1345. PMID: 18048040. DOI: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong DY, Lee JH, Park SO, Baek KJ, Lee KR. Plasma neutrophil gelatinase-associated lipocalin as early biomarker for acute kidney injury in burn patients. J Burn Care Res. 2013;34(6):e326&#x2013;e332. PMID: 23511281. DOI: 10.1097/BCR.0b013 e31827d1f36.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavuz S, Anarat A, Acarturk S, Dalay AC, Kesiktas E, Yavuz M, Acarturk TO. Neutrophil gelatinase associated lipocalin as an indicator of acute kidney injury and inflammation in burned children. Burns. 2014;40(4):648&#x2013;654. PMID: 24060429. DOI: 10.1016/j.burns.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="pubmed">24060429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Godwin ZR, Palmieri T, Greenhalgh D, Steele AN, Tran NK. Whole blood neutrophil gelatinase-associated lipocalin predicts acute kidney injury in burn patients. J Surg Res. 2015;196(2):382&#x2013;387. PMID: 25890435. DOI: 10.1016/j.jss.2015.03.033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447708</ArticleId><ArticleId IdType="pubmed">25890435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjortrup PB, Haase N, Wetterslev M, Perner A. Clinical review: Predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit Care. 2013;17(2):211&#x2013;211. PMID: 23680259. DOI: 10.1186/cc11855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672520</ArticleId><ArticleId IdType="pubmed">23680259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15846719</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2005</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults.</ArticleTitle><Pagination><StartPage>CD004539</StartPage><MedlinePgn>CD004539</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD004539</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Secondary peritonitis is associated with a high mortality rate and if not treated successfully leads to development of abscesses, severe sepsis and multi-organ failure. Source control and adjunctive antibiotics are the mainstay of treatment. However, no conclusive evidence suggest that one antibiotic regimen is better than any other but at the same time have a lower toxicity.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To ascertain the efficacy and adverse effects of different antibiotic regimens in treating intra-abdominal infections in adults. Outcomes were divided into primary (clinical success and effectiveness in reducing mortality) and secondary (microbiological success, preventing wound infection, intra-abdominal abscess, clinical sepsis, remote infection, superinfection, adverse reactions, duration of treatment required, effectiveness in reducing hospitalised stay, and time to defervescence).</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Issue 4, 2004), MEDLINE (from 1966 to November 2004), EMBASE (from 1980 to November 2004) and Cochrane Colorectal Cancer Group specialised register SR-COLOCA. Bibliographies of identified studies were screened for further relevant trials.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised and quasi-randomised controlled trials comparing different antibiotic regimens in the treatment of secondary peritonitis in adults were selected. Trials reporting gynaecological or traumatic peritonitis were excluded from this review. Ambiguity regarding suitability of trials were discussed among the review team.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Six reviewers independently assessed trial quality and extracted data. Data collection was standardised using data collection form to ensure uniformity among reviewers. Statistical analyses were performed using the random effects model and the results expressed as odds ratio for dichotomous outcomes, or weight mean difference for continuous data with 95% confidence intervals.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Fourty studies with 5094 patients met the inclusion criteria. Sixteen different comparative antibiotic regimens were reported. All antibiotics showed equivocal comparability in terms of clinical success. Mortality did not differ between the regimens. Despite the potential high toxicity profile of regimens using aminoglycosides, this was not demonstrated in this review. The reason for this could be the inherent bias within clinical trials in the form of patient selection and stringency in monitoring drug levels.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">No specific recommendations can be made for the first line treatment of secondary peritonitis in adults with antibiotics, as all regimens showed equivocal efficacy. Other factors such as local guidelines and preferences, ease of administration, costs and availability must therefore be taken into consideration in deciding the antibiotic regimen of choice. Future trials should attempt to stratify patients and perform intention-to-treat analysis to allow better external validity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>P F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Professorial Unit of Surgery, University Hospital of North Tees, Hardwick, Stockton on Tees, UK, TS19 8PE. pwong@doctors.net.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilliam</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Shenfine</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Dair</LastName><ForeName>G N</ForeName><Initials>GN</Initials></Author><Author ValidYN="Y"><LastName>Leaper</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1002/14651858.CD004539</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007416" MajorTopicYN="N">Intestinal Perforation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The Professorial Unit of Surgery of whom Professor Leaper was the lead clinician, received a one&#x2010;off limited and unconditional educational grant from Merck Sharpe &amp; Dohme, which was meant for antibiotic trials. The reviewers can however assure that under no circumstances has this grant or Merck Sharpe &amp; Dohme influenced the review or reviewers in any form. The company concerned certainly had no input into the wordings, opinions or conjectures of this review.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15846719</ArticleId><ArticleId IdType="pmc">PMC11297476</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004539.pub2</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Angeras 1996 {published data only}</Title><Reference><Citation>Angeras MH, Darle N, Hamnstrom K, Ekelund M, Engstrom L, Takala J, et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra&#x2010;abdominal infections. Scandinavian Journal of Infectious Diseases 1996;28(5):513&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953684</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Basoli 1997 {published data only}</Title><Reference><Citation>Basoli A, Meli EZ, Mazzocchi P, Speranza V and Study Group. Imipenem/cilastatin (1.5g daily) versus meropenem (3.0g daily) in patients with intra&#x2010;abdominal infections: results of a prospective, randomized, multicentre trial. Scand J of Infect Dis 1997;29:503&#x2010;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435041</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1982 {published data only}</Title><Reference><Citation>Berne TV, Yellin AW, Appleman MD, Heseltine PNR. Antibiotic management of surgically treated gangrenous or perforated appendicitis. The American Journal of Surgery 1982;144(1):8&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">6211996</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1987 {published data only}</Title><Reference><Citation>Berne TV, Appleman MD, Chenella FC, Yellin AE, Gill MA, Heseltine PNR. Surgically treated gangrenous or perforated appendicitis. Ann Surg 1987;205(2):133&#x2010;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492815</ArticleId><ArticleId IdType="pubmed">3545106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1993 {published data only}</Title><Reference><Citation>Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surgery, Gynecology &amp; Obstetrics 1993;177(Suppl):18&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8256187</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Berne 1996 {published data only}</Title><Reference><Citation>Berne TV, Yellin AE, Appleman MD, Heseltine PNR, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. Journal of the American College of Surgeons 1996;182(5):403&#x2010;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620275</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1992 {published data only}</Title><Reference><Citation>Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, et al. Piperacillin&#x2010;tazobactam versus imipenem&#x2010;cilastatin for treatment of intra&#x2010;abdominal infections. Antimicrobial Agents and Chemotherapy 1992;36(12):2766&#x2010;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC245542</ArticleId><ArticleId IdType="pubmed">1336347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1995 {published data only}</Title><Reference><Citation>Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing O, et al. Meropenem versus imipenem/cilastatin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1995;35(1):139&#x2010;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brismar 1996 {published data only}</Title><Reference><Citation>Brismar B, Akerlund J&#x2010;E, Sjostedt S, Johansson C, Tornqvist A, Backstrand B, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra&#x2010;abdominal infections: Report from a Swedish study group. Scandinavian Journal of Infectious Diseases 1996;28(5):507&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953683</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Busuttil 1984 {published data only}</Title><Reference><Citation>Busuttil RW, McGrattan MA, Freischlag J. A comparative study of cefamandole versus gentamicin plus clindamycin in the treatment of documented or suspected bacterial peritonitis. Surgery, Gynecology &amp; Obstetrics 1984;158(1):1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6362043</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christou 1996 {published data only}</Title><Reference><Citation>Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M, et al. Management of intra&#x2010;abdominal infections: The case for intraoperative cultures and comprehensive broad&#x2010;spectrum antibiotic coverage. Archives of Surgery 1996;131(11):1193&#x2010;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8911260</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohn 2000 {published data only}</Title><Reference><Citation>Cohn SM, Lipsett PA, Buchmann TG, Cheadle WG, Milsom JW, O'Marro S, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 2000;232(2):254&#x2010;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421138</ArticleId><ArticleId IdType="pubmed">10903605</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>de Groot 1993 {published data only}</Title><Reference><Citation>Groot HGW, Hustinx PA, Lampe AS, Oosterwijk WM. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1993;32(3):491&#x2010;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">8262872</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dupont 2000 {published data only}</Title><Reference><Citation>Dupont H, Carbon C, Carlet J for The Severe Generalized Peritonitis Study Group. Monotherapy with a broad&#x2010;spectrum beta&#x2010;lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrobial Agents and Chemotherapy 2000;44(8):2028&#x2010;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC90009</ArticleId><ArticleId IdType="pubmed">10898671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eckhauser 1992 {published data only}</Title><Reference><Citation>Eckhauser FE, Knol JA, Raper SE, Mulholland MW, Helzerman P. Efficacy of two comparative antibiotic regimens in the treatment of serious intra&#x2010;abdominal infections: Results of a multicenter study. Clinical Therapeutics 1992;14(1):97&#x2010;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">1576632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gozenbach 1987 {published data only}</Title><Reference><Citation>Gozenbach HR, Simmen HP, Amgwerd R. Imipenem (N&#x2010;F&#x2010;Thienamycin) versus netilmicin plus clindamycin: A controlled and randomized comparison in intra&#x2010;abdominal infections. Annals of Surgery 1987;205(3):271&#x2010;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492722</ArticleId><ArticleId IdType="pubmed">3548611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Greenberg 1994 {published data only}</Title><Reference><Citation>Greenberg RN, Cayavec P, Danko LS, Bowen K, Montazemi R, Kearney PA, et al. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1994;34(3):391&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">7829413</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hopkins 1994 {published data only}</Title><Reference><Citation>Hopkins JA, Wilson SE, Bobey DG. Adjunctive antimicrobial therapy for complicated appendicitis: Bacterial overkill by combination therapy. World Journal of Surgery 1994;18(6):933&#x2010;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">7846922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Investigators 1994 {published data only}</Title><Reference><Citation>Investigators of the Piperacillin/Tazobactam Intra&#x2010;abdominal Infection Study Group. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra&#x2010;abdominal infections. European Journal of Surgery Supplement 1994, (573):61&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7524798</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaccard 1998 {published data only}</Title><Reference><Citation>Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem/cilastatin and piperacillin/tazobactam in nosocomial pneumonia and peritonitis. Antimicrobial Agents and Chemotherapy 1998;42(11):2966&#x2010;2972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105974</ArticleId><ArticleId IdType="pubmed">9797234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jauregui 1990 {published data only}</Title><Reference><Citation>Jauregui LE, Appelbaum PC, Fabian TC, Hageage G, Strausbaugh L, Martin LF. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1990;25(3):423&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">2187014</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kanellakopoulou 1993 {published data only}</Title><Reference><Citation>Kanellakopoulou K, Giamarellou H, Papadothomakos P, Tsipras H, Chloroyiannis J, Theakou R, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. European Journal of Clinical Microbiological Infectious Diseases 1993;12(6):449&#x2010;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">8359165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kempf 1996 {published data only}</Title><Reference><Citation>Kempf P, Bauernfeind A, Muller A, Blum J. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra&#x2010;abdominal infections. Infection 1996;24(6):473&#x2010;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leal del Rosal 1995 {published data only}</Title><Reference><Citation>Leal del Rosal P. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra&#x2010;abdominal infections. Journal of Chemotherapy 1995;7(2):143&#x2010;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8622103</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leaper 1987 {published data only}</Title><Reference><Citation>Leaper DJ, Kennedy RH, Sutton A, Johnson E, Roberts N. Treatment of acute bacterial peritonitis: A trial of imipenem/cilastatin against ampicillin&#x2010;metronidazole&#x2010;gentamicin. Scandinavian Journal of Infectious Diseases 1987;52(Suppl):7&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331045</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Malangoni 1985 {published data only}</Title><Reference><Citation>Malangoni MA, Condon RE, Spiegel CA. Treatment of intra&#x2010;abdominal infections is appropriate with single&#x2010;agent or combination antibiotic therapy. Surgery 1985;98(4):648&#x2010;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">3901372</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Paakkonen 1991 {published data only}</Title><Reference><Citation>Paakkonen M, Alhava EM, Huttunen R, Karjalainen K, Lahtinen J, Miettinen P, et al. Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. European Journal of Surgery 1991;157(9):535&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683578</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Poenaru 1990 {published data only}</Title><Reference><Citation>Poenaru D, Santis M, Christou NV. Imipenem versus tobramycin&#x2010;antianaerobe antibiotic therapy in intra&#x2010;abdominal infections. Canadian Journal of Surgery 1990;33(5):415&#x2010;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">2224663</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scandinavian 1984 {published data only}</Title><Reference><Citation>Report from a Scandinavian Study Group. Imipenem/cilastatin versus gentamicin/clindamycin for the treatment of serious bacterial infections. The Lancet 1984;8382(1):868&#x2010;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">6143185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scott 1987 {published data only}</Title><Reference><Citation>Scott SD, Saddler B, Lowes JA, Karran SJ. Comparison of cefotetan versus combination therapy in peritonitis and serious intra&#x2010;abdominal sepsis. Chemioterapia 1987;6(Pt 2 S):475&#x2010;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">3334604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shyr 1995 {published data only}</Title><Reference><Citation>Shyr YM, Lui WY, Su CH, Wang LS, Liu CY. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra&#x2010;abdominal infections. Chinese Medical Journal 1995;56(2):102&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">7553416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1980 {published data only}</Title><Reference><Citation>Smith JA, Skidmore AG, Forward AD, Clarke AM, Sutherland E. Prospective, randomized, double&#x2010;blinded comparison of metronidazole and tobramycin with clindamycin and tobramycin in the treatment of intra&#x2010;abdominal sepsis. Annals of Surgery 1980;192(2):213&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1344856</ArticleId><ArticleId IdType="pubmed">6996625</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 2001 {published data only}</Title><Reference><Citation>Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Annals of Surgery 2001;233(1):79&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421170</ArticleId><ArticleId IdType="pubmed">11141229</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Study 1986 {published data only}</Title><Reference><Citation>Study Group of Intra&#x2010;abdominal Infections. A randomized controlled trial of ampicillin plus sulbactam versus gentamicin and clindamycin in the treatment of intraabdominal infections: a preliminary report. Reviews of Infectious Diseases 1986;8(Suppl 5):S583&#x2010;S588.</Citation><ArticleIdList><ArticleId IdType="pubmed">2879345</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Swedish 1990 {published data only}</Title><Reference><Citation>Report from a Swedish Study Group. A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl B):173&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">2258346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tornqvist 1985 {published data only}</Title><Reference><Citation>Tornqvist A, Forsgren A, Leandoer L, Ursing J. Antibiotic treatment during surgery for diffuse peritonitis: a prospective randomized study comparing the effects of cefuroxime and of a cefuroxime and metronidazole combination. British Journal of Surgery 1985;72(4):261&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">3986473</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Torres 1999 {published data only}</Title><Reference><Citation>Torres AJ, Valladares LD, Jover JM, Sanchez&#x2010;Pernaute A, Frias J, Carcas AJ, et al. Cefminox versus metronidazole plus gentamicin in intra&#x2010;abdominal infections: A prospective randomized controlled clinical trial. Infections 2000;28(5):318&#x2010;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">11073141</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Walker 1993 {published data only}</Title><Reference><Citation>Walker AP, Nichols RL, Wilson RF, Bivens BA, Trunkey DD, Edmiston CE, et al. Efficacy of a beta&#x2010;lactamase inhibitor combination for serious intra&#x2010;abdominal infections. Annals of Surgery 1993;217(2):115&#x2010;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242749</ArticleId><ArticleId IdType="pubmed">8439209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 1985 {published data only}</Title><Reference><Citation>Yellin AE, Heseltine PNR, Berne TV, Appleman MD, Gill MA, Riggio CE, et al. The role of pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surgery, Gynecology &amp; Obstetrics 1985;161(4):303&#x2010;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">2996161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zanetti 1999 {published data only}</Title><Reference><Citation>Zanetti G, Harbarth SJ, Trampuz A, Ganeo M, Mosimann F, Chautemps R, et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra&#x2010;abdominal infections. International Journal of Antimicrobial Agents 1999;11(2):107&#x2010;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221413</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Allo 1999 {published data only}</Title><Reference><Citation>Allo MD, Bennion RS, Kathir K, Thompson JE, Lentz M, Meute M, et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. The American Surgeon 1999;65(2):99&#x2010;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">9926739</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Andaker 1987 {published data only}</Title><Reference><Citation>Andaker L, Hojer H, Kihlstrom E, Lindagen J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Acta Chirurgica Scandinavica 1987;153(3):185&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">3300120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Arguedas 1996 {published data only}</Title><Reference><Citation>Arguedas A, Sifuentes&#x2010;Osornio J, Loaiza C, Herrera M, Corrales JC, Mohs E, et al. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra&#x2010;abdominal infections. Journal of Chemotherapy 1996;8(2):130&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8708744</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Baird 1983 {published data only}</Title><Reference><Citation>Baird IM. Multicentered study of cefoperazone for treatment of intraabdominal infections and comparison of cefoperazone with cefamandole and clindamycin plus gentamicin for treatment of appendicitis and peritonitis. Reviews of Infectious Diseases 1983;5(Suppl.):S165&#x2010;S172.</Citation><ArticleIdList><ArticleId IdType="pubmed">6221387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ball 1981 {published data only}</Title><Reference><Citation>Ball P, Watson T, Mehtar S. Amoxycillin and clavulanic acid in intra&#x2010;abdominal and pelvic sepsis. Journal of Antimicrobial Chemotherapy 1981;7(4):441&#x2010;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7251526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball P, Watson T, Mehtar S. Amoxycillin and clavulanic acid in intra&#x2010;abdominal and pelvic sepsis. Journal of Antimicrobial Chemotherapy 1981;7(4):441&#x2010;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">7251526</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barboza 1994 {published data only}</Title><Reference><Citation>Barboza E, Castillo M, Yi A, Gotuzzo E. Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. Surgery 1994;116(1):28&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">8023265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barie 1997 {published data only}</Title><Reference><Citation>Barie PS, Vogel SB, Dellinger EP, Rotstein OD, Solomkin JS, Yang JY, et al. A randomized, double&#x2010;blind clinical trial comparing cefepime plus metronidazole with imipenem&#x2010;cilastatin in the treatment of complicated intra&#x2010;abdominal infections. Arch Surg 1997;132(12):1294&#x2010;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403533</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bennion 1990 {published data only}</Title><Reference><Citation>Bennion RS, Thompson JE, Baron EJ, Finegold SM. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clinical Therapeutics 1990;12(Suppl. C):31&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">2202510</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Birolini 1985 {published data only}</Title><Reference><Citation>Birolini D, Moraes MF, Souza OS. Aztreonam plus clindamycin versus tobramycin plus clindamycin for the treatment of intraabdominal infections. Reviews of Infectious Diseases 1985;7(Suppl 4):S724&#x2010;S728.</Citation><ArticleIdList><ArticleId IdType="pubmed">3909330</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Birolini 1989 {published data only}</Title><Reference><Citation>Birolini D, Moraes MF, Souza OS. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra&#x2010;abdominal infections. Chemotherapy 1989;35(Suppl 1):49&#x2010;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">2659290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Biron 1984 {published data only}</Title><Reference><Citation>Biron S, Brochu G, Beland L, Bourque RA, Marceau P, Piche P, et al. Short&#x2010;term antibiotherapy for peritonitis: prospective, randomized trial comparing cefotaxime&#x2010;metronidazole and clindamycin&#x2010;tobramycin. Journal of Antimicrobial Chemotherapy 1984;12(Suppl B):213&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">6094442</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bubrick 1990 {published data only}</Title><Reference><Citation>Bubrick MP, Heim&#x2010;Duthoy KL, Yellin AE, Berne TV, Heseltine PNR, Appleman MD, et al. Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra&#x2010;abdominal infections. The American Surgeon 1990;56(10):613&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">2221611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Busuttil 1982 {published data only}</Title><Reference><Citation>Busuttil RW, McGrattan MA, Winston DJ. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections. Review of Infectious Diseases 1982;4(Suppl):S676&#x2010;S682.</Citation><ArticleIdList><ArticleId IdType="pubmed">6218582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cakmakci 1993 {published data only}</Title><Reference><Citation>Cakmakci M, Stern A, Schilling J, Christen D, Roggo A, Geroulanos S. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra&#x2010; and post&#x2010;operative infections. Drugs Experimental in Clinical Research 1993;19(5):223&#x2010;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8174495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Canadian 1983 {published data only}</Title><Reference><Citation>Canadian Metronidazole&#x2010;Clindamycin Study Group. Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra&#x2010;abdominal infection. Surgery 1983;93(1 (Part 2)):221&#x2010;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chin 1990 {published data only}</Title><Reference><Citation>Chin A, Gill MA, Ito MK, Yellin AE, Berne TV, Heseltine PN, et al. Treatment of intra&#x2010;abdominal infections: cost comparison of ampicillin/sulbactam and clindamycin/gentamicin. Hospital Formulary 1990;25(3):295&#x2010;296, 303&#x2010;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10103837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christen 1987 {published data only}</Title><Reference><Citation>Christen D, Buchmann P, Geroulanos S. Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections. Scandinavian Journal of Infectious Diseases 1987;52(Suppl 1):11&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331039</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Colardyn 1996 {published data only}</Title><Reference><Citation>Colardyn F and Faulkner KL on behalf of the Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Journal of Antimicrobial Chemotherapy 1996;38(3):523&#x2010;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">8889726</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Collier 1981 {published data only}</Title><Reference><Citation>Collier J, Colhoun EM, Hill PL. A multicentre comparison of clindamycin and metronidazole in the treatment of anaerobic infections. Scandinavian Journal of Infectious Diseases Supplement 1981;26:96&#x2010;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">6941465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cometta 1994 {published data only}</Title><Reference><Citation>Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial Agents and Chemotherapy 1994;38(6):1309&#x2010;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188203</ArticleId><ArticleId IdType="pubmed">8092830</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Condon 1995 {published data only}</Title><Reference><Citation>Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double&#x2010;blind clinical trial. Clinical Infectious Diseases 1995;21(3):544&#x2010;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">8527541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Danish 1984 {published data only}</Title><Reference><Citation>The Danish Multicenter Study Group. A Danish multicenter study: cefoxitin versus ampicillin + metronidazole in perforated appendicitis. British Journal of Surgery 1984;71(2):144&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">6692110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Danziger 1988 {published data only}</Title><Reference><Citation>Danziger LH, Creger RJ, Shwed JA, Stellato TA, Hau T. Randomized trial of imipenem/cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections. Pharmacotherapy 1988;8(6):315&#x2010;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3222164</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>de Vries 1990 {published data only}</Title><Reference><Citation>Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once&#x2010;daily versus thrice&#x2010;daily netilmicin regimens in patients with intraabdominal infections. European Journal of Clinical Microbiological Infectious Diseases 1990;9(3):161&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">2186909</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Donahue 1998 {published data only}</Title><Reference><Citation>Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR and the Trovafloxacin Surgical Group. Trovafloxacin in the treatment of intra&#x2010;abdominal infections: Results of a double&#x2010;blind, multicenter comparison with imipenem/cilastatin. American Journal of Surgery 1998;176(Suppl 6A):53S&#x2010;61S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9935258</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dougherty 1995 {published data only}</Title><Reference><Citation>Dougherty SH, Sirinek KR. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra&#x2010;abdominal infections in pediatric and adult patients. American Surgeon 1995;61(4):297&#x2010;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7893090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Drusano 1982 {published data only}</Title><Reference><Citation>Drusano GL, Warren JW, Saah AJ, Caplan ES, Tenney JH, Hansen S, et al. A prospective randomized controlled trial of cefoxitin versus clindamycin&#x2010;aminoglycoside in mixed anaerobic&#x2010;aerobic infections. Surgery, Gynecology &amp; Obstetrics 1982;154(5):715&#x2010;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">7041297</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eklund 1993 {published data only}</Title><Reference><Citation>Eklund A&#x2010;E, Nord CE and Swedish Study Group. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl A):79&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8383657</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fink 1989 {published data only}</Title><Reference><Citation>Fink MP, Helsmoortel CM, Arous EJ, Doern GV, Moriarty KP, Fairchild PG, et al. Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/gentamicin in serious intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1989;24(Suppl B):147&#x2010;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">2691476</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fink 1991 {published data only}</Title><Reference><Citation>Fink MP. Antibiotic therapy of intra&#x2010;abdominal sepsis in the elderly: Experience with ticarcillin and clavulanic acid. Surgery, Gynecology &amp; Obstetrics 1991;172(Suppl):36&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2024225</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geroulanos 1995 {published data only}</Title><Reference><Citation>Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra&#x2010;abdominal infections requiring surgery. Journal of Antimicrobial Chemotherapy 1995;36(Suppl A):191&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543495</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harding 1982 {published data only}</Title><Reference><Citation>Harding G, Vincelette J, Rachlis A, Fong I, Mandell L, Feld R, et al. A preliminary report on the use of ceftizoxime vs. clindamycin/tobramycin for the therapy of intra&#x2010;abdominal and pelvic infections. Journal of Antimicrobial Chemotherapy 1982;10(Suppl C):191&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">6296005</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Henning 1984 {published data only}</Title><Reference><Citation>Henning C, Meden&#x2010;Britth G, Frolander F, Karlsson J, Dornbusch K. Comparative study of netilmicin/tinidazole versus netilmicin/clindamycin in the treatment of severe abdominal infections. Scandinavian Journal of Infectious Diseases 1984;16(3):297&#x2010;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">6494811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Henry 1985 {published data only}</Title><Reference><Citation>Henry SA. Overall clinical experience with aztreonam in the treatment of intraabdominal infections. Reviews of Infectious Diseases 1985;7(Suppl 4):S729&#x2010;S733.</Citation><ArticleIdList><ArticleId IdType="pubmed">3909331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Heseltine 1986 {published data only}</Title><Reference><Citation>Heseltine PNR, Yellin AE, Appleman MD, Gill MA, Chenella FC, Berne TV, et al. Imipenem therapy for perforated and gangrenous appendicitis. Surgery, Gynecoloy &amp; Obstetrics 1986;162(1):43&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">3455671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hollender 1989 {published data only}</Title><Reference><Citation>Hollender LF, Bahnini J, Manzini N, Lau WY, Fan ST, Hermansyur K, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1989;23(5):773&#x2010;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">2668247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Holloway 1989 {published data only}</Title><Reference><Citation>Holloway WJ, Winslow DL, Reinhardt JF. Cefmetazole treatment of intra&#x2010;abdominal infection. Journal of Antimicrobial Chemotherapy 1989;23(Suppl D):47&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2722723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hoogkamp 1995 {published data only}</Title><Reference><Citation>Hoogkamp&#x2010;Korstanje JAA. Ciprofloxacin versus cefotaxime regimens for the treatment of intra&#x2010;abdominal infections. Infections 1995;23(5):278&#x2010;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557385</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huizinga 1988 {published data only}</Title><Reference><Citation>Huizinga WKJ, Baker LW, Kadwa H, Ende J, Francis AJ, Francis GM. Management of severe intra&#x2010;abdominal sepsis: Single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. British Journal of Surgery 1988;75(11):1134&#x2010;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">3061561</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Huizinga 1995 {published data only}</Title><Reference><Citation>Huizinga WKJ, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp&#x2010;Korstanjep JAA, et al. Antibiotic monotherapy with meropenem in the surgical management of intra&#x2010;abdominal infections. Journal of Antimicrobial Chemotherapy 1995;36(Suppl A):179&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">8543493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Inthorn 1989 {published data only}</Title><Reference><Citation>Inthorn D, Muhlbayer D, Hartl WH. Ticarcillin/clavulanate in the treatment of severe peritonitis. Journal of Antimicrobial Chemotherapy 1989;24(Suppl B):141&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">2691475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaspers 1998 {published data only}</Title><Reference><Citation>Jaspers CAJJ, Kieft H, Speelberg B, Buiting A, Marwijk Kooij M, Ruys GJHM, et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrobial Agents and Chemotherapy 1998;42(5):1233&#x2010;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC105786</ArticleId><ArticleId IdType="pubmed">9593156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Joshi 1986 {published data only}</Title><Reference><Citation>Joshi M, Fitzpatrick BJ, Warren JW, Caplan ES, Tenney JH. A randomized controlled rial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections. The American Surgeon 1986;52(9):467&#x2010;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">3530075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kasholm&#x2010;Tengve 1986 {published data only}</Title><Reference><Citation>Kasholm&#x2010;Tengve B, Bartholdson P. Antibiotics in acute abdominal surgery. A clinical trial comparing the combination of ampicillin, mecillinam and metronidazole with cefoxitin alone. Acta Chirurgica Scandinavica 1986;152:267&#x2010;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">3526773</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kirkpatrick 1983 {published data only}</Title><Reference><Citation>Kirkpatrick JR, Anderson BJ, Louie JJ, Stiver HG. Double&#x2010;blind comparison of metronidazole plus gentamicin and clindamycin plus gentamicin in intra&#x2010;abdominal infection. Surgery 1983;93(1 Pt 2):215&#x2010;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849208</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kooi 1990 {published data only}</Title><Reference><Citation>Kooi GH, Pit S. Ceftazidime/metronidazole versus netilmicin/metronidazole in the treatment of perforated appendicitis in children. Clinical Therapeutics 1990;12(1):54&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">2183940</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leal del Rosal 1989 {published data only}</Title><Reference><Citation>Leal del Rosal P, Leal del Rosal L, Riosvelasco A, Nesbitt FC, Alanis VS. Brief report: Prospective, controlled, randomized, non&#x2010;blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of severe surgical infections. The American Journal of Medicine 1989;87(Suppl 5A):183S&#x2010;184S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2686420</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lennard 1985 {published data only}</Title><Reference><Citation>Lennard ES, Minshew BH, Dellinger EP, Wertz MJ, Heimbach DM, Counts GW, et al. Stratified outcome comparison of clindamycin&#x2010;gentamicin versus chloramphenicol&#x2010;gentamicin for treatment of intra&#x2010;abdominal sepsis. Archives of Surgery 1985;120(8):889&#x2010;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">3893387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levine 1989 {published data only}</Title><Reference><Citation>Levine DP, McNeil P, Lerner SA. Randomized, double&#x2010;blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. The American Journal of Medicine 1989;87(Suppl 5A):160S&#x2010;163S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2686416</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lou 1982 {published data only}</Title><Reference><Citation>Lou MA, Chen DF, Bansal M, Balasubramaniam S, Thadepalli H. Evaluation of ceftizoxime in acute peritonitis. Journal of Antimicrobial Chemotherapy 1982;10(Suppl C):183&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">6296004</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Luke 1991 {published data only}</Title><Reference><Citation>Luke M, Iversen J, Sondergaard J, Kvist E, Lund P, Andersen F, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. European Journal of Surgery 1991;157:397&#x2010;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">1681917</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Luke 1999 {published data only}</Title><Reference><Citation>Luke DR, Peterson J. Treatment of complicated intra&#x2010;abdominal infections: Comparison of the tolerability and safety of intravenous/oral trovafloxacin versus intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid. International Journal of Clinical Practice 1999;53(3):166&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">10665126</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marra 1998 {published data only}</Title><Reference><Citation>Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, et al. Piperacillin/tazobactam versus imipenem: A double&#x2010;blind, randomized formulary feasibility study at a major teaching hospital. Diagnostic Microbiology &amp; infectious Diseases 1998;31(2):355&#x2010;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9635910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mehtar 1997 {published data only}</Title><Reference><Citation>Mehtar S, Dewar EP, Leaper DJ, Taylor EW. A multi&#x2010;centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. Journal of Antimicrobial Chemotherapy 1997;39(5):631&#x2010;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184363</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Messick 1998 {published data only}</Title><Reference><Citation>Messick CR, Mamdani M, McNicholl IR, Danziger LH, Rodvold KA, Condon RE, et al. Pharmacoeconomic analysis of ampicillin&#x2010;sulbactam versus cefoxitin in the treatment of intraabdominal infections. Pharmacotherapy 1998;18(1):175&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9469691</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mullick 1987 {published data only}</Title><Reference><Citation>Mullick RN, Zissis NP. Piperacillin versus gentamicin&#x2010;clindamycin combination in intra&#x2010;abdominal infections. Current Therapeutic Research &#x2010; Clinical and Experimental 1987;41(4):536&#x2010;541.</Citation></Reference></ReferenceList><ReferenceList><Title>Najem 1983 {published data only}</Title><Reference><Citation>Najem AZ, Kaminski ZC, Spillert CR, Lazaro EJ. Comparative study of parenteral piperacillin and cefoxitin in the treatment of surgical infections of the abdomen. Surgery, Gynecology &amp; Obstetrics 1983;157(5):423&#x2010;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">6635912</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Niinikoski 1993 {published data only}</Title><Reference><Citation>Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra&#x2010;abdominal infections. Surgery, Gynecology &amp; Obstetrics 1993;176(3):255&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">8382381</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ohlin 1999 {published data only}</Title><Reference><Citation>Ohlin B, Cederberg A, Forssell H, Solhaug JH, Tveit E. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra&#x2010;abdominal infections. European Journal of Surgery 1999;165(9):875&#x2010;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">10533765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Polk 1993 {published data only}</Title><Reference><Citation>Polk HC, Fink MP, Laverdiere M, Wilson SE, Garber GE, Barie JS, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra&#x2010;abdominal infection. American Surgeon 1993;59(9):598&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396374</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Poularas 1988 {published data only}</Title><Reference><Citation>Poularas J, Giamarellou H, Vlachos G, Theakou R, Patoulis J, Lekakos N, et al. The treatment of gynaecological and intra&#x2010;abdominal infections: A comparative study of cefotetan versus netilmicin plus clindamycin. Chemioterapia 1988;7(4):253&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">3180305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Raahave 1970 {published data only}</Title><Reference><Citation>Raahave D, Poulsen PE. Perforated appendicitis and antibiotics. A survey and a controlled clinical trial. Acta Chirurgica Scandinavica 1970;136(8):715&#x2010;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">4931922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rohrborn 2000 {published data only}</Title><Reference><Citation>Rohrborn A, Wacha H, Schoffel U, Billing A, Aeberhard P, Gebhard B, et al. Coverage of enterococci in community acquired secondary peritonitis: Results of a randomized trial. Surgical Infections 2000;1(2):95&#x2010;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">12594897</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schein 1994 {published data only}</Title><Reference><Citation>Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. British Journal of Surgery 1994;81(7):989&#x2010;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">7922094</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scheinin 1994 {published data only}</Title><Reference><Citation>Scheinin H, Havia T, Pekkala E, Huovinen P, Klossner J, Lehto H, et al. Aspoxicillin versus piperacillin in severe abdominal infections &#x2010; a comparative phase III study. Journal of Antimicrobial Chemotherapy 1994;34(5):813&#x2010;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706179</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schentag 1983 {published data only}</Title><Reference><Citation>Schentag JJ, Wels PB, Reitberg DP, Walczak P, Tyle JH, Lascola RJ. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Annals of Surgery 1983;198(1):35&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352928</ArticleId><ArticleId IdType="pubmed">6222710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scott 1987a {published data only}</Title><Reference><Citation>Scott SD, Karran SJ. Cefotetan in the treatment of serious intra&#x2010;abdominal sepsis: a controlled clinical trial. International Journal of Clinical Pharmacological Research 1987;VII(3):229&#x2010;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">3298087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sirinek 1987 {published data only}</Title><Reference><Citation>Sirinek KR, Levine BA. Antimicrobial management of surgically treated gangrenous or perforated appendicitis: comparison of cefoxitin and clindamycin&#x2010;gentamicin. Clinical Therapeutics 1987;9(4):420&#x2010;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">3607822</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sirinek 1991 {published data only}</Title><Reference><Citation>Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surgery, Gynecology &amp; Obstetrics 1991;172(Suppl):30&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">2024224</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1982 {published data only}</Title><Reference><Citation>Smith JA, Forward AD, Skidmore AG, Bell GA, Murphy JM. Metronidazole and tobramycin in intra&#x2010;abdominal sepsis. Surgery, Gynecology &amp; Obstetrics 1982;155(2):235&#x2010;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">7101115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1983 {published data only}</Title><Reference><Citation>Smith JA, Forward AD, Skidmore AG, Bell GA, Murphy JM, Sutherland E. Metronidazole in the treatment of intra&#x2010;abdominal sepsis. Surgery 1983;93(1 Part 2):217&#x2010;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">6336865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Smith 1984 {published data only}</Title><Reference><Citation>Smith CR, Ambinder R, Lipsky JJ, Petty BG, Israel E, Levitt R, et al. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double&#x2010;blind trial. Annals of Internal Medicine 1984;101(4):469&#x2010;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">6089633</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1985 {published data only}</Title><Reference><Citation>Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. The American Journal of Medicine 1985;78(Suppl 6A):85&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">3890538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1990 {published data only}</Title><Reference><Citation>Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra&#x2010;abdominal infections. Annals of Surgery 1990;212(5):581&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1358185</ArticleId><ArticleId IdType="pubmed">2241313</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 1996 {published data only}</Title><Reference><Citation>Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra&#x2010;abdominal infections. Annals of Surgery 1996;223(3):303&#x2010;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235120</ArticleId><ArticleId IdType="pubmed">8604912</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Solomkin 2003 {published data only}</Title><Reference><Citation>Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 2003;237(2):235&#x2010;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1522141</ArticleId><ArticleId IdType="pubmed">12560782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stellato 1988 {published data only}</Title><Reference><Citation>Stellato TA, Danziger LH, Hau T, Gauderer MWL, Ferron JL, Gordon N. Moxalactam versus tobramycin&#x2010;clindamycin. A randomized trial in secondary peritonitis. Archives of Surgery 1988;123(6):714&#x2010;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">3285809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1975 {published data only}</Title><Reference><Citation>Stone HH, Kolb LD, Geheber CE, Currie CA. Treatment of surgical infections with tobramycin. The American Surgeon 1975;41(5):301&#x2010;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">1130763</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1978 {published data only}</Title><Reference><Citation>Stone HH, Guest BS, Geheber CE, Kolb LD. Cefamandole in treatment of peritonitis. Journal of Infectious Diseases 1978;137(Suppl):S103&#x2010;S109.</Citation><ArticleIdList><ArticleId IdType="pubmed">649995</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1981 {published data only}</Title><Reference><Citation>Stone HH, Geheber CE, Kolb LD, Dunlop WE. Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft&#x2010;tissue surgical sepsis. Clinical Therapeutics 1981;4(Suppl A):67&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">6275999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1982a {published data only}</Title><Reference><Citation>Stone HH, Geheber CE, Kolb LD, Strom PR. Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicorbial peritonitis. Clinical Therapeutics 1982;5(A):1&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6293712</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1982b {published data only}</Title><Reference><Citation>Stone HH, Morris ES, Geheber CE, Kolb LD, Dunlop WE. Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft tissue infections. Reviews of Infectious Diseases 1982;4(Suppl):S439&#x2010;S443.</Citation><ArticleIdList><ArticleId IdType="pubmed">6294796</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1983a {published data only}</Title><Reference><Citation>Stone HH. Metronidazole in the treatment of surgical sepsis. Surgery 1983;93(1 Pt 2):230&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">6849210</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1983b {published data only}</Title><Reference><Citation>Stone HH, Strom PR, Fabian TC, Dunlop WE. Third generation cephalosporins for polymicrobial surgical sepsis. Archives of Surgery 1983;118(2):193&#x2010;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6295339</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stone 1984 {published data only}</Title><Reference><Citation>Stone HH, Mullins RJ, Strom PR, Bourneuf AA, Geheber CE. Ceftriaxone versus combined gentamicin and clindamycin for polymicrobial surgical sepsis. The American Journal of Surgery 1984;148(4A):30&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">6091478</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tally 1981 {published data only}</Title><Reference><Citation>Tally FP, McGowan K, Kellum JM, Gorbach SL, O'Donnell TF. A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Annals of Surgery 1981;193(3):318&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345068</ArticleId><ArticleId IdType="pubmed">7011222</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tally 1986 {published data only}</Title><Reference><Citation>Tally FP, Kellum JM, Ho JL, O'Donnell TF, Barza M, Gorbach SL. Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections. Antimicrobial Agents and Chemotherapy 1986;29(2):244&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC176385</ArticleId><ArticleId IdType="pubmed">3717931</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Taylor 2000 {published data only}</Title><Reference><Citation>Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: Is there a minimum intravenous antibiotic requirement? A prospective randomized trial. The American Surgeon 2000;66(9):887&#x2010;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tellado 2002 {published data only}</Title><Reference><Citation>Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H. Ertapenem versus piperacillin&#x2010;tazobactam for treatment of mixed anaerobic complicated intra&#x2010;abdominal, complicated skin and skin structure, and acute pelvic infections. Surgical Infections 2002;3(4):303&#x2010;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697078</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Teppler 2004 {published data only}</Title><Reference><Citation>Teppler H, Meibohm AR, Woods GL. Management of complicated appendicitis and comparison of outcome with other primary sites of intra&#x2010;abdominal infections: Results of a trial comparing ertapenem and piperacillin&#x2010;tazobactam. Journal of Chemotherapy 2004;16(1):62&#x2010;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078001</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vestweber 1994 {published data only}</Title><Reference><Citation>Vestweber K&#x2010;H, Grundel E. Efficacy and safety of piperacillin/tazobactam in intra&#x2010;abdominal infections. European Journal of Surgery 1994;Suppl 573:57&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7524797</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Walters 1999 {published data only}</Title><Reference><Citation>Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem&#x2010;cilastatin in the treatment of intra&#x2010;abdominal infections. Pharmacoeconomics 1999;16(5 Pt 2):551&#x2010;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">10662480</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Williams 1991 {published data only}</Title><Reference><Citation>Williams RR, Hotchkin D. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections. Reviews of Infectious Diseases 1991;13(Suppl 7):S629&#x2010;S633.</Citation><ArticleIdList><ArticleId IdType="pubmed">2068472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wilson 1988a {published data only}</Title><Reference><Citation>Wilson SE, Boswick JA Jr, Duma RJ, Echols RM, Jemsek JG, Lerner R, et al. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam and cefoxitin. The American Journal of Surgery 1988;155(5A):61&#x2010;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">3287971</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wilson 1997 {published data only}</Title><Reference><Citation>Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra&#x2010;abdominal infections. Clinical Infectious Diseases 1997;24(Suppl 2):S197&#x2010;S206.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Winston 1980 {published data only}</Title><Reference><Citation>Winston DJ, Murphy W, Young LS, Hewitt WL. Piperacillin therapy for serious bacterial infections. The American Journal of Medicine 1980;69(2):255&#x2010;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">6447455</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 1993 {published data only}</Title><Reference><Citation>Yellin AE, Berne TV, Heseltine PNR, Appleman MD, Gill M, Chin A, et al. Prospective randomized study of two different doses of clindamycin admixed with gentamicin in the management of perforated appendicitis. The American Surgeon 1993;59(4):248&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yellin 2002 {published data only}</Title><Reference><Citation>Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B, Woods GL, et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra&#x2010;abdominal infections in adults. International Journal of Antimicrobial Agents 2002;20(3):165&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12385694</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yoshioka 1991 {published data only}</Title><Reference><Citation>Yoshioka K, Youngs DJ, Keighley MRB. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra&#x2010;abdominal infection. Infection 1991;19(1):25&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">2013505</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Alderson 2004</Title><Reference><Citation>Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers&#x2019; Handbook 4.2.2 [updated March 2004]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp; Sons, Ltd, 2004.</Citation></Reference></ReferenceList><ReferenceList><Title>Bohnen 1983</Title><Reference><Citation>Bohnen J, Boulanger M, Meakins JL, McLean AP. Prognosis in generalized peritonitis. Relation to cause and risk factors. Archives of Surgery 1983;118(3):285&#x2010;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">6824428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bohnen 1992</Title><Reference><Citation>Bohnen JMA, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti&#x2010;infective agents for intra&#x2010;abdominal infection. A Surgical Infection Society policy statement. Archives of Surgery 1992;127:83&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734854</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bosscha 1999</Title><Reference><Citation>Bosscha K, Vroonhoven TJMV, Werken C. Surgical management of severe secondary peritonitis. British Journal of Surgery 1999;86(11):1371&#x2010;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">10583280</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Christou 1993</Title><Reference><Citation>Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra&#x2010;abdominal infection study. Prospective evaluation of management techniques and outcome. Archives of Surgery 1993;128(2):193&#x2010;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Copeland 2002</Title><Reference><Citation>Copeland GP. The POSSUM system of surgical audit. Archives of Surgery 2002;137(1):15&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11772209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Egger 2001</Title><Reference><Citation>Egger M, Smith GD, Altman DG. Systematic reviews in health care: Meta&#x2010;analysis in context. Second Edition. London: BMJ Publishing Group, 2001.</Citation></Reference></ReferenceList><ReferenceList><Title>Holzheimer 2001</Title><Reference><Citation>Holzheimer RG, Dralle H. Antibiotic therapy in intra&#x2010;abdominal infections: a review on randomised clinical trials. European Journal of Medical Research 2001;6(7):277&#x2010;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485888</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jones 1992</Title><Reference><Citation>Jones DR, Copeland GP, Cossart L. Comparison of POSSUM with APACHE II for prediction of outcome from a surgical high&#x2010;dependency unit. British Journal of Surgery 1992;79(12):1293&#x2010;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">1486421</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knaus 1985</Title><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical Care Medicine 1985;13(10):818&#x2010;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazuski 2002a</Title><Reference><Citation>Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA and Yowler C for The Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra&#x2010;abdominal infections: an executive summary. Surgical Infections 2002;3(3):161&#x2010;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542922</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazuski 2002b</Title><Reference><Citation>Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA and Yowler C for The Therapeutic Agents Committee of the Surgical Infection Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra&#x2010;abdominal infections: evidence for the recommendations. Surgical Infections 2002;3(3):175&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12542923</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mc Lauchlan 1995</Title><Reference><Citation>McLauchlan GJ, Anderson ID, Grant IS, Fearon KCH. Outcome of patients with abdominal sepsis treated in an intensive care unit. British Journal of Surgery 1995;82(4):524&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7613902</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mulier 2003</Title><Reference><Citation>Mulier S, Penninckx F, Verwaest C, Filez L, Aerts R, Fieuws S, Lauwers P. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World Journal of Surgery 2003;27(4):379&#x2010;384. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">12658477</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nichols 1992</Title><Reference><Citation>Nichols RL, Muzik AC. Enterococcal infection in surgical patients: the mystery continues. Clinical Infectious Diseases 1992;15(1):72&#x2010;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1617075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ohmann 1993</Title><Reference><Citation>Ohmann C, Wittmann DH, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. European Journal of Surgery 1993;159(5):267&#x2010;274. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">8103360</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pacelli 1996</Title><Reference><Citation>Pacelli F, Doglietto GB, Alfieri S, Piccioni E, Sgadari A, Gui D, Crucitti F. Prognosis in intra&#x2010;abdominal infections. Multivariate analysis on 604 patients. Archives of Surgery 1996;131(6):641&#x2010;645. [MEDLINE: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">8645072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schein 2002</Title><Reference><Citation>Schein M, Marshall JC. Source control: A guide to the management of surgical infections. Italy: Springer&#x2010;Verlag, 2002.</Citation></Reference></ReferenceList><ReferenceList><Title>Solomkin 1984</Title><Reference><Citation>Solomkin JS, Meakin JL, Alo MD, Dellinger EP, Simmons RL. Antibiotics trials in intra&#x2010;abdominal infections. A critical evaluation of study design and outcome reporting. Annals of Surgery 1984;200:29&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250388</ArticleId><ArticleId IdType="pubmed">6375597</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tellado 2000</Title><Reference><Citation>Tellado JM, Christou NV. Intra&#x2010;abdominal infections. Madrid: Harcourt, 2000.</Citation></Reference></ReferenceList><ReferenceList><Title>Wittmann 1990</Title><Reference><Citation>Wittmann DH, Aprahamian C, Bergstein JM. Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, slide fastener, and Velcro analogue for temporary abdominal closure. World Journal of Surgery 1990;14(2):218&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2183485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wittmann 1996</Title><Reference><Citation>Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Annals of Surgery 1996;224(1):10&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235241</ArticleId><ArticleId IdType="pubmed">8678610</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25616698</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2015</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Surgical treatment of ipsilateral multi-level femoral fractures.</ArticleTitle><Pagination><StartPage>7</StartPage><MedlinePgn>7</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-014-0149-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Concurrent ipsilateral fractures of the proximal and shaft of the femur are rare complex fracture combinations. In this prospective cohort study, we evaluated clinical and radiological long-term results after operative treatment using several surgical strategies: the so-called "rendezvous" surgical technique, e.g., the combination of retrograde intramedullary nailing and dynamic hip screw (DHS) osteosynthesis, or the all-in-one device technique, e.g., long cephalomedullary nail, compared with two non-overlapping implants (e.g., conventional technique).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a 10-year-period from 2004 to 2013, we treated 65 patients with complex ipsilateral multi-level femoral fractures. Median age was 45&#xa0;years (range 19-90 years). Fractures were classified according to the AO/OTA classification. Four patients died during intensive care unit treatment due to multi-organ failure prior to definitive osteosynthesis. Clinical long-term outcome using the functional system of Friedman/Wyman as well as radiological outcome was evaluated 2&#xa0;years after trauma (range 13-42 months).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All-in-one device was used in 36 patients, "rendezvous" technique in 9 patients, and the conventional technique in the remaining 16 patients. Two years after trauma, complete fracture healing was found in 57 out of 61 patients ("rendezvous": 9, all-in-one device: 33, conventional: 15; p-value: 0.66). There was no significant difference regarding the complication rate in the cohort groups ("rendezvous": 3, all-in-one device: 13, conventional: 5; p-value: 0.94). Using the functional assessment system of Friedman/Wyman 2&#xa0;years after trauma, a good clinical result was found in 77.7% in the "rendezvous" group, in 77.8% in the all-in-one device group, and in 75% in the conventional group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The indication for operative stabilization of ipsilateral multi-level femoral fractures is considered an urgent and emergency procedure. Based on the successful long-term results of this study, we prefer the "rendezvous" technique with fracture stabilization from distally to proximally. Both fracture components require stable fixation. It is advisable to stabilize the shaft fracture primarily using external fixation (damage control orthopedics) and the proximal femoral fracture using early definitive internal fixation. In a second and staged operation, the external fixator is removed and the shaft fracture is stabilized using retrograde nail osteosynthesis with overlapping of the DHS and nail implants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von R&#xfc;den</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. christian.vonrueden@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tauber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. markus.tauber@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltmann</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. alexander.woltmann@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friederichs</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. jan.friederichs@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackl</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. simon.hackl@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;hren</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. volker.buehren@bgu-murnau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hierholzer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Trauma Center Murnau, 82418, Murnau, Germany. christian.hierholzer@bgu-murnau.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005264" MajorTopicYN="N">Femoral Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005594" MajorTopicYN="N">Fracture Fixation, Intramedullary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069076" MajorTopicYN="N">Fractures, Multiple</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25616698</ArticleId><ArticleId IdType="pmc">PMC4335365</ArticleId><ArticleId IdType="doi">10.1186/s13018-014-0149-5</ArticleId><ArticleId IdType="pii">s13018-014-0149-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chaturvedi S, Sahu SC. Ipsilateral concomitant fractures of the femoral neck and shaft. Injury. 1993;24:243&#x2013;6. doi: 10.1016/0020-1383(93)90178-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-1383(93)90178-9</ArticleId><ArticleId IdType="pubmed">8325681</ArticleId></ArticleIdList></Reference><Reference><Citation>Alho A, Ekeland A, Grogaard B, Dokke JR. A locked hip screw-intramedullary nail (cephalomedullary nail) for the treatment of fractures of the proximal part of the femur combined with fractures of the femoral shaft. J Trauma. 1996;40:10&#x2013;6. doi: 10.1097/00005373-199601000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199601000-00003</ArticleId><ArticleId IdType="pubmed">8576969</ArticleId></ArticleIdList></Reference><Reference><Citation>Alho A. Concurrent ipsilateral fractures of the hip and shaft of the femur: a systematic review of 722 cases. Ann Chir Gynaecol. 1997;86:326&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas NP, Sch&#xfc;tz M, Mauch C, Hoffmann R, S&#xfc;dkamp NP. Management of ipsilateral fractures of the femur shaft and proximal femur - therapy overview and current management. Zentralbl Chir. 1995;120:856&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8533480</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman RJ, Wyman ET. Ipsilateral hip and femoral shaft fractures. Clin Orthop Relat Res. 1986;208:188&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">3720122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuler TE, Gruen GS, DiTano O, Riemer BL. Ipsilateral proximal and shaft femoral fractures: spectrum of injury involving the femoral neck. Injury. 1997;28(4):293&#x2013;7. doi: 10.1016/S0020-1383(96)00199-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(96)00199-4</ArticleId><ArticleId IdType="pubmed">9282185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SH, Lo CW, Cheng SC, Kuo MY, Chin LS. Use of reconstruction nails to manage ipsilateral displaced femoral neck-shaft fractures: assessment of a new approach. J Orthop Surg. 2002;20:185&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493933</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Labler L, Trentz O. &#x201c;Damage control&#x201d; in severely injured patients. Why, when, and how? Eur J Trauma Emerg Surg. 2005;31:212&#x2013;21. doi: 10.1007/s00068-005-2034-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-005-2034-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover GK, Browner BD, Cole JD, Comstock CP, Cotler HB. Initial experience with a second generation locking femoral nail: the Russel-Taylor reconstruction nail. Contemp Orthop. 1991;23(3):199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10149652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali K, Gahlot N, Aggarwal S, Goni V. Cephalomedullary fixation for femoral neck/intertrochanteric and ipsilateral shaft fractures: surgical tips and pitfalls. Chin J Traumatol. 2013;16(1):40&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23384870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsarouhas A, Hantes ME, Karachalios T, Bargiotas K, Malizos KN. Reconstruction nailing for ipsilateral femoral neck and shaft fractures. Strategies Traum Limb Reconstr. 2011;6:69&#x2013;75. doi: 10.1007/s11751-011-0117-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11751-011-0117-0</ArticleId><ArticleId IdType="pmc">PMC3150652</ArticleId><ArticleId IdType="pubmed">21779894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadegone WM, Lokhande V, Salphale Y, Ramteke A. Long proximal femoral nail in ipsilateral fractures of proximal femur and shaft of femur. Indian J Orthop. 2013;47(3):272&#x2013;7. doi: 10.4103/0019-5413.109441.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5413.109441</ArticleId><ArticleId IdType="pmc">PMC3687904</ArticleId><ArticleId IdType="pubmed">23798758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MC, Wu CC, Hsiao CW, Huang JW, Kao HK, Hsu YT. Reconstruction intramedullary nailing for ipsilateral femoral neck and shaft fractures: main factors determining prognosis. Chang Gung Med J. 2009;32(5):563&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19840514</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KS, So WS, Lam TP, Leung PC. Treatment of ipsilateral femoral shaft fractures and hip fractures. Injury. 1993;24(1):41&#x2013;5. doi: 10.1016/0020-1383(93)90082-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-1383(93)90082-H</ArticleId><ArticleId IdType="pubmed">8432574</ArticleId></ArticleIdList></Reference><Reference><Citation>Okcu G, Aktuglu K. Antegrade nailing of femoral shaft fractures combined with neck or distal femur fractures. Arch Orthop Trauma Surg. 2003;123:544&#x2013;50. doi: 10.1007/s00402-003-0584-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-003-0584-y</ArticleId><ArticleId IdType="pubmed">13680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Anup K, Mehra MM. Retrograde femoral interlocking nail in complex fractures. J Orthop Surg. 2002;10(1):17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Chen TB, Cheng YM, Chang JK, Lin SY, Hung SH. Ipsilateral fractures of the femoral neck and shaft. Injury. 2000;31:719&#x2013;22. doi: 10.1016/S0020-1383(00)00096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(00)00096-6</ArticleId><ArticleId IdType="pubmed">11084160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36305702</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2037-7452</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of translational myology</Title><ISOAbbreviation>Eur J Transl Myol</ISOAbbreviation></Journal><ArticleTitle>Cortical bridging a union predictor: A prospective study after intramedullary nailing of the femoral shaft fractures.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10835</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4081/ejtm.2022.10835</ELocationID><Abstract><AbstractText>Early prediction of the union helps for timely intervention, reduction of hospitalization, treatment costs, and disability in cases of nonunion. With this in mind, we tried to find how long any cortical bridging predicts the union in femoral shaft fractures. A prospective study of 113 femoral shaft fractures treated with reamed, locked intramedullary nailing was performed. Radiographs were taken during months 2 to 4, 6, 9, and one-year follow-up. The cortical bridging (presence and number) was assessed by anterior-posterior and lateral views. The ROC curve provides the prediction of the union. The overall nonunion rate was 10.6% (12 of 113 fractures). Age and diabetes mellitus were statistically significant with nonunion (p value &lt; 0.001). The final analysis demonstrated that any cortical bridging at four months postoperatively was the most accurate and earlier indicator (105 of 113, 92.9% accuracy), while it was 84.9% at six months in bicortical and 80.5% accuracy at nine months in tricortical bridging. Low-cost and simple radiographic imaging presents cortical bridging in any form 4 months after surgery that precisely predicts a union in femoral shaft fractures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Najafi</LastName><ForeName>Arvin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Arvin.najafi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahbazi</LastName><ForeName>Parmida</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Parmida.shabazi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azarsina</LastName><ForeName>Salman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. salmanazarsina@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zargar</LastName><ForeName>Danoosh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. danooshzargar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahrizi</LastName><ForeName>Mohammad Saeed</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Miladkahrizi1994@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadavi</LastName><ForeName>Dorsa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj. Hadavidorsa@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minaei-Noshahr</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bone, Joint and Related Tissues Research Center, Shahid Beheshti University of Medical Sciences, Tehran. reza.minaie@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur J Transl Myol</MedlineTA><NlmUniqueID>101576208</NlmUniqueID><ISSNLinking>2037-7452</ISSNLinking></MedlineJournalInfo><CoiStatement>We confirm that we have read the Journal&#x2019;s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. <b>M</b>idshaft femoral fractures, with an incidence of 10 in 100000 per year, are one of the most reasons for morbidity and mortality in lower extremity injuries. High-energy traumas, including falls, motor vehicle and motorcycle accidents, and high-velocity bullets in gunshots, are important causes of adult femoral shaft fractures. Another population suffering from these fractures are elderly females with a history of osteoporosis, experiencing low-energy traumas such as ground-level falls. Common crucial complications of femoral shaft fractures which could cause death include acute respiratory distress syndrome, fat embolism syndrome, and multi-organ failure.<sup>,</sup> Patients with femoral fractures complain about major physical impairments due to treatments such as fracture shortening or malalignment (resulting in limping and post-traumatic arthritis) and prolonged immobilization. The most important goal of the treatments is that the patients start their regular physical activities as soon as possible. While various treatment methods are available, interlocking intramedullary nailing is preferred for femoral shaft fracture fixation (successful union in 85-100%). As the beneficial results of this technique are assessed in an enormous number of studies, open reduction and plating do not assume to be the proper treatment for these fractures. One of the painful complications after the fixation surgery is nonunion, defined as proximal and distal segments' failure to unite after eight months or more than six months with no progression in the last three months.<sup>,</sup> It is worth noting that despite these timelines, some kinds of literature with more strict guidelines would suggest that we should consider the nonunion diagnosis as early as two months after the surgery. Nonunion is a common problem for most surgeons as it requires much more time to recover and increases the costs of multiple hospitalizations and healthcare services.<sup>,</sup> A method used to assess the union is radiographic cortical bridging in the cortices of the femur, which by various studies has been considered a reliable source of information to predict the union better than measuring the callus area and its quality. Although a healed fracture is described as the complete construction of all three cortices of the femur, there is still a lack of information about the cortical bridging exact numbers in different postoperative intervals to evaluate and consider the healing process as a successful result in that proper timeline. [Table: see text] The main purpose of this study was to collect precise data about the number of cortical bridgings in different intervals to obtain the accuracy of any cortical bridging callus as well as bicortical and tricortical bridging for the prediction of union or nonunion in the final results of healed fractures. [Figure: see text]</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36305702</ArticleId><ArticleId IdType="pmc">PMC9830402</ArticleId><ArticleId IdType="doi">10.4081/ejtm.2022.10835</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asplund CA, Mezzanotte TJ. Midshaft femur fractures in adults. UpToDate, Medilib, 2021. https://www.medilib.ir/uptodate/show/228</Citation></Reference><Reference><Citation>Rahman AF. The burden of road traffic injuries in South Asia: a commentary. J Coll Physicians Surg Pak. 2004;14(12):707-8. doi: 12.2004/jcpsp. 707708</Citation><ArticleIdList><ArticleId IdType="pubmed">15610625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan IA, Ahmad S, Shah MA, Ahmed S, Shafiq M, Shafaq SA. Static versus dynamic interlocking intramedullary nailing in fractures shaft of femur. Gomal Journal of Medical Sciences. 2015;13(2).</Citation></Reference><Reference><Citation>Omerovic D, Lazovic F, Hadzimehmedagic A. Static or dynamic intramedullary nailing of femur and tibia. Med Arch. 2015. Apr;69(2):110-3. doi: 10.5455/medarh.2015.69.110-113. Epub 2015 Apr 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430006</ArticleId><ArticleId IdType="pubmed">26005261</ArticleId></ArticleIdList></Reference><Reference><Citation>Karadimas EJ, Papadimitriou G, Theodoratos G, Papanikolaou A, Maris J. The effectiveness of the antegrade reamed technique: the experience and complications from 415 traumatic femoral shaft fractures. Strategies Trauma Limb Reconstr. 2009. Dec;4(3):113-21. doi: 10.1007/s11751-009-0071-2. Epub 2009 Nov 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787205</ArticleId><ArticleId IdType="pubmed">19936887</ArticleId></ArticleIdList></Reference><Reference><Citation>Basumallick MN, Bandopadhyay A. Effect of dynamization in open interlocking nailing of femoral fractures. A prospective randomized comparative study of 50 cases with a 2-year follow-up. Acta Orthop Belg. 2002. Feb;68(1):42-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11915458</ArticleId></ArticleIdList></Reference><Reference><Citation>Shroeder JE, Mosheiff R, Khoury A, Liebergall M, Weil YA. The outcome of closed, intramedullary exchange nailing with reamed insertion in the treatment of femoral shaft nonunions. J Orthop Trauma. 2009. Oct;23(9):653-7. doi: 10.1097/BOT.0b013e3181a2a337.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher W, Hamblen D. Problems and pitfalls of compression fixation of long bone fractures: a review of results and complications. Injury. 1979;10(2):99-107. doi: 10.1016/s0020-1383(79)80069-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">730343</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoster TA, Miller RA. Closed locked intramedullary nailing of femoral shaft fractures in the elderly. Iowa Orthop J. 2003;23:43-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888404</ArticleId><ArticleId IdType="pubmed">14575248</ArticleId></ArticleIdList></Reference><Reference><Citation>Devnani AS. Open reamed femoral intramedullary nailing&#x2013;revisited. Eastern J Med. 2003;8(1):7-11.</Citation></Reference><Reference><Citation>Meena R, Kundnani V, Hussain Z. Fracture of the shaft of the femur: Close vs open interlocking nailing. Indian J Orthop. 2006;40(4):243.</Citation></Reference><Reference><Citation>Bashir A, Mir B, Halwai M, Qayum A. First experience with locked intramedullary nailing of femur in Kashmir. Internet J Orthop Surg. 2008;8:1.</Citation></Reference><Reference><Citation>Nicoll E. Fractures of the tibial shaft. J Bone Joint Surg Br. 1964. Aug;46:373-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">14216447</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller ME, Perren S, Allg&#xf6;wer M, M&#xfc;ller ME, Schneider R, Willenegger H. Manual of internal fixation: techniques recommended by the AO-ASIF group: Springer Science &amp; Business Media; 1991.</Citation></Reference><Reference><Citation>Bishop JA, Palanca AA, Bellino MJ, Lowenberg DW. Assessment of compromised fracture healing. J Am Acad Orthop Surg. 2012. May;20(5):273-82. doi: 10.5435/JAAOS-20-05-273.</Citation><ArticleIdList><ArticleId IdType="pubmed">22553099</ArticleId></ArticleIdList></Reference><Reference><Citation>Canale ST, Beaty JH. Campbell's operative orthopaedics e-book: Elsevier Health Sciences; 2012.</Citation></Reference><Reference><Citation>Tay WH, de Steiger R, Richardson M, Gruen R, Balogh ZJ. Health outcomes of delayed union and nonunion of femoral and tibial shaft fractures. Injury. 2014. Oct;45(10):1653-8. doi: 10.1016/ j.injury.2014.06.025. Epub 2014 Jul 7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25062602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierholzer C, Glowalla C, Herrler M, von R&#xfc;den C, Hungerer S, B&#xfc;hren V, Friederichs J. Reamed intramedullary exchange nailing: treatment of choice of aseptic femoral shaft nonunion. J Orthop Surg Res. 2014. Oct 10;9:88. doi: 10.1186/s13018-014-0088-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201668</ArticleId><ArticleId IdType="pubmed">25300373</ArticleId></ArticleIdList></Reference><Reference><Citation>DiSilvio Jr F, Foyil S, Schiffman B, Bernstein M, Summers H, Lack WD. Long bone union accurately predicted by cortical bridging within 4 months. JBJS Open Access. 2018;3(4). doi: 10.2106/JBJS.OA.18.00012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400511</ArticleId><ArticleId IdType="pubmed">30882051</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000. Jul;82(5):655-8. doi: 10.1302/0301-620x.82b5.9899.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963160</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik MH, Harwood P, Diggle P, Khan SA. Factors affecting rates of infection and nonunion in intramedullary nailing. J Bone Joint Surg Br. 2004. May;86(4):556-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174553</ArticleId></ArticleIdList></Reference><Reference><Citation>Strotman PK, Karunakar MA, Seymour R, Lack WD. Any Cortical Bridging Predicts Healing of Supracondylar Femur Fractures After Treatment With Locked Plating. J Orthop Trauma. 2017. Oct;31(10):538-544. doi: 10.1097/BOT.00000000 00000887.</Citation><ArticleIdList><ArticleId IdType="pubmed">28538286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma YG, Hu GL, Hu W, Liang F. Surgical factors contributing to nonunion in femoral shaft fracture following intramedullary nailing. Chin J Traumatol. 2016. Apr 1;19(2):109-12. doi: 10.1016/j.cjtee.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897920</ArticleId><ArticleId IdType="pubmed">27140219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zura R, Mehta S, Della Rocca GJ, Steen RG. Biological Risk Factors for Nonunion of Bone Fracture. JBJS Rev. 2016. Jan 5;4(1):e5. doi: 10.2106/JBJS.RVW.O.00008.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson RG, Clement RGE, Edwards KL, Scammell BE. Do smokers have greater risk of delayed and non-union after fracture, osteotomy and arthrodesis? A systematic review with meta-analysis. BMJ Open. 2016;6(11):e010303. doi: 10.1136/bmjopen-2015-010303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129177</ArticleId><ArticleId IdType="pubmed">28186922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19615062</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2009</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>BioGlue and Peri-strips in lung volume reduction surgery: pilot randomised controlled trial.</ArticleTitle><Pagination><StartPage>37</StartPage><MedlinePgn>37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1749-8090-4-37</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both tissue sealants and buttressing have been advocated to reduce alveolar air leaks from staple lines following Lung Volume Reduction Surgery (LVRS). However, the long term detrimental effects of buttressing material are increasingly apparent. We performed a pilot prospective randomised self controlled trial in patients undergoing LVRS comparing BioGlue and Peri-strips as adjuncts in preventing alveolar air-leaks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A pilot prospective self controlled clinical trial was conducted in patients undergoing LVRS. Each patient was treated with BioGlue on one side and pericardial buttress on the other side as an adjunct to the staple line. The sides were randomised for adjuncts with each patient acting as his own control. Duration of air leak, intercostal drainage and time to chest drain removal were the study end points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">10 patients undergoing the procedure were recruited between December 2005 and October 2007. There were 6 men and the mean age was 59.8 +/- 4.9 years. There was one mortality due to multi-organ failure. The BioGlue treated side had a shorter mean duration of air-leak (3.0 +/- 4.6 versus 6.5 +/- 6.9 days), lesser chest drainage volume (733 +/- 404 ml versus 1001 +/- 861) and shorter time to chest drain removal (9.7 +/- 10.6 versus 11.5 +/- 11.1 days) compared with Peri-strips.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrates comparable efficacy of BioGlue and Peri-strips, however there is a trend favouring the BioGlue treated side in terms of reduction in air-leak, chest drainage volumes, duration of chest drainage and significant absence of complications. A larger sample size is needed to validate this result.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rathinam</LastName><ForeName>Sridhar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regional Department of Thoracic Surgery, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, UK. srathinam@rcsed.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Babu V</ForeName><Initials>BV</Initials></Author><Author ValidYN="Y"><LastName>Nanjaiah</LastName><ForeName>Prakash</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Loubani</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kalkat</LastName><ForeName>Maninder S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Rajesh</LastName><ForeName>Pala B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C472676">Bio-glue</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001672">Biocompatible Materials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014014">Tissue Adhesives</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001672" MajorTopicYN="N">Biocompatible Materials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011013" MajorTopicYN="N">Pneumonectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011650" MajorTopicYN="N">Pulmonary Alveoli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014014" MajorTopicYN="N">Tissue Adhesives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19615062</ArticleId><ArticleId IdType="pmc">PMC2722608</ArticleId><ArticleId IdType="doi">10.1186/1749-8090-4-37</ArticleId><ArticleId IdType="pii">1749-8090-4-37</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sundaresan RS, Roper CL. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1995;109:106&#x2013;116. doi: 10.1016/S0022-5223(95)70426-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(95)70426-4</ArticleId><ArticleId IdType="pubmed">7815786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059&#x2013;2073. doi: 10.1056/NEJMoa030287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030287</ArticleId><ArticleId IdType="pubmed">12759479</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCamp MM, Blackstone EH, Naunheim KS, Krasna MJ, Wood DE, Meli YM, McKenna RJ., Jr Patient and surgical factors influencing air leak after lung volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. Ann Thorac Surg. 2006;82:197&#x2013;206. doi: 10.1016/j.athoracsur.2006.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.02.050</ArticleId><ArticleId IdType="pubmed">16798215</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill SJ, Goldstraw P. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med. 2000;343:239&#x2013;245. doi: 10.1056/NEJM200007273430402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200007273430402</ArticleId><ArticleId IdType="pubmed">10911005</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD. Technique to reduce air leaks after resection of emphysematous lung. Ann Thorac Surg. 1994;57:1038&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">8166510</ArticleId></ArticleIdList></Reference><Reference><Citation>Stammberger U, Klepetko W, Stamatis G, Hamacher J, Schmid RA, Wisser W, Hillerjan L, Weder W. Buttressing the staple line in lung volume reduction surgery: a randomized three-center study. Ann Thorac Surg. 2000;70:1820&#x2013;1825. doi: 10.1016/S0003-4975(00)01903-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)01903-2</ArticleId><ArticleId IdType="pubmed">11156078</ArticleId></ArticleIdList></Reference><Reference><Citation>Porte HL, Jany t, Akkad R, Conti M, Gillet PA, Guidat A, Wurtz AJ. Randomized controlled trial of a synthetic sealent for preventing alveolar airleaks after lobectomy. Ann Thorac Surg. 2001;71:1618&#x2013;1622. doi: 10.1016/S0003-4975(01)02468-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(01)02468-7</ArticleId><ArticleId IdType="pubmed">11383810</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra-Mitjans M, Belda-Sanchis J, Rami-Porta R. Surgical sealent for preventing air leaks after pulmonary resections in patients with lung cancer update of Cochrane Database Syst Rev 2001. Cochrane Database Syst Rev. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16034884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansley P, Al-Mulhim F, Lim E, Ladas G, Goldstraw P. A prospective, randomized, controlled trial of the effectiveness of BioGlue in treating alveolar air leaks. J Thorac Cardiovasc Surg. 2006;132:105&#x2013;112. doi: 10.1016/j.jtcvs.2006.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2006.02.022</ArticleId><ArticleId IdType="pubmed">16798309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sundaresan RS, Roper CL. Trial of a novel synthetic sealent in preventing air leaks after lung resection. Ann Thorac Surg . 2000;71:1623&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">11383811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brantigan OC, Mueller E. Surgical treatment of pulmonary emphysema. Am Surg. 1957;23:789&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">13470332</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna RJ, Jr, Benditt JO, DeCamp M, Deschamps C, Kaiser L, Lee SM, Mohsenifar Z, Piantadosi S, Ramsey S, Reilly J, Utz J. Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. J Thorac Cardiovasc Surg. 2004;127:1350&#x2013;1360. doi: 10.1016/j.jtcvs.2003.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.11.025</ArticleId><ArticleId IdType="pubmed">15115992</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell GI, Solin P, Chin W, Rabinov M, Williams TJ, Esmore DS, Smith JA. Lung volume reduction surgery for emphysema. Med J Aust. 1997;167:529&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">9397040</ArticleId></ArticleIdList></Reference><Reference><Citation>Weder W, Schmid RA, Russi EW. Thoracoscopic lung volume reduction surgery for emphysema. Int Surg. 1996;81:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028978</ArticleId></ArticleIdList></Reference><Reference><Citation>Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, Deschamps CC, Martinez FJ, Sciurba FC, Tonascia J, Fishman AP. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006;82:431&#x2013;443. doi: 10.1016/j.athoracsur.2006.05.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.05.069</ArticleId><ArticleId IdType="pubmed">16888872</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Yoshinaga Y, Shirakusa T. Successful removal of bovine pericardium by bronchoscope after lung volume reduction surgery. Ann Thorac Surg. 2004;78:2156&#x2013;2157. doi: 10.1016/S0003-4975(03)01467-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(03)01467-X</ArticleId><ArticleId IdType="pubmed">15561058</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencher S, Deslauriers J. Late complication of bovine pericardium patches used for lung volume reduction surgery. Eur J Cardiothorac Surg. 2003;23:1059&#x2013;1061. doi: 10.1016/S1010-7940(03)00155-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(03)00155-6</ArticleId><ArticleId IdType="pubmed">12829092</ArticleId></ArticleIdList></Reference><Reference><Citation>Oey I, Waller DA. Metalloptysis: a late complication of lung volume reduction surgery. Ann Thorac Surg. 2001;71:1694&#x2013;1695. doi: 10.1016/S0003-4975(00)02303-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(00)02303-1</ArticleId><ArticleId IdType="pubmed">11383832</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamji MF, Maziak DE, Shamji FM, Matzinger FR, Perkins DG. Surgical staple metalloptysis after apical bullectomy: a reaction to bovine pericardium? Ann Thorac Surg. 2002;74:258&#x2013;261. doi: 10.1016/S0003-4975(02)03541-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(02)03541-5</ArticleId><ArticleId IdType="pubmed">12118780</ArticleId></ArticleIdList></Reference><Reference><Citation>Potaris K, Mihos P, Gakidis I. Preliminary results with the use of an albumin-glutaraldehyde tissue adhesive in lung surgery. Med Sci Monit . 2003;9:PI79&#x2013;PI83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15854933</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-6259</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>The Annals of thoracic surgery</Title><ISOAbbreviation>Ann Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Daily assessment of organ dysfunction and survival in intensive care unit cardiac surgical patients.</ArticleTitle><Pagination><StartPage>1555</StartPage><EndPage>1562</EndPage><MedlinePgn>1555-62</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to develop a specific postoperative score for intensive care unit (ICU) cardiac surgical patients for assessment of organ dysfunction and survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study consisted of all consecutive adult patients admitted after cardiac surgery to our ICU over a period of 3 years. Evaluation of variables was performed using the first year patients who stayed in the ICU for at least 24 hours. The reproducibility was then tested in two validation sets using all patients. Performance was assessed with the Hosmer-Lemeshow (chi2 statistics) goodness-of-fit test and receiver operating characteristic (ROC) curves and compared with the Acute Physiology and Chronic Health Evaluation (APACHE II) and Multiple Organ Dysfunction Score (MODS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3,230 patients were admitted to the ICU after cardiac surgery. Mean chi2 values for the new score were 5.8 (APACHE II, 11.3; MODS, 9.7) for the construction set, 7.2 (APACHE II, 8.0; MODS, 4.5) for the validation set I, and 5.9 for the validation set II. The mean area under the ROC curve was 0.91 (APACHE II, 0.86; MODS, 0.84) for the new score in the construction set, 0.88 (APACHE II, 0.84; MODS, 0.84) in the validation set I, and 0.92 in the validation set II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our new 10-variable risk index performs very well, with calibration and discrimination very high, better than general severity systems; and it is an appropriate tool for daily risk stratification in ICU cardiac surgery patients. Thus, it may serve as an "expert system" for diagnosing organ failure, decision making, resource evaluation, and predicting mortality among ICU cardiac surgical patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hekmat</LastName><ForeName>Khosro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, University of Cologne, Cologne, Germany. khosro.hekmat@uk-koeln.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroener</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stuetzer</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwinger</LastName><ForeName>Robert H G</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Kampe</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennink</LastName><ForeName>Gerardus B W E</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Mehlhorn</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Thorac Surg</MedlineTA><NlmUniqueID>15030100R</NlmUniqueID><ISSNLinking>0003-4975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15854933</ArticleId><ArticleId IdType="doi">10.1016/j.athoracsur.2004.10.017</ArticleId><ArticleId IdType="pii">S0003-4975(04)02119-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15148271</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4539</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>22</Issue><PubDate><Year>2004</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery.</ArticleTitle><Pagination><StartPage>2755</StartPage><EndPage>2760</EndPage><MedlinePgn>2755-60</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Leukocytes in allogeneic blood transfusions are believed to be the cause of immunomodulatory events. A few trials on leukocyte removal from transfusions in cardiac surgery have been conducted, and they showed inconclusive results. We found in a previous study a decrease in mortality rates and number of infections in a subgroup of more heavily transfused patients.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Patients (n=496) undergoing valve surgery (with or without CABG) were randomly assigned in a double-blind fashion to receive standard buffy coat-depleted (PC) or prestorage, by filtration, leukocyte-depleted erythrocytes (LD). The primary end point was mortality at 90 days, and secondary end points were in-hospital mortality, multiple organ dysfunction syndrome, infections, intensive care unit stay, and hospital stay. The difference in mortality at 90 days was not significant (PC 12.7% versus LD 8.4%; odds ratio [OR], 1.52; 95% confidence interval [CI], 0.84 to 2.73). The in-hospital mortality rate was almost twice as high in the PC group (10.1% versus 5.5% in the LD group; OR, 1.99; 95% CI, 0.99 to 4.00). The incidence of multiple organ dysfunction syndrome in both groups was similar, although more patients with multiple organ dysfunction syndrome died in the PC group. LD was associated with a significantly reduced infection rate (PC 31.6% versus LD 21.6%; OR, 1.64; 95% CI, 1.08 to 2.49). In both groups, intensive care unit stay and hospital stay were similar, and postoperative complications increased with the number of transfused units.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mortality at 90 days was not significantly different; however, a beneficial effect of LD in valve surgery was found for the secondary end points of in-hospital mortality and infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands. m.y.bilgin@lumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>L M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Eijsman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Versteegh</LastName><ForeName>M I M</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van Oers</LastName><ForeName>M H J</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001026" MajorTopicYN="N">Coronary Artery Bypass</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006351" MajorTopicYN="N">Heart Valves</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047589" MajorTopicYN="N">Leukocyte Reduction Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15148271</ArticleId><ArticleId IdType="doi">10.1161/01.CIR.0000130162.11925.21</ArticleId><ArticleId IdType="pii">01.CIR.0000130162.11925.21</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33931112</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>The potential of adipokines in identifying multiple trauma patients at risk of developing multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">38</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-021-00511-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) and the consecutive multiple organ failure (MOF) are severe and dreaded complications with a high mortality in multiple trauma patients. The aim of this study was to investigate the potential of the adipokines leptin, resistin, interleukin-17A and interleukin-33 as possible biomarkers in the early posttraumatic inflammatory response and for identifying severely traumatized patients at risk of developing MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In total, 14 multiple trauma patients with an injury severity score (ISS)&#x2009;&#x2265;&#x2009;16 as well as a control group of 14 non-multiple trauma patients were included in this study and blood samples were taken at the time points 0, 6, 24, 48 and 72&#xa0;h after admission. For the trauma patients, the SIRS and Denver MOF score were determined daily. The quantitative measurement of the plasma concentrations of the adipokines was performed using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the statistical analysis, the multiple trauma patients showed statistically significant higher plasma concentrations of leptin, resistin, IL-17A and IL-33 compared to the control group. In addition, there was a statistically significant positive correlation between the concentrations of resistin, IL-17A and IL-33 and the corresponding SIRS scores and between the concentrations of resistin, IL-17A and IL-33 and the corresponding Denver MOF scores. Finally, ROC curve analysis revealed that the adipokines leptin and IL-17A are suitable diagnostic markers for the discrimination between multiple trauma patients with and without MOF.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Leptin and IL-17A could be suitable diagnostic markers to identify severely injured patients with a developing SIRS and MOF earlier, to adjust surgical therapy planning and intensive care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2608-3444</Identifier><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Neuherbergstrasse 11, 80937, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krysiak</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogner-Flatz</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Hospital Munich, Ludwig-Maximilians-University, Nussbaumstrasse 20, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanschen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology-Inspired Tissue Engineering (cBITE), MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haug</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedics and Sports Orthopedics, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054392">Adipokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054392" MajorTopicYN="N">Adipokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adipokines</Keyword><Keyword MajorTopicYN="N">Interleukin-17A</Keyword><Keyword MajorTopicYN="N">Interleukin-33</Keyword><Keyword MajorTopicYN="N">Leptin</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Multiple organ failure</Keyword><Keyword MajorTopicYN="N">Multiple trauma</Keyword><Keyword MajorTopicYN="N">Resistin</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33931112</ArticleId><ArticleId IdType="pmc">PMC8086117</ArticleId><ArticleId IdType="doi">10.1186/s40001-021-00511-z</ArticleId><ArticleId IdType="pii">10.1186/s40001-021-00511-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wick M, Ekkernkamp A, Muhr G. The epidemiology of multiple trauma. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 1997. 68(11):1053&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9518193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R. Das schwere Trauma. Notfall+ Rettungsmedizin. 2008;11(6):373&#x2013;6.</Citation></Reference><Reference><Citation>Ornato JP, Craren EJ, Nelson NM, Kimball KF. Impact of improved emergency medical services and emergency trauma care on the reduction in mortality from trauma. J Trauma. 1985;25(7):575&#x2013;579. doi: 10.1097/00005373-198507000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198507000-00001</ArticleId><ArticleId IdType="pubmed">4009762</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker CC. Epidemiology of trauma: the civilian perspective. Ann Emerg Med. 1986;15(12):1389&#x2013;1391. doi: 10.1016/S0196-0644(86)80921-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0196-0644(86)80921-0</ArticleId><ArticleId IdType="pubmed">3777610</ArticleId></ArticleIdList></Reference><Reference><Citation>Regel G, Lobenhoffer P, Grotz M, Pape H, Lehmann U, Tscherne H. Treatment results of patients with multiple trauma: an analysis of 3406 cases treated between 1972 and 1991 at a German Level I Trauma Center. J Trauma Acute Care Surg. 1995;38(1):70&#x2013;78. doi: 10.1097/00005373-199501000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199501000-00020</ArticleId><ArticleId IdType="pubmed">7745664</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36(6):691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>van Griensven M, Krettek C, Pape H-C. Immune Reactions afterTrauma. Eur J Trauma. 2003;29(4):181&#x2013;192. doi: 10.1007/s00068-001-1324-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-001-1324-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Lezotte DC. Early risk factors for postinjury multiple organ failure. World J Surg. 1996;20(4):392&#x2013;400. doi: 10.1007/s002689900062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002689900062</ArticleId><ArticleId IdType="pubmed">8662125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock (Augusta, Ga) 2009;31(5):438. doi: 10.1097/SHK.0b013e31818ba4c6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31818ba4c6</ArticleId><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40(9):912&#x2013;918. doi: 10.1016/j.injury.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2009.05.024</ArticleId><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644&#x2013;1655. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#x2013;97. doi: 10.1038/nri2921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2921</ArticleId><ArticleId IdType="pmc">PMC3518031</ArticleId><ArticleId IdType="pubmed">21252989</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939&#x2013;949. doi: 10.1161/01.RES.0000163635.62927.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000163635.62927.34</ArticleId><ArticleId IdType="pubmed">15890981</ArticleId></ArticleIdList></Reference><Reference><Citation>Javier C, Morena S, Rodolfo G, Ver&#xf3;nica L, Jes&#xfa;s GRJ, Francisca L, et al. Adipokines: Biofactors from white adipose tissue A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37(6):413&#x2013;420. doi: 10.1002/biof.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.185</ArticleId><ArticleId IdType="pubmed">22038756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68(4):437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11037963</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371&#x2013;379. doi: 10.1038/nri1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1350</ArticleId><ArticleId IdType="pubmed">15122202</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck BN, Johnson RW. Tumor necrosis factor (TNF)-&#x3b1; induces leptin production through the p55 TNF receptor. Am J Physiol Regulatory Integrative Comparative Physiol. 2000;278(2):R537&#x2013;R543. doi: 10.1152/ajpregu.2000.278.2.R537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.2000.278.2.R537</ArticleId><ArticleId IdType="pubmed">10666158</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Alvarez J, Goberna R, S&#xe1;nchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999;194(1):6&#x2013;11. doi: 10.1006/cimm.1999.1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cimm.1999.1490</ArticleId><ArticleId IdType="pubmed">10357875</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrin LL, Jahn A, van Griensven M. Leptin protects against mortality and organ dysfunction in a two-hit trauma/sepsis model and is IL-6-dependent. Shock. 2017;48(1):130&#x2013;137. doi: 10.1097/SHK.0000000000000837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000837</ArticleId><ArticleId IdType="pubmed">28114167</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98(2):502&#x2013;506. doi: 10.1073/pnas.98.2.502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.502</ArticleId><ArticleId IdType="pmc">PMC14616</ArticleId><ArticleId IdType="pubmed">11209052</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300(2):472&#x2013;476. doi: 10.1016/S0006-291X(02)02841-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)02841-3</ArticleId><ArticleId IdType="pubmed">12504108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309(2):286&#x2013;290. doi: 10.1016/j.bbrc.2003.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.07.003</ArticleId><ArticleId IdType="pubmed">12951047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789&#x2013;5795. doi: 10.4049/jimmunol.174.9.5789.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.9.5789</ArticleId><ArticleId IdType="pubmed">15843582</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149&#x2013;162. doi: 10.1016/j.immuni.2011.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.02.012</ArticleId><ArticleId IdType="pubmed">21349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402&#x2013;407. doi: 10.1016/j.cyto.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.07.017</ArticleId><ArticleId IdType="pmc">PMC2582446</ArticleId><ArticleId IdType="pubmed">18701318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R, Witte E, Witte K, Wolk K. IL-22 and IL-17: An Overview. In: Quesniaux V, Ryffel B, Padova F, editors. IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. Basel: Springer Basel; 2013. pp. 11&#x2013;35.</Citation></Reference><Reference><Citation>Mitsdoerffer M, Lee Y, J&#xe4;ger A, Kim H-J, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci. 2010;107(32):14292&#x2013;14297. doi: 10.1073/pnas.1009234107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009234107</ArticleId><ArticleId IdType="pmc">PMC2922571</ArticleId><ArticleId IdType="pubmed">20660725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479&#x2013;490. doi: 10.1016/j.immuni.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.09.015</ArticleId><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384(1):105&#x2013;109. doi: 10.1016/j.bbrc.2009.04.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.04.081</ArticleId><ArticleId IdType="pubmed">19393621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31(1):5&#x2013;7. doi: 10.1016/j.immuni.2009.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.06.011</ArticleId><ArticleId IdType="pubmed">19604486</ArticleId></ArticleIdList></Reference><Reference><Citation>Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37(10):2779&#x2013;2786. doi: 10.1002/eji.200737547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200737547</ArticleId><ArticleId IdType="pubmed">17853410</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484&#x2013;1490. doi: 10.1016/j.jaci.2008.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2008.04.005</ArticleId><ArticleId IdType="pmc">PMC2821937</ArticleId><ArticleId IdType="pubmed">18539196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli T, Wodzin E, Barrington I. Association for the Advancement of Automotive Medicine: The Abbreviated Injury Scale 2005. Update. 2008.</Citation></Reference><Reference><Citation>Keller WK, Dillihunt R, Fenner H, Jolley F, Keeney A, Weygandt P, et al. Rating the severity of tissue damage: I The abbreviated injury scale. JAMA. 1971;215(2):277&#x2013;280. doi: 10.1001/jama.1971.03180150059012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1971.03180150059012</ArticleId><ArticleId IdType="pubmed">5107365</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W, Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma Acute Care Surg. 1974;14(3):187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B. The injury severity score: an update. J Trauma Acute Care Surg. 1976;16(11):882&#x2013;885. doi: 10.1097/00005373-197611000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197611000-00006</ArticleId><ArticleId IdType="pubmed">994270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sektion Notfall- &amp; Intensivmedizin, Schwerverletztenversorgung (NIS) der Deutschen Gesellschaft f&#xfc;r Unfallchirurgie (DGU). TraumaRegister Jahresbericht 2015. 2015.</Citation></Reference><Reference><Citation>Fr&#xf6;hlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg. 2014;76(4):921&#x2013;928. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz M, van Griensven M, Stalp M, Kaufmann U, Hildebrand F, Pape H. Scoring des Multiorganversagens nach schwerem Trauma Vergleich des Goris- Marshall-und Moore-Scores Der Chirurg. 2001;72(6):723&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, Sequential Organ Failure Assessment and Marshall scoring systems. J Trauma Acute Care Surg. 2017;82(3):534. doi: 10.1097/TA.0000000000001328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000001328</ArticleId><ArticleId IdType="pmc">PMC5328408</ArticleId><ArticleId IdType="pubmed">28030507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chachkhiani I, Gurlich R, Maruna P, Frasko R, Lindner J. The postoperative stress response and its reflection in cytokine network and leptin plasma levels. Physiol Res. 2005;54(3):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection. J Surg Res. 2006;133(2):102&#x2013;112. doi: 10.1016/j.jss.2005.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.10.025</ArticleId><ArticleId IdType="pubmed">16386757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef AAAM, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-&#x3b1; in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33. doi: 10.1186/cc8911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8911</ArticleId><ArticleId IdType="pmc">PMC2887140</ArticleId><ArticleId IdType="pubmed">20230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AM, Sattar N, Mcmillan DC. The co-ordinated cytokine/hormone response to acute injury incorporates leptin. Cytokine. 2000;12(7):1042&#x2013;1045. doi: 10.1006/cyto.2000.0674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0674</ArticleId><ArticleId IdType="pubmed">10880250</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X-Q, Yang S-B, Zhu F-L, Lv Q-W, Zhang G-H, Huang H-B. Resistin is associated with mortality in patients with traumatic brain injury. Crit Care. 2010;14(5):R190. doi: 10.1186/cc9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9307</ArticleId><ArticleId IdType="pmc">PMC3219297</ArticleId><ArticleId IdType="pubmed">21029428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade CE, Mora AG, Shields BA, Pidcoke HF, Baer LA, Chung KK, et al. Signals from fat after injury: plasma adipokines and ghrelin concentrations in the severely burned. Cytokine. 2013;61(1):78&#x2013;83. doi: 10.1016/j.cyto.2012.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.08.031</ArticleId><ArticleId IdType="pmc">PMC3505238</ArticleId><ArticleId IdType="pubmed">23021431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sund&#xe9;n-Cullberg J, Nystr&#xf6;m T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med. 2007;35(6):1536&#x2013;1542. doi: 10.1097/01.CCM.0000266536.14736.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000266536.14736.03</ArticleId><ArticleId IdType="pubmed">17452927</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud A, Namas RA, Ramadan M, Mi Q, Almahmoud K, Abdul-Malak O, et al. Computational analysis supports an early, type 17 cell-associated divergence of blunt trauma survival and mortality. Crit Care Med. 2016;44(11):e1074. doi: 10.1097/CCM.0000000000001951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001951</ArticleId><ArticleId IdType="pmc">PMC5201164</ArticleId><ArticleId IdType="pubmed">27513538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefele F, Ditsch A, Krysiak N, Caldwell C, Biberthaler P, van Griensven M, et al. Trauma induces interleukin-17A expression on Th17 Cells and CD4+ regulatory T cells as well as platelet dysfunction. Front Immunol. 2019;10:2389. doi: 10.3389/fimmu.2019.02389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02389</ArticleId><ArticleId IdType="pmc">PMC6797820</ArticleId><ArticleId IdType="pubmed">31681282</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelkader A, El-Sayed M, Eladawy A, Elsayed R, Mukhtar A, Hammimy W. Interleukin-17a as a predictor of occurrence of sepsis in polytrauma patients: a prospective observational study. Intensive Care Med Exp. 2015;3(1):A790. doi: 10.1186/2197-425X-3-S1-A790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2197-425X-3-S1-A790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsiger S, Simmen H-P, Werner CM, Wanner GA, Rittirsch D. Danger signals activating the immune response after trauma. Mediators of inflammation. 2012;2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388465</ArticleId><ArticleId IdType="pubmed">22778496</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Guardado J, Hoffman R, Xu H, Namas R, Vodovotz Y, et al. IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS Med. 2017;14(7):e1002365. doi: 10.1371/journal.pmed.1002365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002365</ArticleId><ArticleId IdType="pmc">PMC5526517</ArticleId><ArticleId IdType="pubmed">28742815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35506746</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-4029</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of forensic sciences</Title><ISOAbbreviation>J Forensic Sci</ISOAbbreviation></Journal><ArticleTitle>Perimortem dynamics of blood potassium concentration in patients dying in intensive care unit: A prospective nested cohort study.</ArticleTitle><Pagination><StartPage>1550</StartPage><EndPage>1556</EndPage><MedlinePgn>1550-1556</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1556-4029.15054</ELocationID><Abstract><AbstractText>To enable diagnosis of hyperkalemia from the perimortem blood sample, we aim to describe the natural dynamics of blood potassium [K<sup>+</sup> ] in patients dying after withdrawal of care while in an intensive care unit. In a nested sub-study of international Death Prediction and Physiology after Removal of Therapy (DePPaRT) project, we obtained serial whole-blood samples and analyzed ions and acid-base parameters in 23 patients just before life-sustaining treatment withdrawal, at the time of death, and after 5 and 30&#x2009;min after death. Of the 631 patients in the DePPaRT study, we obtained consent and enrolled 23 subjects in the [K<sup>+</sup> ] sub-study (12&#x2009;M, 11F, aged 73&#x2009;&#xb1;&#x2009;14&#x2009;years), mostly dying from irreversible brain damage or multi-organ failure. Blood [K<sup>+</sup> ] rose from the median 4.3 (IQR 3.9; 4.8) mEq/L at treatment withdrawal to 5.2 (IQR 5.0; 6.8) mEq/L at death and then to 5.85 (IQR 5.2; 6.8) mEq/L after 30&#x2009;min (mean rise of +0.64&#x2009;mEq.L<sup>-1</sup> .h<sup>-1</sup> ). These changes were associated with progressive lactic and hypercapnic acidemia. After correcting the measured [K+] for pH by subtracting 0.6&#xa0;mEq/L from [K+] for every 0.1 pH decrease from 7.40, the calculated [K+] remained normal or decreased from that measured at treatment withdrawal. In contrast to the late autolysis phase, the early changes of blood [K<sup>+</sup> ] after death are slow and can be fully explained by progressive acidemia. Our data suggest that the diagnosis of hyperkalemia at death from a blood sample obtained within 30&#x2009;min after death can be made by adjusting the [K+] concentration to a pH&#xa0;7.40.</AbstractText><CopyrightInformation>&#xa9; 2022 American Academy of Forensic Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matou&#x161;</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0605-6393</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldauf</LastName><ForeName>Petr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4668-5837</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krbec</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2692-6904</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du&#x161;ka</LastName><ForeName>Franti&#x161;ek</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1559-4078</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care Medicine, 3rd Faculty of Medicine of Charles University and FNKV University Hospital in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1004120</GrantID><Agency>Grantov&#xe1; Agentura, Univerzita Karlova</Agency><Country/></Grant><Grant><GrantID>COOPERATIO ICM</GrantID><Agency>Univerzita Karlova v Praze</Agency><Country/></Grant><Grant><Agency>the Karel Pavlik Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Forensic Sci</MedlineTA><NlmUniqueID>0375370</NlmUniqueID><ISSNLinking>0022-1198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007477">Ions</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006947" MajorTopicYN="Y">Hyperkalemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007477" MajorTopicYN="N">Ions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="Y">Potassium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dynamics of blood potassium</Keyword><Keyword MajorTopicYN="N">forensic pathology</Keyword><Keyword MajorTopicYN="N">hyperkalemia</Keyword><Keyword MajorTopicYN="N">perimortem blood potassium</Keyword><Keyword MajorTopicYN="N">perimortem changes</Keyword><Keyword MajorTopicYN="N">physiology of dying</Keyword><Keyword MajorTopicYN="N">postmortem chemistry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35506746</ArticleId><ArticleId IdType="doi">10.1111/1556-4029.15054</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med. 2015;373(1):60-72. https://doi.org/10.1056/NEJMra1313341</Citation></Reference><Reference><Citation>Hunter RW, Bailey MA. Hyperkalemia: Pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34((Suppl 3)):iii2-11. https://doi.org/10.1093/ndt/gfz206</Citation></Reference><Reference><Citation>Fejfar Z. A practical approach to cardiac anesthesia, 2nd edition. Edited by Frederick a. Hensley, Jr., and Donald E. Martin. Little, Brown and Company, Boston (1995) 7 13 pages, illustrated, $59.95 ISBN: 0-316-35786-3. Clin Cardiol. 1996;19(7):601-2. https://doi.org/10.1002/clc.4960190718</Citation></Reference><Reference><Citation>Gawande A, Denno DW, Truog RD, Waisel D. Physicians and execution-highlights from a discussion of lethal injection. N Engl J Med. 2008;358(5):448-51. https://doi.org/10.1056/NEJMp0800378</Citation></Reference><Reference><Citation>Kothari D, Kothari S, Agrawal J. Potassium chloride: a high risk drug for medication error. Indian J Anaesth. 2012;56(1):90-1. https://doi.org/10.4103/0019-5049.93357</Citation></Reference><Reference><Citation>Palmiere C, Scarpelli MP, Varlet V, Baumann P, Michaud K, Augsburger M. Fatal intravenous injection of potassium: is postmortem biochemistry useful for the diagnosis? Forensic Sci Int. 2017;274:27-32. https://doi.org/10.1016/j.forsciint.2016.11.035</Citation></Reference><Reference><Citation>Coulibaly B, Piercecchi-Marti M-D, Bartoli C, Liprandi A, L&#xe9;onetti G, Pellissier J-F. Lethal injection of potassium chloride: first description of the pathological appearance of organs. J Appl Toxicol. 2010;30(4):378-80. https://doi.org/10.1002/jat.1500</Citation></Reference><Reference><Citation>Bertol E, Politi L, Mari F. Death by potassium chloride intravenous injection: evaluation of analytical detectability. J Forensic Sci. 2012;57(1):273-5. https://doi.org/10.1111/j.1556-4029.2011.01907.x</Citation></Reference><Reference><Citation>Dhanani S, Hornby L, van Beinum A, Scales NB, Hogue M, Baker A, et al. Resumption of cardiac activity after withdrawal of life-sustaining measures. N Engl J Med. 2021;384(4):345-52. https://doi.org/10.1056/NEJMoa2022713</Citation></Reference><Reference><Citation>Larivi&#xe8;re S. When is dead really dead? The death prediction and physiology after removal of therapy study (DePPaRT study). Canadian Donation and Transplantation Research Program. [cited 2022 Apr 16]. Available from: https://cdtrp.ca/en/deppart-study/</Citation></Reference><Reference><Citation>Burnell JM, Scribner BH, Uyeno BT, Villamil MF. The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest. 1956;35(9):935-9. https://doi.org/10.1172/JCI103352</Citation></Reference><Reference><Citation>Adrogu&#xe9; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981;71(3):456-67. https://doi.org/10.1016/0002-9343(81)90182-0</Citation></Reference><Reference><Citation>CLSI standards &amp; guidelines: Shop for CLSI standards. Clinical &amp; Laboratory Standards Institute. [cited 2021 Oct 5]. Available from: https://clsi.org/standards/</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran&#xe7;ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686. https://doi.org/10.21105/joss.01686</Citation></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1-48. https://doi.org/10.18637/jss.v067.i01</Citation></Reference><Reference><Citation>Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82(13):1-26. https://doi.org/10.18637/jss.v082.i13</Citation></Reference><Reference><Citation>emmeans package - RDocumentation. [cited 2022 Apr 16]. Available from: https://www.rdocumentation.org/packages/emmeans/versions/1.7.3</Citation></Reference><Reference><Citation>R: The R project for statistical computing [cited 2021 Oct 18]. Available from: https://www.r-project.org/</Citation></Reference><Reference><Citation>Makoff DL, da Silva JA, Rosenbaum BJ, Levy SE, Maxwell MH. Hypertonic expansion: acid-base and electrolyte changes. Am J Physiol. 1970;218(4):1201-7. https://doi.org/10.1152/ajplegacy.1970.218.4.1201</Citation></Reference><Reference><Citation>Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Invest. 1991;87(6):1953-7. https://doi.org/10.1172/JCI115221</Citation></Reference><Reference><Citation>Williams ME, Rosa RM, Silva P, Brown RS, Epstein FH. Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation. N Engl J Med. 1984;311(3):145-9. https://doi.org/10.1056/NEJM198407193110303</Citation></Reference><Reference><Citation>Ellingsen O. Myocardial potassium balance during adrenergic stimulation. J Oslo City Hosp. 1989;39(4-5):39-51.</Citation></Reference><Reference><Citation>Walia BN, Chandra RK, Sarin GS, Ghai OP. Preterminal and postmortem changes in serum-potassium of children. Lancet Lond Engl. 1963;1(7292):1187-8. https://doi.org/10.1016/s0140-6736(63)92481-4</Citation></Reference><Reference><Citation>Singh D, Prashad R, Parkash C, Bansal YS, Sharma SK, Pandey AN. Linearization of the relationship between serum sodium, potassium concentration, their ratio and time since death in Chandigarh zone of north-West India. Forensic Sci Int. 2002;130(1):1-7. https://doi.org/10.1016/s0379-0738(02)00267-0</Citation></Reference><Reference><Citation>Jashnani KD, Kale SA, Rupani AB. Vitreous humor: biochemical constituents in estimation of postmortem interval. J Forensic Sci. 2010;55(6):1523-7. https://doi.org/10.1111/j.1556-4029.2010.01501.x</Citation></Reference><Reference><Citation>Bortolotti F, Pascali JP, Davis GG, Smith FP, Brissie RM, Tagliaro F. Study of vitreous potassium correlation with time since death in the postmortem range from 2 to 110 hours using capillary ion analysis. Med Sci Law. 2011;51(Suppl 1):S20-3. https://doi.org/10.1258/msl.2010.010063</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35656036</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0972-5229</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine</Title><ISOAbbreviation>Indian J Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Patient Characteristics and Outcomes in Necrotizing Soft-tissue Infections: Results from a Prospective Cohort Study in a Tertiary Care Center Intensive Care Unit in South India.</ArticleTitle><Pagination><StartPage>452</StartPage><EndPage>456</EndPage><MedlinePgn>452-456</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5005/jp-journals-10071-24153</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Necrotizing soft tissue infections (NSTIs) are life-threatening infections characterized by progressive destruction of muscle, fascia, and overlying subcutaneous tissue. Prospective studies in the field are few, and data from the Indian subcontinent are bleak. Prompt diagnosis and timely treatment are critical for optimal outcomes. The aims of this study are to provide detailed information on the clinical profile of patients with NSTIs and to identify predictors of mortality in order to pick up reversible factors that may improve outcomes.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">This study was a prospective cohort study of adult patients with NSTIs in a tertiary center in South India. All patients who were admitted to the surgical intensive care unit (ICU) of the institute with a diagnosis of NSTI were screened and enrolled. All patients were managed according to the local protocol for treatment of NSTIs and intensive care support.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In our cohort of patients, simple and multiple logistic regression analysis showed that four factors, namely, AKIN stage 3, shock, need for mechanical ventilation for more than 3 days, and low serum albumin values were found to be significantly associated with higher mortality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The successful management of these patients calls for early diagnosis, resuscitation, surgical debridement, appropriate and timely antibiotics, and early ventilatory weaning before multi-organ failure associated with shock and AKI occurs.</AbstractText><AbstractText Label="HOW TO CITE THIS ARTICLE" NlmCategory="UNASSIGNED">Kurian GP, Korula PJ, Jacob JM, Desha AMK, Karuppusami R, Kandasamy S. Patient Characteristics and Outcomes in Necrotizing Soft-tissue Infections: Results from a Prospective Cohort Study in a Tertiary Care Center Intensive Care Unit in South India. Indian J Crit Care Med 2022;26(4):452-456.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022; Jaypee Brothers Medical Publishers (P) Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurian</LastName><ForeName>George Prashanth</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0001-8398-7194</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korula</LastName><ForeName>Pritish John</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-9544-8427</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Jubin Merin</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-5810-2136</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desha</LastName><ForeName>Ashok Madhu Kumar</ForeName><Initials>AMK</Initials><Identifier Source="ORCID">0000-0003-3526-2556</Identifier><AffiliationInfo><Affiliation>Jaiswi Hospital, Tadipatri, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuppusami</LastName><ForeName>Reka</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9913-2713</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandasamy</LastName><ForeName>Subramani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7628-5335</Identifier><AffiliationInfo><Affiliation>Division of Critical Care and Surgical ICU, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Crit Care Med</MedlineTA><NlmUniqueID>101208863</NlmUniqueID><ISSNLinking>0972-5229</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AKIN stage 3</Keyword><Keyword MajorTopicYN="N">Hypoalbuminemia</Keyword><Keyword MajorTopicYN="N">Mechanical ventilation</Keyword><Keyword MajorTopicYN="N">Necrotizing fasciitis</Keyword><Keyword MajorTopicYN="N">Shock</Keyword></KeywordList><CoiStatement>Source of support: Fluid Research Grant, CMC, Vellore. Conflict of interest: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35656036</ArticleId><ArticleId IdType="pmc">PMC9067491</ArticleId><ArticleId IdType="doi">10.5005/jp-journals-10071-24153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stevens DL, Bryant AE. Necrotizing soft-tissue infections. N Engl J Med. 2017;377(23):2253&#x2013;65. doi: 10.1056/NEJMra1600673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1600673</ArticleId><ArticleId IdType="pubmed">29211672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infect Dis Clin North Am. 2017;31(3):497&#x2013;511. doi: 10.1016/j.idc.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5656282</ArticleId><ArticleId IdType="pubmed">28779832</ArticleId></ArticleIdList></Reference><Reference><Citation>Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990&#x2013;2006. J Infect. 2011;63(6):429&#x2013;433. doi: 10.1016/j.jinf.2011.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2011.07.019</ArticleId><ArticleId IdType="pubmed">21864570</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen MB, Skrede S, Perner A, Arnell P, Nekludov M, Bruun T, et al. Patient's characteristics and outcomes in necrotising soft-tissue infections: results from a Scandinavian, multicentre, prospective cohort study. Intensive Care Med. 2019;45(9):1241&#x2013;1251. doi: 10.1007/s00134-019-05730-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05730-x</ArticleId><ArticleId IdType="pubmed">31440795</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie CM, Miclau T. Necrotizing soft tissue infections of the extremities and back. Clin Orthop Relat Res. 2006;447:179&#x2013;186. doi: 10.1097/01.blo.0000218734.46376.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.blo.0000218734.46376.89</ArticleId><ArticleId IdType="pubmed">16672902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter OL, Guillamondegui OD, May AK, Diaz JJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect (Larchmt) 2008;9(4):443&#x2013;4450. doi: 10.1016/j.cmi.2019.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.06.031</ArticleId><ArticleId IdType="pubmed">18759681</ArticleId></ArticleIdList></Reference><Reference><Citation>Endorf FW, Klein MB, Mack CD, Jurkovich GJ, Rivara FP. Necrotizing soft-tissue infections: differences in patients treated at burn centers and non-burn centers. J Burn Care Res. 2008;29(6):933&#x2013;938. doi: 10.1097/BCR.0b013e31818ba112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e31818ba112</ArticleId><ArticleId IdType="pmc">PMC3042354</ArticleId><ArticleId IdType="pubmed">18997557</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya DA, Bulger EM, Kwon YS, Kao LS, Evans H, Nathens AB. Predicting death in necrotizing soft tissue infections: a clinical score. Surg Infect (Larchmt) 2009;10(6):517&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001332</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass GE, Sheil F, Ruston JC, Butler PEM. Necrotising soft tissue infection in a UK metropolitan population. Ann R Coll Surg Engl. 2015;97(1):46&#x2013;51. doi: 10.1308/003588414X14055925058553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/003588414X14055925058553</ArticleId><ArticleId IdType="pmc">PMC4473899</ArticleId><ArticleId IdType="pubmed">25519266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari V, Yogi V, Ghori HU, Singh OP, Peepre K, Yadav S, et al. Identifying the factors causing delayed presentation of cancer patients to a government medical college of Central India. J Clin Diagn Res. 2015;9(9):XC09&#x2013;XC12. doi: 10.7860/JCDR/2015/15104.6512.</Citation><ArticleIdList><ArticleId IdType="doi">10.7860/JCDR/2015/15104.6512</ArticleId><ArticleId IdType="pmc">PMC4606325</ArticleId><ArticleId IdType="pubmed">26500996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal NP, Latenser BA, Born JM, Liao J. Trends in 393 necrotizing acute soft tissue infection patients 2000&#x2013;2008. Burns. 2012;38(2):252&#x2013;260. doi: 10.1016/j.burns.2011.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2011.07.008</ArticleId><ArticleId IdType="pubmed">22030440</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445&#x2013;1453. doi: 10.1056/NEJMoa042683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa042683</ArticleId><ArticleId IdType="pubmed">15814880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucca K, Spencer R, Orford N, Cattigan C, Athan E, McDonald A. Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study. ANZ J Surg. 2013;83(5):365&#x2013;370. doi: 10.1111/j.1445-2197.2012.06251.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2012.06251.x</ArticleId><ArticleId IdType="pubmed">22989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon N, Anjana RM, Mohan V, Kaur T, Afshin A, Ong K, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease study 1990&#x2013;2016. The Lancet Global Health. 2018;6(12):e1352&#x2013;e1362. doi: 10.1016/S2214-109X(18)30387-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(18)30387-5</ArticleId><ArticleId IdType="pmc">PMC6227383</ArticleId><ArticleId IdType="pubmed">30219315</ArticleId></ArticleIdList></Reference><Reference><Citation>Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007;38(Suppl 5):S19&#x2013;S26. doi: 10.1016/j.injury.2007.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.030</ArticleId><ArticleId IdType="pubmed">18048033</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh G, Sinha SK, Adhikary S, Babu KS, Ray P, Khanna SK. Necrotising infections of soft tissues&#x2014;a clinical profile. Eur J Surg. 2003;168(6):366&#x2013;371. doi: 10.1080/11024150260284897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/11024150260284897</ArticleId><ArticleId IdType="pubmed">12428876</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh N. Necrotizing fasciitis: a decade of surgical intensive care experience. Ind J of Critic Care Med. 2006;10(4):225&#x2013;229. doi: 10.4103/0972-5229.29840.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.29840</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador VBDG, San Juan MD, Salisi JA, Consunji RJ. Clinical and microbiological spectrum of necrotizing fasciitis in surgical patients at a Philippine university medical centre. Asian J Surg. 2010;33(1):51&#x2013;58. doi: 10.1016/S1015-9584(10)60009-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1015-9584(10)60009-7</ArticleId><ArticleId IdType="pubmed">20497883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao LS, Lew DF, Arab SN, Todd SR, Awad SS, Carrick MM, et al. Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. Am J Surg. 2011;202(2):139&#x2013;145. doi: 10.1016/j.amjsurg.2010.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2010.07.041</ArticleId><ArticleId IdType="pmc">PMC3150284</ArticleId><ArticleId IdType="pubmed">21545997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudarsky LA, Laschinger JC, Coppa GF, Spencer FC. Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg. 1987;206(5):661&#x2013;665. doi: 10.1097/00000658-198711000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-198711000-00018</ArticleId><ArticleId IdType="pmc">PMC1493283</ArticleId><ArticleId IdType="pubmed">3314752</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007;44(5):705&#x2013;710. doi: 10.1086/511638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/511638</ArticleId><ArticleId IdType="pubmed">17278065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C-H, Chang H-C, Pasupathy S, Khin L-W, Tan J-L, Low C-O. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85(8):1454&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925624</ArticleId></ArticleIdList></Reference><Reference><Citation>Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schal&#xe9;n C, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007;45(4):450&#x2013;458. doi: 10.1086/519936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519936</ArticleId><ArticleId IdType="pubmed">17638193</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil MH, Henning RJ, Puri VK. Colloid oncotic pressure: clinical significance. Crit Care Med. 1979;7(3):113&#x2013;116. doi: 10.1097/00003246-197903000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-197903000-00006</ArticleId><ArticleId IdType="pubmed">436426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975;11(6):824&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">1207674</ArticleId></ArticleIdList></Reference><Reference><Citation>On the sulfhydryl group of human plasma albumin-PubMed [Internet]. doi: 10.1016/j.redox.2017.10.007. [cited 2020 Oct 17].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.007</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA. 1992;89(16):7674&#x2013;7677. doi: 10.1073/pnas.89.16.7674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.16.7674</ArticleId><ArticleId IdType="pmc">PMC49773</ArticleId><ArticleId IdType="pubmed">1502182</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves RB. Temperature-induced changes in blood acid-base status: Donnan rCl and red cell volume. J Appl Physiol. 1976;40(5):762&#x2013;767. doi: 10.1152/jappl.1976.40.5.762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1976.40.5.762</ArticleId><ArticleId IdType="pubmed">6425</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois M-J, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34(10):2536&#x2013;2540. doi: 10.1097/01.CCM.0000239119.57544.0C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000239119.57544.0C</ArticleId><ArticleId IdType="pubmed">16915107</ArticleId></ArticleIdList></Reference><Reference><Citation>Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247&#x2013;2256. doi: 10.1056/NEJMoa040232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa040232</ArticleId><ArticleId IdType="pubmed">15163774</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(9):1434&#x2013;1436. doi: 10.1093/cid/ciy401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy401</ArticleId><ArticleId IdType="pmc">PMC6186853</ArticleId><ArticleId IdType="pubmed">29788397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25536735</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-0144</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Turkish journal of medical sciences</Title><ISOAbbreviation>Turk J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Thromboelastography in the evaluation of coagulation disorders in patients with sepsis.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>272</EndPage><MedlinePgn>267-72</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Unbalanced hemostasis and disseminated intravenous coagulopathy serve as key participants in organ dysfunction and disability. In this study we evaluated the coagulation profiles of patients diagnosed with systemic inflammatory syndrome (SIRS)-sepsis and multiple organ dysfunction syndrome. We also researched coagulation in sepsis by comparing thromboelastography (TEG) data with those of nonsepsis patients to determine the usefulness of the TEG device.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Data were collected from 55 anesthesiology and surgery intensive care unit (ICU) patients: 21 with SIRS-sepsis (Group S) and 34 patients without SIRS-sepsis (Group C). Blood samples were taken upon admission to the ICU (t1) and on day 3 of the ICU stay (t2). TEG data (R = reaction time, K = coagulation time, a = alpha angle, and MA = maximum amplitude) were recorded. TEG parameters were compared with routine coagulation and hemogram studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean R value in Group C was higher than that of Group S at both t1 and t2. Group S had a significantly lower K value and higher alpha angle at t1 compared to Group C (P &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hypercoagulability was observed in SIRS-sepsis patients in the ICU, as measured with TEG. We believe that TEG will be a useful tool in the evaluation of coagulation disorders developing in septic critically ill patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kili&#xe7;</LastName><ForeName>Yeliz</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Top&#xe7;u</LastName><ForeName>&#x130;smet</ForeName><Initials>&#x130;</Initials></Author><Author ValidYN="Y"><LastName>Bambal</LastName><ForeName>Hamza</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Civi</LastName><ForeName>Melek</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk J Med Sci</MedlineTA><NlmUniqueID>9441758</NlmUniqueID><ISSNLinking>1300-0144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006400" MajorTopicYN="N">Hematocrit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019934" MajorTopicYN="N">International Normalized Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010314" MajorTopicYN="N">Partial Thromboplastin Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011517" MajorTopicYN="N">Prothrombin Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013599" MajorTopicYN="N">Systole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013916" MajorTopicYN="Y">Thrombelastography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25536735</ArticleId><ArticleId IdType="doi">10.3906/sag-1210-99</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20203290</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-3365</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of sports medicine</Title><ISOAbbreviation>Am J Sports Med</ISOAbbreviation></Journal><ArticleTitle>A new histology scoring system for the assessment of the quality of human cartilage repair: ICRS II.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>890</EndPage><MedlinePgn>880-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0363546509359068</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A reliable and reproducible method is needed to assess cartilage repair.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study was undertaken to test the reproducibility of 2 established histological scoring systems, the Modified O'Driscoll Scale (MODS) and International Cartilage Research Society (ICRS) Visual Assessment Scale (ICRS I), and subsequently to develop and evaluate a new grading system for cartilage repair.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Cohort study; Level of evidence, 2.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 107 cartilage biopsy specimens were graded using MODS and ICRS I, and the reader variability was measured. The new grading system, ICRS II, was developed and the inter- and intrareader variability determined by 3 independent readers. Collagen type II deposition was assessed immunohistochemically.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The MODS and ICRS I demonstrated high interreader variability, with MODS also showing high intrareader variability. A new histological scoring system, ICRS II, was developed comprising 14 criteria to assess parameters related to chondrocyte phenotype and tissue structure. The ICRS II demonstrated lower inter- and intrareader variability compared with MODS or ICRS I. The overall assessment and matrix staining scores had the best correlation coefficients for inter- and intrareader variability (r = .81 and .82, respectively). The extent of collagen type II in cartilage, considered a marker of differentiation toward hyaline cartilage, could represent a measure of good cartilage repair. A correlation coefficient of .56 was obtained between the extent of collagen type II staining and the overall assessment score.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ICRS II represents an improvement over current histological cartilage repair grading systems in terms of reader reproducibility. The clinical relevance and its ability to predict long-term repair durability will be assessed once long-term clinical data become available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mainil-Varlet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Boudewijn</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nesic</LastName><ForeName>Dobrila</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Knutsen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kandel</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Sports Med</MedlineTA><NlmUniqueID>7609541</NlmUniqueID><ISSNLinking>0363-5465</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Sports Med. 2010 May;38(5):877-9. doi: 10.1177/0363546510369651.</RefSource><PMID Version="1">20436051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002358" MajorTopicYN="N">Cartilage, Articular</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006652" MajorTopicYN="Y">Histological Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019637" MajorTopicYN="N">Orthopedic Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="Y">Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20203290</ArticleId><ArticleId IdType="doi">10.1177/0363546509359068</ArticleId><ArticleId IdType="pii">0363546509359068</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39244800</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-3984</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><PubDate><Year>2024</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Geriatric nursing (New York, N.Y.)</Title><ISOAbbreviation>Geriatr Nurs</ISOAbbreviation></Journal><ArticleTitle>Predicting mortality of elderly patients undergoing open heart surgery with delirium using sequential organ failure assessment (SOFA), multi-organ dysfunction (MODS), and logistic organ dysfunction system (LODS) scores.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>149</EndPage><MedlinePgn>146-149</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gerinurse.2024.08.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4572(24)00265-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aims to assess the predictive accuracy of SOFA, MODS, and LODS scores in determining the mortality of elderly undergoing open heart surgery with delirium.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study involved 111 elderly patients who met the inclusion criteria. Data were collected using scoring systems: SOFA, MODS, and LODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Upon final follow-up, 86.5 % of the patients had recovered, 13.5 % had died. Sensitivity, specificity, negative, and positive predictive values for predicting mortality in elderly patients were calculated for the SOFA score as 99 %, 73 %, 98 %, and 76 %, respectively. For the MODS score, these values were 95 %, 60 %, 95 %, and 67 %; for the LODS score, they were 92 %, 73 %, 92 %, and 75 %, respectively. The overall accuracy of the three scores-SOFA, MODS, and LODS-was 84 %, 76 %, and 82 %, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicated that the SOFA score exhibited the highest sensitivity and specificity in predicting mortality among elderly individuals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mousabeygi</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salari</LastName><ForeName>Nader</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jalali</LastName><ForeName>Rostam</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: ks_jalali@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatr Nurs</MedlineTA><NlmUniqueID>8309633</NlmUniqueID><ISSNLinking>0197-4572</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delirium</Keyword><Keyword MajorTopicYN="N">Lods</Keyword><Keyword MajorTopicYN="N">Mods</Keyword><Keyword MajorTopicYN="N">Open heart surgery</Keyword><Keyword MajorTopicYN="N">Organ dysfunction scores</Keyword><Keyword MajorTopicYN="N">Sofa</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>8</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>22</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>8</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39244800</ArticleId><ArticleId IdType="doi">10.1016/j.gerinurse.2024.08.023</ArticleId><ArticleId IdType="pii">S0197-4572(24)00265-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31270381</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Systemic release of heat-shock protein 27 and 70 following severe trauma.</ArticleTitle><Pagination><StartPage>9595</StartPage><MedlinePgn>9595</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9595</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-46034-w</ELocationID><Abstract><AbstractText>Trauma represents a major cause of morbidity and mortality worldwide. The endogenous inflammatory response to trauma remains not fully elucidated. Pro-inflammation in the early phase is followed by immunosuppression leading to infections, multi-organ failure and mortality. Heat-shock proteins (HSPs) act as intracellular chaperons but exert also extracellular functions. However, their role in acute trauma remains unknown. The aim of this study was to evaluate serum concentrations of HSP 27 and HSP 70 in severely injured patients. We included severely injured patients with an injury severity score of at least 16 and measured serum concentration of both markers at admission and on day two. We found significantly increased serum concentrations of both HSP 27 and HSP 70 in severely injured patients. Concomitant thoracic trauma lead to a further increase of both HSPs. Also, elevated concentrations of HSP 27 and HSP 70 were associated with poor outcome in these patients. Standard laboratory parameters did not correlate with neither HSP 27, nor with HSP 70. Our findings demonstrate involvement of systemic release of HSP 27 and HSP 70 after severe trauma and their potential as biomarker in polytraumatized patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haider</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3192-8453</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.a.haider@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simader</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gl&#xfc;ck</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ankersmit</LastName><ForeName>Hendrik J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Austrian Research Promotion Agency FFG Projects 852748 and 862068 "APOSEC", Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajdu</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negrin</LastName><ForeName>Lukas L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-7195-2223</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013898" MajorTopicYN="N">Thoracic Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31270381</ArticleId><ArticleId IdType="pmc">PMC6610099</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-46034-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-46034-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380, 2095-2128 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich Matthias, Lefering Rolf, Probst Christian, Paffrath Thomas, Schneider Marco M., Maegele Marc, Sakka Samir G., Bouillon Bertil, Wafaisade Arasch. Epidemiology and risk factors of multiple-organ failure after multiple trauma. Journal of Trauma and Acute Care Surgery. 2014;76(4):921&#x2013;928. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider T, Halat G, Heinz T, Hajdu S, Negrin LL. Thoracic trauma and acute respiratory distress syndrome in polytraumatized patients: a retrospective analysis. Minerva Anestesiol. 2017;83:1026&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">28402091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, N. S., Casserly, B. &amp; Ayala, A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med29, 617&#x2013;625, viii (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786900</ArticleId><ArticleId IdType="pubmed">18954697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 2014;20:224&#x2013;233. doi: 10.1016/j.molmed.2014.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2014.01.002</ArticleId><ArticleId IdType="pmc">PMC3976785</ArticleId><ArticleId IdType="pubmed">24485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862&#x2013;874. doi: 10.1038/nri3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz DH, et al. Inflammatory alterations in a novel combination model of blunt chest trauma and hemorrhagic shock. J Trauma. 2011;70:189&#x2013;196. doi: 10.1097/TA.0b013e3181d7693c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181d7693c</ArticleId><ArticleId IdType="pubmed">20495485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnthaller C, et al. The molecular fingerprint of lung inflammation after blunt chest trauma. Eur J Med Res. 2015;20:70. doi: 10.1186/s40001-015-0164-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-015-0164-y</ArticleId><ArticleId IdType="pmc">PMC4548898</ArticleId><ArticleId IdType="pubmed">26303896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebherz-Eichinger D, et al. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clin Chim Acta. 2012;413:282&#x2013;286. doi: 10.1016/j.cca.2011.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2011.10.010</ArticleId><ArticleId IdType="pubmed">22032827</ArticleId></ArticleIdList></Reference><Reference><Citation>Salari S, et al. Extracellular HSP27 acts as a signaling molecule to activate NF-kappaB in macrophages. Cell Stress Chaperones. 2013;18:53&#x2013;63. doi: 10.1007/s12192-012-0356-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-012-0356-0</ArticleId><ArticleId IdType="pmc">PMC3508120</ArticleId><ArticleId IdType="pubmed">22851137</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruden G, et al. Serum levels of heat shock protein 27 in patients with acute ischemic stroke. Cell Stress Chaperones. 2013;18:531&#x2013;533. doi: 10.1007/s12192-013-0403-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-013-0403-5</ArticleId><ArticleId IdType="pmc">PMC3682014</ArticleId><ArticleId IdType="pubmed">23334892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersmit H, et al. Increased serum levels of HSP27 as a marker for incipient chronic obstructive pulmonary disease in young smokers. Respiration. 2012;83:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">22469636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study. Clin Chim Acta. 2012;413:1115&#x2013;1120. doi: 10.1016/j.cca.2012.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2012.03.008</ArticleId><ArticleId IdType="pubmed">22465083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacker S, et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal. 2009;23:372&#x2013;379. doi: 10.1002/jcla.20348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.20348</ArticleId><ArticleId IdType="pmc">PMC6649135</ArticleId><ArticleId IdType="pubmed">19927353</ArticleId></ArticleIdList></Reference><Reference><Citation>Janik S, et al. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications. Sci Rep. 2016;6:24267. doi: 10.1038/srep24267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24267</ArticleId><ArticleId IdType="pmc">PMC4838882</ArticleId><ArticleId IdType="pubmed">27097982</ArticleId></ArticleIdList></Reference><Reference><Citation>ArdsDefinitionTaskForce, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrin LL, et al. Soluble Receptor for Advanced Glycation End Products Quantifies Lung Injury in Polytraumatized Patients. Ann Thorac Surg. 2017;103:1587&#x2013;1593. doi: 10.1016/j.athoracsur.2016.09.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.09.021</ArticleId><ArticleId IdType="pubmed">27865475</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider, T. et al. Increased serum concentrations of soluble ST2 are associated with pulmonary complications and mortality in polytraumatized patients. Clin Chem Lab Med (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29341938</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, et al. Assessment of the clinical course with inflammatory parameters. Injury. 2007;38:1358&#x2013;1364. doi: 10.1016/j.injury.2007.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.026</ArticleId><ArticleId IdType="pubmed">18048038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>De AK, Kodys KM, Yeh BS, Miller-Graziano C. Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. J Immunol. 2000;165:3951&#x2013;3958. doi: 10.4049/jimmunol.165.7.3951.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.7.3951</ArticleId><ArticleId IdType="pubmed">11034403</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Dynamic activity of NF-kappaB in multiple trauma patients and protective effects of ulinastain. Chin J Traumatol. 2011;14:354&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">22152139</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo AP, et al. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal. 2005;7:414&#x2013;422. doi: 10.1089/ars.2005.7.414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2005.7.414</ArticleId><ArticleId IdType="pubmed">15706088</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderwood SK, Gong J, Murshid A. Extracellular HSPs: The Complicated Roles of Extracellular HSPs in Immunity. Front Immunol. 2016;7:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842758</ArticleId><ArticleId IdType="pubmed">27199984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mambula SS, Calderwood SK. Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia. 2006;22:575&#x2013;585. doi: 10.1080/02656730600976042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02656730600976042</ArticleId><ArticleId IdType="pubmed">17079215</ArticleId></ArticleIdList></Reference><Reference><Citation>Batulan Z, et al. Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation. Front Immunol. 2016;7:285. doi: 10.3389/fimmu.2016.00285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00285</ArticleId><ArticleId IdType="pmc">PMC4960997</ArticleId><ArticleId IdType="pubmed">27507972</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin RP, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 2002;23:130&#x2013;135. doi: 10.1016/S1471-4906(01)02168-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(01)02168-8</ArticleId><ArticleId IdType="pubmed">11864840</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc. 2005;2:403&#x2013;411. doi: 10.1513/pats.200508-090JS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/pats.200508-090JS</ArticleId><ArticleId IdType="pmc">PMC2713330</ArticleId><ArticleId IdType="pubmed">16322590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenauer M, et al. Transient hypoxia leads to increased serum levels of heat shock protein-27, -70 and caspase-cleaved cytokeratin 18. Clin Lab. 2014;60:323&#x2013;328. doi: 10.7754/Clin.Lab.2013.130303.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2013.130303</ArticleId><ArticleId IdType="pubmed">24660549</ArticleId></ArticleIdList></Reference><Reference><Citation>Guisasola MC, Ortiz A, Chana F, Alonso B, Vaquero J. Early inflammatory response in polytraumatized patients: Cytokines and heat shock proteins. A pilot study. Orthop Traumatol Surg Res. 2015;101:607&#x2013;611. doi: 10.1016/j.otsr.2015.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2015.03.014</ArticleId><ArticleId IdType="pubmed">26068807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi N, et al. Enhanced expression of heat shock proteins in activated polymorphonuclear leukocytes in patients with sepsis. J Trauma. 2001;51:1104&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740261</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe SB, et al. Origin of immunomodulation after soft tissue trauma: potential involvement of extracellular heat-shock proteins. Shock. 2007;27:494&#x2013;502. doi: 10.1097/shk.0b013e31802dec51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/shk.0b013e31802dec51</ArticleId><ArticleId IdType="pubmed">17438454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet Jean-Fran&#xe7;ois, Lee H., Morabito Diane, Howard M. B., Welch William J., Mackersie Robert C. Serum Levels of Hsp 72 Measured Early after Trauma Correlate with Survival. The Journal of Trauma: Injury, Infection, and Critical Care. 2002;52(4):611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956372</ArticleId></ArticleIdList></Reference><Reference><Citation>Guisasola MC, Alonso B, Bravo B, Vaquero J, Chana F. An overview of cytokines and heat shock response in polytraumatized patients. Cell Stress Chaperones. 2018;23:483&#x2013;489. doi: 10.1007/s12192-017-0859-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-017-0859-9</ArticleId><ArticleId IdType="pmc">PMC6045557</ArticleId><ArticleId IdType="pubmed">29101529</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxler D, Lainscak M, Simader E, Ankersmit HJ, Jug B. Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. Clin Chim Acta. 2017;473:127&#x2013;132. doi: 10.1016/j.cca.2017.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.08.028</ArticleId><ArticleId IdType="pubmed">28844461</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian M, et al. Hsp-27 levels and thrombus burden relate to clinical outcomes in patients with ST-segment elevation myocardial infarction. Oncotarget. 2017;8:73733&#x2013;73744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650295</ArticleId><ArticleId IdType="pubmed">29088740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa F, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol. 2008;26:659&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">18799101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18564662</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0250-636X</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Tropical gastroenterology : official journal of the Digestive Diseases Foundation</Title><ISOAbbreviation>Trop Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>A prospective study of the aetiology, severity and outcome of acute pancreatitis in Eastern India.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>22</EndPage><MedlinePgn>20-2</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis is a common cause of hospital admission. The aim of this study was to evaluate the aetiology, severity and outcome of acute pancreatitis in our tertiary referral center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between August 2002 and December 2003, 45 cases of acute pancreatitis were admitted to the hospital. Diagnosis was ascertained by clinical examination and investigations (hyperamylasaemia). The severity was assessed by the Acute Physiology and Chronic Health Evaluation scoring system and contrast enhanced computed tomography scan. The patients were treated according to a designed protocol. The data related to aetiology, severity and outcome were noted for subsequent analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 45 patients, 33 were male and 12 were female. The mean age was 30 years. Of the 45 patients, 34 patients had mild pancreatitis and 11 had severe pancreatitis. The aetiology spectrum of mild pancreatitis included the following: alcoholism in 14 (41.1%), gallstones in 8 (23.5%), trauma in 6 (17.6%), idiopathic in 4 (11.7%) and post-endoscopic retrograde cholangiopancreatography in 2 (5.8%). The causes of severe acute pancreatitis came under the following headers: trauma in 3 (27.2%), idiopathic in 2 (18.1%), gallstones in 2 (18.1%), alcoholism in 2 (18.1%) and post-endoscopic retrograde cholangiopancreatography in 2(18.1%). Mild pancreatitis led on to the following: pancreatic abscess in 1, pseudocyst in 3 and readmission for pain relapse within 6 months in 10 patients. The remainder had uneventful recoveries. There was no mortality in this group. Severe acute pancreatitis led on to the following: symptomatic sterile pancreatic necrosis in 2, infected pancreatic necrosis in 2, pancreatic abscess in 2 and presentation 8 months later with colonic stricture in 1 patient. There were 2 deaths in this group due to multi-organ failure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although gallstones have largely been implicated as a common cause of acute pancreatitis our study found alcoholism as the main aetiological factor. Blunt abdominal trauma was also seen as a common cause of acute severe pancreatitis, particularly severe acute pancreatitits, as seen in our series. The outcome in mild pancreatitis was good, severe acute pancreatitis leads to more complications and greater mortality, thus requiring careful medical and surgical management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baig</LastName><ForeName>Sarfaraz Jalil</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical College Kolkata, India. docsarfarazbaig@yahoo.co.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahed</LastName><ForeName>Abdur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Trop Gastroenterol</MedlineTA><NlmUniqueID>8107122</NlmUniqueID><ISSNLinking>0250-636X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002760" MajorTopicYN="N">Cholangiopancreatography, Endoscopic Retrograde</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042882" MajorTopicYN="N">Gallstones</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007049" MajorTopicYN="N">Iatrogenic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019512" MajorTopicYN="N">Pancreatitis, Alcoholic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18564662</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27867562</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Analysis of risk factors for and the prognosis of postoperative acute respiratory distress syndrome in patients with Stanford type A aortic dissection.</ArticleTitle><Pagination><StartPage>2862</StartPage><EndPage>2871</EndPage><MedlinePgn>2862-2871</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To explore the risk factors for and the prognosis of postoperative acute respiratory distress syndrome (ARDS) in patients with Stanford type A aortic dissection (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective nested case-control study included 527 Stanford type A AD patients who were divided into ARDS groups and non-ARDS groups. The clinical features of the groups were examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The fifty-nine patients in the ARDS group exhibited extended durations of cardiopulmonary bypass (CPB) (P=0.004), deep hypothermic circulatory arrest (DHCA) (P=0.000), ventilator support (P=0.013) and intensive care unit (ICU) stay (P=0.045), higher hospital costs (P=0.000), larger perioperative transfusions volumes [red blood cells (RBC): P=0.002, platelets (PLT): P=0.040, fresh frozen plasma (FFP): P=0.001], more frequent pulmonary infection (P=0.018) and multiple organ dysfunction syndrome (MODS) (P=0.040) and a higher rate of in-hospital mortality (P=0.020). The ARDS group exhibited worse statuses in terms of oxygenation index (OI) values (P=0.000) and Apache II scores (P=0.000). DHCA [P=0.000, odds ratio (OR) =2.589] and perioperative transfusion (RBC: P=0.000, OR =2.573; PLT: P=0.027, OR =1.571; FFP: P=0.002, OR =1.929) were independent risk factors for postoperative ARDS. The survival rates and median survival times after discharge were similar between the two groups (P=0.843).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DHCA duration and perioperative transfusion volume were independent risk factors for postoperative ARDS which warrants greater attention by the cardiac surgeons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Liang-Wan</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">adult</Keyword><Keyword MajorTopicYN="N">aortic aneurysm</Keyword><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">circulatory arrest</Keyword><Keyword MajorTopicYN="N">deep hypothermia induced</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27867562</ArticleId><ArticleId IdType="pmc">PMC5107558</ArticleId><ArticleId IdType="doi">10.21037/jtd.2016.10.10</ArticleId><ArticleId IdType="pii">jtd-08-10-2862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pierrakos C, Karanikolas M, Scolletta S, et al. Acute respiratory distress syndrome: pathophysiology and therapeutic options. J Clin Med Res 2012;4:7-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279495</ArticleId><ArticleId IdType="pubmed">22383921</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller-Redetzky HC, Felten M, Hellwig K, et al. Increasing the inspiratory time and I:E ratio during mechanical ventilation aggravates ventilator-induced lung injury in mice. Crit Care 2015;19:23. 10.1186/s13054-015-0759-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0759-2</ArticleId><ArticleId IdType="pmc">PMC4336519</ArticleId><ArticleId IdType="pubmed">25888164</ArticleId></ArticleIdList></Reference><Reference><Citation>Makita S, Ohira A, Tachieda R, et al. Behavior of C-reactive protein levels in medically treated aortic dissection and intramural hematoma. Am J Cardiol 2000;86:242-4. 10.1016/S0002-9149(00)00869-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(00)00869-9</ArticleId><ArticleId IdType="pubmed">10913496</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto N, Morimoto K, Morimoto Y, et al. Sivelestat attenuates postoperative pulmonary dysfunction after total arch replacement under deep hypothermia. Eur J Cardiothorac Surg 2008;34:798-804. 10.1016/j.ejcts.2008.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2008.07.010</ArticleId><ArticleId IdType="pubmed">18722781</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31. 10.1053/j.jvca.2008.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2008.08.007</ArticleId><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortelliti MP, Manning HL. Acute respiratory distress syndrome. Am Fam Physician 2002;65:1823-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12018805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZG, Sun LZ, Chang Q, et al. Should the "elephant trunk" be skeletonized? Total arch replacement combined with stented elephant trunk implantation for Stanford type A aortic dissection. J Thorac Cardiovasc Surg 2006;131:107-13. 10.1016/j.jtcvs.2005.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2005.09.015</ArticleId><ArticleId IdType="pubmed">16399301</ArticleId></ArticleIdList></Reference><Reference><Citation>ARDS Definition Task Force , Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta RL. Indications for dialysis in the ICU: renal replacement vs. renal support. Blood Purif 2001;19:227-32. 10.1159/000046946</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000046946</ArticleId><ArticleId IdType="pubmed">11150815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Zhang GC, et al. Total aortic arch reconstruction with open placement of triple-branched stent graft for acute type A dissection. J Thorac Cardiovasc Surg 2010;139:1654-1655.e1. 10.1016/j.jtcvs.2009.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.10.022</ArticleId><ArticleId IdType="pubmed">20074749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma WG, Zhu JM, Zheng J, et al. Sun's procedure for complex aortic arch repair: total arch replacement using a tetrafurcate graft with stented elephant trunk implantation. Ann Cardiothorac Surg 2013;2:642-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791186</ArticleId><ArticleId IdType="pubmed">24109575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-64. 10.1016/S0140-6736(07)60604-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60604-7</ArticleId><ArticleId IdType="pubmed">17482987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V, Vlachou A, Ghannadian S, et al. Acute respiratory distress syndrome: new definition, current and future therapeutic options. J Thorac Dis 2013;5:326-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698298</ArticleId><ArticleId IdType="pubmed">23825769</ArticleId></ArticleIdList></Reference><Reference><Citation>Milberg JA, Davis DR, Steinberg KP, et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995;273:306-9. 10.1001/jama.1995.03520280052039</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520280052039</ArticleId><ArticleId IdType="pubmed">7815658</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds HN, McCunn M, Borg U, et al. Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base. Crit Care 1998;2:29-34. 10.1186/cc121</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc121</ArticleId><ArticleId IdType="pmc">PMC28999</ArticleId><ArticleId IdType="pubmed">11056707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge QG, Hou J, Zhou H, et al. Multiple organ failure induced by acute respiration distress syndrome: a report of 15 cases. Mod Surg 2000;6:41-4.</Citation></Reference><Reference><Citation>He X, Han B, Mura M, et al. Anti-human tissue factor antibody ameliorated intestinal ischemia reperfusion-induced acute lung injury in human tissue factor knock-in mice. PLoS One 2008;3:e1527. 10.1371/journal.pone.0001527</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001527</ArticleId><ArticleId IdType="pmc">PMC2211395</ArticleId><ArticleId IdType="pubmed">18231608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hei ZQ, Gan XL, Huang HQ, et al. Protective effects of cromolyn sodium on intestinal ischaemia-reperfusion-triggered lung injury in rats. Br J Anaesth 2007;98:407-8. 10.1093/bja/ael383</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/ael383</ArticleId><ArticleId IdType="pubmed">17307785</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkin DW, Arnold R, Hoper M. Anti-endotoxin hyperimmune globulin attenuates portal cytokinaemia, phagocytic cell priming, and acute lung injury after lower limb ischaemia-reperfusion injury. Eur J Vasc Endovasc Surg 2007;33:330-9. 10.1016/j.ejvs.2006.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2006.10.024</ArticleId><ArticleId IdType="pubmed">17161961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao DQ, Chen YP, Chang YT, et al. Effects of aminoguanidine on the lung injury induced by the total hepatic ischemia-reperfusion in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006;31:94-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16562685</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller MC, Tuinman PR, Vlaar AP, et al. Contribution of damage-associated molecular patterns to transfusion-related acute lung injury in cardiac surgery. Blood Transfus 2014;12:368-75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111819</ArticleId><ArticleId IdType="pubmed">24887223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkawa T, Sato N, Kojika M, et al. Significance of measuring S100A12 and sRAGE in the serum of sepsis patients with postoperative acute lung injury. Dig Surg 2010;27:307-12. 10.1159/000313687</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000313687</ArticleId><ArticleId IdType="pubmed">20689292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39317599</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-3911</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Early selective enteral feeding in combination with active decompression of duodenum in treatment of moderate and severe acute pancreatitis - A proof-of-concept clinical study.</ArticleTitle><Pagination><StartPage>1012</StartPage><EndPage>1020</EndPage><MedlinePgn>1012-1020</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pan.2024.09.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1424-3903(24)00746-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis (AP) is a significant clinical challenge with rising global incidence and substantial mortality rates, necessitating effective treatment strategies. Current guidelines recommend pain and fluid management and early enteral feeding to mitigate complications, yet optimal feeding route remains debated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective, randomized, controlled trial at nine centers from October 2020 to May 2023, enrolling 154 patients with moderate to severe AP. Patients were stratified into biliary and non-biliary categories and randomized 1:1 to receive either standard of care (SoC) or SoC plus PandiCath&#xae;, a novel catheter enabling selective enteral feeding and duodenal decompression. The primary clinical endpoint (PCE) was a composite of de novo multiple organ dysfunction syndrome (MODS), infectious complications, pancreatic and intestinal fistula formation, bleeding, abdominal compartment syndrome, obstructive jaundice, and AP-related mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the primary modified intention-to-treat analysis, PandiCath&#xae; significantly reduced the PCE compared to SoC alone (P&#xa0;=&#xa0;0.032). The Relative Risk (RR&#xa0;=&#xa0;0.469, 95&#xa0;% CI 0.228-0.964) and Number Needed to Treat (NNT&#xa0;=&#xa0;6.384, 95&#xa0;% CI 3.349-68.167) indicated its substantial clinical benefit, primarily driven by reduced rates of de novo MODS and infectious complications. These findings were further supported by the evaluation of other populations, including the standard intention-to-treat analysis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PandiCath&#xae;, facilitating targeted enteral feeding while isolating and decompressing the duodenum, demonstrates promise in improving outcomes for AP patients at risk of severe complications. Further studies are warranted to validate these findings and explore optimal timing and patient selection for this intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kashintsev</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>PANDICA LTD, 22 Great James Street, London, WC1N 3ES, UK. Electronic address: alexey.kashintsev@pandica.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunda</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Advanced Interventional Endoscopy, Dept of Surgery (HPB), Dept of Gastroenterology and Hepatology, Brussels University Hospital (UZB), Vrije Universiteteit Brussel (VUB), Brussels, Belgium. Electronic address: rastikunda@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proutski</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>PANDICA LTD, 22 Great James Street, London, WC1N 3ES, UK. Electronic address: vitali.proutski@pandica.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="Y">Enteral Nutrition</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="Y">Pancreatitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019299" MajorTopicYN="Y">Decompression, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004386" MajorTopicYN="Y">Duodenum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Duodenal Decompression</Keyword><Keyword MajorTopicYN="N">Enteral feeding</Keyword><Keyword MajorTopicYN="N">Multimodal treatment approach</Keyword><Keyword MajorTopicYN="N">Nutritional support</Keyword></KeywordList><CoiStatement>Declaration of competing interest Kunda R. received compensation from PANDICA LTD for consultancy services.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39317599</ArticleId><ArticleId IdType="doi">10.1016/j.pan.2024.09.013</ArticleId><ArticleId IdType="pii">S1424-3903(24)00746-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37035317</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.</ArticleTitle><Pagination><StartPage>1122367</StartPage><MedlinePgn>1122367</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1122367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1122367</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Mid-regional pro-adrenomedullin (MR-proADM), an endothelium-related peptide, is a predictor of death and multi-organ failure in respiratory infections and sepsis and seems to be effective in identifying COVID-19 severe forms. The study aims to evaluate the effectiveness of MR-proADM in comparison to routine inflammatory biomarkers, lymphocyte subpopulations, and immunoglobulin (Ig) at an intensive care unit (ICU) admission and over time in predicting mortality in patients with severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All adult patients with COVID-19 pneumonia admitted between March 2020 and June 2021 in the ICUs of a university hospital in Italy were enrolled. MR-proADM, lymphocyte subpopulations, Ig, and routine laboratory tests were measured within 48 h and on days 3 and 7. The log-rank test was used to compare survival curves with MR-proADM cutoff value of &gt;1.5 nmol/L. Predictive ability was compared using the area under the curve (AUC) and 95% confidence interval (CI) of different receiver-operating characteristic curves.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 209 patients, with high clinical severity [SOFA 7, IQR 4-9; SAPS II 52, IQR 41-59; median viral pneumonia mortality score (MuLBSTA)-11, IQR 9-13] were enrolled. ICU and overall mortality were 55.5 and 60.8%, respectively. Procalcitonin, lactate dehydrogenase, D-dimer, the N-terminal prohormone of brain natriuretic peptide, myoglobin, troponin, neutrophil count, lymphocyte count, and natural killer lymphocyte count were significantly different between survivors and non-survivors, while lymphocyte subpopulations and Ig were not different in the two groups. MR-proADM was significantly higher in non-survivors (1.17 &#xb1; 0.73 vs. 2.31 &#xb1; 2.63, <i>p</i> &lt; 0.0001). A value of &gt;1.5 nmol/L was an independent risk factor for mortality at day 28 [odds ratio of 1.9 (95% CI: 1.220-3.060)] after adjusting for age, lactate at admission, SOFA, MuLBSTA, superinfections, cardiovascular disease, and respiratory disease. On days 3 and 7 of the ICU stay, the MR-proADM trend evaluated within 48 h of admission maintained a correlation with mortality (<i>p</i> &lt; 0.0001). Compared to all other biomarkers considered, the MR-proADM value within 48 h had the best accuracy in predicting mortality at day 28 [AUC = 0.695 (95% CI: 0.624-0.759)].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">MR-proADM seems to be the best biomarker for the stratification of mortality risk in critically ill patients with COVID-19. The Ig levels and lymphocyte subpopulations (except for natural killers) seem not to be correlated with mortality. Larger, multicentric studies are needed to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Montrucchio, Sales, Balzani, Lombardo, Giaccone, Cant&#xf9;, D'Antonio, Rumbolo, Corcione, Simonetti, Bonetto, Zanierato, Fanelli, Filippini, Mengozzi and Brazzi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montrucchio</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sales</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balzani</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giaccone</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cant&#xf9;</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Antonio</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rumbolo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Biochemistry Laboratory, Department of Laboratory Medicine, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcione</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanierato</LastName><ForeName>Marinella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanelli</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mengozzi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Biochemistry Laboratory, Department of Laboratory Medicine, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brazzi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Emergency, "Citt&#xe0; della Salute e della Scienza" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MR-proADM</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">adrenomedullin</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">immunoglobulins</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">lymphocyte subpopulations</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37035317</ArticleId><ArticleId IdType="pmc">PMC10080079</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1122367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weidmann MD, Ofori K, Rai AJ. Laboratory biomarkers in the management of patients with COVID-19. Am J Clin Pathol. (2021) 155:333&#x2013;42. 10.1093/ajcp/aqaa205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa205</ArticleId><ArticleId IdType="pmc">PMC7665296</ArticleId><ArticleId IdType="pubmed">33107558</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. . Biomarkers and outcomes of COVID-19 hospitalizations: systematic review and meta-analysis. BMJ Evid Based Med. (2021) 26:107&#x2013;8. 10.1136/bmjebm-2020-111536</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjebm-2020-111536</ArticleId><ArticleId IdType="pmc">PMC7493072</ArticleId><ArticleId IdType="pubmed">32934000</ArticleId></ArticleIdList></Reference><Reference><Citation>Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, et al. . Laboratory biomarkers associated with COVID-19 severity and management. Clin Immunol. (2020) 221:108614. 10.1016/j.clim.2020.108614</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108614</ArticleId><ArticleId IdType="pmc">PMC7581344</ArticleId><ArticleId IdType="pubmed">33153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg OHM, Bergenzaun L, Ryd&#xe9;n J, Rosenqvist M, Melander O, Chew MS. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit Care. (2016) 20:178. 10.1186/s13054-016-1361-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1361-y</ArticleId><ArticleId IdType="pmc">PMC4899903</ArticleId><ArticleId IdType="pubmed">27282767</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wang C, Pang S. The diagnostic accuracy of mid-regional pro-adrenomedullin for sepsis: a systematic review and meta-analysis. Minerva Anestesiol. (2021) 87:1117&#x2013;27. 10.23736/S0375-9393.21.15585-3</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0375-9393.21.15585-3</ArticleId><ArticleId IdType="pubmed">34134460</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed K, Legramante JM, Angeletti S, Curcio F, Miguens I, Poole S, et al. . Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department. Expert Rev Mol Diagn. (2021) 21:397&#x2013;404. 10.1080/14737159.2021.1902312</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2021.1902312</ArticleId><ArticleId IdType="pubmed">33736553</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a de Guadiana-Romualdo L, Calvo Nieves MD, Rodr&#xed;guez Mulero MD, Calcerrada Alises I, Hern&#xe1;ndez Olivo M, Trapiello Fern&#xe1;ndez W, et al. . MR-proADM as marker of endotheliitis predicts COVID-19 severity. Eur J Clin Invest. (2021) 51:e13511. 10.1111/eci.13511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13511</ArticleId><ArticleId IdType="pmc">PMC7995076</ArticleId><ArticleId IdType="pubmed">33569769</ArticleId></ArticleIdList></Reference><Reference><Citation>de Montmollin E, Peoc'h K, Marzouk M, Ruckly S, Wicky PH, Patrier J, et al. . Mid-regional pro-adrenomedullin as a prognostic factor for severe COVID-19 ARDS. Antibiotics. (2022) 11:1166. 10.3390/antibiotics11091166</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11091166</ArticleId><ArticleId IdType="pmc">PMC9495198</ArticleId><ArticleId IdType="pubmed">36139946</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Balzani E, Lombardo D, Giaccone A, Vaninetti A, D'Antonio G, et al. . Proadrenomedullin in the management of COVID-19 critically ill patients in intensive care unit: a systematic review and meta-analysis of evidence and uncertainties in existing literature. J Clin Med. (2022) 11:4543. 10.3390/jcm11154543</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11154543</ArticleId><ArticleId IdType="pmc">PMC9369672</ArticleId><ArticleId IdType="pubmed">35956159</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. . The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. (2020) 127:104361. 10.1016/j.jcv.2020.104361</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104361</ArticleId><ArticleId IdType="pmc">PMC7152870</ArticleId><ArticleId IdType="pubmed">32344320</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. (2020) 9:1123&#x2013;30. 10.1080/22221751.2020.1770129</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. . Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.00827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00827</ArticleId><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, et al. . Immune parameters and COVID-19 infection - associations with clinical severity and disease prognosis. Front Cell Infect Microbiol. (2020) 10:364. 10.3389/fcimb.2020.00364</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00364</ArticleId><ArticleId IdType="pmc">PMC7338601</ArticleId><ArticleId IdType="pubmed">32695683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamura APD, Tavares da Silva MR, H&#xfc;mmelgen AL, Soeiro Pereira PV, Falcai A, Grumach AS, et al. . Immunity and inflammatory biomarkers in COVID-19: a systematic review. Rev Med Virol. (2021) 31:e2199. 10.1002/rmv.2199</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2199</ArticleId><ArticleId IdType="pubmed">34260778</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Sales G, Rumbolo F, Palmesino F, Fanelli V, Urbino R, et al. . Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: an observational prospective study. PLoS ONE. (2021) 16:e0246771. 10.1371/journal.pone.0246771</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246771</ArticleId><ArticleId IdType="pmc">PMC7870047</ArticleId><ArticleId IdType="pubmed">33556140</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization&#x2013;Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance. Available online at: https://www.who.int/publications/i/item/laboratorytesting-strategy-recommendations-for-covid-19-interim-guidance (accessed November 30, 2022).</Citation></Reference><Reference><Citation>IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available online at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed November 30, 2022).</Citation></Reference><Reference><Citation>The National Institutes of Health. Available online at: https://www.covid19treatmentguidelines.nih.gov/ (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Surveillance of Healthcare-Associated Infections and Prevention Indicators in European Intensive Care Units. Available online at: https://www.ecdc.europa.eu/sites/default/files/documents/HAI-Net-ICU-protocol-v2.2_0.pdf (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Istituto Superiore di Sanit&#xe0;. Available online at: https://www.iss.it/web/guest/long-covid-linee-guida (accessed November 30, 2022).</Citation></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, D&#xed;az Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. . Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. (2021) 374:n2231. 10.1136/bmj.n2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2231</ArticleId><ArticleId IdType="pmc">PMC8459162</ArticleId><ArticleId IdType="pubmed">34556486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. (2017) 45:486&#x2013;552. 10.1097/CCM.0000000000002255</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002255</ArticleId><ArticleId IdType="pubmed">28098591</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. (2021) 47:1181&#x2013;247. 10.1007/s00134-021-06506-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06506-y</ArticleId><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Sanjuan G, Moreno-Garc&#xed;a E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. . Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. (2021) 27:83&#x2013;8. 10.1016/j.cmi.2020.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.041</ArticleId><ArticleId IdType="pmc">PMC7836762</ArticleId><ArticleId IdType="pubmed">32745596</ArticleId></ArticleIdList></Reference><Reference><Citation>Godinjak A, Iglica A, Rama A, Tan&#x10d;ica I, Jusufovi&#x107; S, Ajanovi&#x107; A, et al. . Predictive value of SAPS II and APACHE II scoring systems for patient outcome in a medical intensive care unit. Acta Med Acad. (2016) 45:97&#x2013;103. 10.5644/ama2006-124.165</Citation><ArticleIdList><ArticleId IdType="doi">10.5644/ama2006-124.165</ArticleId><ArticleId IdType="pubmed">28000485</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. . Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol. (2019) 10:2752. 10.3389/fmicb.2019.02752</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02752</ArticleId><ArticleId IdType="pmc">PMC6901688</ArticleId><ArticleId IdType="pubmed">31849894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartsonaki C. Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19. medRxiv. [Preprint]. (2021).</Citation></Reference><Reference><Citation>COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study . Infection. (2021) 49:889&#x2013;905. 10.1007/s15010-021-01599-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01599-5</ArticleId><ArticleId IdType="pmc">PMC8231091</ArticleId><ArticleId IdType="pubmed">34170486</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC Clinical Characterisation Group. Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, et al. . Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. Elife. (2021) 10:e70970. 10.7554/eLife.70970</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70970</ArticleId><ArticleId IdType="pmc">PMC8791638</ArticleId><ArticleId IdType="pubmed">34812731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. . Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. (2021) 72:e206&#x2013;e14. 10.1093/cid/ciaa1012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1012</ArticleId><ArticleId IdType="pmc">PMC7454425</ArticleId><ArticleId IdType="pubmed">32674114</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. (2020) 24:179. 10.1186/s13054-020-02902-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02902-w</ArticleId><ArticleId IdType="pmc">PMC7187660</ArticleId><ArticleId IdType="pubmed">32345311</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. . Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. (2020) 180:1345&#x2013;55. 10.1001/jamainternmed.2020.3539</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3539</ArticleId><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicka V, Januskeviciute E, Miskinyte S, Ringaitiene D, Serpytis M, Klimasauskas A, et al. . Comparison of mortality risk evaluation tools efficacy in critically ill COVID-19 patients. BMC Infect Dis. (2021) 21:1173. 10.1186/s12879-021-06866-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06866-2</ArticleId><ArticleId IdType="pmc">PMC8607225</ArticleId><ArticleId IdType="pubmed">34809594</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gallo E, Merson L, Kennon K, Kelly S, Citarella BW, Fryer DV, et al. . ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19. Sci Data. (2022) 9:454. 10.1038/s41597-022-01534-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01534-9</ArticleId><ArticleId IdType="pmc">PMC9339000</ArticleId><ArticleId IdType="pubmed">35908040</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K, et al. . Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health. (2021) 11:98&#x2013;104. 10.2991/jegh.k.200928.001</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/jegh.k.200928.001</ArticleId><ArticleId IdType="pmc">PMC7958266</ArticleId><ArticleId IdType="pubmed">33095982</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco M, De Corte T, Ercole A, Antonelli M, Azoulay E, Citerio G, et al. . Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. Intensive Care Med. (2022) 48:690&#x2013;705. 10.1007/s00134-022-06705-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06705-1</ArticleId><ArticleId IdType="pmc">PMC9123859</ArticleId><ArticleId IdType="pubmed">35596752</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodeir MM, Shabana HA, Alkhamiss AS, Rasheed Z, Alsoghair M, Alsagaby SA, et al. . Early prediction keys for COVID-19 cases progression: a meta-analysis. J Infect Public Health. (2021) 14:561&#x2013;9. 10.1016/j.jiph.2021.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7934660</ArticleId><ArticleId IdType="pubmed">33848885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Li Y, Ma Y, Zhang H, Deng Y, Zhu Z. Multi-biomarker is an early-stage predictor for progression of Coronavirus disease 2019 (COVID-19) infection. Int J Med Sci. (2021) 18:2789&#x2013;98. 10.7150/ijms.58742</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.58742</ArticleId><ArticleId IdType="pmc">PMC8241766</ArticleId><ArticleId IdType="pubmed">34220307</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo AKG, Milby KM, Caparroz A, Pinto A, Santos RRP, Rocha AP, et al. . Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis. PLoS ONE. (2021) 16:e0253894. 10.1371/journal.pone.0253894</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253894</ArticleId><ArticleId IdType="pmc">PMC8241122</ArticleId><ArticleId IdType="pubmed">34185801</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B, Brell B, D&#xe1;vid I, Dorenberg M, Adolphs J, Schmeck B, et al. . Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. (2007) 33:703&#x2013;10. 10.1007/s00134-007-0561-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-007-0561-y</ArticleId><ArticleId IdType="pubmed">17318497</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmesfeld-Wollbr&#xfc;ck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost. (2007) 98:944&#x2013;51. 10.1160/TH07-02-0128</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH07-02-0128</ArticleId><ArticleId IdType="pubmed">18000597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bima P, Montrucchio G, Caramello V, Rumbolo F, Dutto S, Boasso S, et al. . Prognostic value of mid-regional Proadrenomedullin sampled at presentation and after 72 hours in septic patients presenting to the emergency department: an observational two-center study. Biomedicines. (2022) 10:719. 10.3390/biomedicines10030719</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10030719</ArticleId><ArticleId IdType="pmc">PMC8945269</ArticleId><ArticleId IdType="pubmed">35327521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozio E, Moore NA, Fabris M, Ripoli A, Rumbolo F, Minieri M, et al. . Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir Res. (2022) 23:221. 10.1186/s12931-022-02151-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02151-1</ArticleId><ArticleId IdType="pmc">PMC9420187</ArticleId><ArticleId IdType="pubmed">36031619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620&#x2013;9. 10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. (2020) 19:102537. 10.1016/j.autrev.2020.102537</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497&#x2013;506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020) 180:934&#x2013;43. 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. (2021) 184:861&#x2013;80. 10.1016/j.cell.2021.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, et al. . Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. (2020) 97:772&#x2013;6. 10.1002/cyto.a.24172</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24172</ArticleId><ArticleId IdType="pmc">PMC7323417</ArticleId><ArticleId IdType="pubmed">32542842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Du W, Yang T, Zhao L, Xiong R, Li Y, et al. . Lymphocyte subsets as a predictor of severity and prognosis in COVID-19 patients. Int J Immunopathol Pharmacol. (2021) 35:20587384211048567. 10.1177/20587384211048567</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20587384211048567</ArticleId><ArticleId IdType="pmc">PMC8504275</ArticleId><ArticleId IdType="pubmed">34619994</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. . Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. (2020) 17:1281&#x2013;92. 10.7150/ijms.46614</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.46614</ArticleId><ArticleId IdType="pmc">PMC7294915</ArticleId><ArticleId IdType="pubmed">32547323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. . Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. (2015) 136:1186&#x2013;205.e 1&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26371839</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. . Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. (2020) 81:318&#x2013;56. 10.1016/j.jinf.2020.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.044</ArticleId><ArticleId IdType="pmc">PMC7151471</ArticleId><ArticleId IdType="pubmed">32283154</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Vad&#xe1;sz I, Wilhelm J, Walmrath HD, Seeger W, Birk HW, et al. . Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. Am J Physiol Lung Cell Mol Physiol. (2021) 320:L590&#x2013;l9. 10.1152/ajplung.00359.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00359.2020</ArticleId><ArticleId IdType="pmc">PMC8057306</ArticleId><ArticleId IdType="pubmed">33237794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Yue D, Wang Y, Wang F, Wu S, Hou H. The dynamics of immune response in COVID-19 patients with different illness severity. J Med Virol. (2021) 93:1070&#x2013;7. 10.1002/jmv.26504</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26504</ArticleId><ArticleId IdType="pubmed">32910461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorusso R, Combes A, Lo Coco V, De Piero ME, Belohlavek J. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med. (2021) 47:344&#x2013;8. 10.1007/s00134-020-06272-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06272-3</ArticleId><ArticleId IdType="pmc">PMC7796689</ArticleId><ArticleId IdType="pubmed">33420797</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Sales G, Urbino R, Simonetti U, Bonetto C, Cura Stura E, et al. . ECMO support and operator safety in the context of COVID-19 outbreak: a regional center experience. Membranes. (2021) 11:334. 10.3390/membranes11050334</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/membranes11050334</ArticleId><ArticleId IdType="pmc">PMC8147243</ArticleId><ArticleId IdType="pubmed">33946566</ArticleId></ArticleIdList></Reference><Reference><Citation>Loforte A, Di Mauro M, Pellegrini C, Monterosso C, Pelenghi S, Degani A, et al. . Extracorporeal membrane oxygenation for COVID-19 respiratory distress syndrome: an Italian society for cardiac surgery report. ASAIO J. (2021) 67:385&#x2013;91. 10.1097/MAT.0000000000001399</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0000000000001399</ArticleId><ArticleId IdType="pubmed">33470643</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V, Giani M, Grasselli G, Mojoli F, Martucci G, Grazioli L, et al. . Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. (2022) 26:34. 10.1186/s13054-022-03906-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03906-4</ArticleId><ArticleId IdType="pmc">PMC8817653</ArticleId><ArticleId IdType="pubmed">35123562</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Corcione S, Lupia T, Shbaklo N, Olivieri C, Poggioli M, et al. . The burden of carbapenem-resistant Acinetobacter baumannii in ICU COVID-19 patients: a regional experience. J Clin Med. (2022) 11:5208. 10.3390/jcm11175208</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11175208</ArticleId><ArticleId IdType="pmc">PMC9456723</ArticleId><ArticleId IdType="pubmed">36079137</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa FG, Brazzi L. Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball. J Glob Antimicrob Resist. (2020) 23:398&#x2013;400. 10.1016/j.jgar.2020.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7682477</ArticleId><ArticleId IdType="pubmed">33242674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupia T, Montrucchio G, Gaviraghi A, Musso G, Puppo M, Bolla C, et al. . A Regional observational study on COVID-19-associated pulmonary aspergillosis (CAPA) within intensive care unit: trying to break the mold. J Fungi. (2022) 8:1264. 10.3390/jof8121264</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jof8121264</ArticleId><ArticleId IdType="pmc">PMC9785727</ArticleId><ArticleId IdType="pubmed">36547597</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34686556</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Multicentre, longitudinal, observational cohort study to examine the relationship between neutrophil function and sepsis in adults and children with severe thermal injuries: a protocol for the Scientific Investigation of the Biological Pathways Following Thermal Injury-2 (SIFTI-2) study.</ArticleTitle><Pagination><StartPage>e052035</StartPage><MedlinePgn>e052035</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e052035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-052035</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Burn-induced changes in the phenotype and function of neutrophils, cells which provide front-line protection against rapidly dividing bacterial infections, are emerging as potential biomarkers for the early prediction of sepsis. In a longitudinal study of adult burns patients, we recently demonstrated that a combined measurement of neutrophil phagocytic capacity, immature granulocyte (IG) count and plasma cell-free DNA (cfDNA) levels on the day of injury gave good discriminatory power for the prediction of later sepsis development. However, limited by a small sample size, single-centre design and focus on adult burns patients, these biomarkers require prospective validation in a larger patient cohort. The Scientific Investigation of the Biological Pathways Following Thermal Injury-2 study aims to prospectively validate neutrophil phagocytic activity, IG count and plasma cfDNA levels as early prognostic biomarkers of sepsis in thermally injured adult and paediatric patients.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This multicentre, longitudinal, observational cohort study will enrol 245 paediatric and adult patients with moderate to severe burns within 24 hours of injury. Blood samples will be obtained at 19 postinjury time points (days 1-14, day 28, months 3, 6, 12 and 24) and analysed for neutrophil phagocytic activity, IG count and cfDNA levels. Patients will be screened daily for sepsis using the 2007 American Burn Association diagnostic criteria for sepsis. In addition, daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores will be recorded relationships between neutrophil phagocytic activity, IG count and plasma cfDNA levels on day 1 of injury and the development of sepsis will be examined using logistic regression models.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study received ethics approval from the West Midlands, Coventry and Warwickshire Research Ethics Committee (REC reference:16/WM/0217). Findings will be presented at national and international conferences, and submitted for publication in peer-reviewed journals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04693442.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Kirsty C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Tarrah</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassouna</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Krupali</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Rizwana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1641-2478</Identifier><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamford</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St Andrews Centre for Plastic Surgery and Burns, Mid and South Essex NHS Foundation Trust, Essex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-1030-6786</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moiemen</LastName><ForeName>Naiem S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK naiem.moiemen2@nhs.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04693442</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult intensive &amp; critical care</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">paediatric intensive &amp; critical care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34686556</ArticleId><ArticleId IdType="pmc">PMC8543641</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-052035</ArticleId><ArticleId IdType="pii">bmjopen-2021-052035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jackson PC, Hardwicke J, Bamford A, et al. . Revised estimates of mortality from the Birmingham burn centre, 2001-2010: a continuing analysis over 65 years. Ann Surg 2014;259:979&#x2013;84. 10.1097/SLA.0b013e31829160ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31829160ca</ArticleId><ArticleId IdType="pubmed">23598383</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;lhan B, Kan&#x131;k Y&#xfc;ksek S, Hayran M, et al. . Infections in pediatric burn patients: an analysis of one hundred eighty-one patients. Surg Infect 2020;21:357&#x2013;62. 10.1089/sur.2019.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2019.010</ArticleId><ArticleId IdType="pubmed">31589562</ArticleId></ArticleIdList></Reference><Reference><Citation>Holl&#xe9;n L, Hughes R, Dodds N, et al. . Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns. Trauma 2019;21:192&#x2013;200. 10.1177/1460408618760940</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1460408618760940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan KM, Jayaraman V, Mathivanan T, et al. . Profile of burn sepsis challenges and outcome in an exclusive children's hospital in Chennai, India. Ann Burns Fire Disasters 2012;25:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431721</ArticleId><ArticleId IdType="pubmed">23012610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann EA, Baun MM, Meininger JC, et al. . Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: a systematic review of the literature. Shock 2012;37:4&#x2013;16. 10.1097/SHK.0b013e318237d6bf</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318237d6bf</ArticleId><ArticleId IdType="pubmed">21941222</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. . The third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801&#x2013;10. 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams FN, Herndon DN, Hawkins HK, et al. . The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009;13:R183. 10.1186/cc8170</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8170</ArticleId><ArticleId IdType="pmc">PMC2811947</ArticleId><ArticleId IdType="pubmed">19919684</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina JA, Rosique MJ, Rosique RG. Curbing inflammation in burn patients. Int J Inflam 2013;2013:1&#x2013;9. 10.1155/2013/715645</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/715645</ArticleId><ArticleId IdType="pmc">PMC3671671</ArticleId><ArticleId IdType="pubmed">23762773</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, et al. . American burn association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776&#x2013;90. 10.1097/BCR.0b013e3181599bc9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644&#x2013;55. 10.1378/chest.101.6.1644</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez Lopez O, Cambiaso-Daniel J, Branski LK, et al. . Predicting and managing sepsis in burn patients: current perspectives. Ther Clin Risk Manag 2017;13:1107&#x2013;17. 10.2147/TCRM.S119938</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S119938</ArticleId><ArticleId IdType="pmc">PMC5584891</ArticleId><ArticleId IdType="pubmed">28894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely AN, Fowler LA, Kagan RJ, et al. . Procalcitonin in pediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil 2004;25:76&#x2013;80. 10.1097/01.BCR.0000105095.94766.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000105095.94766.89</ArticleId><ArticleId IdType="pubmed">14726743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargues L, Chancerelle Y, Catineau J, et al. . Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns 2007;33:860&#x2013;4. 10.1016/j.burns.2006.10.401</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.401</ArticleId><ArticleId IdType="pubmed">17532575</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gesten F, Prescott HC, et al. . Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235&#x2013;44. 10.1056/NEJMoa1703058</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1703058</ArticleId><ArticleId IdType="pmc">PMC5538258</ArticleId><ArticleId IdType="pubmed">28528569</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CN, Moore M, Dimisko L, et al. . Spontaneous neutrophil migration patterns during sepsis after major burns. PLoS One 2014;9:e114509. 10.1371/journal.pone.0114509</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114509</ArticleId><ArticleId IdType="pmc">PMC4260850</ArticleId><ArticleId IdType="pubmed">25489947</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler KL, Ambravaneswaran V, Agrawal N, et al. . Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS One 2010;5:e11921. 10.1371/journal.pone.0011921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011921</ArticleId><ArticleId IdType="pmc">PMC2912851</ArticleId><ArticleId IdType="pubmed">20689600</ArticleId></ArticleIdList></Reference><Reference><Citation>Arturson G. Neutrophil granulocyte functions in severely burned patients. Burns Incl Therm Inj 1985;11:309&#x2013;19. 10.1016/0305-4179(85)90093-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0305-4179(85)90093-2</ArticleId><ArticleId IdType="pubmed">4027746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, et al. . Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann Surg 2017;265:1241&#x2013;9. 10.1097/SLA.0000000000001807</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with large burns. Blood Cells 1990;16:127&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190644</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinsdale RJ, Devi A, Hampson P, et al. . Changes in novel haematological parameters following thermal injury: a prospective observational cohort study. Sci Rep 2017;7:3211. 10.1038/s41598-017-03222-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03222-w</ArticleId><ArticleId IdType="pmc">PMC5468303</ArticleId><ArticleId IdType="pubmed">28607467</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith R. What is gillick competence? Hum Vaccin Immunother 2016;12:244&#x2013;7. 10.1080/21645515.2015.1091548</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1091548</ArticleId><ArticleId IdType="pmc">PMC4962726</ArticleId><ArticleId IdType="pubmed">26619366</ArticleId></ArticleIdList></Reference><Reference><Citation>. DOI.Jeschke MG, Chinkes DL, Finnerty CC, et al. . Pathophysiologic response to severe burn injury. Ann Surg 2008;248:387&#x2013;401. 10.1097/SLA.0b013e3181856241</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181856241</ArticleId><ArticleId IdType="pmc">PMC3905467</ArticleId><ArticleId IdType="pubmed">18791359</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, et al. . Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med 2008;14:553&#x2013;60. 10.2119/2007-00132.Finnerty</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2007-00132.Finnerty</ArticleId><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder PPG, Vlig M, Boekema BKHL, et al. . Persistent systemic inflammation in patients with severe burn injury is accompanied by influx of immature neutrophils and shifts in T cell subsets and cytokine profiles. Front Immunol 2020;11:621222. 10.3389/fimmu.2020.621222</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.621222</ArticleId><ArticleId IdType="pmc">PMC7879574</ArticleId><ArticleId IdType="pubmed">33584717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist M, H&#xe4;stbacka J, Glaumann C, et al. . The time-course of the inflammatory response to major burn injury and its relation to organ failure and outcome. Burns 2019;45:354&#x2013;63. 10.1016/j.burns.2018.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.001</ArticleId><ArticleId IdType="pubmed">30274808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Kulp GA, et al. . Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011;6:e21245. 10.1371/journal.pone.0021245</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021245</ArticleId><ArticleId IdType="pmc">PMC3138751</ArticleId><ArticleId IdType="pubmed">21789167</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehne MG, Sablotzki A, Hoffmann A, et al. . Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns 2002;28:535&#x2013;42. 10.1016/S0305-4179(02)00050-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(02)00050-5</ArticleId><ArticleId IdType="pubmed">12220910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur J, Yang HT, Chun W, et al. . Inflammatory cytokines and their prognostic ability in cases of major burn injury. Ann Lab Med 2015;35:105&#x2013;10. 10.3343/alm.2015.35.1.105</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2015.35.1.105</ArticleId><ArticleId IdType="pmc">PMC4272939</ArticleId><ArticleId IdType="pubmed">25553289</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BZ, McAlister S, McGuire HM, et al. . Pediatric burn survivors have long-term immune dysfunction with diminished vaccine response. Front Immunol 2020;11:1481. 10.3389/fimmu.2020.01481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01481</ArticleId><ArticleId IdType="pmc">PMC7385079</ArticleId><ArticleId IdType="pubmed">32793203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fear VS, Boyd JH, Rea S, et al. . Burn injury leads to increased long-term susceptibility to respiratory infection in both mouse models and population studies. PLoS One 2017;12:e0169302. 10.1371/journal.pone.0169302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169302</ArticleId><ArticleId IdType="pmc">PMC5221812</ArticleId><ArticleId IdType="pubmed">28068397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, et al. . Occurrence of multiorgan dysfunction in pediatric burn patients: incidence and clinical outcome. Ann Surg 2014;259:381&#x2013;7. 10.1097/SLA.0b013e31828c4d04</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828c4d04</ArticleId><ArticleId IdType="pmc">PMC3731402</ArticleId><ArticleId IdType="pubmed">23511841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33933851</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19.</ArticleTitle><Pagination><StartPage>107569</StartPage><MedlinePgn>107569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2021.107569</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(21)00205-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To investigate the prognostic value of a novel immune-inflammatory index, the interleukin-6-to-lymphocyte ratio (IL-6/LY), with the clinical outcomes of severe coronavirus disease 2019 (COVID-19) cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cohort study of COVID-19 patients in Tongji Hospital, from January 2020 to February 2020, was evaluated. Kaplan-Meier method and the log-rank test was performed to analyze survival data. Univariate and multivariate analyses were performed with COX proportional hazard regression model. The primary and secondary outcomes were in-hospital mortality and multiple organ dysfunction syndrome (MODS), respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Total 320 adult patients were enrolled in our analyses. Patients were divided into low IL-6/LY group and high IL-6/LY group based on the cutoff value with 2.50. The Kaplan-Meier survival curves showed that high-value group (IL-6/LY&#xa0;&#x2265;&#xa0;2.50) had a greater risk of poor prognosis (P&#xa0;&lt;&#xa0;0.001, respectively). Multivariate analysis indicated that IL-6/LY was the independent risk predictor for in-hospital mortality (hazard ratio [HR],&#xa0;3.404; 95% confidence interval [CI],&#xa0;1.090-10.633, P&#xa0;=&#xa0;0.035) and MODS development (HR, 4.143; 95%CI, 1.321-12.986, P&#xa0;=&#xa0;0.015). Meanwhile, IL-6/LY was positively correlated with the MuLBSTA score (r&#xa0;=&#xa0;0.137, P&#xa0;=&#xa0;0.031), suggesting that IL-6/LY was associated with long-term mortality (90-day). Furthermore, kinetic analysis revealed that the dynamic changes of inflammatory immune indexes were related to the severity of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The elevated IL-6/LY was related with the increased risk of poor prognosis. Not only that, IL-6/LY could be used for risk stratification and early clinical identification of high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Boyi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiabao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Practice, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Zhilong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Forth Hospital of Wuhan Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cuntai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: lihongniuniu2014@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Immune-inflammatory index</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Lymphocyte</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>20</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33933851</ArticleId><ArticleId IdType="pmc">PMC7953449</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2021.107569</ArticleId><ArticleId IdType="pii">S1567-5769(21)00205-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarzi-Puttini P., et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 2020;38(2):337&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">32202240</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health, Coronavirus disease (COVID-19): Situation Report128. 2019:2020.</Citation></Reference><Reference><Citation>Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169239</ArticleId><ArticleId IdType="pubmed">29052924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.-W., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M.D., et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 2016;375(13):1303&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">27682053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020:ciaa248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. 2020:ciaa449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappelli F., et al. COVID-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147500</ArticleId><ArticleId IdType="pubmed">32308263</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health . World Health Organization; Geneva: 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance.</Citation></Reference><Reference><Citation>Ramirez M. Multiple organ dysfunction syndrome. Curr. Probl. Pediatr. Adolesc. Health Care. 2013;43(10):273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y., et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020:102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol. 2020;214:108393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102614</ArticleId><ArticleId IdType="pubmed">32222466</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39(5):529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousterman B.G., et al. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017;39(5):517&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020:e200994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifaldi L., et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67(11):3037&#x2013;3046.</Citation><ArticleIdList><ArticleId IdType="pubmed">26251193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis. 2020;221(11):1762&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184346</ArticleId><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Wan, et al., Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv (2020) 2020.02.10.20021832.</Citation></Reference><Reference><Citation>Xu Z., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 2004;189(4):648&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109946</ArticleId><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecere T.E., et al. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4(5):833&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386620</ArticleId><ArticleId IdType="pubmed">22754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-H., et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J. Infect. 2020;80(4):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102535</ArticleId><ArticleId IdType="pubmed">32109443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.J., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufan A., et al. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 2020;50(SI-1):620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195984</ArticleId><ArticleId IdType="pubmed">32299202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonggang Z., et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu B., et al. Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 2020;18(1):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154566</ArticleId><ArticleId IdType="pubmed">32290839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Busetto L., et al. Obesity and COVID-19: an Italian snapshot. Obesity (Silver Spring, Md.) 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283686</ArticleId><ArticleId IdType="pubmed">32463545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020:e3319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. 2020;S0735-1097(20):35008&#x2013;35017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus. Med. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135848</ArticleId><ArticleId IdType="pubmed">32107119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 2020;382(17):e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir. Res. 2020;21(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156898</ArticleId><ArticleId IdType="pubmed">32293449</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32154377</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2397-5776</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Trauma surgery &amp; acute care open</Title><ISOAbbreviation>Trauma Surg Acute Care Open</ISOAbbreviation></Journal><ArticleTitle>Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured.</ArticleTitle><Pagination><StartPage>e000398</StartPage><MedlinePgn>e000398</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e000398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/tsaco-2019-000398</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The recent decrease in multiple organ dysfunction syndrome (MODS)-associated and adult respiratory distress syndrome (ARDS)-associated mortality could be considered a success of improvements in trauma care. However, the incidence of infections remains high in patients with polytrauma, with high morbidity and hospital resources usage. Infectious complications might be a residual effect of the decrease in MODS-related/ARDS-related mortality. This study investigated the current incidence of infectious complications in polytrauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 5.5-year prospective population-based cohort study included consecutive severely injured patients (age &gt;15) admitted to a (Level-1) trauma center intensive care unit (ICU) who survived &gt;48&#x2009;hours. Demographics, physiologic and resuscitation parameters, multiple organ failure and ARDS scores, and infectious complications (pneumonia, fracture-related infection, meningitis, infections related to blood, wound, and urinary tract) were prospectively collected. Data are presented as median (IQR), p&lt;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">297 patients (216 (73%) men) were included with median age of 46 (27-60) years, median Injury Severity Score was 29 (22-35), 96% sustained blunt injuries. 44 patients (15%) died. One patient (2%) died of MODS and 1 died of ARDS. 134 patients (45%) developed 201 infectious complications. Pneumonia was the most common complication (50%). There was no difference in physiologic parameters on arrival in emergency department and ICU between patients with and without infectious complications. Patients who later developed infections underwent more often a laparotomy (32% vs 18%, p=0.009), had more often pelvic fractures (38% vs 25%, p=0.02), and received more blood products &lt;8&#x2009;hours. They had more often MODS (25% vs 13%, p=0.005), stayed longer on the ventilator (10 (5-15) vs 5 (2-8) days, p&lt;0.001), longer in ICU (11 (6-17) vs 6 (3-10) days, p&lt;0.001), and in hospital (30 (20-44) vs 16 (10-24) days, p&lt;0.001). There was however no difference in mortality (12% vs 17%, p=0.41) between both groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">45% of patients developed infectious complications. These patients had similar mortality rates, but used more hospital resources. With low MODS-related and ARDS-related mortality, infections might be a residual effect, and are one of the remaining challenges in the treatment of patients with polytrauma.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level 3.</AbstractText><AbstractText Label="STUDY TYPE" NlmCategory="METHODS">Population-based cohort study.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hietbrink</LastName><ForeName>Falco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trauma Surg Acute Care Open</MedlineTA><NlmUniqueID>101698646</NlmUniqueID><ISSNLinking>2397-5776</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32154377</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pii">tsaco-2019-000398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demetriades D, Kimbrell B, Salim A, Velmahos G, Rhee P, Preston C, Gruzinski G, Chan L. Trauma deaths in a mature urban trauma system: is "trimodal" distribution a valid concept? J Am Coll Surg 2005;201:343&#x2013;8. 10.1016/j.jamcollsurg.2005.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2005.05.003</ArticleId><ArticleId IdType="pubmed">16125066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Paffrath T, Bouamra O, Coats TJ, Woodford M, Jenks T, Wafaisade A, Nienaber U, Lecky F. Epidemiology of in-hospital trauma deaths. Eur J Trauma Emerg Surg 2012;38:3&#x2013;9. 10.1007/s00068-011-0168-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-011-0168-4</ArticleId><ArticleId IdType="pubmed">26815666</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JA, van Wessem KJP, McDougall D, Lee KA, Lyons T, Balogh ZJ. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg 2010;34:158&#x2013;63. 10.1007/s00268-009-0266-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0266-1</ArticleId><ArticleId IdType="pubmed">19882185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselink L, Spijkerman R, van Wessem KJP, Koenderman L, Leenen LPH, Huber-Lang M, Hietbrink F. Neutrophil heterogeneity and its role in infectious complications after severe trauma. World J Emerg Surg 2019;14:24 10.1186/s13017-019-0244-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-019-0244-3</ArticleId><ArticleId IdType="pmc">PMC6542247</ArticleId><ArticleId IdType="pubmed">31164913</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Incidence of acute respiratory distress syndrome and associated mortality in a polytrauma population. Trauma Surg Acute Care Open 2018;3:e000232 10.1136/tsaco-2018-000232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2018-000232</ArticleId><ArticleId IdType="pmc">PMC6307585</ArticleId><ArticleId IdType="pubmed">30623025</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Reduction in mortality rates of Postinjury multiple organ dysfunction syndrome: a shifting paradigm? A prospective population-based cohort study. Shock 2018;49:33&#x2013;8. 10.1097/SHK.0000000000000938</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId><ArticleId IdType="pubmed">28682941</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level I trauma centers in three international trauma systems. World J Surg 2015;39:2677&#x2013;84. 10.1007/s00268-015-3162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg 2013;74:774&#x2013;9. 10.1097/TA.0b013e31827a6e69</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg 2014;77:624&#x2013;9. 10.1097/TA.0000000000000406</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 1994;129:39&#x2013;45. 10.1001/archsurg.1994.01420250051006</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, ARDS Definition Task Force . Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526&#x2013;33. 10.1001/jama.2012.5669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich M, Wafaisade A, Mansuri A, Koenen P, Probst C, Maegele M, Bouillon B, Sakka SG. Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores. Scand J Trauma Resusc Emerg Med 2016;24:130 10.1186/s13049-016-0321-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13049-016-0321-5</ArticleId><ArticleId IdType="pmc">PMC5094147</ArticleId><ArticleId IdType="pubmed">27809885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, sequential organ failure assessment, and Marshall scoring systems. J Trauma Acute Care Surg 2017;82:534&#x2013;41. 10.1097/TA.0000000000001328</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000001328</ArticleId><ArticleId IdType="pmc">PMC5328408</ArticleId><ArticleId IdType="pubmed">28030507</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostdijk EAN, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EHR, Bernards AT, Purmer I, Brimicombe R, Bergmans D, et al. . Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 2014;312:1429&#x2013;37. 10.1001/jama.2014.7247</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.7247</ArticleId><ArticleId IdType="pubmed">25271544</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309&#x2013;32. 10.1016/j.ajic.2008.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2008.03.002</ArticleId><ArticleId IdType="pubmed">18538699</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Surgeons Guide for the prevention of surgical site infection. Bull Am Coll Surg 2000;85:23&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11349547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Davenport R, Willett K, Brohi K. The burden of infection in severely injured trauma patients and the relationship with admission shock severity. J Trauma Acute Care Surg 2014;76:730&#x2013;5. 10.1097/TA.0b013e31829fdbd7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31829fdbd7</ArticleId><ArticleId IdType="pubmed">24487318</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, McFadyen I, Scarborough M, Athanasou NA, Ochsner PE, Kuehl R, Raschke M, et al. . Fracture-related infection: a consensus on definition from an international expert group. Injury 2018;49:505&#x2013;10. 10.1016/j.injury.2017.08.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2017.08.040</ArticleId><ArticleId IdType="pubmed">28867644</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent J-L, Ramsay G, et al. . 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250&#x2013;6. 10.1097/01.CCM.0000050454.01978.3B</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000050454.01978.3B</ArticleId><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Wafaisade A, Lefering R, Bouillon B, Sakka SG, Thamm OC, Paffrath T, Neugebauer E, Maegele M, Trauma Registry of the German Society for Trauma Surgery . Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the trauma registry of the German Society for trauma surgery. Crit Care Med 2011;39:621&#x2013;8. 10.1097/CCM.0b013e318206d3df</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318206d3df</ArticleId><ArticleId IdType="pubmed">21242798</ArticleId></ArticleIdList></Reference><Reference><Citation>Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. Arch Surg 2011;146:794&#x2013;801. 10.1001/archsurg.2011.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2011.41</ArticleId><ArticleId IdType="pmc">PMC3336161</ArticleId><ArticleId IdType="pubmed">21422331</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JV, Gordon LE, Hall H, Heinzelmann M, Polk HC. Differences between bacterial species shown by simultaneous assessment of neutrophil phagocytosis and generation of reactive oxygen intermediates in trauma patients. Arch Surg 1999;134:1222&#x2013;7. discussion 1227-8 10.1001/archsurg.134.11.1222</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.134.11.1222</ArticleId><ArticleId IdType="pubmed">10555637</ArticleId></ArticleIdList></Reference><Reference><Citation>Pechous RD. With friends like these: the complex role of neutrophils in the progression of severe pneumonia. Front Cell Infect Microbiol 2017;7:160 10.3389/fcimb.2017.00160</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2017.00160</ArticleId><ArticleId IdType="pmc">PMC5410563</ArticleId><ArticleId IdType="pubmed">28507954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadjadi J, Cureton EL, Twomey P, Victorino GP. Transfusion, not just injury severity, leads to posttrauma infection: a matched cohort study. Am Surg 2009;75:307&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19385290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Meyer W, Scalea TM. Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study. World J Surg 2008;32:2185&#x2013;9. 10.1007/s00268-008-9655-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-008-9655-0</ArticleId><ArticleId IdType="pubmed">18575931</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PMM, Vroom MB, Dankert J, Kesecioglu J. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011&#x2013;6. 10.1016/S0140-6736(03)14409-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14409-1</ArticleId><ArticleId IdType="pubmed">14522530</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitinck S, Jansen R, Rijkenberg S, Wester JPJ, Bosman RJ, van der Meer NJM, van der Voort PHJ. The ecological effects of selective decontamination of the digestive tract (SDD) on antimicrobial resistance: a 21-year longitudinal single-centre study. Crit Care 2019;23:208 10.1186/s13054-019-2480-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2480-z</ArticleId><ArticleId IdType="pmc">PMC6555978</ArticleId><ArticleId IdType="pubmed">31174575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33854308</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-1998</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Clinical interventions in aging</Title><ISOAbbreviation>Clin Interv Aging</ISOAbbreviation></Journal><ArticleTitle>Association Between High-Sensitivity Troponin T on Admission and Organ Dysfunction During Hospitalization in Patients Aged 80 Years and Older with Hip Fracture: A Single-Centered Prospective Cohort Study.</ArticleTitle><Pagination><StartPage>583</StartPage><EndPage>591</EndPage><MedlinePgn>583-591</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CIA.S303246</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prognostic evaluation of elderly patients with hip fracture is an issue that has been highly concerned by clinicians. Only a few studies have focused on organ dysfunction after hip fracture in the elderly. This study aimed to investigate the association between high-sensitivity troponin T (hs-TnT) at admission and organ dysfunction during hospitalization in elderly patients with hip fracture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 168 patients with hip fracture who were aged 80 years and older at Geriatric Orthopaedic Center of Sichuan Provincial Orthopedic Hospital between January 2020 and August 2020. Baseline characteristics, perioperative information, and short-term clinical outcomes were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 208 patients admitted during the study period, 168 met the inclusion criteria; of these, 91 (54.2%) had higher hs-TnT than the 99th percentile in the normal population. After adjustment for confounders, elevated hs-TnT was independently associated with multiple organ dysfunction syndrome in the elderly (MODSE) (adjusted OR, 5.76; 95% CI, 1.74-19.10; <i>P</i> = 0.004), heart dysfunction (adjusted OR, 7.48; 95% CI, 2.17-25.82; <i>P</i> = 0.001), MODS severity score &gt; 3 (adjusted OR, 5.22; 95% CI, 1.32-20.60; <i>P</i> = 0.018), and length of hospital stay &gt; 14 days (adjusted OR, 2.38; 95% CI, 1.05-5.36; <i>P</i> = 0.037).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Increased hs-TnT on admission is an independent risk factor for MODSE after hip fracture in patients aged 80 years and older. Effective measures should be applied to avoid progression of MODSE from pre-failure stage to failure stage.</AbstractText><CopyrightInformation>&#xa9; 2021 Qin et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Zhi-Jun</ForeName><Initials>ZJ</Initials><Identifier Source="ORCID">0000-0003-3664-090X</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qian-Yun</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xuan-Di</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheng-Jie</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Geriatric Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Jun-Feng</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Geriatric Orthopedics, Sichuan Provincial Orthopedic Hospital, Chengdu, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Interv Aging</MedlineTA><NlmUniqueID>101273480</NlmUniqueID><ISSNLinking>1176-9092</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020107">Troponin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020107" MajorTopicYN="N">Troponin T</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">high-sensitivity troponin T</Keyword><Keyword MajorTopicYN="N">hip fracture</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome in the elderly</Keyword><Keyword MajorTopicYN="N">short-term outcomes</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>7</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33854308</ArticleId><ArticleId IdType="pmc">PMC8039433</ArticleId><ArticleId IdType="doi">10.2147/CIA.S303246</ArticleId><ArticleId IdType="pii">303246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leer-Salvesen S, Enges&#xe6;ter LB, Dybvik E, Furnes O, Kristensen TB, Gjertsen JE. Does time from fracture to surgery affect mortality and intraoperative medical complications for hip fracture patients? An observational study of 73 557 patients reported to the Norwegian hip fracture register. Bone Joint J. 2019;101-B(9):1129&#x2013;1137. doi:10.1302/0301-620X.101B9.BJJ-2019-0295.R1</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.101B9.BJJ-2019-0295.R1</ArticleId><ArticleId IdType="pubmed">31474142</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaupre LA, Khong H, Smith C, et al. The impact of time to surgery after hip fracture on mortality at 30- and 90-days: does a single benchmark apply to all? Injury. 2019;50(4):950&#x2013;955. doi:10.1016/j.injury.2019.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2019.03.031</ArticleId><ArticleId IdType="pubmed">30948037</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa KA, G&#xe9;lvez AG, Torres LP, Garc&#xed;a MF, Pe&#xf1;a OR. Pre-operative factors associated with increased mortality in elderly patients with a hip fracture: a cohort study in a developing country. Injury. 2018;49(6):1162&#x2013;1168. doi:10.1016/j.injury.2018.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.04.007</ArticleId><ArticleId IdType="pubmed">29674111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson MH, Bentzer P, Turkiewicz A, Hommel A. Accuracy of the physiological and operative severity score for the enUmeration of mortality and morbidity score and the Nottingham risk score in hip fracture patients in Sweden &#x2013; a prospective observational study. Acta Anaesthesiol Scand. 2018;62(8):1057&#x2013;1063. doi:10.1111/aas.13131</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13131</ArticleId><ArticleId IdType="pmc">PMC6099275</ArticleId><ArticleId IdType="pubmed">29687439</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns WL, Strong B, Kates S, Patel NK. POSSUM and P-POSSUM scoring in hip fracture mortalities. Geriatr Orthop Surg Rehabil. 2020;11:2151459320931674. doi:10.1177/2151459320931674</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2151459320931674</ArticleId><ArticleId IdType="pmc">PMC7290268</ArticleId><ArticleId IdType="pubmed">32577320</ArticleId></ArticleIdList></Reference><Reference><Citation>Laulund AS, Lauritzen JB, Duus BR, Mosfeldt M, J&#xf8;rgensen HL. Routine blood tests as predictors of mortality in hip fracture patients. Injury. 2012;43(7):1014&#x2013;1020. doi:10.1016/j.injury.2011.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2011.12.008</ArticleId><ArticleId IdType="pubmed">22236368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P, Lv H, Li Y, et al. Hip fracture patients who experience a greater fluctuation in RDW during hospital course are at heightened risk for all-cause mortality: a prospective study with 2-year follow-up. Osteoporos Int. 2018;29(7):1559&#x2013;1567. doi:10.1007/s00198-018-4516-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-018-4516-7</ArticleId><ArticleId IdType="pubmed">29656346</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot B, Verdoorn RC, Lameijer J, van der Velden J. High-sensitivity cardiac troponin T is an independent predictor of inhospital mortality in emergency department patients with suspected infection: a prospective observational derivation study. Emerg Med J. 2014;31(11):882&#x2013;888. doi:10.1136/emermed-2013-202865</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emermed-2013-202865</ArticleId><ArticleId IdType="pubmed">23965276</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf8;iseth AD, Brynildsen J, Hagve TA, et al. The influence of heart failure co-morbidity on high-sensitivity troponin T levels in COPD exacerbation in a prospective cohort study: data from the akershus cardiac examination (ACE) 2 study. Biomarkers. 2016;21(2):173&#x2013;179. doi:10.3109/1354750X.2015.1126645</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1354750X.2015.1126645</ArticleId><ArticleId IdType="pubmed">26754170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neukamm A, Einvik G, Didrik h&#xf8;iseth A, et al. The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm Med. 2016;16(1):164. doi:10.1186/s12890-016-0319-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-016-0319-9</ArticleId><ArticleId IdType="pmc">PMC5124304</ArticleId><ArticleId IdType="pubmed">27887619</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Wang J, Dong W. The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. BMC Neurol. 2018;18(1):118. doi:10.1186/s12883-018-1121-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1121-5</ArticleId><ArticleId IdType="pmc">PMC6102797</ArticleId><ArticleId IdType="pubmed">30124165</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Hryniewiecki T, Ku&#x15b;mierczyk M, Szyma&#x144;ski P. High-sensitivity troponin T predicts postoperative cardiogenic shock requiring mechanical circulatory support in patients with valve disease. Shock. 2020;53(2):175&#x2013;178. doi:10.1097/SHK.0000000000001360</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001360</ArticleId><ArticleId IdType="pubmed">31162290</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Hryniewiecki T, Ku&#x15b;mierczyk M, Szymanski P. Red cell distribution width as a predictor of multiple organ dysfunction syndrome in patients undergoing heart valve surgery. Biol Open. 2018;7(10):bio036251. doi:10.1242/bio.036251</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.036251</ArticleId><ArticleId IdType="pmc">PMC6215413</ArticleId><ArticleId IdType="pubmed">30127093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391&#x2013;e479. doi:10.1161/CIRCULATIONAHA.109.192065</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.192065</ArticleId><ArticleId IdType="pubmed">19324966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580&#x2013;586. doi:10.1378/chest.93.3.580</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.93.3.580</ArticleId><ArticleId IdType="pubmed">3342669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira D, Reis E. Swallowing disorders in nursing home residents: how can the problem be explained? Clin Interv Aging. 2013;8:221&#x2013;227. doi:10.2147/CIA.S39452</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S39452</ArticleId><ArticleId IdType="pmc">PMC3581290</ArticleId><ArticleId IdType="pubmed">23449951</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SW, Wang JD, Chen KJ, Wang YT, Wang XD, Mu CS. Diagnostic criteria of multiple organ dysfunction syndrome in elderly (Draft, 2003). Chin Crit Care Med. 2004;16(1):1. doi:10.3760/cma.j.issn.1003-0603.2004.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1003-0603.2004.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Society of Combining Traditional Chinese and Western Medicine Professional Committee of Emergency Medicine. [Replacing &#x201c;Lushan conference in 1995&#x201d; guideline of the staging diagnosis and severity score standard of multiple organ dysfunction syndrome (2015)]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016;28(2):99&#x2013;101. Chinese. doi:10.3760/cma.j.issn.2095-4352.2016.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.2095-4352.2016.02.002</ArticleId><ArticleId IdType="pubmed">26911937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargani L, Pang PS, Frassi F, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. Cardiovasc Ultrasound. 2015;13:40. doi:10.1186/s12947-015-0033-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12947-015-0033-4</ArticleId><ArticleId IdType="pmc">PMC4558829</ArticleId><ArticleId IdType="pubmed">26337295</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P, Szyma&#x144;ski P, Ku&#x15b;mierczyk M, Hryniewiecki T. Usefulness of FRAIL scale in heart valve diseases. Clin Interv Aging. 2020;15:1071&#x2013;1075. doi:10.2147/CIA.S239054</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S239054</ArticleId><ArticleId IdType="pmc">PMC7358089</ArticleId><ArticleId IdType="pubmed">32753858</ArticleId></ArticleIdList></Reference><Reference><Citation>Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113(14):1708&#x2013;1718. doi:10.1093/cvr/cvx183</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvx183</ArticleId><ArticleId IdType="pmc">PMC5852618</ArticleId><ArticleId IdType="pubmed">29016754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SJ, Wang Q, Cui YJ, et al. High-sensitivity cardiac troponin T in geriatric inpatients. Arch Gerontol Geriatr. 2016;65:111&#x2013;115. doi:10.1016/j.archger.2016.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2016.03.010</ArticleId><ArticleId IdType="pubmed">27017416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Li DX, Wang Q, Xu Y, Cui YJ. Relationship between high-sensitivity cardiac troponin T and the prognosis of elderly inpatients with non-acute coronary syndromes. Clin Interv Aging. 2018;13:1091&#x2013;1098. doi:10.2147/CIA.S157048</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S157048</ArticleId><ArticleId IdType="pmc">PMC5995414</ArticleId><ArticleId IdType="pubmed">29922047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinaels EP, Daamen MA, Bekers O, et al. Clinical interpretation of elevated concentrations of cardiac troponin T, but not troponin I, in nursing home residents. J Am Med Dir Assoc. 2015;16(10):884&#x2013;891. doi:10.1016/j.jamda.2015.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2015.06.026</ArticleId><ArticleId IdType="pubmed">26255708</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65&#x2013;75. doi:10.1161/CIRCULATIONAHA.111.080770</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.080770</ArticleId><ArticleId IdType="pubmed">22615345</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pablos L, Jorge-Brito RA, Amarnani V, Jim&#xe9;nez-Sosa A, Harmand MG, Dom&#xed;nguez-Rodr&#xed;guez A. Delirium in patients with heart failure: influence of attendance times in an emergency department. Rev Esp Cardiol (Engl Ed). 2019;72(1):82&#x2013;84. doi:10.1016/j.rec.2017.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2017.10.045</ArticleId><ArticleId IdType="pubmed">29373255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail. 2017;23(6):464&#x2013;475. doi:10.1016/j.cardfail.2017.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2017.04.007</ArticleId><ArticleId IdType="pubmed">28433667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatabe N, Takeuchi K, Izumi M, et al. Decreased cognitive function is associated with dysphagia risk in nursing home older residents. Gerodontology. 2018;35(4):376&#x2013;381. doi:10.1111/ger.12366</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ger.12366</ArticleId><ArticleId IdType="pubmed">30028036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghannouchi I, Speyer R, Doma K, Cordier R, Verin E. Swallowing function and chronic respiratory diseases: systematic review. Respir Med. 2016;117:54&#x2013;64. doi:10.1016/j.rmed.2016.05.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2016.05.024</ArticleId><ArticleId IdType="pubmed">27492514</ArticleId></ArticleIdList></Reference><Reference><Citation>Suttrup I, Warnecke T. Dysphagia in parkinson&#x2019;s disease. Dysphagia. 2016;31(1):24&#x2013;32. doi:10.1007/s00455-015-9671-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-015-9671-9</ArticleId><ArticleId IdType="pubmed">26590572</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Srikusalanukul W, Fisher L, Smith P. The neutrophil to lymphocyte ratio on admission and short-term outcomes in orthogeriatric patients. Int J Med Sci. 2016;13(8):588&#x2013;602. doi:10.7150/ijms.15445</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.15445</ArticleId><ArticleId IdType="pmc">PMC4974907</ArticleId><ArticleId IdType="pubmed">27499691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38394174</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Traditional herbal medicine use doubled the risk of multi-organ dysfunction syndrome in children: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e0286233</StartPage><MedlinePgn>e0286233</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0286233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0286233</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional herbal medicine (THM) is frequently used in pediatric populations in many low-income countries as a form of healthcare and has been associated with a range of adverse events, including liver toxicity, renal failure, and allergic reactions. Despite these concerns, its impact on multi-organ dysfunction syndrome (MODS) risk has not been thoroughly investigated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the incidence and predictors of MODS in a pediatric intensive care unit (PICU) in Ethiopia, with a focus on the association between THM use and the risk of MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a single-center prospective cohort study conducted at a PICU in the university of Gondar Comprehensive Specialized hospital, Northwest Ethiopia. The study enrolled eligible patients aged one month to 18 years admitted to the PICU during the study period. Data on demographic characteristics, medical history, clinical and laboratory data, and outcome measures using standard case record forms, physical examination, and patient document reviews. The predictors of MODS were assessed using Cox proportional hazards models, with a focus on the association between traditional herbal medicine use and the risk of MODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 310 patients were included in the final analysis, with a median age of 48 months and a male-to-female ratio of 1.5:1. The proportion and incidence of MODS were 30.96% (95% CI:25.8, 36.6) and 7.71(95% CI: 6.10, 9.40) per 100-person-day observation respectively. Renal failure (17.74%), neurologic failure (15.16%), and heart failure (14.52%) were the leading organ failures identified. Nearly one-third of patients (32.9%) died in the PICU, of which 59.8% had MODS. The rate of mortality was higher in patients with MODS than in those without. The Cox proportional hazards model identified renal disease (AHR = 6.32 (95%CI: 3.17,12.61)), intake of traditional herbal medication (AHR = 2.45, 95% CI:1.29,4.65), modified Pediatric Index of Mortality 2 (mPIM 2) score (AHR = 1.54 (95% CI: 1.38,1.71), and critical illness diagnoses (AHR = 2.68 (95% CI: 1.77,4.07)) as predictors of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of MODS was high. Renal disease, THM use, mPIM 2 scores, and critical illness diagnoses were independent predictors of MODS. A more than twofold increase in the risk of MODS was seen in patients who used TMH. Healthcare providers should be aware of risks associated with THM, and educate caregivers about the potential harms of these products. Future studies with larger sample sizes and more comprehensive outcome measures are needed.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Teshager et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teshager</LastName><ForeName>Nahom Worku</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amare</LastName><ForeName>Ashenafi Tazebew</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamirat</LastName><ForeName>Koku Sisay</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeleke</LastName><ForeName>Mulualem Endeshaw</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taddese</LastName><ForeName>Asefa Adimasu</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="Y">Renal Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There were no competing interests, and patients/public were not involved in the research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38394174</ArticleId><ArticleId IdType="pmc">PMC10889611</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0286233</ArticleId><ArticleId IdType="pii">PONE-D-23-14246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. In: Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000149131.72248.E6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109(4):1033&#x2013;7. doi: 10.1378/chest.109.4.1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantale&#xe1;n JA, Le&#xf3;n RJ, Santos AA, S&#xe1;nchez E. Multiple organ dysfunction syndrome in children. Pediatr Crit Care Med. 2003;4(2):181&#x2013;5. doi: 10.1097/01.PCC.0000059421.13161.88</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000059421.13161.88</ArticleId><ArticleId IdType="pubmed">12749649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti E, Di Nardo M, Ricci Z. Multiple Organ Dysfunction in the Pediatric Intensive Care Unit. In: Critical Care Nephrology: Third Edition. 2017.</Citation></Reference><Reference><Citation>Typpo KV, Petersen NJ, Markovitz BP MM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med. 2009;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780005</ArticleId><ArticleId IdType="pubmed">19741445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler M, Swinger N, Rahrig AL, Skiles J, Rowan CM. Multiple Organ Dysfunction and Critically Ill Children With Acute Myeloid Leukemia: Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022; doi: 10.1097/PCC.0000000000003153</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000003153</ArticleId><ArticleId IdType="pmc">PMC10081947</ArticleId><ArticleId IdType="pubmed">36728709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LW, Oster RA, Tofil NM, Tolwani AJ. Outcomes of critically ill children requiring continuous renal replacement therapy. J Crit Care. 2009; doi: 10.1016/j.jcrc.2008.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2008.12.017</ArticleId><ArticleId IdType="pubmed">19327959</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartman ME, Lacroix J, Odetola FO. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017; doi: 10.1097/PCC.0000000000001047</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001047</ArticleId><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenk J, G&#xf3;mez-Dant&#xe9;s O. The Triple Burden Disease in Developing Nations. Harvard Int Rev. 2011;</Citation></Reference><Reference><Citation>Berendes S, Heywood P, Oliver S, Garner P. Quality of private and public ambulatory health care in low and middle income countries: Systematic review of comparative studies. PLoS Med. 2011; doi: 10.1371/journal.pmed.1000433</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000433</ArticleId><ArticleId IdType="pmc">PMC3075233</ArticleId><ArticleId IdType="pubmed">21532746</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Bestati N, Duhamel A, Proulx F, Grandbastien B, Lacroix J, et al.. 1218 Differences in Organ Dysfunctions Between Neonates and Other Children. Pediatr Res. 2010;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219976</ArticleId><ArticleId IdType="pubmed">21062434</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink EL, Kissoon N. Pediatric multiple organ dysfunction in resource limited settings. Pediatric Critical Care Medicine. 2017. doi: 10.1097/PCC.0000000000001045</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001045</ArticleId><ArticleId IdType="pubmed">28248837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. Crit Care Med. 1996; doi: 10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Wong HR, Shanley TP. Pediatric critical care medicine: Volume 1: Care of the critically ill or injured child, second edition. Pediatr Crit Care Med Vol 1 Care Crit Ill or Inj Child, Second Ed. 2014;1&#x2013;771.</Citation></Reference><Reference><Citation>Emr BM, Alcamo AM, Carcillo JA, Aneja RK, Mollen KP. Pediatric Sepsis Update: How Are Children Different? Surg Infect (Larchmt). 2018;</Citation><ArticleIdList><ArticleId IdType="pubmed">29394150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Neurology. 2014. doi: 10.3389/fphar.2013.00177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2013.00177</ArticleId><ArticleId IdType="pmc">PMC3887317</ArticleId><ArticleId IdType="pubmed">24454289</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA, Steenkamp V, Stewart MJ. Acute renal failure associated with the use of traditional folk remedies in South Africa. Ren Fail. 2005;</Citation><ArticleIdList><ArticleId IdType="pubmed">15717633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, et al.. Corrigendum: Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol. 2016; doi: 10.1038/ajg.2016.349</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.349</ArticleId><ArticleId IdType="pmc">PMC5516923</ArticleId><ArticleId IdType="pubmed">27045922</ArticleId></ArticleIdList></Reference><Reference><Citation>K.A. O, I.O. S, O.F. N, A. S. Use of complementary and alternative medicines for children with chronic health conditions in Lagos, Nigeria. BMC Complementary and Alternative Medicine. 2008. doi: 10.1186/1472-6882-8-66</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-8-66</ArticleId><ArticleId IdType="pmc">PMC2628640</ArticleId><ArticleId IdType="pubmed">19113999</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994; doi: 10.1097/00003246-199406000-00023</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Khilnani P, Sarma D, Zimmerman J. Epidemiology and peculiarities of pediatric multiple organ dysfunction syndrome in New Delhi, India. Intensive Care Med. 2006; doi: 10.1007/s00134-006-0373-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0373-5</ArticleId><ArticleId IdType="pubmed">16977482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, Tucci M, Bush JL, Nadkarni VM, et al.. New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis. Pediatr Crit Care Med. 2017;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingma JG, Simard D, Rouleau JR, Drolet B, Simard C. The physiopathology of cardiorenal syndrome: A review of the potential contributions of inflammation. Journal of Cardiovascular Development and Disease. 2017. doi: 10.3390/jcdd4040021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd4040021</ArticleId><ArticleId IdType="pmc">PMC5753122</ArticleId><ArticleId IdType="pubmed">29367550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SA, Cozzi M, Bush EL, Rabb H. Distant Organ Dysfunction in Acute Kidney Injury: A Review. American Journal of Kidney Diseases. 2018. doi: 10.1053/j.ajkd.2018.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2018.03.028</ArticleId><ArticleId IdType="pmc">PMC6252108</ArticleId><ArticleId IdType="pubmed">29866457</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Rosner MH, Ronco C. Distant organ dysfunction in acute kidney injury. Acta Physiologica. 2020. doi: 10.1111/apha.13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13357</ArticleId><ArticleId IdType="pubmed">31379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzarino V, Lesser J, Cassani FA. Pediatric Chronic Kidney Disease. Advances in Pediatrics. 2022. doi: 10.1016/j.yapd.2022.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yapd.2022.03.008</ArticleId><ArticleId IdType="pubmed">35985704</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;n E, Akova B&#x15e;, Botan E, &#xc7;elik DB, Balaban B, &#xd6;zen H, et al.. Clinical features and outcomes of children admitted to the pediatric intensive care unit due to posterior reversible encephalopathy syndrome. Clin Neurol Neurosurg. 2022;</Citation><ArticleIdList><ArticleId IdType="pubmed">36265243</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JF, Mott AR, Dickerson HA, Jefferies JL, Nelson DP, Chang AC, et al.. Worsening renal function in children hospitalized with decompensated heart failure: Evidence for a pediatric cardiorenal syndrome? Pediatr Crit Care Med. 2008; doi: 10.1097/PCC.0b013e31816c6ed1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31816c6ed1</ArticleId><ArticleId IdType="pubmed">18446113</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley A J. Gebhard D, Akcan-Arikan A. Acute Kidney Injury in Pediatric Heart Failure. Curr Cardiol Rev. 2016; doi: 10.2174/1573403x12666151119165628</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403x12666151119165628</ArticleId><ArticleId IdType="pmc">PMC4861941</ArticleId><ArticleId IdType="pubmed">26585035</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PMF, de Carvalho ST, Fradico PF, Cazumb&#xe1; MLB, Campos RGB, Sim&#xf5;es e Silva AC. Hepatorenal syndrome in children: a review. Pediatric Nephrology. 2021. doi: 10.1007/s00467-020-04762-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04762-6</ArticleId><ArticleId IdType="pmc">PMC7527294</ArticleId><ArticleId IdType="pubmed">33001296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; C, Sol&#xe0; E, Huelin P, Carol M, Moreira R, Cereijo U, et al.. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int. 2019; doi: 10.1111/liv.14037</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14037</ArticleId><ArticleId IdType="pmc">PMC6767546</ArticleId><ArticleId IdType="pubmed">30597709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazory A, Ronco C. Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. CardioRenal Medicine. 2019. doi: 10.1159/000492791</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492791</ArticleId><ArticleId IdType="pubmed">30223273</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International. 2013. doi: 10.1038/ki.2012.440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.440</ArticleId><ArticleId IdType="pubmed">23325079</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA. Nephrotoxicity of Alternative Medicine Practice. Advances in Chronic Kidney Disease. 2012. doi: 10.1053/j.ackd.2012.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2012.04.005</ArticleId><ArticleId IdType="pubmed">22578672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KC, Lu R, Iqbal U, Hsu KC, Chen BL, Nguyen PA, et al.. Interactions between traditional Chinese medicine and western drugs in Taiwan: A population-based study. Comput Methods Programs Biomed. 2015; doi: 10.1016/j.cmpb.2015.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2015.09.006</ArticleId><ArticleId IdType="pubmed">26470816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakerink JA, Gospe SM, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics. 1996;</Citation><ArticleIdList><ArticleId IdType="pubmed">8909490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam PCA, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia. 2002. doi: 10.1046/j.1365-2044.2002.02823.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2044.2002.02823.x</ArticleId><ArticleId IdType="pubmed">12392455</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpan EE, Ekrikpo UE. Acute Renal Failure Induced by Chinese Herbal Medication in Nigeria. Case Rep Med. 2015; doi: 10.1155/2015/150204</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/150204</ArticleId><ArticleId IdType="pmc">PMC4496464</ArticleId><ArticleId IdType="pubmed">26199625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MZ, Saleh MA, Alkhayyat M, Roberts DE, Lindenmeyer CC. Multiorgan Dysfunction Related to Kratom Ingestion. ACG Case Reports J. 2021; doi: 10.14309/crj.0000000000000647</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/crj.0000000000000647</ArticleId><ArticleId IdType="pmc">PMC8389947</ArticleId><ArticleId IdType="pubmed">34476274</ArticleId></ArticleIdList></Reference><Reference><Citation>Perazella MA. Renal vulnerability to drug toxicity. Clinical Journal of the American Society of Nephrology. 2009. doi: 10.2215/CJN.02050309</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02050309</ArticleId><ArticleId IdType="pubmed">19520747</ArticleId></ArticleIdList></Reference><Reference><Citation>George P. Concerns regarding the safety and toxicity of medicinal plants&#x2014;An overview. J Appl Pharm Sci. 2011;</Citation></Reference><Reference><Citation>Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001; doi: 10.1053/jhep.2001.27445</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2001.27445</ArticleId><ArticleId IdType="pubmed">11526548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers SL, Kronenfeld JJ. Delays in seeking conventional medical care and complementary and alternative medicine utilization. Health Serv Res. 2012; doi: 10.1111/j.1475-6773.2012.01406.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2012.01406.x</ArticleId><ArticleId IdType="pmc">PMC3513619</ArticleId><ArticleId IdType="pubmed">22985034</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997; doi: 10.1002/j.1552-4604.1997.tb04312.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1552-4604.1997.tb04312.x</ArticleId><ArticleId IdType="pubmed">9115061</ArticleId></ArticleIdList></Reference><Reference><Citation>Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): An overview of systematic reviews. European Journal of Clinical Pharmacology. 2013. doi: 10.1007/s00228-012-1353-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-012-1353-z</ArticleId><ArticleId IdType="pubmed">22843016</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyman T, Stewart MJ, Grove A, Steenkamp V. Adulteration of South African traditional herbal remedies. Ther Drug Monit. 2005; doi: 10.1097/00007691-200502000-00015</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007691-200502000-00015</ArticleId><ArticleId IdType="pubmed">15665751</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian Journal of Medical and Biological Research. 2000. doi: 10.1590/s0100-879x2000000200004</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-879x2000000200004</ArticleId><ArticleId IdType="pubmed">10657057</ArticleId></ArticleIdList></Reference><Reference><Citation>Efferth T, Kaina B. Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine. Curr Drug Metab. 2011; doi: 10.2174/138920011798062328</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920011798062328</ArticleId><ArticleId IdType="pubmed">21892916</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh AYT, Chan PWK, Lum LCS. Sepsis, severe sepsis and septic shock in paediatric multiple organ dysfunction syndrome. J Paediatr Child Health. 1999; doi: 10.1046/j.1440-1754.1999.355409.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1754.1999.355409.x</ArticleId><ArticleId IdType="pubmed">10571765</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al.. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015; doi: 10.1164/rccm.201412-2323OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201412-2323OC</ArticleId><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: A prospective national survey. Intensive Care Med. 2008; doi: 10.1007/s00134-008-1148-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1148-y</ArticleId><ArticleId IdType="pubmed">18500425</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al.. Validation of the paediatric logistic organ dysfunction (PELOD) score: Prospective, observational, multicentre study. Lancet. 2003; doi: 10.1016/S0140-6736(03)13908-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)13908-6</ArticleId><ArticleId IdType="pubmed">12885479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, Cotting J. Severity of illness and organ dysfunction scoring in children. Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000161287.61028.D4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000161287.61028.D4</ArticleId><ArticleId IdType="pubmed">15857545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulla K, Sachdev A. Illness severity and organ dysfunction scoring in Pediatric Intensive Care Unit. Indian J Crit Care Med. 2016; doi: 10.4103/0972-5229.173685</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.173685</ArticleId><ArticleId IdType="pmc">PMC4759990</ArticleId><ArticleId IdType="pubmed">26955214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33546739</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.</ArticleTitle><Pagination><StartPage>116</StartPage><MedlinePgn>116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05072-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endocytosis by AP2-associated protein kinase 1 (AAK1) inhibition. We propose the use of baricinitib to prevent the progression of the respiratory insufficiency in SARS-CoV2 pneumonia in onco-haematological patients. In this phase Ib/II study, the primary objective in the safety cohort is to describe the incidence of severe adverse events associated with baricitinib administration. The primary objective of the randomized phase (baricitinib cohort versus standard of care cohort) is to evaluate the number of patients who did not require mechanical oxygen support since start of therapy until day +14 or discharge (whichever it comes first). The secondary objectives of the study (only randomized phase of the study) are represented by the comparison between the two arms of the study in terms of mortality and toxicity at day+30. Moreover, a description of the immunological related changes between the two arms of the study will be reported.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">The trial is a phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized controlled trial with an experimental arm compared to a standard of care arm.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The study will be performed at the Institut Catal&#xe0; d'Oncologia, a tertiary level oncological referral center in the Catalonia region (Spain). The eligibility criteria are: patients &gt; 18 years affected by oncological diseases; ECOG performance status &lt; 2 (Karnofsky score &gt; 60%); a laboratory confirmed infection with SARS-CoV-2 by means of real -time PCR; radiological signs of low respiratory tract disease; absence of organ dysfunction (a total bilirubin within normal institutional limits, AST/ALT&#x2264;2.5 X institutional upper limit of normal, alkaline phosphatase &#x2264;2.5 X institutional upper limit of normal, coagulation within normal institutional limits, creatinine clearance &gt;30 mL/min/1.73 m<sup>2</sup> for patients with creatinine levels above institutional normal); absence of HIV infection; no active or latent HBV or HCV infection. The exclusion criteria are: patients with oncological diseases who are not candidates to receive any active oncological treatment; hemodynamic instability at time of study enrollment; impossibility to receive oral medication; medical history of recent or active pulmonary embolism or deep venous thrombosis or patients at high-risk of suffering them (surgical intervention, immobilization); multi organ failure, rapid worsening of respiratory function with requirement of fraction of inspired oxygen (FiO<sub>2</sub>) &gt; 50% or high-flow nasal cannula before initiation of study treatment; uncontrolled intercurrent illness (ongoing or severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements); allergy to one or more of study treatments; pregnant or breastfeeding women; positive pregnancy test in a pre-dose examination. Patients should have the ability to understand, and the willingness to sign, a written informed consent document; the willingness to accept randomization to any assigned treatment arm; and must agree not to enroll in another study of an investigational agent prior to completion of Day +28 of study. An electronic Case Report Form in the Research Electronic Data Capture (REDCap) platform will be used to collect the data of the trial. Removal from the study will apply in case of unacceptable adverse event(s), development of an intercurrent illness, condition or procedural complication, which could interfere with the patient's continued participation and voluntary patient withdrawal from study treatment (all patients are free to withdraw from participation in this study at any time, for any reasons, specified or unspecified, and without prejudice).</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">Treatment will be administered on an inpatient basis. We will compare the experimental treatment with baricitinib plus the institutional standard of care compared with the standard of care alone. During the phase I, we will define the dose-limiting toxicity of baricitinib and the dose to be used in the phase 2 part of the study. The starting baricitinib dose will be an oral tablet 4 mg-once daily which can be reduced to 2 mg depending on the observed toxicity. The minimum duration of therapy will be 5 days and it can be extended to 7 days. The standard of care will include the following therapies. Antibiotics will be individualized based on clinical suspicion, including the management of febrile neutropenia. Prophylaxis of thromboembolic disease will be administered to all participants. Remdesivir administration will be considered only in patients with severe pneumonia (SatO<sub>2</sub> &lt;94%) with less than 7 days of onset of symptoms and with supplemental oxygen requirements but not using high-flow nasal cannula, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In the randomized phase, tocilizumab or interferon will not be allowed in the experimental arm. Tocilizumab can be used in patients in the standard of care arm at the discretion of the investigator. If it is prescribed it will be used according to the following criteria: patients who, according to his baseline clinical condition, would be an ICU tributary, interstitial pneumonia with severe respiratory failure, patients who are not on mechanical ventilation or ECMO and who are still progressing with corticoid treatment or if they are not candidates for corticosteroids. Mild ARDS (PAFI &lt;300 mmHg) with radiological or blood gases deterioration that meets at least one of the following criteria: CRP &gt;100mg/L D-Dimer &gt;1,000&#x3bc;g/L LDH &gt;400U/L Ferritin &gt;700ng/ml Interleukin 6 &#x2265;40ng/L. The use of tocilizumab is not recommended if there are AST/ALT values greater than 10 times the upper limit of normal, neutrophils &lt;500 cells/mm3, sepsis due to other pathogens other than SARS-CoV-2, presence of comorbidity that can lead to a poor prognosis, complicated diverticulitis or intestinal perforation, ongoing skin infection. The dose will be that recommended by the Spanish Medicine Agency in patients &#x2265;75Kg: 600mg dose whereas in patients &lt;75kg: 400mg dose. Exceptionally, a second infusion can be assessed 12 hours after the first in those patients who experience a worsening of laboratory parameters after a first favourable response. The use of corticosteroids will be recommended in patients who have had symptoms for more than 7 days and who meet all the following criteria: need for oxygen support, non-invasive or invasive mechanical ventilation, acute respiratory failure or rapid deterioration of gas exchange, appearance or worsening of bilateral alveolar-interstitial infiltrates at the radiological level. In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days.</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Phase 1 part: to describe the toxicity profile of baricitinib in COVID19 oncological patients during the 5-7 day treatment period and until day +14 or discharge (whichever it comes first). Phase 2 part: to describe the number of patients in the experimental arm that will not require mechanical oxygen support compared to the standard of care arm until day +14 or discharge (whichever it comes first).</AbstractText><AbstractText Label="RANDOMISATION" NlmCategory="METHODS">For the phase 2 of the study, the allocation ratio will be 1:1. Randomization process will be carried out electronically through the REDcap platform ( https://www.project-redcap.org/ ) BLINDING (MASKING): This is an open label study. No blinding will be performed.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">The first part of the study (safety run-in cohort) will consist in the enrollment of 6 to 12 patients. In this population, we will test the toxicity of the experimental treatment. An incidence of severe adverse events grade 3-4 (graded by Common Terminology Criteria for Adverse Events v.5.0) inferior than 33% will be considered sufficient to follow with the next part of the study. The second part of the study we will perform an interim analysis of efficacy at first 64 assessed patients and a definitive one will analyze 128 assessed patients. Interim and definitive tests will be performed considering in both cases an alpha error of 0.05. We consider for the control arm this rate is expected to be 0.60 and for the experimental arm of 0.80. Considering this data, a superiority test to prove a difference of 0.20 with an overall alpha error of 0.10 and a beta error of 0.2 will be performed. Considering a 5% of dropout rate, it is expected that a total of 136 patients, 68 for each study arm, will be required to complete study accrual.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Version 5.0. 14<sup>th</sup> October 2020 Recruitment started on the 16<sup>th</sup> of December 2020. Expected end of recruitment is June 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">AEMPs: 20-0356 EudraCT: 2020-001789-12, https://www.clinicaltrialsregister.eu/ctr-search/search (Not publically available as Phase I trial) Clinical trials: BARCOVID19, https://www.clinicaltrials.gov/ (In progress) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Gonz&#xe1;lez</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussetti</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albasanz-Puig</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudiol</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Haba Vaca</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coma</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz-Linares</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dura</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontanals</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma&#xf1;ez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">baricitinib</Keyword><Keyword MajorTopicYN="N">jak inhibitors</Keyword><Keyword MajorTopicYN="N">oncological patients</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword><Keyword MajorTopicYN="N">respiratory insufficiency</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests in relation to the trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33546739</ArticleId><ArticleId IdType="pmc">PMC7862837</ArticleId><ArticleId IdType="doi">10.1186/s13063-021-05072-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-021-05072-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24589345</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-7241</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2014</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Scandinavian journal of trauma, resuscitation and emergency medicine</Title><ISOAbbreviation>Scand J Trauma Resusc Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Interleukin-6 as inflammatory marker referring to multiple organ dysfunction syndrome in severely injured children.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1757-7241-22-16</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the suggestion that the inflammatory response in traumatized children is functionally unique, prognostic markers predicting pediatric multiple organ failure are lacking. We intended to verify whether Interleukin-6 (IL-6) displays a pivotal role in pediatric trauma similar to adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Traumatized children less than 18 years of age with an Injury Severity Score &gt;9 points and consecutive admission to the hospital's pediatric intensive care unit were included. Organ function was evaluated according to the score by Marshall et al. while IL-6 levels were measured repetitively every morning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">59 traumatized children were included (8.4 &#xb1; 4.4 years; 57.6% male gender). Incidence of MODS was 11.9%. No differences were found referring to age, gender, injury distribution or overall injury severity between children with and without MODS. Increased IL-6 levels during hospital admission were associated with injury severity (Spearman correlation: r = 0.522, p &lt; 0.001), while an inconsistent association towards the development of MODS was proven at that time point (Spearman correlation: r = 0.180, p = 0.231; Pearson's correlation: r = 0.297, p = 0.045). However, increased IL-6 levels during the first two days were no longer associated with the injury severity but a significant correlation to MODS was measured.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presented prospective study is the first providing evidence for a correlation of IL-6 levels with injury severity and the incidence of MODS in traumatized children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Hagen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Janika</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sasse</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brunnemer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Julia Helga Karla</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>G&#xe4;nsslen</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frink</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Trauma, Hand and Reconstructive Surgery, University Medical Center Marburg, Baldingerstr, 35043 Marburg, Germany. frink@med.uni-marburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Trauma Resusc Emerg Med</MedlineTA><NlmUniqueID>101477511</NlmUniqueID><ISSNLinking>1757-7241</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24589345</ArticleId><ArticleId IdType="pmc">PMC3942614</ArticleId><ArticleId IdType="doi">10.1186/1757-7241-22-16</ArticleId><ArticleId IdType="pii">1757-7241-22-16</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Valadka S, Poenaru D, Dueck A. Long-term disability after trauma in children. J Pediatr Surg. 2000;35:684&#x2013;687. doi: 10.1053/jpsu.2000.5943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpsu.2000.5943</ArticleId><ArticleId IdType="pubmed">10813323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalamon J, V Bismarck S, Schober PH, Hollwarth ME. Multiple trauma in pediatric patients. Pediatr Surg Int. 2003;19:417&#x2013;423. doi: 10.1007/s00383-003-0954-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00383-003-0954-0</ArticleId><ArticleId IdType="pubmed">12861420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton SL. Early management of the child with multiple injuries. Clin Orthop Relat Res. 2000;376:6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906852</ArticleId></ArticleIdList></Reference><Reference><Citation>Musgrave DS, Mendelson SA. Pediatric orthopedic trauma: principles in management. Crit Care Med. 2002;30:S431&#x2013;S443. doi: 10.1097/00003246-200211001-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200211001-00008</ArticleId><ArticleId IdType="pubmed">12528785</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelgawad AA, Kanlic EM. Orthopedic management of children with multiple injuries. J Trauma. 2011;70:1568&#x2013;1574. doi: 10.1097/TA.0b013e318204eafc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318204eafc</ArticleId><ArticleId IdType="pubmed">21817996</ArticleId></ArticleIdList></Reference><Reference><Citation>Letts M, Davidson D, Lapner P. Multiple trauma in children: predicting outcome and long-term results. Can J Surg. 2002;45:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686935</ArticleId><ArticleId IdType="pubmed">11939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkins CM, Bensard DD, Moore EE, McIntyre RC, Silliman CC, Biffl W, Harken AH, Partrick DA, Offner PJ. The injured child is resistant to multiple organ failure: a different inflammatory response? J Trauma. 2002;53:1058&#x2013;1063. doi: 10.1097/00005373-200212000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200212000-00005</ArticleId><ArticleId IdType="pubmed">12478028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, Glass NL, Yeh TS. Outcome of pediatric patients with multiple organ system failure. Crit Care Med. 1986;14:271&#x2013;274. doi: 10.1097/00003246-198604000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198604000-00002</ArticleId><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Joyal JS, Mariscalco MM, Leteurtre S, Leclerc F, Lacroix J. The pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2009;10:12&#x2013;22. doi: 10.1097/PCC.0b013e31819370a9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31819370a9</ArticleId><ArticleId IdType="pubmed">19057438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JH, Partrick DA, Johnston RB Jr. The inflammatory response to injury in children. Curr Opin Pediatr. 2010;22:315&#x2013;320. doi: 10.1097/MOP.0b013e328338da48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0b013e328338da48</ArticleId><ArticleId IdType="pubmed">20386451</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994;22:1025&#x2013;1031. doi: 10.1097/00003246-199406000-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">7899997</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25:1789&#x2013;1795. doi: 10.1097/00003246-199711000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199711000-00014</ArticleId><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24:1125&#x2013;1128. doi: 10.1097/00003246-199607000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199607000-00010</ArticleId><ArticleId IdType="pubmed">8674323</ArticleId></ArticleIdList></Reference><Reference><Citation>Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC Jr, Jack A. Barney resident research award winner: the inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. Am J Surg. 1996;172:425&#x2013;429. doi: 10.1016/S0002-9610(96)00252-8. discussed 429-431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(96)00252-8</ArticleId><ArticleId IdType="pubmed">8942538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O&#x2019;Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Inflammation and the HOST Response to Injury Collaborative Research Program: Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock. 2010;34:346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291&#x2013;295. doi: 10.1001/archsurg.135.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.135.3.291</ArticleId><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med. 2011;26:73&#x2013;87. doi: 10.1177/0885066610384188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066610384188</ArticleId><ArticleId IdType="pmc">PMC6223019</ArticleId><ArticleId IdType="pubmed">21464062</ArticleId></ArticleIdList></Reference><Reference><Citation>Andruszkow H, Lefering R, Frink M, Mommsen P, Zeckey C, Rahe K, Krettek C, Hildebrand F. Survival benefit of helicopter emergency medical services compared to ground emergency medical services in traumatized patients. Crit Care. 2013;17:R124. doi: 10.1186/cc12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12796</ArticleId><ArticleId IdType="pmc">PMC4056624</ArticleId><ArticleId IdType="pubmed">23799905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Paffrath T, Linker R, Bouillon B, Neugebauer EA. Deutsche Gesellschaft fur Unfallchirurgie/German Society for Trauma S. Head injury and outcome&#x2013;what influence do concomitant injuries have? J Trauma. 2008;65:1036&#x2013;1043. doi: 10.1097/TA.0b013e318184ee48. discussion 1043-1034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318184ee48</ArticleId><ArticleId IdType="pubmed">19001971</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC, Engelhardt W, Grabitz RG, Faymonville ME, Hornchen H, Messmer BJ, von Bernuth G. Multiple system organ failure after open heart surgery in infants and children. Thorac Cardiovasc Surg. 1993;41:49&#x2013;53. doi: 10.1055/s-2007-1013820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1013820</ArticleId><ArticleId IdType="pubmed">8367856</ArticleId></ArticleIdList></Reference><Reference><Citation>Feickert HJ, Schepers AK, Rodeck B, Geerlings H, Hoyer PF. Incidence, impact on survival, and risk factors for multi-organ system failure in children following liver transplantation. Pediatr Transplant. 2001;5:266&#x2013;273. doi: 10.1034/j.1399-3046.2001.005004266.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3046.2001.005004266.x</ArticleId><ArticleId IdType="pubmed">11472605</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Bratton SL, Martin LD, Crawford SW, Weiss NS. Outcome of children who require mechanical ventilatory support after bone marrow transplantation. Crit Care Med. 2000;28:830&#x2013;835. doi: 10.1097/00003246-200003000-00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200003000-00036</ArticleId><ArticleId IdType="pubmed">10752837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NJ, Lucking SE, Dillon PW, Cilley RE. Is the injured child different or just treated differently with respect to the development of multiple organ dysfunction syndrome? J Trauma. 2003;55:181&#x2013;182. author repy 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons WS, Calkins CM, Moore EE, Bensard DD, Partrick DA, McIntyre RC, Harken AH. &#x201c;Resistance&#x201d; to the inflammatory response and multiple organ failure in children. J Trauma. 2003;55:182&#x2013;184. author reply 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingarelli B, Hake PW, O&#x2019;Connor M, Burroughs TJ, Wong HR, Solomkin JS, Lentsch AB. Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med. 2009;37:1978&#x2013;1987. doi: 10.1097/CCM.0b013e31819feb4d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819feb4d</ArticleId><ArticleId IdType="pmc">PMC2765201</ArticleId><ArticleId IdType="pubmed">19384226</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, Gamelli R, Gibran N, Klein M, Silver G, Arnoldo B, Remick D, Tompkins RG. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med. 2008;14:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, Carles M, Howard M, Pittet JF. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174. doi: 10.1186/cc8152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65:646&#x2013;652. doi: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181820d48</ArticleId><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, Di Rocco C. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst. 2005;21:185&#x2013;193. doi: 10.1007/s00381-004-1032-1. discussion 194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00381-004-1032-1</ArticleId><ArticleId IdType="pubmed">15455248</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain C, Cohen D, Phillips R, Ott L, Young B. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 1991;118:225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1919295</ArticleId></ArticleIdList></Reference><Reference><Citation>Saissy JM, Cellard-Peyle F, Vitris M, Demaziere J, Gaye M, Poli L, Trossaert M, Dieye A, Sarthou JL. Severe malaria in an African seasonal endemic area: comparison of aspects in adults and children and prognostic value of cytokines. Presse Med. 1994;23:1426&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824455</ArticleId></ArticleIdList></Reference><Reference><Citation>From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest. 1997;111:744&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118716</ArticleId></ArticleIdList></Reference><Reference><Citation>Strecker W, Gebhard F, Perl M, Rager J, Buttenschon K, Kinzl L, Beck A. Biochemical characterization of individual injury pattern and injury severity. Injury. 2003;34:879&#x2013;887. doi: 10.1016/S0020-1383(03)00022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(03)00022-6</ArticleId><ArticleId IdType="pubmed">14636727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45. doi: 10.1001/archsurg.1994.01420250051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F. Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999;19:399&#x2013;410. doi: 10.1177/0272989X9901900408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9901900408</ArticleId><ArticleId IdType="pubmed">10520678</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33:1484&#x2013;1491. doi: 10.1097/01.CCM.0000170943.23633.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000170943.23633.47</ArticleId><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33246196</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Decreased serial scores of severe organ failure assessments are associated with survival in mechanically ventilated patients; the prospective Maastricht Intensive Care COVID cohort.</ArticleTitle><Pagination><StartPage>38</StartPage><EndPage>45</EndPage><MedlinePgn>38-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2020.11.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(20)30761-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">The majority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are admitted to the Intensive Care Unit (ICU) for mechanical ventilation. The role of multi-organ failure during ICU admission as driver for outcome remains to be investigated yet.</AbstractText><AbstractText Label="DESIGN AND SETTING">Prospective cohort of mechanically ventilated critically ill with SARS-CoV-2 infection.</AbstractText><AbstractText Label="PARTICIPANTS AND METHODS">94 participants of the MaastrICCht cohort (21% women) had a median length of stay of 16&#xa0;days (maximum of 77). After division into survivors (n&#xa0;=&#xa0;59) and non-survivors (n&#xa0;=&#xa0;35), we analysed 1555 serial SOFA scores using linear mixed-effects models.</AbstractText><AbstractText Label="RESULTS">Survivors improved one SOFA score point more per 5&#xa0;days (95% CI: 4-8) than non-survivors. Adjustment for age, sex, and chronic lung, renal and liver disease, body-mass index, diabetes mellitus, cardiovascular risk factors, and Acute Physiology and Chronic Health Evaluation II score did not change this result. This association was stronger for women than men (P-interaction&#xa0;=&#xa0;0.043).</AbstractText><AbstractText Label="CONCLUSIONS">The decrease in SOFA score associated with survival suggests multi-organ failure involvement during mechanical ventilation in patients with SARS-CoV-2. Surviving women appeared to improve faster than surviving men. Serial SOFA scores may unravel an unfavourable trajectory and guide decisions in mechanically ventilated patients with SARS-CoV-2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bels</LastName><ForeName>Julia L M</ForeName><Initials>JLM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: julia.bels@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuijk</LastName><ForeName>Sander M J</ForeName><Initials>SMJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: sander.van.kuijk@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghossein-Doha</LastName><ForeName>Chahinda</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Cardiology, Maastricht University Medical Centre+, Maastricht, the Netherlands; School for Oncology &amp; Developmental Biology (GROW), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: chahinda.ghossein@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijssen</LastName><ForeName>Fabian H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Pain Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: fabian.tijssen@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gassel</LastName><ForeName>Rob J J</ForeName><Initials>RJJ</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: r.vangassel@maastrichtuniversity.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tas</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: jeanette.tas@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collaborators</LastName><ForeName>MaastrICCht</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnabel</LastName><ForeName>Ronny M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands. Electronic address: r.schnabel@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aries</LastName><ForeName>Marcel J H</ForeName><Initials>MJH</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre+, Maastricht, the Netherlands. Electronic address: marcel.aries@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Poll</LastName><ForeName>Marcel C G</ForeName><Initials>MCG</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands; School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: marcel.vande.poll@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmans</LastName><ForeName>Dennis C J J</ForeName><Initials>DCJJ</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands. Electronic address: d.bergmans@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meex</LastName><ForeName>Steven J R</ForeName><Initials>SJR</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht University Medical Centre+, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: steven.meex@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Mook</LastName><ForeName>Walther N K A</ForeName><Initials>WNKA</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; School of Health Professions Education, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, the Netherlands. Electronic address: w.van.mook@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Horst</LastName><ForeName>Iwan C C</ForeName><Initials>ICC</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: iwan.vander.horst@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bussel</LastName><ForeName>Bas C T</ForeName><Initials>BCT</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Maastricht University Medical Centre+, P. Debyelaan 25, 6202 AZ Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, the Netherlands. Electronic address: bas.van.bussel@mumc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Repeated data</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SOFA score</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>27</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33246196</ArticleId><ArticleId IdType="pmc">PMC7669472</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2020.11.006</ArticleId><ArticleId IdType="pii">S0883-9441(20)30761-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gattinoni L., Coppola S., Cressoni M., Busana M., Rossi S., Chiumello D. Covid-19 does not lead to a &#x201c;typical&#x201d; acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201(10):1299&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233352</ArticleId><ArticleId IdType="pubmed">32228035</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi Y.M., Murthy S., Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020;46:833&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080134</ArticleId><ArticleId IdType="pubmed">32125458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Wang X., Jia X., Li J., Hu K., Chen G., et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26:767&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159868</ArticleId><ArticleId IdType="pubmed">32304745</ArticleId></ArticleIdList></Reference><Reference><Citation>Organisation WH Epidemiology: Q&amp;A: similarities and differences - COVID19 and influenza. 2020. https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza viewed 16.04.2020.</Citation></Reference><Reference><Citation>Phua J., Weng L., Ling L., Egi M., Lim C.M., Divatia J.V., et al. Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir Med. 2020;8:506&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198848</ArticleId><ArticleId IdType="pubmed">32272080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J.P.A., Axfors C., Contoupoulos-Ioannidis D.G. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020;188:109890. doi: 10.1016/j.envres.2020.109890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2020.109890</ArticleId><ArticleId IdType="pmc">PMC7327471</ArticleId><ArticleId IdType="pubmed">32846654</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;91:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. JAMA Cardiol. 2020;5(7):831&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira M., Blin T., Collercandy N., Szychowiak P., Dequin P.F., Jouan Y., et al. Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA. Ann Intensive Care. 2020;10(1):43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167215</ArticleId><ArticleId IdType="pubmed">32307609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihle-Hansen H., Berge T., Tveita A., Ronning E.J., Erno P.E., Andersen E.L., et al. COVID-19: Symptoms, course of illness and use of clinical scoring systems for the first 42 patients admitted to a Norwegian local hospital. Tidsskr Nor Laegeforen. 2020;140(7)</Citation><ArticleIdList><ArticleId IdType="pubmed">32378844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X., Du R., Wang R., Cao T., Guan L., Yang C., et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020;158:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151343</ArticleId><ArticleId IdType="pubmed">32224074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Yin Y., Hu C., Liu X., Zhang X., Zhou S., et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan. China Crit Care. 2020;24(1):188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192564</ArticleId><ArticleId IdType="pubmed">32354360</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Q., Wang P., Wang X., Qie G., Meng M., Tong X., et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J., et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101507</ArticleId><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Piano S., Dalbeni A., Vettore E., Benfaremo D., Mattioli M., Gambino C.G., et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int. 2020;40(10):2394&#x2013;2406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307119</ArticleId><ArticleId IdType="pubmed">32526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar S., Lecourtois A., Diouf M., Goldberg E., Bourbon C., Arnaud E., et al. The association of lung ultrasound images with COVID-19 infection in an emergency room cohort. Anaesthesia. 2020;75:1620&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300460</ArticleId><ArticleId IdType="pubmed">32520406</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld S.C., Caridi-Scheible M., Blum J.M., Robichaux C., Kraft C., Jacob J.T., et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Critical Care Med. 2020;48(9):e799&#x2013;e804. Online First.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255393</ArticleId><ArticleId IdType="pubmed">32452888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M., et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. The Lancet. 2020;395(10239):1763&#x2013;1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237188</ArticleId><ArticleId IdType="pubmed">32442528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Xu D., Fu S., Zhang J., Yang X., Xu L., et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: A cross-sectional study. Crit Care. 2020;24(1):219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223395</ArticleId><ArticleId IdType="pubmed">32410714</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R.H., Liu L.M., Yin W., Wang W., Guan L.L., Yuan M.L., et al. Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan. China Ann Am Thorac Soc. 2020;17(7):839&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328178</ArticleId><ArticleId IdType="pubmed">32255382</ArticleId></ArticleIdList></Reference><Reference><Citation>W-j Guan, Ni Z.-y., Hu Y., Liang W.-h., Ou C.-q., He J.-x., et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Tu G.W., Ju M.J., Yu S.J., Zheng J.L., Ma G.G., et al. Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19. J Infect. 2020;81(4):647&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204730</ArticleId><ArticleId IdType="pubmed">32389785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X., Li S., Fang M., Hu M., Bian Y., Ling J., et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Critical Care Med. 2020;48(8):e657&#x2013;e665. Online First.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217128</ArticleId><ArticleId IdType="pubmed">32697506</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonca A., Bruining H., et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on Sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Raith E.P., Udy A.A., Bailey M., McGloughlin S., MacIsaac C., Bellomo R., et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">28114553</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour C.W., Kennedy J.N., Wang S., Chang C.H., Elliott C.F., Xu Z., et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahpori R., Stelfox H.T., Doig C.J., Boiteau P.J., Zygun D.A. Sequential organ failure assessment in H1N1 pandemic planning. Crit Care Med. 2011;39(4):827&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">21263327</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P., et al. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas J., van Gassel R.J.J., Heines S.J.H., Mulder M.M.G., Heijnen N.F.L., Acampo-de Jong M.J., et al. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht) BMJ Open. 2020;10(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526030</ArticleId><ArticleId IdType="pubmed">32994259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Kang H., Liu X., Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020;92(6):538&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233289</ArticleId><ArticleId IdType="pubmed">32096564</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K.J., Greenland S., Lash T.L. 3th ed. Lippincott Williams &amp; Wilkins; 2008. Modern Epidemiology.</Citation></Reference><Reference><Citation>Knaus W.A., Zimmerman J.E., Wagner D.P., Draper E.A., Lawrence D.E. APACHE-acute physiology and chronic health evaluation: A physiologically based classification system. Crit Care Med. 1981;9(8):591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">7261642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli V., Fiorentino M., Cantaluppi V., Gesualdo L., Stallone G., Ronco C., et al. Acute kidney injury in SARS-CoV-2 infected patients. Crit Care. 2020;24(1):155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161433</ArticleId><ArticleId IdType="pubmed">32299479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso F.S., Pereira R., Germano N. Liver injury in critically ill patients with COVID-19: A case series. Crit Care. 2020;24(1):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198236</ArticleId><ArticleId IdType="pubmed">32366282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P., Zhu L., et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72(2):389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267515</ArticleId><ArticleId IdType="pubmed">32359177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling L., So C., Shum H.P., Chan P.K.S., Lai C.K.C., Kandamby D.H., et al. Critically ill patients with COVID-19 in Hong Kong: A multicentre retrospective observational cohort study. Crit Care Resusc. 2020;22(2):119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692444</ArticleId><ArticleId IdType="pubmed">32248675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194884</ArticleId><ArticleId IdType="pubmed">32311650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira F.L., Bota D.P., Bross A., Melot C., Vincent J.L. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286(14):1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz S., Arabi Y.M., Alhazzani W., Evans L., Citerio G., Fischkoff K., et al. Managing ICU surge during the COVID-19 crisis: Rapid guidelines. Intensive Care Med. 2020;46:1303&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276667</ArticleId><ArticleId IdType="pubmed">32514598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W., Zhang W., Jin R., Liang L., Xu B., Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: A retrospective cohort study. Infect Dis (Lond) 2020:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212540</ArticleId><ArticleId IdType="pubmed">32370577</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Cheng A., Lin S., Zhu Y., Chen G. Individualized prediction nomograms for disease progression in mild COVID-19. J Med Virol. 2020;92:2074&#x2013;2080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267495</ArticleId><ArticleId IdType="pubmed">32369205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L., Van Calster B., Bonten M.M.J., Collins G.S., Debray T.P.A., De Vos M., et al. Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal. BMJ. 2020;369:m1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakike E., Kyriazopoulou E., Tsangaris I., Routsi C., Vincent J.L., Giamarellos-Bourboulis E.J. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: Analysis through a derivation and a validation cohort. Crit Care. 2019;23(1):387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884794</ArticleId><ArticleId IdType="pubmed">31783881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40278166</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-9116</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vascular and endovascular surgery</Title><ISOAbbreviation>Vasc Endovascular Surg</ISOAbbreviation></Journal><ArticleTitle>A Systematic Review of Transcarotid Approach for Endovascular Aortic Repair in Treating Aortic Disease.</ArticleTitle><Pagination><StartPage>654</StartPage><EndPage>664</EndPage><MedlinePgn>654-664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/15385744251335775</ELocationID><Abstract><AbstractText>PurposeThe purpose of this study is to evaluate the feasibility, efficacy, and safety of transcarotid approach endovascular aortic repair (EVAR) in patients where conventional femoral access is not possible.Materials and MethodsA systematic review of all articles discussing transcarotid approach EVAR published in the PubMed, Embase, Ovid, Web of Science, and Cochrane Library databases were conducted. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.ResultsIn accordance with the inclusion criteria, 17 articles discussing transcarotid approach EVAR were retrieved, encompassing 18 patients. Among these patients, 6 patients were related to ascending aortic disease, including 4 cases of pseudoaneurysms, 1 case of penetrating ulcer, and 1 case of dissection. 9 patients had descending aortic disease, comprising 6 aneurysms, 2 penetrating ulcers, and 1 pseudoaneurysm. There were 3 cases of abdominal aortic disease, including 2 aneurysms and 1 endoleak. Among these patients, 10 cases had access through the left common carotid artery, and 8 cases had access through the right common carotid artery. One patient experienced spinal cord ischemia and subsequently died of multi-organ failure caused by acute pancreatitis. Additionally, there was one case of minor embolization in the nonsurgical carotid supply area. No cerebral infarctions were observed in the vascular territory of the ipsilateral carotid artery at the surgical approach site.ConclusionsResearch on transcarotid approach EVAR is limited and predominantly consists of case reports, with a notable absence of randomized controlled trials. This systematic review suggests that transcarotid approach EVAR may be a viable alternative for selecting patient groups when the conventional femoral artery approach is not feasible. These findings indicate that this method is associated with a relatively manageable perioperative complications and mortality rates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Haofan</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9790-4679</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xingyou</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Surgery, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Chengkai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Haoyue</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yihuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinlong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.</Affiliation><Identifier Source="RINGGOLD">12520</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zhenya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.</Affiliation><Identifier Source="RINGGOLD">74566</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vasc Endovascular Surg</MedlineTA><NlmUniqueID>101136421</NlmUniqueID><ISSNLinking>1538-5744</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019917" MajorTopicYN="Y">Blood Vessel Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001018" MajorTopicYN="Y">Aortic Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017536" MajorTopicYN="Y">Carotid Artery, Common</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094682" MajorTopicYN="N">Endovascular Aneurysm Repair</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alternative approach</Keyword><Keyword MajorTopicYN="N">aortic disease</Keyword><Keyword MajorTopicYN="N">aortoiliac artery occlusion</Keyword><Keyword MajorTopicYN="N">carotid artery access</Keyword><Keyword MajorTopicYN="N">endovascular aortic repair</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>7</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40278166</ArticleId><ArticleId IdType="doi">10.1177/15385744251335775</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33935162</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.</ArticleTitle><Pagination><StartPage>1769</StartPage><EndPage>1778</EndPage><MedlinePgn>1769-1778</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0000000000005055</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Traumatic brain injury is a leading cause of death and disability in the United States. While the impact of early multiple organ dysfunction syndrome has been studied in many critical care paradigms, the clinical impact of early multiple organ dysfunction syndrome in traumatic brain injury is poorly understood. We examined the incidence and impact of early multiple organ dysfunction syndrome on clinical, functional, and disability outcomes over the year following traumatic brain injury.</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING">Patients enrolled in the Transforming Clinical Research and Knowledge in Traumatic Brain Injury study, an 18-center prospective cohort study of traumatic brain injury patients evaluated in participating level 1 trauma centers.</AbstractText><AbstractText Label="SUBJECTS">Adult (age &gt; 17 yr) patients with moderate-severe traumatic brain injury (Glasgow Coma Scale &lt; 13). We excluded patients with major extracranial injury (Abbreviated Injury Scale score &#x2265; 3).</AbstractText><AbstractText Label="INTERVENTIONS">Development of early multiple organ dysfunction syndrome, defined as a maximum modified Sequential Organ Failure Assessment score greater than 7 during the initial 72 hours following admission.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">The main outcomes were: hospital mortality, length of stay, 6-month functional and disability domains (Glasgow Outcome Scale-Extended and Disability Rating Scale), and 1-year mortality. Secondary outcomes included: ICU length of stay, 3-month Glasgow Outcome Scale-Extended, 3-month Disability Rating Scale, 1-year Glasgow Outcome Scale-Extended, and 1-year Disability Rating Scale. We examined 373 subjects with moderate-severe traumatic brain injury. The mean (sd) Glasgow Coma Scale in the emergency department was 5.8 (3.2), with 280 subjects (75%) classified as severe traumatic brain injury (Glasgow Coma Scale 3-8). Among subjects with moderate-severe traumatic brain injury, 252 (68%) developed early multiple organ dysfunction syndrome. Subjects that developed early multiple organ dysfunction syndrome had a 75% decreased odds of a favorable outcome (Glasgow Outcome Scale-Extended 5-8) at 6 months (adjusted odds ratio, 0.25; 95% CI, 0.12-0.51) and increased disability (higher Disability Rating Scale score) at 6 months (adjusted mean difference, 2.04; 95% CI, 0.92-3.17). Subjects that developed early multiple organ dysfunction syndrome experienced an increased hospital length of stay (adjusted mean difference, 11.4 d; 95% CI, 7.1-15.8), with a nonsignificantly decreased survival to hospital discharge (odds ratio, 0.47; 95% CI, 0.18-1.2).</AbstractText><AbstractText Label="CONCLUSIONS">Early multiple organ dysfunction following moderate-severe traumatic brain injury is common and independently impacts multiple domains (mortality, function, and disability) over the year following injury. Further research is necessary to understand underlying mechanisms, improve early recognition, and optimize management strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temkin</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komisarow</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korley</LastName><ForeName>Fred K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laskowitz</LastName><ForeName>Daniel T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartz</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghunathan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University. Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Michigan, Ann Arbor, MI.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, NC..</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markowitz</LastName><ForeName>Amy J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Brain and Spinal Injury Center, University of California at San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vavilala</LastName><ForeName>Monica S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>and the Transforming Clinical Research and Knowledge in TBI (TRACK-TBI) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS109274</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085542" MajorTopicYN="Y">Functional Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015600" MajorTopicYN="N">Glasgow Coma Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023261" MajorTopicYN="N">Glasgow Outcome Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Drs. Krishnamoorthy&#x2019;s and Foreman&#x2019;s institutions received funding from the National Institutes of Health (NIH). Drs. Krishnamoorthy, Temkin, Foreman, Goldstein, and Vavilala received support for article research from the NIH. Dr. Temkin&#x2019;s institution also received funding from the U.S. Federal Government; she received funding from several pharmaceutical companies and the University of Southern California. Dr. Foreman&#x2019;s institution received funding from the National Institute of Neurological Disorders and Stroke, the Department of Defense, and the National Science Foundation; he received funding from UCB Pharma. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33935162</ArticleId><ArticleId IdType="mid">NIHMS1682406</ArticleId><ArticleId IdType="pmc">PMC8448900</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000005055</ArticleId><ArticleId IdType="pii">00003246-202110000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention (2019). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths&#x2014;United States, 2014. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services.</Citation></Reference><Reference><Citation>Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL. Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study. Intensive Care Med. 2008;34(4):720&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">18175107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar SN, Millham FH, Chang Y, et al.Presenting blood pressure in traumatic brain injury: a bimodal distribution of death. J Trauma. 2011;71(5):1179&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">21502878</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremitsky E, Omert L, Dunham CM, Protetch J, Rodriguez A. Harbingers of poor outcome the day after severe brain injury: hypothermia, hypoxia, and hypoperfusion. J Trauma. 2003;54(2):312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">12579057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner M, Stein DM, Hu PF, Aarabi B, Sheth K, Scalea TM. Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury. J Trauma Acute Care Surg. 2012;72(5):1135&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22673237</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry C, Ley EJ, Bukur M, et al.Redefining hypotension in traumatic brain injury. Injury. 2012;43(11):1833&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">21939970</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray GD, Butcher I, McHugh GS, et al.Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 2007;24(2):329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">17375997</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisiku IP, Yamal JM, Doshi P, et al.The incidence of ARDS and associated mortality in severe TBI using the Berlin definition. J Trauma Acute Care Surg. 2016;80(2):308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731296</ArticleId><ArticleId IdType="pubmed">26491799</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore EM, Bellomo R, Nichol A, Harley N, Macisaac C, Cooper DJ. The incidence of acute kidney injury in patients with traumatic brain injury. Ren Fail. 2010;32(9):1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">20863210</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral L, Javierre CF, Ventura JL, Marcos P, Herrero JI, Manez R. Impact of non-neurological complications in severe traumatic brain injury outcome. Crit Care. 2012;16(2):R44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681369</ArticleId><ArticleId IdType="pubmed">22410278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramtinfar S, Chabok SY, Chari AJ, Reihanian Z, Leili EK, Alizadeh A. Early detection of nonneurologic organ failure in patients with severe traumatic brain injury: Multiple organ dysfunction score or sequential organ failure assessment? Indian J Crit Care Med. 2016;20(10):575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5073771</ArticleId><ArticleId IdType="pubmed">27829712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodien YG, McCrea M, Dikmen S, et al.Optimizing Outcome Assessment in Multicenter TBI Trials: Perspectives From TRACK-TBI and the TBI Endpoints Development Initiative. J Head Trauma Rehabil. 2018;33(3):147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5940527</ArticleId><ArticleId IdType="pubmed">29385010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde EA, Whiteneck GG, Bogner J, et al.Recommendations for the use of common outcome measures in traumatic brain injury research. Arch Phys Med Rehabil. 2010;91(11):1650&#x2013;1660 e1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21044708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler AA 3rd, Truwit JD, Hite RD, et al.Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322(13):1261&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777268</ArticleId><ArticleId IdType="pubmed">31573637</ArticleId></ArticleIdList></Reference><Reference><Citation>Javed A, Guirgis FW, Sterling SA, et al.Clinical predictors of early death from sepsis. J Crit Care. 2017;42:30&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733694</ArticleId><ArticleId IdType="pubmed">28668774</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevskis EE, Pandharipande PP, Graves AJ, et al.Validity of a Modified Sequential Organ Failure Assessment Score Using the Richmond Agitation-Sedation Scale. Crit Care Med. 2016;44(1):138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748963</ArticleId><ArticleId IdType="pubmed">26457749</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmatinejad Z, Reihani H, Tohidinezhad F, et al.Predictive performance of the SOFA and mSOFA scoring systems for predicting in-hospital mortality in the emergency department. Am J Emerg Med. 2019;37(7):1237&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">30213476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23(1):374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Hwang H, Yamal JM, et al.IMPACT probability of poor outcome and plasma cytokine concentrations are associated with multiple organ dysfunction syndrome following traumatic brain injury. J Neurosurg. 2019;131(6):1931&#x2013;1937.</Citation><ArticleIdList><ArticleId IdType="pubmed">30641838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeole U, Krishnakumar M, Gopalakrishna KN, Sekar A, Sadashiva N, Shukla D. Surgical outcomes in traumatic brain injuries with bilateral mass occupying lesions. Analysis of prognostic factors. Clin Neurol Neurosurg. 2020;196:106017.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619900</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner MJ, Newsome HH, Becker DP. Mechanical brain injury: the sympathoadrenal response. J Neurosurg. 1984;61(1):76&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">6726414</ArticleId></ArticleIdList></Reference><Reference><Citation>Koiv L, Merisalu E, Zilmer K, Tomberg T, Kaasik AE. Changes of sympatho-adrenal and hypothalamo-pituitary-adrenocortical system in patients with head injury. Acta Neurol Scand. 1997;96(1):52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Jaja BN, Di Battista AP, et al.Catecholamines as outcome markers in isolated traumatic brain injury: the COMA-TBI study. Crit Care. 2017;21(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322658</ArticleId><ArticleId IdType="pubmed">28228155</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald SJ, Sharkey JM, Sun M, et al.Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury. J Neurotrauma. 2020;37(5):770&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">32041478</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich M, Wafaisade A, Mansuri A, et al.Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores. Scand J Trauma Resusc Emerg Med. 2016;24(1):130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094147</ArticleId><ArticleId IdType="pubmed">27809885</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41(1):11&#x2013;17; discussion 17-19.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218290</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B, Klingelhofer J, Perkes I, Czosnyka M. Cerebral autoregulatory response depends on the direction of change in perfusion pressure. J Neurotrauma. 2009;26(5):651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">19281414</ArticleId></ArticleIdList></Reference><Reference><Citation>Casault C, Al Sultan AS, Banoei M, Couillard P, Kramer A, Winston BW. Cytokine Responses in Severe Traumatic Brain Injury: Where There Is Smoke, Is There Fire? Neurocrit Care. 2019;30(1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29569129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16294072</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5282</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Prone positioning improves oxygenation in post-traumatic lung injury--a prospective randomized trial.</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>343</EndPage><MedlinePgn>333-41; discussion 341-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In a prospective randomized trial the effect of prone positioning on the duration of mechanical ventilation was evaluated in multiple trauma patients and was compared with patients ventilated in supine position.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Multiple trauma patients of the intensive care units of two university hospitals were considered eligible if they met the criteria for acute lung injury or the acute respiratory distress syndrome. Patients in the prone group (N = 21) were kept prone for at least eight hours and a maximum of 23 hours per day. Prone positioning was continued until a PaO2:FiO2 ratio of more than 300 was present in prone as well as supine position over a period of 48 hours. Patients in the supine group (N = 19) were positioned according to standard care guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The duration of ventilatory support did not differ significantly (30 +/- 17 days in the prone group and 33 +/- 23 days in the supine group). Worst case analysis (death and deterioration of gas exchange) displayed ventilatory support for 41 +/- 29 days in the prone group and 61 +/- 35 days in the supine group (p = 0.06). The PaO2:FiO2 ratio increased significantly more in the prone group in the first four days (p = 0.03). The prevalence of Acute Respiratory Distress Syndrome (ARDS) following acute lung injury (p = 0.03) and the prevalence of pneumonia (p = 0.048) were reduced also. One patient in the prone and three patients in the supine group died due to multi organ failure (p = 0.27).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intermittent prone positioning was not able to reduce the duration of mechanical ventilation in this limited number of patients. However the oxygenation improved significantly over the first four days of treatment, and the prevalence of ARDS and pneumonia were reduced.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voggenreiter</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Hospital Mannheim, 68135 Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aufmkolk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stiletto</LastName><ForeName>Raphael J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Baacke</LastName><ForeName>Markus G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Waydhas</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ose</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gotzen</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Obertacke</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Nast-Kolb</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011175" MajorTopicYN="N">Positive-Pressure Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016684" MajorTopicYN="Y">Prone Position</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011659" MajorTopicYN="N">Pulmonary Gas Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016683" MajorTopicYN="N">Supine Position</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16294072</ArticleId><ArticleId IdType="doi">10.1097/01.ta.0000179952.95921.49</ArticleId><ArticleId IdType="pii">00005373-200508000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32743995</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>30</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January-May 2020.</ArticleTitle><Pagination><StartPage>e280</StartPage><MedlinePgn>e280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2020.35.e280</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The fatality rate of patients with coronavirus disease 2019 (COVID-19) varies among countries owing to demographics, patient comorbidities, surge capacity of healthcare systems, and the quality of medical care. We assessed the clinical outcomes of patients with COVID-19 during the first wave of the epidemic in Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a modified World Health Organization clinical record form, we obtained clinical data for 3,060 patients with COVID-19 treated at 55 hospitals in Korea. Disease severity scores were defined as: 1) no limitation of daily activities; 2) limitation of daily activities but no need for supplemental oxygen; 3) supplemental oxygen via nasal cannula; 4) supplemental oxygen via facial mask; 5) non-invasive mechanical ventilation; 6) invasive mechanical ventilation; 7) multi-organ failure or extracorporeal membrane oxygenation therapy; and 8) death. Recovery was defined as a severity score of 1 or 2, or discharge and release from isolation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the patients was 43 years of age; 43.6% were male. The median time from illness onset to admission was 5 days. Of the patients with a disease severity score of 3-4 on admission, 65 (71.5%) of the 91 patients recovered, and 7 (7.7%) died due to illness by day 28. Of the patients with disease severity scores of 5-7, 7 (19.5%) of the 36 patients recovered, and 8 (22.2%) died due to illness by day 28. None of the 1,324 patients who were &lt; 50 years of age died; in contrast, the fatality rate due to illness by day 28 was 0.5% (2/375), 0.9% (2/215), 5.8% (6/104), and 14.0% (7/50) for the patients aged 50-59, 60-69, 70-79, and &#x2265; 80 years of age, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In Korea, almost all patients of &lt; 50 years of age with COVID-19 recovered without supplemental oxygen. In patients of &#x2265; 50 years of age, the fatality rate increased with age, reaching 14% in patients of &#x2265; 80 years of age.</AbstractText><CopyrightInformation>&#xa9; 2020 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Ho Kyung</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0002-1207-0298</Identifier><AffiliationInfo><Affiliation>National Emergency Medical Center, National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-4306-1597</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeonghun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9534-2921</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Busan Medical Center, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Haesook</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3554-6172</Identifier><AffiliationInfo><Affiliation>Department of Tuberculosis, Seoul Metropolitan Seobuk Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Young Soo</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0003-3586-9446</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Seoul Metropolitan Seonam Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyewon</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3491-1059</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Chungju Medical Center, Chungju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Bo Ram</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-8810-1417</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Gyeonggi Provincial Medical Center Ansung Hospital, Anseong, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Neungsun</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4622-9655</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Gongju Medical Center, Gongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hong Sang</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-4535-6305</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Young Mi</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-8314-6317</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Seosan Medical Center, Seosan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyung Hwa</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0003-2836-6963</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shon</LastName><ForeName>Jeung A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-9515-7665</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Yeongju Red Cross Hospital, Yeongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Chul</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-4410-5608</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joon Ho</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-4127-2312</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Gyeonggi Provincial Medical Center Uijeongbu Hospital, Uijeongbu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hyun Ha</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0002-9405-2121</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yukyung</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0660-9867</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea Workers' Compensation &amp; Welfare Services Daegu Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yu Min</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-4368-9878</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Myongji Hospital, Goyang, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-1179-1664</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungcheongnam-do Cheonan Medical Center, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-9990-6042</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-4104-9583</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jeonllanam-do Suncheon Medical Center, Suncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kyoung Ho</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-4517-3840</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0003-1104-268X</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Cheongju Medical Center, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyeongseok</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4539-079X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Yeon</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-2788-1392</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ja Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-1044-644X</Identifier><AffiliationInfo><Affiliation>Intensive Care Team, Gyeonggi Provincial Medical Center Paju Hospital, Paju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jihee</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5255-1352</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Eun Hwa</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0001-5814-7636</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Korea Worker's Compensation &amp; Welfare Service Changwon Hospital, Changwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Ki Hyun</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-7100-2519</Identifier><AffiliationInfo><Affiliation>National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Myoung Don</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-2344-7695</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. mdohmd@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Korea National Committee for Clinical Management of COVID-19</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>4838-330-320-01</GrantID><Acronym>KCDC</Acronym><Agency>Korea Centers for Disease Control &amp; Prevention</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Korean Med Sci. 2020 Sep 28;35(38):e353. doi: 10.3346/jkms.2020.35.e353.</RefSource><PMID Version="1">32989937</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010356" MajorTopicYN="N">Patient Isolation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055872" MajorTopicYN="N">Surge Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort Study</Keyword><Keyword MajorTopicYN="N">Korea</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32743995</ArticleId><ArticleId IdType="pmc">PMC7402927</ArticleId><ArticleId IdType="doi">10.3346/jkms.2020.35.e280</ArticleId><ArticleId IdType="pii">35.e280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus disease (COVID-2019) situation report-143.  [Updated 2020].  [Accessed 15 June, 2020].   https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation></Reference><Reference><Citation>Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020;35(5):e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008073</ArticleId><ArticleId IdType="pubmed">32030925</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Coronavirus disease-19 main website.  [Updated 2020].  [Accessed June 15, 2020].   http://ncov.mohw.go.kr/en.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72&#x202f;314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. I.S.A.R.E.I.C., Global COVID-19: clinical platform: novel coronavius (&#x200e;COVID-19)&#x200e;: rapid version. Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Press release. Coronavirus disease-19, Republic of Korea.  [Updated 2020].  [Accessed June 12, 2020].   http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_idhttp://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_id=</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30483-7. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020;35(13):e142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131901</ArticleId><ArticleId IdType="pubmed">32242348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NJ, Choe PG, Park SJ, Lim J, Lee WJ, Kang CK, et al. A cluster of tertiary transmissions of 2019 novel coronavirus (SARS-CoV-2) in the community from infectors with common cold symptoms. Korean J Intern Med. 2020;35(4):758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373952</ArticleId><ArticleId IdType="pubmed">32506866</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073313</ArticleId><ArticleId IdType="pubmed">32174069</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007764. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pubmed">32649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang E, Lee SY, Jung H, Kim MS, Cho B, Kim YS. Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea. Emerging. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201460. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201460</ArticleId><ArticleId IdType="pmc">PMC7510742</ArticleId><ArticleId IdType="pubmed">32568665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Hong CM, Kim DH, Lee TH, Lee J. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201620. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201620</ArticleId><ArticleId IdType="pmc">PMC7510714</ArticleId><ArticleId IdType="pubmed">32568662</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411&#x2013;2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224609</ArticleId><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17992396</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-3180</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Sao Paulo medical journal = Revista paulista de medicina</Title><ISOAbbreviation>Sao Paulo Med J</ISOAbbreviation></Journal><ArticleTitle>Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial.</ArticleTitle><Pagination><StartPage>237</StartPage><EndPage>241</EndPage><MedlinePgn>237-41</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Sepsis and septic shock are very common conditions among critically ill patients that lead to multiple organ dysfunction syndrome (MODS) and death. Our purpose was to investigate the efficacy of early administration of dexamethasone for patients with septic shock, with the aim of halting the progression towards MODS and death.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Prospective, randomized, double-blind, single-center study, developed in a surgical intensive care unit at Hospital das Cl&#xed;nicas, Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study involved 29 patients with septic shock. All eligible patients were prospectively randomized to receive either a dose of 0.2 mg/kg of dexamethasone (group D) or placebo (group P), given three times at intervals of 36 hours. The patients were monitored over a seven-day period by means of the sequential organ failure assessment score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients treated with dexamethasone did not require vasopressor therapy for as much time over the seven-day period as did the placebo group (p = 0.043). Seven-day mortality was 67% in group P (10 out of 15) and 21% in group D (3 out of 14) (relative risk = 0.31, 95% confidence interval 0.11 to 0.88). Dexamethasone enhanced the effects of vasopressor drugs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early treatment with dexamethasone reduced the seven-day mortality among septic shock patients and showed a trend towards reduction of 28-day mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cicarelli</LastName><ForeName>Domingos Dias</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, Porto, Portugal. dcicarelli@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Joaquim Edson</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Bense&#xf1;or</LastName><ForeName>F&#xe1;bio Ely Martins</ForeName><Initials>FE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Sao Paulo Med J</MedlineTA><NlmUniqueID>100897261</NlmUniqueID><ISSNLinking>1516-3180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="CONTEXTO E OBJETIVO:">Sepse e choque s&#xe9;ptico s&#xe3;o doen&#xe7;as muito comuns em pacientes gravemente enfermos, evoluindo muitas vezes com s&#xed;ndrome de disfun&#xe7;&#xe3;o de m&#xfa;ltiplos &#xf3;rg&#xe3;os (SDMO) e morte. A proposta do trabalho foi investigar a efic&#xe1;cia da administra&#xe7;&#xe3;o precoce de dexametasona a estes pacientes, tentando evitar a progress&#xe3;o do choque s&#xe9;ptico para SDMO e morte.</AbstractText><AbstractText Label="TIPO DE ESTUDO E LOCAL:">Estudo prospectivo, aleat&#xf3;rio, duplamente encoberto, monoc&#xea;ntrico, realizado na Unidade de Terapia Intensiva p&#xf3;s-operat&#xf3;ria do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Foram estudados 29 pacientes com choque s&#xe9;ptico. Os participantes foram aleatoriamente divididos em dois grupos que receberam 0,2 mg/kg de dexametasona (grupo D) ou placebo (grupo P), repetidas a cada 36 horas. Os pacientes foram acompanhados durante sete dias de interna&#xe7;&#xe3;o na Unidade de Terapia Intensiva atrav&#xe9;s do escore SOFA (Sequential Organ Failure Assessment).</AbstractText><AbstractText Label="RESULTADOS:">Os pacientes que receberam dexametasona necessitaram de menos tempo de tratamento com vasopressores durante o per&#xed;odo de sete dias (p = 0,043). A mortalidade em sete dias no grupo P foi de 67% (10 em 15) e no grupo D foi de 21% (3 em 14) (risco relativo = 0.31, intervalo de confian&#xe7;a 95% 0.11-0.88).</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">O tratamento precoce com dexametasona dos pacientes com choque s&#xe9;ptico reduziu a mortalidade em sete dias de acompanhamento e mostrou tend&#xea;ncia de redu&#xe7;&#xe3;o da mortalidade em 28 dias.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> Not declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17992396</ArticleId><ArticleId IdType="pmc">PMC11020550</ArticleId><ArticleId IdType="doi">10.1590/s1516-31802007000400009</ArticleId><ArticleId IdType="pii">S1516-31802007000400009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094907</ArticleId><ArticleId IdType="pubmed">9876974</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569975</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321661</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, International Sepsis Forum Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93&#x2013;S103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicarelli DD, Bense&#xf1;or FE, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Med J. 2006;124(2):90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11060357</ArticleId><ArticleId IdType="pubmed">16878192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 1459&#x2013;1485.</Citation></Reference><Reference><Citation>Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaesthesia. 2003;58(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12492660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700393</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettil&#xe4; V, Pettil&#xe4; M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32(9):1928&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pubmed">15343024</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR. Medical epidemiology. 3rd ed. New York: McGraw-Hill; 2001.</Citation></Reference><Reference><Citation>MacLaren R, Jung R. Stress-dose corticosteroids therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794402</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186608</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, S&#xe9;bille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186604</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559592</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GS, Bernard GR, International Sepsis Forum Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307371</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32015566</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Changes in inflammatory and vasoactive mediator profiles during valvular surgery with or without infective endocarditis: A case control pilot study.</ArticleTitle><Pagination><StartPage>e0228286</StartPage><MedlinePgn>e0228286</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0228286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0228286</ELocationID><Abstract><AbstractText Label="BACKGROUND">More than 50% of patients with infective endocarditis (IE) develop an indication for surgery. Despite its benefit, surgery is associated with a high incidence of multiple organ dysfunction syndrome (MODS) and mortality, which may be linked to increased release of inflammatory mediators during cardiopulmonary bypass (CPB). We therefore assessed plasma cytokine profiles in patients undergoing valve surgery with or without IE.</AbstractText><AbstractText Label="METHODS">We performed a prospective case-control pilot study comparing patients undergoing cardiac valve surgery with or without IE. Plasma profiles of inflammatory mediators were measured at 7 defined time points and reported as median (interquartile). The degree of MODS was measured using sequential organ failure assessment (SOFA) score.</AbstractText><AbstractText Label="RESULTS">Between May and December 2016 we included 40 patients (20 in each group). Both groups showed similar distribution of age and gender. Patients with IE had higher preoperative SOFA (6.9&#xb1; 2.6 vs 3.8 &#xb1; 1.1, p&lt;0.001) and operative risk scores (EuroSCORE II 18.6&#xb1;17.4 vs. 1.8&#xb1;1.3, p&lt;0.001). In-hospital mortality was higher in IE patients (35% vs. 5%; p&lt;0.001). Multiple organ failure was the cause of death in all non-survivors. At the end of CPB, median levels of following inflammatory mediators were higher in IE compared to control group: IL-6 (119.73 (226.49) vs. 24.48 (40.09) pg/ml, p = 0.001); IL-18 (104.82 (105.99) vs. 57.30 (49.53) pg/ml, p&lt;0.001); Mid-regional pro-adrenomedullin (MR-proADM) (2.06 (1.58) vs. 1.11 (0.53) nmol/L, p = 0.003); MR- pro-atrial natriuretic peptide (MR-proANP) (479.49 (224.74) vs. 266.55 (308.26) pmol/l, p = 0.028). IL-1&#x3b2; and TNF- &#x3b1; were only detectable in IE patients and first after starting CPB. Plasma levels of IL-6, IL-18, MRproADM, and MRproANP during CPB were significantly lower in survivors than in those who died.</AbstractText><AbstractText Label="CONCLUSION">The presence of infective endocarditis during cardiac valve surgery is associated with increased inflammatory response as evident by higher plasma cytokine levels and other inflammatory mediators. Actively reducing inflammatory response appears to be a plausible therapeutic concept.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov, ID: NCT02727413.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diab</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1529-6046</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasar</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sponholz</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Clinical Studies, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletz</LastName><ForeName>Mathias W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University of Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunkhorst</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Center for Sepsis Control and Care, Jena, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Clinical Studies, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doenst</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Jena, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02727413</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004696" MajorTopicYN="N">Endocarditis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006351" MajorTopicYN="N">Heart Valves</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All other authors declare no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32015566</ArticleId><ArticleId IdType="pmc">PMC6996967</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0228286</ArticleId><ArticleId IdType="pii">PONE-D-19-17603</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation. 2010;121(9):1141&#x2013;52. 10.1161/CIRCULATIONAHA.108.773598</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.773598</ArticleId><ArticleId IdType="pubmed">20212293</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, et al. A systematic review of population-based studies of infective endocarditis. Chest. 2007;132(3):1025&#x2013;35. 10.1378/chest.06-2048</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-2048</ArticleId><ArticleId IdType="pubmed">17873196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yew HS, Murdoch DR. Global trends in infective endocarditis epidemiology. Current infectious disease reports. 2012;14(4):367&#x2013;72. 10.1007/s11908-012-0265-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11908-012-0265-5</ArticleId><ArticleId IdType="pubmed">22592632</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr., Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Archives of internal medicine. 2009;169(5):463&#x2013;73. 10.1001/archinternmed.2008.603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2008.603</ArticleId><ArticleId IdType="pmc">PMC3625651</ArticleId><ArticleId IdType="pubmed">19273776</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvez-Acebal J, Rodriguez-Bano J, Martinez-Marcos FJ, Reguera JM, Plata A, Ruiz J, et al. Prognostic factors in left-sided endocarditis: results from the Andalusian multicenter cohort. BMC infectious diseases. 2010;10:17 10.1186/1471-2334-10-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-10-17</ArticleId><ArticleId IdType="pmc">PMC2822778</ArticleId><ArticleId IdType="pubmed">20096116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelsomino S, Maessen JG, van der Veen F, Livi U, Renzulli A, Luca F, et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. The Annals of thoracic surgery. 2012;93(5):1469&#x2013;76. 10.1016/j.athoracsur.2011.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.11.025</ArticleId><ArticleId IdType="pubmed">22342063</ArticleId></ArticleIdList></Reference><Reference><Citation>Musci M, Weng Y, Hubler M, Chavez T, Qedra N, Kosky S, et al. Predictors of early mortality in patients with active infective native or prosthetic aortic root endocarditis undergoing homograft aortic root replacement. Clinical research in cardiology: official journal of the German Cardiac Society. 2009;98(7):443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">19350313</ArticleId></ArticleIdList></Reference><Reference><Citation>Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2002;21(2):232&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota AL, Rodrigues AJ, Evora PR. [Adult cardiopulmonary bypass in the twentieth century: science, art or empiricism?]. Rev Bras Cir Cardiovasc. 2008;23(1):78&#x2013;92. 10.1590/s0102-76382008000100013</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0102-76382008000100013</ArticleId><ArticleId IdType="pubmed">18719832</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante J, Arevalo A, Tamayo E, Sarria C, Aguilar-Blanco EM, Heredia M, et al. Cytokine profiles linked to fatal outcome in infective prosthetic valve endocarditis. APMIS. 2014;122(6):526&#x2013;9. 10.1111/apm.12189</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.12189</ArticleId><ArticleId IdType="pubmed">24106887</ArticleId></ArticleIdList></Reference><Reference><Citation>Araujo IR, Ferrari TC, Teixeira-Carvalho A, Campi-Azevedo AC, Rodrigues LV, Guimaraes Junior MH, et al. Cytokine Signature in Infective Endocarditis. PLoS One. 2015;10(7):e0133631 10.1371/journal.pone.0133631</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133631</ArticleId><ArticleId IdType="pmc">PMC4520569</ArticleId><ArticleId IdType="pubmed">26225421</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr., Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;30(4):633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770721</ArticleId></ArticleIdList></Reference><Reference><Citation>Munzel U, Brunner E. Nonparametric methods in multivariate factorial designs. J Stat Plan Infer. 2000;88(1):117&#x2013;32.</Citation></Reference><Reference><Citation>Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardio-Thorac. 2002;21(2):232&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of internal medicine. 2007;167(15):1655&#x2013;63. 10.1001/archinte.167.15.1655</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.15.1655</ArticleId><ArticleId IdType="pmc">PMC4495652</ArticleId><ArticleId IdType="pubmed">17698689</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustamante-Munguira J, Arevalo A, Sarria C, Saez C, Aguilar-Blanco EM, Almansa R, et al. The Role of Pro-Inflammatory Cytokines in Late Prosthetic Valve Endocarditis. Brit J Surg. 2014;101:14&#x2013;.</Citation></Reference><Reference><Citation>Kern WV, Engel A, Schieffer S, Prummer O, Kern P. Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infection and immunity. 1993;61(12):5413&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281334</ArticleId><ArticleId IdType="pubmed">8225616</ArticleId></ArticleIdList></Reference><Reference><Citation>Capo C, Amirayan N, Ghigo E, Raoult D, Mege J. Circulating cytokine balance and activation markers of leucocytes in Q fever. Clin Exp Immunol. 1999;115(1):120&#x2013;3. 10.1046/j.1365-2249.1999.00786.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1999.00786.x</ArticleId><ArticleId IdType="pmc">PMC1905180</ArticleId><ArticleId IdType="pubmed">9933430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi MH, Rinoesl H, Dragosits K, Ristl R, Hoffelner F, Opfermann P, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery&#x2014;a blinded, randomized, controlled pilot study using a novel adsorbent. Critical care. 2016;20:96 10.1186/s13054-016-1270-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1270-0</ArticleId><ArticleId IdType="pmc">PMC4826492</ArticleId><ArticleId IdType="pubmed">27059056</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatachalam K, Prabhu SD, Reddy VS, Boylston WH, Valente AJ, Chandrasekar B. Neutralization of Interleukin-18 Ameliorates Ischemia/Reperfusion-induced Myocardial Injury. Journal of Biological Chemistry. 2009;284(12):7853&#x2013;65. 10.1074/jbc.M808824200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808824200</ArticleId><ArticleId IdType="pmc">PMC2658078</ArticleId><ArticleId IdType="pubmed">19164288</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher CJ Jr., Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12&#x2013;21. 10.1097/00003246-199401000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199401000-00008</ArticleId><ArticleId IdType="pubmed">8124953</ArticleId></ArticleIdList></Reference><Reference><Citation>Elke G, Bloos F, Wilson DC, Meybohm P, Grp SCCT. Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores. Critical care. 2018;22 10.1186/s13054-018-1946-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-1946-8</ArticleId><ArticleId IdType="pmc">PMC5989334</ArticleId><ArticleId IdType="pubmed">29871660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad T, Fiuzat M, Felker GM, O'Connor C. Novel biomarkers in chronic heart failure. Nature reviews Cardiology. 2012;9(6):347&#x2013;59. 10.1038/nrcardio.2012.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2012.37</ArticleId><ArticleId IdType="pubmed">22450126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrmann P, Bahrmann A, Hofner B, Christ M, Achenbach S, Sieber CC, et al. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department. Eur Heart J Acute Cardiovasc Care. 2015;4(2):137&#x2013;47. 10.1177/2048872614541904</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2048872614541904</ArticleId><ArticleId IdType="pubmed">25002708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014;52(10):1447&#x2013;56. 10.1515/cclm-2014-0379</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2014-0379</ArticleId><ArticleId IdType="pubmed">24940718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Takata S, Kawahara Y, Takai Y, Chino N, Kimura T, et al. Molecular mechanism of action by atrial natriuretic peptide in rat vascular smooth muscle cells. Jpn Circ J. 1988;52(12):1430&#x2013;5. 10.1253/jcj.52.1430</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/jcj.52.1430</ArticleId><ArticleId IdType="pubmed">2853774</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Journal of the American College of Cardiology. 2010;55(19):2062&#x2013;76. 10.1016/j.jacc.2010.02.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2010.02.025</ArticleId><ArticleId IdType="pubmed">20447528</ArticleId></ArticleIdList></Reference><Reference><Citation>Guignant C, Venet F, Voirin N, Poitevin F, Malcus C, Bohe J, et al. Proatrial natriuretic peptide is a better predictor of 28-day mortality in septic shock patients than proendothelin-1. Clin Chem Lab Med. 2010;48(12):1813&#x2013;20. 10.1515/CCLM.2010.341</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2010.341</ArticleId><ArticleId IdType="pubmed">20704539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcmurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma Endothelin in Chronic Heart-Failure. Circulation. 1992;85(4):1374&#x2013;9. 10.1161/01.cir.85.4.1374</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.85.4.1374</ArticleId><ArticleId IdType="pubmed">1532540</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman BD, Machado FS, Tanowitz HB, Desruisseaux MS. Endothelin-1 and its role in the pathogenesis of infectious diseases. Life Sci. 2014;118(2):110&#x2013;9. 10.1016/j.lfs.2014.04.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2014.04.021</ArticleId><ArticleId IdType="pmc">PMC4538933</ArticleId><ArticleId IdType="pubmed">24780317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000;28(6):1854&#x2013;60. 10.1097/00003246-200006000-00028</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200006000-00028</ArticleId><ArticleId IdType="pubmed">10890632</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem. 2006;52(6):1144&#x2013;51. 10.1373/clinchem.2005.065581</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2005.065581</ArticleId><ArticleId IdType="pubmed">16627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Buendgens L, Yagmur E, Bruensing J, Herbers U, Baeck C, Trautwein C, et al. C-terminal proendothelin-1 (CT-proET-1) is associated with organ failure and predicts mortality in critically ill patients. Journal of Intensive Care. 2017;5 10.1186/s40560-016-0201-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-016-0201-0</ArticleId><ArticleId IdType="pmc">PMC5359904</ArticleId><ArticleId IdType="pubmed">28331622</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Li X, Zhang X, Li Z, Wang L, Sun Y, et al. Elevated levels of plasma TNF-alpha are associated with microvascular endothelial dysfunction in patients with sepsis through activating the NF-kappaB and p38 mitogen-activated protein kinase in endothelial cells. Shock. 2014;41(4):275&#x2013;81. 10.1097/SHK.0000000000000116</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000116</ArticleId><ArticleId IdType="pubmed">24430552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittar MN, Carey JA, Barnard JB, Pravica V, Deiraniya AK, Yonan N, et al. Tumor necrosis factor alpha influences the inflammatory response after coronary surgery. The Annals of thoracic surgery. 2006;81(1):132&#x2013;7. 10.1016/j.athoracsur.2005.07.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2005.07.037</ArticleId><ArticleId IdType="pubmed">16368349</ArticleId></ArticleIdList></Reference><Reference><Citation>Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993;21(10 Suppl):S447&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8403983</ArticleId></ArticleIdList></Reference><Reference><Citation>Frencken JF, van Vught LA, Peelen LM, Ong DSY, Klein Klouwenberg PMC, Horn J, et al. An Unbalanced Inflammatory Cytokine Response Is Not Associated With Mortality Following Sepsis: A Prospective Cohort Study. Crit Care Med. 2017;45(5):e493&#x2013;e9. 10.1097/CCM.0000000000002292</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002292</ArticleId><ArticleId IdType="pubmed">28257334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862&#x2013;74. 10.1038/nri3552</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3552</ArticleId><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II dagger. Eur J Cardio-Thorac. 2012;41(4):734&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22378855</ArticleId></ArticleIdList></Reference><Reference><Citation>Remadi JP, Habib G, Nadji G, Brahim A, Thuny F, Casalta JP, et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. The Annals of thoracic surgery. 2007;83(4):1295&#x2013;302. 10.1016/j.athoracsur.2006.09.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.09.093</ArticleId><ArticleId IdType="pubmed">17383330</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Sponholz C, von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. Infection. 2017;45(6):857&#x2013;66. 10.1007/s15010-017-1064-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-017-1064-6</ArticleId><ArticleId IdType="pubmed">28856632</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab M, Guenther A, Sponholz C, Lehmann T, Faerber G, Matz A, et al. Pre-operative stroke and neurological disability do not independently affect short- and long-term mortality in infective endocarditis patients. Clinical Research in Cardiology. 2016;105(10):847&#x2013;57. 10.1007/s00392-016-0993-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-016-0993-x</ArticleId><ArticleId IdType="pubmed">27122133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33320284</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Geriatric polytrauma patients should not be excluded from aggressive injury treatment based on age alone.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>365</EndPage><MedlinePgn>357-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-020-01567-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Age in severely injured patients has been increasing for decades. Older age is associated with increasing mortality. However, morbidity and mortality could possibly be reduced when accurate and aggressive treatment is provided. This study investigated age-related morbidity and mortality in polytrauma including age-related decisions in initial injury management and withdrawal of life-sustaining therapy (WLST).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 6.5-year prospective cohort study included consecutive severely injured&#xa0;trauma patients admitted to a Level-1 Trauma Center ICU. Demographics, data on physiology, resuscitation, MODS/ARDS, and infectious complications were prospectively collected. Patients were divided into age subgroups (&lt;&#x2009;25, 25-49, 50-69, and&#x2009;&#x2265;&#x2009;70&#xa0;years) to make clinically relevant comparisons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">391 patients (70% males) were included with median ISS of 29 (22-36), 95% sustained blunt injuries. There was no difference in injury severity, resuscitation, urgent surgeries, nor in ventilator days, ICU-LOS, and H-LOS between age groups. Adjusted odds of MODS, ARDS and infectious complications were similar between age groups. 47% of patients&#x2009;&#x2265;&#x2009;70&#xa0;years died, compared to 10-16% in other age groups (P&#x2009;&lt;&#x2009;0.001). WLST increased with older age, contributing to more than half of deaths&#x2009;&#x2265;&#x2009;70&#xa0;years. TBI was the most common cause of death and decision for treatment withdrawal in all age groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients&#x2009;&#x2265;&#x2009;70&#xa0;years had higher mortality risk even though injury severity and complication rates were similar to other age groups. WLST increased with age with the vast majority due to brain injury. More than half of patients&#x2009;&#x2265;&#x2009;70&#xa0;years survived suggesting geriatric polytrauma patients should not be excluded from aggressive injury treatment based on age alone.</AbstractText><CopyrightInformation>&#xa9; 2020. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Trauma Surgeon, Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. kwessem@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><AffiliationInfo><Affiliation>Professor of Trauma Surgery, Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggressive treatment</Keyword><Keyword MajorTopicYN="N">Geriatric polytrauma</Keyword><Keyword MajorTopicYN="N">Withdrawal of life-sustaining therapy</Keyword></KeywordList><CoiStatement>All authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33320284</ArticleId><ArticleId IdType="pmc">PMC7736672</ArticleId><ArticleId IdType="doi">10.1007/s00068-020-01567-y</ArticleId><ArticleId IdType="pii">10.1007/s00068-020-01567-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kuhne CA, Ruchholtz S, Kaiser GM, Nast-Kolb D. Working group on multiple trauma of the german society of trauma. Mortality in severely injured elderly trauma patients&#x2013;when does age become a risk factor? World J Surg. 2005;29(11):1476&#x2013;1482. doi: 10.1007/s00268-005-7796-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-005-7796-y</ArticleId><ArticleId IdType="pubmed">16228923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima M, Endo A, Shiraishi A, Otomo Y. Age-related characteristics and outcomes for patients with severe trauma: analysis of Japan's nationwide trauma registry. Ann Emerg Med. 2019;73(3):281&#x2013;290. doi: 10.1016/j.annemergmed.2018.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2018.09.034</ArticleId><ArticleId IdType="pubmed">30447945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nenberger A, Billeter AT, Seifert B, Neuhaus V, Trentz O, Turina M. Opportunities for improved trauma care of the elderly - a single center analysis of 2090 severely injured patients. Arch Gerontol Geriatr. 2012;55(3):660&#x2013;666. doi: 10.1016/j.archger.2012.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2012.02.013</ArticleId><ArticleId IdType="pubmed">22465302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammy I, Lecky F, Sutton A, Leaviss J, O'Cathain A. Factors affecting mortality in older trauma patients-A systematic review and meta-analysis. Injury. 2016;47(6):1170&#x2013;1183. doi: 10.1016/j.injury.2016.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2016.02.027</ArticleId><ArticleId IdType="pubmed">27015751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitriou R, Calori GM, Giannoudis PV. Polytrauma in the elderly: specific considerations and current concepts of management. Eur J Trauma Emerg Surg. 2011;37(6):539&#x2013;548. doi: 10.1007/s00068-011-0137-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-011-0137-y</ArticleId><ArticleId IdType="pubmed">26815464</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Court-Brown C, Pape HC. Severe and multiple trauma in older patients; incidence and mortality. Injury. 2009;40(4):362&#x2013;367. doi: 10.1016/j.injury.2008.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2008.10.016</ArticleId><ArticleId IdType="pubmed">19217104</ArticleId></ArticleIdList></Reference><Reference><Citation>Friese RS, Wynne J, Joseph B, et al. Age and mortality after injury: is the association linear? Eur J Trauma Emerg Surg. 2014;40(5):567&#x2013;572. doi: 10.1007/s00068-014-0380-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-014-0380-0</ArticleId><ArticleId IdType="pubmed">26814513</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodmanson NW, Rosengart MR, Barnato AE, Sperry JL, Peitzman AB, Marshall GT. Defining geriatric trauma: when does age make a difference? Surgery. 2012;152(4):668&#x2013;675. doi: 10.1016/j.surg.2012.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2012.08.017</ArticleId><ArticleId IdType="pmc">PMC4070315</ArticleId><ArticleId IdType="pubmed">23021136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand F, Pape HC, Horst K, et al. Impact of age on the clinical outcomes of major trauma. Eur J Trauma Emerg Surg. 2016;42(3):317&#x2013;332. doi: 10.1007/s00068-015-0557-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-015-0557-1</ArticleId><ArticleId IdType="pubmed">26253883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler CR, Woschek M, Verboket RD, et al. Registry-based mortality analysis reveals a high proportion of patient decrees and presumed limitation of therapy in severe geriatric trauma. J Clin Med. 2020;9(9):E2686. doi: 10.3390/jcm9092686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9092686</ArticleId><ArticleId IdType="pmc">PMC7565431</ArticleId><ArticleId IdType="pubmed">32825084</ArticleId></ArticleIdList></Reference><Reference><Citation>Spering C, Lefering R, Bouillon B, et al. It is time for a change in the management of elderly severely injured patients! An analysis of 126,015 patients from the TraumaRegister DGU&#xae;. Eur J Trauma Emerg Surg. 2020;46(3):487&#x2013;497. doi: 10.1007/s00068-019-01229-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-019-01229-8</ArticleId><ArticleId IdType="pubmed">31520156</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterino JM, Valasek T, Werman HA. Identification of an age cutoff for increased mortality in patients with elderly trauma. Am J Emerg Med. 2010;28(2):151&#x2013;158. doi: 10.1016/j.ajem.2008.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2008.10.027</ArticleId><ArticleId IdType="pubmed">20159383</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatovich DM, Jacobs IG, Langford SA, Phillips M. The effect of age, severity, and mechanism of injury on risk of death from major trauma in Western Australia. J Trauma Acute Care Surg. 2013;74(2):647&#x2013;651. doi: 10.1097/TA.0b013e3182788065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182788065</ArticleId><ArticleId IdType="pubmed">23354264</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzunegui T, Grad&#xed;n C, Fort&#xfa;n M, Cabodevilla A, Barbachano A, Sanz JA. Major trauma registry of Navarre (Spain): the accuracy of different survival prediction models. Am J Emerg Med. 2013;31(9):1382&#x2013;1388. doi: 10.1016/j.ajem.2013.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2013.06.026</ArticleId><ArticleId IdType="pubmed">23891602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level-1 trauma centers in three international trauma systems. World J Surg. 2015;39(11):2677&#x2013;2684. doi: 10.1007/s00268-015-3162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg. 2013;74(3):774&#x2013;779. doi: 10.1097/TA.0b013e31827a6e69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg. 2014;77:624&#x2013;629. doi: 10.1097/TA.0000000000000406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45. doi: 10.1001/archsurg.1994.01420250051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, et al. ARDS definition task force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured. Trauma Surg Acute Care Open. 2020;5(1):e000398. doi: 10.1136/tsaco-2019-000398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="pubmed">32154377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the glasgow outcome scale and the extended glasgow outcome scale: guidelines for their use. J Neurotrauma. 1998;15(8):573&#x2013;585. doi: 10.1089/neu.1998.15.573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1998.15.573</ArticleId><ArticleId IdType="pubmed">9726257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton GE, McNutt MK, Cotton BA, Hudson JA, Wade CE, Kao LS. Age-dependent association of occult hypoperfusion and outcomes in trauma. J Am Coll Surg. 2020;230(4):417&#x2013;425. doi: 10.1016/j.jamcollsurg.2019.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2019.12.011</ArticleId><ArticleId IdType="pmc">PMC7719288</ArticleId><ArticleId IdType="pubmed">31954820</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RM. Immunity, trauma and the elderly. Injury. 2007;38(12):1401&#x2013;1404. doi: 10.1016/j.injury.2007.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.013</ArticleId><ArticleId IdType="pubmed">18045600</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochems D, van Wessem KJP, Houwert RM, et al. Outcome in patients with isolated moderate to severe traumatic brain injury. Crit Care Res Pract. 2018;2018:3769418. doi: 10.1155/2018/3769418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3769418</ArticleId><ArticleId IdType="pmc">PMC6174733</ArticleId><ArticleId IdType="pubmed">30345113</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm A, Maegele M, Wendt K, Lefering R, Wyen H, TraumaRegister DGU. Pre-hospital rescue times and interventions in severe trauma in Germany and the Netherlands: a matched-pairs analysis. Eur J Trauma Emerg Surg. 2019;45(6):1059&#x2013;1067. doi: 10.1007/s00068-018-0978-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-018-0978-8</ArticleId><ArticleId IdType="pubmed">30014270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22152134</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Postoperative mortality and morbidity in octogenarians and nonagenarians with hip fracture: an analysis of perioperative risk factors.</ArticleTitle><Pagination><StartPage>323</StartPage><EndPage>328</EndPage><MedlinePgn>323-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the role of high risk factors in octogenarians and nonagenarians with hip trauma, which may lead to excessive mortality and morbi- dity postoperatively.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-four octogenarians and nonagenarians patients were enrolled in the study, receiving surgical repair of hip fracture in our hospital from January 2006 to January 2010. High risk factors were recorded preoperatively in detail. Complications and survival state were followed up by telephone for 2 years postoperatively. All the data were analyzed by Chi-square test with SPSS 13.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-six males (48.1%), aged from 80 to 94 years with a mean age of 84.2 years, and twenty-eight females (51.9%), aged from 80 to 95 years with a mean age of 83.4 years, were presented in the cohort study. The hip traumas were caused by daily slight injuries (52 cases) and car accidents (2 cases), respectively. Twenty-eight patients (51.9%) with femoral neck fracture while 26 patients (48.1%) with intertrochanteric fracture were diagnosed through an anterior-posterior pelvic radiophotograph. In this series, 39 patients (72.2%) suffered from one or more comorbidities preoperatively. The morbidity was 48.1% and the major cause was urinary tract infection, while a significant difference was noted between females and males. The mortality was 20.4% with a predominant cause of acute renal failure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The gender should be considered as a critical high risk factor in octogenarians and nonagenarians with hip trauma postoperatively. Females are more likely to suffer complications postoperatively, which is especially obvious in senile patients over 80 years (P less than 0.05). Urinary tract infection is the most frequent complication after hip surgery, followed by low limb embolism and malnutrition. The mortality is dramatically greater in patients over 80 years old than those below, and major causes are acute renal failure, multiple organ dysfunction syndrome and mental deterioration. Multidisciplinary consultations and mental assessment are encouraged in patients over 80 years old after hip trauma and surgery. Hip fractures in octogenarians and nonagenarians deserve special attention because of their advanced age and comorbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Ren-Shi</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, First Hospital of Jilin University, Changchun 130021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Gui-Shan</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xu</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Hai-Yu</ForeName><Initials>HY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005265" MajorTopicYN="N">Femoral Neck Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22152134</ArticleId><ArticleId IdType="pii">S1008-1275(16)30003-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29178943</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial.</ArticleTitle><Pagination><StartPage>289</StartPage><MedlinePgn>289</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">289</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-017-1878-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sepsis and septic shock occur commonly in severe burns. Acute kidney injury (AKI) is also common and often results as a consequence of sepsis. Mortality is unacceptably high in burn patients who develop AKI requiring renal replacement therapy and is presumed to be even higher when combined with septic shock. We hypothesized that high-volume hemofiltration (HVHF) as a blood purification technique would be beneficial in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of HVHF on the hemodynamic profile of burn patients with septic shock and AKI involving seven burn centers in the United States. Subjects randomized to the HVHF were prescribed a dose of 70&#xa0;ml/kg/hour for 48&#xa0;hours while control subjects were managed in standard fashion in accordance with local practices.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a 4-year period, a total of nine subjects were enrolled for the intervention during the ramp-in phase and 28 subjects were randomized, 14 each into the control and HVHF arms respectively. The study was terminated due to slow enrollment. Ramp-in subjects were included along with those randomized in the final analysis. Our primary endpoint, the vasopressor dependency index, decreased significantly at 48&#xa0;hours compared to baseline in the HVHF group (p&#x2009;=&#x2009;0.007) while it remained no different in the control arm. At 14&#xa0;days, the multiple organ dysfunction syndrome score decreased significantly in the HVHF group when compared to the day of treatment initiation (p&#x2009;=&#x2009;0.02). No changes in inflammatory markers were detected during the 48-hour intervention period. No significant difference in survival was detected. No differences in adverse events were noted between the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HVHF was effective in reversing shock and improving organ function in burn patients with septic shock and AKI, and appears safe. Whether reversal of shock in these patients can improve survival is yet to be determined.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov NCT01213914 . Registered 30 September 2010.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kevin K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Brooke Army Medical Center, Fort Sam Houston, TX, USA. kevin.k.chung.mil@mail.mil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Uniformed Services University of the Health Sciences, Bethesda, MD, USA. kevin.k.chung.mil@mail.mil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Elsa C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>United States Army Institute of Surgical Research, Fort Sam Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>University of South Florida Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlnoski</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>University of South Florida Tampa General Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickerson</LastName><ForeName>William L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>University of Tennessee Firefighters' Regional Burn Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold-Ross</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of Tennessee Firefighters' Regional Burn Center, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosier</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Loyola University Medical Center, Maywood, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halerz</LastName><ForeName>Marcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Loyola University Medical Center, Maywood, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprague</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Doctors Hospital Joseph M. Still Burn Center, Augusta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullins</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Doctors Hospital Joseph M. Still Burn Center, Augusta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Arizona Burn Center Maricopa Integrated Health Systems, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Arizona Burn Center Maricopa Integrated Health Systems, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnoldo</LastName><ForeName>Brett D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burris</LastName><ForeName>Agnes M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Sandra L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>University of California Davis, Sacramento, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Randomized controlled Evaluation of high-volume hemofiltration in adult burn patients with Septic shoCk and acUte kidnEy injury (RESCUE) Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01213914</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>W81XWH-09-2-0194</GrantID><Agency>United States Army Medical Research and Materiel Command</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">Burns</Keyword><Keyword MajorTopicYN="N">High-volume hemofiltration</Keyword><Keyword MajorTopicYN="N">Multicenter</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword></KeywordList><CoiStatement>AUTHORS&#x2019; INFORMATION: Not applicable. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved in a multilevel institutional review process. The core protocol was initially reviewed by the United States Army Medical Research and Materiel Command (USAMRMC) Institutional Review Board (IRB) and reviewed again for final approval by the Army Human Research Protection Office (AHRPO). The core protocol was then submitted to each participating site&#x2019;s local IRB with site-specific addendums and approved again by AHRPO. All amendments to the core protocol required multilevel review with final approval by the AHRPO. A list of IRBs for each specific site is listed in Additional file 1. Informed consent was obtained from all participating subjects through their surrogates. CONSENT FOR PUBLICATION: All authors gave final approval of the final manuscript to be published. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Booker T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pamplin</LastName><ForeName>Jeremy C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Driscoll</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renz</LastName><ForeName>Evan M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lundy</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cancio</LastName><ForeName>Leopoldo C</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruse</LastName><ForeName>Carl W</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>McFarren</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kimberly S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Showkat</LastName><ForeName>Arif</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Lekha</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Aneel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birmingham</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruce</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanford</LastName><ForeName>Arthur P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullins</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassan</LastName><ForeName>Zaheed</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaver</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fosters</LastName><ForeName>Kevin N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peck</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phelan</LastName><ForeName>Herb A</ForeName><Initials>HA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxena</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howard</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhavsar</LastName><ForeName>Dhaval</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponnuru</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSouza</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarlagadda</LastName><ForeName>Sri G</ForeName><Initials>SG</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29178943</ArticleId><ArticleId IdType="pmc">PMC5702112</ArticleId><ArticleId IdType="doi">10.1186/s13054-017-1878-8</ArticleId><ArticleId IdType="pii">10.1186/s13054-017-1878-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzwater J, Purdue GF, Hunt JL, et al. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma. 2003;54(5):959&#x2013;66. doi: 10.1097/01.TA.0000029382.26295.AB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000029382.26295.AB</ArticleId><ArticleId IdType="pubmed">12777910</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Monstrey S, Colpaert K, et al. Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis. Intensive Care Med. 2010;36:915&#x2013;25. doi: 10.1007/s00134-010-1861-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-1861-1</ArticleId><ArticleId IdType="pubmed">20333353</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart IJ, Tilley MA, Cotant CL, et al. Association of AKI with adverse outcomes in burned military casualties. Clin J Am Soc Nephrol. 2012;7(2):199&#x2013;206. doi: 10.2215/CJN.04420511.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04420511</ArticleId><ArticleId IdType="pubmed">22156751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41:3&#x2013;11. doi: 10.1097/SHK.0000000000000052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000052</ArticleId><ArticleId IdType="pmc">PMC3918942</ArticleId><ArticleId IdType="pubmed">24346647</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813&#x2013;8. doi: 10.1001/jama.294.7.813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.7.813</ArticleId><ArticleId IdType="pubmed">16106006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung KK, Lundy JB, Matson JR, et al. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. Crit Care. 2009;13:R62. doi: 10.1186/cc7801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7801</ArticleId><ArticleId IdType="pmc">PMC2717417</ArticleId><ArticleId IdType="pubmed">19409089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26&#x2013;30. doi: 10.1016/S0140-6736(00)02430-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)02430-2</ArticleId><ArticleId IdType="pubmed">10892761</ArticleId></ArticleIdList></Reference><Reference><Citation>Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28(11):3581&#x2013;7. doi: 10.1097/00003246-200011000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200011000-00001</ArticleId><ArticleId IdType="pubmed">11098957</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccinni P, Dan M, Barbacini S, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006;32(1):80&#x2013;6. doi: 10.1007/s00134-005-2815-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-005-2815-x</ArticleId><ArticleId IdType="pubmed">16328222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratanarat R, Brendolan A, Ricci Z, et al. Pulse high-volume hemofiltration in critically ill patients: a new approach for patients with septic shock. Semin Dial. 2006;19(1):69&#x2013;74. doi: 10.1111/j.1525-139X.2006.00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-139X.2006.00121</ArticleId><ArticleId IdType="pubmed">16423184</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420(6917):885&#x2013;91. doi: 10.1038/nature01326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01326</ArticleId><ArticleId IdType="pubmed">12490963</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo LCP, Park M, Schettino GPP. Novel potential therapies for septic shock. Shock. 2008;30(Suppl 1):60&#x2013;6. doi: 10.1097/SHK.0b013e318181a425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318181a425</ArticleId><ArticleId IdType="pubmed">18704007</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden K, Stewart IJ, Kreyer SF, et al. Extracorporeal blood purification in burns: a review. Burns. 2014;40(6):1071&#x2013;8. doi: 10.1016/j.burns.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.01.013</ArticleId><ArticleId IdType="pubmed">24548734</ArticleId></ArticleIdList></Reference><Reference><Citation>Borthwick EM, Hill CJ, Rabindranath KS, et al. High-volume haemofiltration for sepsis in adults. Cochrane Database Syst Rev. 2017;1:1&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464723</ArticleId><ArticleId IdType="pubmed">28141912</ArticleId></ArticleIdList></Reference><Reference><Citation>Joannes-Boyau O, Honore PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicenter randomized controlled trial. Intensive Care Med. 2013;39:1535&#x2013;46. doi: 10.1007/s00134-013-2967-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-013-2967-z</ArticleId><ArticleId IdType="pubmed">23740278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248:387&#x2013;401. doi: 10.1097/SLA.0b013e318176c4b3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e318176c4b3</ArticleId><ArticleId IdType="pmc">PMC3905467</ArticleId><ArticleId IdType="pubmed">18791359</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587220</ArticleId><ArticleId IdType="pubmed">23401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28(6):776&#x2013;90. doi: 10.1097/BCR.0b013e3181599bc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Palevsky PM, Zhang JH, O&#x2019;Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7&#x2013;20. doi: 10.1056/NEJMoa0802639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802639</ArticleId><ArticleId IdType="pmc">PMC2574780</ArticleId><ArticleId IdType="pubmed">18492867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz DN, Antonelli M, Fumagalli R, et al. Early use of Polymyxin B Hemoperfusion in Abdominal Septic Shock: the EUPHAS Randomized Controlled Trial. JAMA. 2009;301:2445&#x2013;52. doi: 10.1001/jama.2009.856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.856</ArticleId><ArticleId IdType="pubmed">19531784</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;52. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 2008;34(9):1646&#x2013;53. doi: 10.1007/s00134-008-1127-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1127-3</ArticleId><ArticleId IdType="pubmed">18542921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Lipcsey M, Calzavacca P, et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Med. 2013;39:429&#x2013;36. doi: 10.1007/s00134-012-2800-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2800-0</ArticleId><ArticleId IdType="pubmed">23306586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowan MP, Cancio LC, Elster EA, et al. Burn wound healing and treatment: review and advancements. Crit Care. 2015;19:243. doi: 10.1186/s13054-015-0961-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0961-2</ArticleId><ArticleId IdType="pmc">PMC4464872</ArticleId><ArticleId IdType="pubmed">26067660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitzschke SL, Aden JK, Serio-Melvin ML, et al. Wound healing trajectories in burn patients and their impact on mortality. J Burn Care Res. 2014;35:474&#x2013;9. doi: 10.1097/BCR.0000000000000039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000039</ArticleId><ArticleId IdType="pubmed">25144807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan RJ, Peck MD, Ahrenholz DH, et al. Surgical management of the burn wound and the use of skin substitutes: an expert panel white paper. J Burn Care Res. 2014;34:e60&#x2013;79. doi: 10.1097/BCR.0b013e31827039a6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e31827039a6</ArticleId><ArticleId IdType="pubmed">23446645</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamme K, Maddison L, Kruusat R, et al. Effects of high volume haemodiafiltration on inflammatory response profile and microcirculation in patients with septic shock. Biomed Res Int. 2015;2015:125615. doi: 10.1155/2015/125615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/125615</ArticleId><ArticleId IdType="pmc">PMC4429196</ArticleId><ArticleId IdType="pubmed">26064875</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Eng J Med. 2017;377:419&#x2013;30. doi: 10.1056/NEJMoa1704154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1704154</ArticleId><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz C, Hernandez G, Godoy C, et al. Sublingual microcirculatory changes during high-volume hemofiltration in hyperdynamic septic shock patients. Crit Care. 2010;14:R170. doi: 10.1186/cc9271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9271</ArticleId><ArticleId IdType="pmc">PMC3219271</ArticleId><ArticleId IdType="pubmed">20875109</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark E, Molnar A, Joannes-Boyau O, et al. High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis. Crit Care 2014;18:R7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057068</ArticleId><ArticleId IdType="pubmed">24398168</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268&#x2013;82. doi: 10.1097/CCM.0b013e3181aab3d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181aab3d0</ArticleId><ArticleId IdType="pubmed">19487930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgram I, Roberts JA, Wallis SC, et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2010;54:2974&#x2013;8. doi: 10.1128/AAC.01582-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01582-09</ArticleId><ArticleId IdType="pmc">PMC2897321</ArticleId><ArticleId IdType="pubmed">20479205</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers KS, Rowan MP, Niece KL, et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;59:46&#x2013;52. doi: 10.1128/AAC.03783-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.03783-14</ArticleId><ArticleId IdType="pmc">PMC4291386</ArticleId><ArticleId IdType="pubmed">25313211</ArticleId></ArticleIdList></Reference><Reference><Citation>Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2011;55:4639&#x2013;42. doi: 10.1128/AAC.00374-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00374-11</ArticleId><ArticleId IdType="pmc">PMC3186982</ArticleId><ArticleId IdType="pubmed">21825289</ArticleId></ArticleIdList></Reference><Reference><Citation>Terayama T, Yamakawa K, Umemura Y, et al. Polymyxin B hemoperfusion for sepsis and septic shock: a systematic review and meta-analysis. Surg Infect. 2017;18:225&#x2013;33. doi: 10.1089/sur.2016.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2016.168</ArticleId><ArticleId IdType="pubmed">28092497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18:699. doi: 10.1186/s13054-014-0699-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-014-0699-2</ArticleId><ArticleId IdType="pmc">PMC4318234</ArticleId><ArticleId IdType="pubmed">25527094</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesecke S, Stecher SS, Gross S, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. June 6 2017. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">28589286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010;38:S534&#x2013;8. doi: 10.1097/CCM.0b013e3181f208ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181f208ac</ArticleId><ArticleId IdType="pubmed">21164394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter. 2012;2:1&#x2013;138. doi: 10.1038/kisup.2012.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum JA, Gomez H, Gomez A, et al. Acute dialysis quality initiative (ADQI) XIV sepsis phenotypes and targets for blood purification in sepsis: the Bogota consensus. Shock. 2015;45:242&#x2013;8. doi: 10.1097/SHK.0000000000000485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000485</ArticleId><ArticleId IdType="pubmed">26871663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35638038</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Biliary complications after adult to adult right-lobe living donor liver transplantation (A-ARLLDLT): Analysis of 245 cases during 16 years period at a single high centre- A retrospective cohort study.</ArticleTitle><Pagination><StartPage>103577</StartPage><MedlinePgn>103577</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2022.103577</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Biliary complications (BCs) after adult to adult living donor liver transplantation (A-ALDLT) result in poor graft and patient survival. This study aimed to analyze these complications.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We retrospectively analyzed BCs in 245 recipients who underwent A-ALDLT using the right-lobe graft during 16 years period in our centre. The overall male/female ratio was 215/30.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">One hundred fifty-five BCs affected 102 of our recipients (95 early (&#x2264;3months) and 60 late (&#x2265;3months)). They were classified as 67/245(27.3%) early bile leak, 10/245(4.1%) early biliary stricture, 44/245(17.9%) late biliary stricture, 4/245(1.6%) early cholangitis, 10/245(4.1%) late cholangitis, 14/245(5.7%) early biloma, and 6/245(2.4%) late cholangitic abscesses. Multiple biliary anastomoses were independently correlated with Post liver transplantation (LT) overall BCs; moreover, post LT hepatic artery thrombosis or stenosis (HAT/S) was an independent predictor of overall BCs, strictures and leaks. The mortality affected 96(39.2%) cases mostly due to sepsis, bleeding and multi-organ failure (MOF). On the other hand, the biliary related mortality was 10.6% of cases. Multiple cholangitic hepatic abscesses were significant predictors of poor graft and patient outcomes. Conclusions: Multiple biliary anastomoses and post LT HAT/S lead to a poor biliary outcome, furthermore, cholangitis, cholangitic abscesses and sepsis lead to poor graft and patient outcomes, so proper management of those variables is mandatory to improve outcomes after A-ARLLDLT.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gad</LastName><ForeName>Emad Hamdy</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoup</LastName><ForeName>Eslam</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Amr M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhelbawy</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd-Elsamee</LastName><ForeName>Mohammed Al-Sayed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Radiology, National Liver Institute, Menoufiya University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallam</LastName><ForeName>Ahmed Nabil</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Hepatobiliary Surgery, National Liver Institute, Menoufia University, Shebeen Elkoum, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biliary complications</Keyword><Keyword MajorTopicYN="N">Liver transplantation</Keyword><Keyword MajorTopicYN="N">Morbidity</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>No conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35638038</ArticleId><ArticleId IdType="pmc">PMC9142388</ArticleId><ArticleId IdType="doi">10.1016/j.amsu.2022.103577</ArticleId><ArticleId IdType="pii">S2049-0801(22)00337-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atwal T., Pastrana M., Sandhu B. Post-liver transplant biliary complications. J. Clin. Exp. Hepatol. 2012;2:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3940277</ArticleId><ArticleId IdType="pubmed">25755409</ArticleId></ArticleIdList></Reference><Reference><Citation>Server S., Sabet S., Sahin T., Guven K., Ayd&#x131;n U., Tokat Y., et al. Novel application of internal-external drainage catheter as biliary stent for percutaneous transhepatic treatment of biliary strictures in living donor liver transplantation recipient patients. Transplant. Proc. 2019;51:2469&#x2013;2472.</Citation><ArticleIdList><ArticleId IdType="pubmed">31405740</ArticleId></ArticleIdList></Reference><Reference><Citation>Todo S., Furukawa H., Kamiyama T. How to prevent and manage biliary complications in living donor liver transplantation? J. Hepatol. 2005;43:22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15921817</ArticleId></ArticleIdList></Reference><Reference><Citation>Polese L., Cillo U., Brolese A., Boccagni P., Neri D., Bassi D., et al. Endoscopic treatment of bile duct complications after orthotopic liver transplantation. Transplant. Proc. 2007;39:1942&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pubmed">17692660</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidi R.F., Elias N., Ko D.S., Kawai T., Markmann J., Cosimi A.B., et al. Biliary reconstruction and complications after living-donor liver transplantation. HPB. 2009;11:505&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756638</ArticleId><ArticleId IdType="pubmed">19816615</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C.S., Jung B.H., Hwang S., Park Y.H., Kang S.H., Park G.C., et al. External biliary drainage in living donor liver transplantation using duct-to-duct anastomosis. Transplant. Proc. 2014;46:678&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">24767322</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegadeesan M., Goyal N., Rastogi H., Gupta S. Percutaneous transhepatic biliary drainage for biliary stricture after endotherapy failure in living donor liver transplantation: a Single-centre experience from India. J. Clin. Exp. Hepatol. 2019;9:684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6926189</ArticleId><ArticleId IdType="pubmed">31889748</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikan T., Emek E., Bozkurt B., Mammadov E., Ceyhan O., Sahin T., et al. Does multiple bile duct anastomosis in living donor liver transplantation affect the postoperative biliary complications? Transplant. Proc. 2019;51:2473&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pubmed">31405743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung D.H., Ikegami T., Balci D., Bhangui P. Biliary reconstruction and complications in living donor liver transplantation. Int. J. Surg. 2020;82S:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387205</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes M.P., Fern&#xe1;ndez Aguilar J.L., de Cabo S.N., Le&#xf3;n D&#xed;az F.J., Rodr&#xed;guez M.P., P&#xe9;rez B.S., et al. Influence of bile duct diameter on biliary complications after liver transplantation. Transplant. Proc. 2020;52:569&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.D., Jwa E.K., Choi D.L. Novel method for reconstructing multiple graft bile ducts during right lobe living donor liver transplant: dunking with mucosal eversion technique. Transplant. Proc. 2020;52:1807&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">32448651</ArticleId></ArticleIdList></Reference><Reference><Citation>Koksal A.S., Eminler A.T., Parlak E., Gurakar A. Management of biliary anastomotic strictures after liver transplantation. Transplant. Rev. 2017;31:207&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427741</ArticleId></ArticleIdList></Reference><Reference><Citation>Na B.G., Park G.C., Hwang S., Kim K.H., Ahn C.S., Moon D.B., et al. Biliary complications after single-and dual-graft living-donor liver transplantation using a right posterior section graft of donor with a type III portal vein variation. Transplant. Proc. 2020;52:1838&#x2013;1843.</Citation><ArticleIdList><ArticleId IdType="pubmed">32444130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew G., Agha R., for the STROCSS Group STROCSS 2021: strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery. Int. J. Surg. 2021;96</Citation><ArticleIdList><ArticleId IdType="pubmed">34774726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gad E.H., Alsebaey A., Lotfy M., Eltabbakh M., Sherif A.A. Complications and mortality after adult to adult living donor liver transplantation: a retrospective cohort study. Ann. Med. Surg. 2015;4(2):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434206</ArticleId><ArticleId IdType="pubmed">26005570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gad E.H., Abdelsamee M.A., Kamel Y. Hepatic arterial and portal venous complications after adult and pediatric living donor liver transplantation, risk factors, management and outcome (A retrospective cohort study) Ann Med Surg (Lond) 2016;8:28&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878848</ArticleId><ArticleId IdType="pubmed">27257483</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoreem H., Gad E.H., Soliman H., Hegazy O., Saleh S., Zakaria H., et al. Small for size syndrome difficult dilemma: lessons from 10 years single centre experience in living donor liver transplantation. World J. Hepatol. 2017;9(21):930&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5545138</ArticleId><ArticleId IdType="pubmed">28824744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.W., Bae B.K., Lee J.M., Won J.H., Park Y.K., Xu W.G., et al. duct-to-duct biliary reconstructions and complications in 100 living donor liver transplantations. Transplant. Proc. 2009;41:1749&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pubmed">19545721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiso S., Kamei H., Onishi Y., Kurata N., Jobara K., Kawashima H., et al. Decreased long-term graft survival in persistent biliary complications after right-lobe living-donor liver transplantation. Clin. Transplant. 2020;34</Citation><ArticleIdList><ArticleId IdType="pubmed">31846118</ArticleId></ArticleIdList></Reference><Reference><Citation>Larghi A., Tringali A., Rimbas M., Barbaro F., Perri V., Rizzatti G., et al. Endoscopic management of benign biliary strictures after liver transplantation. Liver Transplant. 2019;25:323&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">30329213</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaldo E.T., Austin M.T., Pinson C.W., Chari R.S. Management of the bile duct anastomosis and its complications after liver transplantation. Transplant. Rev. 2007;21:26&#x2013;33.</Citation></Reference><Reference><Citation>Sendino O., Fern&#xe1;ndez-Simon A., Law R., Abu Dayyeh B., Leise M., Chavez-Rivera K., et al. Endoscopic management of bile leaks after liver transplantation: an analysis of two high-volume transplant centers. U. Eur. Gatroenterol. J. 2018;6(1):89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802677</ArticleId><ArticleId IdType="pubmed">29435318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S., Liu N.J., Lee C.F., Chou H.S., Wu T.J., Pan K.T., et al. Endoscopic management of biliary complications after adult right-lobe living donor liver transplantation without initial biliary decompression. Transplant. Proc. 2008;40:2542&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">18929795</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.S., Kim M.-H., Lee S.K., Seo D.W., Lee S.S., Han J., et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest. Endosc. 2003;57:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12518136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawansa N., McCall J.L., Holden A., Plank L., Munn S.R. Biliary complications following orthotopic liver transplantation: a 10-year audit. HPB. 2011;13:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103095</ArticleId><ArticleId IdType="pubmed">21609371</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaprak O., Dayangac M., Akyildiz M., Demirbas T., Guler N., Bulutcu F., et al. Biliary complications after right lobe living donor liver transplantation: a single-centre experience. HPB. 2012;14:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252991</ArticleId><ArticleId IdType="pubmed">22151451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez A.R., Morris M.C., Brown N.G., Winer L.K., Safdar K., Poreddy S., et al. Is surgery necessary? Endoscopic management of post-transplant biliary complications in the modern era. J. Gastrointest. Surg. 2020;24:1639&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">31228080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisatsune H., Yazumi S., Egawa H., Asada M., Hasegawa K., Kodama Y., et al. Endoscopic management of biliary strictures after duct-to-duct biliary reconstruction in right-lobe living-donor liver transplantation. Transplantation. 2003;76:810&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao H.B., Koshy A.K., Sudhindran S., Prabhu N.K., Venu R.P. Paradigm shift in the management of bile duct strictures complicating living donor liver transplantation. Indian J. Gastroenterol. 2019;38(6):488&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">32065353</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi M., Kumagi T., Kuroda T., Imamura Y., Kanemitsu K., Ogawa K., et al. Endoscopic stent placement above the sphincter of Oddi for biliary strictures after living donor liver transplantation. BMC Gastroenterol. 2020;20:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137274</ArticleId><ArticleId IdType="pubmed">32252630</ArticleId></ArticleIdList></Reference><Reference><Citation>You M.S., Paik W.H., Choi Y.H., Shin B.-S., Lee S.H., Ryu J.K., et al. Optimal biliary drainage for patients with biliary anastomotic strictures after right lobe living donor liver transplantation. Liver Transplant. 2019;25:1209&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">30980451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Kogure H., Nakai Y., Hamada T., Takahara N., Mizuno S., et al. Long&#x2010;term outcomes of endoscopic treatment for duct&#x2010;to&#x2010;duct anastomotic strictures after living donor liver transplantation. Liver Int. 2019;39:1954&#x2013;1963.</Citation><ArticleIdList><ArticleId IdType="pubmed">31436017</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.K., Yang J.-I., Lee J.K., Park J.K., Lee K.H., Lee K.T., et al. Long-term outcome of endoscopic retrograde biliary drainage of biliary stricture following living donor liver transplantation. Gut Liver. 2020;14:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974332</ArticleId><ArticleId IdType="pubmed">30970446</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S.I., Chung T.R., Cho J.H., Lee K.H., Joo S.M., Choi J.H., et al. Short fully covered self-expandable metal stent for treatment of proximal anastomotic benign biliary stricture after living-donor liver transplantation. Dig. Endosc. 2021;33(5):840&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">33043522</ArticleId></ArticleIdList></Reference><Reference><Citation>Moy B.T., Birk J.W. A Review on the management of biliary complications after orthotopic liver transplantation. J. Clin. Transl. Hepatol. 2019;7(1):61&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441650</ArticleId><ArticleId IdType="pubmed">30944822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.S., Chen C.L., Concejero A.M., Yap A.Q., Lin Y.H., Liu C.Y., et al. Early and long-term results of routine microsurgical biliary reconstruction in living donor liver transplantation. Liver Transplant. 2013;19:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.H., Ko G.Y., Sung K.B., Yoon H.K., Gwon D.I., Kim K.R., et al. Bile leak following living donor liver transplantation: clinical efficacy of percutaneous transhepatic treatment. Liver Transplant. 2008;14:1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18668647</ArticleId></ArticleIdList></Reference><Reference><Citation>Icoz G., Kilic M., Zeytunlu M., Celebi A., Ersoz G., Killi R., et al. Biliary reconstructions and complications encountered in 50 consecutive right-lobe living donor liver transplantations. Liver Transplant. 2003;9(6):575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Wadhawan M., Taneja S., Shandil R. Biliary complications after liver transplantation. Apollo Med. 2012;9(1):32&#x2013;37.</Citation></Reference><Reference><Citation>Wang S.H., Lin P.Y., Wang J.Y., Lin H.C., Hsieh C.E., Chen Y.L. Predictors of biliary leakage after T-Tube removal in living donor liver transplantation recipients. Transplant. Proc. 2015;47:2488&#x2013;2492.</Citation><ArticleIdList><ArticleId IdType="pubmed">26518957</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerwonko M.E., Huespe P., Elizondo C.M., Pekolj J., Gadano A., Barc&#xe1;n L., et al. Risk factors and outcomes of pyogenic liver abscess in adult liver recipients: a matched case-control study. HPB. 2018;20:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496466</ArticleId></ArticleIdList></Reference><Reference><Citation>Justo I., Jime&#x144;ez-Romero C., Manrique A., Caso O., Calvo J., Cambra F., et al. Management and outcome of liver abscesses after liver transplantation. World J. Surg. 2018;42:3341&#x2013;3349.</Citation><ArticleIdList><ArticleId IdType="pubmed">29633100</ArticleId></ArticleIdList></Reference><Reference><Citation>Girometti R., Pancot M., Como G., Zuiani C. Imaging of liver transplantation. Eur. J. Radiol. 2017;93:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">28545872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachopoulou O.A., Vogt D.P., Henderson J.M., Baker M., Keys T.F. Hepatic abscess after liver transplantation: 1990&#x2013;2000. Transplantation. 2003;75:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikeghbalian S., Salahi R., Salahi H., Bahador A., Kakaie F., Kazemi K., et al. Hepatic abscesses after liver transplant: 1997&#x2013;2008. Exp. Clin. Transplant. 2009;4:256&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20353378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharzehi K. Biliary strictures in the liver transplant patient. Tech. Gastrointest. Endosc. 2016;18:91&#x2013;97.</Citation></Reference><Reference><Citation>Hashimoto K., Miller C.M., Quintini C., Aucejo F.N., Hirose K., Uso T.D., et al. Is impaired hepatic arterial buffer response a risk factor for biliary anastomotic stricture in liver transplant recipients? Surgery. 2010;148:582&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">20227098</ArticleId></ArticleIdList></Reference><Reference><Citation>Na G.H., Kim D.G., Choi H.J., Han J.H., Hong T.H., You Y.K. Interventional treatment of biliary stricture after adult right-lobe living-donor liver transplantation with duct-to-duct anastomosis. HPB. 2014;16:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967882</ArticleId><ArticleId IdType="pubmed">23981034</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S.W., Kim D.S., Yu Y.D., Suh S.O. Clinical outcome of internal stent for biliary anastomosis in liver transplantation. Transplant. Proc. 2014;46:856&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">24767365</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;z&#xe7;elik &#xdc;., Eren E., Toka&#xe7; M., &#x15e;ahin T., Parlak H., Din&#xe7;kan A. Results of using the cystic duct for reconstruction of one of the multiple bile ducts in right lobe living donor liver transplantation. Transplant. Proc. 2021;53:1962&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">34233848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawachi S., Shimazu M., Wakabayashi G., Hoshino K., Tanabe M., Yoshida M., et al. Biliary complications in adult living donor liver transplantation with duct-to-duct hepaticocholedochostomy or Roux-en- Y hepaticojejunostomy biliary reconstruction. Surgery. 2002;132(1):48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T., Sato Y., Yamamoto S., Oya H., Hara Y., Watanabe T., et al. Long-term follow-up study of biliary reconstructions and complications after adult living donor liver transplantation: feasibility of duct-to-duct reconstruction with a t-tube stent. Transplant. Proc. 2009;41:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">19249531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciato G., Varotti G., Quintini C., Masetti M., Di Benedetto F., Grazi G.L., et al. Impact of biliary complications in right lobe living donor liver transplantation. Transpl. Int. 2006;19(2):122&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">16441361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S.Y., Hu X.G., Lee H.Y., Won J.H., Kim J.W., Shen X.Y., et al. Long-term analysis of biliary complications after duct-to-duct biliary reconstruction in living donor liver transplantations. Liver Transplant. 2018;24:1050&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">29633539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hann A., Seth R., Mergental H., Hartog H., Alzoubi M., Stangou A., et al. Biliary strictures are associated with both early and late hepatic artery stenosis. Transplant. Direct. 2020;7(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738047</ArticleId><ArticleId IdType="pubmed">33335982</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nning J., Berglund E., Arnelo U., Ericzon B.G., Nowak G. Long-term outcome of endoscopic and percutaneous transhepatic approaches for biliary complications in liver transplant recipients. Transplant. Direct. 2019;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411220</ArticleId><ArticleId IdType="pubmed">30882037</ArticleId></ArticleIdList></Reference><Reference><Citation>Matar A.J., Driscoll K.R., Kenney L., Wichmann H.K., Magliocca J.F., Kitchens W.H. Biliary complications following adult deceased donor liver transplantation: risk factors and implications at a high-volume US center. Transplant. Direct. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425824</ArticleId><ArticleId IdType="pubmed">34514109</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro F., Tringali A., Larghi A., Baldan A., Onder G., Familiari P., et al. Endoscopic management of non-anastomotic biliary strictures following liver transplantation: long-term results from a single-centre experience. Dig. Endosc. 2021;33(5):849&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">33080081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32758298</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>699</StartPage><MedlinePgn>699</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">699</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-020-04632-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">&#x2022; Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19. &#x2022; Secondary objectives: &#x25e6; To evaluate the effect of IVM on ICU length of stay. &#x25e6; To evaluate the effect of IVM on the length of mechanical ventilation (MV). &#x25e6; To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days. &#x25e6; To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale. &#x25e6; To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena. &#x25e6; To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6. &#x25e6; To evaluate if the use of IVM is associated with an improvement in hematologic parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in biochemical parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in blood gas analysis parameters. &#x25e6; To evaluate adverse events during the 28 day study period.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">Phase II, single center, double-blind, placebo-controlled randomized trial with a two-arm parallel group design and 2:1 allocation ratio.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Only critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included. The study will be conducted in a mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year. &#x2022; Inclusion criteria: &#x25e6; Patient, family member or legal guardian has provided written Informed Consent. &#x25e6; Age &#x3b5; 18 years. &#x25e6; Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR. &#x25e6; Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection. &#x25e6; ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission). &#x2022; Exclusion criteria: &#x25e6; Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization. &#x25e6; Liver enzymes &gt; 5 times the upper normal range. &#x25e6; Chronic kidney disease with GFR &lt; 30 mL/min/1.73 m<sup>2</sup> (stage 4 or greater) or need for hemodialysis. &#x25e6; Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion. &#x25e6; Terminal surgical or medical illness. &#x25e6; Autoimmune disease. &#x25e6; Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">All patients will receive standard-of-care treatment according to the current institutional protocols. In addition, patients will be randomized in a 2:1 ratio to receive: &#x2022; Experimental group (12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day. &#x2022; Control group (6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours. After 3 days of treatment, 3 intensive care physicians will evaluate the participant and decide whether or not to complete the treatment based on their clinical assessment: &#x2022; If objective or subjective signs of improvement or no worsening of the general clinical condition, respiratory failure, inflammatory state or multi-organ failure are observed, the participant will continue the treatment until completion. &#x2022; If an adverse effect or clinical impairment is observed that is objectively or subjectively attributable to the study drug the treatment will be stopped.</AbstractText><AbstractText Label="MAIN OUTCOME" NlmCategory="RESULTS">Mortality in each study group represented in frequency and time-to-event at day 28 after randomization RANDOMIZATION: The randomization sequence was created using SAS version 9.4 statistical software (programmed and validated macros) with a 2:1 allocation. No randomization seed was pre-specified. The randomization seed was generated using the time on the computer where the program was executed.</AbstractText><AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">Participants, caregivers and study groups will be blinded to arm allocation.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMIZED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Protocol version 2.0, June 5<sup>th</sup> 2020. Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rubio</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueira</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acu&#xf1;a-Castroviejo</LastName><ForeName>Dar&#xed;o</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratories, San Cecilio University Hospital, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borobia</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Department, Clinical Trial Unit, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escames</LastName><ForeName>Germaine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Oliva</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2444-0556</Identifier><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="Y">Melatonin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">protocol</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>GE and DA-C are Scientific Advisors of Pharmamel LTD, the Sponsor of the clinical trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32758298</ArticleId><ArticleId IdType="pmc">PMC7403786</ArticleId><ArticleId IdType="doi">10.1186/s13063-020-04632-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-020-04632-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38777667</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>The impact and validity of the Berlin criteria on burn-induced ARDS: Examining mortality rates, and inhalation injury influences. A single center observational cohort study.</ArticleTitle><Pagination><StartPage>1528</StartPage><EndPage>1535</EndPage><MedlinePgn>1528-1535</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2024.05.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0305-4179(24)00149-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">As several recent studies have shown low mortality rates in burn injury induced ARDS early (&#x2264;7 days) after the burn, the Berlin criteria for the ARDS diagnosis in this setting may be disputed. Related to this issue, the present study investigated the incidence, trajectory and risk factors of early Acute Respiratory Distress Syndrome (ARDS) and outcome in burn patients, as per the Berlin criteria, along with the concurrent prevalence and influence of inhalation injury, and ventilator-acquired pneumonia (VAP).</AbstractText><AbstractText Label="METHODS">Over a 2.5-year period, burn patients with Total Burn Surface Area (TBSA) exceeding 10% admitted to a national burn center were included. The subgroup of interest comprised patients with more than 48&#xa0;h of ventilatory support. This group was assessed for ARDS, inhalation injury, and VAP.</AbstractText><AbstractText Label="RESULTS">Out of 292 admissions, 62 sustained burns &gt;&#xa0;10% TBSA. Of these, 28 (45%) underwent ventilatory support for over 48&#xa0;h, almost all, 24 out of 28, meeting the criteria for ARDS early, within 7 days post-injury and with a P<sub>a</sub>O<sub>2</sub>/F<sub>i</sub>O<sub>2</sub> (PF) rat<sub>i</sub>o nadir at day 5. The mortality rate for this early ARDS group was under 10%, regardless of PF ratios (mean TBSA% 34,8%). Patients with concurrent inhalation injury and early ARDS showed significantly lower PF ratios (p&#xa0;&lt;&#xa0;0.001), and higher SOFA scores (p&#xa0;=&#xa0;0.004) but without impact on mortality. Organ failure, indicated by SOFA scores, peaked early (day 3) and declined in the first week, mirroring PF ratio trends (p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The low mortality associated with early ARDS in burn patients in this study challenges the Berlin criteria's for the early ARDS diagnosis, which for its validity relies on that higher mortality is linked to worsening PF ratios. The finding suggests alternative mechanisms, leading to the early ARDS diagnosis, such as the significant impact of inhalation injury on early PF ratios and organ failure, as seen in this study. The concurrence of early organ failure with declining PF ratios, supports, as expected, the hypothesis of trauma-induced inflammation/multi-organ failure mechanisms contributing to early ARDS. The study highlights the complexity in differentiating between the contributions of inhalation injury to early ARDS and the related organ dysfunction early in the burn care trajectory. The Berlin criteria for the ARDS diagnosis may not be fully applicable in the burn care setting, where the low mortality significantly deviates from that described in the original Berlin ARDS criteria publication but is as expected when considering the actual not very extensive burn injury sizes/Baux scores as in the present study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sjoberg</LastName><ForeName>Folke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden. Electronic address: folke.sjoberg@liu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmasry</LastName><ForeName>Moustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelrahman</LastName><ForeName>Islam</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Gusten</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiology both at Link&#xf6;ping University Hospital and Link&#xf6;ping, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T-Elserafi</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology both at Link&#xf6;ping University Hospital and Link&#xf6;ping, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursing</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinvall</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, Plastic Surgery, and Burns and Link&#xf6;ping, 58185 Link&#xf6;ping, Sweden; Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, 58185 Link&#xf6;ping,&#xa0;Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015208" MajorTopicYN="Y">Smoke Inhalation Injury</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053717" MajorTopicYN="Y">Pneumonia, Ventilator-Associated</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001830" MajorTopicYN="N">Body Surface Area</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002059" MajorTopicYN="N">Burns, Inhalation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">Burns</Keyword><Keyword MajorTopicYN="N">Inhalation injury</Keyword><Keyword MajorTopicYN="N">Mortality ventilatory acquired pneumonia</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest On behalf of all co-authors, I hereby affirm no conflicts of interest associated with this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>22</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38777667</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2024.05.005</ArticleId><ArticleId IdType="pii">S0305-4179(24)00149-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28719602</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e1002338</StartPage><MedlinePgn>e1002338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002338</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Almost all studies that have investigated the immune response to trauma have analysed blood samples acquired post-hospital admission. Thus, we know little of the immune status of patients in the immediate postinjury phase and how this might influence patient outcomes. The objective of this study was therefore to comprehensively assess the ultra-early, within 1-hour, immune response to trauma and perform an exploratory analysis of its relationship with the development of multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">The immune and inflammatory response to trauma was analysed in 89 adult trauma patients (mean age 41 years, range 18-90 years, 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were acquired within 1 hour of injury (mean time to sample 42 minutes, range 17-60 minutes). Within minutes of trauma, a comprehensive leukocytosis, elevated serum pro- and anti-inflammatory cytokines, and evidence of innate cell activation that included neutrophil extracellular trap generation and elevated surface expression of toll-like receptor 2 and CD11b on monocytes and neutrophils, respectively, were observed. Features consistent with immune compromise were also detected, notably elevated numbers of immune suppressive CD16BRIGHT CD62LDIM neutrophils (82.07 x 106/l &#xb1; 18.94 control versus 1,092 x 106/l &#xb1; 165 trauma, p &lt; 0.0005) and CD14+HLA-DRlow/- monocytes (34.96 x 106/l &#xb1; 4.48 control versus 95.72 x 106/l &#xb1; 8.0 trauma, p &lt; 0.05) and reduced leukocyte cytokine secretion in response to lipopolysaccharide stimulation. Exploratory analysis via binary logistic regression found a potential association between absolute natural killer T (NKT) cell numbers and the subsequent development of MODS. Study limitations include the relatively small sample size and the absence of data relating to adaptive immune cell function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study highlighted the dynamic and complex nature of the immune response to trauma, with immune alterations consistent with both activation and suppression evident within 1 hour of injury. The relationship of these changes, especially in NKT cell numbers, to patient outcomes such as MODS warrants further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>David N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0003-2243-2325</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toman</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><Identifier Source="ORCID">0000-0003-1789-5886</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Zhangjie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinsdale</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crombie</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Midlands Air Ambulance, Unit 16 Enterprise Trading Estate, Brierley Hill, West Midlands, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duggal</LastName><ForeName>Niharika Arora</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4610-8909</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3211-9933</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28719602</ArticleId><ArticleId IdType="pmc">PMC5515405</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002338</ArticleId><ArticleId IdType="pii">PMEDICINE-D-17-00334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giannoudis PV. Current concepts of the inflammatory response after major trauma: an update. Injury. 2003; 34:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeldine J, Hampson P, Lord JM. The diagnostic and prognostic value of systems biology research in major traumatic and thermal injury: a review. Burns and Trauma. 2016. 
doi: 10.1186/s41038-016-0059-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-016-0059-3</ArticleId><ArticleId IdType="pmc">PMC5030723</ArticleId><ArticleId IdType="pubmed">27672669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JR, Hazeldine J, et al.
Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study. Ann.Surg. 2016. 
doi: 10.1097/SLA.0000000000001807
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS ONE. 2013. 
8: e68963
doi: 10.1371/journal.pone.0068963
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068963</ArticleId><ArticleId IdType="pmc">PMC3722225</ArticleId><ArticleId IdType="pubmed">23894384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Itagaki K, Sandler N, Gallo D, Galenkamp A, Kaczmarek E, et al.
Mitochondrial damage-associated molecular patterns from fractures suppress pulmonary immune responses via formyl peptide receptors 1 and 2. J.Trauma Acute.Care Surg. 2015;78: 272&#x2013;279. doi: 10.1097/TA.0000000000000509
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000509</ArticleId><ArticleId IdType="pmc">PMC4357317</ArticleId><ArticleId IdType="pubmed">25757111</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks W, Dropiewska G, Bryl E, Dudek R, Wieruszewski J, Stasiak M, et al. Immunomonitoring in patients with early moderate and severe head trauma. Cent. Eur. J. Public Health. 2013;38: 494&#x2013;499.</Citation></Reference><Reference><Citation>Perez-Barcena J, Regueiro V, Crespi C, Pierola J, Oliver A, Llompart-Pou JA, et al.
Expression of toll-like receptors 2 and 4 is upregulated during hospital admission in traumatic patients: lack of correlation with blunted innate immune responses. Ann.Surg. 2010;251: 521&#x2013;527. doi: 10.1097/SLA.0b013e3181cc8f84
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181cc8f84</ArticleId><ArticleId IdType="pubmed">20134316</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al.
Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc.Natl.Acad.Sci.U.S.A
2006;103: 15564&#x2013;15569. doi: 10.1073/pnas.0607028103
</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607028103</ArticleId><ArticleId IdType="pmc">PMC1592643</ArticleId><ArticleId IdType="pubmed">17032758</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Cole E, De'Ath HD, Vulliamy P, Meier U, Pennington D, et al.
Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Crit Care
2016;20: 176
doi: 10.1186/s13054-016-1341-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1341-2</ArticleId><ArticleId IdType="pmc">PMC4895987</ArticleId><ArticleId IdType="pubmed">27268230</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van LA, et al.
Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med. 2016;42: 551&#x2013;561. doi: 10.1007/s00134-015-4205-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4205-3</ArticleId><ArticleId IdType="pmc">PMC5413532</ArticleId><ArticleId IdType="pubmed">26912315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch.Surg. 2000;135: 291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch.Surg. 2001;386: 241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Koenderman L, Althuizen M, Pillay J, Kamp V, Leenen LP. Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. Shock
2013;40: 21&#x2013;27. doi: 10.1097/SHK.0b013e318295a40a
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318295a40a</ArticleId><ArticleId IdType="pubmed">23603769</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser T, Hietbrink F, Groeneveld KM, Koenderman L, Leenen LP. Isolated blunt chest injury leads to transient activation of circulating neutrophils. Eur.J.Trauma Emerg.Surg. 2011;37: 177&#x2013;184. doi: 10.1007/s00068-010-0041-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-010-0041-x</ArticleId><ArticleId IdType="pmc">PMC3150797</ArticleId><ArticleId IdType="pubmed">21837259</ArticleId></ArticleIdList></Reference><Reference><Citation>West SD, Goldberg D, Ziegler A, Krencicki M, Du Clos TW, Mold C. Transforming growth factor-beta, macrophage colony-stimulating factor and C-reactive protein levels correlate with CD14(high)CD16+ monocyte induction and activation in trauma patients. PLoS ONE. 2012;7: e52406
doi: 10.1371/journal.pone.0052406
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052406</ArticleId><ArticleId IdType="pmc">PMC3532215</ArticleId><ArticleId IdType="pubmed">23285029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolach B, Sazbon L, Gavrieli R, Broda A, Schlesinger M. Early immunological defects in comatose patients after acute brain injury. J.Neurosurg. 2001;94: 706&#x2013;711. doi: 10.3171/jns.2001.94.5.0706
</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2001.94.5.0706</ArticleId><ArticleId IdType="pubmed">11354400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasten KR, Goetzman HS, Reid MR, Rasper AM, Adediran SG, Robinson CT, et al.
Divergent adaptive and innate immunological responses are observed in humans following blunt trauma. BMC.Immunol. 2010;11: 4
doi: 10.1186/1471-2172-11-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-11-4</ArticleId><ArticleId IdType="pmc">PMC2823662</ArticleId><ArticleId IdType="pubmed">20100328</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al.
A genomic storm in critically injured humans. J.Exp.Med. 2011;208: 2581&#x2013;2590. doi: 10.1084/jem.20111354
</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111354</ArticleId><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanzant EL, Hilton RE, Lopez CM, Zhang J, Ungaro RF, Gentile LF, et al.
Advanced age is associated with worsened outcomes and a unique genomic response in severely injured patients with hemorrhagic shock. Crit Care
2015. 
19: 77
doi: 10.1186/s13054-015-0788-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0788-x</ArticleId><ArticleId IdType="pmc">PMC4404112</ArticleId><ArticleId IdType="pubmed">25880307</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr SK, Butler KL, Hayden D, Tompkins RG, Serhan CN, Irimia D. Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. Crit Care Med. 2015;43: 2642&#x2013;2650. doi: 10.1097/CCM.0000000000001312
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001312</ArticleId><ArticleId IdType="pmc">PMC4651815</ArticleId><ArticleId IdType="pubmed">26488221</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Vodovotz Y, Almahmoud K, Abdul-Malak O, Zaaqoq A, Namas R, et al.
Temporal Patterns of Circulating Inflammation Biomarker Networks Differentiate Susceptibility to Nosocomial Infection Following Blunt Trauma in Humans. Ann.Surg. 2016; 263: 191&#x2013;198. doi: 10.1097/SLA.0000000000001001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001001</ArticleId><ArticleId IdType="pmc">PMC5136774</ArticleId><ArticleId IdType="pubmed">25371118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Finnerty CC, Kraft R, Mlcak RP, Herndon DN. Survivors versus nonsurvivors postburn: differences in inflammatory and hypermetabolic trajectories. Ann.Surg. 2014;259: 814&#x2013;823. doi: 10.1097/SLA.0b013e31828dfbf1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828dfbf1</ArticleId><ArticleId IdType="pmc">PMC3732513</ArticleId><ArticleId IdType="pubmed">23579577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study. Shock
2015;43: 222&#x2013;227. doi: 10.1097/SHK.0000000000000294
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000294</ArticleId><ArticleId IdType="pmc">PMC4425645</ArticleId><ArticleId IdType="pubmed">25514427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, et al.
Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock
2010;34: 346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LC, Regner A, Miotto KD, Moura S, Ikuta N, Vargas AE, et al.
Increased levels of interleukin-6, -8 and -10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj. 2014;28: 1311&#x2013;1316. doi: 10.3109/02699052.2014.916818
</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02699052.2014.916818</ArticleId><ArticleId IdType="pubmed">24830571</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007;28: 668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L, et al.
Innate immune function predicts the development of nosocomial infection in critically injured children. Shock
2014;42: 313&#x2013;321. doi: 10.1097/SHK.0000000000000217
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000217</ArticleId><ArticleId IdType="pmc">PMC4167175</ArticleId><ArticleId IdType="pubmed">24978895</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS ONE
2012;7: e33095
doi: 10.1371/journal.pone.0033095
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033095</ArticleId><ArticleId IdType="pmc">PMC3303782</ArticleId><ArticleId IdType="pubmed">22431998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C, et al.
Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care
2010;14: R208
doi: 10.1186/cc9331
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9331</ArticleId><ArticleId IdType="pmc">PMC3220028</ArticleId><ArticleId IdType="pubmed">21092108</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995. 57: 289&#x2013;300.</Citation></Reference><Reference><Citation>Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al.
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology
2010;21: 128&#x2013;138. doi: 10.1097/EDE.0b013e3181c30fb2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J.Clin.Epidemiol. 2001;54: 774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, Gozani OP, et al.
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res.Ther. 2012;14: R25
doi: 10.1186/ar3707
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3707</ArticleId><ArticleId IdType="pmc">PMC3392818</ArticleId><ArticleId IdType="pubmed">22300536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Kamp VM, van HE, Visser T, Tak T, Lammers JW, et al.
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J.Clin.Invest
2012; 122: 327&#x2013;336. doi: 10.1172/JCI57990
</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57990</ArticleId><ArticleId IdType="pmc">PMC3248287</ArticleId><ArticleId IdType="pubmed">22156198</ArticleId></ArticleIdList></Reference><Reference><Citation>Laborde RR, Lin Y, Gustafson MP, Bulur PA, Dietz AB. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. Front Immunol. 2014;5: 147
doi: 10.3389/fimmu.2014.00147
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00147</ArticleId><ArticleId IdType="pmc">PMC3983500</ArticleId><ArticleId IdType="pubmed">24772111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Biberthaler P, Mutschler WE, Faist E, Jochum M, Zedler S. Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study. Crit Care
2009; 13: R88
doi: 10.1186/cc7914
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7914</ArticleId><ArticleId IdType="pmc">PMC2717459</ArticleId><ArticleId IdType="pubmed">19519886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainer TH, Ng MH, Lam NY, Chan TY, Cocks RA. Role of monocyte L-selectin in the development of post-traumatic organ failure. Resuscitation 2001;51: 139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al.
Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J.Trauma Acute.Care Surg. 2012;72: 1491&#x2013;1501. doi: 10.1097/TA.0b013e318256e000
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318256e000</ArticleId><ArticleId IdType="pmc">PMC3705923</ArticleId><ArticleId IdType="pubmed">22695412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Terashima T, D'yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998;98: 2307&#x2013;2313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9826319</ArticleId></ArticleIdList></Reference><Reference><Citation>Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med. 2013;41: 820&#x2013;832. doi: 10.1097/CCM.0b013e318274647d
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318274647d</ArticleId><ArticleId IdType="pubmed">23348516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, et al.
Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J.Leukoc.Biol. 2010;88: 211&#x2013;220. doi: 10.1189/jlb.1209793
</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1209793</ArticleId><ArticleId IdType="pubmed">20400675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauce D, Dong Y, Campillo-Gimenez L, Casulli S, Bayard C, Autran B, et al.
Reduced Oxidative Burst by Primed Neutrophils in the Elderly Individuals Is Associated With Increased Levels of the CD16bright/CD62Ldim Immunosuppressive Subset. J.Gerontol.A Biol.Sci.Med.Sci. 2017;72: 163&#x2013;172. doi: 10.1093/gerona/glw062
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw062</ArticleId><ArticleId IdType="pubmed">27069096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood
2011;117: 872&#x2013;881. doi: 10.1182/blood-2010-05-283820
</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-283820</ArticleId><ArticleId IdType="pmc">PMC3035079</ArticleId><ArticleId IdType="pubmed">21063024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al.
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate
2010;70: 443&#x2013;455. doi: 10.1002/pros.21078
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.21078</ArticleId><ArticleId IdType="pmc">PMC2935631</ArticleId><ArticleId IdType="pubmed">19902470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al.
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology
2008;135: 234&#x2013;243. doi: 10.1053/j.gastro.2008.03.020
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.03.020</ArticleId><ArticleId IdType="pubmed">18485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology
2009;50: 799&#x2013;807. doi: 10.1002/hep.23054
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23054</ArticleId><ArticleId IdType="pmc">PMC6357774</ArticleId><ArticleId IdType="pubmed">19551844</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, et al.
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J. 2015; 5: e328
doi: 10.1038/bcj.2015.56
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2015.56</ArticleId><ArticleId IdType="pmc">PMC4526782</ArticleId><ArticleId IdType="pubmed">26230952</ArticleId></ArticleIdList></Reference><Reference><Citation>Aneja R, Odoms K, Dunsmore K, Shanley TP, Wong HR. Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J.Immunol. 2006;177: 7184&#x2013;7192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal J, Thurman GW, Cusack N, Peterson VM, Malech HL, Ambruso DR. Neutrophils from patients after burn injury express a deficiency of the oxidase components p47-phox and p67-phox. Blood 1996;88: 4321&#x2013;4329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943869</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG, Rhind SG, Rizoli SB, Cuschieri J, Baker AJ, Shek PN, et al.
Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. Shock
2013;40: 366&#x2013;374. doi: 10.1097/SHK.0000000000000038
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000038</ArticleId><ArticleId IdType="pmc">PMC3913169</ArticleId><ArticleId IdType="pubmed">24088993</ArticleId></ArticleIdList></Reference><Reference><Citation>Benna JE, Dang PM, Gaudry M, Fay M, Morel F, Hakim J, et al. Phosphorylation of the respiratory burst oxidase subunit p67(phox) during human neutrophil activation. Regulation by protein kinase C-dependent and independent pathways. J.Biol.Chem. 1997; 272: 17204&#x2013;17208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauseef WM, Volpp BD, McCormick S, Leidal KG, Clark RA. Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes cytoskeletal and membrane association of cytosolic oxidase components. J.Biol.Chem. 1991;266: 5911&#x2013;5917.</Citation><ArticleIdList><ArticleId IdType="pubmed">1848559</ArticleId></ArticleIdList></Reference><Reference><Citation>Raad H, Paclet MH, Boussetta T, Kroviarski Y, Morel F, Quinn MT, et al.
Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J. 2009;23: 1011&#x2013;1022. doi: 10.1096/fj.08-114553
</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-114553</ArticleId><ArticleId IdType="pmc">PMC2660639</ArticleId><ArticleId IdType="pubmed">19028840</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarlowe MH, Kannan KB, Itagaki K, Adams JM, Livingston DH, Hauser CJ. Inflammatory chemoreceptor cross-talk suppresses leukotriene B4 receptor 1-mediated neutrophil calcium mobilization and chemotaxis after trauma. J.Immunol. 2003;171: 2066&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">12902512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, et al.
Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS ONE. 2014;9: e111755
doi: 10.1371/journal.pone.0111755
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111755</ArticleId><ArticleId IdType="pmc">PMC4230949</ArticleId><ArticleId IdType="pubmed">25392950</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, et al.
Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology
2015;62: 600&#x2013;614. doi: 10.1002/hep.27841
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27841</ArticleId><ArticleId IdType="pmc">PMC4515210</ArticleId><ArticleId IdType="pubmed">25855125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al.
Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care
2009;13: R174
doi: 10.1186/cc8152
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Vivian ME, Brohi K, Prowle JR, Pearse RM, Owen HC, et al.
Changes in gene expression following trauma are related to the age of transfused packed red blood cells. J.Trauma Acute.Care Surg. 2015;78: 535&#x2013;542. doi: 10.1097/TA.0000000000000534
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000534</ArticleId><ArticleId IdType="pubmed">25710424</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Brohi K, Pearse RM, Mein CA, Wozniak E, Prowle JR, et al.
Association between gene expression biomarkers of immunosuppression and blood transfusion in severely injured polytrauma patients. Ann.Surg. 2015; 261: 751&#x2013;759. doi: 10.1097/SLA.0000000000000653
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000000653</ArticleId><ArticleId IdType="pubmed">24670848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40922409</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-6576</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta anaesthesiologica Scandinavica</Title><ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation></Journal><ArticleTitle>Pro- and Anti-Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study.</ArticleTitle><Pagination><StartPage>e70117</StartPage><MedlinePgn>e70117</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70117</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/aas.70117</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro- and anti-inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this secondary, explorative analysis of a prospective single-centre cohort (n&#x2009;=&#x2009;459), we assessed associations between endotheliopathy biomarkers (syndecan-1, soluble thrombomodulin (sTM), platelet endothelial cell adhesion molecule-1 (PECAM-1)) and inflammatory biomarkers (pro-inflammatory: IFN-&#x3d2;, IL-1&#x3b2;, IL-2, IL-6, IL-8, IL-12p70, TNF-&#x3b1;; anti-inflammatory: IL-4, IL-10, IL-13) at ICU admission using linear regression. Associations with 30-day clinical outcomes were analysed using linear and Cox regression. All models were adjusted for age, sex, septic shock, pre-ICU surgery and chronic disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher levels of all three endotheliopathy biomarkers were associated with higher levels of inflammatory biomarkers. PECAM-1, however, showed no significant association with IFN-&#x3d2;, IL-1&#x3b2; and IL-12p70. IL-4 was excluded from linear regression due to &gt;&#x2009;50% imputed values. Higher levels of all three endotheliopathy biomarkers were significantly associated with increased mean and maximum modified Sequential Organ Failure Assessment (mSOFA) scores over 30&#x2009;days, as well as with renal, hepatic, and coagulation failure, and 30-day all-cause mortality. Only sTM was significantly associated with cardiovascular failure; none were significantly associated with respiratory failure. Higher levels of sTM were associated with the highest levels of inflammatory biomarkers, the largest increases in mean and maximum mSOFA scores, and the highest hazard ratios for organ failure and 30-day all-cause mortality, compared with syndecan-1 and PECAM-1.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this cohort of critically ill ICU patients, endotheliopathy was associated with (1) higher levels of pro- and anti-inflammatory biomarkers at ICU admission and (2) MODS, single organ failure, and 30-day all-cause mortality. Among the three endotheliopathy biomarkers, sTM demonstrated the most consistent and strongest associations with both inflammatory biomarkers and clinical outcomes. These findings are exploratory and should be interpreted as hypothesis-generating.</AbstractText><AbstractText Label="EDITOR'S COMMENT" NlmCategory="UNASSIGNED">In this analysis of different biomarkers in a critically ill cohort, associations are demonstrated between markers related to endothelial stress, cytokines related to modulation of inflammation, and severity of illness scores.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Acta Anaesthesiologica Scandinavica published by John Wiley &amp; Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Humble</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7919-2946</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf8;nemann-Lund</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruun-Rasmussen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bestle</LastName><ForeName>Morten H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-6585-2659</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hiller&#xf8;d, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>P&#xe4;r I</ForeName><Initials>PI</Initials><Identifier Source="ORCID">0000-0001-9778-5964</Identifier><AffiliationInfo><Affiliation>Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulsen</LastName><ForeName>Lone M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-7030-3395</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathiesen</LastName><ForeName>Ole</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4544-0619</Identifier><AffiliationInfo><Affiliation>Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Greater Copenhagen Health Science Partners</Agency><Country/></Grant><Grant><Agency>Region Zealand Health Science Research Fund</Agency><Country/></Grant><Grant><Agency>Clinical Academic Group (CAG) Center for Endotheliomics</Agency><Country/></Grant><Grant><Agency>Intensive Care Symposium Hindsgavl</Agency><Country/></Grant><Grant><Agency>A. P. Moller Foundation</Agency><Country/></Grant><Grant><Agency>King Christian X Fund</Agency><Country/></Grant><Grant><Agency>The Danish Society of Anaesthesiology and Intensive Care Medicine (DASAIM)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Anaesthesiol Scand</MedlineTA><NlmUniqueID>0370270</NlmUniqueID><ISSNLinking>0001-5172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019408">Platelet Endothelial Cell Adhesion Molecule-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018180">Thrombomodulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019408" MajorTopicYN="N">Platelet Endothelial Cell Adhesion Molecule-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018180" MajorTopicYN="N">Thrombomodulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40922409</ArticleId><ArticleId IdType="pmc">PMC12417775</ArticleId><ArticleId IdType="doi">10.1111/aas.70117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adhikari N. K., Fowler R. A., Bhagwanjee S., and Rubenfeld G. D., &#x201c;Critical Care and the Global Burden of Critical Illness in Adults,&#x201d; Lancet 376, no. 9749 (2010): 1339&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136988</ArticleId><ArticleId IdType="pubmed">20934212</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoli C. J., Reynolds M. A., Sinha M., Gitlin M., and Crouser E., &#x201c;Epidemiology and Costs of Sepsis in the United States&#x2014;An Analysis Based on Timing of Diagnosis and Severity Level,&#x201d; Critical Care Medicine 46, no. 12 (2018): 1889&#x2013;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250243</ArticleId><ArticleId IdType="pubmed">30048332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiru B., DiNino E. K., Orenstein A., et&#xa0;al., &#x201c;The Economic and Humanistic Burden of Severe Sepsis,&#x201d; PharmacoEconomics 33, no. 9 (2015): 925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">25935211</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd K. E., Johnson S. C., Agesa K. M., et&#xa0;al., &#x201c;Global, Regional, and National Sepsis Incidence and Mortality, 1990&#x2013;2017: Analysis for the Global Burden of Disease Study,&#x201d; Lancet 395, no. 10219 (2020): 200&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970225</ArticleId><ArticleId IdType="pubmed">31954465</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y., Jaschinski U., Wittebole X., et&#xa0;al., &#x201c;Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care Over Nations Audit,&#x201d; Open Forum Infectious Diseases 5, no. 12 (2018): ofy313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289022</ArticleId><ArticleId IdType="pubmed">30555852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Jones G., David S., Olariu E., and Cadwell K. K., &#x201c;Frequency and Mortality of Septic Shock in Europe and North America: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Critical Care 23, no. 1 (2019): 196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545004</ArticleId><ArticleId IdType="pubmed">31151462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pool R., Gomez H., and Kellum J. A., &#x201c;Mechanisms of Organ Dysfunction in Sepsis,&#x201d; Critical Care Clinics 34, no. 1 (2018): 63&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6922007</ArticleId><ArticleId IdType="pubmed">29149942</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J. C., &#x201c;Inflammation, Coagulopathy, and the Pathogenesis of Multiple Organ Dysfunction Syndrome,&#x201d; Critical Care Medicine 29 (2001): S99&#x2013;S106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445742</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M., Deutschman C. S., Seymour C. W., et&#xa0;al., &#x201c;The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis&#x2010;3),&#x201d; Journal of the American Medical Association 315, no. 8 (2016): 801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Aird W. C., &#x201c;The Role of the Endothelium in Severe Sepsis and Multiple Organ Dysfunction Syndrome,&#x201d; Blood 101, no. 10 (2003): 3765&#x2013;3777.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543869</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D. C. and June C. H., &#x201c;Cytokine Storm,&#x201d; New England Journal of Medicine 383, no. 23 (2020): 2255&#x2013;2273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal S. M., Dellinger R. P., Vincent J. L., Masur H., and Angus D. C., &#x201c;The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?*,&#x201d; Critical Care Medicine 42, no. 7 (2014): 1714&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135726</ArticleId><ArticleId IdType="pubmed">24717456</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Stensballe J., and Ostrowski S. R., &#x201c;Shock Induced Endotheliopathy (SHINE) in Acute Critical Illness &#x2010; a Unifying Pathophysiologic Mechanism,&#x201d; Critical Care 21, no. 1 (2017): 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299749</ArticleId><ArticleId IdType="pubmed">28179016</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a de Lomana A. L., Vilhj&#xe1;lmsson A. I., McGarrity S., et&#xa0;al., &#x201c;Metabolic Response in Endothelial Cells to Catecholamine Stimulation Associated With Increased Vascular Permeability,&#x201d; International Journal of Molecular Sciences 23, no. 6 (2022): 3162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950318</ArticleId><ArticleId IdType="pubmed">35328583</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlicka J., Becker B. F., and Chappell D., &#x201c;Endothelial Glycocalyx,&#x201d; Critical Care Clinics 36, no. 2 (2020): 217&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">32172810</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto T., Tanigami H., Suzuki K., and Shimaoka M., &#x201c;Thrombomodulin: A Bifunctional Modulator of Inflammation and Coagulation in Sepsis,&#x201d; Critical Care Research and Practice 2012 (2012): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299293</ArticleId><ArticleId IdType="pubmed">22482044</ArticleId></ArticleIdList></Reference><Reference><Citation>Morser J., &#x201c;Thrombomodulin Links Coagulation to Inflammation and Immunity,&#x201d; Current Drug Targets 13, no. 3 (2012): 421&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme M. W. J., Galle P., and Stremmel W., &#x201c;Kinetics of Thrombomodulin Release and Endothelial Cell Injury by Neutrophil&#x2010;Derived Proteases and Oxygen Radicals,&#x201d; Immunology 107, no. 3 (2002): 340&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782804</ArticleId><ArticleId IdType="pubmed">12423310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii H. and Majerus P. W., &#x201c;Thrombomodulin Is Present in Human Plasma and Urine,&#x201d; Journal of Clinical Investigation 76, no. 6 (1985): 2178&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424339</ArticleId><ArticleId IdType="pubmed">3001144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lertkiatmongkol P., Liao D., Mei H., Hu Y., and Newman P. J., &#x201c;Endothelial Functions of Platelet/Endothelial Cell Adhesion Molecule&#x2010;1 (CD31),&#x201d; Current Opinion in Hematology 23, no. 3 (2016): 253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986701</ArticleId><ArticleId IdType="pubmed">27055047</ArticleId></ArticleIdList></Reference><Reference><Citation>Privratsky J. R. and Newman P. J., &#x201c;PECAM&#x2010;1: Regulator of Endothelial Junctional Integrity,&#x201d; Cell and Tissue Research 355, no. 3 (2014): 607&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975704</ArticleId><ArticleId IdType="pubmed">24435645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Ince C., and Pickkers P., &#x201c;Endothelial Dysfunction: A Therapeutic Target in Bacterial Sepsis?,&#x201d; Expert Opinion on Therapeutic Targets 25, no. 9 (2021): 733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">34602020</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas A., Lichtman A., and Pillai S., &#x201c;Innate Immunity: The Early Defense Against Infections,&#x201d; in Basic Immunology: Functions and Disorders of the Immune System, 6th ed., ed. Abbas A., Lichtman A., and Pillai S. (Elsevier, 2020), 24&#x2013;29.</Citation></Reference><Reference><Citation>Johansen M. E., Johansson P. I., Ostrowski S. R., et&#xa0;al., &#x201c;Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis,&#x201d; Seminars in Thrombosis and Hemostasis 41, no. 1 (2015): 16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25590523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf8;nemann&#x2010;Lund M., Itenov T. S., Larsson J. E., Lindegaard B., Johansson P. I., and Bestle M. H., &#x201c;Endotheliopathy Is Associated With Slower Liberation From Mechanical Ventilation: A Cohort Study,&#x201d; Critical Care 26, no. 1 (2022): 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801241</ArticleId><ArticleId IdType="pubmed">35094711</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Henriksen H. H., Stensballe J., et&#xa0;al., &#x201c;Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients,&#x201d; Annals of Surgery 265, no. 3 (2017): 597&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5300027</ArticleId><ArticleId IdType="pubmed">27144442</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Haase N., Perner A., and Ostrowski S. R., &#x201c;Association Between Sympathoadrenal Activation, Fibrinolysis, and Endothelial Damage in Septic Patients: A Prospective Study,&#x201d; Journal of Critical Care 29, no. 3 (2014): 327&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">24581948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski S. R., Haase N., M&#xfc;ller R. B., et&#xa0;al., &#x201c;Association Between Biomarkers of Endothelial Injury and Hypocoagulability in Patients With Severe Sepsis: A Prospective Study,&#x201d; Critical Care 19, no. 1 (2015): 191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423170</ArticleId><ArticleId IdType="pubmed">25907781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski S. R., Pedersen S. H., Jensen J. S., Mogelvang R., and Johansson P. I., &#x201c;Acute Myocardial Infarction Is Associated With Endothelial Glycocalyx and Cell Damage and a Parallel Increase in Circulating Catecholamines,&#x201d; Critical Care 17, no. 1 (2013): R32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057225</ArticleId><ArticleId IdType="pubmed">23433357</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Bro&#x2010;Jeppesen J., Kjaergaard J., Wanscher M., Hassager C., and Ostrowski S. R., &#x201c;Sympathoadrenal Activation and Endothelial Damage Are Inter Correlated and Predict Increased Mortality in Patients Resuscitated After Out&#x2010;Of&#x2010;Hospital Cardiac Arrest. A Post Hoc Sub&#x2010;Study of Patients From the TTM&#x2010;Trial,&#x201d; PLoS One 10, no. 3 (2015): e0120914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366381</ArticleId><ArticleId IdType="pubmed">25789868</ArticleId></ArticleIdList></Reference><Reference><Citation>Itenov T. S., Jensen J. U., Ostrowski S. R., et&#xa0;al., &#x201c;Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients,&#x201d; Shock 47, no. 6 (2017): 696&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">28505627</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama S., Nunomiya S., Koyama K., et&#xa0;al., &#x201c;Markers of Acute Kidney Injury in Patients With Sepsis: The Role of Soluble Thrombomodulin,&#x201d; Critical Care 21 (2017): 229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574079</ArticleId><ArticleId IdType="pubmed">28841902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapru A., Calfee C. S., Liu K. D., et&#xa0;al., &#x201c;Plasma Soluble Thrombomodulin Levels Are Associated With Mortality in the Acute Respiratory Distress Syndrome,&#x201d; Intensive Care Medicine 41, no. 3 (2015): 470&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500527</ArticleId><ArticleId IdType="pubmed">25643902</ArticleId></ArticleIdList></Reference><Reference><Citation>Damas P., Canivet J. L., De Groote D., et&#xa0;al., &#x201c;Sepsis and Serum Cytokine Concentrations,&#x201d; Critical Care Medicine 25, no. 3 (1997): 405&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogos C. A., Drosou E., Bassaris H. P., and Skoutelis A., &#x201c;Pro&#x2010; Versus Anti&#x2010;Inflammatory Cytokine Profile in Patients With Severe Sepsis: A Marker for Prognosis and Future Therapeutic Options,&#x201d; Journal of Infectious Diseases 181, no. 1 (2000): 176&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozza F. A., Salluh J. I., Japiassu A. M., et&#xa0;al., &#x201c;Cytokine Profiles as Markers of Disease Severity in Sepsis: A Multiplex Analysis,&#x201d; Critical Care 11, no. 2 (2007): R49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206478</ArticleId><ArticleId IdType="pubmed">17448250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jekarl D. W., Kim J. Y., Ha J. H., et&#xa0;al., &#x201c;Diagnosis and Prognosis of Sepsis Based on Use of Cytokines, Chemokines, and Growth Factors,&#x201d; Disease Markers 2019 (2019): 1089107&#x2013;1089111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754872</ArticleId><ArticleId IdType="pubmed">31583025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Gupta E., Kaushik S., Kumar Srivastava V., Mehta S., and Jyoti A., &#x201c;Evaluation of Oxidative Stress and Antioxidant Status: Correlation With the Severity of Sepsis,&#x201d; Scandinavian Journal of Immunology 87, no. 4 (2018): e12653.</Citation><ArticleIdList><ArticleId IdType="pubmed">29484685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Gupta E., Srivastava V. K., et&#xa0;al., &#x201c;Nitrosative Stress and Cytokines Are Linked With the Severity of Sepsis and Organ Dysfunction,&#x201d; British Journal of Biomedical Science 76, no. 1 (2019): 29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30379116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharamti A. A., Samara O., Monzon A., et&#xa0;al., &#x201c;Proinflammatory Cytokines Levels in Sepsis and Healthy Volunteers, and Tumor Necrosis Factor&#x2010;Alpha Associated Sepsis Mortality: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cytokine 158 (2022): 156006.</Citation><ArticleIdList><ArticleId IdType="pubmed">36044827</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Stensballe J., Rasmussen L. S., and Ostrowski S. R., &#x201c;A High Admission Syndecan&#x2010;1 Level, a Marker of Endothelial Glycocalyx Degradation, Is Associated With Inflammation, Protein C Depletion, Fibrinolysis, and Increased Mortality in Trauma Patients,&#x201d; Annals of Surgery 254, no. 2 (2011): 194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">21772125</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C. S., Janz D. R., Bernard G. R., et&#xa0;al., &#x201c;Distinct Molecular Phenotypes of Direct vs Indirect ARDS in Single&#x2010;Center and Multicenter Studies,&#x201d; Chest 147, no. 6 (2015): 1539&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451708</ArticleId><ArticleId IdType="pubmed">26033126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikacenic C., Hahn W. O., Price B. L., et&#xa0;al., &#x201c;Biomarkers of Endothelial Activation Are Associated With Poor Outcome in Critical Illness,&#x201d; PLoS One 10, no. 10 (2015): e0141251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619633</ArticleId><ArticleId IdType="pubmed">26492036</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson&#x2010;Cohen C., Katz R., Price B. L., et&#xa0;al., &#x201c;Association of Markers of Endothelial Dysregulation Ang1 and Ang2 With Acute Kidney Injury in Critically Ill Patients,&#x201d; Critical Care 20, no. 1 (2016): 207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930837</ArticleId><ArticleId IdType="pubmed">27372077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Li L., Chen Y., et&#xa0;al., &#x201c;Syndecan&#x2010;1, an Indicator of Endothelial Glycocalyx Degradation, Predicts Outcome of Patients Admitted to an ICU With COVID&#x2010;19,&#x201d; Molecular Medicine 27, no. 1 (2021): 151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640509</ArticleId><ArticleId IdType="pubmed">34861818</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D. G., Egger M., Pocock S. J., G&#xf8;tzsche P. C., and Vandenbroucke J. P., &#x201c;The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies,&#x201d; Lancet 370, no. 9596 (2007): 1453&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf8;nemann&#x2010;Lund M., Itenov T. S., Larsson J. E., Lindegaard B., Johansson P. I., and Bestle M. H., &#x201c;Novel Subgroups in Acute Respiratory Failure Based on the Trajectories of Three Endotheliopathy Biomarkers: A Cohort Study,&#x201d; Acta Anaesthesiologica Scandinavica 67, no. 7 (2023): 896&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">37042167</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., Henriksen H. H., Karvelsson S. T., et&#xa0;al., &#x201c;LASSO Regression Shows Histidine and Sphingosine 1 Phosphate Are Linked to Both Sepsis Mortality and Endothelial Damage,&#x201d; European Journal of Medical Research 29 (2024): 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799523</ArticleId><ArticleId IdType="pubmed">38245777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen K. M., Itenov T. S., Stensballe J., et&#xa0;al., &#x201c;Changes in Nitric Oxide Inhibitors and Mortality in Critically Ill Patients: A Cohort Study,&#x201d; Annals of Intensive Care 14, no. 1 (2024): 133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11349968</ArticleId><ArticleId IdType="pubmed">39190083</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. Y., Kemp T. J., Pfeiffer R. M., Pinto L. A., Hildesheim A., and Purdue M. P., &#x201c;Impact of Freeze&#x2010;Thaw Cycles on Circulating Inflammation Marker Measurements,&#x201d; Cytokine 95 (2017): 113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6411278</ArticleId><ArticleId IdType="pubmed">28260648</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng S. X., McElhaney J. E., Walston J. D., Xie D., Fedarko N. S., and Kuchel G. A., &#x201c;ELISA and Multiplex Technologies for Cytokine Measurement in Inflammation and Aging Research,&#x201d; Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63, no. 8 (2008): 879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562869</ArticleId><ArticleId IdType="pubmed">18772478</ArticleId></ArticleIdList></Reference><Reference><Citation>Humble C., Sch&#xf8;nemann&#x2010;Lund M., Bruun&#x2010;Rasmussen P., et&#xa0;al., &#x201c;Pro&#x2010; and Anti&#x2010;Inflammatory Response in Critically Ill Patients With Endothelial Damage (ENDO&#x2010;FLAME),&#x201d; OSF (2023), 10.17605/OSF.IO/CEWR9.</Citation><ArticleIdList><ArticleId IdType="doi">10.17605/OSF.IO/CEWR9</ArticleId></ArticleIdList></Reference><Reference><Citation>Textor J., van der Zander B., Gilthorpe M. S., Liskiewicz M., and Ellison G. T., &#x201c;Robust Causal Inference Using Directed Acyclic Graphs: The R Package &#x201c;Dagitty&#x201d;,&#x201d; International Journal of Epidemiology 45, no. 6 (2016): 1887&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">28089956</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A. C., Santhakumaran S., Al&#x2010;Beidh F., et&#xa0;al., &#x201c;Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis,&#x201d; New England Journal of Medicine 375, no. 17 (2016): 1638&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">27705084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestle M. H., Clausen N. E., S&#xf8;e&#x2010;Jensen P., et&#xa0;al., &#x201c;Efficacy and Safety of Iloprost in Patients With Septic Shock&#x2010;Induced Endotheliopathy&#x2010;Protocol for the Multicenter Randomized, Placebo&#x2010;Controlled, Blinded, Investigator&#x2010;Initiated Trial,&#x201d; Acta Anaesthesiologica Scandinavica 64, no. 5 (2020): 705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186821</ArticleId><ArticleId IdType="pubmed">31950481</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent J. L., Moreno R., Takala J., et&#xa0;al., &#x201c;The SOFA (Sepsis&#x2010;Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure. On Behalf of the Working Group on Sepsis&#x2010;Related Problems of the European Society of Intensive Care Medicine,&#x201d; Intensive Care Medicine 22, no. 7 (1996): 707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozenne B., S&#xf8;rensen A., Scheike T., Torp&#x2010;Pedersen C., and Gerds T., &#x201c;riskRegression: Predicting the Risk of an Event Using Cox Regression Models,&#x201d; R Journal 9 (2017): 440&#x2013;460.</Citation></Reference><Reference><Citation>Benjamini Y. and Hochberg Y., &#x201c;Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,&#x201d; Journal of the Royal Statistical Society. Series B, Statistical Methodology 57 (1995): 289&#x2013;300.</Citation></Reference><Reference><Citation>Altman D. G. and Bland J. M., &#x201c;How to Obtain the P Value From a Confidence Interval,&#x201d; BMJ 343 (2011): d2304.</Citation><ArticleIdList><ArticleId IdType="pubmed">22803193</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S. and Groothuis&#x2010;Oudshoorn K., &#x201c;Mice: Multivariate Imputation by Chained Equations in R,&#x201d; Journal of Statistical Software 45 (2011): 1&#x2013;67.</Citation></Reference><Reference><Citation>Lambden S., Laterre P. F., Levy M. M., and Francois B., &#x201c;The SOFA Score&#x2010;Development, Utility and Challenges of Accurate Assessment in Clinical Trials,&#x201d; Critical Care 23, no. 1 (2019): 374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880479</ArticleId><ArticleId IdType="pubmed">31775846</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevskis E. E., Pandharipande P. P., Graves A. J., et&#xa0;al., &#x201c;Validity of a Modified Sequential Organ Failure Assessment Score Using the Richmond Agitation&#x2010;Sedation Scale,&#x201d; Critical Care Medicine 44, no. 1 (2016): 138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4748963</ArticleId><ArticleId IdType="pubmed">26457749</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbers J., Miller R., Walther A., et&#xa0;al., &#x201c;How to Deal With Non&#x2010;Detectable and Outlying Values in Biomarker Research: Best Practices and Recommendations for Univariate Imputation Approaches,&#x201d; Comprehensive Psychoneuroendocrinology 7 (2021): 100052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9216349</ArticleId><ArticleId IdType="pubmed">35757062</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team
, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2023), https://www.R&#x2010;project.org/.</Citation></Reference><Reference><Citation>Loisa P., Rinne T., Laine S., Hurme M., and Kaukinen S., &#x201c;Anti&#x2010;Inflammatory Cytokine Response and the Development of Multiple Organ Failure in Severe Sepsis,&#x201d; Acta Anaesthesiologica Scandinavica 47, no. 3 (2003): 319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648199</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D. M., Kim&#x2010;Schulze S., Huang H. H., et&#xa0;al., &#x201c;An Inflammatory Cytokine Signature Predicts COVID&#x2010;19 Severity and Survival,&#x201d; Nature Medicine 26, no. 10 (2020): 1636&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana S., Kumari M., Bhardwaj N., Kumar S., Malhotra R., and Mathur P., &#x201c;T&#x2010;Helper&#x2010;17, Regulatory T&#x2010;Helper Cells Related Serum Markers and IL&#x2010;13 in the Outcome of Polytraumatic Patients With Bacteremia,&#x201d; Iranian Journal of Immunology 15, no. 4 (2018): 302&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">30593744</ArticleId></ArticleIdList></Reference><Reference><Citation>Platchek M., Lu Q., Tran H., and Xie W., &#x201c;Comparative Analysis of Multiple Immunoassays for Cytokine Profiling in Drug Discovery,&#x201d; SLAS Discovery 25, no. 10 (2020): 1197&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">32924773</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson P. I., S&#xf8;e&#x2010;Jensen P., Bestle M. H., et&#xa0;al., &#x201c;Prostacyclin in Intubated Patients With COVID&#x2010;19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial,&#x201d; American Journal of Respiratory and Critical Care Medicine 205, no. 3 (2022): 324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8886993</ArticleId><ArticleId IdType="pubmed">34813414</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;e&#x2010;Jensen P., Clausen N. E., Bestle M. H., et&#xa0;al., &#x201c;Efficacy and Safety of a 72&#x2010;h Infusion of Prostacyclin (1&#x2009;Ng/Kg/Min) in Mechanically Ventilated Patients With Pulmonary Infection and Endotheliopathy&#x2014;Protocol for the Multicenter Randomized, Placebo&#x2010;Controlled, Blinded, Investigator&#x2010;Initiated COMBAT&#x2010;ARF Trial,&#x201d; Acta Anaesthesiologica Scandinavica 69, no. 1 (2025): e14565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11660193</ArticleId><ArticleId IdType="pubmed">39704260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellum J., Lameire N., Aspelin P., et&#xa0;al., &#x201c;KDIGO Clinical Practice Guideline for Acute Kidney Injury,&#x201d; Kidney International. Supplement 2, no. 1 (2012): 1&#x2013;138.</Citation></Reference><Reference><Citation>Zarbock A., Nadim M. K., Pickkers P., et&#xa0;al., &#x201c;Sepsis&#x2010;Associated Acute Kidney Injury: Consensus Report of the 28th Acute Disease Quality Initiative Workgroup,&#x201d; Nature Reviews. Nephrology 19, no. 6 (2023): 401&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">36823168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer L., Jordan B., Druml W., Bauer P., and Metnitz P. G. H., &#x201c;Incidence and Prognosis of Early Hepatic Dysfunction in Critically Ill Patients&#x2014;A Prospective Multicenter Study,&#x201d; Critical Care Medicine 35, no. 4 (2007): 1099&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334250</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrakos C., Velissaris D., Felleiter P., et&#xa0;al., &#x201c;Increased Mortality in Critically Ill Patients With Mild or Moderate Hyperbilirubinemia,&#x201d; Journal of Critical Care 40 (2017): 31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28314169</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jager W., Bourcier K., Rijkers G. T., Prakken B. J., and Seyfert&#x2010;Margolis V., &#x201c;Prerequisites for Cytokine Measurements in Clinical Trials With Multiplex Immunoassays,&#x201d; BMC Immunology 10 (2009): 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761376</ArticleId><ArticleId IdType="pubmed">19785746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn R. G., Patel V., and Dull R. O., &#x201c;Human Glycocalyx Shedding: Systematic Review and Critical Appraisal,&#x201d; Acta Anaesthesiologica Scandinavica 65, no. 5 (2021): 590&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595101</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. H., Kuo C. H., Shi G. Y., and Wu H. L., &#x201c;The Role of Thrombomodulin Lectin&#x2010;Like Domain in Inflammation,&#x201d; Journal of Biomedical Science 19, no. 1 (2012): 34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342133</ArticleId><ArticleId IdType="pubmed">22449172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25518299</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-2208</ISSN><JournalIssue CitedMedium="Print"><Volume>97 Suppl 8</Volume><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</Title><ISOAbbreviation>J Med Assoc Thai</ISOAbbreviation></Journal><ArticleTitle>A randomized trial between different suture materials (polydioxanone vs. poliglecaprone 25) and different suturing techniques (running subcuticular suture alone vs. with running horizontal mattress) in prevention of hypertrophic scar development in median sternotomy wound.</ArticleTitle><Pagination><StartPage>S88</StartPage><EndPage>S94</EndPage><MedlinePgn>S88-94</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hypertrophic scar development after median sternotomy wound in cardiac surgery patients is quite common in surgical practice and becomes a major concern nowadays.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare cosmetic outcome between different suture materials and different suture techniques for skin closure in median sternotomy wound.</AbstractText><AbstractText Label="MATERIAL AND METHOD" NlmCategory="METHODS">A randomized clinical trial was conducted in 80 patients who underwent cardiac surgery in Thammasat University Hospital, Thailand. In respect of the materials and the techniques used to suture the skin, the patients were randomly allocated to four groups. In group 1, the skin was closed with subcuticular running 4-0 Poliglecaprone 25 (Monocryl). In group 2, the skin was closed with subcuticular running 4-0 Polydioxanone (PDS). In group 3, the skin was closed with subcuticular running 4-0 Poliglecaprone 25 (Monocryl) and running horizontal mattress 6-0 Nylon. In group 4, the skin was closed with subcuticular running 4-0 Polydioxanone (PDS) and running horizontal mattress 6-0 Nylon. Postoperative evaluation was performed at 2 and 6 weeks, 3 and 6 months follow-up visits. The scar was analyzed in three parts: upper, middle and lower one third of the sternal wound. The outcome measures for surgical wound were width, height and overall appearance of the scar using the Vancouver scar scale (VSS). A linear visual analogue score (VAS) was preformed to assess pain and itch.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 6 months, there were no significant differences between 4 groups ofpatients in every parameters (width, height, VSS, pain score and itch score) at three different wound sites (upper middle and lower). There was a statistically significant and progressive increase in scar stretching, height and total VSSfrom top to bottom of the sternum with the same pattern in all groups ofpatients (p&lt;0. 05). At 6 months, scar showed a statistically significant difference in width when compares to6 weeks and 3 months (p&lt;O.001).Female had a statistically significant difference ofscar stretching at upper two third of the sternum (p&lt;0. 05). Female scar width was approximately 2folds greater than male patient. Duringfollow-up in group 3, two patients died postoperatively due to multi-organ failure and one patient developed wound infection.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There were no significant differences in cosmetic outcomes between different suture materials and different suture techniques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Homvises</LastName><ForeName>Boonlawat</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><MedlineTA>J Med Assoc Thai</MedlineTA><NlmUniqueID>7507216</NlmUniqueID><ISSNLinking>0125-2208</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004146">Dioxanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical><Chemical><RegistryNumber>31621-87-1</RegistryNumber><NameOfSubstance UI="D016687">Polydioxanone</NameOfSubstance></Chemical><Chemical><RegistryNumber>41706-81-4</RegistryNumber><NameOfSubstance UI="C095495">glycolide E-caprolactone copolymer</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017439" MajorTopicYN="N">Cicatrix, Hypertrophic</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004146" MajorTopicYN="Y">Dioxanes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016687" MajorTopicYN="Y">Polydioxanone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="Y">Polyesters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056346" MajorTopicYN="N">Sternotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013536" MajorTopicYN="Y">Suture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013537" MajorTopicYN="Y">Sutures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25518299</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35630062</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Volume, but Not the Location of Necrosis, Is Associated with Worse Outcomes in Acute Pancreatitis: A Prospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina58050645</ELocationID><Abstract><AbstractText>Background and Objectives: The course and clinical outcomes of acute pancreatitis (AP) are highly variable. Up to 20% of patients develop pancreatic necrosis. Extent and location of it might affect the clinical course and management. The aim was to determine the clinical relevance of the extent and location of pancreatic necrosis in patients with AP. Materials and Methods: A cohort of patients with necrotizing AP was collected from 2012 to 2018 at the Hospital of Lithuanian University of Health Sciences. Patients were allocated to subgroups according to the location (entire pancreas, left and right sides of pancreas) and extent (&lt;30%, 30&#x2212;50%, &gt;50%) of pancreatic necrosis. Patients were reviewed for demographic features, number of performed surgical interventions, local and systemic complications, hospital stay and mortality rate. All contrast enhanced computed tomography (CECT) scans were evaluated by at least two experienced abdominal radiologists. All patients were treated according to the standard treatment protocol based on current international guidelines. Results: The study included 83 patients (75.9% males (n = 63)) with a mean age of 53 &#xb1; 1.7. The volume of pancreatic necrosis exceeded 50% in half of the patients (n = 42, 51%). Positive blood culture (n = 14 (87.5%)), multiple organ dysfunction syndrome (n = 17 (73.9%)) and incidences of respiratory failure (n = 19 (73.1%)) were significantly more often diagnosed in patients with pancreatic necrosis exceeding 50% (p &lt; 0.05). Patients with &gt;50% of necrosis were significantly (p &lt; 0.05) more often diagnosed with moderately severe (n = 24 (41.4%)) and severe (n = 18 (72%)) AP. The number of surgical interventions (n = 18 (72%)) and ultrasound-guided interventions (n = 26 (65%)) was also significantly higher. In patients with whole-pancreas necrosis, incidence of renal insufficiency (n = 11 (64.7%)) and infected pancreatic necrosis (n = 19 (57.6%)) was significantly higher (p &lt; 0.05). Conclusions: The clinical course and outcome were worse in the case of pancreatic necrosis exceeding 50%, rendering the need for longer and more complex treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dekeryte</LastName><ForeName>Inga</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zviniene</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieliuniene</LastName><ForeName>Edita</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dambrauskas</LastName><ForeName>Zilvinas</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2173-1294</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ignatavicius</LastName><ForeName>Povilas</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6112-6235</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="Y">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute pancreatitis</Keyword><Keyword MajorTopicYN="N">computed tomography</Keyword><Keyword MajorTopicYN="N">management</Keyword><Keyword MajorTopicYN="N">necrotizing pancreatitis</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">surgery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35630062</ArticleId><ArticleId IdType="pmc">PMC9144437</ArticleId><ArticleId IdType="doi">10.3390/medicina58050645</ArticleId><ArticleId IdType="pii">medicina58050645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Grinsven J., van Brunschot S., Bakker O.J., Bollen T.L., Boermeester M.A., Bruno M.J., Dejong C.H., Dijkgraaf M.G., van Eijck C.H., Fockens P., et al. Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: An international expert survey and case vignette study. HPB. 2015;18:49&#x2013;56. doi: 10.1016/j.hpb.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hpb.2015.07.003</ArticleId><ArticleId IdType="pmc">PMC4766363</ArticleId><ArticleId IdType="pubmed">26776851</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxhoorn L., Voermans R.P., Bouwense S.A., Bruno M.J., Verdonk R.C., Boermeester M.A., van Santvoort H.C., Besselink M.G. Acute Pancreatitis. Lancet. 2020;396:726&#x2013;734. doi: 10.1016/S0140-6736(20)31310-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31310-6</ArticleId><ArticleId IdType="pubmed">32891214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiantella W., Rondelli F., Boni M., Stella P., Polistena A., Sanguinetti A., Avenia N. Necrotizing pancreatitis: A review of the interventions. Int. J. Surg. 2015;28:S163&#x2013;S171. doi: 10.1016/j.ijsu.2015.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2015.12.038</ArticleId><ArticleId IdType="pubmed">26708848</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov M.S., Shanbhag S., Chakraborty M., Phillips A.R., Windsor J.A. Organ Failure and Infection of Pancreatic Necrosis as Determinants of Mortality in Patients with Acute Pancreatitis. Gastroenterology. 2010;139:813&#x2013;820. doi: 10.1053/j.gastro.2010.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.06.010</ArticleId><ArticleId IdType="pubmed">20540942</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks P.A., Freeman M.L., Fass R., Baroni D.S., Mutlu E.A., Bernstein D.E., Parkman H.P., Bharucha A.E., Prather C., Brugge W.R., et al. Practice Guidelines in Acute Pancreatitis. Am. J. Gastroenterol. 2006;101:2379&#x2013;2400. doi: 10.1111/j.1572-0241.2006.00856.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00856.x</ArticleId><ArticleId IdType="pubmed">17032204</ArticleId></ArticleIdList></Reference><Reference><Citation>Llukacaj A., Gjata A. The Importance of Haematocrit in Prediction of The Importance of Haematocrit in Prediction of Severe Acute Pancreatitis. Int. J. Sci. Res. 2016;5:ART2016404.</Citation></Reference><Reference><Citation>Yang Z., Dong L., Zhang Y., Yang C., Gou S., Li Y., Xiong J., Wu H., Wang C. Prediction of Severe Acute Pancreatitis Using a Decision Tree Model Based on the Revised Atlanta Classification of Acute Pancreatitis. PLoS ONE. 2015;10:e0143486. doi: 10.1371/journal.pone.0143486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0143486</ArticleId><ArticleId IdType="pmc">PMC4651493</ArticleId><ArticleId IdType="pubmed">26580397</ArticleId></ArticleIdList></Reference><Reference><Citation>IAP/APA Evidence-Based Guidelines for the Management of Acute Pancreatitis. Pancreatology. 2013;13:E1&#x2013;E15. doi: 10.1016/j.pan.2013.07.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2013.07.063</ArticleId><ArticleId IdType="pubmed">24054878</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdonk R.C., Sternby H., Dimova A., Ignatavicius P., Koiva P., Penttila A.K., Ilzarbe L., Regner S., Rosendahl J., Bollen T.L. Short Article: Presence, Extent and Location of Pancreatic Necrosis Are Independent of Aetiology in Acute Pan-creatitis. Eur. J. Gastroenterol. Hepatol. 2018;30:342. doi: 10.1097/MEG.0000000000001053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000001053</ArticleId><ArticleId IdType="pubmed">29280919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M.J., Neal C.P., Ngu W.S., Dennison A.R., Garcea G. Early warning score independently predicts adverse outcome and mortality in patients with acute pancreatitis. Langenbeck&#x2019;s Arch. Surg. 2017;402:811&#x2013;819. doi: 10.1007/s00423-017-1581-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-017-1581-x</ArticleId><ArticleId IdType="pmc">PMC5506178</ArticleId><ArticleId IdType="pubmed">28434059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepp&#xe4;niemi A., Tolonen M., Tarasconi A., Lohse H.A.S., Gamberini E., Kirkpatrick A.W., Ball C.G., Parry N., Sartelli M., Wolbrink D.R.J., et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J. Emerg. Surg. 2019;14:1&#x2013;20. doi: 10.1186/s13017-019-0247-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-019-0247-0</ArticleId><ArticleId IdType="pmc">PMC6567462</ArticleId><ArticleId IdType="pubmed">31210778</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron T.H., DiMaio C.J., Wang A.Y., Morgan K.A. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology. 2020;158:67&#x2013;75.e1. doi: 10.1053/j.gastro.2019.07.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.07.064</ArticleId><ArticleId IdType="pubmed">31479658</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Brunschot S., Hollemans R.A., Bakker O.J., Besselink M.G., Baron T.H., Beger H.G., Boermeester M.A., Bollen T.L., Bruno M.J., Carter R., et al. Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: A pooled analysis of individual data for 1980 patients. Gut. 2017;67:697&#x2013;706. doi: 10.1136/gutjnl-2016-313341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313341</ArticleId><ArticleId IdType="pubmed">28774886</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Santvoort H.C., Besselink M.G., Bakker O.J., Hofker H.S., Boermeester M.A., Dejong C.H., van Goor H., Schaapherder A.F., van Eijck C.H., Bollen T.L., et al. A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis. N. Engl. J. Med. 2010;362:1491&#x2013;1502. doi: 10.1056/NEJMoa0908821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908821</ArticleId><ArticleId IdType="pubmed">20410514</ArticleId></ArticleIdList></Reference><Reference><Citation>Manrai M., Kochhar R., Gupta V., Yadav T.D., Dhaka N., Kalra N., Sinha S.K., Khandelwal N. Outcome of Acute Pancreatic and Peripancreatic Collections Occurring in Patients with Acute Pancreatitis. Ann. Surg. 2018;267:357&#x2013;363. doi: 10.1097/SLA.0000000000002065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002065</ArticleId><ArticleId IdType="pubmed">27805963</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhan R.K., Jain S., Agarwal S., Harikrishnan S., Vadiraja P., Behera S., Jain S.K., Dhingra R., Dash N.R., Sahni P., et al. Primary and secondary organ failures cause mortality differentially in acute pancreatitis and should be distinguished. Pancreas. 2018;47:302&#x2013;307. doi: 10.1097/MPA.0000000000000998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPA.0000000000000998</ArticleId><ArticleId IdType="pubmed">29401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Taydas O., Unal E., Karaosmanoglu A.D., Onur M.R., Akpinar E. Accuracy of early CT findings for predicting disease course in patients with acute pancreatitis. Jpn. J. Radiol. 2017;36:151&#x2013;158. doi: 10.1007/s11604-017-0709-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11604-017-0709-9</ArticleId><ArticleId IdType="pubmed">29164450</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamies-Guilabert J., Anto&#xf1;ana A.D.V., Collado J.J., Rudenko P., Meseguer A. Pancreatic necrosis volume&#x2014;A new imaging biomarker of acute pancreatitis severity. Eur. J. Radiol. 2020;130:109193. doi: 10.1016/j.ejrad.2020.109193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2020.109193</ArticleId><ArticleId IdType="pubmed">32768889</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., He J., Hu X., Xu S.-F., Su W., Luo J.-F., Wang Q.-F., Guo F. Acute necrotising pancreatitis: Measurements of necrosis volume and mean CT attenuation help early prediction of organ failure and need for intervention. Eur. Radiol. 2021;31:7705&#x2013;7714. doi: 10.1007/s00330-021-07840-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-021-07840-x</ArticleId><ArticleId IdType="pubmed">33758956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mole D.J., McClymont K.L., Lau S., Mills R., Stamp-Vincent C., Garden O.J., Parks R.W. Discrepancy Between the Extent of Pancreatic Necrosis and Multiple Organ Failure Score in Severe Acute Pancreatitis. World J. Surg. 2009;33:2427&#x2013;2432. doi: 10.1007/s00268-009-0161-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0161-9</ArticleId><ArticleId IdType="pubmed">19641951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding L., Yu C., Deng F., He W.H., Xia L., Zhou M., Lan G.L., Huang X., Lei Y.P., Zhou X.J., et al. New Risk Factors for Infected Pancreatic Necrosis Secondary to Severe Acute Pancreatitis: The Role of Initial Contrast-Enhanced Computed Tomography. Dig. Dis. Sci. 2019;64:553. doi: 10.1007/s10620-018-5359-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-018-5359-y</ArticleId><ArticleId IdType="pubmed">30465178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30795954</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2157</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</Title><ISOAbbreviation>Eur J Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>Perioperative immune function and pain control may underlie early hospital readmission and 90 day mortality following lung cancer resection: A prospective cohort study of 932 patients.</ArticleTitle><Pagination><StartPage>863</StartPage><EndPage>869</EndPage><MedlinePgn>863-869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejso.2019.02.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0748-7983(19)30270-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mortality following lung cancer resection has been shown to double between 30 and 90 days and readmission following surgery is associated with an increased risk of mortality. The aim of this study was to describe the causes of readmission and mortality and enable the identification of potentially modifiable factors associated with these events.</AbstractText><AbstractText Label="METHODS">Prospective cohort study at a United Kingdom tertiary referral centre conducted over 55 months. Binary logistic regression was used to identify factors associated with death within 90 days of surgery.</AbstractText><AbstractText Label="RESULTS">The 30 day and 90 day mortality rates were 1.4% and 3.3% respectively. The most common causes of death were pneumonia, lung cancer and Acute Respiratory Distress Syndrome/Multi Organ Failure. Potentially modifiable risk factors for death identified were: Postoperative pulmonary complications (Odds ratio 6.1), preoperative lymphocyte count (OR 0.25), readmission within 30 days (OR 4.2) and type of postoperative analgesia (OR for intrathecal morphine 4.8). The most common causes of readmission were pneumonia, shortness of breath and pain.</AbstractText><AbstractText Label="CONCLUSIONS">Postoperative mortality is not simply due to fixed factors; the impacts of age, gender and surgical procedure on postoperative survival are reduced when the postoperative course of recovery is examined. Perioperative immune function, as portrayed by the occurrence of infection and lower lymphocyte count in the immediate perioperative period, and pain control method are strongly associated with 90 day mortality; further studies in these fields are indicated as are studies of psychological factors in recovery.</AbstractText><AbstractText Label="CLINICAL REGISTRATION NUMBER">ISRCTN00061628.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oswald</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom; Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halle-Smith</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom. Electronic address: b.naidu@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webb</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agostini</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishay</LastName><ForeName>Ehab</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkat</LastName><ForeName>Maninder</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steyn</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Babu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Birmingham, Birmingham, United Kingdom; Department of Thoracic Surgery, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Surg Oncol</MedlineTA><NlmUniqueID>8504356</NlmUniqueID><ISSNLinking>0748-7983</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Readmission</Keyword><Keyword MajorTopicYN="N">Thoracic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30795954</ArticleId><ArticleId IdType="doi">10.1016/j.ejso.2019.02.001</ArticleId><ArticleId IdType="pii">S0748-7983(19)30270-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31138135</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>The relationship of preoperative estimated glomerular filtration rate and outcomes after cardiovascular surgery in patients with normal serum creatinine: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>88</StartPage><MedlinePgn>88</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">88</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-019-0763-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although serum creatinine concentration has been traditionally used as an index of renal function in clinical practice, it is considered relatively inaccurate, especially in patients with mild renal dysfunction. This study investigated the usefulness of preoperative estimated glomerular filtration rate (eGFR) in predicting complications after cardiovascular surgery in patients with normal serum creatinine concentrations.</AbstractText><AbstractText Label="METHODS">This study included 2208 adults undergoing elective cardiovascular surgery. Preoperative eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration equations. The relationships between preoperative eGFR and 90&#x2009;day postoperative composite major complications were analyzed, including 90&#x2009;day all-cause mortality, major adverse cardiac and cerebrovascular events, severe acute kidney injury, respiratory and gastrointestinal complications, wound infection, sepsis, and multi-organ failure.</AbstractText><AbstractText Label="RESULTS">Of the 2208 included patients, 185 (8.4%) had preoperative eGFR &lt;&#x2009;60&#x2009;mL/min/1.73&#x2009;m<sup>2</sup> and 328 (14.9%) experienced postoperative major complications. Multivariable logistic regression analyses showed that preoperatively decreased eGFR was independently associated with an increased risk of composite 90&#x2009;day major postoperative complications (adjusted odds ratio: 1.232; 95% confidence interval [CI]: 1.148-1.322; P&#x2009;&lt;&#x2009;&#xa0;0.001). eGFR was a better discriminator of composite 90&#x2009;day major postoperative complications than serum creatinine, with estimated c-statistics of 0.724 (95% CI: 0.694-0.754) for eGFR and 0.712 (95% CI: 0.680-0.744) for serum creatinine (P&#x2009;=&#x2009;0.008).</AbstractText><AbstractText Label="CONCLUSIONS">Decreased eGFR was significantly associated with an increased risk of major complications after cardiovascular surgery in patients with preoperatively normal serum creatinine concentrations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Myung-Soo</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, College of Medicine, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Jae-Sik</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Jun-Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Chang-Hwa</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seung Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun-Ho</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0002-6369-7429</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. leho@naver.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In-Cheol</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013504" MajorTopicYN="N">Cardiovascular Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular surgery</Keyword><Keyword MajorTopicYN="N">Glomerular filtration rate, creatinine</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31138135</ArticleId><ArticleId IdType="pmc">PMC6540432</ArticleId><ArticleId IdType="doi">10.1186/s12871-019-0763-1</ArticleId><ArticleId IdType="pii">10.1186/s12871-019-0763-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang F, Dupuis JY, Nathan H, Williams K. An analysis of the association between preoperative renal dysfunction and outcome in cardiac surgery: estimated creatinine clearance or plasma creatinine level as measures of renal function. Chest. 2003;124:1852&#x2013;1862. doi: 10.1378/chest.124.5.1852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.124.5.1852</ArticleId><ArticleId IdType="pubmed">14605060</ArticleId></ArticleIdList></Reference><Reference><Citation>Miceli A, Bruno VD, Capoun R, Romeo F, Angelini GD, Caputo M. Occult renal dysfunction: a mortality and morbidity risk factor in coronary artery bypass grafting surgery. J Thorac Cardiovasc Surg. 2011;141:771&#x2013;776. doi: 10.1016/j.jtcvs.2010.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2010.08.016</ArticleId><ArticleId IdType="pubmed">20884025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney JF, Ranasinghe I, Chow CK, et al. Preoperative estimates of glomerular filtration rate as predictors of outcome after surgery: a systematic review and meta-analysis. Anesthesiology. 2013;118:809&#x2013;824. doi: 10.1097/ALN.0b013e318287b72c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318287b72c</ArticleId><ArticleId IdType="pubmed">23377223</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuRahma AF, Alhalbouni S, Abu-Halimah S, Dean LS, Stone PA. Impact of chronic renal insufficiency on the early and late clinical outcomes of carotid artery stenting using serum creatinine vs glomerular filtration rate. J Am Coll Surg. 2014;218:797&#x2013;805. doi: 10.1016/j.jamcollsurg.2013.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.12.038</ArticleId><ArticleId IdType="pmc">PMC4501578</ArticleId><ArticleId IdType="pubmed">24655873</ArticleId></ArticleIdList></Reference><Reference><Citation>Prowle JR, Kam EP, Ahmad T, Smith NC, Protopapa K, Pearse RM. Preoperative renal dysfunction and mortality after non-cardiac surgery. Br J Surg. 2016;103:1316&#x2013;1325. doi: 10.1002/bjs.10186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.10186</ArticleId><ArticleId IdType="pubmed">27346181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JS, Gu A, Wei C, et al. Preoperative estimated glomerular filtration rate is a marker for postoperative complications following revision total knee arthroplasty. J Arthroplast. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30616975</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi MH, Schmidlin D, Schiferer A, et al. Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort study. Br J Anaesth. 2015;114:53&#x2013;62. doi: 10.1093/bja/aeu316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeu316</ArticleId><ArticleId IdType="pubmed">25240162</ArticleId></ArticleIdList></Reference><Reference><Citation>Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003;24:881&#x2013;882. doi: 10.1016/S0195-668X(02)00799-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-668X(02)00799-6</ArticleId><ArticleId IdType="pubmed">12727160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011;124:381&#x2013;387. doi: 10.1161/CIRCULATIONAHA.110.015701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.015701</ArticleId><ArticleId IdType="pubmed">21730309</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001;16:1042&#x2013;1046. doi: 10.1093/ndt/16.5.1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/16.5.1042</ArticleId><ArticleId IdType="pubmed">11328914</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473&#x2013;2483. doi: 10.1056/NEJMra054415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra054415</ArticleId><ArticleId IdType="pubmed">16760447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeysundera DN, Karkouti K, Beattie WS, Rao V, Ivanov J. Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology. 2006;104:65&#x2013;72. doi: 10.1097/00000542-200601000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200601000-00012</ArticleId><ArticleId IdType="pubmed">16394692</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi M, Goodarzynejad H, Karimi A, et al. Is preoperative serum creatinine a reliable indicator of outcome in patients undergoing coronary artery bypass surgery? J Thorac Cardiovasc Surg. 2009;137:304&#x2013;308. doi: 10.1016/j.jtcvs.2008.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2008.08.001</ArticleId><ArticleId IdType="pubmed">19185142</ArticleId></ArticleIdList></Reference><Reference><Citation>Cywinski JB, Mascha EJ, Kurz A, Sessler DI. Estimated glomerular filtration rate better predicts 30-day mortality after non-cardiac surgery than serum creatinine: a retrospective analysis of 92,888 patients. Can J Anaesth. 2015;62:745&#x2013;752. doi: 10.1007/s12630-015-0398-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-015-0398-8</ArticleId><ArticleId IdType="pubmed">25920903</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622&#x2013;627. doi: 10.1053/j.ajkd.2010.02.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2010.02.337</ArticleId><ArticleId IdType="pmc">PMC2846308</ArticleId><ArticleId IdType="pubmed">20338463</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49&#x2013;61. doi: 10.1038/ki.2013.444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.444</ArticleId><ArticleId IdType="pubmed">24284513</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung KW, Jo JY, Kim WJ, et al. Association of preoperative uric acid and acute kidney injury following cardiovascular surgery. J Cardiothorac Vasc Anesth. 2014;28:1440&#x2013;1447. doi: 10.1053/j.jvca.2014.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2014.04.020</ArticleId><ArticleId IdType="pubmed">25245579</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806&#x2013;808. doi: 10.1136/bmj.39335.541782.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EH, Chin JH, Choi DK, et al. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011;25:462&#x2013;468. doi: 10.1053/j.jvca.2010.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.09.008</ArticleId><ArticleId IdType="pubmed">21093290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European perioperative clinical outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015;32:88&#x2013;105. doi: 10.1097/EJA.0000000000000118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000118</ArticleId><ArticleId IdType="pubmed">25058504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen MS, Petersen EE, Dahl JB, Wetterslev J. Post-operative serious adverse events in a mixed surgical population - a retrospective register study. Acta Anaesthesiol Scand. 2016;60:1209&#x2013;1221. doi: 10.1111/aas.12762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.12762</ArticleId><ArticleId IdType="pubmed">27417678</ArticleId></ArticleIdList></Reference><Reference><Citation>Delong ER, Delong DM, Clarkepearson DI. Comparing the areas under 2 or more correlated receiver operating characteristic curves - a nonparametric approach. Biometrics. 1988;44:837&#x2013;845. doi: 10.2307/2531595.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Botev R, Mallie JP, Wetzels JF, Couchoud C, Schuck O. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol. 2011;6:937&#x2013;950. doi: 10.2215/CJN.09241010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.09241010</ArticleId><ArticleId IdType="pubmed">21454722</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo BW, Koh YY, Toh QC, et al. Performance of the CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equations in a multiethnic Asian population. Singap Med J. 2014;55:656&#x2013;659. doi: 10.11622/smedj.2014181.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2014181</ArticleId><ArticleId IdType="pmc">PMC4292005</ArticleId><ArticleId IdType="pubmed">25630321</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong TD, Lee W, Yun YM, Chun S, Song J, Min WK. Development and validation of the Korean version of CKD-EPI equation to estimate glomerular filtration rate. Clin Biochem. 2016;49:713&#x2013;719. doi: 10.1016/j.clinbiochem.2016.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2016.01.023</ArticleId><ArticleId IdType="pubmed">26968101</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo BW, Zhang L, Guh JY, et al. Glomerular filtration rates in Asians. Adv Chronic Kidney Dis. 2018;25:41&#x2013;48. doi: 10.1053/j.ackd.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2017.10.005</ArticleId><ArticleId IdType="pubmed">29499886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28007459</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-3911</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Endothelial markers are associated with pancreatic necrosis and overall prognosis in acute pancreatitis: A preliminary cohort study.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>50</EndPage><MedlinePgn>45-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pan.2016.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1424-3903(16)31252-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endothelial injury is believed to play an important role in the evolution of pancreatic microcirculatory dysfunction and pancreatic necrosis (PN) in patients with acute pancreatitis (AP). The aim of this study was to investigate the role of three endothelial markers (von Willebrand factor, vWF; E-selectin; endothelial protein C receptor, EPCR) in the early phase of AP, especially the relationship between endothelial markers and PN.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From March 2015 to March 2016, 57 AP patients admitted within 72&#xa0;h of symptom onset in our hospital were included for this study. Blood samples were taken on admission and the clinical characteristics and outcomes of these patients were recorded. The levels of vWF, E-selectin and EPCR were measured using ELISA for analysis and compared with other severity markers of AP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All the three markers were significantly different in healthy control, mild, moderate and severe AP patients. Moreover, the endothelial markers, especially vWF, also showed significant difference in patients with different extent of PN, as well as those with or without MODS. Additionally, the levels of endothelial markers correlated well with other commonly used markers of AP severity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated endothelium-related mediators (vWF, E-selectin and EPCR) appear to participate in the development of PN and may be a potential indicator of overall prognosis. Our results may help clinicians better understand the pathophysiological process of the development of PN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yizhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: kkb9832@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yiyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiqin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: njzy_pancrea@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jieshou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019040">E-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074283">Endothelial Protein C Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478370">PROCR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546936">SELE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019040" MajorTopicYN="N">E-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074283" MajorTopicYN="N">Endothelial Protein C Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">E-selectin</Keyword><Keyword MajorTopicYN="N">Endothelial protein C receptor</Keyword><Keyword MajorTopicYN="N">Pancreatic necrosis</Keyword><Keyword MajorTopicYN="N">von Willebrand factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28007459</ArticleId><ArticleId IdType="doi">10.1016/j.pan.2016.12.005</ArticleId><ArticleId IdType="pii">S1424-3903(16)31252-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31288746</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Clinical parameters and outcomes of necrotizing soft tissue infections secondary to gastrointestinal fistulas.</ArticleTitle><Pagination><StartPage>597</StartPage><MedlinePgn>597</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">597</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-019-4248-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Necrotizing soft tissue infections (NSTIs) is severe surgical infections which can occur following trauma or abdominal surgery. NSTIs secondary to gastrointestinal (GI) fistula is a rare but severe complication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cohort study was performed on all subjects presenting with GI fistulas associated NSTIs were included. Clinical characteristics, microbiological profile, operations performed, and outcomes of patients were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2014 and 2017, 39 patients were finally enrolled. The mean age were 46.9&#x2009;years and male were the dominant. For the etiology of fistula, 25 (64.1%) of the patients was due to trauma. Overall, in-hospital death occurred in 15 (38.5%) patients. Microbiologic findings were obtained from 31 patients and Klebsiella pneumoniae was the most common species (41.0%). Eight patients were treated with an open abdomen; negative pressure wound therapy was used in 33 patients and only 2 patients received hyperbaric oxygen therapy. Younger age and delayed abdominal wall reconstruction repair were more common in trauma than in non-trauma. Non-survivors had higher APACHE II score, less source control&lt;&#x2009;48&#x2009;h and lower platelet count on admission than survivors. Multiple organ dysfunction syndrome, multidrug-resistant organisms and source control failure were the main cause of in-hospital mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Trauma is the main cause of GI fistulas associated NSTIs. Sepsis continues to be the most important factor related to mortality. Our data may assist providing enlightenment for quality improvement in these special populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Wenbin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of General Surgery, School of Medicine, Southeast University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Zhiwu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiuwen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Huajian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gefei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Guosheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nthumba</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AIC Kijabe Hospital, Kijabe, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jianan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4697-4762</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China. jiananr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jieshou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medical School of Nanjing University, Jinling Hospital, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BE2016752</GrantID><Agency>Key Project of Jiangsu Social Development</Agency><Country/></Grant><Grant><GrantID>16CXZ007</GrantID><Agency>Innovation Project of Military Medicine</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016154" MajorTopicYN="N">Digestive System Fistula</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="N">Hyperbaric Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007711" MajorTopicYN="N">Klebsiella pneumoniae</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018461" MajorTopicYN="N">Soft Tissue Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gastrointestinal fistula</Keyword><Keyword MajorTopicYN="N">Necrotizing soft tissue infections</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31288746</ArticleId><ArticleId IdType="pmc">PMC6617561</ArticleId><ArticleId IdType="doi">10.1186/s12879-019-4248-0</ArticleId><ArticleId IdType="pii">10.1186/s12879-019-4248-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2001;49(Suppl. 4):iv2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766897</ArticleId><ArticleId IdType="pubmed">11878790</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly PT, Teubner A, Lees NP, Anderson ID, Scott NA, Carlson GL. Outcome of reconstructive surgery for intestinal fistula in the open abdomen. Ann Surg. 2008;247(3):440&#x2013;444. doi: 10.1097/SLA.0b013e3181612c99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181612c99</ArticleId><ArticleId IdType="pubmed">18376187</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P, Novelli A, Menichetti F, Petrosillo N, Tinelli M, Tumbarello M, Sanguinetti M, Viale P, Venditti M, Viscoli C. Italian Society of Infectious and Tropical Diseases. Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. J Chemother. 2017;29(4):197&#x2013;214. doi: 10.1080/1120009X.2017.1311398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1120009X.2017.1311398</ArticleId><ArticleId IdType="pubmed">28378613</ArticleId></ArticleIdList></Reference><Reference><Citation>Schecter WP, Hirshberg A, Chang DS, Harris HW, Napolitano LM, Wexner SD, Dudrick SJ. Enteric fistulas: principles of management. J Am Coll Surg. 2009;209(4):484&#x2013;491. doi: 10.1016/j.jamcollsurg.2009.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2009.05.025</ArticleId><ArticleId IdType="pubmed">19801322</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khoury G, Kaufman D, Hirshberg A. Improved control of exposed fistula in the open abdomen. J Am Coll Surg. 2008;206(2):397&#x2013;398. doi: 10.1016/j.jamcollsurg.2007.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2007.07.027</ArticleId><ArticleId IdType="pubmed">18222399</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LJ, Zolfaghari S, Boushey RP. Complications of enterocutaneous fistulas and their management. Clin Colon Rectal Surg. 2010;23(3):209&#x2013;220. doi: 10.1055/s-0030-1263062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0030-1263062</ArticleId><ArticleId IdType="pmc">PMC2967321</ArticleId><ArticleId IdType="pubmed">21886471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram P, Treutner KH, Stumpf M, Schumpelick V. Postoperative necrotizing soft-tissue infections of the abdominal wall. Langenbeck&#x2019;s Arch Surg. 2000;385(1):39&#x2013;41. doi: 10.1007/s004230050009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004230050009</ArticleId><ArticleId IdType="pubmed">10664119</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh T, Goh LG, Ang CH, Wong CH. Early diagnosis of necrotizing fasciitis. Br J Surg. 2013;101(1):e119&#x2013;ee25. doi: 10.1002/bjs.9371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9371</ArticleId><ArticleId IdType="pubmed">24338771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg. 2009;208(2):279&#x2013;288. doi: 10.1016/j.jamcollsurg.2008.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2008.10.032</ArticleId><ArticleId IdType="pubmed">19228540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JC, Zhang BR, Shi K, Zhang X, Xie CH, Wang J, Yu QH, Gao XX, Hong L, Yu JA. Necrotizing soft tissue infection: clinical characteristics and outcomes at a reconstructive center in Jilin Province. BMC Infect Dis. 2017;17(1):792. doi: 10.1186/s12879-017-2907-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-017-2907-6</ArticleId><ArticleId IdType="pmc">PMC5745726</ArticleId><ArticleId IdType="pubmed">29281989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu GL, Wang L, Wei XM, Li M, Zhang J. Necrotizing fasciitis secondary to enterocutaneous fistula: three case reports. World J Gastroenterol. 2014;20(24):7988&#x2013;7992. doi: 10.3748/wjg.v20.i24.7988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i24.7988</ArticleId><ArticleId IdType="pmc">PMC4069328</ArticleId><ArticleId IdType="pubmed">24976737</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda M, Higashi Y, Shoji T, Hiraide T, Maruo H. Necrotizing fasciitis caused by a primary appendicocutaneous fistula. Surg Today. 2012;42(8):781&#x2013;784. doi: 10.1007/s00595-012-0140-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00595-012-0140-x</ArticleId><ArticleId IdType="pmc">PMC3396344</ArticleId><ArticleId IdType="pubmed">22318638</ArticleId></ArticleIdList></Reference><Reference><Citation>Husnoo N, Patil S, Jackson A, Khan M. Necrotising fasciitis secondary to a colocutaneous fistula. Ann R Coll Surg Engl. 2016;98(7):e130&#x2013;e132. doi: 10.1308/rcsann.2016.0177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/rcsann.2016.0177</ArticleId><ArticleId IdType="pmc">PMC5210003</ArticleId><ArticleId IdType="pubmed">27241606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter OL, Guillamondegui OD, May AK, Diaz JJ. Outcome of necrotizing skin and soft tissue infections. Surg Infect. 2008;9(4):443&#x2013;450. doi: 10.1089/sur.2007.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2007.053</ArticleId><ArticleId IdType="pubmed">18759681</ArticleId></ArticleIdList></Reference><Reference><Citation>Brafa A, Grimaldi L, Brandi C, Nisi G, Calabro M, Campa A, D'Aniello C. Abdominoplasty as a reconstructive surgical treatment of necrotising fasciitis of the abdominal wall. J Plast Reconstr Aesthet Surg. 2009;62(6):e136&#x2013;e139. doi: 10.1016/j.bjps.2008.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2008.07.031</ArticleId><ArticleId IdType="pubmed">19058770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertl CW, Carpp NC, Johnson J, Burke L. Evaluation of factors associated with death in patients with necrotizing fasciitis of the Abdominal Wall. Surg Infect. 2017;18(2):176&#x2013;180. doi: 10.1089/sur.2016.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2016.167</ArticleId><ArticleId IdType="pubmed">27929925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu WH, Lai LJ, Peng KT, Lee CY. Acute pyogenic inguinal abscess from complex soft-tissue infection or intra-abdominal pathology. Surg Infect. 2014;15(5):467&#x2013;473. doi: 10.1089/sur.2012.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2012.008</ArticleId><ArticleId IdType="pubmed">24818646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulla ZD, Gibbs SG, Aronoff DM. Correlates of length of stay, cost of care, and mortality among patients hospitalized for necrotizing fasciitis. Epidemiol Infect. 2007;135(5):868&#x2013;876. doi: 10.1017/S0950268806007448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268806007448</ArticleId><ArticleId IdType="pmc">PMC2870628</ArticleId><ArticleId IdType="pubmed">17083749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonne SL, Kadri SS. Evaluation and Management of Necrotizing Soft Tissue Infections. Infect Dis Clin N Am. 2017;31(3):497&#x2013;411. doi: 10.1016/j.idc.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5656282</ArticleId><ArticleId IdType="pubmed">28779832</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10&#x2013;e52. doi: 10.1093/cid/ciu296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu296</ArticleId><ArticleId IdType="pubmed">24973422</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, et al. Assessment of clinical criteria for Sepsis: for the third international consensus definitions for Sepsis and septic shock (Sepsis-3) Jama. 2016;315(8):762&#x2013;774. doi: 10.1001/jama.2016.0288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0288</ArticleId><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomkin JS, Ristagno RL, Das AF, Cone JB, Wilson SE, Rotstein OD, Murphy BS, Severin KS, Bruss JB. Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections. Clin Infect Dis. 2013;56(12):1765&#x2013;1773. doi: 10.1093/cid/cit128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit128</ArticleId><ArticleId IdType="pubmed">23463643</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486&#x2013;552. doi: 10.1097/CCM.0000000000002255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002255</ArticleId><ArticleId IdType="pubmed">28098591</ArticleId></ArticleIdList></Reference><Reference><Citation>de Prost N, Sbidian E, Chosidow O, Brun-Buisson C, Amathieu R. Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med. 2015;41(8):1506&#x2013;1508. doi: 10.1007/s00134-015-3916-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3916-9</ArticleId><ArticleId IdType="pubmed">26109399</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolandelli R, Roslyn JJ. Surgical management and treatment of sepsis associated with gastrointestinal fistulas. Surg Clin North Am. 1996;76(5):1111&#x2013;1122. doi: 10.1016/S0039-6109(05)70500-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6109(05)70500-4</ArticleId><ArticleId IdType="pubmed">8841366</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SA, Levy BH, Prematilake C, Dissanaike S. The prediction predicament: rethinking necrotizing soft tissue infections mortality. Surg Infect. 2015;16(6):813&#x2013;821. doi: 10.1089/sur.2015.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2015.002</ArticleId><ArticleId IdType="pmc">PMC4663638</ArticleId><ArticleId IdType="pubmed">26258645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IC, Li WC, Hong YC, Shie SS, Fann WC, Hsiao CT. The microbiological profile and presence of bloodstream infection influence mortality rates in necrotizing fasciitis. Crit Care. 2011;15(3):R152. doi: 10.1186/cc10278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc10278</ArticleId><ArticleId IdType="pmc">PMC3219026</ArticleId><ArticleId IdType="pubmed">21693053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng NC, Yu YC, Tai HC, Hsueh PR, Chang SC, Lai SY, Yi WC, Fang CT. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis. 2012;55(7):930&#x2013;939. doi: 10.1093/cid/cis565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cis565</ArticleId><ArticleId IdType="pubmed">22715175</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GL, Patrick H, Amin AI, McPherson G, MacLennan G, Afolabi E, Mowatt G, Campbell B. Management of the open abdomen: a national study of clinical outcome and safety of negative pressure wound therapy. Ann Surg. 2013;257(6):1154&#x2013;1159. doi: 10.1097/SLA.0b013e31828b8bc8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828b8bc8</ArticleId><ArticleId IdType="pubmed">23478532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers WK, Garcia L. Intraabdominal hypertension, abdominal compartment syndrome, and the open abdomen. Chest. 2018;153(1):238&#x2013;250. doi: 10.1016/j.chest.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.07.023</ArticleId><ArticleId IdType="pubmed">28780148</ArticleId></ArticleIdList></Reference><Reference><Citation>Seternes A, Rekstad LC, Mo S, Klepstad P, Halvorsen DL, Dahl T, Bjorck M, Wibe A. Open abdomen treated with negative pressure wound therapy: indications, management and survival. World J Surg. 2017;41(1):152&#x2013;161. doi: 10.1007/s00268-016-3694-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-016-3694-8</ArticleId><ArticleId IdType="pubmed">27541031</ArticleId></ArticleIdList></Reference><Reference><Citation>Arif N, Yousfi S, Vinnard C. Deaths from necrotizing fasciitis in the United States, 2003-2013. Epidemiol Infect. 2016;144(6):1338&#x2013;1344. doi: 10.1017/S0950268815002745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268815002745</ArticleId><ArticleId IdType="pmc">PMC5725950</ArticleId><ArticleId IdType="pubmed">26548496</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass GE, Murphy GF, Esmaeili A, Lai LM, Nanchahal J. Systematic review of molecular mechanism of action of negative-pressure wound therapy. Br J Surg. 2014;101(13):1627&#x2013;1636. doi: 10.1002/bjs.9636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9636</ArticleId><ArticleId IdType="pubmed">25294112</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoye O, Talving P, Lam L, Smith J, Teixeira PG, Inaba K, Koronakis N, Demetriades D. Timing of redebridement after initial source control impacts survival in necrotizing soft tissue infection. Am Surg. 2013;79(10):1081&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">24160803</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao WN, Tsai CF, Chang HR, Chan KS, Su CH, Lee YT, Ueng KC, Chen CC, Chen SC, Lee MC. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg. 2013;206(1):32&#x2013;39. doi: 10.1016/j.amjsurg.2012.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2012.08.008</ArticleId><ArticleId IdType="pubmed">23414632</ArticleId></ArticleIdList></Reference><Reference><Citation>Montravers P, Blot S, Dimopoulos G, Eckmann C, Eggimann P, Guirao X, Paiva JA, Sganga G, De Waele J. Therapeutic management of peritonitis: a comprehensive guide for intensivists. Intensive Care Med. 2016;42(8):1234&#x2013;1247. doi: 10.1007/s00134-016-4307-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4307-6</ArticleId><ArticleId IdType="pubmed">26984317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30257648</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of risk factors for a fulminant Clostridium difficile infection after cardiac surgery: a single-center, retrospective cohort study.</ArticleTitle><Pagination><StartPage>133</StartPage><MedlinePgn>133</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">133</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-018-0597-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Clostridium difficile (CD) is the most common pathogen causing nosocomial diarrhea. The clinical presentation ranges from mild diarrhea to severe complications, including pseudomembranous colitis, toxic megacolon, sepsis, and multi-organ failure. When the disease takes a fulminant course, death ensues rapidly in severe and complex cases. Preventive screening or current prophylactic therapies are not useful. Therefore, this study was conducted to detect risk factors for a fulminant CD infection (CDI) in patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS">Between April 1999 and April 2011, a total of 41,466 patients underwent cardiac surgery at our institution. A review of our hospital database revealed 1256 patients (3.0%) with post-operative diarrheal disease who tested positive for CD; these patients comprised the cohort of this observational study. A fulminant CDI occurred in 153 of these patients (12.2%), which was diagnosed on the basis of gastrointestinal complications, e.g. pseudomembranous colitis, and/or the need for post-cardiac surgery laparotomy. Demographic, peri-operative, and survival data were analyzed, and predictors of a fulminant CDI were assessed by binary logistic regression analysis.</AbstractText><AbstractText Label="RESULTS">The 30-day mortality was 6.1% (n&#x2009;=&#x2009;77) for the entire cohort, with significantly higher mortality among patients with a fulminant CDI (21.6% vs. 4.0%, p&#x2009;&lt;&#x2009;&#xa0;0.001). Overall mortality (27.7%, n&#x2009;=&#x2009;348) was also higher for patients with a fulminant course of the disease (63.4% vs. 22.8%, p&#x2009;&lt;&#x2009;&#xa0;0.001), and a laparotomy was required in 36.6% (n&#x2009;=&#x2009;56) of the fulminant cases. Independent predictors of a fulminant CDI were: diabetes mellitus type 2 (OR 1.74, CI 1.15-2.63, p&#x2009;=&#x2009;0.008), pre-operative ventilation (OR 3.52, CI 1.32-9.35, p&#x2009;=&#x2009;0.012), utilization of more than 8&#xa0;units of red blood cell concentrates (OR 1.95, CI 1.01-3.76, p&#x2009;=&#x2009;0.046) or of more than 5 fresh-frozen plasma units (OR 3.38, CI 2.06-5.54, p&#x2009;&lt;&#x2009;&#xa0;0.001), and a cross-clamp time&#x2009;&gt;&#x2009;130&#xa0;min (OR 1.93, CI 1.12-3.33, p&#x2009;=&#x2009;0.017).</AbstractText><AbstractText Label="CONCLUSIONS">We identified several independent risk factors for the development of a fulminant CDI after cardiac surgery. Close monitoring of high-risk patients is important in order to establish an early onset of therapy and thus to prevent a CDI from developing a fulminant course after cardiac surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vondran</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Thoracic and Vascular Surgery, University Hospital Marburg (UKGM), Baldingerstr, 35043, Marburg, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Center of Cardiovascular Diseases Rotenburg a. d. Fulda, Heinz-Meise-Str. 100, 36199, Rotenburg a. d. F, Germany. m.vondran@hkz-rotenburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schack</LastName><ForeName>Senta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbade</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binner</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mende</LastName><ForeName>Meinhard</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Clinical Trials, University of Leipzig, H&#xe4;rtelstra&#xdf;e 16/18, 04107, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rastan</LastName><ForeName>Ardawan Julian</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Thoracic and Vascular Surgery, University Hospital Marburg (UKGM), Baldingerstr, 35043, Marburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Center of Cardiovascular Diseases Rotenburg a. d. Fulda, Heinz-Meise-Str. 100, 36199, Rotenburg a. d. F, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borger</LastName><ForeName>Michael Andrew</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3159-1440</Identifier><AffiliationInfo><Affiliation>University Department for Cardiac Surgery, Heart Center Leipzig, Struempellstr. 39, 04289, Leipzig, Germany. thomas.schroeter@helios-gesundheit.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004761" MajorTopicYN="N">Enterocolitis, Pseudomembranous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Clostridium difficile</Keyword><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">High risk</Keyword><Keyword MajorTopicYN="N">Intensive care</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The local ethics committee approved the study (University of Leipzig, Az.: 212&#x2013;15-01062015). The study design, anonymous data acquisition, and the publication of the data were in accordance with the Declaration of Helsinki. CONSENT FOR PUBLICATION: Not applicable COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30257648</ArticleId><ArticleId IdType="pmc">PMC6158878</ArticleId><ArticleId IdType="doi">10.1186/s12871-018-0597-2</ArticleId><ArticleId IdType="pii">10.1186/s12871-018-0597-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med. 1989;110:255&#x2013;257. doi: 10.7326/0003-4819-110-4-255.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-110-4-255</ArticleId><ArticleId IdType="pubmed">2643913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758&#x2013;764. doi: 10.7326/0003-4819-145-10-200611210-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-145-10-200611210-00008</ArticleId><ArticleId IdType="pubmed">17116920</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbut F, Leluan P, Antoniotti G, Collignon A, Sedallian A, Petit J. Value of routine stool cultures in hospitalized patients with diarrhea. Eur J Clin Microbiol Infect Dis. 1995;14:346&#x2013;349. doi: 10.1007/BF02116530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02116530</ArticleId><ArticleId IdType="pubmed">7649200</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohner P, Pittet D, Pepey B, Nije-Kinge T, Auckenthaler R. Etiological agents of infectious diarrhea: implications for requests for microbial culture. J Clin Microbiol. 1997;35:1427&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229762</ArticleId><ArticleId IdType="pubmed">9163457</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ, et al. Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome. Ann Thorac Surg. 2007;83:1396&#x2013;1402. doi: 10.1016/j.athoracsur.2006.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2006.10.067</ArticleId><ArticleId IdType="pubmed">17383346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesperance K, Causey MW, Spencer M, Steele SR. The morbidity of Clostridium difficile infection after elective colonic resection&#x2014;results from a national population database. Am J Surg. 2011;201:141&#x2013;148. doi: 10.1016/j.amjsurg.2010.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2010.09.017</ArticleId><ArticleId IdType="pubmed">21266214</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz P, Giannella M, Alcala L, Sarmiento E, Fernandez Yanez J, Palomo J, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26:907&#x2013;914. doi: 10.1016/j.healun.2007.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2007.07.010</ArticleId><ArticleId IdType="pubmed">17845929</ArticleId></ArticleIdList></Reference><Reference><Citation>Flagg A, Koch CG, Schiltz N, Chandran Pillai A, Gordon SM, Pettersson GB, et al. Analysis of Clostridium difficile infections after cardiac surgery: epidemiologic and economic implications from national data. J Thorac Cardiovasc Surg. 2014;148:2404&#x2013;2409. doi: 10.1016/j.jtcvs.2014.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.04.017</ArticleId><ArticleId IdType="pubmed">24823282</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavamurthy S, Koch CG, Fraser TG, Gordon SM, Houghtaling PL, Soltesz EG, et al. Clostridium difficile infection after cardiac surgery: prevalence, morbidity, mortality, and resource utilization. J Thorac Cardiovasc Surg. 2014;148:3157&#x2013;3165. doi: 10.1016/j.jtcvs.2014.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2014.08.017</ArticleId><ArticleId IdType="pubmed">25242055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemaire A, Dombrovskiy V, Batsides G, Scholz P, Solina A, Brownstone N, et al. The effect of Clostridium difficile infection on cardiac surgery outcomes. Surg Infect. 2015;16:24&#x2013;28. doi: 10.1089/sur.2013.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2013.097</ArticleId><ArticleId IdType="pubmed">25402213</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold G. Innere Medizin : eine vorlesungsorientierte Darstellung : 2017 : unter Ber&#xfc;cksichtigung des Gegenstandskataloges f&#xfc;r die &#xc4;rztliche Pr&#xfc;fung : mit ICD 10-Schl&#xfc;ssel im Text und Stichwortverzeichnis. K&#xf6;ln: Gerd Herold, 2017.</Citation></Reference><Reference><Citation>Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13:450&#x2013;455. doi: 10.1097/MCC.0b013e3282638879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0b013e3282638879</ArticleId><ArticleId IdType="pubmed">17599017</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutros M, Al-Shaibi M, Chan G, Cantarovich M, Rahme E, Paraskevas S, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation. 2012;93:1051&#x2013;1057. doi: 10.1097/TP.0b013e31824d34de.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e31824d34de</ArticleId><ArticleId IdType="pubmed">22441318</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubberke ER, Riddle DJ, Practice ASTIDCo. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009;9 Suppl 4:S35&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899697</ArticleId><ArticleId IdType="pubmed">20070693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuijper EJ, Coignard B, Tull P, difficile ESGfC, States EUM, European Centre for Disease P et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2&#x2013;18. doi: 10.1111/j.1469-0691.2006.01580.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2006.01580.x</ArticleId><ArticleId IdType="pubmed">16965399</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonberg R, Gastmeier P. Clostridium-difficile-assoziierte Diarrh&#xf6;: Zunehmende Inzidenz in Deutschland. Epidemiol Bull. 2008;119.</Citation></Reference><Reference><Citation>Vonberg R-P, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients. Germany Emerging infectious diseases. 2007;13:179. doi: 10.3201/eid1301.060611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.060611</ArticleId><ArticleId IdType="pmc">PMC2913657</ArticleId><ArticleId IdType="pubmed">17370545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B, Kuehnen E, et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill. 2007;12:E071115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346&#x2013;353. doi: 10.1086/338260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338260</ArticleId><ArticleId IdType="pubmed">11774082</ArticleId></ArticleIdList></Reference><Reference><Citation>Musa SA, Moran C, Thomson SJ, Cowan ML, McAnulty G, Grounds M, et al. Clostridium difficile-associated disease acquired in the cardiothoracic intensive care unit. J Cardiothorac Vasc Anesth. 2011;25:263&#x2013;267. doi: 10.1053/j.jvca.2010.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.05.004</ArticleId><ArticleId IdType="pubmed">20638863</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53:1173&#x2013;1178. doi: 10.1093/cid/cir668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cir668</ArticleId><ArticleId IdType="pubmed">21976459</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;373:287&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">26176396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1&#x2013;15. doi: 10.1016/S0195-6701(98)90019-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0195-6701(98)90019-6</ArticleId><ArticleId IdType="pubmed">9777516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543&#x2013;1549. doi: 10.1086/523582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/523582</ArticleId><ArticleId IdType="pubmed">18190314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SM, Lee JJ, Yoon HJ. Clinical risk factors for Clostridium difficile-associated diseases. Braz J Infect Dis. 2012;16:256&#x2013;261. doi: 10.1590/S1413-86702012000300007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1413-86702012000300007</ArticleId><ArticleId IdType="pubmed">22729193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreugdenhil H, Heijnen C, Pl&#xf6;tz F, Zijlstra J, Jansen N, Haitsma J, et al. Mechanical ventilation of healthy rats suppresses peripheral immune function. Eur Respir J. 2004;23:122&#x2013;128. doi: 10.1183/09031936.03.00035003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.03.00035003</ArticleId><ArticleId IdType="pubmed">14738243</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunson M, Alexander J. Mechanisms of transfusion-induced immunosuppression. Transfusion. 1990;30:651&#x2013;658. doi: 10.1046/j.1537-2995.1990.30790385527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1990.30790385527.x</ArticleId><ArticleId IdType="pubmed">2205953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings DL, Chopra A, Chambers R, Morgan JA. Clinical outcomes associated with chronic antimicrobial suppression therapy in patients with continuous-flow left ventricular assist devices. Artif Organs. 2014;38:875&#x2013;879. doi: 10.1111/aor.12254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12254</ArticleId><ArticleId IdType="pubmed">24571683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Tillmann E, Subramanian S, Lehmkuhl L, Funkat AK, Leontyev S, et al. Visceral arterial compromise during intra-aortic balloon counterpulsation therapy. Circulation. 2010;122:S92&#x2013;S99. doi: 10.1161/CIRCULATIONAHA.109.929810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.929810</ArticleId><ArticleId IdType="pubmed">20837932</ArticleId></ArticleIdList></Reference><Reference><Citation>Vondran M, Rastan AJ, Tillmann E, Seeburger J, Schroter T, Dhein S, et al. Intra-aortic balloon pump malposition reduces visceral artery perfusion in an acute animal model. Artif Organs. 2016;40:334&#x2013;340. doi: 10.1111/aor.12563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aor.12563</ArticleId><ArticleId IdType="pubmed">26366459</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin N Am. 2009;23:727&#x2013;743. doi: 10.1016/j.idc.2009.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2009.04.011</ArticleId><ArticleId IdType="pmc">PMC2726831</ArticleId><ArticleId IdType="pubmed">19665092</ArticleId></ArticleIdList></Reference><Reference><Citation>Carchman EH, Peitzman AB, Simmons RL, Zuckerbraun BS. The role of acute care surgery in the treatment of severe, complicated Clostridium difficile-associated disease. J Trauma Acute Care Surg. 2012;73:789&#x2013;800. doi: 10.1097/TA.0b013e318265d19f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318265d19f</ArticleId><ArticleId IdType="pubmed">23026914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35067344</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Mortality in polytrauma patients with moderate to severe TBI on par with isolated TBI patients: TBI as last frontier in polytrauma patients.</ArticleTitle><Pagination><StartPage>1443</StartPage><EndPage>1448</EndPage><MedlinePgn>1443-1448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2022.01.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0020-1383(22)00004-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mortality caused by Traumatic Brain Injury (TBI) remains high, despite improvements in trauma and critical care. Polytrauma is naturally associated with high mortality. This study compared mortality rates between isolated TBI (<sub>I</sub>TBI) patients and polytrauma patients with TBI (<sub>P</sub>TBI) admitted to ICU to investigate if concomitant injuries lead to higher mortality amongst TBI patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 3-year cohort study compared polytrauma patients with TBI (<sub>P</sub>TBI) with AIS head &#x2265;3 (and AIS of other body regions &#x2265;3) from a prospective collected database to isolated TBI (<sub>I</sub>TBI) patients from a retrospective collected database with AIS head &#x2265;3 (AIS of other body regions &#x2264;2), both admitted to a single level-I trauma center ICU. Patients &lt;16 years of age, injury caused by asphyxiation, drowning, burns and ICU transfers from and to other hospitals were excluded. Patient demographics, shock and resuscitation parameters, multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), and mortality data were collected and analyzed for group differences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">259 patients were included; 111 <sub>P</sub>TBI and 148 <sub>I</sub>TBI patients. The median age was 54 [33-67] years, 177 (68%) patients were male, median ISS was 26 [20-33]. Seventy-nine (31%) patients died. Patients with <sub>P</sub>TBI developed more ARDS (7% vs. 1%, p&#xa0;=&#xa0;0.041) but had similar MODS rates (18% vs. 10%, p&#xa0;=&#xa0;0.066). They also stayed longer on the ventilator (7 vs. 3 days, p=&lt;0.001), longer in ICU (9 vs. 4 days, p=&lt;0.001) and longer in hospital (24 vs. 11 days, p=&lt;0.001). TBI was the most prevalent cause of death in polytrauma patients. Patients with <sub>P</sub>TBI showed no higher in-hospital mortality rate. Moreover, mortality rates were skewed towards <sub>I</sub>TBI patients (24% vs. 35%, p&#xa0;=&#xa0;0.06).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">There was no difference in mortality rates between <sub>P</sub>TBI and <sub>I</sub>TBI patients, suggesting TBI-severity as the predominant factor for ICU mortality in an era of ever improving acute trauma care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niemeyer</LastName><ForeName>Mjs</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands. Electronic address: m.j.s.niemeyer@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jochems</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houwert</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Lph</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Kjp</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Trauma surgery, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute care</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Multitrauma</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">TBI2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest, financially or otherwise.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35067344</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2022.01.009</ArticleId><ArticleId IdType="pii">S0020-1383(22)00004-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33178897</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2397-5776</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Trauma surgery &amp; acute care open</Title><ISOAbbreviation>Trauma Surg Acute Care Open</ISOAbbreviation></Journal><ArticleTitle>Dilemma of crystalloid resuscitation in non-exsanguinating polytrauma: what is too much?</ArticleTitle><Pagination><StartPage>e000593</StartPage><MedlinePgn>e000593</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e000593</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/tsaco-2020-000593</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aggressive crystalloid resuscitation increases morbidity and mortality in exsanguinating patients. Polytrauma patients with severe tissue injury and subsequent inflammatory response without major blood loss also need resuscitation. This study investigated crystalloid and blood product resuscitation in non-exsanguinating polytrauma patients and studied possible adverse outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 6.5-year prospective cohort study included consecutive trauma patients admitted to a Level 1 Trauma Center intensive care unit (ICU) who survived 48&#x2009;hours. Demographics, physiologic and resuscitation parameters in first 24&#x2009;hours, Denver Multiple Organ Failure scores, adult respiratory distress syndrome (ARDS) data and infectious complications were prospectively collected. Patients were divided in 5&#x2009;L crystalloid volume subgroups (0-5, 5-10, 10-15 and &gt;15&#x2009;L) to make clinically relevant comparisons. Data are presented as median (IQR); p value &lt;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">367 patients (70% men) were included with median age of 46 (28-61) years, median Injury Severity Score was 29 (22-35) and 95% sustained blunt injuries. 17% developed multiple organ dysfunction syndrome (MODS), 4% ARDS and 14% died. Increasing injury severity, acidosis and coagulopathy were associated with more crystalloid administration. Increasing crystalloid volumes were associated with more blood products, increased ventilator days, ICU length of stay, hospital length of stay, MODS, infectious complications and mortality rates. Urgent laparotomy was found to be the most important independent predictor for crystalloid resuscitation in multinominal regression analysis. Further, fresh frozen plasma (FFP) &lt;8&#x2009;hours was less likely to be administered in patients &gt;5&#x2009;L compared with the group 0-5&#x2009;L. With increasing crystalloid volume, the adjusted odds of MODS, ARDS and infectious complications increased 3-4-fold, although not statistically significant. Mortality increased 6-fold in patients who received &gt;15&#x2009;L crystalloids (p=0.03).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Polytrauma patients received large amounts of crystalloids with few FFPs &lt;24&#x2009;hours. In patients with &lt;10 L crystalloids, &lt;24-hour mortality and MODS rates were not influenced by crystalloid resuscitation. Mortality increased 6-fold in patients who received &gt;15&#x2009;L crystalloids &#x2264;24&#x2009;hours. Efforts should be made to balance resuscitation with modest crystalloids and sufficient amount of FFPs.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level 3.</AbstractText><AbstractText Label="STUDY TYPE" NlmCategory="METHODS">Population-based cohort study.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hietbrink</LastName><ForeName>Falco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trauma Surg Acute Care Open</MedlineTA><NlmUniqueID>101698646</NlmUniqueID><ISSNLinking>2397-5776</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">multiple trauma</Keyword><Keyword MajorTopicYN="N">resuscitation</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33178897</ArticleId><ArticleId IdType="pmc">PMC7594544</ArticleId><ArticleId IdType="doi">10.1136/tsaco-2020-000593</ArticleId><ArticleId IdType="pii">tsaco-2020-000593</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bickell WH, Wall MJ, Pepe PE, Martin RR, Ginger VF, Allen MK, Mattox KL. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105&#x2013;9. 10.1056/NEJM199410273311701</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199410273311701</ArticleId><ArticleId IdType="pubmed">7935634</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am 2007;87:55&#x2013;72. 10.1016/j.suc.2006.09.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suc.2006.09.015</ArticleId><ArticleId IdType="pubmed">17127123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton BA, Guy JS, Morris JA, Abumrad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock 2006;26:115&#x2013;21. 10.1097/01.shk.0000209564.84822.f2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000209564.84822.f2</ArticleId><ArticleId IdType="pubmed">16878017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutcher ME, Kornblith LZ, Narayan R, Curd V, Daley AT, Redick BJ, Nelson MF, Fiebig EW, Cohen MJ. A paradigm shift in trauma resuscitation: evaluation of evolving massive transfusion practices. JAMA Surg 2013;148:834&#x2013;40. 10.1001/jamasurg.2013.2911</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2013.2911</ArticleId><ArticleId IdType="pubmed">23864019</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin ND, Codner P, Greene W, Brasel K, Michetti C, AAST Critical Care Committee . Contemporary hemodynamic monitoring, fluid responsiveness, volume optimization, and endpoints of resuscitation: an AAST critical care Committee clinical consensus. Trauma Surg Acute Care Open 2020;5:e000411. 10.1136/tsaco-2019-000411</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000411</ArticleId><ArticleId IdType="pmc">PMC7066619</ArticleId><ArticleId IdType="pubmed">32201737</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Riddez L, et al. . The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019;23:98. 10.1186/s13054-019-2347-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2347-3</ArticleId><ArticleId IdType="pmc">PMC6436241</ArticleId><ArticleId IdType="pubmed">30917843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasotakis G, Sideris A, Yang Y, de Moya M, Alam H, King DR, Tompkins R, Velmahos G, Inflammation and Host Response to Injury Investigators . Aggressive early crystalloid resuscitation adversely affects outcomes in adult blunt trauma patients: an analysis of the glue grant database. J Trauma Acute Care Surg 2013;74:1215&#x2013;22. 10.1097/TA.0b013e3182826e13</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3182826e13</ArticleId><ArticleId IdType="pmc">PMC3984883</ArticleId><ArticleId IdType="pubmed">23609270</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada MY, Ko A, Barmparas G, Smith EJT, Patel BK, Dhillon NK, Thomsen GM, Ley EJ. 10-Year trend in crystalloid resuscitation: reduced volume and lower mortality. Int J Surg 2017;38:78&#x2013;82. 10.1016/j.ijsu.2016.12.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2016.12.073</ArticleId><ArticleId IdType="pubmed">28040501</ArticleId></ArticleIdList></Reference><Reference><Citation>Maegele M, Fr&#xf6;hlich M, Caspers M, Kaske S. Volume replacement during trauma resuscitation: a brief synopsis of current guidelines and recommendations. Eur J Trauma Emerg Surg 2017;43:439&#x2013;43. 10.1007/s00068-017-0771-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-017-0771-0</ArticleId><ArticleId IdType="pubmed">28243715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet J-F. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 2008;64:1211&#x2013;7. 10.1097/TA.0b013e318169cd3c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318169cd3c</ArticleId><ArticleId IdType="pubmed">18469643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas CE. The water of life: a century of confusion. J Am Coll Surg 2001;192:86&#x2013;93. 10.1016/S1072-7515(00)00761-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1072-7515(00)00761-4</ArticleId><ArticleId IdType="pubmed">11192929</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLS Advanced Trauma Life Support&#xae;, student course manual. Tenth edition: American College of Surgeons, 2018.</Citation></Reference><Reference><Citation>Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, et al. . Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012;367:1901&#x2013;11. 10.1056/NEJMoa1209759</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209759</ArticleId><ArticleId IdType="pubmed">23075127</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PGR, Shulman I, Nelson J, Demetriades D. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957&#x2013;65. 10.1016/j.jamcollsurg.2010.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2010.01.031</ArticleId><ArticleId IdType="pubmed">20510805</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Z, Pati S, Potter D, Brown R, Holcomb JB, Grill R, Wataha K, Park PW, Xue H, Kozar RA, et al. . Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1. Shock 2013;40:195&#x2013;202. 10.1097/SHK.0b013e31829f91fc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31829f91fc</ArticleId><ArticleId IdType="pmc">PMC3764452</ArticleId><ArticleId IdType="pubmed">23807246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 2009;114:3033&#x2013;43. 10.1182/blood-2009-02-204966</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-02-204966</ArticleId><ArticleId IdType="pmc">PMC2756208</ArticleId><ArticleId IdType="pubmed">19638625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, Ko TC, Paredes A. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg 2011;112:1289&#x2013;95. 10.1213/ANE.0b013e318210385c</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e318210385c</ArticleId><ArticleId IdType="pmc">PMC3102787</ArticleId><ArticleId IdType="pubmed">21346161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, Leenen LPH. Demographic patterns and outcomes of patients in level I trauma centers in three international trauma systems. World J Surg 2015;39:2677&#x2013;84. 10.1007/s00268-015-3162-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-015-3162-x</ArticleId><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg 2013;74:774&#x2013;9. 10.1097/TA.0b013e31827a6e69</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31827a6e69</ArticleId><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg 2014;77:624&#x2013;9. 10.1097/TA.0000000000000406</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000406</ArticleId><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg 1994;129:39&#x2013;45. 10.1001/archsurg.1994.01420250051006</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. ARDS Definition Task Force . Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526&#x2013;33. 10.1001/jama.2012.5669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured. Trauma Surg Acute Care Open 2020;5:e000398. 10.1136/tsaco-2019-000398</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2019-000398</ArticleId><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="pubmed">32154377</ArticleId></ArticleIdList></Reference><Reference><Citation>Asensio JA, McDuffie L, Petrone P, Rolda&#x144; G, Forno W, Gambaro E, Salim A, Demetriades D, Murray J, Velmahos G, et al. . Reliable variables in the exsanguinated patient which indicate damage control and predict outcome. Am J Surg 2001;182:743&#x2013;51. 10.1016/S0002-9610(01)00809-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(01)00809-1</ArticleId><ArticleId IdType="pubmed">11839351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf6;hlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, Sakka SG, Bouillon B, Wafaisade A, Committee on Emergency Medicine, Intensive Care and Trauma Management of the German Trauma Society Sektion NIS . Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg 2014;76:921&#x2013;8. 10.1097/TA.0000000000000199</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O'Keefe GE, Cohen MJ, Moldawer LL, Tompkins RG, et al. . The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock. Crit Care Med 2012;40:1129&#x2013;35. 10.1097/CCM.0b013e3182376e9f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182376e9f</ArticleId><ArticleId IdType="pmc">PMC3343366</ArticleId><ArticleId IdType="pubmed">22020243</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Leary MP, Keeley JA, Yule A, Suruki C, Plurad DS, Moazzez A, Neville AL, Putnam BA, Kim DY. Clinical predictors of early acute respiratory distress syndrome in trauma patients. Am J Surg 2016;212:1096&#x2013;100. 10.1016/j.amjsurg.2016.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2016.09.008</ArticleId><ArticleId IdType="pubmed">27780558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahr M, Jones G, O'Neal H, Duchesne J, Tatum D. Acute respiratory distress syndrome incidence, but not mortality, has decreased nationwide: a national trauma data bank study. Am Surg 2017;83:323&#x2013;31. 10.1177/000313481708300416</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313481708300416</ArticleId><ArticleId IdType="pubmed">28424124</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Incidence of acute respiratory distress syndrome and associated mortality in a polytrauma population. Trauma Surg Acute Care Open 2018;3:e000232. 10.1136/tsaco-2018-000232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/tsaco-2018-000232</ArticleId><ArticleId IdType="pmc">PMC6307585</ArticleId><ArticleId IdType="pubmed">30623025</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Leenen LPH. Reduction in mortality rates of postinjury multiple organ dysfunction syndrome: a shifting paradigm? A prospective population-based cohort study. Shock 2018;49:33&#x2013;8. 10.1097/SHK.0000000000000938</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId><ArticleId IdType="pubmed">28682941</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Davenport R, Willett K, Brohi K. The burden of infection in severely injured trauma patients and the relationship with admission shock severity. J Trauma Acute Care Surg 2014;76:730&#x2013;5. 10.1097/TA.0b013e31829fdbd7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31829fdbd7</ArticleId><ArticleId IdType="pubmed">24487318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton GE, Du RE, Wei S, Harvin JA, Finkel KW, Wade CE, Kao LS. Positive fluid balance and association with post-traumatic acute kidney injury. J Am Coll Surg 2020;230:190&#x2013;9. 10.1016/j.jamcollsurg.2019.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2019.10.009</ArticleId><ArticleId IdType="pmc">PMC7220831</ArticleId><ArticleId IdType="pubmed">31733328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DG, Nantais J, Rezende-Neto JB, Yazdani S, Vegas P, Rizoli S. Crystalloid resuscitation in trauma patients: deleterious effect of 5L or more in the first 24h. BMC Surg 2018;18:93. 10.1186/s12893-018-0427-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-018-0427-y</ArticleId><ArticleId IdType="pmc">PMC6219036</ArticleId><ArticleId IdType="pubmed">30400852</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida K, Nishimura T, Hagawa N, Kaga S, Noda T, Shinyama N, Yamamoto H, Mizobata Y. The impact of early administration of vasopressor agents for the resuscitation of severe hemorrhagic shock following blunt trauma. BMC Emerg Med 2020;20:26. 10.1186/s12873-020-00322-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12873-020-00322-1</ArticleId><ArticleId IdType="pmc">PMC7164243</ArticleId><ArticleId IdType="pubmed">32299385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohn SM, McCarthy J, Stewart RM, Jonas RB, Dent DL, Michalek JE. Impact of low-dose vasopressin on trauma outcome: prospective randomized study. World J Surg 2011;35:430&#x2013;9. 10.1007/s00268-010-0875-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-010-0875-8</ArticleId><ArticleId IdType="pubmed">21161222</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrois A, Hamada SR, Duranteau J. Fluid resuscitation and vasopressors in severe trauma patients. Curr Opin Crit Care 2014;20:632&#x2013;7. 10.1097/MCC.0000000000000159</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCC.0000000000000159</ArticleId><ArticleId IdType="pubmed">25340381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16433601</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>375</EndPage><MedlinePgn>369-75</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the large body of evidence suggesting a beneficial role of fever in the host response, antipyretic therapy is commonly employed for febrile critically ill patients. Our objective was to evaluate the impact of antipyretic therapy strategies on the outcomes of critically ill patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients admitted to the Trauma Intensive Care Unit over a nine-month period were eligible for inclusion, except those with traumatic brain injury. Patients were randomized on day three of the ICU stay into aggressive or permissive groups. The aggressive group received acetaminophen 650 mg every 6 h for temperature of &gt;38.5 degrees C and a cooling blanket was added for temperature of &gt;39.5 degrees C. The permissive group received no treatment for temperature of &gt;38.5 degrees C, but instead had treatment initiated at temperature of &gt;40 degrees C, at which time acetaminophen and cooling blankets were used until temperature was &lt;40 degrees C. Patient demographics, daily temperatures, systemic inflammatory response syndrome (SIRS) scores, multiple organ dysfunction syndrome (MODS) scores, and infections and complications were recorded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between December, 2002 and September, 2003, 572 patients were screened, of whom 82 met criteria for enrollment. Forty-four patients were randomized to the aggressive group and 38 patients were randomized to the permissive group for a total of 961 and 751 ICU days, respectively. There were 131 infections in the aggressive group and 85 infections in the permissive group (4 +/- 6 vs. 3 +/- 2 infections per patient, p = 0.26). There were seven deaths in the aggressive group and only one death in the permissive group (p = 0.06, Fisher Exact Test). The study was stopped after the first interim analysis due to the mortality difference, related to the issues of waiver of consent and the mandate for minimal risk.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Aggressively treating fever in critically ill patients may lead to a higher mortality rate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulman</LastName><ForeName>Carl I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care, University of Miami Leonard M. Miller School of Medicine, Miami, Florida 33101, USA. carl@miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namias</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Elhaddad</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lasko</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Amortegui</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dy</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Dlugasch</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Baracco</LastName><ForeName>Gio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Surg Infect (Larchmt). 2010 Oct;11(5):495</RefSource><Note>Li, Pam [corrected to Li, Pamela]; Alhaddad, Ahmed [corrected to Elhaddad, Ahmed]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="N">Body Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001833" MajorTopicYN="N">Body Temperature Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16433601</ArticleId><ArticleId IdType="doi">10.1089/sur.2005.6.369</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26998845</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur J Cancer</ISOAbbreviation></Journal><ArticleTitle>Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>33</EndPage><MedlinePgn>22-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2016.01.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(16)00072-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL).</AbstractText><AbstractText Label="MATERIAL AND METHODS">This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI&#x2265;8 or&#x2264;12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS followed by systemic adjuvant chemotherapy (arm A, standard), or NACT followed by IDS (NACT/IDS) (arm B, experimental). Co-primary outcome measures were postoperative complications (graded according to the Memorial Sloan Kettering Cancer Center&#xa0;surgical secondary events grading system) and progression free survival (PFS); secondary outcomes were overall survival, and quality of life (QoL). QoL was assessed using the EORTC QoL questionnaires. A sample size of 110 patients was required for the analysis of the first co-primary end-point (major peri-operative morbidity) whereas recruitment is still on-going to achieve the statistical power on PFS.</AbstractText><AbstractText Label="RESULTS">Between October 2011 and November 2014, we registered 280 AEOC. Of the 110 eligible women, 55 were assigned to arm A and 55 to arm B. Despite different extension of surgery, rates of complete residual disease (residual tumour=0&#xa0;cm) were superimposable between the groups (45.5% versus 57.7%; p=0.206). Twenty-nine patients (52.7%) in arm A experienced early grade III-IV complications versus three patients (5.7%) in IDS (p=0.0001). The most common complication was grade III and consisted of symptomatic pleural effusion requiring thoracic drainage (17/55 women (30.9%) in arm A versus 1/52 (1.9%) in arm B, p=0.0001). Three grade IV (5.4%) (i.e., two re-operations for postoperative haemorrhage and one septic multi-organ failure), and two grade V (3.6%) (two deaths for acute cardiopulmonary failure) early complications were observed in arm A only. Mean QoL scores of several scales/items were shown to ameliorate over time in both arms. Emotional functioning, cognitive functioning, nausea/vomiting, dyspnoea, insomnia and hair loss were statistically and clinically better in NACT/IDS compared to PDS arm.</AbstractText><AbstractText Label="CONCLUSIONS">Perioperative moderate/severe morbidity as well as QoL scores were shown to be more favourable in NACT/IDS arm than PDS in AEOC patients with very HTL. Completion of patient enrolment and analysis of survival data will clarify whether PDS with such a high rate of severe complications is an acceptable treatment in AEOC women with HTL.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagotti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Minimally Invasive Gynecological Surgery, St. Maria Hospital, University of Perugia, Terni, Italy. Electronic address: anna.fagotti@rm.unicatt.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrandina</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizzielli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanfani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallotta</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiantera</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Foundation for Research and Care "Giovanni Paolo II", Catholic University of the Sacred Heart and University of Molise, Campobasso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantini</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margariti</LastName><ForeName>Pasquale Alessandro</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gueli Alletti</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortorella</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scambia</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001828" MajorTopicYN="N">Body Image</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065426" MajorTopicYN="N">Cytoreduction Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced ovarian cancer</Keyword><Keyword MajorTopicYN="N">Cytoreduction</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Peri-operative complications</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Randomised clinical trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26998845</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2016.01.017</ArticleId><ArticleId IdType="pii">S0959-8049(16)00072-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25853746</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>15</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Effects of red-cell storage duration on patients undergoing cardiac surgery.</ArticleTitle><Pagination><StartPage>1419</StartPage><EndPage>1429</EndPage><MedlinePgn>1419-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1414219</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some observational studies have reported that transfusion of red-cell units that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse events. Patients undergoing cardiac surgery may be especially vulnerable to the adverse effects of transfusion.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized trial at multiple sites from 2010 to 2014. Participants 12 years of age or older who were undergoing complex cardiac surgery and were likely to undergo transfusion of red cells were randomly assigned to receive leukocyte-reduced red cells stored for 10 days or less (shorter-term storage group) or for 21 days or more (longer-term storage group) for all intraoperative and postoperative transfusions. The primary outcome was the change in Multiple Organ Dysfunction Score (MODS; range, 0 to 24, with higher scores indicating more severe organ dysfunction) from the preoperative score to the highest composite score through day 7 or the time of death or discharge.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median storage time of red-cell units provided to the 1098 participants who received red-cell transfusion was 7 days in the shorter-term storage group and 28 days in the longer-term storage group. The mean change in MODS was an increase of 8.5 and 8.7 points, respectively (95% confidence interval for the difference, -0.6 to 0.3; P=0.44). The 7-day mortality was 2.8% in the shorter-term storage group and 2.0% in the longer-term storage group (P=0.43); 28-day mortality was 4.4% and 5.3%, respectively (P=0.57). Adverse events did not differ significantly between groups except that hyperbilirubinemia was more common in the longer-term storage group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The duration of red-cell storage was not associated with significant differences in the change in MODS. We did not find that the transfusion of red cells stored for 10 days or less was superior to the transfusion of red cells stored for 21 days or more among patients 12 years of age or older who were undergoing complex cardiac surgery. (Funded by the National Heart, Lung, and Blood Institute; RECESS ClinicalTrials.gov number, NCT00991341.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From Fairview-University Medical Center, Minneapolis (M.E.S., S.P., J.M.), and Mayo Clinic, Rochester (G.A.N.) - both in Minnesota; Johns Hopkins University (P.M.N., G.W.) and University of Maryland (R.C.) - both in Baltimore; New England Research Institutes, Data Coordinating Center, Watertown (S.F.A., S.G.), Boston Children's Hospital (S.R.S.), Massachusetts General Hospital (L.B., C.P.S.), Brigham and Women's Hospital (R.M.K.), Tufts University (R.E.), St. Elizabeth's Medical Center (R.H.), and Beth Israel Deaconess Medical Center (L.U.), Boston, and Baystate Medical Center, Springfield (R.E.) - all in Massachusetts; University of Pittsburgh and University of Pittsburgh-Mercy Hospital, Pittsburgh (D.J.T., P.D.); Puget Sound Blood Center and University of Washington (M.D.) and Swedish Medical Center (S.Y.) - all in Seattle; Duke University, Durham (E.B.-G., J.H.L., T.L.O.), and University of North Carolina, Chapel Hill (Y.P.) - both in North Carolina; McMaster University, Hamilton, ON, Canada (M.A.B.); Indiana-Ohio Heart and St. Joseph Hospital (V.S.) - both in Fort Wayne, IN; Rutgers Robert Wood Johnson Medical School, New Brunswick (J.L.C.), and Newark Beth Israel Medical Center, Newark (R.K.) - both in New Jersey; University of Iowa, Iowa City (T.R.); Aurora St. Luke's Medical Center (K.E.P.) and Froedert Memorial Lutheran Hospital (J.G.M.), Milwaukee, and Aspirus Heart and Vascular Institute, Wausau (R.M.) - all in Wisconsin; Vanderbilt University, Nashville (P.P.Y.); University of Texas Southwestern Medical Center, Dallas (P.E.G.); Children's Healthcare of Atlanta, Emory University, and Emory University Hospital, Atlanta (C.D.J.); St. Luke's-Texas Heart Institute, Houston (A.B.); Weill Cornell Medical College (M.M.C.) and Columbia University Medical Center (E.A.H.) - both in New York; University of Florida, Gainesville (C.T.K.); University of Oklahoma, Oklahoma City (P.R.R.); and University of North Dakota School of Medicine and Health Sciences, Fargo (C.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ness</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Assmann</LastName><ForeName>Susan F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>Darrell J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Delaney</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett-Guerrero</LastName><ForeName>Elliott</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Blajchman</LastName><ForeName>Morris A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Scavo</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Jerrold H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Whitman</LastName><ForeName>Glenn</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pulkrabek</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ortel</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Bornikova</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Raife</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Puca</LastName><ForeName>Kathleen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Nuttall</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Pampee P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Engelman</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Greilich</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Bracey</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Rhonda</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hunsaker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Uhl</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McFarland</LastName><ForeName>Janice G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yara</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cushing</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Klodell</LastName><ForeName>Charles T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Karanam</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Pamela R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Dyke</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hod</LastName><ForeName>Eldad A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00991341</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL101382</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072331</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025758</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283-4. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176390</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001788" MajorTopicYN="N">Blood Grouping and Crossmatching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="Y">Blood Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25853746</ArticleId><ArticleId IdType="mid">NIHMS696944</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91:13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess JR. Red cell changes during storage. Transfus Apher Sci. 2010;43:51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A. 2007;104:17063&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040393</ArticleId><ArticleId IdType="pubmed">17940021</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani A, Steiner ME, Hebbel RP. The dynamic regulation of microcirculatory conduit function: features relevant to transfusion medicine. Transfus Apher Sci. 2010;43:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920132</ArticleId><ArticleId IdType="pubmed">20580315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery in transfusion with &#x201c;fresh&#x201d; and &#x201c;old&#x201d; red blood cells: the experimental evidence. Transfus Apher Sci. 2010;43:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918661</ArticleId><ArticleId IdType="pubmed">20646963</ArticleId></ArticleIdList></Reference><Reference><Citation>Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. Transfus Apher Sci. 2010;43:95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19152602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49:1384&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of &#x201c;old&#x201d; (versus &#x201c;fresh&#x201d;) red blood cells: are we at equipoise? Transfusion. 2010;50:600&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L. Red cell storage and prognosis. Vox Sang. 2011;100:36&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21175654</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Chin-Yee I, Fergusson D, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005;100:1433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Stafford-Smith M, Waweru PM, et al. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion. 2009;49:1375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson DA, H&#xe9;bert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi MM, Yii M, Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503942</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CGH, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thorac Surg. 2008;86:554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640333</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgren G, Kamper-J&#xf8;rgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients. Transfusion. 2010;50:1185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201703</ArticleId><ArticleId IdType="pubmed">20158690</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7) Transfus Apher Sci. 2010;43:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918709</ArticleId><ArticleId IdType="pubmed">20655807</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836558</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. 17th. Bethesda, MD: AABB Press; 2011. p. 192.</Citation></Reference><Reference><Citation>Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4612056</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood. 2011;118:6675&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242722</ArticleId><ArticleId IdType="pubmed">22021369</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker BI, Hinkins S.  The 2011 National blood collection and utilization survey report. Washington, DC: Department of Health and Human Services; 2013.   http://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/11-nbcus-report.pdf.</Citation></Reference><Reference><Citation>Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16607235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert P, Fergusson D, et al. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21505984</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1672-0733</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban</Title><ISOAbbreviation>J Huazhong Univ Sci Technolog Med Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical effects of intensive insulin therapy treating traumatic shock combined with multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>194</StartPage><EndPage>198</EndPage><MedlinePgn>194-198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11596-011-0251-4</ELocationID><Abstract><AbstractText>The therapeutic effects of intensive insulin therapy in treatment of traumatic shock combined with multiple organ dysfunction syndrome (MODS) were investigated. A total of 114 patients with traumatic shock combined with MODS were randomly divided into two groups: control group (n=56) treated with conventional therapy, and intensive insulin therapy group (n=58) treated with conventional therapy plus continuous insulin pumping to control the blood glucose level at range of 4.4-6.1 mmol/L. White blood cells (WBC) counts, prothrombin time (PT), serum creatinine (SCr), alanine aminotransferase (ALT), serum albumin and PaO(2) were measured before and at the day 1, 3, 5, 7 and 14 after treatment. The incidence of gastrointestinal dysfunction, the incidence of MODS, hospital stay and the mortality were also observed and compared. After intensive insulin therapy, the WBC counts, SCr, ALT and PT were significantly reduced (P&lt;0.05), but the level of serum albumin was significantly increased (P&lt;0.05) at the day 3, 5, 7 and 14. In the meantime, the PaO2 was significantly elevated at the day 3, 5 and 7 (P&lt;0.01) after intensive insulin therapy. The incidence of gastrointestinal dysfunction, the incidence of MODS, the length of hospital stay and the mortality were markedly decreased (P&lt;0.01). The results suggest early treatment with intensive insulin therapy is effective for traumatic shock combined with MODS and can decrease the length of hospital stay and the mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Jundong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongming</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, 400042, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China. liurong301@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yongming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Huabo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Huinan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary Surgery, First Affiliated Hospital to General Hospital of PLA, Beijing, 100037, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Huazhong Univ Sci Technolog Med Sci</MedlineTA><NlmUniqueID>101169627</NlmUniqueID><ISSNLinking>1672-0733</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012774" MajorTopicYN="N">Shock, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21505984</ArticleId><ArticleId IdType="doi">10.1007/s11596-011-0251-4</ArticleId><ArticleId IdType="pii">10.1007/s11596-011-0251-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crit Care Med. 1995 Oct;23(10):1638-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Dec;15(12):739-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14659059</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Nov 8;345(19):1359-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11794168</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 2000 Feb;127(2):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10686974</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Clin. 2001 Jan;17(1):107-24</Citation><ArticleIdList><ArticleId IdType="pubmed">11219223</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2002 Oct;6(5):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">12398773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 1995 Jul;4(1):39-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7552775</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2004 Oct;32(10):2029-38</Citation><ArticleIdList><ArticleId IdType="pubmed">15483411</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Surg. 1997 Jul;84(7):920-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9240130</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 1998 Jan;175(1):76-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 1985 Oct;120(10):1109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2002 Oct 15;106(16):2067-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12379575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutrition. 2001 May;17(5):409-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11377135</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1999 May;88(5):1011-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10320160</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2007 Oct 14;13(38):5043-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17876868</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2004 Jan;89(1):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">14715853</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab. 2001 Apr;27(2 Pt 2):233-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11452216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 1985 Jun;74(6):1255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">3889459</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2008;12(1):R29</Citation><ArticleIdList><ArticleId IdType="pubmed">18312617</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2010 Jul;24(7):2583-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20203087</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2000 Mar;66(3):284-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10759201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31629616</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Early hypoalbuminemia is associated with 28-day mortality in severely burned patients: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>630</StartPage><EndPage>638</EndPage><MedlinePgn>630-638</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2019.09.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0305-4179(19)30495-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Hypoalbuminemia is a frequent condition in the first 24&#x2009;h after a severe burn injury and is associated with worse outcomes.</AbstractText><AbstractText Label="METHODOLOGY">We investigated the relation between very early hypoalbuminemia (&lt;6&#x2009;h after admission) and clinical outcome in a retrospective cohort admitted to our unit for severe burn injuries between 2012 and 2017.</AbstractText><AbstractText Label="RESULTS">73 severely burned patients were included, with a delay of admission of 3 (2-4)&#x2009;h. In a context of early exogenous supply of albumin, admission and 4H Albuminemia (Alb4&#x2009;h) were significantly lower in deceased patients (respectively, 34 (29-37) vs 27 (23-30) g/l; p&#x2009;=&#x2009;0.009 and 27 (24-32) vs 21 (17-27) g/l; p&#x2009;=&#x2009;0.022) whereas albuminemia &#x2265;6&#x2009;h were not. The best threshold value of Alb4&#x2009;h to discriminate 28-day mortality was 23&#x2009;g/l. Patients with an Alb4&#x2009;h&#x2009;&lt;&#x2009;23&#x2009;g/l had a higher 28-day mortality than patients with an Alb4&#x2009;h&#x2009;&#x2265;&#x2009;23&#x2009;g/l (42% vs 11%; p&#x2009;=&#x2009;0.003); adjusted OR&#x2009;=&#x2009;4.47 (95% CI 1.15-17.36); p&#x2009;=&#x2009;0.03.</AbstractText><AbstractText Label="CONCLUSION">In severely burned patients receiving early albumin supply, early hypoalbuminemia is associated with higher mortality whereas later albuminemia (&#x2265;6&#x2009;h) is not. Exploration of whether early albumin infusion (8-12&#x2009;h post injury) may alter clinical outcome is warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd and ISBI. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Tymowski</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; INSERM U1149, Centre de Recherche sur l'Inflammation CRI, Paris, France; Laboratoire d'Excellence (Labex) Inflammex, ComUE Sorbonne Paris Cit&#xe9;, Paris, France. Electronic address: chrisdetymowski@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallado</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France. Electronic address: simon.pallado@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anstey</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Royal Melbourne Hospital, Parkville, Melbourne, Australia. Electronic address: James.Anstey@mh.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depret</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: depret.francois@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Nabilla</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Biochemistry laboratory, Paris, France. Electronic address: nabillanabila.moreno@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benyamina</LastName><ForeName>Mourad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France. Electronic address: mourad.benyamina@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cupaciu</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jully</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oueslati</LastName><ForeName>Haikel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratani</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coutrot</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaussard</LastName><ForeName>Mait&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemet</LastName><ForeName>Lucie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudoignon</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimoun</LastName><ForeName>Maurice</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisi&#xe8;re, Plastic Surgery and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaouat</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St Louis-Lariboisi&#xe8;re, Plastic Surgery and Burn Unit, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mebazaa</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: alexandre.mebazaa@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legrand</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: matthieu.m.legrand@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soussi</LastName><ForeName>Sabri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>H&#xf4;pitaux de Paris (AP-HP), Groupe Hospitalier St-Louis-Lariboisi&#xe8;re, Department of Anesthesiology and Critical Care and Burn Unit, Paris, France; University Paris Diderot, Paris, France; Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM), UMR INSERM 942, Lariboisi&#xe8;re Hospital, Paris, France. Electronic address: sabri.soussi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PRONOBURN group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077324">Crystalloid Solutions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002053" MajorTopicYN="N">Burn Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002199" MajorTopicYN="Y">Capillary Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077324" MajorTopicYN="N">Crystalloid Solutions</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034141" MajorTopicYN="N">Hypoalbuminemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albuminemia</Keyword><Keyword MajorTopicYN="N">Burn injury</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31629616</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2019.09.013</ArticleId><ArticleId IdType="pii">S0305-4179(19)30495-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28586262</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-9034</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of laparoendoscopic &amp; advanced surgical techniques. Part A</Title><ISOAbbreviation>J Laparoendosc Adv Surg Tech A</ISOAbbreviation></Journal><ArticleTitle>Effect of Laparoscopic Peritoneal Lavage and Drainage and Continuous Venovenous Diahemofiltration on Severe Acute Pancreatitis.</ArticleTitle><Pagination><StartPage>1145</StartPage><EndPage>1150</EndPage><MedlinePgn>1145-1150</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/lap.2016.0637</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute pancreatitis (SAP), one severe and fatal disease, the therapy of which is pretty hard. This study aimed to study the effect of laparoscopic peritoneal lavage and drainage (LPLD) and continuous venovenous diahemofiltration (CVVDH) on SAP.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Two hundred forty-five patients with SAP in total were randomly assigned into four groups according to the therapeutic plan: basic treatment; LPLD; CVVDH; or LPLD+CVVDH. Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, the ratios of multiple organ dysfunction syndrome (MODS), mortality, hospitalization time, hospitalization cost, ratios of complications, the abdominal distention relief time, abdominal pain relief time, plasma concentration of endotoxin, tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), interleukin (IL)-6, and IL-8 were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ratios of MODS, mortality, hospitalization time, hospitalization cost, the abdominal distention relief time, abdominal pain relief time, concentration of endotoxin, TNF-&#x3b1;, IL-6, IL-8, and APACHE II scores were significantly decreased in the CVVDH, LPLD, and CVVDH+LPLD groups, while ratios of recovery were significantly increased in the CVVDH, LPLD, and CVVDH+LPLD groups, especially in the CVVDH+LPLD group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LPLD and CVVDH are effective in the treatment of SAP by eliminating endotoxin, TNF-&#x3b1;, IL-6, and IL-8. The combination of CVVDH and LPLD can further improve the treatment effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guiliang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>2 Department of Scientific Research, Gannan Medical University , Gan Zhou, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Linfang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Jianbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1 Department of Hepatobiliary Surgery, Gannan Medical University Pingxiang Hospital , Pingxiang, People's Republic of China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shu-Feng</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>3 Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida , Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xianzhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>4 Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University , Changsha, People's Republic of China .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Laparoendosc Adv Surg Tech A</MedlineTA><NlmUniqueID>9706293</NlmUniqueID><ISSNLinking>1092-6429</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004322" MajorTopicYN="N">Drainage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010533" MajorTopicYN="N">Peritoneal Lavage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">continuous venovenous diahemofiltration</Keyword><Keyword MajorTopicYN="N">drainage</Keyword><Keyword MajorTopicYN="N">laparoscopic debridement</Keyword><Keyword MajorTopicYN="N">severe acute pancreatitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28586262</ArticleId><ArticleId IdType="doi">10.1089/lap.2016.0637</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31640724</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>The risk factors for postoperative cerebral complications in patients with Stanford type a aortic dissection.</ArticleTitle><Pagination><StartPage>178</StartPage><MedlinePgn>178</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">178</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-019-1009-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postoperative cerebral complications (PCC) are common and serious postoperative complications for patients with Stanford type A aortic dissection (AAD). The aim of this study was to evaluate the risk factors for PCC in these patients and to provide a scientific basis for effective prevention of PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective case-control study, 125 patients with AAD who underwent thoracotomy in our department from October 2017 to October 2018 in the department of cardiovascular surgery, Fujian Medical University Union Hospital were divided into two groups: patients with PCC (n&#x2009;=&#x2009;12), and patients without PCC (n&#x2009;=&#x2009;113). The general clinical data, the types of corrective surgeries, the intraoperative situations, the postoperative complications, and the midterm outcomes of the patients were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients with PCC were significantly older than the patients without PCC (P&#x2009;=&#x2009;0.016), and the incidence of the preoperative cerebral disease history in the patients with PCC was significantly higher than those of the PCC (-) group (P&#x2009;=&#x2009;0.024). The Euro SCORE II of patients with PCC was dramatically higher than the patients without PCC (P&#x2009;=&#x2009;0.005). There were significant differences between the two groups in terms of the duration of cardiopulmonary bypass (CPB) (P&#x2009;=&#x2009;0.010) and the length of moderate hypothermic circulatory arrest (MHCA) combined with selective cerebral perfusion (SCP) (P&#x2009;=&#x2009;0.000). The monitoring of rcSO<sub>2</sub> indicated that there was significant difference between the two groups in terms of the bilateral baseline (P&#x2009;=&#x2009;0.000). Patients with PCC were observed to have experienced significantly longer intubation times (P&#x2009;=&#x2009;0.000), ICU stays (P&#x2009;=&#x2009;0.001), and postoperative hospital stays (P&#x2009;=&#x2009;0.009), and they also had dramatically higher rates of pulmonary infection (P&#x2009;=&#x2009;0.000), multiple organ dysfunction syndrome (P&#x2009;=&#x2009;0.041) and tracheotomy (P&#x2009;=&#x2009;0.022) after surgeries. The duration of MHCA+SCP (OR:9.009, P&#x2009;=&#x2009;0.034) and the average baseline value of rcSO<sub>2</sub> (OR:0.080, P&#x2009;=&#x2009;0.009) were ultimately identified as significant risk factors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PCC has a serious influence on the prognoses of patients following surgical treatment with AAD. The duration of MHCA+SCP and the average baseline value of rcSO<sub>2</sub> were the independent risk factors for PCC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1442-5654</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China. birdman1983@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Fang</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruo-Meng</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Liang-Wan</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou City, 350001, Fujian Province, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000784" MajorTopicYN="N">Aortic Dissection</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001011" MajorTopicYN="N">Aorta</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003128" MajorTopicYN="N">Coma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055191" MajorTopicYN="N">Delayed Emergence from Anesthesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007036" MajorTopicYN="N">Hypothermia, Induced</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010477" MajorTopicYN="N">Perfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057234" MajorTopicYN="N">Preoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013575" MajorTopicYN="N">Syncope</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013908" MajorTopicYN="Y">Thoracotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aneurysm, dissecting</Keyword><Keyword MajorTopicYN="N">Circulatory arrest, deep hypothermia induced</Keyword><Keyword MajorTopicYN="N">Oximetry</Keyword><Keyword MajorTopicYN="N">Postoperative complications</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31640724</ArticleId><ArticleId IdType="pmc">PMC6805587</ArticleId><ArticleId IdType="doi">10.1186/s13019-019-1009-5</ArticleId><ArticleId IdType="pii">10.1186/s13019-019-1009-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Bartolomeo R, Berretta P, Pantaleo A, Murana G, Cefarelli M, Alfonsi J, et al. Long-term outcomes of open arch repair after a prior aortic operation: our experience in 154 patients. Ann Thorac Surg. 2017;103:1406&#x2013;1412. doi: 10.1016/j.athoracsur.2016.08.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.08.090</ArticleId><ArticleId IdType="pubmed">27825691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefarelli M, Murana G, Surace GG, Castrovinci S, Jafrancesco G, Kelder JC, et al. Elective aortic arch repair: factors influencing neurologic outcome in 791 patients. Ann Thorac Surg. 2017;104:2016&#x2013;2023. doi: 10.1016/j.athoracsur.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.05.009</ArticleId><ArticleId IdType="pubmed">28760465</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerny M, Kr&#xe4;henb&#xfc;hl E, Reineke D, Sodeck G, Englberger L, Weber A, et al. Mortality and neurologic injury after surgical repair with hypothermic circulatory arrest in acute and chronic proximal thoracic aortic pathology: effect of age on outcome. Circulation. 2011;124:1407&#x2013;1413. doi: 10.1161/CIRCULATIONAHA.110.010124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.010124</ArticleId><ArticleId IdType="pubmed">21875908</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 guidelines for the early Management of Patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2018;49:e46&#x2013;e110. doi: 10.1161/STR.0000000000000158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0000000000000158</ArticleId><ArticleId IdType="pubmed">29367334</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, et al. 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883&#x2013;1948. doi: 10.5603/KP.2018.0161.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.2018.0161</ArticleId><ArticleId IdType="pubmed">29562304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Margolin R, Francis J, May L, Truman B, Speroff T, et al. Evaluation of delirium in critically ill patients: validation of the confusion assessment method for the intensive care unit (CAM-ICU) Crit Care Med. 2001;29:1370&#x2013;1379. doi: 10.1097/00003246-200107000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200107000-00012</ArticleId><ArticleId IdType="pubmed">11445689</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81&#x2013;84. doi: 10.1016/S0140-6736(74)91639-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(74)91639-0</ArticleId><ArticleId IdType="pubmed">4136544</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzabazis A, Miller C, Dobrow MF, Zheng K. Delayed emergence after anesthesia. J Clin Anesth. 2015;27:353&#x2013;360. doi: 10.1016/j.jclinane.2015.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2015.03.023</ArticleId><ArticleId IdType="pubmed">25912729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond agitation-sedation scale (RASS) JAMA. 2003;289:2983&#x2013;2991. doi: 10.1001/jama.289.22.2983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.22.2983</ArticleId><ArticleId IdType="pubmed">12799407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Wu XJ, Liao DS, Hu YN, Zhang H, et al. Ascending aorta and Hemiarch replacement combined with modified triple-branched stent graft implantation for repair of acute DeBakey type I aortic dissection. Ann Thorac Surg. 2017;103:595&#x2013;601. doi: 10.1016/j.athoracsur.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.06.017</ArticleId><ArticleId IdType="pubmed">27553503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Qi R, Zhu J, Liu Y, Chang Q, Zheng J. Repair of acute type a dissection: our experiences and results. Ann Thorac Surg. 2011;91:1147&#x2013;1152. doi: 10.1016/j.athoracsur.2010.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2010.12.005</ArticleId><ArticleId IdType="pubmed">21440135</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin W, Zhang X, Yang S, Li Y, Yuan J, Yang L, et al. Risk factors for multiple organ dysfunction syndrome in severe stroke patients. PLoS One. 2016;11:e0167189. doi: 10.1371/journal.pone.0167189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167189</ArticleId><ArticleId IdType="pmc">PMC5125686</ArticleId><ArticleId IdType="pubmed">27893797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YC, Qi ZW, Guo SG, Wang Z, Yu XZ, Ma S, et al. Role of corticotrophin releasing hormone in cerebral infarction-related gastrointestinal barrier dysfunction. World J Emerg Med. 2011;2:59&#x2013;65. doi: 10.5847/wjem.j.1920-8642.2011.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2011.01.011</ArticleId><ArticleId IdType="pmc">PMC4129739</ArticleId><ArticleId IdType="pubmed">25214985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CJ, Hung JW, Cho CY, Tseng CY, Chen HY, Lin FC, et al. Poststroke constipation in the rehabilitation ward: incidence, clinical course and associated factors. Singapore Med J. 2013;54:624&#x2013;629. doi: 10.11622/smedj.2013222.</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2013222</ArticleId><ArticleId IdType="pubmed">24276098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller BJ, Graf R, Jacobs AH. Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol. 2006;101:1655&#x2013;1665. doi: 10.1111/j.1572-0241.2006.00540.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00540.x</ArticleId><ArticleId IdType="pubmed">16863574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji R, Wang D, Shen H, Pan Y, Liu G, et al. Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke. 2013;44:3436&#x2013;3444. doi: 10.1111/j.1572-0241.2006.00540.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00540.x</ArticleId><ArticleId IdType="pubmed">24178914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CM, Hsu HC, Chuang YW, Chang CH, Lin CH, Hong CZ. Study on factors affecting the occurrence of upper gastrointestinal bleeding in elderly acute stroke patients undergoing rehabilitation. J Nutr Health Aging. 2011;15:632&#x2013;636. doi: 10.1007/s12603-011-0052-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-011-0052-2</ArticleId><ArticleId IdType="pubmed">21968857</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Li J, Lv F, Li K, Luo T, Xie P. A multidetector CT angiography study of variations in the circle of Willis in a Chinese population. J Clin Neurosci. 2011;18:379&#x2013;383. doi: 10.1016/j.jocn.2010.07.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2010.07.137</ArticleId><ArticleId IdType="pubmed">21251838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14:575&#x2013;585. doi: 10.1016/j.cmet.2011.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.07.015</ArticleId><ArticleId IdType="pmc">PMC3217209</ArticleId><ArticleId IdType="pubmed">22055501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos D, van der Rijk MJ, Geeraedts TE, Hofman A, Krestin GP, Witteman JC, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke. 2012;43:1878&#x2013;1884. doi: 10.1161/STROKEAHA.111.648667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.648667</ArticleId><ArticleId IdType="pubmed">22569939</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooy MJ, Pretorius E. Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events. Curr Med Chem. 2014;21:2121&#x2013;2129. doi: 10.2174/0929867321666131227162950.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666131227162950</ArticleId><ArticleId IdType="pubmed">24372218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LW, Dai XF, Lu L, Zhang GC, Cao H. Extensive primary repair of the thoracic aorta in acute type a aortic dissection by means of ascending aorta replacement combined with open placement of triple-branched stent graft: early results. Circulation. 2010;122:1373&#x2013;1378. doi: 10.1161/CIRCULATIONAHA.110.946012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.946012</ArticleId><ArticleId IdType="pubmed">20855660</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Wang L, Zhang H, Wei W, Chen Y, Tang W, et al. Effect of mild hypothermia on cerebral microcirculation in a murine cardiopulmonary resuscitation model. Microcirculation. 2019. 10.1111/micc.12537.</Citation><ArticleIdList><ArticleId IdType="pubmed">30801897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ji B, Yang B, Liu G, Miao N, Yang J, et al. Real-time continuous neuromonitoring combines transcranial cerebral Doppler with near-infrared spectroscopy cerebral oxygen saturation during total aortic arch replacement procedure: a pilot study. ASAIO J. 2012;58:122&#x2013;126. doi: 10.1097/MAT.0b013e318241abd3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAT.0b013e318241abd3</ArticleId><ArticleId IdType="pubmed">22370681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17702589</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1010-7940</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.</ArticleTitle><Pagination><StartPage>629</StartPage><EndPage>633</EndPage><MedlinePgn>629-33</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Levosimendan is a promising new inotrope. We investigate the proper time for its infusion during or after open-heart surgery to avoid complications related with low-output syndrome and high dosage of inotropes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-five consecutive patients were randomised to receive levosimendan in addition to the conventional therapy, its infusion starting in the operating theatre (Group OT) or in the ICU (Group ICU) when low-output syndrome was certified and were consequently dependent on classical inotropic support and IABP. Levosimendan was infused at a rate of 0.1 microg/kg min without loading dose, the infusion being for at least 24h to a maximum 48 h.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Levosimendan was well tolerated, with the simultaneous infusion of norepinephrine if required. Its efficacy was identical in both groups with improvement in the haemodynamic and functional status of patients (amelioration of stroke volume, cardiac index and mixed venous blood oxygen saturation, increase of left ventricular ejection fraction by echo study, de-escalation of traditional inotropes, subtraction of IABP and reduction in BNP plasma levels). The ICU stay and hospital stay were significantly decreased in patients of Group OT, compared to patients of Group ICU. Four patients died because of multiple organs dysfunction syndrome (MODS) due to sepsis (all patients of Group ICU).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Levosimendan is a safe and efficient choice in the management of low-output syndrome during and after open-heart surgery. The shortening of hospitalisation and the trend for better outcome confirm its clear superiority when the infusion starts from the operating theatre.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tasouli</LastName><ForeName>Androniki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ICU, Onassis Cardiac Surgery Center, Marathonamahon 18, 14572 Athens, Greece. atacard@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Kirillos</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Theophanie</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kriaras</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Stavridis</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Degiannis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Geroulanos</LastName><ForeName>Stephanos</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011724">Pyridazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>349552KRHK</RegistryNumber><NameOfSubstance UI="D000077464">Simendan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Cardiothorac Surg. 2008 Mar;33(3):521</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002303" MajorTopicYN="N">Cardiac Output, Low</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="N">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011724" MajorTopicYN="N">Pyridazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077464" MajorTopicYN="N">Simendan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17702589</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2007.07.010</ArticleId><ArticleId IdType="pii">S1010-7940(07)00624-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31376011</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2218</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Surgical endoscopy</Title><ISOAbbreviation>Surg Endosc</ISOAbbreviation></Journal><ArticleTitle>Laparoscopy versus conventional laparotomy in the management of abdominal trauma: a multi-institutional matched-pair study.</ArticleTitle><Pagination><StartPage>2237</StartPage><EndPage>2242</EndPage><MedlinePgn>2237-2242</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00464-019-07013-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Laparoscopy is being increasingly applied as either a diagnostic or therapeutic intervention in the management of abdominal trauma. However, its outcomes in comparison with conventional laparotomy remain unclear, especially in terms of therapeutic management.</AbstractText><AbstractText Label="METHODS">This retrospective cohort study included patients from three trauma centers in Beijing, China. Fifty-four patients undergoing laparoscopic interventions for abdominal trauma by experienced laparoscopists were enrolled in the laparoscopy group (LP group). Another 54 patients who underwent laparotomy (LT group) were matched according to the patients' baseline characteristics, causes of injury, and hemodynamic parameters. Perioperative clinical parameters and short-term survival were compared between these two groups.</AbstractText><AbstractText Label="RESULTS">The baseline characteristics were comparable between these two groups (LP vs. LT: Age, p&#x2009;=&#x2009;0.112; Sex, p&#x2009;=&#x2009;0.820; Injury severity score, p&#x2009;=&#x2009;0.158; Cause distribution, p&#x2009;=&#x2009;0.840). The most common cause was traffic accident (36.1%) and the most frequent surgical intervention was bowel repair/resection (34.3%) in our study. The operation time was similar in these two groups (LP vs. LT: 202.2&#x2009;&#xb1;&#x2009;72.58 vs. 194.11&#x2009;&#xb1;&#x2009;82.95&#xa0;min, p&#x2009;=&#x2009;0.295) while post-operative complication rate was slightly reduced in LP group (7.7% vs. 13.5%) with no statistical significance (p&#x2009;=&#x2009;0.383). Opioid use was lower in the LP than LT group (11.67&#x2009;&#xb1;&#x2009;4.08 vs. 26.0&#x2009;&#xb1;&#x2009;13.42 morphine equivalents (MEQ), p&#x2009;=&#x2009;0.034). The hospital stay was significantly shorter in the LP group (13.48&#x2009;&#xb1;&#x2009;10.9 vs. 18.64&#x2009;&#xb1;&#x2009;14.73&#xa0;days, p&#x2009;=&#x2009;0.021). One patient in the LT group died of an intra-abdominal abscess and multiple organ dysfunction syndrome 19&#xa0;days postoperatively, while all patients in the LP group recovered and were discharged.</AbstractText><AbstractText Label="CONCLUSION">Laparoscopy is feasible and safe in treating abdominal trauma patients in hemodynamically stable conditions performed by experienced surgeons. Laparoscopy might have the advantages of reduced pain and quicker recovery with similarly favorable clinical outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yunhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shaoqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Hongqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Shibo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kecheng</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feide</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The First Affiliated Hospital of the PLA General Hospital (304 Hospital), Beijing, 100048, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yixun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Baohua</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China. drqiaozhi@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Chinese People's Liberation Army General Hospital, Fuxing Road 28, Beijing, 100853, People's Republic of China. chenlinbj@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, 100853, China. chenlinbj@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Surg Endosc</MedlineTA><NlmUniqueID>8806653</NlmUniqueID><ISSNLinking>0930-2794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068476" MajorTopicYN="N" Type="Geographic">Beijing</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal trauma</Keyword><Keyword MajorTopicYN="N">Hemodynamically stable</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Laparotomy</Keyword><Keyword MajorTopicYN="N">Therapeutic value</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31376011</ArticleId><ArticleId IdType="doi">10.1007/s00464-019-07013-4</ArticleId><ArticleId IdType="pii">10.1007/s00464-019-07013-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Trauma. 1993 Jun;34(6):822-7; discussion 827-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8315677</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2015 Jun;39(6):1381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25446491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J Traumatol. 2018 Apr;21(2):73-76</Citation><ArticleIdList><ArticleId IdType="pubmed">29395429</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2013 Mar;205(3):317-20; discussion 321</Citation><ArticleIdList><ArticleId IdType="pubmed">23375706</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2017 Aug;44:94-98</Citation><ArticleIdList><ArticleId IdType="pubmed">28629766</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2003 Mar;17(3):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12457215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laparoendosc Adv Surg Tech A. 2018 May;28(5):506-513</Citation><ArticleIdList><ArticleId IdType="pubmed">29293406</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2016 Oct;34:127-136</Citation><ArticleIdList><ArticleId IdType="pubmed">27575832</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2017 Aug;44:21-25</Citation><ArticleIdList><ArticleId IdType="pubmed">28529193</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Clin North Am. 2011 Feb;91(1):195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21184909</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Laparosc Endosc Percutan Tech. 2013 Dec;23(6):507-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24300927</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Emerg Surg. 2015 Mar 12;10:16</Citation><ArticleIdList><ArticleId IdType="pubmed">26056529</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2007 Jan;38(1):60-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17129583</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2016 Jan 14;22(2):668-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26811616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2009 Sep;67(3):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19741405</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2016 Jul;47(7):1393-403</Citation><ArticleIdList><ArticleId IdType="pubmed">27157986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Laparoendosc Adv Surg Tech A. 2017 Apr;27(4):383-387</Citation><ArticleIdList><ArticleId IdType="pubmed">28253051</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2008 Jan;22(1):228-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17721808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma Acute Care Surg. 2016 Aug;81(2):307-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27032004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1974 Mar;14(3):187-96</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Med Clin North Am. 2018 Feb;36(1):149-160</Citation><ArticleIdList><ArticleId IdType="pubmed">29132574</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Surg. 2019 Dec;108(4):273-279</Citation><ArticleIdList><ArticleId IdType="pubmed">30522416</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2013 Jan;37(1):113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23052797</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2019 May;33(5):1618-1625</Citation><ArticleIdList><ArticleId IdType="pubmed">30209608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2004 Aug;240(2):205-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15273542</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Laparosc Endosc Percutan Tech. 2018 Feb;28(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">28915204</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Today. 2017 Jul;47(7):802-809</Citation><ArticleIdList><ArticleId IdType="pubmed">27830364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28895204</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Clinical transplantation</Title><ISOAbbreviation>Clin Transplant</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation in critically ill patients: Preoperative predictive factors of post-transplant mortality to avoid futility.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.13115</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The allocation of liver transplants to patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) with multi-organ failure who are admitted in ICU remains controversial due to their high post-transplant mortality rate and the absence of identified mortality risk factors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a single-center retrospective cohort study to determine the post-transplant mortality rate of patients with ALF and ACLF requiring ICU care prior to liver transplant (LT) and identified pretransplant factors of post-transplant mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-four patients (29 with ALF and 55 with ACLF) received a liver transplant while they were hospitalized at the ICU. Their mean model for end-stage liver disease (MELD) score was 41, and their mean sequential organ failure assessment (SOFA) was 15 the day before transplant. The overall 1-year survival rate was 66%. In multivariate analysis, pretransplant lactate level and acute respiratory distress syndrome (ARDS) were the only two independent factors associated with post-transplant mortality. The absence of ARDS and a pretransplant lactate level&lt; 5 mmol/L led to the identification of a subgroup of ICU patients with a good 1-year post-transplant survival (&gt;80%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low lactatemia lactate level and the absence of ARDS could be useful criteria in selecting those patients in ICU who could be eligible for liver transplant.</AbstractText><CopyrightInformation>&#xa9; 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michard</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5605-9229</Identifier><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artzner</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebas</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besch</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillot</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Gastro-Ent&#xe9;rologie, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faitot</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de Sant&#xe9; Publique, D&#xe9;partement d'Information M&#xe9;dicale, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachellier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Chirurgie G&#xe9;n&#xe9;rale et Transplantation h&#xe9;patique, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelain</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maestraggi</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, H&#xf4;pital de Hautepierre, H&#xf4;pitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FMTS, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1121, Facult&#xe9; de M&#xe9;decine de Strasbourg, Universit&#xe9; de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Clin Transplant</MedlineTA><NlmUniqueID>8710240</NlmUniqueID><ISSNLinking>0902-0063</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017114" MajorTopicYN="N">Liver Failure, Acute</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018447" MajorTopicYN="Y">Medical Futility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">cirrhosis</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">lactate</Keyword><Keyword MajorTopicYN="N">liver failure</Keyword><Keyword MajorTopicYN="N">liver transplantation</Keyword><Keyword MajorTopicYN="N">prognostic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28895204</ArticleId><ArticleId IdType="doi">10.1111/ctr.13115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23274325</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2329-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Annals of transplantation</Title><ISOAbbreviation>Ann Transplant</ISOAbbreviation></Journal><ArticleTitle>Fungal infection in patients after liver transplantation in years 2003 to 2012.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>63</EndPage><MedlinePgn>59-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fungal infections after liver transplantation have received considerable interests because of their association with substantial morbidity and mortality. This study investigated risk factors of fungal infection after liver transplantation.</AbstractText><AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">Retrospective analysis was performed based on clinical data from 120 patients with fungal infection after liver transplantation from January 1, 2003 to May 30, 2012. &#x3c7;2 test was used to analyze risk factors for fungal infections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The fungal infection rate after liver transplantation is 13.5% (120/886) and the case fatality rate reaches 70.8%; most are infected by Candida albicans (67.5%), with infection located in the lung (73.3%). Acute physiology and chronic health evaluation scores of the infected group are higher than those of the control group 24 hours after the surgery (27.1&#xb1;5.2 vs. 21.9&#xb1;5.0). The percentage of primary liver cancer patients in the infected group was lower than in the control group (26.7% vs. 45.8%). Compared to the control group, the infected group had a higher percentage of patients with HBV, gestational diabetes mellitus, and multiple organ dysfunction syndrome. Percentages of patients with long continuous parenteral nutrition time, poorly controlled high blood sugar, long-term mechanical ventilation, and antibiotics use were higher in the infected group than in the control group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preoperative original attack, postoperative critical condition, chronically high blood sugar, long-term use of antibiotics, and mechanical ventilation are probably vital risk factors for fungal infection after liver transplantation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chun-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, First Affiliated Hospital of Sun Yat-Sen, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xiao-Shun</ForeName><Initials>XS</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Min-Ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wen-Feng</ForeName><Initials>WF</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Dong-Hua</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xue-Xia</ForeName><Initials>XX</Initials></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Xiang-Dong</ForeName><Initials>XD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Transplant</MedlineTA><NlmUniqueID>9802544</NlmUniqueID><ISSNLinking>1425-9524</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001228" MajorTopicYN="N">Aspergillosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002177" MajorTopicYN="N">Candidiasis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016469" MajorTopicYN="N">Fungemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008172" MajorTopicYN="N">Lung Diseases, Fungal</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014552" MajorTopicYN="N">Urinary Tract Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23274325</ArticleId><ArticleId IdType="doi">10.12659/aot.883695</ArticleId><ArticleId IdType="pii">883695</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21684023</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-6976</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Archives of gerontology and geriatrics</Title><ISOAbbreviation>Arch Gerontol Geriatr</ISOAbbreviation></Journal><ArticleTitle>Elderly patients with acute kidney injury (AKI): clinical features and risk factors for mortality.</ArticleTitle><Pagination><StartPage>e47</StartPage><EndPage>e51</EndPage><MedlinePgn>e47-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.archger.2011.05.011</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Elderly patients with AKI are associated with considerable mortality. The clinical features and risk factors predicting poor outcomes of these patients are not known. The aim of this study is to investigate the clinical features and risk factors affecting mortality in elderly patients with AKI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study on the elderly patients with AKI (age &#x2265;65 years old) was conducted. A consecutive sample of 99 elderly patients with AKI was evaluated. These patients were divided into survivor group and non-survivor group according their outcomes. Factors including clinical characteristics and laboratory features were compared between these two groups. Analysis of correlations between death and categorized risk factors was done by means of Pearson's chi-squared test (or Fisher's exact test). Multivariate logistic regression was performed to analyze the possible risk factors for death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main causes of the elderly patients with AKI were ischemia (53.34%), surgery (33.33%), sepsis/infection (10.10%), nephrotoxic drug (3.03%). The mortality rate of the elderly patients with AKI was 42%. Significant differences were found between the survival group and non-survival group of the elderly patients in concomitant disease, complicated with multiple organ dysfunction syndrome (MODS), albumin, etc. Concomitant disease and MODS were found to be the independent risk factors for death of the elderly patients with AKI after adjusting for age, sex, pre-albumin, sepsis/infection, and serum creatinine (SCr).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study found that concomitant disease and MODS were the independent risk factors for the death of elderly patients with AKI.</AbstractText><CopyrightInformation>Crown Copyright &#xc2;&#xa9; 2011. Published by Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Huashan Hospital, Fudan University, 12 Wulumuqi Road (Middle), Shanghai 200040, China. guyonghs@126.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Arch Gerontol Geriatr</MedlineTA><NlmUniqueID>8214379</NlmUniqueID><ISSNLinking>0167-4943</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21684023</ArticleId><ArticleId IdType="doi">10.1016/j.archger.2011.05.011</ArticleId><ArticleId IdType="pii">S0167-4943(11)00121-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40786094</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Clinical prediction model and 2-year mortality for multiple organ dysfunction in patients aged 80&#x202f;years or older following hip fracture surgery: a prospective cohort study.</ArticleTitle><Pagination><StartPage>1515557</StartPage><MedlinePgn>1515557</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1515557</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2025.1515557</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The prediction of postoperative complications is vital in the management of hip fracture. This study specifically examined the occurrence of multiple organ dysfunction syndrome in the elderly (MODSE) following hip fracture surgery and explored its predictive model and correlation with long-term mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This prospective cohort study included all patients aged 80&#x202f;years and older who underwent hip fracture surgery at a tertiary orthopedic hospital between January 2020 and March 2021. The patients were categorized into the MODSE and non-MODSE groups. The pre, peri, and postoperative variables were retrospectively screened to establish and validate prediction model for MODSE. The patients were subsequently followed up prospectively until 2&#x202f;years after discharge in order to explore the association between MODSE and long-term mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Significant discrepancies in clinical characteristics were observed between MODSE and non-MODSE patients. Those with a preoperative age-adjusted Charlson Comorbidity Index &gt; 5, Impaired swallowing, an Acute Physiology and Chronic Health Evaluation II score &#x2265; 12 within the initial 24&#x202f;h post-surgery, prothrombin time &gt; 14&#x202f;s, along with high-sensitivity cardiac troponin T&#x202f;&gt;&#x202f;14&#x202f;pg./mL and procalcitonin levels &gt; 0.25&#x202f;ng/mL on the first day after surgery were found to have a higher likelihood of developing MODSE. Moreover, the presence of MODSE correlated with a 3.13-fold and 2.88-fold increased risk of mortality at 1 and 2&#x202f;years post-discharge, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Predicting postoperative MODSE in elderly hip fracture patients is essential and feasible, as its occurrence represents poor outcome during hospitalization and predicts heightened long-term mortality rates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Liu, Deng, Qin, Zhang, Yang, Feng and Yin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Infection Management Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Qin</LastName><ForeName>Zhijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Chenzhu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Anesthesiology Department, Sichuan Province Orthopedic Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">hip fracture surgery</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">prediction model</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>17</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40786094</ArticleId><ArticleId IdType="pmc">PMC12331632</ArticleId><ArticleId IdType="doi">10.3389/fmed.2025.1515557</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexiou KI, Roushias A, Varitimidis SE, Malizos KN. Quality of life and psychological consequences in elderly patients after a hip fracture: a review. Clin Interv Aging. (2018) 13:143&#x2013;50. doi: 10.2147/CIA.S150067, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S150067</ArticleId><ArticleId IdType="pmc">PMC5790076</ArticleId><ArticleId IdType="pubmed">29416322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SR, Macey R, Parker MJ, Cook JA, Griffin XL. Arthroplasties for hip fracture in adults. Cochrane Database Syst Rev. (2022) 2022:CD013410. doi: 10.1002/14651858.CD013410.pub2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013410.pub2</ArticleId><ArticleId IdType="pmc">PMC8841979</ArticleId><ArticleId IdType="pubmed">35156194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu WJ, Zeng X, Liu Q. Aging tsunami coming: the main finding from China's seventh national population census. Aging Clin Exp Res. (2022) 34:1159&#x2013;63. doi: 10.1007/s40520-021-02017-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-021-02017-4</ArticleId><ArticleId IdType="pubmed">34727357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, et al. Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med. (2020) 17:e1003180. doi: 10.1371/journal.pmed.1003180, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003180</ArticleId><ArticleId IdType="pmc">PMC7410202</ArticleId><ArticleId IdType="pubmed">32760065</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Medical Administration of National Health Commission of the People&#x2019;s Republic of China . Guideline for the diagnosis, treatment and management of older adults with hip fracture. (2022). (Chinese). Available online at:
https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fwww.nhc.gov.cn%2Fyzygj%2Fs7659%2F202212%2F7fa334c35f724362892e0d0ba35951c5%2Ffiles%2F4084ec42de9a44a397cc9e26d8b2138b.docx&amp;wdOrigin=BROWSELINK</Citation></Reference><Reference><Citation>Rocos B, Whitehouse MR, Kelly MB. Resuscitation in hip fractures: a systematic review. BMJ Open. (2017) 7:e015906. doi: 10.1136/bmjopen-2017-015906, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-015906</ArticleId><ArticleId IdType="pmc">PMC5623376</ArticleId><ArticleId IdType="pubmed">28473523</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsanos S, Sioutis S, Reppas L, Mitsiokapa E, Tsatsaragkou A, Mastrokalos D, et al. What do hip fracture patients die from? Eur J Orthop Surg Traumatol. (2023) 33:751&#x2013;7. doi: 10.1007/s00590-022-03250-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-022-03250-x</ArticleId><ArticleId IdType="pubmed">35377075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan KJ, Guerrero EM, Tainter D, Dial B, Milton-Cole R, Blair JA, et al. Prognostic factors of in-hospital complications after hip fracture surgery: a scoping review. Osteoporos Int. (2019) 30:1339&#x2013;51. doi: 10.1007/s00198-019-04976-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-019-04976-x</ArticleId><ArticleId IdType="pubmed">31037362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SW, Wang JD, Chen KJ, Wang YT, Wang XD, Mu CS. Diagnostic criteria of multipleorgan dysfunction syndrome in the elderly (draft, 2003). Chin Crit Care Med. (2004) 16:1. (Chinese)</Citation></Reference><Reference><Citation>Yang X, Qin Z, Li Y, Deng Y, Li M. Hypotension following hip fracture surgery in patients aged 80 years or older: a prospective cohort study. Heliyon. (2022) 8:e10202. doi: 10.1016/j.heliyon.2022.e10202, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e10202</ArticleId><ArticleId IdType="pmc">PMC9404332</ArticleId><ArticleId IdType="pubmed">36033291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin B, Kili&#xe7; J, Ta&#x15f;kin G, Solmaz &#x130;, Tezel O, Ba&#x15f;g&#xf6;z BB. The comparison of scoring systems: SOFA, APACHE-II, LODS, MODS, and SAPS-II in critically ill elderly sepsis patients. J Infect Dev Ctries. (2024) 18:122&#x2013;30. doi: 10.3855/jidc.18526, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.18526</ArticleId><ArticleId IdType="pubmed">38377099</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z, Feng H, Meng X, Zhuang S, Liu Z, Ye K, et al. Age-specific 1-year mortality rates after hip fracture based on the populations in mainland China between the years 2000 and 2018: a systematic analysis. Arch Osteoporos. (2019) 14:55. doi: 10.1007/s11657-019-0604-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-019-0604-3</ArticleId><ArticleId IdType="pmc">PMC6535151</ArticleId><ArticleId IdType="pubmed">31129721</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergara I, Vrotsou K, Orive M, Gonzalez N, Garcia S, Quintana JM. Factors related to functional prognosis in elderly patients after accidental hip fractures: a prospective cohort study. BMC Geriatr. (2014) 14:124. doi: 10.1186/1471-2318-14-124, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-14-124</ArticleId><ArticleId IdType="pmc">PMC4280690</ArticleId><ArticleId IdType="pubmed">25425462</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth T, Kammerlander C, Gosch M, Luger TJ, Blauth M. Outcome in geriatric fracture patients and how it can be improved. Osteoporos Int. (2010) 21:615&#x2013;9. doi: 10.1007/s00198-010-1401-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-010-1401-4</ArticleId><ArticleId IdType="pubmed">21058001</ArticleId></ArticleIdList></Reference><Reference><Citation>Meals C, Roy S, Medvedev G, Wallace M, Neviaser RJ, O'Brien J. Identifying the risk of swallowing-related pulmonary complications in older patients with hip fracture. Orthopedics. (2016) 39:e93&#x2013;7. doi: 10.3928/01477447-20151222-07</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20151222-07</ArticleId><ArticleId IdType="pubmed">26726985</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Jia P, Zhang J, Wang X, Jiang H, Jiang W. Prevalence and risk factors of postoperative delirium in elderly hip fracture patients. J Int Med Res. (2016) 44:317&#x2013;27. doi: 10.1177/0300060515624936, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060515624936</ArticleId><ArticleId IdType="pmc">PMC5580064</ArticleId><ArticleId IdType="pubmed">26920926</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin KH, Han SB. Early postoperative hypoalbuminemia is a risk factor for postoperative acute kidney injury following hip fracture surgery. Injury. (2018) 49:1572&#x2013;6. doi: 10.1016/j.injury.2018.05.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.05.001</ArticleId><ArticleId IdType="pubmed">29908852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ushirozako H, Ohishi T, Fujita T, Suzuki D, Yamamoto K, Banno T, et al. Does N-terminal pro-brain type natriuretic peptide predict cardiac complications after hip fracture surgery? Clin Orthop Relat Res. (2017) 475:1730&#x2013;6. doi: 10.1007/s11999-017-5245-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-017-5245-5</ArticleId><ArticleId IdType="pmc">PMC5406336</ArticleId><ArticleId IdType="pubmed">28101755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakomkin N, Goz V, Cheng JS, Brodke DS, Spiker WR. The utility of preoperative laboratories in predicting postoperative complications following posterolateral lumbar fusion. Spine J. (2018) 18:993&#x2013;7. doi: 10.1016/j.spinee.2017.10.010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2017.10.010</ArticleId><ArticleId IdType="pubmed">29055738</ArticleId></ArticleIdList></Reference><Reference><Citation>Forget P, Moreau N, Engel H, Cornu O, Boland B, De Kock M, et al. The neutrophil-to-lymphocyte ratio (NLR) after surgery for hip fracture (HF). Arch Gerontol Geriatr. (2015) 60:366&#x2013;71. doi: 10.1016/j.archger.2014.11.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2014.11.008</ArticleId><ArticleId IdType="pubmed">25488015</ArticleId></ArticleIdList></Reference><Reference><Citation>National Clinical Guideline Centre (UK) . The management of hip fracture in adults. London: Royal College of Physicians (UK) (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22420011</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths R, Babu S, Dixon P, Freeman N, Hurford D, Kelleher E, et al. Guideline for the management of hip fractures 2020: guideline by the Association of Anaesthetists. Anaesthesia. (2021) 76:225&#x2013;37. doi: 10.1111/anae.15291, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15291</ArticleId><ArticleId IdType="pubmed">33289066</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco JF, da Casa C, Pablos-Hern&#xe1;ndez C, Gonz&#xe1;lez-Ram&#xed;rez A, Juli&#xe1;n-Enr&#xed;quez JM, D&#xed;az-&#xc1;lvarez A. 30-day mortality after hip fracture surgery: influence of postoperative factors. PLoS One. (2021) 16:e0246963. doi: 10.1371/journal.pone.0246963, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246963</ArticleId><ArticleId IdType="pmc">PMC7886122</ArticleId><ArticleId IdType="pubmed">33592047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterton BD, Moores TS, Ahmad S, Cattell A, Roberts PJ. Cause of death and factors associated with early in-hospital mortality after hip fracture. Bone Joint J. (2015) 97-B:246&#x2013;51. doi: 10.1302/0301-620X.97B2.35248, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.97B2.35248</ArticleId><ArticleId IdType="pubmed">25628290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd R, Baker G, MacDonald J, Thompson NW. Co-morbidities in patients with a hip fracture. Ulster Med J. (2019) 88:162&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790636</ArticleId><ArticleId IdType="pubmed">31619850</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RMY, Zu Y, Chau WW, Tso CY, Liu WH, Ng RWK, et al. High Charlson comorbidity index score is associated with early fracture-related complication for internal fixation of neck of femur fractures. Sci Rep. (2022) 12:4749. doi: 10.1038/s41598-022-08855-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08855-0</ArticleId><ArticleId IdType="pmc">PMC8934361</ArticleId><ArticleId IdType="pubmed">35306533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DL, Cong YX, Zhuang Y, Xu X, Zhang BF. Age-adjusted Charlson comorbidity index predicts postoperative mortality in elderly patients with hip fracture: a prospective cohort. Front Med (Lausanne). (2023) 10:1066145. doi: 10.3389/fmed.2023.1066145, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1066145</ArticleId><ArticleId IdType="pmc">PMC10027731</ArticleId><ArticleId IdType="pubmed">36960340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Wang X, Dou Y, Wang H, Zhang Y. Analysis of risk factors for perioperative mortality in elderly patients with intertrochanteric fracture. Eur J Orthop Surg Traumatol. (2019) 29:59&#x2013;63. doi: 10.1007/s00590-018-2285-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-018-2285-9</ArticleId><ArticleId IdType="pubmed">30120536</ArticleId></ArticleIdList></Reference><Reference><Citation>Love AL, Cornwell PL, Whitehouse SL. Oropharyngeal dysphagia in an elderly post-operative hip fracture population: a prospective cohort study. Age Ageing. (2013) 42:782&#x2013;5. doi: 10.1093/ageing/aft037, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/aft037</ArticleId><ArticleId IdType="pubmed">23531439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyburski JG, Dente C, Wilson RF, Steffes C, Devlin J, Carlin AM, et al. Differences in arterial and mixed venous IL-6 levels: the lungs as a source of cytokine storm in sepsis. Surgery. (2001) 130:748&#x2013;751. discussion 751-2. doi: 10.1067/msy.2001.118094</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/msy.2001.118094</ArticleId><ArticleId IdType="pubmed">11602907</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. (2016) 8:959&#x2013;70. doi: 10.2217/imt-2016-0020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2016-0020</ArticleId><ArticleId IdType="pubmed">27381687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce A, Pittet JF. Inflammatory response to trauma: implications for coagulation and resuscitation. Curr Opin Anaesthesiol. (2014) 27:246&#x2013;52. doi: 10.1097/ACO.0000000000000047, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000000047</ArticleId><ArticleId IdType="pmc">PMC4124829</ArticleId><ArticleId IdType="pubmed">24419158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaint R, Afshari A, Bouillon B, Cerny V, Cimpoesu D, Curry N, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. (2023) 27:80. doi: 10.1186/s13054-023-04327-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-023-04327-7</ArticleId><ArticleId IdType="pmc">PMC9977110</ArticleId><ArticleId IdType="pubmed">36859355</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallet H, Chenevier-Gobeaux C, Villain C, Cohen-Bittan J, Ray P, Epelboin L, et al. Prognostic value of serum procalcitonin after orthopedic surgery in the elderly population. J Gerontol A Biol Sci Med Sci. (2017) 72:438&#x2013;43. doi: 10.1093/gerona/glw097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw097</ArticleId><ArticleId IdType="pubmed">27231388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsantes AG, Trikoupis IG, Papadopoulos DV, Tsante KA, Mavrogenis AF, Koulouvaris P, et al. Higher coagulation activity in hip fracture patients: a case-control study using rotational thromboelastometry. Int J Lab Hematol. (2021) 43:477&#x2013;84. doi: 10.1111/ijlh.13409, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13409</ArticleId><ArticleId IdType="pubmed">33231378</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomina MJ, M&#xe9;ndez E, Sabate A. Altered fibrinolysis during and after surgery. Semin Thromb Hemost. (2021) 47:512&#x2013;9. doi: 10.1055/s-0041-1722971, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1722971</ArticleId><ArticleId IdType="pubmed">33878781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultynck C, Munim N, Harrington DJ, Judd L, Ataklte F, Shah Z, et al. Prevalence of vitamin K deficiency in older people with hip fracture. Acta Clin Belg. (2020) 75:136&#x2013;40. doi: 10.1080/17843286.2018.1564174, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2018.1564174</ArticleId><ArticleId IdType="pubmed">30618350</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin ZJ, Wu QY, Deng Y, Li X, Wei XD, Tang CJ, et al. Association between high-sensitivity troponin T on admission and organ dysfunction during hospitalization in patients aged 80 years and older with hip fracture: a single-centered prospective cohort study. Clin Interv Aging. (2021) 16:583&#x2013;91. doi: 10.2147/CIA.S303246, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S303246</ArticleId><ArticleId IdType="pmc">PMC8039433</ArticleId><ArticleId IdType="pubmed">33854308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Park HS, Lee DW. Outcome of nonoperative treatment for hip fractures in elderly patients: a systematic review of recent literature. J Orthop Surg (Hong Kong). (2020) 28:2309499020936848. doi: 10.1177/2309499020936848, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2309499020936848</ArticleId><ArticleId IdType="pubmed">32638635</ArticleId></ArticleIdList></Reference><Reference><Citation>Loggers SAI, Van Lieshout EMM, Joosse P, Verhofstad MHJ, Willems HC. Prognosis of nonoperative treatment in elderly patients with a hip fracture: a systematic review and meta-analysis. Injury. (2020) 51:2407&#x2013;13. doi: 10.1016/j.injury.2020.08.027, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2020.08.027</ArticleId><ArticleId IdType="pubmed">32907702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33129099</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>Pt B</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.</ArticleTitle><Pagination><StartPage>107088</StartPage><MedlinePgn>107088</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.107088</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)32189-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1&#x3b2;, IL-6, TNF-&#x3b1; and IL-18 were assessed by Real-time PCR and ELISA, respectively.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Our primary results indicated that the mRNA expression and cytokine secretion of IL-1&#x3b2;, IL-6, TNF-&#x3b1;, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P&#xa0;=&#xa0;0.0003, 0.0038, and 0.0001, respectively) and IL-1&#x3b2; gene expression and secretion level in serum and supernatant (P&#xa0;=&#xa0;0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-&#x3b1; concentration were not influenced by Nano-curcumin.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1&#x3b2; and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valizadeh</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdolmohammadi-Vahid</LastName><ForeName>Samaneh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student's Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danshina</LastName><ForeName>Svetlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of propaedeutics of dental diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziya Gencer</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Yassawi International Kazakh-Turkish University Hospital, Turkistan, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammari</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshangar</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslani</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaeilzadeh</LastName><ForeName>Abdolreza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaebi</LastName><ForeName>Mahnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valizadeh</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ahmadi.m@tbzmed.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008823">Micelles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036103" MajorTopicYN="N">Nanotechnology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine storm</Keyword><Keyword MajorTopicYN="N">IL-1&#x3b2;</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">Nano-curcumin</Keyword></KeywordList><CoiStatement>The authors declared that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33129099</ArticleId><ArticleId IdType="pmc">PMC7574843</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2020.107088</ArticleId><ArticleId IdType="pii">S1567-5769(20)32189-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiss S.R., Leibowitz J.L. Coronavirus pathogenesis, advances in virus research. Elsevier. 2011:85&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149603</ArticleId><ArticleId IdType="pubmed">22094080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., MacAry P.A., Ng L.F. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 2005;69(4):635&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1306801</ArticleId><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19), Statpearls [internet] StatPearls Publishing. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X. Coronavirus infections and immune responses. J. Med. Virol. 2020;92(4):424&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166547</ArticleId><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ma X. Acute respiratory failure in COVID-19: is it &#x201c;typical&#x201d; ARDS? Crit. Care. 2020;24:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202792</ArticleId><ArticleId IdType="pubmed">32375845</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Taghizadieh, H. Mikaeili, M. Ahmadi, H. Valizadeh, Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran, Respiratory medicine case reports (2020) 101090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219375</ArticleId><ArticleId IdType="pubmed">32405454</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Ghaebi, A. Osali, H. Valizadeh, L. Roshangar, M. Ahmadi, Vaccine development and therapeutic design for 2019&#x2010;nCoV/SARS&#x2010;CoV&#x2010;2: Challenges and chances, Journal of cellular physiology (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323389</ArticleId><ArticleId IdType="pubmed">32557648</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P., Ronconi G., Caraffa A., Gallenga C., Ross R., Frydas I., Kritas S. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020;34(2):1.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti C., Swartzwelter B., Koenders M.I., Azam T., Tengesdal I.W., Powers N., de Graaf D.M., Dinarello C.A., Joosten L.A. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res. Therapy. 2018;20(1):169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091035</ArticleId><ArticleId IdType="pubmed">30075804</ArticleId></ArticleIdList></Reference><Reference><Citation>Z.S. Ulhaq, G.V. Soraya, Interleukin-6 as a potential biomarker of COVID-19 progression, M&#xe9;decine et Maladies Infectieuses (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129451</ArticleId><ArticleId IdType="pubmed">32259560</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes Infect. 2020;9(1):1123&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmann M., Maini R.N., Woody J.N., Holgate S.T., Winter G., Rowland M., Richards D., Hussell T. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. The Lancet. 2020;395(10234):1407&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158940</ArticleId><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolati S., Ahmadi M., Aghebti-Maleki L., Nikmaram A., Marofi F., Rikhtegar R., Ayromlou H., Yousefi M. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol. Rep. 2018;70(6):1158&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">30340096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavarpour-Bali H., Ghasemi-Kasman M., Pirzadeh M. Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders. Int. J. Nanomed. 2019;14:4449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592058</ArticleId><ArticleId IdType="pubmed">31417253</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535097</ArticleId><ArticleId IdType="pubmed">23143785</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1/A):363&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">12680238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewlings S.J., Kalman D.S. Curcumin: a review of its&#x2019; effects on human health. Foods. 2017;6(10):92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664031</ArticleId><ArticleId IdType="pubmed">29065496</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolati S., Ahmadi M., Rikhtegar R., Babaloo Z., Ayromlou H., Aghebati-Maleki L., Nouri M., Yousefi M. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. Int. Immunopharmacol. 2018;61:74&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29852475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose S., Panda A.K., Mukherjee S., Sa G. Curcumin and tumor immune-editing: resurrecting the immune system. Cell division. 2015;10(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603973</ArticleId><ArticleId IdType="pubmed">26464579</ArticleId></ArticleIdList></Reference><Reference><Citation>Afolayan F.I., Erinwusi B., Oyeyemi O.T. Immunomodulatory activity of curcumin-entrapped poly d, l-lactic-co-glycolic acid nanoparticles in mice. Integrative Medicine Res. 2018;7(2):168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035456</ArticleId><ArticleId IdType="pubmed">29989030</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi M.K., Mondal S.C., Gangwar M., Jana S. Immunomodulatory potential of nanocurcumin-based formulation. Inflammopharmacology. 2017;25(6):609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">28921388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatamipour M., Sahebkar A., Alavizadeh S.H., Dorri M., Jaafari M.R. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iranian J. Basic Medical Sci. 2019;22(3):282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528723</ArticleId><ArticleId IdType="pubmed">31156789</ArticleId></ArticleIdList></Reference><Reference><Citation>Corkum C.P., Ings D.P., Burgess C., Karwowska S., Kroll W., Michalak T.I. Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT&#x2122;) and standard density gradient. BMC immunology. 2015;16(1):1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549105</ArticleId><ArticleId IdType="pubmed">26307036</ArticleId></ArticleIdList></Reference><Reference><Citation>T. Okabayashi, H. Kariwa, S.i. Yokota, S. Iki, T. Indoh, N. Yokosawa, I. Takashima, H. Tsutsumi, N. Fujii, Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections, Journal of medical virology 78(4) (2006) 417-424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166776</ArticleId><ArticleId IdType="pubmed">16482545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Z. Wang, B. Yang, Q. Li, L. Wen, R. Zhang, Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China, Clinical infectious diseases (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184452</ArticleId><ArticleId IdType="pubmed">32176772</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry B.M., De Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chem. Laboratory Medicine (CCLM) 2020;58(7):1021&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">32286245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G., Liu Y., Yi X., Wang Y., Qiao S., Li Z., Ni J., Song Z. Curcumin inhibiting Th17 cell differentiation by regulating the metabotropic glutamate receptor-4 expression on dendritic cells. Int. Immunopharmacol. 2017;46:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28273557</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanzaro M., Corsini E., Rosini M., Racchi M., Lanni C. Immunomodulators inspired by nature: a review on curcumin and echinacea. Molecules. 2018;23(11):2778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278270</ArticleId><ArticleId IdType="pubmed">30373170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dei Cas M., Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019;11(9):2147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6770259</ArticleId><ArticleId IdType="pubmed">31500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Gera M., Sharma N., Ghosh M., Huynh D.L., Lee S.J., Min T., Kwon T., Jeong D.K. Nanoformulations of curcumin: an emerging paradigm for improved remedial application. Oncotarget. 2017;8(39):66680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630447</ArticleId><ArticleId IdType="pubmed">29029547</ArticleId></ArticleIdList></Reference><Reference><Citation>Z.Y. Ay, B. Bak&#x131;r, &#x15e;.B. Bozkurt, S.A. Kayis, S.S. Hakki, Positive effect of curcumin on experimental peridontitis via suppression of IL-1-beta and IL-6 expression level, International Journal for Vitamin and Nutrition Research (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32718217</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A., Hossain I., VanderMolen J., Nicol K. Comparison of remicade to curcumin for the treatment of Crohn&#x2019;s disease: A systematic review. Complementary Therapies Medicine. 2017;33:32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouzaoui S., Rahim I., Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-&#x3b1;-induced oxidative stress, colitis and hepatotoxicity in mice. Int. Immunopharmacol. 2012;12(1):302&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">22036766</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa G., Maffioli P., Simental-Mendia L.E., Bo S., Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2016;111:394&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">27392742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebkar A., Cicero A.F., Simental-Mend&#xed;a L.E., Aggarwal B.B., Gupta S.C. Curcumin downregulates human tumor necrosis factor-&#x3b1; levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 2016;107:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">27025786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27379496</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1438-8359</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of anesthesia</Title><ISOAbbreviation>J Anesth</ISOAbbreviation></Journal><ArticleTitle>Impact of aspirin use on morbidity and mortality in massively transfused cardiac surgery patients: a propensity score matched cohort study.</ArticleTitle><Pagination><StartPage>817</StartPage><EndPage>825</EndPage><MedlinePgn>817-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00540-016-2213-2</ELocationID><Abstract><AbstractText Label="PURPOSE">Aspirin may prevent organ dysfunction in critically ill patients and mitigate transfusion associated acute lung injury. We hypothesized that aspirin use might be associated with decreased morbidity and mortality in massively transfused cardiac surgery patients.</AbstractText><AbstractText Label="METHODS">A single center retrospective cohort study was performed using data from an 8.5-year period (2006-2014). Massive transfusion was defined as receiving at least 2400&#xa0;ml (8 units) of red blood cell units intraoperatively. A propensity score model was created to account for the likelihood of receiving aspirin and matched pairs were identified using global optimal matching. The primary endpoint, in-hospital mortality, was compared between aspirin users and non-users. Secondary outcomes including: ICU hours, mechanical lung ventilation hours, prolonged mechanical lung ventilation (&gt;24&#xa0;h), pneumonia, stroke, acute renal failure, atrial fibrillation, deep sternal wound infection, and multiple organ dysfunction syndrome were also compared.</AbstractText><AbstractText Label="RESULTS">Of 7492 cardiac surgery patients, 452 (6&#xa0;%) were massively transfused and mortality was 30.6&#xa0;%. There were 346 patients included in the matched cohort. No significant association was found between preoperative aspirin use and in-hospital mortality; absolute risk reduction with aspirin&#xa0;=&#xa0;7.5&#xa0;% (95&#xa0;% CI -2.0 to 16.9&#xa0;%, p&#xa0;=&#xa0;0.12). Preoperative aspirin use was associated with fewer total mechanical lung ventilation hours (p&#xa0;=&#xa0;0.02) and less prolonged mechanical lung ventilation; absolute risk reduction&#xa0;=&#xa0;11.0&#xa0;% (95&#xa0;% CI 1.1-20.5&#xa0;%, p&#xa0;=&#xa0;0.02).</AbstractText><AbstractText Label="CONCLUSIONS">Preoperative aspirin use is not associated with decreased in-hospital mortality in massively transfused cardiac surgery patients, but may be associated with less mechanical lung ventilation time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzeffi</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2955-4915</Identifier><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA. mmazzeffi@anes.umm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galvagno</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gammie</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Cardiothoracic Surgery, 419 Redwood Street #360, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Maryland School of Medicine, Anesthesiology, 22 South Greene Street S11C00, Baltimore, MD, 21201, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Anesth</MedlineTA><NlmUniqueID>8905667</NlmUniqueID><ISSNLinking>0913-8668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="Y">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspirin</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Lung injury</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27379496</ArticleId><ArticleId IdType="doi">10.1007/s00540-016-2213-2</ArticleId><ArticleId IdType="pii">10.1007/s00540-016-2213-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Invest. 2009 Nov;119(11):3450-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19809160</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2006 Aug;53(8):781-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16873345</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2013 Aug;60(8):761-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23609882</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2011 Nov;39(11):2393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">21725238</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Serv Res. 2014 Oct;49(5):1701-20</Citation><ArticleIdList><ArticleId IdType="pubmed">24779867</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2013 Oct;111(4):549-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23661406</ArticleId></ArticleIdList></Reference><Reference><Citation>Vox Sang. 2011 Jul;101(1):44-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21438884</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2004 Oct;44(10):1453-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15383018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Thorac Surg. 1998 Jan;65(1):101-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9456103</ArticleId></ArticleIdList></Reference><Reference><Citation>Multivariate Behav Res. 2011 May;46(3):399-424</Citation><ArticleIdList><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2005 May;127(5):1622-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15888837</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jul 31;10(7):e0134670</Citation><ArticleIdList><ArticleId IdType="pubmed">26230605</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2015 Apr;55(4):782-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25393772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Card Anaesth. 2013 Apr-Jun;16(2):117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23545866</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2007 May 1;115(17):2340-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17470708</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2009 Feb;102(2):168-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19151047</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2004 Sep;143(1):159-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15289285</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2015 Aug;121(2):271-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25993389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiothorac Vasc Anesth. 2009 Feb;23(1):34-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19081268</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Nov 4;363(19):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">21047223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Card Surg. 2007 May-Jun;22(3):247-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17488432</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Hematol. 2007 Sep;14(5):455-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17934352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21575208</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2011</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Predictors of mortality and short-term physical and cognitive dependence in critically ill persons 75 years and older: a prospective cohort study.</ArticleTitle><Pagination><StartPage>35</StartPage><MedlinePgn>35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1477-7525-9-35</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to identify predictors of 3-month mortality in critically ill older persons under medical care and to assess the clinical impact of an ICU stay on physical and cognitive dependence and subjective health status in survivors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective observational cohort study including all older persons 75 years and older consecutively admitted into ICU during a one-year period, except those admitted after cardiac arrest, All patients were followed for 3 months or until death. Comorbidities were assessed using the Charlson index and physical dependence was evaluated using the Katz index of Activity of Daily Living (ADL). Cognitive dependence was determined by a score based on the individual components of the Lawton index of Daily Living and subjective health status was evaluated using the Nottingham Health Profile (NHP) score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred patients were included in the analysis. The mean age was 79.3 &#xb1; 3.4 years. The median Charlson index was 6 [IQR, 4 to 7] and the mean ADL and cognitive scores were 5.4 &#xb1; 1.1 and 1.2 &#xb1; 1.4, respectively, corresponding to a population with a high level of comorbidities but low physical and cognitive dependence. Mortality was 61/100 (61%) at 3 months. In multivariate analysis only comorbidities assessed by the Charlson index [Adjusted Odds Ratio, 1.6; 95% CI, 1.2-2.2; p &lt; 0.003] and the number of organ failures assessed by the SOFA score [Adjusted Odds Ratio, 2.5; 95% CI, 1.1-5.2; p &lt; 0.02] were independently associated with 3-month mortality. All 22 patients needing renal support after Day 3 died. Compared with pre-admission, physical (p = 0.04), and cognitive (p = 0.62) dependence in survivors had changed very little at 3 months. In addition, the mean NHP score was 213.1 &#xb1; 132.8 at 3 months, suggesting an acceptable perception of their quality of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In a selected population of non surgical patients 75 years and older, admission into the ICU is associated with a 3-month survival rate of 38% with little impact on physical and cognitive dependence and subjective health status. Nevertheless, a high comorbidity level (ie, Charlson index), multi-organ failure, and the need for extra-renal support at the early phase of intensive care could be considered as predictors of death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daubin</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Intensive Care, Avenue C&#xf4;te de Nacre, Caen University Hospital, 14033 Caen Cedex, France. daubin-c@chu-caen.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>S&#xe9;guin</LastName><ForeName>Am&#xe9;lie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Valette</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Pr&#xe9;vost</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Terzi</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parienti</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>du Cheyron</LastName><ForeName>Damien</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Charbonneau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003858" MajorTopicYN="Y">Dependency, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21575208</ArticleId><ArticleId IdType="pmc">PMC3112374</ArticleId><ArticleId IdType="doi">10.1186/1477-7525-9-35</ArticleId><ArticleId IdType="pii">1477-7525-9-35</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angus DC, Barnato AE, Linde-Zwirble WT, Weissfeld LA, Watson S, Rickert T, Rudenfeld GD. Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med. 2004;32:638&#x2013;643. doi: 10.1097/01.CCM.0000114816.62331.08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000114816.62331.08</ArticleId><ArticleId IdType="pubmed">15090940</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrouste-Orgeas M, Timsit JF, Montuclard L, Colvez A, Gattolliat O, Philippart F, Rigal G, Misset B, Carlet J. Decision-making process, outcome, and 1-year quality of life of octogenarians referred for intensive care unit admission. Intensive Care Med. 2006;32:1045&#x2013;1051. doi: 10.1007/s00134-006-0169-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0169-7</ArticleId><ArticleId IdType="pubmed">16791667</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rooij SE, Govers A, Korevaar JC, Abu-Hanna A, Levi M, de Jonge E. Short-term and long-term mortality in very elderly patients admitted to an intensive care unit. Intensive Care Med. 2006;32:1039&#x2013;1044. doi: 10.1007/s00134-006-0171-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0171-0</ArticleId><ArticleId IdType="pubmed">16791666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy D, Juzwishin K, Yergens D, Noseworthy, Doig C. Outcomes of Elderly Survivors of Intensive Care: A Review of Lliterature. Chest. 2005;127:1764&#x2013;1774. doi: 10.1378/chest.127.5.1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.127.5.1764</ArticleId><ArticleId IdType="pubmed">15888857</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlani P, Chenaud C, Mariotti N, Ricou B. Long-term outcome of elderly patients requiring intensive care admission for abdominal pathologies: survival and quality of life. Acta Anaesthesiology Scandinavia. 2007;51:530&#x2013;37. doi: 10.1111/j.1399-6576.2007.01273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2007.01273.x</ArticleId><ArticleId IdType="pubmed">17430312</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuclard L, Garrouste-Orgeas M, Timsit JF, Misset B, De Jonghe B, Carlet J. Outcome, functional autonomy, and quality of life of elderly patients with a long-term intensive care unit stay. Crit Care Med. 2000;28:3389&#x2013;95. doi: 10.1097/00003246-200010000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200010000-00002</ArticleId><ArticleId IdType="pubmed">11057791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigaud AS. La qualit&#xe9; de vie des personnes &#xe2;g&#xe9;es apr&#xe8;s un s&#xe9;jour en r&#xe9;animation. Annales de r&#xe9;adaptation et de m&#xe9;decine physique. 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17451834</ArticleId></ArticleIdList></Reference><Reference><Citation>Viricel L, Auboyer C, Sauron C, Mathern P, Gonthier R. Devenir et qualit&#xe9; de vie d'une population &#xe2;g&#xe9;e de plus de 80 ans trois mois apr&#xe8;s un s&#xe9;jour en r&#xe9;animation. Annales de r&#xe9;adaptation et de m&#xe9;decine physiques. 2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">17521767</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKensie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz S, Dowtn TD, Cash HR. Progress in the development of the index of ADL. Gerontologist. 1970;10:20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">5420677</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF. Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. Am Geriatr Soc. 1992;40:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">1401698</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. J Am Med Assoc. 1993;270:2957&#x2013;2963. doi: 10.1001/jama.270.24.2957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.270.24.2957</ArticleId><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauss WA, Wagner DP, Draper EA, Zimmerman JE. APACHE II severity of disease classification system. Crit Care Med. 1985;13:818&#x2013;829. doi: 10.1097/00003246-198510000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198510000-00009</ArticleId><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucquet D, Condon S, Ritchie K. the French version of the Nottingham health profile. A comparison of items weights with those of the source version. Soc Sci Med. 1990;30:829&#x2013;835. doi: 10.1016/0277-9536(90)90207-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0277-9536(90)90207-9</ArticleId><ArticleId IdType="pubmed">2315749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dram&#xe9; M, Novella JL, Lang PO, Somme D, Jovenin N, Lani&#xe8;ce I, Couturier P, Heitz D, Gauvain JB, Voisin T, De Wazi&#xe8;res B, Gonthier R, Ankri J, Jeandel C, Saint-Jean O, Blanchard F, Jolly D. Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES study. Eur J Epidemiol. 2008;23:783&#x2013;91. doi: 10.1007/s10654-008-9290-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-008-9290-y</ArticleId><ArticleId IdType="pubmed">18941907</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288&#x2013;94. doi: 10.1016/j.jclinepi.2004.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.03.012</ArticleId><ArticleId IdType="pubmed">15617955</ArticleId></ArticleIdList></Reference><Reference><Citation>Buntinx F, Niclaes L, Suetens C, Jans B, Mertens R, Van den Akker M. Evaluation of Charlson's comorbidity index in elderly living in nursing homes. J Clin Epidemiol. 2002;55:1144&#x2013;7. doi: 10.1016/S0895-4356(02)00485-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(02)00485-7</ArticleId><ArticleId IdType="pubmed">12507679</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik PE. Management of the critically ill geriatric patient. Crit Care Med. 2006;34:S176&#x2013;182. doi: 10.1097/01.CCM.0000232624.14883.9A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000232624.14883.9A</ArticleId><ArticleId IdType="pubmed">16917421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass JE, Castriotta RJ, Malakoff F. Intensive care unit outcome in the very elderly. Crit Care Med. 1992;20:1666&#x2013;1671. doi: 10.1097/00003246-199212000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199212000-00011</ArticleId><ArticleId IdType="pubmed">1458943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelluri L, Pinsky MR, Grenvik AN. Outcome of intensive care of the "oldest-old" critically ill patients. Crit Care Med. 1992;20:757&#x2013;761. doi: 10.1097/00003246-199206000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199206000-00010</ArticleId><ArticleId IdType="pubmed">1597028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelluri G, Pinsky MR, Donahoe MP, Grenvik A. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA. 1993;269:3119&#x2013;23. doi: 10.1001/jama.269.24.3119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.269.24.3119</ArticleId><ArticleId IdType="pubmed">8505814</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh GJ, Havill JH, Armistead SH, Ullal RR, Fayers TM. Follow up of elderly patients after cardiac surgery and intensive care unit admission, 1991 to 1995. N Z Med J. 1997;110:432&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">9418838</ArticleId></ArticleIdList></Reference><Reference><Citation>Boumendil A, Maury E, Reinhard I, Luquel L, Offenstadt G, Guidet B. Prognosis of patients aged 80 years and over admitted in medical intensive care unit. Intensive Care Med. 2004;30:647&#x2013;654. doi: 10.1007/s00134-003-2150-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-2150-z</ArticleId><ArticleId IdType="pubmed">14985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vosylius S, Sipylaite J, Ivaskevicius J. Determinants of outcome in elderly patients admitted to the intensive care unit. Age Ageing. 2005;34:157&#x2013;162. doi: 10.1093/ageing/afi037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afi037</ArticleId><ArticleId IdType="pubmed">15713860</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardaine V, Dequin PF, Ripault H, Constans T, Gini&#xe8;s G. Outcome of older patients requiring ventilatory support in intensive care: impact of nutritional status. J Am Geriatr Soc. 2001;49:564&#x2013;570. doi: 10.1046/j.1532-5415.2001.49114.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2001.49114.x</ArticleId><ArticleId IdType="pubmed">11380748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaarlola A, Tallgren M, Pettil&#xe4; V. Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Crit Care Med. 2006;34:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">16763517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrand E, Robert R, Ingrand P, Lemaire F. French LATAREA Group. Withholding and withdrawal of life support in intensive-care units in France: a prospective survey. French LATAREA Group. Lancet. 2001;357:9&#x2013;14. doi: 10.1016/S0140-6736(00)03564-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)03564-9</ArticleId><ArticleId IdType="pubmed">11197395</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay E, Pochard F, Garrouste-Orgeas M, Moreau D, Montesino L, Adrie C, de Lassence A, Cohen Y, Timsit JF. Outcomerea Study Group. Decisions to forgo life-sustaining therapy in ICU patients independently predict hospital death. Intensive Care Med. 2003;29:1895&#x2013;1901. doi: 10.1007/s00134-003-1989-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-003-1989-3</ArticleId><ArticleId IdType="pubmed">14530857</ArticleId></ArticleIdList></Reference><Reference><Citation>Poses RM, Clish Mc, Smith WR. Prediction of survival of critically ill patients by admission comorbidities. J Clin Epidemiol. 1996;49:743&#x2013;747. doi: 10.1016/0895-4356(96)00021-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(96)00021-2</ArticleId><ArticleId IdType="pubmed">8691223</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres Olga H, Francia E, Longobardi V, Gich I, Benito S, Ruiz D. Short and long term outcomes of older patients in intermediate care units. Intensive Care Med. 2006;32:1052&#x2013;1059. doi: 10.1007/s00134-006-0170-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0170-1</ArticleId><ArticleId IdType="pubmed">16791668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LY, Moran JL, Clarke C, Martin J, Solomon PJ. Mortality and cost outcomes of elderly trauma patients admitted to intensive care and the general wards of an Australian tertiary referral hospital. Anaesth Intensive Care. 2009;37:773&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">19775042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Finn J, Knuiman M, Finn J, Webb SA. Combining multiple comorbidities with Acute Physiology Score to predict hospital mortality of critically ill patients: a linked data cohort study. Anaesthesia. 2007;62:1095&#x2013;1100. doi: 10.1111/j.1365-2044.2007.05231.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.2007.05231.x</ArticleId><ArticleId IdType="pubmed">17924888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Knuiman M, Finn J, Webb SA. Estimating long-term survival of critically ill patients: the PREDICT model. PLoS One. 2008;3:e3226. doi: 10.1371/journal.pone.0003226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003226</ArticleId><ArticleId IdType="pmc">PMC2528946</ArticleId><ArticleId IdType="pubmed">18797505</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabah A, Philippart F, Timsit JF, Willems V, Francais A, Leplege A, Carlet J, Bruel C, Misset B, Garrouste-Orgeas M. Quality of life in patients aged 80 or over after ICU discharge. Crit Care. 2010;14(1):R2. doi: 10.1186/cc8231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8231</ArticleId><ArticleId IdType="pmc">PMC2875504</ArticleId><ArticleId IdType="pubmed">20064197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahul P, Perrot D, Tempelhoff G, Gaussorgues P, Jospe R, Ducreux JC, Dumont A, Motin J, Auboyer C, Robert D. Short- and long-term prognosis, functional outcome following ICU for elderly. Intensive Care Med. 1991;17:7&#x2013;10. doi: 10.1007/BF01708401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01708401</ArticleId><ArticleId IdType="pubmed">2037727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo M, Massaia M, Raspo S, Bosco F, Cena P, Molaschi M, Fabris F. Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. JAGS. 2003;51:519&#x2013;523. doi: 10.1046/j.1532-5415.2003.51161.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2003.51161.x</ArticleId><ArticleId IdType="pubmed">12657074</ArticleId></ArticleIdList></Reference><Reference><Citation>Niskanen M, Ruokonen E, Takala J, Rissanen P, Kari A. Quality of life after prolonged intensive care. Crit Care Med. 1999;27:1132&#x2013;1139. doi: 10.1097/00003246-199906000-00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199906000-00035</ArticleId><ArticleId IdType="pubmed">10397218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurel D, Loirat P, Saulnier F, Nicolas F, Brivet F. Quality of life 6 months after intensive care: results of a prospective multicenter study using a generic health status scale and a satisfaction scale. Intensive Care Med. 1997;23:331&#x2013;337. doi: 10.1007/s001340050336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050336</ArticleId><ArticleId IdType="pubmed">9083237</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines of intensive care unit admission discharge and triage. Society of Critical Care Medicine Task Force of American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med. 1999;27:633&#x2013;638. doi: 10.1097/00003246-199903000-00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199903000-00048</ArticleId><ArticleId IdType="pubmed">10199547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40731293</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial.</ArticleTitle><Pagination><StartPage>262</StartPage><MedlinePgn>262</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">262</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-025-08979-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sepsis is the leading cause of death in critically ill patients, with an in-hospital mortality rate of approximately 25% to 40%. Coagulation activation serves as an initial factor to the progression of sepsis into multiple organ dysfunction syndrome (MODS). Therefore, anticoagulant therapy may be beneficial. Both preclinical experiments and clinical studies have evaluated the protective effect of nafamostat mesilate (NM) in sepsis. However, there is still a lack of randomized controlled trials (RCTs) to further confirm the therapeutic effect and safety of NM in sepsis patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, double-blind, RCT was designed to recruit 778 subjects who met Sepsis 3.0 criteria. Participants will be randomly assigned (1:1) to receive either intravenous administration of NM or glucose along with standard treatment. The primary outcome is the all-cause mortality rate in the intensive care unit (ICU), and the secondary outcomes include the improvement in SOFA scores, changes in Japanese Association for Acute Medicine (JAAM)/International Society on Thrombosis and Hemostasis (ISTH) scores, 28-day all-cause mortality rate, and the incidence of adverse events. The allocation will remain concealed from investigators, participants, and statisticians to maintain blinding.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The EASNMS trial aims to assess the efficacy and safety of NM for treating sepsis across various regions in China. As an additional treatment option, NM may potentially enhance the prognosis of sepsis patients.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">Ethical approval has been obtained from all ethics committees of the involved centers. The findings of this study will be shared in peer-reviewed journals and will be presented at conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT06078839. Registered on September 20, 2023.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Jianshuang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuteng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, North Nanjing Street 155, Shenyang, Liaoning Province, 110001, People's Republic of China. vincentzh002@outlook.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EASNMS investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06078839</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2022YFC2304605</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Y25LQ0H97D</RegistryNumber><NameOfSubstance UI="C032855">nafamostat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001550">Benzamidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001550" MajorTopicYN="Y">Benzamidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="Y">Guanidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coagulation activation</Keyword><Keyword MajorTopicYN="N">Nafamostat mesilate</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study protocol has been approved by the Research and Ethics Committee of the First Affiliated Hospital of China Medical University ([2023] No. 453, Shenyang, China). The findings of this study will be shared in peer-reviewed journals and will be presented at conferences. Consent for publication: Not applicable. Competing interests: The principal investigators of this trial declare no competing financial or non-financial interests relevant to the conduct or outcomes of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40731293</ArticleId><ArticleId IdType="pmc">PMC12309187</ArticleId><ArticleId IdType="doi">10.1186/s13063-025-08979-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-025-08979-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801&#x2013;10. 10.1001/jama.2016.0287. Published Online First: 2016/02/24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552&#x2013;62. 10.1007/s00134-020-06151-x. Published Online First: 2020/06/24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381468</ArticleId><ArticleId IdType="pubmed">32572531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009&#x2013;2014. JAMA. 2017;318(13):1241&#x2013;9. 10.1001/jama.2017.13836. Published Online First: 2017/09/14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710396</ArticleId><ArticleId IdType="pubmed">28903154</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado FR, Cavalcanti AB, Bozza FA, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17(11):1180&#x2013;9. 10.1016/S1473-3099(17)30322-5. Published Online First: 2017/08/23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28826588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037. 10.1038/nrdp.2016.37. Published Online First: 2016/06/03.</Citation><ArticleIdList><ArticleId IdType="pubmed">27250996</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M. The coagulant response in sepsis. Clin Chest Med. 2008;29(4):627&#x2013;42. 10.1016/j.ccm.2008.06.006. Published Online First: 2008/10/29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18954698</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191&#x2013;5. 10.1097/01.ccm.0000281468.94108.4b. Published Online First: 2007/09/15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855836</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Uchino S, Hayakawa M, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2019;50:23&#x2013;30. 10.1016/j.jcrc.2018.11.009[publishedOnlineFirst:20181114]. Published Online First: 20181114.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471557</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Arakawa M, Di Nisio M, et al. Newly proposed sepsis-induced coagulopathy precedes international society on thrombosis and haemostasis overt-disseminated intravascular coagulation and predicts high mortality. J Intensive Care Med. 2020;35(7):643&#x2013;9. 10.1177/0885066618773679. Published Online First: 2018/05/04.</Citation><ArticleIdList><ArticleId IdType="pubmed">29720054</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology. 2020;132(5):1238&#x2013;45. 10.1097/ALN.0000000000003122. Published Online First: 2020/02/12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32044801</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshiyama Y, Ozeki M, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nihon Yakurigaku Zasshi. 1984;84(5):417&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">6519580</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41(2):155&#x2013;62. 10.1254/jjp.41.155. Published Online First: 1986/06/01.</Citation><ArticleIdList><ArticleId IdType="pubmed">2427760</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata M, Shirakawa T, Acharya B, et al. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006;52(3):272&#x2013;5. 10.1097/01.mat.0000209224.94089.bc. Published Online First: 2006/06/09.</Citation><ArticleIdList><ArticleId IdType="pubmed">16760715</ArticleId></ArticleIdList></Reference><Reference><Citation>Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev. 1995;13(1):51&#x2013;65.</Citation></Reference><Reference><Citation>Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003;7(5):483&#x2013;5. 10.1046/j.1526-0968.2003.00088.x. Published Online First: 2004/01/08.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao YG, Chen YC, Hao K, et al. An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31(11):1985&#x2013;9. 10.1248/bpb.31.1985. Published Online First: 2008/11/05.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaori S, Fujiyama N, Kushihara M, et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet. 2006;21(2):147&#x2013;55. 10.2133/dmpk.21.147. Published Online First: 2006/05/17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Li S, Wan R, et al. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials. Pancreas. 2015;44(4):561&#x2013;9. 10.1097/MPA.0000000000000310.</Citation><ArticleIdList><ArticleId IdType="pubmed">25822153</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Lee SH, Park N, et al. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. BMC Gastroenterol. 2022;22(1):271. 10.1186/s12876-022-02345-3. Published Online First: 20220531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9153157</ArticleId><ArticleId IdType="pubmed">35641898</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69(4):e11&#x2013;8. 10.1016/j.gie.2008.10.046.</Citation><ArticleIdList><ArticleId IdType="pubmed">19327467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. 10.1136/bmj.e7586. Published Online First: 20130108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Ding R, Sun H, et al. Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial. Trials. 2024;25(1):4. 10.1186/s13063-023-07853-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10759642</ArticleId><ArticleId IdType="pubmed">38167115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18(5):563. 10.1186/s13054-014-0563-4. Published Online First: 2014/10/17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213495</ArticleId><ArticleId IdType="pubmed">25318353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu S, Yu S, Wang L, et al. Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis. BMC Anesthesiol. 2022;22(1):28. 10.1186/s12871-021-01545-w. Published Online First: 2022/01/23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8777179</ArticleId><ArticleId IdType="pubmed">35062871</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Zou L, Pittet JF, et al. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical presentation, diagnosis, and management strategies. Anesth Analg. 2024;138(4):696&#x2013;711. 10.1213/ANE.0000000000006888. Published Online First: 2024/02/07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10916756</ArticleId><ArticleId IdType="pubmed">38324297</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989&#x2013;94. 10.1111/jth.14578. Published Online First: 2019/08/15.</Citation><ArticleIdList><ArticleId IdType="pubmed">31410983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelewicz A, Prokopowicz J, Bodzenta A, et al. Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis. Digestion. 1988;40(1):19&#x2013;24. 10.1159/000199638.</Citation><ArticleIdList><ArticleId IdType="pubmed">3234615</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki M, Ozeki M, Sato T, et al. Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis. Nihon Yakurigaku Zasshi. 1984;84(4):363&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">6210233</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-S, Jeong S, Kim JM, et al. Preventative effect of nafamostat mesilate infusion into the main pancreatic duct on post-ERCP pancreatitis in a porcine model: initial pilot study. J Invest Surg. 2020;33(4):325&#x2013;31. 10.1080/08941939.2018.1511015.</Citation><ArticleIdList><ArticleId IdType="pubmed">30884994</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumi K, Okada T, Lin Y, et al. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2023;13(1):23012. 10.1038/s41598-023-50181-6. Published Online First: 20231227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10754829</ArticleId><ArticleId IdType="pubmed">38155200</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath IL, Kleiner D, Nagy R, et al. Nafamostat reduces the incidence of post-ERCP pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2024;115(2):206&#x2013;12. 10.1002/cpt.3118. Published Online First: 20231229.</Citation><ArticleIdList><ArticleId IdType="pubmed">38032816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekura S, Umeda Y, Ogawa Y, et al. Effects of intermittent nafamostat mesylate in divided doses in patients with disseminated intravascular coagulation occurring with hematopoietic malignancies. Curr Ther Res. 1996;57(3):203&#x2013;14. 10.1016/s0011-393x(96)80126-3.</Citation></Reference><Reference><Citation>Tanaka S, Ohmine T. A case of abdominal aortic aneurysm presenting as symptomatic disseminated intravascular coagulation treated with endovascular aneurysm repair and postoperative administration of nafamostat mesylate. Surg Case Rep. 2024;10(1):124. 10.1186/s40792-024-01926-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11096137</ArticleId><ArticleId IdType="pubmed">38750283</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakata D, Fujiwara SI, Ikeda T, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141&#x2013;6. 10.1007/s12185-018-02567-w. Published Online First: 20181208.</Citation><ArticleIdList><ArticleId IdType="pubmed">30536180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamijo H, Mochizuki K, Nakamura Y, et al. Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification: a nationwide registry study in Japan. J Clin Med. 2020;9(8):2629. 10.3390/jcm9082629. Published Online First: 2020/08/23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7464767</ArticleId><ArticleId IdType="pubmed">32823637</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaeke P, De Man J, Hens S, et al. Sa1172 - effects of the non-selective protease inhibitor nafamostat mesylate on intestinal permeability and bacterial translocation in a murine model of sepsis. Gastroenterology. 2018;154(6):S267&#x2013;8. 10.1016/s0016-5085(18)31253-8.</Citation></Reference><Reference><Citation>Hryszko T, Inaba K, Ihara H, et al. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. J Trauma. 2006;60(4):859&#x2013;64. 10.1097/01.ta.0000215566.74588.27. PublishedOnlineFirst:2006/04/14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16612309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27422361</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-685X</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of thoracic and cardiovascular surgery</Title><ISOAbbreviation>J Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Outcomes of extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest in adult cardiac surgery patients.</ArticleTitle><Pagination><StartPage>1133</StartPage><EndPage>1139</EndPage><MedlinePgn>1133-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtcvs.2016.06.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5223(16)30644-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">The role of extracorporeal cardiopulmonary resuscitation (ECPR) in adult cardiac surgery patients with refractory cardiac arrest is uncertain. We hypothesized that ECPR would be associated with better than expected outcomes in this group of patients.</AbstractText><AbstractText Label="METHODS">We conducted a single-center retrospective cohort study of adult cardiac surgery patients who underwent ECPR for refractory cardiac arrest during a 6-year period (2010 to 2015). In-hospital mortality, survival at last follow-up, and cerebral performance category (CPC) were examined as outcomes, and potential risk factors for mortality were explored.</AbstractText><AbstractText Label="RESULTS">Twenty-three patients underwent ECPR when spontaneous circulation did not return with conventional resuscitation. Thirty-day mortality was 65.2%, and in-hospital mortality was 69.6%. Six of the 23 patients (26.1%) were discharged with a favorable neurologic outcome, defined as CPC 1 or 2. Most patients who died had multiple organ dysfunction syndrome (43.8%), and a smaller number had severe brain injury (25.0%). Kaplan-Meier survival analysis suggested age as a critical factor affecting survival (P&#xa0;=&#xa0;.04, log-rank test).</AbstractText><AbstractText Label="CONCLUSIONS">ECPR may have a role in younger adult cardiac surgery patients who experience refractory cardiac arrest. Future studies are needed to identify patients who will benefit most from ECPR.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzeffi</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Md; Shock Trauma Critical Care, University of Maryland School of Medicine, Baltimore, Md. Electronic address: mmazzeffi@anes.umm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pablo G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herr</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shock Trauma Critical Care, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krause</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rector</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCormick</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Si</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Bartley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kon</LastName><ForeName>Zachary N</ForeName><Initials>ZN</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Md.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>0376343</NlmUniqueID><ISSNLinking>0022-5223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Cardiovasc Surg. 2016 Oct;152(4):1140-1. doi: 10.1016/j.jtcvs.2016.06.047.</RefSource><PMID Version="1">27460438</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016887" MajorTopicYN="N">Cardiopulmonary Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="N">Heart Arrest</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">cardiac arrest</Keyword><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">resuscitation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27422361</ArticleId><ArticleId IdType="doi">10.1016/j.jtcvs.2016.06.014</ArticleId><ArticleId IdType="pii">S0022-5223(16)30644-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23530720</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-2197</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>ANZ journal of surgery</Title><ISOAbbreviation>ANZ J Surg</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal complications after cardiac surgery: 10-year experience of a single Australian centre.</ArticleTitle><Pagination><StartPage>651</StartPage><EndPage>656</EndPage><MedlinePgn>651-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ans.12134</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastrointestinal (GI) complications after cardiac surgery are uncommon, but are associated with high morbidity and mortality as well as significant hospital resource utilization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed a prospectively collected database containing all adult cardiac surgery procedures performed from July 2001 to March 2011 at Monash Medical Centre and Jessie McPherson Private Hospital. Patients with post-operative GI complications were compared to patients without GI complications who were operated in the same period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of GI complications was 1.1% (61 out of 5382 patients) with an overall 30-day mortality of 33% (versus 3% in the non-GI complication group). The most common complications were GI bleeding, gastroenteritis and bowel ischaemia. Patients who had GI complications were significantly older, had higher incidence of renal impairment, chronic lung disease and anticoagulation therapy and were more likely to be in cardiogenic shock. Emergency procedures, combined coronary artery bypass grafting and valve surgery and aortic dissection cases were more common in the GI complication group. The GI complication group also had higher incidence of return to theatre, renal failure, stroke, septicaemia and multi-organ failure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GI complications after cardiac surgery remain an uncommon but dreadful complication associated with high mortality. Our findings should prompt a high degree of clinical vigilance in order to make an early diagnosis especially in high risk patients. Further studies aiming to identify independent predictors for GI complications after cardiac surgery are warranted.</AbstractText><CopyrightInformation>&#xa9; 2013 The Authors. ANZ Journal of Surgery &#xa9; 2013 Royal Australasian College of Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viana</LastName><ForeName>Fabiano F</ForeName><Initials>FF</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Monash Medical Centre, Clayton, Victoria, Australia. ff_viana@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Heather D</ForeName><Initials>HD</Initials></Author><Author ValidYN="Y"><LastName>Cochrane</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Julian A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>ANZ J Surg</MedlineTA><NlmUniqueID>101086634</NlmUniqueID><ISSNLinking>1445-1433</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041881" MajorTopicYN="N">Cholecystitis, Acute</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017091" MajorTopicYN="N">Colitis, Ischemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="N">Gastroenteritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048550" MajorTopicYN="N">Hepatic Insufficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045823" MajorTopicYN="N">Ileus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007416" MajorTopicYN="N">Intestinal Perforation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014739" MajorTopicYN="N" Type="Geographic">Victoria</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">gastrointestinal tract</Keyword><Keyword MajorTopicYN="N">post-operative complications</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23530720</ArticleId><ArticleId IdType="doi">10.1111/ans.12134</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19519886</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study.</ArticleTitle><Pagination><StartPage>R88</StartPage><MedlinePgn>R88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc7914</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Severe tissue trauma results in a general inflammatory immune response (SIRS) representing an overall inflammatory reaction of the immune system. However, there is little known about the functional alterations of monocytes in the early posttraumatic phase, characterized by the battle of the individual with the initial trauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirteen patients with severe multiple injury; injury severity score (ISS) &gt;16 points (17 to 57) were included. The cytokine synthesis profiles of monocytes were characterized on admission, and followed up 6, 12, 24, 48, and 72 hours after severe multiple injury using flow cytometry. Whole blood was challenged with lipopolysaccharide (LPS) and subsequently analyzed for intracellular monocyte-related TNF-alpha, IL-1beta, IL-6, and IL-8. The degree of organ dysfunction was assessed using the multiple organ dysfunction syndrome (MODS)-score of Marshall on admission, 24 hours and 72 hours after injury.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our data clearly show that the capacity of circulating monocytes to produce these mediators de novo was significantly diminished very early reaching a nadir 24 hours after severe injury followed by a rapid and nearly complete recovery another 48 hours later compared with admission and controls, respectively. In contrast to the initial injury severity, there was a significant correlation detectable between the clinical signs of multiple organ dysfunction and the ex vivo cytokine response.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">As our data derived from very narrow intervals of measurements, they might contribute to a more detailed understanding of the early immune alterations recognized after severe trauma. It can be concluded that indeed as previously postulated an immediate hyperactivation of circulating monocytes is rapidly followed by a substantial paralysis of cell function. Moreover, our findings clearly demonstrate that the restricted capacity of monocytes to produce proinflammatory cytokines after severe injury is not only an in vitro phenomenon but also undistinguishable associated with the onset of organ dysfunction in the clinical scenario.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Chlodwig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Traumatology, Klinikum Rechts der Isar, Technische Universitaet, 81675 Munich, Germany. chlodwig.kirchhoff@mac.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mutschler</LastName><ForeName>Wolf E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Faist</LastName><ForeName>Eugen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Jochum</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zedler</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="Y">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19519886</ArticleId><ArticleId IdType="pmc">PMC2717459</ArticleId><ArticleId IdType="doi">10.1186/cc7914</ArticleId><ArticleId IdType="pii">cc7914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zedler S, Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care. 2006;12:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077693</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11951032</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C. Influence of surgical intervention in the immune response of severely injured patients. Intensive Care Med. 2004;30:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">14605804</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, van Griensven M, Rice J, Gansslen A, Hildebrand F, Zech S, Winny M, Lichtinghagen R, Krettek C. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma. 2001;50:989&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426112</ArticleId></ArticleIdList></Reference><Reference><Citation>Seekamp A, Jochum M, Ziegler M, van Griensven M, Martin M, Regel G. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion. J Trauma. 1998;44:874&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">9603092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoch RC, Rodriguez R, Manning T, Bishop M, Mead P, Shoemaker WC, Abraham E. Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med. 1993;21:839&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">8504650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nast-Kolb D, Waydhas C, Gippner-Steppert C, Schneider I, Trupka A, Ruchholtz S, Zettl R, Schweiberer L, Jochum M. Indicators of the posttraumatic inflammatory response correlate with organ failure in patients with multiple injuries. J Trauma. 1997;42:446&#x2013;454. discussion 454&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095112</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992;216:117&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242583</ArticleId><ArticleId IdType="pubmed">1503516</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med. 1997;25:1813&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366763</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol. 2000;74:162&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608087</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrie C, Bachelet M, Vayssier-Taussat M, Russo-Marie F, Bouchaert I, Adib-Conquy M, Cavaillon JM, Pinsky MR, Dhainaut JF, Polla BS. Mitochondrial membrane potential and apoptosis peripheral blood monocytes in severe human sepsis. Am J Respir Crit Care Med. 2001;164:389&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11500338</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora SK. Analysis of intracellular cytokines using flowcytometry. Methods Cell Sci. 2002;24:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815288</ArticleId></ArticleIdList></Reference><Reference><Citation>Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods. 1995;188:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8551029</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Leidel BA, Kirchhoff S, Braunstein V, Bogner V, Kreimeier U, Mutschler W, Biberthaler P. Analysis of N-terminal pro-B-type natriuretic peptide and cardiac index in multiple injured patients: a prospective cohort study. Crit Care. 2008;12:R118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592747</ArticleId><ArticleId IdType="pubmed">18789145</ArticleId></ArticleIdList></Reference><Reference><Citation>WinMDI software </Citation></Reference><Reference><Citation>DeLong WG, Jr, Born CT. Cytokines in patients with polytrauma. Clin Orthop Relat Res. 2004;422:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose S, Marzi I. Mediators in polytrauma &#x2013; pathophysiological significance and clinical relevance. Langenbecks Arch Surg. 1998;383:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9776443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkel C, Faist E, Zimmer S, Piltz S, Walz A, Rose R, Hocherl E, Herndon D, Schildberg FW. Kinetics of circulating adhesion molecules and chemokines after mechanical trauma and burns. Eur J Surg. 1996;162:763&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934104</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris BH, Gelfand JA. The immune response to trauma. Semin Pediatr Surg. 1995;4:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">7633853</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy T, Paterson H, Rogers S, Mannick JA, Lederer JA. Use of intracellular cytokine staining and bacterial superantigen to document suppression of the adaptive immune system in injured patients. Ann Surg. 2003;238:401&#x2013;410. discussion 410&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422703</ArticleId><ArticleId IdType="pubmed">14501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E. T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med. 1999;27:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9934895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods. 1993;159:197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">8445253</ArticleId></ArticleIdList></Reference><Reference><Citation>Faist E, Storck M, Hultner L, Redl H, Ertel W, Walz A, Schildberg FW. Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care. Surgery. 1992;112:562&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">1519173</ArticleId></ArticleIdList></Reference><Reference><Citation>Adib-Conquy M, Moine P, Asehnoune K, Edouard A, Espevik T, Miyake K, Werts C, Cavaillon JM. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med. 2003;168:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12738604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10:233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1751079</ArticleId><ArticleId IdType="pubmed">17044947</ArticleId></ArticleIdList></Reference><Reference><Citation>Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, Denny T, Deitch EA. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med. 2003;31:1722&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794411</ArticleId></ArticleIdList></Reference><Reference><Citation>Flohe S, Lendemans S, Selbach C, Waydhas C, Ackermann M, Schade FU, Kreuzfelder E. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med. 2003;31:2462&#x2013;2469.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530752</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmann S, Kerner T, Ahlers O, Keh D, Gerlach M, Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand. 2001;45:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207475</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995;23:1835&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimopoulou I, Orfanos S, Kotanidou A, Livaditi O, Giamarellos-Bourboulis E, Athanasiou C, Korovesi I, Sotiropoulou C, Kopterides P, Ilias I, Kanellakopoulou K, Armaganidis A. Plasma pro- and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. Cytokine. 2008;41:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191577</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Remmers D, Grotz M, Schedel I, von Glinski S, Oberbeck R, Dahlweit M, Tscherne H. Levels of antibodies to endotoxin and cytokine release in patients with severe trauma: does posttraumatic dysergy contribute to organ failure? J Trauma. 1999;46:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">10338411</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22:768&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8181284</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21513997</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8332</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Lung cancer (Amsterdam, Netherlands)</Title><ISOAbbreviation>Lung Cancer</ISOAbbreviation></Journal><ArticleTitle>CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>257</EndPage><MedlinePgn>253-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lungcan.2011.03.006</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to assess the technical feasibility, efficacy, and complications of CT-guided interstitial brachytherapy for treating inoperable non-small cell lung cancer (NSCLC).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Twenty one patients were included in this prospective study. The median age was 72.6 years (57-85). Tumors were treated with brachytherapy that was positioned under CT-fluoroscopy. The treatment planning system (TPS) was used preoperatively to reconstruct three dimensional images of the tumor and to calculate the estimated seed number and distribution. The median matched peripheral dose (MPD) was 130 Gy (range, 100-160 Gy). All procedures were performed under local anesthesia. A follow-up CT was performed 6 weeks later and every 3 months post implantation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Follow-up period was 2-30 months. The mean diameter of the 21 lung tumors was 4.6 cm (range, 2.8-6.5 cm). The response rate of pain relief was 83.3% (10/12). The pain-free duration was 0-12 months (median: 6 months; 95% CI: 3-9 months). Overall responding rate (CR+PR) for this group of patients was 71.4%. Local tumor control rate was 85.7%. Six (28.6%) patients died as a result of primary tumor progression; thirteen (61.9%) patients died of multi-organ failure or other metastases. Two (9.5%) patients survived to follow-up. At the time of analysis, the median survival time for all patients was 10 months (95% CI: 6.6-13.4 months), with 1 year and 2 year survival rates were 42.4% and 6.5%, respectively. Median survival time for stage II, stage III, and stage IV was 20 months, 9 months, and 8 months, respectively. No major complications were observed. Minor complications (19%) included mild pneumothorax (n=1), hemosputum (n=1), pleural effusion (n=1), and localized skin erythema (n=1). None of these complications required further treatment, although hospital discharge was delayed. No (125)I seeds migrated to other tissues or organs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Minimally invasive CT-guided interstitial brachytherapy is safe, useful, less complicated and considered as a palliative treatment option for inoperable non-small cell lung cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhong-Min</ForeName><Initials>ZM</Initials><AffiliationInfo><Affiliation>School of Radiation Medicine and Public Health, Soochow University, 199 Ren Ai Road, Suzhou Industrial Park, Suzhou 215123, Jiangsu, China. wzm0722@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ke-Min</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fen-Ju</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Lung Cancer</MedlineTA><NlmUniqueID>8800805</NlmUniqueID><ISSNLinking>0169-5002</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007456">Iodine Isotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001918" MajorTopicYN="Y">Brachytherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007456" MajorTopicYN="N">Iodine Isotopes</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010996" MajorTopicYN="N">Pleural Effusion</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011030" MajorTopicYN="N">Pneumothorax</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21513997</ArticleId><ArticleId IdType="doi">10.1016/j.lungcan.2011.03.006</ArticleId><ArticleId IdType="pii">S0169-5002(11)00167-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15048552</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0342-4642</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Effect of bicarbonate and lactate buffer on glucose and lactate metabolism during hemodiafiltration in patients with multiple organ failure.</ArticleTitle><Pagination><StartPage>1103</StartPage><EndPage>1110</EndPage><MedlinePgn>1103-10</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the effects of sodium bicarbonate and lactate for continuous veno-venous hemodiafiltration (CVVHDF) in critically ill patients.</AbstractText><AbstractText Label="DESIGN AND SETTINGS" NlmCategory="METHODS">Prospective crossed-over controlled trial in the surgical and medical ICUs of a university hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eight patients with multiple organ dysfunction syndrome (MODS) requiring CVVHDF.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Each patient received the two buffers in a randomized sequence over two consecutive days.</AbstractText><AbstractText Label="MEASUREMENTS AND RESULTS" NlmCategory="RESULTS">The following variables were determined: acid-base parameters, lactate production and utilization ((13)C lactate infusion), glucose turnover (6,6(2)H(2)-glucose), gas exchange (indirect calorimetry). No side effect was observed during lactate administration. Baseline arterial acid-base variables were equal with the two buffers. Arterial lactate (2.9 versus 1.5 mmol/l), glycemia (+18%) and glucose turnover (+23%) were higher in the lactate period. Bicarbonate and glucose losses in CVVHDF were substantial, but not lactate elimination. Infusing (13)C lactate increased plasma lactate levels equally with the two buffers. Lactate clearance (7.8+/-0.8 vs 7.5+/-0.8 ml/kg per min in the bicarbonate and lactate periods) and endogenous production rates (14.0+/-2.6 vs 13.6+/-2.6 mmol/kg per min) were similar. (13)C lactate was used as a metabolic substrate, as shown by (13)CO(2) excretion. Glycemia and metabolic rate increased significantly and similarly during the two periods during lactate infusion.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lactate was rapidly cleared from the blood of critically ill patients without acute liver failure requiring CVVHDF, being transformed into glucose or oxidized. Lactate did not exert undesirable effects, except moderate hyperglycemia, and achieved comparable effects on acid-base balance to bicarbonate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bollmann</LastName><ForeName>Marc-Daniel</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit, University Hospital CHUV, 1011 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revelly</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Tappy</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Mette M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Schaller</LastName><ForeName>Marie-Denise</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Cayeux</LastName><ForeName>Marie-Christine</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chiol&#xe9;ro</LastName><ForeName>Ren&#xe9;-Louis</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002021">Buffers</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8MDF5V39QO</RegistryNumber><NameOfSubstance UI="D017693">Sodium Bicarbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000136" MajorTopicYN="N">Acid-Base Equilibrium</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002021" MajorTopicYN="N">Buffers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017583" MajorTopicYN="N">Hemodiafiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017693" MajorTopicYN="N">Sodium Bicarbonate</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014882" MajorTopicYN="N">Water-Electrolyte Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15048552</ArticleId><ArticleId IdType="doi">10.1007/s00134-004-2251-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crit Care Med. 1997 Jan;25(1):4-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8989168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Nutr Metab. 1982;26(4):254-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7137947</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1992 Nov 26;327(22):1564-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1435883</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Clin Nutr Metab Care. 1999 Mar;2(2):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10453348</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephrol Dial Transplant. 1989;4(9):800-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2516612</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 1999 Dec;27(12):2690-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10628611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Fail. 1990;12(2):99-101</Citation><ArticleIdList><ArticleId IdType="pubmed">2236733</ArticleId></ArticleIdList></Reference><Reference><Citation>QJM. 1998 Apr;91(4):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9666950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2000 Oct;58(4):1751-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11012909</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1995 Apr;268(4 Pt 1):E630-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7733261</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1988 Apr;47(4):608-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3281434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 1999 Apr;229(4):505-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10203083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 2000 Oct;58(4):1765-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11012911</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Dec 22-29;270(24):2957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1991 Oct;261(4 Pt 1):E457-65</Citation><ArticleIdList><ArticleId IdType="pubmed">1928337</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Physiol. 1978 Apr;33(1):9-26</Citation><ArticleIdList><ArticleId IdType="pubmed">27857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11251027</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Clin Nutr. 1993 Nov;58(5):608-13</Citation><ArticleIdList><ArticleId IdType="pubmed">8237864</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ren Replace Ther. 2002 Oct;9(4):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12382232</ArticleId></ArticleIdList></Reference><Reference><Citation>JPEN J Parenter Enteral Nutr. 1980 Mar-Apr;4(2):147-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7401260</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1021-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9563714</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1999 Jul;277(1):E176-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10409142</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1999 Nov;25(11):1244-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10654208</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1994 Jul;97(1):47-54</Citation><ArticleIdList><ArticleId IdType="pubmed">8030656</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Artif Organs. 1994 Jun;17(6):315-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7806416</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1996 Jul;22(7):707-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1980 Feb;92(2 Pt 1):227-37</Citation><ArticleIdList><ArticleId IdType="pubmed">6766289</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Invest. 1993 Aug;23(8):448-54</Citation><ArticleIdList><ArticleId IdType="pubmed">8404995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">29181605</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-086X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cardiovascular and interventional radiology</Title><ISOAbbreviation>Cardiovasc Intervent Radiol</ISOAbbreviation></Journal><ArticleTitle>Symptomatic Heart Failure After Transjugular Intrahepatic Portosystemic Shunt Placement: Incidence, Outcomes, and Predictors.</ArticleTitle><Pagination><StartPage>564</StartPage><EndPage>571</EndPage><MedlinePgn>564-571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00270-017-1848-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the incidence of symptomatic heart failure (SHF) occurring after transjugular intrahepatic portosystemic shunt (TIPS) placement, identify potential predictors of SHF, and evaluate clinical presentation and outcomes in cases of post-TIPS SHF.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospectively maintained TIPS database was used to identify patients who underwent new TIPS placements at a large urban tertiary care center between 1995 and 2014. SHF was defined as otherwise unexplained new-onset dyspnea, hypoxemia, radiologic pulmonary edema, an increased need for diuretics, or need for intubation within 7&#xa0;days after TIPS placement. Cases of deaths occurring within 7&#xa0;days due to septic shock, continuing gastrointestinal bleed, or multi-organ failure were excluded. A control group consisting of a random sample of 40 patients from the same TIPS database was created. Uni-variable analysis was performed to assess differences between patients with and without post-TIPS SHF.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 934 TIPS procedures performed during the study period, 883 met the inclusion criteria. Eight (0.9%) patients developed SHF, usually manifested by hypoxemia (50%) or dyspnea (25%) within 48&#xa0;h. Patients with SHF had higher pre-TIPS right atrial (p&#xa0;=&#xa0;0.03) and portal vein (p&#xa0;=&#xa0;0.01) pressures, higher albumin (p&#xa0;=&#xa0;0.02), and higher prothrombin time (p&#xa0;=&#xa0;0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-TIPS SHF is rare. Higher pre-TIPS right atrial and portal vein pressures are likely to predispose patients to this complication. Close monitoring may be warranted in these patients. In our eight patients, post-TIPS SHF did not result in poor outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modha</LastName><ForeName>Kunjam</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Cleveland Clinic, 9500 Euclid Avenue, M2 Annex, Cleveland, OH, 44195, USA. modhak@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Baljendra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Vascular and Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sands</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Vascular and Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carey</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Intervent Radiol</MedlineTA><NlmUniqueID>8003538</NlmUniqueID><ISSNLinking>0174-1551</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006975" MajorTopicYN="N">Hypertension, Portal</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011169" MajorTopicYN="N">Portal Vein</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019168" MajorTopicYN="N">Portasystemic Shunt, Transjugular Intrahepatic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac output</Keyword><Keyword MajorTopicYN="N">Cirrhosis</Keyword><Keyword MajorTopicYN="N">Hypervolemia</Keyword><Keyword MajorTopicYN="N">Portal hypertension</Keyword><Keyword MajorTopicYN="N">Portal pressure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29181605</ArticleId><ArticleId IdType="doi">10.1007/s00270-017-1848-1</ArticleId><ArticleId IdType="pii">10.1007/s00270-017-1848-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28682941</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Reduction in Mortality Rates of Postinjury Multiple Organ Dysfunction Syndrome: A Shifting Paradigm? A Prospective Population-Based Cohort Study.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>38</EndPage><MedlinePgn>33-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SHK.0000000000000938</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The incidence of multiple organ dysfunction syndrome (MODS) has decreased in the last decade by improvement in trauma care. However, it still remains a major cause of morbidity and mortality. This study investigated the current incidence and mortality of MODS in polytrauma patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A 3-year prospective study included consecutive trauma patients admitted to a Level-1 Trauma Center Intensive Care Unit (ICU). Isolated head injuries, drowning, asphyxiation, and burns were excluded. Demographics, Injury Severity Score (ISS), physiologic parameters, resuscitation parameters, and Denver multiple organ failure (MOF) scores were prospectively collected. Data are presented as median (interquartile range [IQR]), P&#x200a;&lt;&#x200a;0.05 was considered significant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred fifty-seven patients were included. Median age was 45 (26-61) years, 118 males (75%), ISS was 29 (22-37), 151 (96%) patients had blunt injuries. Thirty-one patients developed MODS (20%). Twenty-seven patients (17%) died, 24 due to brain and/or spinal cord injuries (89%). Only one patient (3%) died of MODS. Median highest Denver MOF score was 4 (4-5). Median time to MODS onset was 3 (3-4) days after injury with a length of 2 (1-3) days. Only seven patients (23%) had MODS for more than 3 consecutive days. Patients who developed MODS were older, needed more blood products in the emergency department, more platelets &#x200a;&lt;&#x200a;8&#x200a;h and &lt;24&#x200a;h, stayed longer on the ventilator, longer in ICU and developed more often adult respiratory distress syndrome. There was however no difference in mortality between both groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this polytrauma population mortality was predominantly caused by brain injury. Even though MODS was still present in severely injured polytrauma patients, its presentation was only early onset, less severe during a shorter time period, and accompanied by lower mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28682941</ArticleId><ArticleId IdType="doi">10.1097/SHK.0000000000000938</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30152434</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1319-2442</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia</Title><ISOAbbreviation>Saudi J Kidney Dis Transpl</ISOAbbreviation></Journal><ArticleTitle>Clinical spectrum of hospital acquired acute kidney injury: A prospective study from Central India.</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>955</EndPage><MedlinePgn>946-955</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/1319-2442.239650</ELocationID><Abstract><AbstractText>Acute kidney injury (AKI) is a common disorder worldwide that is associated with severe morbidity, mortality and cost. If managed adequately and in a timely manner, the majority of these cases are preventable, treatable and often reversible with simple measures. We conducted a two years prospective study of patients admitted to medical and surgical units of a tertiary care center in Central India to identify the causes of Hospital Acquired AKI (HAAKI) and its impact on patient outcomes. HAAKI occurred in 215 of 9,800 patients (2.1%). Sepsis (75; 34.88%), volume depletion and hypo perfusion (62; 28.83%), drugs (50; 23.25%), multifactorial (18; 8.37%) and radiocontrast agents (9; 4.2%) were the causes of HAAKI. Thirty-nine percent of patients had complete recovery and 9.3% had partial recovery of renal function. The overall inhospital mortality due to HAAKI was 41.86%. On multivariate analysis, oliguria, multi-organ failure, metabolic acidosis, anemia, and sepsis showed significant association with in-hospital mortality. The mortality and morbidity associated with HAAKI mandates the need for active measures to decrease its incidence. Knowledge of incidence and risk factors is crucial because it drives local and international efforts on detection and treatment. To the best of our knowledge, no epidemiological study has been conducted or published on HAAKI from the Central India.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>Shraddha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vohra</LastName><ForeName>Rubina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raju</LastName><ForeName>Bhavani M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Saudi Arabia</Country><MedlineTA>Saudi J Kidney Dis Transpl</MedlineTA><NlmUniqueID>9436968</NlmUniqueID><ISSNLinking>1319-2442</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020896" MajorTopicYN="N">Hypovolemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30152434</ArticleId><ArticleId IdType="doi">10.4103/1319-2442.239650</ArticleId><ArticleId IdType="pii">SaudiJKidneyDisTranspl_2018_29_4_946_239650</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25555146</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2210-2612</ISSN><JournalIssue CitedMedium="Print"><Volume>6C</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>International journal of surgery case reports</Title><ISOAbbreviation>Int J Surg Case Rep</ISOAbbreviation></Journal><ArticleTitle>Group A Streptococci: A rare and often misdiagnosed cause of spontaneous bacterial peritonitis in adults.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>255</EndPage><MedlinePgn>251-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijscr.2014.10.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2210-2612(14)00311-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Acute primary peritonitis due to group A Streptococci (GAS) is a rare but life-threatening infection. Unlike other forms of primary peritonitis it affects predominantly young previously healthy individuals and thus is often confused with the more frequent secondary peritonitis. A case series of three patients is presented as well as a review of the literature focusing on pitfalls in the diagnose and therapy of GAS peritonitis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis of three patients with primary GAS peritonitis was performed. Furthermore a systematic review of all cases of primary GAS peritonitis published from 1990 to 2013 was performed comparing demographics and clinical presentation, as well as radiological imaging, treatment and outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All three female patients presented initially with high fever, nausea and severe abdominal pain. Radiological imaging revealed intraperitoneal fluid collections of various degrees, but no underlying cause of peritonitis. Broad antibiotic treatment was started and surgical exploration was performed for acute abdomen in all three cases. Intraoperatively fibrinous peritonitis was observed, but the correct diagnosis was not made until microbiological analysis confirmed GAS peritonitis. One patient died within 24h after admission. The other two patients recovered after multiple surgeries and several weeks on the intensive care unit due to multiple organ dysfunction syndrome. The fulminant clinical course of the three patients resembled those of many of the published cases: flu-like symptoms, high fever, severe acute abdominal pain and fibrinous peritonitis without obvious infectious focus were the most common symptoms reported in the literature.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GAS primary peritonitis should be considered in particular in young, previously healthy women who present with peritonitis but lack radiological findings of an infectious focus. The treatment of choice is immediate antibiotic therapy. Surgical intervention is difficult to avoid, since the diagnosis of GAS peritonitis is usually not confirmed until other causes of secondary peritonitis have been excluded.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malota</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany. Electronic address: mark.malota@klinikum-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felbinger</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care and Pain Medicine, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruppert</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfc;ssler</LastName><ForeName>Natascha C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Endocrine Surgery and Coloproctology, Klinikum Neuperlach, St&#xe4;dtisches Klinikum M&#xfc;nchen GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Surg Case Rep</MedlineTA><NlmUniqueID>101529872</NlmUniqueID><ISSNLinking>2210-2612</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Group A Streptococcus</Keyword><Keyword MajorTopicYN="N">Peritonitis</Keyword><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">acute abdomen</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25555146</ArticleId><ArticleId IdType="pmc">PMC4347958</ArticleId><ArticleId IdType="doi">10.1016/j.ijscr.2014.10.060</ArticleId><ArticleId IdType="pii">S2210-2612(14)00311-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiest R., Krag A., Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut. 2012;61(February (2)):297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomkin J.S. Evaluating evidence and grading recommendations: the SIS/IDSA guidelines for the treatment of complicated intra-abdominal infections. Surg Infect. 2010;11(June (3)):269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20583865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamagni T.L., Efstratiou A., Vuopio-Varkila J. The epidemiology of severe Streptococcus pyogenes-associated disease in Europe. Eur Surveill. 2005;10:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">16280610</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J., Murchan S., O&#x2019;Flanagan D., Fitzpatrick F. Invasive Group A streptococcal disease in Ireland, 2004 to 2010. Eur Surveill. 2011;16 pii:19988.</Citation><ArticleIdList><ArticleId IdType="pubmed">22008200</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen R.D., Moser R., Schlup P., Neftel K.A. Fulminant group A streptococcal infections: Report of two cases. Klin Wochenschr. 1990;68:427&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190045</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Pirofski L., Catalano M.T. Primary group A streptococcal peritonitis in adults. Am J Med. 1990;88:63N&#x2013;64N.</Citation><ArticleIdList><ArticleId IdType="pubmed">2195887</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuilleumier H., Halkic N. Streptococcal toxic shock syndrome revealed by a peritonitis. Swiss Surg. 2001;7:25&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11234313</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham J.C., Moss P.J., McKendrick M.W. Primary group A streptococcal peritonitis. Scand J Infect Dis. 1995;27:171&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">7660084</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskovitz M., Ehrenberg E., Grieco R. Primary peritonitis due to group A Streptococcus. J Clin Gastroenterol. 2000;30:325&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">10777203</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia S.M., Low D.E., Andrighetti S., Rau N.V. Group A streptococcal sepsis secondary to peritonitis and acute pelvic inflammatory disease. Eur J Clin Microbiol Infect Dis. 2001;20:437&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476452</ArticleId></ArticleIdList></Reference><Reference><Citation>Doloy A., Godin C., Decousser J.W. Primary peritonitis due to Streptococcus pyogenes with reduced susceptibility to fluoroquinolones. Diagn Microbiol Infect Dis. 2008;62:447&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">18842379</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lelyveld-Haas L.E., Dekkers A.J., Postma B., Tjan D.H. An unusual cause of a spontaneous bacterial peritonitis in a young healthy woman. N Z Med J. 2008;121:82&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">18670478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gribbin JC1, Cox C.J. Spontaneous bacterial peritonitis in a healthy adult male. Aust N Z J Surg. 1990;60(September (9)):723&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">2204334</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox K.L., Born M.W., Cohen M.A. Fulminant infection and toxic shock syndrome caused by Streptococcus pyogenes. J Emerg Med. 2002;22:357&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">12113845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueyama N., Kuwashima S., Nakayama A. Ileal adenomyoma accompanied by primary peritonitis: report of a case. Surg Today. 2001;31:826&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">11686566</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura K., Schroff R., Campbell R. Group A streptococcal puerperal sepsis with retroperitoneal involvement developing in a late postpartum woman: case report. Am Surg. 2004;70:730&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">15328810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez N.C., Lancaster B.A. A rare case of primary group A streptococcal peritonitis. Am Surg. 2001;67:633&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">11450776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanetake K., Hayashi M., Hino A. Primary peritonitis associated with streptococcal toxic shock-like syndrome: report of a case. Surg Today. 2004;34:1053&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580392</ArticleId></ArticleIdList></Reference><Reference><Citation>Brivet F.G., Smadja C., Hilbert U. Usefulness of abdominal CT scan in severe peritoneal sepsis linked to primary peritonitis. Scand J Infect Dis. 2005;37:76&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis J., Trivedi S., Sheda S., Frizelle F.A. Primary peritonitis in adults: is it time to look for a better diagnostic classification? ANZ J Surg. 2006;76:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626348</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha P., Morewood T., Naftalin J., Hopkins S. Acute abdomen in a healthy woman: primary peritonitis due to Group A Streptococcus. J Obstet Gynaecol. 2006;26:700&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071450</ArticleId></ArticleIdList></Reference><Reference><Citation>Haap M., Haas C.S., Teichmann R. Mystery or misery? Primary group A streptococcal peritonitis in women: case report. Am J Crit Care. 2010;19:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635804</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Perpoint T., Dauwalder O. In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome. Eur J Clin Microbiol Infect Dis. 2009;28:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">19020908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella A., Kavanagh D.O., McGiobuin S. Primary peritonitis from an insect bite. Ir Med J. 2009;102:87&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">19489198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilanus A.M., de Geus H.R., Rijnders B.J. Severe group A streptococcal toxic shock syndrome presenting as primary peritonitis: a case report and brief review of the literature. Int J Infect Dis. 2010;14(Suppl. 3):e208&#x2013;e212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19914115</ArticleId></ArticleIdList></Reference><Reference><Citation>Monneuse O., Tissot E., Gruner L. Diagnosis and treatment of spontaneous group A streptococcal peritonitis. Br J Surg. 2010;97:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">20013929</ArticleId></ArticleIdList></Reference><Reference><Citation>Legras A., LoDico R., Ferre R. Primary peritonitis due to Streptococcus A: laparoscopic treatment. J Vasc Surg. 2011;148:e315&#x2013;e317.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogami Y., Tsuji K. Case of streptococcal toxic shock syndrome caused by rapidly progressive group A hemolytic streptococcal infection during postoperative chemotherapy for cervical cancer. J Obstet Gynaecol Res. 2014;40(January (1)):250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937219</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S.Y., Kim Y.H., Park W.S. Acute phlegmonous gastritis complicated by delayed perforation. World J Gastroenterol. 2014;20(March (12)):3383&#x2013;3387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964411</ArticleId><ArticleId IdType="pubmed">24696618</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens D.L. Group A streptococcal sepsis. Curr Infect Dis Rep. 2003;5:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101722</ArticleId><ArticleId IdType="pubmed">13678567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray S., Morgan J. Two cases of group A streptococcal vulvovaginitis in premenopausal adults in a sexual health setting. Sex Health. 2006;3:187&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17044225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha N.K. Infectious disease emergencies. In: Carey W.D., editor. Cleveland Clinic: Current Clinical Medicine. Second ed. Saunders Elsevier; Philadelphia: 2009. pp. 733&#x2013;742.</Citation></Reference><Reference><Citation>Morgan M.S. Diagnosis and management of necrotizing fasciitis: a multiparametric approach. J Hosp Infect. 2010;75:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">20542593</ArticleId></ArticleIdList></Reference><Reference><Citation>Little P. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management) BMJ. 2013;347(October):f5806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805475</ArticleId><ArticleId IdType="pubmed">24114306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood T.F., Potter M.A., Jonasson O. Streptococcal toxic shocklike syndrome: the importance of surgical intervention. Ann Surg. 1993;217:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1242748</ArticleId><ArticleId IdType="pubmed">8439208</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B., Andersson J., Holm S. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis. 1999;180:410&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">10395857</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens D.L., Gibbons A.E., Bergstrom R., Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3292661</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael Haap Mystery or misery? Primary group A streptococcal peritonitis in women: case report. Am J Crit Care. 2010;19:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">19635804</ArticleId></ArticleIdList></Reference><Reference><Citation>Guss C., Larsen J.G. Group A beta-hemolytic streptococcal proctocolitis. Pediatr Infect Dis. 1984;3(September&#x2013;October (5)):442&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">6387643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger R.P., Levy M.M., Carlet J.M. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">18158437</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst F.M., Engel C., Bloos F. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184958</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood D.A., Roberts R.H. Management of primary group A streptococcal peritonitis: a systematic review. Surg Infect. 2013;14(April (2)):171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23464678</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto C.C. Peritonitis rates of the past thirty years: from improvement to stagnation. Perit Dial Int. 2014;34(March&#x2013;April (2)):151&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968099</ArticleId><ArticleId IdType="pubmed">24676740</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16542484</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>R40</StartPage><MedlinePgn>R40</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Disturbances in microcirculatory homeostasis have been hypothesized to play a key role in the pathophysiology of multiple organ dysfunction syndrome and vasopressor-associated ischemic skin lesions. The effects of a supplementary arginine vasopressin (AVP) infusion on microcirculation in vasodilatory shock and postoperative multiple organ dysfunction syndrome are unknown.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Included in the study were 18 patients who had undergone cardiac or major surgery and had a mean arterial blood pressure below 65 mmHg, despite infusion of more than 0.5 microg/kg per min norepinephrine. Patients were randomly assigned to receive a combined infusion of AVP/norepinephrine or norepinephrine alone. Demographic and clinical data were recorded at study entry and after 1 hour. A laser Doppler flowmeter was used to measure the cutaneous microcirculatory response at randomization and after 1 hour. Reactive hyperaemia and oscillatory changes in the Doppler signal were measured during the 3 minutes before and after a 5-minute period of forearm ischaemia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients receiving AVP/norepinephrine had a significantly higher mean arterial pressure (P = 0.047) and higher milrinone requirements (P = 0.025) than did the patients who received norepinephrine only at baseline. Mean arterial blood pressure significantly increased (P &lt; 0.001) and norepinephrine requirements significantly decreased (P &lt; 0.001) in the AVP/norepinephrine group. Patients in the AVP/norepinephrine group exhibited a significantly higher oscillation frequency of the Doppler signal before ischaemia and during reperfusion at randomization. During the study period, there were no differences in either cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone between groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Supplementary AVP infusion in patients with advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome did not compromise cutaneous reactive hyperaemia and flowmotion when compared with norepinephrine infusion alone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luckner</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;nser</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Stadlbauer</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Viktoria D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Jochberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Hanno</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Pajk</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Hasibeder</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Friesenecker</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Knotzer</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>113-79-1</RegistryNumber><NameOfSubstance UI="D001127">Arginine Vasopressin</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2006;10(2):135. doi: 10.1186/cc4884.</RefSource><PMID Version="1">16594988</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001127" MajorTopicYN="N">Arginine Vasopressin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001783" MajorTopicYN="N">Blood Flow Velocity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006940" MajorTopicYN="N">Hyperemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16542484</ArticleId><ArticleId IdType="pmc">PMC1550871</ArticleId><ArticleId IdType="doi">10.1186/cc4845</ArticleId><ArticleId IdType="pii">cc4845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haisjackl M, Hasibeder W, Klaunzer S, Altenberger H, Koller W. Diminished reactive hyperemia in the skin of critically ill patients. Crit Care Med. 1990;18:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">2379393</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer D, Creteur J, Preiser JC, Dubois MD, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166:98&#x2013;104. doi: 10.1164/rccm.200109-016OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200109-016OC</ArticleId><ArticleId IdType="pubmed">12091178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis. Crit Care. 2005:S9&#x2013;S12. doi: 10.1186/cc3748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc3748</ArticleId><ArticleId IdType="pmc">PMC3226162</ArticleId><ArticleId IdType="pubmed">16168075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32:1825&#x2013;1831. doi: 10.1097/01.CCM.0000138558.16257.3F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000138558.16257.3F</ArticleId><ArticleId IdType="pubmed">15343008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Surviving Sepsis Campaign Management Guidelines Committee Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858&#x2013;873. doi: 10.1097/01.CCM.0000117317.18092.E4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000117317.18092.E4</ArticleId><ArticleId IdType="pubmed">15090974</ArticleId></ArticleIdList></Reference><Reference><Citation>Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med. 2004;32:S455&#x2013;S465. doi: 10.1097/01.CCM.0000142909.86238.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000142909.86238.B1</ArticleId><ArticleId IdType="pubmed">15542956</ArticleId></ArticleIdList></Reference><Reference><Citation>LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28:2729&#x2013;2732. doi: 10.1097/00003246-200008000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200008000-00007</ArticleId><ArticleId IdType="pubmed">10966242</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;nser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313&#x2013;2319. doi: 10.1161/01.CIR.0000066692.71008.BB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000066692.71008.BB</ArticleId><ArticleId IdType="pubmed">12732600</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576&#x2013;582. doi: 10.1097/00000542-200203000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200203000-00011</ArticleId><ArticleId IdType="pubmed">11873030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15103461</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesenecker B, Tsai AG, D&#xfc;nser MW, Mayr AJ, Martini J, Knotzer H, Hasibeder W, Intaglietta M. Oxygen distribution in microcirculation after arginine vasopressin-induced arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol. 2004;287:H1792&#x2013;H1800. doi: 10.1152/ajpheart.00283.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00283.2004</ArticleId><ArticleId IdType="pubmed">15191895</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunser MW, Mayr AJ, Tur A, Pajk W, Friesenecker B, Knotzer H, Ulmer H, Hasibeder W. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med. 2003;31:1394&#x2013;1398. doi: 10.1097/01.CCM.0000059722.94182.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000059722.94182.79</ArticleId><ArticleId IdType="pubmed">12771608</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple organ failure. Generalized autodestructive inflammation? Arch Surg. 1985;120:1109&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbink EJ, Wollersheim H, Netten PM, Smits P. Reproducibility of skin microcirculatory measurements in humans, with special emphasis on capillaroscopy. Vasc Med. 2001;6:203&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958384</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JD, Cameron EM. Dynamics of skin blood flow in human sepsis. Intensive Care Med. 1995;21:669&#x2013;674. doi: 10.1007/BF01711546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01711546</ArticleId><ArticleId IdType="pubmed">8522672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson H, Aalkjaer C. Vasomotion: mechanisms and physiologic importance. Mol Interv. 2003;3:79&#x2013;89. doi: 10.1124/mi.3.2.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.3.2.79</ArticleId><ArticleId IdType="pubmed">14993429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschenbaum LA, Astiz ME, Rackow EC, Saha DC, Lin R. Microvascular response in patients with cardiogenic shock. Crit Care Med. 2000;28:1290&#x2013;1294. doi: 10.1097/00003246-200005000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200005000-00005</ArticleId><ArticleId IdType="pubmed">10834667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl WH, Gunther B, Inthorn D, Heberer G. Reactive hyperemia in patients with septic conditions. Surgery. 1988;103:440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">3353857</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer C, de Vries G, Davidge ST, Mayes DC. Reassessing the mathematical modelling of the contribution of vasomotion to vascular resistance. J Appl Physiol. 2002;92:888&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838438</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588&#x2013;595. doi: 10.1056/NEJMra002709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra002709</ArticleId><ArticleId IdType="pubmed">11529214</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth BL, Spitzer JA. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol. 1987;252:E699&#x2013;E702.</Citation><ArticleIdList><ArticleId IdType="pubmed">3034072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez de Turco EB, Spitzer JA. Impairments in vasopressin-stimulated inositol lipid metabolism in hepatocytes of septic rats. Circ Shock. 1988;25:299&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">2844434</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer JA, Turco EB, Deaciuc IV, Roth BL. Perturbation of transmembrane signaling mechanisms in acute and chronic endotoxemia. Prog Clin Biol Res. 1987;236A:401&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">3039527</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med. 2003;29:1020&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">12736775</ArticleId></ArticleIdList></Reference><Reference><Citation>Boerma EC, Van der Voort PHJ, Ince C. Sublingual microcirculatory flow is impaired by the vasopressin-analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiol Scand. 2005;49:1387&#x2013;1390. doi: 10.1111/j.1399-6576.2005.00752.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2005.00752.x</ArticleId><ArticleId IdType="pubmed">16146482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowell LB. Cutaneous and skeletal muscle circulations. In: Rowell LB, editor. Human circulation Regulation during physical stress. New York, Oxford: Oxford University Press; 1986. pp. 96&#x2013;116.</Citation></Reference><Reference><Citation>Cryer HM, Garrison RN, Kaebnick HW, Harris PD, Flint LM. Skeletal microcirculatory responses to hyperdynamic Escherichia coli sepsis in unanesthetized rats. Arch Surg. 1987;122:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">3541855</ArticleId></ArticleIdList></Reference><Reference><Citation>Piper RD, Pitt-Hyde M, Li F, Sibbald WJ, Potter RF. Microcirculatory changes in rat skeletal muscle in sepsis. Am J Respir Crit Care Med. 1996;154:931&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">8887588</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal SS. Regulation of blood flow in the microcirculation. Microcirculation. 2005;12:33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24594915</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Relationship between pre-implant interleukin-6 levels, inflammatory response, and early outcome in patients supported by left ventricular assist device: a prospective study.</ArticleTitle><Pagination><StartPage>e90802</StartPage><MedlinePgn>e90802</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e90802</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0090802</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The immune response is crucial in the development of multi-organ failure (MOF) and complications in end-stage heart failure patients supported by left ventricular assist device (LVAD). However, at pre-implant, the association between inflammatory state and post-LVAD outcome is not yet clarified. Aim of the study was to assess the relationship among pre-implant levels of immune-related cytokines, postoperative inflammatory response and 3-month outcome in LVAD-patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 41 patients undergoing LVAD implantation, plasma levels of interleukin (IL)-6, IL-8, crucial for monocyte modulation, and urine neopterin/creatinine ratio (Neo/Cr), marker of monocyte activation, were assessed preoperatively, at 3 days, 1 and 4 weeks post-LVAD. MOF was evaluated by total sequential organ failure assessment (tSOFA) score. Intensive care unit (ICU)-death and/or post-LVAD tSOFA &#x2265;11 was considered as main adverse outcome. Length of ICU-stay, 1 week-tSOFA score, hospitalisation and 3-month survival were considered additional end-points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During ICU-stay, 8 patients died of MOF, while 8 of the survivors experienced severe MOF with postoperative tSOFA score &#x2265;11. Pre-implant level of IL-6 &#x2265; 8.3 pg/mL was identified as significant marker of discrimination between patients with or without adverse outcome (OR 6.642, 95% CI 1.201-36.509, p&#x200a;=&#x200a;0.030). Patients were divided according to pre-implant IL-6 cutoff of 8.3 pg/ml in A [3.5 (1.2-6.1) pg/mL] and B [24.6 (16.4-38.0) pg/mL] groups. Among pre-implant variables, only white blood cells count was independently associated with pre-implant IL-6 levels higher than 8.3 pg/ml (OR 1.491, 95% CI 1.004-2.217, p&#x200a;=&#x200a;0.048). The ICU-stay and hospitalisation resulted longer in B-group (p&#x200a;=&#x200a;0.001 and p&#x200a;=&#x200a;0.030, respectively). Postoperatively, 1 week-tSOFA score, IL-8 and Neo/Cr levels were higher in B-group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LVAD-candidates with elevated pre-implant levels of IL-6 are associated, after intervention, to higher release of monocyte activation related-markers, a clue for the development of MOF, longer clinical course and poor outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caruso</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology, CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botta</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milazzo</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vecchi</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivella</LastName><ForeName>Maria Giovanna</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology and University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paino</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parodi</LastName><ForeName>Oberdan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CNR Institute of Clinical Physiology, CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="N">Heart-Assist Devices</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24594915</ArticleId><ArticleId IdType="pmc">PMC3942482</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0090802</ArticleId><ArticleId IdType="pii">PONE-D-13-27037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lund LH, Matthews J, Aaronson K (2010) Patient selection for left ventricular assist devices. Eur J Heart Fail 12: 434&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">20172939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. ESC Committee for Practice Guidelines (CPG) (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">18826876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) American College of Cardiology Foundation; American Heart Association (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391&#x2013;e479.</Citation><ArticleIdList><ArticleId IdType="pubmed">19324966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SR, Mudge GH, Stewart Jr GC, Givertz MM (2009) Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 119: 2225&#x2013;2232.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga T, Kinugawa K, Hatano M, Yao A, Nishimura T, et al. (2011) Age and preoperative total bilirubin level can stratify prognosis after extracorporeal pulsatile left ventricular assist device implantation. Circ J 75: 121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">21116070</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso R, Trunfio S, Milazzo F, Campolo J, De Maria R, et al. (2010) Early expression of pro- and anti-Inflammatory cytokines in left ventricular assist device recipients with multiple organ failure syndrome. ASAIO J 56: 313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">20445439</ArticleId></ArticleIdList></Reference><Reference><Citation>Masai T, Sawa Y, Ohtake S, Nishida T, Nishimura M, et al. (2002) Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 73: 549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11845873</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng MC, Edwards LB, Hertz MI, Rowe AW, Keck BM, et al. (2005) International Society for Heart and Lung Transplantation (2005) Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third Annual Report-2005. J Heart Lung Transplant 24: 1182&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143231</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso R, Verde A, Cabiati M, Milazzo F, Boroni C, et al. (2012) Association of pre-operative interleukin-6 levels with Interagency Registry for Mechanically Assisted Circulatory Support profiles and intensive care unit stay in left ventricular assist device patients. J Heart Lung Transplant 31: 625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">22386451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiel E, Vallet B, ten Cate H (2005) The endothelium in intensive care. Crit Care Clin 21: 403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, et al. (2005) ESC Committee for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26: 384&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681577</ArticleId></ArticleIdList></Reference><Reference><Citation>Minne L, Abu-Hanna A, de Jonge E (2008) Evaluation of SOFA-based models for predicting mortality in the ICU: a systematic review. Crit Care 12: R161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646326</ArticleId><ArticleId IdType="pubmed">19091120</ArticleId></ArticleIdList></Reference><Reference><Citation>Palardy M, Nohria A, Rivero J, Lakdawala N, Campbell P, et al. (2010) Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading. J Card Fail 16: 218&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913073</ArticleId><ArticleId IdType="pubmed">20206896</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Greene T, Kusek JW, Beck GJ (2000) Simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: 828A.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira FL, Bota DP, Bross A, M&#xe9;lot C, Vincent JL (2001) Serial evaluation of the t-SOFA score to predict outcome in critically ill patients. JAMA 286: 1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Cirillo P, Pacileo M, Petrillo G, D&#x2019;Ascoli GL, et al. (2011) Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharm 9: 188&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">21143176</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, et al. (2012) Impact of RANTES, MCP-1 and IL-8 in mast cells. J Biol Regul Homeost Agents 24: 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385066</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasier AR (2010) The nuclear factor-kB&#x2013;interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86: 211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912657</ArticleId><ArticleId IdType="pubmed">20202975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87: 241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926876</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, et al. (2002) Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or copper. Free Radic Res 36: 509&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch M, Boval B, Damy T, Ghendouz S, Vermes E, et al. (2012) Importance of monocyte deactivation in determining early outcome after ventricular assist device implantation. Int J Artif Organs 35: 169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22461111</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DS, Thavichaigarn P, Pattanapanyasat K, Siritongtaworn P, Kongcharoen P, et al. (2005) Characterization of circulating monocytes expressing HLA-DR or CD71 and related soluble factors for 2 weeks after severe, non-thermal injury. J Surg Res 29: 221&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">16045935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, et al. (2006) Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 25: 129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">16525350</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, et al. (2000) Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 26: 883&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">10990102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39918592</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>The optimal timing for definitive operative stabilization of pelvic fractures in polytrauma patients: effects on clinical outcomes - a systematic review.</ArticleTitle><Pagination><StartPage>100</StartPage><MedlinePgn>100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-025-02774-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The optimal timing for definitive surgical treatment of pelvic fractures in polytrauma patients remains a topic of ongoing discussion due to the complexity of these injuries. This analysis therefore aims to systematically compare early versus late definitive operative stabilization of pelvic fractures on outcome in polytrauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, CENTRAL and Web of Science were systematically searched to identify relevant completed and ongoing studies from the inception of each database to March 13, 2023. Systematic reviews, randomized control trials (RCTs) and observational studies comparing early (&lt;&#x2009;24&#xa0;h) versus late (&gt;&#x2009;24&#xa0;h) definitive operative stabilization in adult polytrauma patients admitted to the ICU were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Since no systematic reviews and RCTs were available on this subject, one observational study was identified, including a total of 418 polytrauma patients (n<sub>early</sub> = 165, n<sub>late</sub> = 253), median age: 40.3 years (early 40.1 years, late 40.4 years). Early definitive stabilization was associated with a decreased risk of acute respiratory distress syndrome (ARDS) compared to late stabilization of unstable pelvis and acetabulum fractures (RR 0.38, 95% CI 0.18-0.81; RD 78 fewer per 1000, 95% CI 104 fewer to 24 fewer; 1 study, 418 participants; very low certainty of evidence). Furthermore, early definitive stabilization may decrease the risk of pneumonia compared to late stabilization of unstable pelvis and acetabulum fractures (RR 0.50, 95% CI 0.28-0.88; RD 85 fewer per 1000, 95% CI 122 fewer to 20 fewer); 1 study, 418 participants; very low certainty of evidence).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is limited evidence regarding early definitive fracture repair (&#x2264;&#x2009;24&#xa0;h) compared to late repair of pelvic fractures in polytrauma patients. One observational study showed a reduced incidence of septic respiratory complications, ARDS, and multi-organ failure (MOF) in polytrauma patients who received early definitive fracture repair.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dormann</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany. jdormann@ukaachen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horst</LastName><ForeName>Klemens</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahms</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinfeld</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansems</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janka</LastName><ForeName>Heidrun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzendorf</LastName><ForeName>Maria-Inti</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breuer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benstoem</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, D-52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolierakis</LastName><ForeName>Eftychios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Trauma and Reconstructive Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010384" MajorTopicYN="Y">Pelvic Bones</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="Y">Fractures, Bone</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005592" MajorTopicYN="Y">Fracture Fixation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Early stabilization</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Late stabilization</Keyword><Keyword MajorTopicYN="N">Pelvic fracture</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39918592</ArticleId><ArticleId IdType="pmc">PMC11805852</ArticleId><ArticleId IdType="doi">10.1007/s00068-025-02774-1</ArticleId><ArticleId IdType="pii">10.1007/s00068-025-02774-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>L&#xf6;gters T, Lefering R, Schneppendahl J, Alldinger I, Witte I, Windolf J, et al. Abbruch Der Schockraumdiagnostik Und Notfalloperation Beim Polytrauma &#x2013; Inzidenz und klinische Relevanz. Der Unfallchirurg. 2010;113l&#x2013;(10):832&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393832</ArticleId></ArticleIdList></Reference><Reference><Citation>Enninghorst N, Toth L, King KL, McDougall D, Mackenzie S, Balogh ZJ. Acute definitive internal fixation of pelvic ring fractures in polytrauma patients: a feasible option. J Trauma Acute Care Surg. 2010;68(4):935&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20386287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel W, Keel M, Eid K, Platz A, Trentz O. Control of severe hemorrhage using C-Clamp and pelvic packing in multiply injured patients with pelvic ring disruption. J Orthop Trauma. 2001;15(7):468&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimbanassi S, O&#x2019;Toole R, Maegele M, Henry S, Scalea TM, Bove F et al. Orthopedic injuries in patients with multiple injuries: results of the 11th trauma update international consensus conference Milan, December 11, 2017. Journal of Trauma and Acute Care Surgery. 2020;88(2):e53-e76.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150031</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz MRW, Allami MK, Harwood P, Pape HC, Krettek C, Giannoudis PV. Open pelvic fractures: epidemiology, current concepts of management and outcome. Injury. 2005;36(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15589906</ArticleId></ArticleIdList></Reference><Reference><Citation>Balogh Z, Caldwell E, Heetveld M, D&#x2019;Amours S, Schlaphoff G, Harris I, et al. Institutional practice guidelines on management of pelvic fracture-related hemodynamic instability: do they make a difference? J Trauma Acute Care Surg. 2005;58(4):778&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondo MF, Zonies DH. The damage control sequence, and underlying logic. Surg Clin North Am. 1997;77(4):761&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Yoon YC, Chung JY, Song HK. Strategies for the management of hemodynamically unstable pelvic fractures: from preperitoneal pelvic packing to definitive internal fixation. Asian J Surg. 2019;42(11):941&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer R, Klingebiel FK-L, Halvachizadeh S, Kalbas Y, Pape H-C. How to clear polytrauma patients for fracture fixation: results of a systematic review of the literature. Injury. 2023;54(2):292&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">36404162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Halvachizadeh S, Leenen L, Velmahos GD, Buckley R, Giannoudis PV. Timing of major fracture care in polytrauma patients &#x2013; an update on principles, parameters and strategies for 2020. Injury. 2019;50(10):1656&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31558277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Pfeifer R. Safe definitive orthopaedic surgery (SDS): repeated assessment for tapered application of early definitive care and damage control? An inclusive view of recent advances in polytrauma management. Injury. 2015;46(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25540874</ArticleId></ArticleIdList></Reference><Reference><Citation>Tscherne H. The treatment of the severly injured at an emergency station. Chirurg. 1966;37:249&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">5995039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan&#x2014;a web and mobile app for systematic reviews. Syst Reviews. 2016;5(1):210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Microsoft Corporation. (2018). Microsoft Excel [Version 2018].</Citation></Reference><Reference><Citation>Review Manager (RevMan). Version 5.3. The Cochrane Collaboration. 2020. Available at revman.cochrane.org.</Citation></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, Savovi&#x107; J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>GRADEpro Guideline Development Tool. McMaster University and Evidence Prime. 2023. Available at gradepro.org.</Citation></Reference><Reference><Citation>Vallier HA, Cureton BA, Ekstein C, Oldenburg FP, Wilber JH. Early definitive stabilization of unstable pelvis and acetabulum fractures reduces morbidity. J Trauma. 2010;69(3):677&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20838139</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor NA, Smith AA, Marr A, Stuke L, Greiffenstein P, Schoen J, et al. Does time to pelvic fixation influence outcomes in trauma patients? Am Surgeon&#x2122;. 2022;88(5):840&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34797191</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaney GL, Bulman J, King KL, Balogh ZJ. Time to definitive fixation of pelvic and acetabular fractures. J Trauma Acute Care Surg. 2020;89(4):730&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535089</ArticleId><ArticleId IdType="pubmed">33017134</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey B, Rodseth RN, Muckart DJ. Early fracture stabilisation in the presence of subclinical hypoperfusion. Injury. 2013;44(2):217&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22995980</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas DG, Coleman JR, Moore EE, Dean CS, Parry JA, Elrick BP, et al. The association of surgical timing and injury severity with systemic complications in severely injured patients with pelvic ring injuries. J Orthop Trauma. 2021;35(4):171&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">33727520</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisier BR, Meldon SW, Super DM, Malangoni MA. Improved outcome after early fixation of acetabular fractures. Injury. 2000;31(2):81&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10748809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotwica Z, Balcewicz L, Jagodzi&#x144;ski Z. Head injuries coexistent with pelvic or lower extremity fractures&#x2013;early or delayed osteosynthesis. Acta Neurochir (Wien). 1990;102(1&#x2013;2):19&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">2305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Latenser BA, Gentilello LM, Tarver AA, Thalgott JS, Batdorf JW. Improved outcome with early fixation of skeletally unstable pelvic fractures. J Trauma. 1991;31(1):28&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1986129</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst C, Probst T, Gaensslen A, Krettek C, Pape HC. Timing and duration of the initial pelvic stabilization after multiple trauma in patients from the German trauma registry: is there an influence on outcome? J Trauma. 2007;62(2):370&#x2013;7. discussion 6&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22040928</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1409</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Incidence of early burn-induced effects on liver function as reflected by the plasma disappearance rate of indocyanine green: a prospective descriptive cohort study.</ArticleTitle><Pagination><StartPage>214</StartPage><EndPage>224</EndPage><MedlinePgn>214-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.burns.2011.08.017</ELocationID><Abstract><AbstractText>Organ dysfunction and failure are important for burned patients as they increase morbidity and mortality. Recent evidence has suggested that organ injuries are occurring earlier after burns, and are more common than previously thought. In this study we have assessed the extent to which liver function, assessed by the plasma disappearance rate of indocyanine green (PDR(ICG)), is affected in patients with severe burns. This is a prospective, descriptive exploratory study at a national burn centre. Consecutive adult patients with a percent total body surface area burned (TBSA%) of 20% or more, were examined prospectively by dynamic (PDR(ICG)) and static liver function tests (plasma: bilirubin concentration, prothrombin complex, and alanine aminotransferase and alkaline phosphatase activities). Early liver dysfunction was common, as it is assessed by both dynamic (7 of 17) and static liver function tests (6-17 of 17). A regression model showed that changes in PDR(ICG) were associated with age, TBSA%, plasma bilirubin concentration, plasma C-reactive protein concentration, and cardiac index. Persistent and advanced hepatic dysfunction was associated with mortality. The PDR(ICG) seems to give a comprehensive assessment of liver function after major burns. Hepatic dysfunction seems to be as common as dysfunction in other organs. We interpret the recorded effects on liver function as part of a multiple organ dysfunction syndrome, primarily induced by the burn itself. However, this needs to be further investigated.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2011 Elsevier Ltd and ISBI. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinvall</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Burn Unit, Department of Hand and Plastic Surgery, Link&#xf6;ping University Hospital, Link&#xf6;ping, 58185, Sweden. ingrid.steinvall@lio.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fredrikson</LastName><ForeName>Mats</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Sjoberg</LastName><ForeName>Folke</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>IX6J1063HV</RegistryNumber><NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22040928</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2011.08.017</ArticleId><ArticleId IdType="pii">S0305-4179(11)00255-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19770739</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome.</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>160</EndPage><MedlinePgn>152-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3181b78671</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction with cardiogenic shock (CS) are often treated with intra-aortic balloon pump counterpulsation (IABP), even though the evidence to support this is limited. We determined whether IABP as an addition to PCI-centered therapy ameliorates multiorgan dysfunction syndrome (MODS) in patients with acute myocardial infarction complicated by CS.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective, randomized, controlled, open-label clinical trial recruiting patients between March 2003 and June 2004 (ClinicalTrials.gov ID NCT00469248).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary care university hospital.</AbstractText><AbstractText Label="PATIENTS AND INTERVENTIONS" NlmCategory="METHODS">Forty-five consecutive patients with AMI and CS undergoing PCI were randomized to treatment with or without IABP.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Acute Physiology and Chronic Health Evaluation (APACHE) II scores (primary outcome measure), hemodynamic values, inflammatory markers, and plasma brain natriuretic peptide (BNP) levels (secondary outcomes) were collected over 4 days from randomization. The prospective hypothesis was that adding IABP therapy to "standard care" would improve CS-triggered MODS. The addition of IABP to standard therapy did not result in a significant improvement in MODS (measured by serial APACHE II scoring over 4 days). IABP use had no significant effect on cardiac index or systemic inflammatory activation, although BNP levels were significantly lower in IABP-treated patients. Initial and serial APACHE II scoring correlated with mortality better than cardiac index, systemic inflammatory state, and BNP levels in this group of patients. Nonsurvivors had significantly higher initial APACHE II scores (29.9 +/- 2.88) than survivors (18.1 +/- 1.66, p &lt; .05). Nevertheless, discrepancies among patients within the groups cannot be ruled out and might interfere with our results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this randomized trial addressing addition of IABP in CS patients, mechanical support was associated only with modest effects on reduction of APACHE II score as a marker of severity of disease, improvement of cardiac index, reduction of inflammatory state, or reduction of BNP biomarker status compared with medical therapy alone. However, the limitations of our present trial preclude any definitive conclusion, but request for a larger prospective, randomized, multicentered trial with mortality as primary end point.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prondzinsky</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine III, Department of Biometrics and Statistics (SU), Martin-Luther-University, Halle-Wittenberg, Halle/Saale, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemm</LastName><ForeName>Henning</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Swyter</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wegener</LastName><ForeName>Nikolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schlitt</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Buerke</LastName><ForeName>Ute</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Christoph</LastName><ForeName>Arnd</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thiery</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Werdan</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Buerke</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00469248</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2010 Jan;38(1):321-2. doi: 10.1097/CCM.0b013e3181c30c67.</RefSource><PMID Version="1">20023483</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015908" MajorTopicYN="N">Counterpulsation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007423" MajorTopicYN="N">Intra-Aortic Balloon Pumping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19770739</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3181b78671</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22033056</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2012</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>The evaluation of the effect of body positioning on intra-abdominal pressure measurement and the effect of intra-abdominal pressure at different body positioning on organ function and prognosis in critically ill patients.</ArticleTitle><Pagination><StartPage>222.e1</StartPage><EndPage>222.e2226</EndPage><MedlinePgn>222.e1-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2011.08.010</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Current literatures confirmed the widespread and frequent development of both intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS) among the critically ill with a significant associated risk of organ failure and increased mortality. The 2004 International ACS Consensus Conference committee proposed that intra-abdominal pressure (IAP) be measured in complete supine position; however, the supine position of intensive care unit (ICU) patients (&lt;30&#xb0; of bed increase) presented a significant risk for ventilator-associated pneumonia. Therefore, the potential contribution of head of bed (HOB) position in elevating IAP should be considered. The purpose of this study was to evaluate the effect of body positioning on IAP measurement and the effect of IAP at different body positions on organ function and prognosis in critically ill patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospective cohort study to investigate the effect of different patient positioning on IAP, organ function, and prognosis was conducted on 88 patients admitted to a medical-surgical ICU. On admission, patients' epidemiological data and risk factors for IAH were studied; daily mean IAPs, abdominal perfusion pressure, filtration gradient, Acute Physiology and Chronic Health Evaluation II score, sequential organ failure assessment score, and multiple organ dysfunction scores were registered; next, conventional hemodynamic variables, intrathoracic blood volume index, global end-diastolic volume index and extravascular lung water using the pulse contour cardiac output system were recorded. Intra-abdominal pressures were recorded through a bladder catheter every 4 hours on the first day. Intra-abdominal pressure was measured with the patient HOB increases from 0&#xb0; to 45&#xb0;. Mean arterial pressure was recorded simultaneously, whereas abdominal perfusion pressure and filtration gradient (FG) were also calculated simultaneously.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main results of this study were the incidence of IAH (28.4%) and ACS (2.3%) in ICU patients; the significant and independent relationship between IAP and HOB increases. Considering the absolute numbers of IAP, the HOB of 10&#xb0; and 20&#xb0; showed slight differences, whereas that of 30&#xb0; and 45&#xb0; showed clinically significant differences; HOB elevation was associated with clinically significant decreases in abdominal perfusion pressure and FG; patients with IAH were prone to the development of shock and multiple organ dysfunction syndrome and exhibited significantly lower intrathoracic blood volume index and global end-diastolic volume index and higher extravascular lung water.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is a significant and independent relationship between IAP and HOB positioning in critically ill patients, with the HOB of 30&#xb0; and 45&#xb0; showing significant difference. Abdominal perfusion pressure and FG are significantly decreased when the patient's HOB is elevated. The potential contribution of body position in elevating IAP should be considered in critically ill patients with the risk of IAH and ACS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Peking University Third Hospital, Beijing 100191, PR China. minyi0101@yahoo.com.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Gaiqi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xi</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D034841" MajorTopicYN="N">Abdominal Cavity</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059325" MajorTopicYN="N">Intra-Abdominal Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056888" MajorTopicYN="N">Patient Positioning</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22033056</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2011.08.010</ArticleId><ArticleId IdType="pii">S0883-9441(11)00386-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15142885</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>328</Volume><Issue>7451</Issue><PubDate><Year>2004</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery.</ArticleTitle><Pagination><StartPage>1281</StartPage><MedlinePgn>1281</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, randomised, double blinded trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">19 hospitals throughout the Netherlands (three university; 10 clinical; six general).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the buffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Mortality and duration of stay in intensive care. Secondary end points were occurrence of multi-organ failure, infections, and length of hospital stay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multi-organ failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98, 0.73 to 1.32).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multi-organ failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Joost A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center and Sanquin Blood Supply, PO Box 9600, 2300 RC Leiden, Netherlands. J.A.van_Hilten@lumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>Leo M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>van Bockel</LastName><ForeName>J Hajo</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>van de Velde</LastName><ForeName>Cornelis J H</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Kievit</LastName><ForeName>Job</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van den Hout</LastName><ForeName>Wilbert B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Geelkerken</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Roumen</LastName><ForeName>Rudi M H</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Wesselink</LastName><ForeName>Ronald M J</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Koopman-van Gemert</LastName><ForeName>Ankie W M M</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Koning</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Anneke</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001014" MajorTopicYN="N">Aortic Aneurysm</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="N">Aortic Rupture</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007937" MajorTopicYN="N">Leukapheresis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15142885</ArticleId><ArticleId IdType="pmc">PMC420164</ArticleId><ArticleId IdType="doi">10.1136/bmj.38103.735266.55</ArticleId><ArticleId IdType="pii">bmj.38103.735266.55</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wobbes T, Bemelmans BL, Kuypers JH, Beerthuizen GI, Theeuwes Ag. Risk of postoperative septic complications after abdominal surgical treatment in relation to perioperative blood transfusion. Surg Gynecol Obstet 1990;171: 59-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto V, Baldonedo R, Nicolas C, BPreez A, Aza J. Relationship of transfusion and infectious complications after gastric carcinoma operation. Transfusion 1991;31: 114-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1996479</ArticleId></ArticleIdList></Reference><Reference><Citation>Spark JI, Chetter IC, Kester RC, Scott DJ. Allogeneic versus autologous blood during abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 1997;14: 482-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467524</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29: 227-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy G, Neal KR. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomised and nonrandomised studies. Transfusion Med 1996;6: 325-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2000;97:5: 1180-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11222359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: Perioperative indications, adverse effects and cost analysis. Anesth Analg 2000;90: 1315-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825313</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld AB, Raijmakers PG, Rauwerda JA, Hack CE. The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function. Eur J Vasc Endovasc Surg 1997;14: 351-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapaport FT, Dausset J. The possible role of leukocyte components in the production of the beneficial effects of blood transfusion in human transplantation. Transplant Proc 1983;15: 952-5.</Citation></Reference><Reference><Citation>Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann T, Lane TA. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The viral activation transfusion study: a randomised controlled trial. JAMA 2001;285: 1592-601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268267</ArticleId></ArticleIdList></Reference><Reference><Citation>Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, et al. Randomised controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344: 573-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914960</ArticleId></ArticleIdList></Reference><Reference><Citation>Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomised study. Int J Colorectal Dis 2001;16: 147-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459288</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Anderson AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79: 513-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1611441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartter PI, Mohandas K, Azar P. Randomised trial comparing packed red blood cell transfusion with and without leukocyte depletion in gastrointestinal surgery. Am J Surg 1998;176: 462-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Kissmeyer-Nielsen P, Wolff B. Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348: 841-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8826808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Multicentre randomised controlled trials in transfusion medicine. Transfusion Med Rev 2000;14: 137-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782498</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, et al. A beneficial effect of leukocyte depletion of transfused blood on postoperative mortality in patients undergoing cardiac surgery: a randomised clinical trial. Circulation 1998;97: 562-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9494026</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JKS, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120: 1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342: 1334-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathens AB, Marshall JC. Sepsis, SIRS and MODS: what's in a name? World J Surg 1996;20: 386-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662129</ArticleId></ArticleIdList></Reference><Reference><Citation>Asimakopoulos G. Mechanisms of the systemic inflammatory response. Perfusion 1999;14: 269-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10456781</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of report of parallel-group randomised trials. Lancet 2001;357: 1191-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323066</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trial. Lancet 2000;255: 1064-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744093</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ system failure. Ann Surg 1985;202: 685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250999</ArticleId><ArticleId IdType="pubmed">4073980</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1985;16: 128-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841893</ArticleId></ArticleIdList></Reference><Reference><Citation>Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13: 487-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10180748</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg N, Heal JM, Cowles JW, Hicks GL Jr, Risher WH, Samuel PK, et al. Leukocyte-reduced transfusions in cardiac surgery. Results of an implementation trial. Am J Clin Pathol 2002;118: 376-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12219779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin YM, van de Watering LMG, Lorinser JE, Versteegh MIM, Eijsman L, van Oers MHJ, et al. The effect of prestorage-leukocyte-depletion of erythrocyte concentrates in cardiac surgery: a double-blind randomised clinical trial. Blood 2001;98(suppl): 828-9a.</Citation></Reference><Reference><Citation>Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al. Clinical outcomes following institutions of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289: 1941-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D, Hebert PC, Lee SK, Walker CR, Barrington KJ, Joseph L, et al. Clinical outcomes following institution of universal leukocyte depletion of blood transfusions for premature infants. JAMA 2003;289: 1950-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42: 1114-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23599623</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>13</Issue><PubDate><Year>2013</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Effects of different resuscitation fluid on severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>2044</StartPage><EndPage>2052</EndPage><MedlinePgn>2044-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v19.i13.2044</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To compare effects of different resuscitation fluid on microcirculation, inflammation, intestinal barrier and clinical results in severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and twenty patients with SAP were enrolled at the Pancreatic Disease Institute between January 2007 and March 2010. The patients were randomly treated with normal saline (NS group), combination of normal saline and hydroxyethyl starch (HES) (SH group), combination of normal saline, hydroxyethyl starch and glutamine (SHG group) in resuscitation. The ratio of normal saline to HES in the SH and SHG groups was 3:1. The glutamine (20% glutamine dipeptide, 100 mL/d) was supplemented into the resuscitation liquid in the SHG group. Complications and outcomes including respiratory and abdominal infection, sepsis, abdominal hemorrhage, intra-abdominal hypertension, abdominal compartment syndrome (ACS), renal failure, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), operation intervention, length of intensive care unit stay, length of hospital stay, and mortality at 60 d were compared. Moreover, blood oxygen saturation (SpO2), gastric intramucosal pH value (pHi), intra-abdominal pressure (IAP), inflammation cytokines, urine lactulose/mannitol (L/M) ratio, and serum endotoxin were investigated to evaluate the inflammatory reaction and gut barrier.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to the NS group, patients in the SH and SHG groups accessed the endpoint more quickly (3.9 &#xb1; 0.23 d and 4.1 &#xb1; 0.21 d vs 5.8 &#xb1; 0.25 d, P &lt; 0.05) with less fluid volume (67.26 &#xb1; 28.53 mL/kg/d, 61.79 &#xb1; 27.61 mL/kg per day vs 85.23 &#xb1; 21.27 mL/kg per day, P &lt; 0.05). Compared to the NS group, incidence of renal dysfunction, ARDS, MODS and ACS in the SH and SHG groups was obviously lower. Furthermore, incidence of respiratory and abdominal infection was significantly decreased in the SH and SHG groups, while no significant difference in sepsis was seen. Moreover, less operation time was needed in the SH and SHG group than the NS group, but the difference was not significant. The mortality did not differ significantly among these groups. Blood SpO2 and gastric mucosal pHi in the SH and SHG groups increased more quickly than in the NS group, while IAP was significantly decreased in the SH and SHG group. Moreover, the serum tumor necrosis factor-&#x3b1;, interleukin-8 and C-reactive protein levels in the SH and SHG groups were obviously lower than in the NS group at each time point. Furthermore, urine L/M ratio and serum endotoxin were significantly lower in the SH group and further decreased in the SHG group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results indicated that combination of normal saline, HES and glutamine are more efficient in resuscitation of SAP by relieving inflammation and sustaining the intestinal barrier.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pancreatic Disease Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun-Gang</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>He-Shui</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Shi-Chang</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Kui</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shuai</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chun-You</ForeName><Initials>CY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006895">Hydroxyethyl Starch Derivatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RH81L854J</RegistryNumber><NameOfSubstance UI="D005973">Glutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3OWL53L36A</RegistryNumber><NameOfSubstance UI="D008353">Mannitol</NameOfSubstance></Chemical><Chemical><RegistryNumber>451W47IQ8X</RegistryNumber><NameOfSubstance UI="D012965">Sodium Chloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>4618-18-2</RegistryNumber><NameOfSubstance UI="D007792">Lactulose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="Y">Fluid Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006895" MajorTopicYN="N">Hydroxyethyl Starch Derivatives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007792" MajorTopicYN="N">Lactulose</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008353" MajorTopicYN="N">Mannitol</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012965" MajorTopicYN="N">Sodium Chloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Capillary leakage syndrome</Keyword><Keyword MajorTopicYN="N">Inflammatory reaction</Keyword><Keyword MajorTopicYN="N">Intestinal barrier</Keyword><Keyword MajorTopicYN="N">Intra-abdominal hypertension</Keyword><Keyword MajorTopicYN="N">Microcirculation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23599623</ArticleId><ArticleId IdType="pmc">PMC3623981</ArticleId><ArticleId IdType="doi">10.3748/wjg.v19.i13.2044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitchell RM, Byrne MF, Baillie J. Pancreatitis. Lancet. 2003;361:1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727412</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez A, Whang EE, Brooks DC, Moore FD, Hughes MD, Sica GT, Zinner MJ, Ashley SW, Banks PA. Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? Pancreas. 2002;25:229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnala PJ, Kuttila KT, Gr&#xf6;nroos JM, Havia TV, Nevalainen TJ, Niinikoski JH. Pancreatic tissue perfusion in experimental acute pancreatitis. Eur J Surg. 2001;167:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi D, Kollias N, Fernandez-del Castillo C, Foitzik T, Warshaw AL, Rattner DW. Impairment of pancreatic microcirculation correlates with the severity of acute experimental pancreatitis. J Am Coll Surg. 1994;179:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">8069418</ArticleId></ArticleIdList></Reference><Reference><Citation>Beger HG, Rau B, Mayer J, Pralle U. Natural course of acute pancreatitis. World J Surg. 1997;21:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CM, Schmidt J, Lewandrowski K, Compton CC, Rattner DW, Warshaw AL, Tompkins RG. Gut macromolecular permeability in pancreatitis correlates with severity of disease in rats. Gastroenterology. 1993;104:890&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">8440440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M, McMahon MJ. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg. 1999;3:252&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">10481118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicalese L, Sahai A, Sileri P, Rastellini C, Subbotin V, Ford H, Lee K. Acute pancreatitis and bacterial translocation. Dig Dis Sci. 2001;46:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11341659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner S. Initial management of acute pancreatitis: critical issues during the first 72 hours. Am J Gastroenterol. 2004;99:2489&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571599</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckerwall G, Olin H, Andersson B, Andersson R. Fluid resuscitation and nutritional support during severe acute pancreatitis in the past: what have we learned and how can we do better? Clin Nutr. 2006;25:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerner T, Vollmar B, Menger MD, Waldner H, Messmer K. Determinants of pancreatic microcirculation in acute pancreatitis in rats. J Surg Res. 1996;62:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632634</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldt J. Volume therapy in the intensive care patient--we are still confused, but. Intensive Care Med. 2000;26:1181&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg. 2001;93:405&#x2013;409 , 3rd contents page.</Citation><ArticleIdList><ArticleId IdType="pubmed">11473870</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M. Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kd), but not Ringer&#x2019;s solution maintains plasma volume and systemic oxygenation. Shock. 2004;21:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">15179134</ArticleId></ArticleIdList></Reference><Reference><Citation>Eibl G, Hotz HG, Faulhaber J, Kirchengast M, Buhr HJ, Foitzik T. Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis. Gut. 2000;46:390&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1727839</ArticleId><ArticleId IdType="pubmed">10673302</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol. 2003;20:429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">12803259</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitag M, Standl TG, Kleinhans H, Gottschalk A, Mann O, Rempf C, Bachmann K, Gocht A, Petri S, Izbicki JR, et al. Improvement of impaired microcirculation and tissue oxygenation by hemodilution with hydroxyethyl starch plus cell-free hemoglobin in acute porcine pancreatitis. Pancreatology. 2006;6:232&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534248</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Liu J, Yu M, Zhu S, Xu J. Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and survival in rats challenged with polymicrobial sepsis. Clin Chim Acta. 2007;376:60&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin H, Mercanligil SM, Inan&#xe7; N, Ok E. Effects of glutamine-enriched total parenteral nutrition on acute pancreatitis. Eur J Clin Nutr. 2007;61:1429&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17311061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce CB, Sadek SA, Walters AM, Goggin PM, Somers SS, Toh SK, Johns T, Duncan HD. A double-blind, randomised, controlled trial to study the effects of an enteral feed supplemented with glutamine, arginine, and omega-3 fatty acid in predicted acute severe pancreatitis. JOP. 2006;7:361&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao G, Wang CY, Wang F, Xiong JX. Clinical study on nutrition support in patients with severe acute pancreatitis. World J Gastroenterol. 2003;9:2105&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656684</ArticleId><ArticleId IdType="pubmed">12970916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489394</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonham MJ, Abu-Zidan FM, Simovic MO, Windsor JA. Gastric intramucosal pH predicts death in severe acute pancreatitis. Br J Surg. 1997;84:1670&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9448612</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda S, Hirasawa H, Shiga H, Matsuda K, Nakamura M, Watanabe E, Moriguchi T. Management of intra-abdominal hypertension in patients with severe acute pancreatitis with continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter. Ther Apher Dial. 2005;9:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16076382</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer P, Pernet P, Hejblum G, Baudel JL, Maury E, Offenstadt G, Guidet B. Haemodilution induced by hydroxyethyl starches 130/0.4 is similar in septic and non-septic patients. Acta Anaesthesiol Scand. 2008;52:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">18034867</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M. Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med. 2006;34:3005&#x2013;3010.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv R, Zhou W, Chu C, Xu J. Mechanism of the effect of hydroxyethyl starch on reducing pulmonary capillary permeability in a rat model of sepsis. Ann Clin Lab Sci. 2005;35:174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15943182</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Yan W, Liu X, Duan M, Zhang X, Xu J. Effects of hydroxyethyl starch 130/0.4 on pulmonary capillary leakage and cytokines production and NF-kappaB activation in CLP-induced sepsis in rats. J Surg Res. 2006;135:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616763</ArticleId></ArticleIdList></Reference><Reference><Citation>Handrigan MT, Burns AR, Donnachie EM, Bowden RA. Hydroxyethyl starch inhibits neutrophil adhesion and transendothelial migration. Shock. 2005;24:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang K, Suttner S, Boldt J, Kumle B, Nagel D. Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth. 2003;50:1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;per J, Ahmed R, Sch&#xe4;fer T, Elster A, Enigk F, Habazettl H, Mousa S, Sch&#xe4;fer M, Welte M. Volume therapy with colloid solutions preserves intestinal microvascular perfusion in endotoxaemia. Resuscitation. 2008;76:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">17697734</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint RS, Phillips AR, Power SE, Dunbar PR, Brown C, Delahunt B, Cooper GJ, Windsor JA. Acute pancreatitis severity is exacerbated by intestinal ischemia-reperfusion conditioned mesenteric lymph. Surgery. 2008;143:404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291262</ArticleId></ArticleIdList></Reference><Reference><Citation>Warndorf MG, Kurtzman JT, Bartel MJ, Cox M, Mackenzie T, Robinson S, Burchard PR, Gordon SR, Gardner TB. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. Clin Gastroenterol Hepatol. 2011;9:705&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3143229</ArticleId><ArticleId IdType="pubmed">21554987</ArticleId></ArticleIdList></Reference><Reference><Citation>Trikudanathan G, Navaneethan U, Vege SS. Current controversies in fluid resuscitation in acute pancreatitis: a systematic review. Pancreas. 2012;41:827&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">22781906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mole DJ, Hall A, McKeown D, Garden OJ, Parks RW. Detailed fluid resuscitation profiles in patients with severe acute pancreatitis. HPB (Oxford) 2011;13:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019542</ArticleId><ArticleId IdType="pubmed">21159104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31183748</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1720-8319</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Aging clinical and experimental research</Title><ISOAbbreviation>Aging Clin Exp Res</ISOAbbreviation></Journal><ArticleTitle>Hospital-acquired acute kidney injury in very elderly men: clinical characteristics and short-term outcomes.</ArticleTitle><Pagination><StartPage>1121</StartPage><EndPage>1128</EndPage><MedlinePgn>1121-1128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40520-019-01196-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We explored the risk factors for, and the clinical characteristics of, acute kidney injury (AKI), and the causes of death 28&#xa0;days after such injury, in very elderly men.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective cohort study using data from the Geriatric Department of the Chinese PLA General Hospital. A total of 3464 elderly patients (&#x2265;&#x2009;75&#xa0;years) were enrolled from January 2007 to December 2015. All patients were followed for 28&#xa0;days or until death after AKI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 668 patients (39.0%) developed AKI, and 623 men were included for the final analysis. The median age was 87&#xa0;years. The 28-day mortality rate was 25.7%. The AKI etiologies were infections (39.6%), hypovolemia (23.8%), cardiovascular events (15.9%), nephrotoxicity (12.0%), and surgery (7.1%). Multiple organ dysfunction syndrome (46.4%) and pulmonary infection (22.5%) were the principal causes of death. Multivariate analysis revealed that time for AKI to develop (HR&#x2009;=&#x2009;0.865; 95% CI 0.799-0.937; P&#x2009;&lt;&#x2009;0.001), low mean arterial pressure (HR&#x2009;=&#x2009;0.970; 95% CI 0.958-0.981; P&#x2009;&lt;&#x2009;0.001), low serum prealbumin (HR&#x2009;=&#x2009;0.924; 95% CI 0.894-0.955; P&#x2009;&lt;&#x2009;0.001) level, oliguria (HR&#x2009;=&#x2009;2.261; 95% CI 1.424-3.590; P&#x2009;=&#x2009;0.001), mechanical ventilation (HR&#x2009;=&#x2009;1.492; 95% CI 1.047-2.124; P&#x2009;=&#x2009;0.027), blood urea nitrogen (HR&#x2009;=&#x2009;1.037; 95% CI 1.025-1.049; P&#x2009;&lt;&#x2009;0.001) level, magnesium (HR&#x2009;=&#x2009;2.512; 95% CI 1.243-5.076; P&#x2009;=&#x2009;0.010) level, and more severe AKI stages (stage 2: HR&#x2009;=&#x2009;3.709; 95% CI 1.926-7.141; P&#x2009;&lt;&#x2009;0.001 and stage 3: HR&#x2009;=&#x2009;5.660; 95% CI 2.990-10.717; P&#x2009;&lt;&#x2009;0.001) were independent risk factors for 28-day mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The incidence of AKI increases significantly as age advanced. Identification of risk factors might lead to more intensive monitoring and early prevention, and might improve AKI patients' outcomes in the very elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qinglin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, the First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Data Repository, Chinese PLA General Hospital, Beijing, 100853, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Feihu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, the First Medical Center, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. feihuzhou301@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NCRCG-PLAGH-2017008</GrantID><Agency>National Clinical Research Center for Geriatric Diseases of China</Agency><Country/></Grant><Grant><GrantID>320.6750.18383</GrantID><Agency>WU JIEPING MEDICAL FOUNDATION</Agency><Country/></Grant><Grant><GrantID>Z161100000116054</GrantID><Agency>Beijing Municipal Capital Specialized Clinical Application Research Program of Science and Technology&#x2003;Commission Foundatio</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Aging Clin Exp Res</MedlineTA><NlmUniqueID>101132995</NlmUniqueID><ISSNLinking>1594-0667</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Very elderly</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31183748</ArticleId><ArticleId IdType="pmc">PMC7260277</ArticleId><ArticleId IdType="doi">10.1007/s40520-019-01196-5</ArticleId><ArticleId IdType="pii">10.1007/s40520-019-01196-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson S, Eldadah B, Halter JB, et al. Acute kidney injury in older adults. J Am Soc Nephrol. 2011;22:28&#x2013;38. doi: 10.1681/ASN.2010090934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2010090934</ArticleId><ArticleId IdType="pubmed">21209252</ArticleId></ArticleIdList></Reference><Reference><Citation>Coca SG. Acute kidney injury in elderly persons. Am J Kidney Dis. 2010;56:122&#x2013;131. doi: 10.1053/j.ajkd.2009.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2009.12.034</ArticleId><ArticleId IdType="pmc">PMC2902696</ArticleId><ArticleId IdType="pubmed">20346560</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins AJ, Foley RN, Herzog C, et al. US renal data system 2012 annual data report. Am J Kidney Dis. 2013;61:e1&#x2013;e476. doi: 10.1053/j.ajkd.2012.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2012.11.031</ArticleId><ArticleId IdType="pubmed">23253259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannu N, James M, Hemmelgarn B, et al. Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin J Am Soc Nephrol. 2013;8:194&#x2013;202. doi: 10.2215/CJN.06480612.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.06480612</ArticleId><ArticleId IdType="pmc">PMC3562863</ArticleId><ArticleId IdType="pubmed">23124779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012;82:516&#x2013;524. doi: 10.1038/ki.2012.208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.208</ArticleId><ArticleId IdType="pubmed">22673882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rewa O, Bagshaw SM. Acute kidney injury&#x2014;epidemiology, outcomes and economics. Nat Rev Nephrol. 2014;10:193&#x2013;207. doi: 10.1038/nrneph.2013.282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2013.282</ArticleId><ArticleId IdType="pubmed">24445744</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisula S, Kaukonen KM, Vaara ST, et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med. 2013;39:420&#x2013;428. doi: 10.1007/s00134-012-2796-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-012-2796-5</ArticleId><ArticleId IdType="pubmed">23291734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. Lancet. 2015;386:1465&#x2013;1471. doi: 10.1016/S0140-6736(15)00344-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00344-X</ArticleId><ArticleId IdType="pubmed">26466051</ArticleId></ArticleIdList></Reference><Reference><Citation>Eknoyan G, Lameire N, Eckardt K, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1&#x2013;138. doi: 10.1038/kisup.2012.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CY, Chertow GM, McCulloch CE, et al. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4:891&#x2013;898. doi: 10.2215/CJN.05571008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05571008</ArticleId><ArticleId IdType="pmc">PMC2676192</ArticleId><ArticleId IdType="pubmed">19406959</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CT, Tsai HB, Wu CY, et al. The severity of initial acute kidney injury at admission of geriatric patients significantly correlates with subsequent in-hospital complications. Sci Rep. 2015;5:13925. doi: 10.1038/srep13925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13925</ArticleId><ArticleId IdType="pmc">PMC4564739</ArticleId><ArticleId IdType="pubmed">26355041</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49&#x2013;61. doi: 10.1038/ki.2013.444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.444</ArticleId><ArticleId IdType="pubmed">24284513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CT, Lin YF, Tsai HB, et al. Acute kidney injury network staging in geriatric postoperative acute kidney injury patients: shortcomings and improvements. J Am Coll Surg. 2013;217:240&#x2013;250. doi: 10.1016/j.jamcollsurg.2013.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2013.03.024</ArticleId><ArticleId IdType="pubmed">23870218</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmistekawy E, McDonald B, Hudson C, et al. Clinical impact of mild acute kidney injury after cardiac surgery. Ann Thoracic Surg. 2014;98:815&#x2013;822. doi: 10.1016/j.athoracsur.2014.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2014.05.008</ArticleId><ArticleId IdType="pubmed">25086946</ArticleId></ArticleIdList></Reference><Reference><Citation>Reents W, Hilker M, Borgermann J, et al. Acute kidney injury after on-pump or off-pump coronary artery bypass grafting in elderly patients. Ann Thorac Surg. 2014;98:9&#x2013;14. doi: 10.1016/j.athoracsur.2014.01.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2014.01.088</ArticleId><ArticleId IdType="pubmed">24881861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18:1292&#x2013;1298. doi: 10.1681/ASN.2006070756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2006070756</ArticleId><ArticleId IdType="pubmed">17314324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennen P, Douglas IS, Anderson R. Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med. 2010;38:261&#x2013;275. doi: 10.1097/CCM.0b013e3181bfb0b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181bfb0b5</ArticleId><ArticleId IdType="pubmed">19829099</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine. 2003;82:159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12792302</ArticleId></ArticleIdList></Reference><Reference><Citation>Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care. 2008;12:S2. doi: 10.1186/cc7025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7025</ArticleId><ArticleId IdType="pmc">PMC2607112</ArticleId><ArticleId IdType="pubmed">19105795</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CT, Wu VC, Lai CF, et al. Advanced age affects the outcome-predictive power of RIFLE classification in geriatric patients with acute kidney injury. Kidney Int. 2012;82:920&#x2013;927. doi: 10.1038/ki.2012.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.237</ArticleId><ArticleId IdType="pubmed">22763817</ArticleId></ArticleIdList></Reference><Reference><Citation>Akposso K, Hertig A, Couprie R, et al. Acute renal failure in patients over 80&#xa0;years old: 25-years&#x2019; experience. Intensive Care Med. 2000;26:400&#x2013;406. doi: 10.1007/s001340051173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340051173</ArticleId><ArticleId IdType="pubmed">10872131</ArticleId></ArticleIdList></Reference><Reference><Citation>White LE, Hassoun HT. Inflammatory mechanisms of organ crosstalk during ischemic acute kidney injury. Int J Nephrol. 2012;2012:505197. doi: 10.4061/2012/505197.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2012/505197</ArticleId><ArticleId IdType="pmc">PMC3118535</ArticleId><ArticleId IdType="pubmed">21826270</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies. Intensive Care Med. 2010;36:1657&#x2013;1665. doi: 10.1007/s00134-010-1928-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-1928-z</ArticleId><ArticleId IdType="pmc">PMC7728653</ArticleId><ArticleId IdType="pubmed">20517593</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Valdivieso JR, Bes-Rastrollo M, Monedero P, et al. Impact of prealbumin levels on mortality in patients with acute kidney injury: an observational cohort study. J Renal Nutr. 2008;18:262&#x2013;268. doi: 10.1053/j.jrn.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jrn.2007.11.003</ArticleId><ArticleId IdType="pubmed">18410882</ArticleId></ArticleIdList></Reference><Reference><Citation>Beier K, Eppanapally S, Bazick HS, et al. Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of &#x201c;normal&#x201d; creatinine. Crit Care Med. 2011;39:305&#x2013;313. doi: 10.1097/CCM.0b013e3181ffe22a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181ffe22a</ArticleId><ArticleId IdType="pmc">PMC3448784</ArticleId><ArticleId IdType="pubmed">21099426</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KD, Himmelfarb J, Paganini E, et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915&#x2013;919. doi: 10.2215/CJN.01430406.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01430406</ArticleId><ArticleId IdType="pubmed">17699307</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavi M, Honarmand A. Admission hypomagnesemia&#x2013;impact on mortality or morbidity in critically ill patients. Middle East J Anaesthesiol. 2007;19:645&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18044292</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar MS, Wani J, Karim R, et al. Significance of serum magnesium levels in critically ill-patients. Int J Appl Basic Med Res. 2014;4:34. doi: 10.4103/2229-516X.125690.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2229-516X.125690</ArticleId><ArticleId IdType="pmc">PMC3931212</ArticleId><ArticleId IdType="pubmed">24600576</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye CS, Londhey VA, Nadkart MY, et al. Hypomagnesemia in critically ill medical patients. J Assoc Physicians India. 2011;59:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">21751660</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves SC, Tomasi CD, Constantino L, et al. Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dialysis Transplant. 2013;28:910&#x2013;916. doi: 10.1093/ndt/gfs268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs268</ArticleId><ArticleId IdType="pubmed">22764195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17309964</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-0010</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of surgery (Chicago, Ill. : 1960)</Title><ISOAbbreviation>Arch Surg</ISOAbbreviation></Journal><ArticleTitle>Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>142</EndPage><MedlinePgn>134-42</MedlinePgn></Pagination><Abstract><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Infections and sepsis are major complications in secondary peritonitis and still represent a diagnostic challenge. We hypothesized that the laboratory marker procalcitonin would provide an early and reliable assessment of septic complications.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, international, multicenter inception cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Five European surgical referral centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Eighty-two patients with intraoperatively proven secondary peritonitis were enrolled within 96 hours of symptom onset.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Procalcitonin and the laboratory routine marker C-reactive protein (CRP) were prospectively assessed and monitored for a maximum of 21 consecutive days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Procalcitonin concentrations were most closely correlated with the development of septic multiorgan dysfunction syndrome (MODS), with peak levels occurring early after symptom onset or during the immediate postoperative course. No such correlation was observed for CRP. According to receiver operating characteristic analysis, a procalcitonin value of 10.0 ng/mL or greater on 2 consecutive days was superior to a CRP level of 210 mg/L or greater for predicting septic MODS, with sensitivity, specificity, and positive and negative predictive values of 65%, 92%, 83%, and 81% for procalcitonin and 67%, 58%, 49%, and 74% for CRP, respectively (P&lt;.001). Assessment of septic MODS was already possible on the first 2 postoperative days, with similar sensitivity and specificity. Persisting procalcitonin levels greater than 1.0 ng/mL beyond the first week after disease onset strongly indicated nonsurvival and were significantly better than CRP in assessing overall prognosis (P&lt;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Procalcitonin monitoring is a fast and reliable approach to assessing septic MODS and overall prognosis in secondary peritonitis. This single-test marker improves stratification of patients who will develop clinically relevant complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rau</LastName><ForeName>Bettina M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of General, Visceral, and Vascular Surgery, University of the Saarland, Homburg/Saar, Germany. bettina.rau@uniklinikum-saarland.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frigerio</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>B&#xfc;chler</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Wegscheider</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Puolakkainen</LastName><ForeName>Pauli A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Beger</LastName><ForeName>Hans G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Martin K</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Surg</MedlineTA><NlmUniqueID>9716528</NlmUniqueID><ISSNLinking>0004-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606589">CALCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>JHB2QIZ69Z</RegistryNumber><NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Surg. 2007 Aug;142(8):803; author reply 803-4. doi: 10.1001/archsurg.142.8.803-a.</RefSource><PMID Version="1">17709736</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015740" MajorTopicYN="N">Calcitonin Gene-Related Peptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008163" MajorTopicYN="N">Luminescent Measurements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17309964</ArticleId><ArticleId IdType="doi">10.1001/archsurg.142.2.134</ArticleId><ArticleId IdType="pii">142/2/134</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19077606</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Decreasing magnitude of multiple organ dysfunction syndrome despite increasingly severe critical surgical illness: a 17-year longitudinal study.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1235</EndPage><MedlinePgn>1227-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e31818c12dd</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) remains prevalent and the leading cause of mortality in the surgical intensive care unit (ICU). Improvements in ICU care in the last 10 years (e.g., tight glycemic control, activated protein C, fewer transfusions causing fewer nosocomial infections) may have decreased the incidence, magnitude, and mortality of MODS, as hypothesized in this study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Longitudinal 17-year prospective study of 11,314 ICU patients (academic/tertiary unit, Level I trauma center), 5,157 (45.5%) of whom developed any degree of MODS (Marshall score, cumulative). Data collected included Admission Acute Physiology and Chronic Health Evaluation (APACHE)-II and APACHE-III scores, MOD score (MODsc), hospital mortality, and the incidence and magnitude of MODS. The ratio of MODsc: APACHE III was calculated. Analyses (X +/- SEM, chi2, repeated-measures ANOVA, linear and polynomial regression, c-statistic) were performed for calendar-year intervals beginning in 1990 through 2006.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among MODS patients, the mean MODsc was 6.3 +/- 0.1 points, and the mortality rate was 22%. The APACHE III score increased significantly (p &lt; 0.0001) over time, but the mortality rate was unchanged (r2 = 0.02). Adjusted for illness severity (MODsc:A3), the magnitude of MODS decreased significantly (p &lt; 0.0001) during the time period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite significant increases in admission APACHE III score over 17 years, the adjusted magnitude of MODS (MODsc:A3) decreased. Given the strong association between MODS and mortality for critically ill surgical patients, it is likely that the unchanged risk-adjusted mortality observed over time is due to the reduced magnitude of MODS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barie</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Critical Care and Trauma, Anne and Max A. Cohen Surgical Intensive Care Unit, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York 10065, USA. pbarie@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hydo</LastName><ForeName>Lynn J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eachempati</LastName><ForeName>Soumitra R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008432" MajorTopicYN="N">Mathematical Computing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009519" MajorTopicYN="N" Type="Geographic">New York City</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19077606</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31818c12dd</ArticleId><ArticleId IdType="pii">00005373-200812000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15288631</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2004</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-5884</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</Title><ISOAbbreviation>Eur J Vasc Endovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Cytokines, their genetic polymorphisms, and outcome after abdominal aortic aneurysm repair.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>280</EndPage><MedlinePgn>274-80</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Excessive cytokine production has been implicated in the development of organ failure. Polymorphic sites in cytokine genes have been shown to affect levels of production in vitro and may influence cytokine production in vivo. The aims of this study were to determine if cytokines or their genetic polymorphisms were related to outcome after abdominal aortic aneurysm (AAA) repair.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study of 135 patients undergoing open AAA repair. Plasma levels of TNF-alpha, IL-1beta, IL-6 and IL-10 were measured 24 h post-operatively and genotypes for the TNF-alpha -308, IL-1beta+3953, IL-6 -174, IL-10 -1082 and IL-10 -592 polymorphisms were determined for each patient.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After elective AAA high levels of IL-10 were associated with both prolonged critical care (P&lt;0.001) and hospital stay (P=0.001). The presence of a G allele at the IL-6 -174 locus was associated with a higher incidence of organ failure (P=0.04) and an A allele at TNF-alpha -308 with prolonged critical care stay (P=0.03). After ruptured AAA the development of multi-organ failure was associated with high levels of IL-6 (P=0.01) and TNF-alpha (P=0.04). High TNF-alpha levels were also associated with mortality (P=0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Post-operative cytokine levels are related to outcome after AAA repair. Cytokine gene polymorphisms may provide a method for determining which patients are at high risk of complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bown</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Leicester, Leicester, UK. mjb42@le.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horsburgh</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>P R F</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Sayers</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Vasc Endovasc Surg</MedlineTA><NlmUniqueID>9512728</NlmUniqueID><ISSNLinking>1078-5884</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="N">Aortic Rupture</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15288631</ArticleId><ArticleId IdType="doi">10.1016/j.ejvs.2004.05.008</ArticleId><ArticleId IdType="pii">S107858840400245X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19835422</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2009</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-3907</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>12</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of proteome research</Title><ISOAbbreviation>J Proteome Res</ISOAbbreviation></Journal><ArticleTitle>Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach.</ArticleTitle><Pagination><StartPage>5423</StartPage><EndPage>5430</EndPage><MedlinePgn>5423-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/pr900576y</ELocationID><Abstract><AbstractText>Progression of critically ill patients from Systemic Inflammatory Response Syndrome (SIRS) to Multiple Organ Dysfunction Syndrome (MODS) accounts for more than 75% of deaths in adult surgical intensive care units. Currently, there is no practical clinical technique to predict the progression of SIRS or MODS. In this report, we describe an NMR-based metabonomic method to aid detection of these conditions based on abnormal metabolic signatures. We applied pattern recognition methods to analyze one-dimensional (1)H NMR spectra of SIRS and MODS patient sera. By using Principal Component Analysis (PCA) and Partial Least Squares-Discriminant Analysis (PLS-DA), we could distinguish critically ill patients (n = 52) from healthy controls (n = 26). After noise reduction by Orthogonal Signal Correction (OSC), PLS-DA was also able to clearly discriminate SIRS and MODS patients. The corresponding coefficients indicated that spectra responsible for the discrimination were located in delta3.06-3.86 NMR integral regions from SIRS, mainly composed of sugars, amino acids and glutamine signals, and delta1.18-1.3 and delta4.02-4.1 integral regions of MODS serum samples, principally consisted of various proton signals of fatty acyl chains and glycerol backbone of lipids, along with creatinine and lactate. Our results are consistent with the clinical observations that carbohydrate and amino acid levels changes in the early course of critical illness (SIRS stage) and significant disturbances in fat metabolism and development of organ abnormalities become the characteristics in the late stage (MODS). These data suggest that NMR-based metabonomic approach can be developed to diagnose the disease progress of critically ill patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Hailei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hospital of Nantong University, Nantong 226001, PR China. hlmao@sibs.ac.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huimin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xia</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Hongchang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hongsheng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Donghai</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Proteome Res</MedlineTA><NlmUniqueID>101128775</NlmUniqueID><ISSNLinking>1535-3893</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002241">Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005223">Fats</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002241" MajorTopicYN="N">Carbohydrates</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016002" MajorTopicYN="N">Discriminant Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005223" MajorTopicYN="N">Fats</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="N">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19835422</ArticleId><ArticleId IdType="doi">10.1021/pr900576y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22185191</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8674</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>449</EndPage><MedlinePgn>443-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/sur.2011.133</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Septic shock causing or complicating critical surgical illness results in high mortality. Drotrecogin alfa (activated), known also as recombinant human activated protein C (rhAPC) has become controversial as therapy, owing to persisting questions of efficacy and safety. We hypothesized rhAPC to be effective therapy for critically ill surgical patients with septic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Open-label therapy with rhAPC (by predefined criteria) of 108 critically ill surgical patients. Treated patients were matched individually in prospect for age, gender, Acute Physiology and Chronic Health Evaluation (APACHE)-II and -III scores, site of infection, and organism (0-2 points each, maximum 12 points) with 108 patients from our 15,000-patient surgical intensive care unit database who did not receive rhAPC. No match was accepted if &lt;6 points. Multiple organ dysfunction (MOD) scores and data regarding cortisol concentrations, bleeding complications, and transfusion requirements were collected. The primary endpoint was 28-day mortality, with mortality for hospitalization and resolution of organ dysfunction as secondary endpoints. Statistical analyses included ANOVA, c statistic, binary logistic regression, and Kaplan-Meier time-to-event and Cox proportional hazards analyses; &#x3b1;=0.05.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean match score was 9.2&#xb1;0.1 points (range, 6-12 points). Patients were well matched by all criteria, including baseline MOD score (9.5&#xb1;0.7 vs. 9.8&#xb1;0.3 points, p=0.66). Mean age was 68.1&#xb1;1.1 years (p=0.49), Mean APACHE-III score was 99.6&#xb1;1.5 points (p=0.87). Mean time to rhAPC administration was 25&#xb1;3 h. Survival at 28 days after rhAPC was 71.3% vs. 49.1% (p=0.001); hospital survival was 57.4% vs. 40.7% (p=0.02). By logistic regression, rhAPC therapy resulted in improved 28-day survival (OR 2.57, 95% CI 1.46-4.52, p=0.001) (model &#x3c7;2 11.244, p=0.001); and hospital survival (OR 1.96, 95% CI 1.14-3.36, p=0.015) (model &#x3c7;2 6.03, p=0.014). The MOD score decreased significantly (p=0.012) during rhAPC therapy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Therapy with rhAPC appeared to improve survival in surgical ICU patients with life-threatening infection characterized by septic shock and organ dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barie</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Burns, Critical Care, and Trauma, Department of Surgery, Weill Cornell Medical College, New York, New York, USA. pbarie@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hydo</LastName><ForeName>Lynn J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Eachempati</LastName><ForeName>Soumitra R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011486">Protein C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>JGH8MYC891</RegistryNumber><NameOfSubstance UI="C421124">drotrecogin alfa activated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011486" MajorTopicYN="N">Protein C</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22185191</ArticleId><ArticleId IdType="doi">10.1089/sur.2011.133</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16878192</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-3180</ISSN><JournalIssue CitedMedium="Print"><Volume>124</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Sao Paulo medical journal = Revista paulista de medicina</Title><ISOAbbreviation>Sao Paulo Med J</ISOAbbreviation></Journal><ArticleTitle>Effects of single dose of dexamethasone on patients with systemic inflammatory response.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>95</EndPage><MedlinePgn>90-5</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Systemic inflammatory response syndrome (SIRS) is a very common condition among critically ill patients. SIRS, sepsis, septic shock and multiple organ dysfunction syndrome (MODS) can lead to death. Our aim was to investigate the efficacy of a single dose of dexamethasone for blocking the progression of systemic inflammatory response syndrome.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Prospective, randomized, double-blind, single-center study in a postoperative intensive care unit (Surgical Support Unit) at Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study involved 29 patients with SIRS. All eligible patients were prospectively randomized to receive either a single dose of 0.2 mg/kg of dexamethasone or placebo, after SIRS was diagnosed. The patients were monitored over a seven-day period using Sequential Organ Failure Assessment score (SOFA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The respiratory system showed an improvement on the first day after dexamethasone was administered, demonstrated by the improved PaO2/FiO2 ratio (p &lt; 0.05). The cardiovascular system of patients requiring vasopressor therapy also improved over the first two days, with a better evolution in the dexamethasone group (p &lt; 0.05). Non-surviving patients presented higher lactate assays than did survivors (p &lt; 0.05) during this period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dexamethasone enhanced the effects of vasopressor drugs and evaluation of the respiratory system showed improvements (better PaO2/FiO2 ratio), one day after its administration. Despite these improvements, the single dose of dexamethasone did not block the evolution of SIRS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cicarelli</LastName><ForeName>Domingos Dias</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Surgical Support Unit, Anesthesia Division, Department of Surgery, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. dcicarelli@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bense&#xf1;or</LastName><ForeName>F&#xe1;bio Ely Martins</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Joaquim Edson</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Sao Paulo Med J</MedlineTA><NlmUniqueID>100897261</NlmUniqueID><ISSNLinking>1516-3180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="CONTEXTO E OBJETIVO:">A s&#xed;ndrome da resposta inflamat&#xf3;ria sist&#xea;mica (SRIS) acomete muitos pacientes internados em unidades de terapia intensiva. A evolu&#xe7;&#xe3;o destes pacientes com SRIS para sepse, choque s&#xe9;ptico e s&#xed;ndrome da disfun&#xe7;&#xe3;o de m&#xfa;ltiplos &#xf3;rg&#xe3;os (SDMO) pode conduzi-los rapidamente para o &#xf3;bito. A proposta do trabalho &#xe9; avaliar a efic&#xe1;cia da dexametasona em dose &#xfa;nica como tratamento da SRIS.</AbstractText><AbstractText Label="TIPO DE ESTUDO E LOCAL:">Estudo prospectivo, aleat&#xf3;rio, duplamente encoberto, realizado na Unidade de Terapia Intensiva p&#xf3;s-operat&#xf3;ria (Unidade de Apoio Cir&#xfa;rgico) do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Foram estudados 29 pacientes com diagn&#xf3;stico de SRIS. Os participantes foram aleatoriamente divididos em dois grupos que receberam dexametasona (0,2 mg/kg em dose &#xfa;nica) ou placebo ap&#xf3;s o diagn&#xf3;stico de SRIS. Os pacientes foram acompanhados durante sete dias de interna&#xe7;&#xe3;o na UTI atrav&#xe9;s do escore SOFA <i>(Sequential Organ Failure Assessment)</i>.</AbstractText><AbstractText Label="RESULTADOS:">Os pacientes que receberam dexametasona apresentaram melhora do sistema respirat&#xf3;rio no primeiro dia, com aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> (p &lt; 0,05). Entre os pacientes que faziam uso de vasopressores, os que receberam dexametasona tiveram diminui&#xe7;&#xe3;o da necessidade destas medica&#xe7;&#xf5;es nos primeiros dois dias ap&#xf3;s a dose de dexametasona (p &lt; 0,05).</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">A dexametasona diminuiu a necessidade de medica&#xe7;&#xf5;es vasopressoras e causou aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> no primeiro dia ap&#xf3;s sua administra&#xe7;&#xe3;o. Apesar destes efeitos, a dexametasona em dose &#xfa;nica n&#xe3;o bloqueou a evolu&#xe7;&#xe3;o dos pacientes com SRIS.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> Not declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16878192</ArticleId><ArticleId IdType="pmc">PMC11060357</ArticleId><ArticleId IdType="doi">10.1590/s1516-31802006000200008</ArticleId><ArticleId IdType="pii">S1516-31802006000200008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sepsis, sepsis syndrome, and systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273(2):155&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094907</ArticleId><ArticleId IdType="pubmed">9876974</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa B. Free Radic Biol Med. 2000;28(9):1317&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569975</ArticleId></ArticleIdList></Reference><Reference><Citation>Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24(1):163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8565523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihari DJ, Tinker J. Steroids in intensive care. Br J Hosp Med. 1982;28(4):323&#x2013;324. 328-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">6753992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumer W. Controversy in shock research. Pro: The role of steroids in septic shock. Circ Shock. 1981;8(6):667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">7337944</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">7634816</ArticleId></ArticleIdList></Reference><Reference><Citation>Demling RH, Smith M, Gunther R, Wandzilak T. Endotoxin-induced lung injury in unanesthetized sheep: effect of methylprednisolone. Circ Shock. 1981;8(3):351&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">7249263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes GS., Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sci. 1984;35(23):2319&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">6390057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass EH. High-dose corticosteroids for septic shock. N Engl J Med. 1984;311(18):1178&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">6482936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheagren JN. Septic shock and corticosteroids. N Engl J Med. 1981;305(8):456&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">7254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer V. Betamethasone sodium phosphate injection: highdose regimen in septic shock. Clin Ther. 1984;6(5):719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">6383616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23(7):1294&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DP. Corticosteroids in the treatment of septic shock and the adult respiratory distress syndrome. Med Clin North Am. 1983;67(3):717&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">6341730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottosson J, Brandberg A, Erikson B, Hedman L, Dawidson I, S&#xf6;derberg R. Experimental septic shock - effects of corticosteroids. Circ Shock. 1982;9(6):571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">6758979</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21(3):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig. 1994;72(10):782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">7865982</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186604</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. Crit Care Med. 1999;27(4):672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321643</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186608</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321661</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaesthesia. 2003;58(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12492660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbald WJ, Doig G, Inman KJ. Sepsis, SIRS and infection. Intensive Care Med. 1995;21(4):299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 9th ed. St Louis: McGraw-Hill; 1996. pp. 1459&#x2013;1485.</Citation></Reference><Reference><Citation>Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700393</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25(11):1789&#x2013;1795.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society on Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR. Quantification of organ dysfunction: seeking standardization. Crit Care Med. 1998;26(11):1767&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824054</ArticleId></ArticleIdList></Reference><Reference><Citation>Timsit JF, Fosse JP, Troch&#xe9; G, et al. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med. 2002;30(9):2003&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840239</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664219</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559592</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, International Sepsis Forum Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307373</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GS, Bernard GR, International Sepsis Forum Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Gando S, Morimoto Y, Nanzaki S, Kemmotsu O. Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Surg Today. 2001;31(10):853&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello CA. The Acute-Phase response. In: Bennett JC, Plum F, editors. Cecil Textbook of Medicine. 20th ed. Philadelphia: Saunders; 1996. pp. 1567&#x2013;1569.</Citation></Reference><Reference><Citation>Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med. 2002;30(3):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11990910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Sch&#xfc;ttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002;30(5):1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006796</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AJ, David CMN. A avalia&#xe7;&#xe3;o do comportamento da prote&#xed;na C-reativa em pacientes com sepse na UTI. Rev Bras Ter Intensiva. 2002;14(4):156&#x2013;165.</Citation></Reference><Reference><Citation>Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28332853</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1945-0257</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Genetic testing and molecular biomarkers</Title><ISOAbbreviation>Genet Test Mol Biomarkers</ISOAbbreviation></Journal><ArticleTitle>Correlations Between LP-PLA2 Gene Polymorphisms and Susceptibility and Severity of Acute Pancreatitis in a Chinese Population.</ArticleTitle><Pagination><StartPage>206</StartPage><EndPage>212</EndPage><MedlinePgn>206-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/gtmb.2016.0243</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This case-control study explored correlations between LP-PLA2 gene polymorphisms (A379V, V279F, and R92H) and susceptibility and severity of acute pancreatitis (AP) in a Chinese population.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">From October 2013 to October 2015, 94 AP patients were chosen as the case group. According to the Acute Physiology and Chronic Health Evaluation (APACHE) II score standard, AP patients were divided into a mild AP (MAP) group (n&#x2009;=&#x2009;46) and severe AP (SAP) group (n&#x2009;=&#x2009;48). The 48 SAP patients were further divided into an SAP with multiple organ dysfunction syndrome (MODS) group (n&#x2009;=&#x2009;42) and SAP without MODS group (n&#x2009;=&#x2009;6). Meanwhile, 96 healthy subjects who received physical examinations at the study hospitals were selected as the control group. Serum lipoprotein-associated phospholipase A2 (LP-PLA2) levels were detected by an enzyme-linked immunosorbent assay (ELISA). The A379V (s1051931), V279F (rs16874954), and R92H (rs13989) polymorphisms of the LP-PLA2 gene were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant differences in the frequencies of the LP-PLA2 gene polymorphisms between the AP group and the control group. The distribution of V279F-AA+AC genotype and R92H-AA+AG genotype in the AP group was higher than that in the control group, whereas the SAP group and SAP with MODS group distributions were higher than those in the MAP group and SAP without MODS group (both p&#x2009;&lt;&#x2009;0.05). G-C-A, G-A-G, and G-C-G haploids formed by A379V, V279F, and R92H may be associated with AP susceptibility. LP-PLA2 gene polymorphisms could affect serum LP-PLA2 level, whereas the V279F-A allele gene, the R92H-A allele gene, serum LP-PLA2 level, and serum amylase may be independent risk factors for AP (all p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrated that the LP-PLA2 gene polymorphisms, V279F and R92H, may be associated with susceptibility to and severity of AP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1 Department of Emergency, Laiwu City People's Hospital , Laiwu, P.R. China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Chun-Xia</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>1 Department of Emergency, Laiwu City People's Hospital , Laiwu, P.R. China .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Cai-Xia</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>2 Department of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University , Changchun, P.R. China .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Test Mol Biomarkers</MedlineTA><NlmUniqueID>101494210</NlmUniqueID><ISSNLinking>1945-0257</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.47</RegistryNumber><NameOfSubstance UI="D043203">1-Alkyl-2-acetylglycerophosphocholine Esterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.47</RegistryNumber><NameOfSubstance UI="C526684">PLA2G7 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D043203" MajorTopicYN="N">1-Alkyl-2-acetylglycerophosphocholine Esterase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A379V</Keyword><Keyword MajorTopicYN="N">LP-PLA2</Keyword><Keyword MajorTopicYN="N">R92H</Keyword><Keyword MajorTopicYN="N">V279F</Keyword><Keyword MajorTopicYN="N">acute pancreatitis susceptibility</Keyword><Keyword MajorTopicYN="N">gene polymorphism</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28332853</ArticleId><ArticleId IdType="doi">10.1089/gtmb.2016.0243</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32539903</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-6834</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infection control and hospital epidemiology</Title><ISOAbbreviation>Infect Control Hosp Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Variation in antibiotic use across intensive care units (ICU): A population-based cohort study in Ontario, Canada.</ArticleTitle><Pagination><StartPage>1035</StartPage><EndPage>1041</EndPage><MedlinePgn>1035-1041</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/ice.2020.217</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Antibiotics are commonly used in intensive care units (ICUs), yet differences in antibiotic use across ICUs are unknown. Herein, we studied antibiotic use across ICUs and examined factors that contributed to variation.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective cohort study using data from Ontario's Critical Care Information System (CCIS), which included 201 adult ICUs and 2,013,397 patient days from January 2012 to June 2016. Antibiotic use was measured in days of therapy (DOT) per 1,000 patient days. ICU factors included ability to provide ventilator support (level 3) or not (level 2), ICU type (medical-surgical or other), and academic status. Patient factors included severity of illness using multiple-organ dysfunction score (MODS), ventilatory support, and central venous catheter (CVC) use. We analyzed the effect of these factors on variation in antibiotic use.</AbstractText><AbstractText Label="RESULTS">Overall, 269,351 patients (56%) received antibiotics during their ICU stay. The mean antibiotic use was 624 (range 3-1460) DOT per 1,000 patient days. Antibiotic use was significantly higher in medical-surgical ICUs compared to other ICUs (697 vs 410 DOT per 1,000 patient days; P &lt; .0001) and in level 3 ICUs compared to level 2 ICUs (751 vs 513 DOT per 1,000 patient days; P &lt; .0001). Higher antibiotic use was associated with higher severity of illness and intensity of treatment. ICU and patient factors explained 47% of the variation in antibiotic use across ICUs.</AbstractText><AbstractText Label="CONCLUSIONS">Antibiotic use varies widely across ICUs, which is partially associated with ICUs and patient characteristics. These differences highlight the importance of antimicrobial stewardship to ensure appropriate use of antibiotics in ICU patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Erika Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detsky</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdepartmental Division of Critical Care Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Chaim M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Control Hosp Epidemiol</MedlineTA><NlmUniqueID>8804099</NlmUniqueID><ISSNLinking>0899-823X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32539903</ArticleId><ArticleId IdType="doi">10.1017/ice.2020.217</ArticleId><ArticleId IdType="pii">S0899823X20002172</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38318959</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Postoperative intra-abdominal hypertension predicts worse hospital outcomes in children after cardiac surgery: a pilot study&#x2020;.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivae019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivae019</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our goal was to determine the incidence and characteristics of postoperative intra-abdominal hypertension (IAH) in paediatric patients undergoing open-heart surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-centre study included consecutive children (aged &lt;16&#x2009;years) who underwent open-heart surgery between July 2020 and February 2021. Patients who entered the study were followed until in-hospital death or hospital discharge. The study consisted of 2 parts. Part I was a prospective observational cohort study that was designed to discover the association between exposures and IAH. Postoperative intra-abdominal pressure was measured immediately after admission to the intensive care unit and every 6&#x2009;h thereafter. Part II was a cross-sectional study to compare the hospital-related adverse outcomes between the IAH and the no-IAH cohorts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Postoperatively, 24.7% (38/154) of the patients exhibited IAH, whereas 3.9% (6/154) developed abdominal compartment syndrome. The majority (29/38, 76.3%) of IAH cases occurred within the first 24&#x2009;h in the intensive care unit. Multivariable analysis showed that the Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery score [odds ratio (OR)&#x2009;=&#x2009;1.86, 95% confidence interval (CI) 1.23-2.83, P&#x2009;=&#x2009;0.004], right-sided heart lesion (OR&#x2009;=&#x2009;5.60, 95% CI 2.34-13.43, P&#x2009;&lt;&#x2009;0.001), redo sternotomy (OR&#x2009;=&#x2009;4.35, 95% CI 1.64-11.57, P&#x2009;=&#x2009;0.003), high baseline intra-abdominal pressure (OR&#x2009;=&#x2009;1.43, 95% CI 1.11-1.83, P&#x2009;=&#x2009;0.005), prolonged cardiopulmonary bypass duration (OR&#x2009;=&#x2009;1.01, 95% CI 1.00-1.01, P&#x2009;=&#x2009;0.005) and deep hypothermic circulatory arrest (OR&#x2009;=&#x2009;5.14, 95% CI 1.15-22.98, P&#x2009;=&#x2009;0.032) were independent predictors of IAH occurrence. IAH was associated with greater inotropic support (P&#x2009;&lt;&#x2009;0.001), more gastrointestinal complications (P&#x2009;=&#x2009;0.001), sepsis (P&#x2009;=&#x2009;0.003), multiple organ dysfunction syndrome (P&#x2009;&lt;&#x2009;0.001) and prolonged intensive care unit stay (z = -4.916, P&#x2009;&lt;&#x2009;0.001) and hospitalization (z = -4.710, P&#x2009;&lt;&#x2009;0.001). The occurrence of a composite outcome (P&#x2009;=&#x2009;0.009) was significantly increased in patients with IAH.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IAH is common in children undergoing cardiac surgery and is associated with worse hospital outcomes. Several factors may be associated with the development of IAH, including basic cardiac physiology and perioperative factors.</AbstractText><AbstractText Label="TRIAL INFORMATION" NlmCategory="UNASSIGNED">This study was registered in the Chinese Clinical Trial Registry (Trial number: ChiCTR2000034322)URL site: https://www.chictr.org.cn/hvshowproject.html?id=41363&amp;v=1.4.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0191-4747</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yibing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shouping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lijing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal compartment syndrome</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Gastrointestinal complication</Keyword><Keyword MajorTopicYN="N">Intra-abdominal hypertension</Keyword><Keyword MajorTopicYN="N">Paediatrics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38318959</ArticleId><ArticleId IdType="pmc">PMC10882438</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivae019</ArticleId><ArticleId IdType="pii">7601456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dabrowski W, Rzecki Z.. Intra-abdominal and abdominal perfusion pressure in patients undergoing coronary artery bypass graft surgery. Acta Clin Belg 2009;64:216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670561</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x131;l&#x131;&#xe7; B, Yap&#x131;c&#x131; N, Yap&#x131;c&#x131; F, Kavakl&#x131; AS, Kudsio&#x11f;lu T, K&#x131;l&#x131;&#xe7; A. et al. Factors associated with increased intra-abdominal pressure in patients undergoing cardiac surgery. Turk Gogus Kalp Damar Cerrahisi Derg 2020;28:134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067007</ArticleId><ArticleId IdType="pubmed">32175154</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit M, Werner MJM, Lansink-Hartgring AO, Dieperink W, Zijlstra JG, van Meurs M.. How central obesity influences intra-abdominal pressure: a prospective, observational study in cardiothoracic surgical patients. Ann Intensive Care 20166:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056912</ArticleId><ArticleId IdType="pubmed">27726116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeffi MA, Stafford P, Wallace K, Bernstein W, Deshpande S, Odonkor P. et al. Intra-abdominal Hypertension and Postoperative Kidney Dysfunction in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2016;30:1571&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">27590464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazer R, Albarrati A, Ullah A, Alamro S, Kashour T.. Intra-abdominal hypertension in obese patients undergoing coronary surgery: a prospective observational study. Surgery 2019;166:1128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson N, Efthymiou C.. Predictive risk factors for intra-abdominal hypertension after cardiac surgery. Interact CardioVasc Thorac Surg 2021. 10;32:719&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691507</ArticleId><ArticleId IdType="pubmed">33471093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome et al.Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 2013;39:1190&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML.. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: a Prospective Epidemiological Study. J Intensive Care Med 2016;31:403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Ejike JC.. Intra-abdominal hypertension and abdominal compartment syndrome in pediatrics. A review. J Crit Care 2017;41:275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">28614762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanayem NS, Dearani JA, Welke KF, B&#xe9;land MJ, Shen I, Ebels T.. Gastrointestinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. Cardiol Young 2008;18 Suppl 2:240&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19063798</ArticleId></ArticleIdList></Reference><Reference><Citation>Butts RJ, Scheurer MA, Zyblewski SC, Wahlquist AE, Nietert PJ, Bradley SM. et al. A composite outcome for neonatal cardiac surgery research. J Thorac Cardiovasc Surg 2014;147:428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004075</ArticleId><ArticleId IdType="pubmed">23587468</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga MA, Manlhiot C, Marwali EM, McCrindle BW, Van Arsdell GS, Schwartz SM.. Hyperglycemia after pediatric cardiac surgery: impact of age and residual lesions. Crit Care Med 2011;39:266&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057314</ArticleId></ArticleIdList></Reference><Reference><Citation>Koponen T, Karttunen J, Musialowicz T, Pietil&#xe4;inen L, Uusaro A, Lahtinen P.. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019;122:428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435836</ArticleId><ArticleId IdType="pubmed">30857599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalfino L, Sicolo A, Paparella D, Mongelli M, Rubino G, Brienza N.. Intra-abdominal hypertension in cardiac surgery. Interact CardioVasc Thorac Surg 2013;17:644&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781798</ArticleId><ArticleId IdType="pubmed">23820668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaser AR, Bj&#xf6;rck M, De Keulenaer B, Regli A.. Abdominal compliance: a bench-to-bedside review. J Trauma Acute Care Surg 2015;78:1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25909429</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer D, D'Amours S, Aneman A.. Intra-abdominal hypertension in postoperative cardiac surgery patients. Crit Care Resusc 2014;16:214&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25161025</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes JH 4th, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF. et al. Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res 2002;51:579&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofukuji M, Stahl GL, Metais C, Tomita M, Agah A, Bianchi C. et al. Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. Ann Thorac Surg 2000;69:799&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10750764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramser M, Glauser PM, Glass TR, Weixler B, Grapow MTR, Hoffmann H. et al. Abdominal Decompression after Cardiac Surgery: outcome of 42 Patients with Abdominal Compartment Syndrome. World J Surg 2021;45:1242&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">33481080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO.. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg 2017;52:414&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Deindl P, Wagner J, Herden U, Schulz-J&#xfc;rgensen S, Schild R, Vettorazzi E. et al. Monitoring intra-abdominal pressure after liver transplantation in children. Pediatr Transplant 2019;23:e13565.</Citation><ArticleIdList><ArticleId IdType="pubmed">31471942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham ML, Malbrain ML.. Cardiovascular implications of abdominal compartment syndrome. Acta Clin Belg 2007;62 Suppl 1:98&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469707</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15550474</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0009-9147</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical chemistry</Title><ISOAbbreviation>Clin Chem</ISOAbbreviation></Journal><ArticleTitle>Prognostic value of an early soluble L-selectin (sCD62L) assay for risk assessment in blunt multiple trauma: a metaanalysis.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>24</EndPage><MedlinePgn>16-24</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">After severe trauma, decreased plasma concentrations of the soluble adhesion molecule L-selectin (sCD62L) have been linked to an increased incidence of lung failure and multiorgan dysfunction syndrome (MODS). Individual studies have had conflicting results, however. We examined multiple studies in an attempt to determine whether early sCD62L concentrations are predictive of major complications after severe trauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a systematic review of six electronic databases and a manual search for clinical studies comparing outcomes of multiply injured patients (Injury Severity Score &gt; or =16) depending on their early sCD62L blood concentrations. Because of various outcome definitions, acute lung injury (ALI) and adult respiratory distress syndrome (ARDS) were studied as a composite endpoint. Weighted mean differences (WMDs) in sCD62L concentrations were calculated between individuals with and without complications by fixed- and random-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Altogether, 3370 citations were identified. Seven prospective studies including 350 patients were eligible for data synthesis. Published data showed the discriminatory features of sCD62L but did not allow for calculation of measures of test accuracy. Three of four studies showed lower early sCD62L concentrations among individuals progressing to ALI and ARDS (WMD = -229 microg/L; 95% confidence interval, -476 to 18 microg/L). No differences in sCD62L concentrations were noted among patients with or without later MODS. Nonsurvivors had significantly lower early sCD62L plasma concentrations (WMD = 121 microg/L; 95% confidence interval, 63-179 microg/L), but little information was available on potential confounders in this group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early decreased soluble L-selectin concentrations after multiple trauma may signal an increased likelihood of lung injury and ARDS. The findings of this metaanalysis warrant a large cohort study to develop selectin-based models targeting the risk of inflammatory complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stengel</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Division, Department of Orthopedic and Trauma Surgery, Unfallkrankenhaus Berlin, 12683 Berlin, Germany. dirk.stengel@ukb.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauwens</LastName><ForeName>Kai</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Keh</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gerlach</LastName><ForeName>Herwig</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ekkernkamp</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tauber</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Thoralf</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Chem</MedlineTA><NlmUniqueID>9421549</NlmUniqueID><ISSNLinking>0009-9147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126880-86-2</RegistryNumber><NameOfSubstance UI="D019041">L-Selectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019041" MajorTopicYN="N">L-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15550474</ArticleId><ArticleId IdType="doi">10.1373/clinchem.2004.040097</ArticleId><ArticleId IdType="pii">clinchem.2004.040097</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16940457</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-972X</ISSN><JournalIssue CitedMedium="Print"><Volume>91</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical endocrinology and metabolism</Title><ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Copeptin and arginine vasopressin concentrations in critically ill patients.</ArticleTitle><Pagination><StartPage>4381</StartPage><EndPage>4386</EndPage><MedlinePgn>4381-6</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Determination of arginine vasopressin (AVP) concentrations may be helpful to guide therapy in critically ill patients. A new assay analyzing copeptin, a stable peptide derived from the AVP precursor, has been introduced.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our objective was to determine plasma copeptin concentrations.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We conducted a post hoc analysis of plasma samples and data from a prospective study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The setting was a 12-bed general and surgical intensive care unit (ICU) in a tertiary university teaching hospital.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Our subjects were 70 healthy volunteers and 157 ICU patients with sepsis, with systemic inflammatory response syndrome (SIRS), and after cardiac surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">There were no interventions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Copeptin plasma concentrations, demographic data, AVP plasma concentrations, and a multiple organ dysfunction syndrome score were documented 24 h after ICU admission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AVP (P &lt; 0.001) and copeptin (P &lt; 0.001) concentrations were significantly higher in ICU patients than in controls. Patients after cardiac surgery had higher AVP (P = 0.003) and copeptin (P = 0.003) concentrations than patients with sepsis or SIRS. Independent of critical illness, copeptin and AVP correlated highly significantly with each other. Critically ill patients with sepsis and SIRS exhibited a significantly higher ratio of copeptin/AVP plasma concentrations than patients after cardiac surgery (P = 0.012). The American Society of Anesthesiologists' classification (P = 0.046) and C-reactive protein concentrations (P = 0.006) were significantly correlated with the copeptin/AVP ratio.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Plasma concentrations of copeptin and AVP in healthy volunteers and critically ill patients correlate significantly with each other. The ratio of copeptin/AVP plasma concentrations is increased in patients with sepsis and SIRS, suggesting that copeptin may overestimate AVP plasma concentrations in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jochberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. Stefan.Jochberger@uibk.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgenthaler</LastName><ForeName>Nils G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Viktoria D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Luckner</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wenzel</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Hanno</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hasibeder</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Friesenecker</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>D&#xfc;nser</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Endocrinol Metab</MedlineTA><NlmUniqueID>0375362</NlmUniqueID><ISSNLinking>0021-972X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006020">Glycopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C048197">copeptins</NameOfSubstance></Chemical><Chemical><RegistryNumber>113-79-1</RegistryNumber><NameOfSubstance UI="D001127">Arginine Vasopressin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001127" MajorTopicYN="N">Arginine Vasopressin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006020" MajorTopicYN="N">Glycopeptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013903" MajorTopicYN="N">Thoracic Surgery</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16940457</ArticleId><ArticleId IdType="doi">10.1210/jc.2005-2830</ArticleId><ArticleId IdType="pii">jc.2005-2830</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28721572</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1432-2323</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>World journal of surgery</Title><ISOAbbreviation>World J Surg</ISOAbbreviation></Journal><ArticleTitle>I-FABP is a Novel Marker for the Detection of Intestinal Injury in Severely Injured Trauma Patients.</ArticleTitle><Pagination><StartPage>3120</StartPage><EndPage>3127</EndPage><MedlinePgn>3120-3127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00268-017-4124-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Intestinal injury is a rare injury in multiply traumatized patients, and its diagnosis remains difficult. Delayed diagnosis of an intestinal injury increases the risk of sepsis, multiple organ failure and mortality. The intestinal fatty acid-binding protein (I-FABP) is solely expressed in the intestine and is released extracellulary after tissue damage. This study evaluates the validity of I-FABP as an early biomarker to detect an abdominal injury and particularly an injury to the intestine.</AbstractText><AbstractText Label="PATIENTS AND METHODS">Patients with an Abbreviated Injury Scale (AIS) score for abdominal body region (AIS abdomen) &#x2265;3 were included in this study from 07/2006 to 12/2014. Of those, ten patients retrospectively had an intestinal injury (int. injury). According to the Injury Severity Score and the AIS abdomen, corresponding patients with an abdominal injury but without an intestinal injury (no int. injury) were included for matched-pair analysis. Twenty healthy volunteers served as controls. Plasma I-FABP levels were measured at admission to the emergency room and up to 10&#xa0;days daily (d1-d10).</AbstractText><AbstractText Label="RESULTS">Median I-FABP levels were significantly higher in the "int. injury" group compared to the "no int. injury" group [2101.0&#xa0;pg/ml (IQR&#xa0;=&#xa0;1248.1-4117.8) vs. 351.4&#xa0;pg/ml (IQR&#xa0;=&#xa0;287.6-963.3), p&#xa0;&lt;&#xa0;0.05]. Furthermore, I-FABP levels of both groups were significantly higher compared to the control group [Ctrl: 127.2&#xa0;pg/ml (IQR&#xa0;=&#xa0;57.4-310.6), p&#xa0;&lt;&#xa0;0.05]. The time course of I-FABP levels showed a peak on the day of admission and a decline to the control levels in the further post-traumatic course. The development of complications such as single- or multi-organ failure, sepsis, acute respiratory distress syndrome, pneumonia and mortality was higher in the "int. injury" group; however, this difference was not statistically significant.</AbstractText><AbstractText Label="CONCLUSION">This study confirmed our previous observation that I-FABP might be used as a suitable early biomarker for the detection of abdominal injuries in general. In addition and more specific, I-FABP may be a useful and promising parameter in the diagnosis of intestinal injuries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voth</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. maika.voth@kgu.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duchene</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auner</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustenberger</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relja</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzi</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Trauma, Hand and Reconstructive Surgery, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Surg</MedlineTA><NlmUniqueID>7704052</NlmUniqueID><ISSNLinking>0364-2313</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050556">Fatty Acid-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015998" MajorTopicYN="N">Abbreviated Injury Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050556" MajorTopicYN="N">Fatty Acid-Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28721572</ArticleId><ArticleId IdType="doi">10.1007/s00268-017-4124-2</ArticleId><ArticleId IdType="pii">10.1007/s00268-017-4124-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pneumologie. 2012 Dec;66(12):707-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23225407</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Surg. 2006 Sep-Oct;63(5):322-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16971202</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1998 Jul;45(1):69-75; discussion 75-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9680015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2015 Apr;53(5):771-80</Citation><ArticleIdList><ArticleId IdType="pubmed">25324448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1993 Aug;35(2):267-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8355307</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Emerg Med. 2010 Jul;17(7):729-35</Citation><ArticleIdList><ArticleId IdType="pubmed">20653587</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 1994 Dec;168(6):670-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7978016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Surg. 2015 Jul;50(7):1115-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25783297</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosens Bioelectron. 2005 Jun 15;20(12):2566-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15854826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 1995 May;36(5):788-91</Citation><ArticleIdList><ArticleId IdType="pubmed">7797132</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2013 Apr;205(4):414-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23375703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zentralbl Chir. 2014 Aug;139(4):445-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22773415</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Surg. 2014 Dec;12(12):1495-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25046131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1996 Aug;41(2):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8760536</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2007 Dec;194(6):728-32; discussion 732-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18005762</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2015 Jan;46(1):100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25267401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Surg. 1999 Oct;34(10 ):1453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10549746</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Surg. 2005 Nov-Dec;62(6):549-53, quiz 553</Citation><ArticleIdList><ArticleId IdType="pubmed">16293484</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Clin North Am. 1991 Apr;71(2):399-418</Citation><ArticleIdList><ArticleId IdType="pubmed">2003258</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2006 Oct;72(10):955-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17058744</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 2014 Mar;48(3):253-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24100750</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 1974 Mar;14(3):187-96</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2004 Nov;32(11):2234-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15640635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2010 Jul;69(1):84-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20622582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirurg. 1999 Nov;70(11):1269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">10591763</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2017 Jan;47(1):100-106</Citation><ArticleIdList><ArticleId IdType="pubmed">27559695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2007 Nov;28(5):544-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17607153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirurg. 1993 Jul;64(7):552-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8375206</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Surg. 2003 Apr;69(4):293-8; discussion 298-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12716086</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2002 Sep;137(9):1029-32; discussion 1032-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12215153</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Dec 22-29;270(24):2957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulus Travma Acil Cerrahi Derg. 2009 Jan;15(1):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19130330</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Biochem. 2003 Oct;36(7):529-35</Citation><ArticleIdList><ArticleId IdType="pubmed">14563446</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Protein Chem. 1994;45:89-151</Citation><ArticleIdList><ArticleId IdType="pubmed">8154375</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn Med. 1989 Aug;53(8):451-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2766714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 2002 Oct;239(1-2):227-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12479590</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 1996 Jul;22(7):707-10</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Res Hepatol Gastroenterol. 2015 Jun;39(3):373-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25683524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol. 2011 Apr;46(4):492-500</Citation><ArticleIdList><ArticleId IdType="pubmed">21298292</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Imaging. 2013 Sep-Oct;37(5):884-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23886598</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1996 Aug 15;318 ( Pt 1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8761444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Gastroenterol. 2009 Sep;43(8):727-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19359998</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1972 Jul 7;177(4043):56-8</Citation><ArticleIdList><ArticleId IdType="pubmed">5041774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Trauma. 2003 Feb;54(2):289-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12579054</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chim Acta. 2005 Feb;352(1-2):15-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15653098</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2013 Feb;39(1):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26814918</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Trauma Emerg Surg. 2014 Feb;40(1):75-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26815780</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2015 Feb;43(2):117-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25394241</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Lipid Res. 1996 Sep;35(3):243-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9082452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31008819</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-2291</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of orthopaedic trauma</Title><ISOAbbreviation>J Orthop Trauma</ISOAbbreviation></Journal><ArticleTitle>Early Immunologic Response in Multiply Injured Patients With Orthopaedic Injuries Is Associated With Organ Dysfunction.</ArticleTitle><Pagination><StartPage>220</StartPage><EndPage>228</EndPage><MedlinePgn>220-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOT.0000000000001437</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To quantify the acute immunologic biomarker response in multiply injured patients with axial and lower extremity fractures and to explore associations with adverse short-term outcomes including organ dysfunction and nosocomial infection (NI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Level 1 academic trauma center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive multiply injured patients, 18-55 years of age, with major pelvic and lower extremity orthopaedic injuries (all pelvic/acetabular fractures, operative femur and tibia fractures) that presented as a trauma activation and admitted to the intensive care unit from April 2015 through October 2016. Sixty-one patients met inclusion criteria.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Blood was collected upon presentation to the hospital and at the following time points: 8, 24, 48 hours, and daily during intensive care unit admission. Blood was processed by centrifugation, separation into 1.0-mL plasma aliquots, and cryopreserved within 2 hours of collection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASUREMENTS" NlmCategory="METHODS">Plasma analyses of protein levels of cytokines/chemokines were performed using a Luminex panel Bioassay of 20 immunologic mediators. Organ dysfunction was measured by the Marshall Multiple Organ Dysfunction score (MODScore) and nosocomial infection (NI) was recorded. Patients were stratified into low (MODS &#x2264; 4; n = 34) and high (MODS &gt; 4; n = 27) organ dysfunction groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The MODS &gt;4 group had higher circulating levels of interleukin (IL)-6, IL-8, IL-10, monocyte chemoattractant protein-1 (MCP-1), IL-1 receptor antagonist (IL-1RA), and monokine induced by interferon gamma (MIG) compared with the MODS &#x2264;4 group at nearly all time points. MODS &gt;4 exhibited lower levels of IL-21 and IL-22 compared with MODS &#x2264;4. Patients who developed NI (n = 24) had higher circulating concentrations of IL-10, MIG, and high mobility group box 1 (HMGB1) compared with patients who did not develop NI (n = 37).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Temporal quantification of immune mediators identified 8 biomarkers associated with greater levels of organ dysfunction in polytrauma patients with major orthopaedic injuries.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaski</LastName><ForeName>Greg E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessel</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutshall</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodovotz</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinley</LastName><ForeName>Todd O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Orthop Trauma</MedlineTA><NlmUniqueID>8807705</NlmUniqueID><ISSNLinking>0890-5339</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31008819</ArticleId><ArticleId IdType="doi">10.1097/BOT.0000000000001437</ArticleId><ArticleId IdType="pii">00005131-201905000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17215732</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5282</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>55</EndPage><MedlinePgn>44-54; discussion 54-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Near-infrared spectroscopy (NIRS) can continuously and noninvasively monitor tissue oxygen saturation (StO2) in muscle and may be an indicator of shock severity. Our purpose was to evaluate how well StO2 predicted outcome in high-risk torso trauma patients presenting in shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The primary outcome in this prospective study was multiple organ dysfunction syndrome (MODS). StO2 data were obtained upon hospital arrival and for 24 hours along with other known predictors of hypoperfusion and clinical outcomes. Clinicians were blinded to StO2 measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven Level I trauma centers enrolled 383 patients, 50 of whom developed MODS. Minimum StO2 performed similarly to maximum base deficit (BD) in discrimination of MODS patients. The sensitivity for both measures (StO2 cutoff = 75%; BD cutoff = 6 mEq/L) was 78%, the specificity was 34% to 39%, the positive predictive value was 18% to 20% and the negative predictive value was 88% to 91%. StO2 and BD were also comparable in predicting death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NIRS-derived muscle StO2 measurements perform similarly to BD in identifying poor perfusion and predicting the development of MODS or death after severe torso trauma, yet have the additional advantages of being continuous and noninvasive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Texas Health Science Center, San Antonio, Texas 78229, USA. cohn@uthscsa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathens</LastName><ForeName>Avery B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Puyana</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ernest E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Beilman</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><CollectiveName>StO2 in Trauma Patients Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012774" MajorTopicYN="N">Shock, Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17215732</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31802eb817</ArticleId><ArticleId IdType="pii">00005373-200701000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22069445</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>11</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients.</ArticleTitle><Pagination><StartPage>e25748</StartPage><MedlinePgn>e25748</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e25748</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0025748</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Depletion of the circulating actin-binding protein, plasma gelsolin (pGSN) has been described in critically ill surgical patients. We hypothesized that the extent of pGSN reduction might correlate with different outcome of burn patients. The study was performed to evaluate the prognostic implications of pGSN levels on the development of multiple organ dysfunction syndrome (MODS) and fatal outcome in a group of severely burn patients.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">95 patients were included, and they were divided into three groups with different burn area: group I (n&#x200a;=&#x200a;33), group II (n&#x200a;=&#x200a;32) and group III (n&#x200a;=&#x200a;30). According to whether there was development of MODS or not, patients were divided into MODS group (n&#x200a;=&#x200a;28) and none-MODS group (n&#x200a;=&#x200a;67); then the patients with MODS were further divided into non-survivor group (n&#x200a;=&#x200a;17) and survivor group (n&#x200a;=&#x200a;11). The peripheral blood samples were collected on postburn days (PBD) 1, 3, 7, 14, and 21. The levels of pGSN were determined and T cells were procured from the blood. The contents of cytokines (IL-2, IL-4 and IFN-&#x3b3;) released by T cells were also measured. The related factors of prognosis were analyzed by using multivariate logistic regression analysis. The results showed that pGSN concentrations, as well as the levels of IL-2 and IFN-&#x3b3;, decreased markedly on PBD 1-21, whereas, the levels of IL-4 increased markedly in all burn groups as compared with normal controls (P&lt;0.05 or P&lt;0.01), and there were obviously differences between group I and group III (P&lt;0.05 or P&lt;0.01). The similar results were found in MODS patients and the non-survivor group as compared with those without MODS and the survival group on days 3-21 postburn (P&lt;0.05 or P&lt;0.01). Moreover, as the pGSN levels decreased, the incidence of septic complication as well as MODS remarkably increased.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">pGSN levels appear to be an early prognostic marker in patients suffering from major burns.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-feng</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Burns Institute, First Hospital Affiliated to the Chinese PLA General Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Yong-ming</ForeName><Initials>YM</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jin-feng</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Ning</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Li-xin</ForeName><Initials>LX</Initials></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Zhi-yong</ForeName><Initials>ZY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018260">Gelsolin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018260" MajorTopicYN="N">Gelsolin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22069445</ArticleId><ArticleId IdType="pmc">PMC3206022</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0025748</ArticleId><ArticleId IdType="pii">PONE-D-11-07236</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Accardo-Palumbo A, D'Amelio L, Pileri D, D'Arpa N, Mogavero R, et al. Reduction of plasma granzyme acorrelates with severity of sepsis in burn patients. Burns. 2010;36:811&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20362398</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet F, Tissot S, Debard AL, Faudot C, Cramp&#xe9; C, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med. 2007;35:1910&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568330</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin AC, Kaschube M, Wieschaus EF. Pulsed contractions of an actin-myosin network drive apical constriction. Nature. 2009;457:495&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822715</ArticleId><ArticleId IdType="pubmed">19029882</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA. 1990;87:1381&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53479</ArticleId><ArticleId IdType="pubmed">2154744</ArticleId></ArticleIdList></Reference><Reference><Citation>Erukhimov JA, Tang ZL, Johnson BA, Donahoe MP, Razzack JA, et al. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Respir Crit Care Med. 2000;16:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">10903256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemric ME, Tracy PB, Haeberle JR. Caldesmon enhances the binding of myosin to the cytoskeleton during platelet activation. J Biol Chem. 1994;269:4125&#x2013;4128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottiez G, Haverland N, Ciborowski P. Mass spectrometric characterization of gelsolin isoforms. Rapid Commun Mass Spectrom. 2010;24:2620&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286873</ArticleId><ArticleId IdType="pubmed">20740538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferjani I, Fattoum A, Bettache N, Seantier B, Milhiet PE, et al. The gelsolin:calponin complex nucleates actin filaments with distinct morphologies. Biochem Biophys Res Commun. 2010;392:118&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035726</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, et al. Ca2+ binding by domain plays a critical role in the activation and stabilization of gelsolin. Proc Natl Acad Sci USA. 2009;106:13713&#x2013;13718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720848</ArticleId><ArticleId IdType="pubmed">19666512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucki R, Levental I, Kulakowska A, Janmey PA. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci. 2008;9:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">19075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Patel SR, Christiani DC, Bajwa E, Stossel TP, et al. Plasma gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS One. 2008;3:e3712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577888</ArticleId><ArticleId IdType="pubmed">19002257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest. 1986;78:736&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC423663</ArticleId><ArticleId IdType="pubmed">3018044</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol. 2004;96:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730154</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofidou-Solomidou M, Scherpereel A, Solomides CC, Muzykantov VR, Machtay M, et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung. 2002;180:91&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172902</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker PM, Kazi AA, Wadgaonkar R, Pearse DB, Kwiatkowski D, et al. Pulmonary vascular permeability and ischemic injury in gelsolin-deficient mice. Am J Respir Cell Mol Biol. 2003;28:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, et al. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007;35:849&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">17205019</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002;100:4367&#x2013;4371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006;243:399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1448930</ArticleId><ArticleId IdType="pubmed">16495706</ArticleId></ArticleIdList></Reference><Reference><Citation>Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med. 1999;160:1673&#x2013;1681.</Citation><ArticleIdList><ArticleId IdType="pubmed">10556139</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol. 2007;292:C1323&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135294</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997;25:594&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrentieva A, Kontakiotis T, Bitzani M, Papaioannou-Gaki G, Parlapani A, et al. Early coagulation disorders after severe burn injury: impact on mortality. Intensive Care Med. 2008;34:700&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">18193192</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LN, Nguyen TG. Characteristics and outcomes of multiple organ dysfunction syndrome among severe-burn patients. Burns. 2009;35:937&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">19553020</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwacha MG, Schneider CP, Chaudry IH. Differential expression and tissue compartmentalization of the inflammatory response following thermal injury. Cytokine. 2002;17:266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira FL, Bota DP, Bross A, M&#xe9;lot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594901</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28:776&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis TA, Stojadinovic A, Anam K, Amare M, Naik S, et al. Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int Wound J. 2009;6:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7951765</ArticleId><ArticleId IdType="pubmed">19291111</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JO, Shin SD, Kim J, Song KJ, Peck MD. Association between socioeconomic status and burn injury severity. Burns. 2009;35:482&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med. 1992;326:1335&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">1314333</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNubile MJ. Plasma gelsolin as a biomarker of inflammation. Arthritis Res Ther. 2008;10:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656232</ArticleId><ArticleId IdType="pubmed">19105851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PS, Bhan I, Thadhani R. The potential role of plasma gelsolin in dialysis-related protein-energy wasting. Blood Purif. 2010;29:99&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">20093811</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinardi L, Witke W. Gelsolin and diseases. Subcell Biochem. 2007;45:55&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">18193634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin&#x2013;actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis. 1988;138:429&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">2848430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengart MR, Arbabi S, Bauer GJ, Garcia I, Jelacic S, et al. The actin cytoskeleton: an essential component for enhanced TNFalpha production by adherent monocytes. Shock. 2002;17:109&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837785</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis. 1997;24:951&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry. 2005;44:9590&#x2013;9597.</Citation><ArticleIdList><ArticleId IdType="pubmed">16008344</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, et al. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Bio Chem. 2000;275:14573&#x2013;14578.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physio. 2004;96:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730154</ArticleId></ArticleIdList></Reference><Reference><Citation>Demling RH, Kramer G, Harms B. Role of thermal injury-induced hypoproteinemia on fluid flux and protein permeability in burned and nonburned tissue. Surgery. 1984;95:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6695330</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CH, James HJ, Ogle C, Fischer JE, Hasselgren PO. Influence of burn injury on protein metabolism in different types of skeletal muscle and the role of glucocorticoids. J Am Coll Surg. 1995;180:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">8000653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HH, Cheng BL, Chen QX, Wu SJ, Lv C, et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care. 2008;12:R106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575595</ArticleId><ArticleId IdType="pubmed">18706105</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LF, Yao YM, Dong N, Yu Y, He LX, et al. Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study. Crit Care. 2010;14:R3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875505</ArticleId><ArticleId IdType="pubmed">20064232</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LF, Yao YM, Zhang LT, Dong N, Yu Y, et al. The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats. Shock. 2009;31:322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">18665051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao YM, Sheng ZY, Huang LF. The effect of a novel cytokine, high mobility group box 1 protein, on the development of traumatic sepsis. Chin J Integr Med. 2009;15:13&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19271163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LT, Yao YM, Yao FH, Huang LF, Dong N, et al. Association between high-mobility group box-1 protein release and immune function of dendritic cells in thermal injury. J Interferon Cytokine Res. 2010;30:487&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">20233162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23979273</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>258</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>598</EndPage><MedlinePgn>591-6; discussion 596-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0b013e3182a4ea46</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our objective was to execute a prospective cohort study to determine relationships between plasma mtDNA DAMP levels and the occurrence of systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortality.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mitochondrial DNA damage-associated molecular patterns (DAMPs) accumulate in the circulation after severe injury. Observations in animal models demonstrate that mtDNA DAMPs contribute to organ dysfunction; however, the link between plasma mtDNA DAMPs and outcome in severely injured human subjects has not been established.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">DNA was isolated from plasma samples taken from severely injured patients at hospital days 0, 1, and 2. Real-time PCR was used to quantify selected &#x2248;200 base pair sequences of mtDNA within the COX1, ND1, and ND6 genes, as well as from the D-Loop transcriptional regulatory region. MODS was defined as a Denver Multiple Organ Failure score of 4 or greater.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MtDNA DAMPs were quantified as PCR threshold cycle number. Lower threshold cycles indicate increased mtDNA DAMP content. Patients with SIRS had significantly increased mtDNA DAMP levels in all 4 sequences examined (32.14 &#xb1; 0.90 vs 29.00 &#xb1; 1.15 for COX1, 31.90 &#xb1; 0.47 vs 30.16 &#xb1; 1.42 for ND1, 32.40 &#xb1; 0.61 vs 28.94 &#xb1; 1.13 for ND6, and 33.12 &#xb1; 0.83 vs 28.30 &#xb1; 1.14 for D-Loop). Patients who developed MODS also had elevated mtDNA DAMP levels compared with those who did not (32.57 &#xb1; 0.74 vs 27.12 &#xb1; 0.66 for COX1, 32.45 &#xb1; 0.65 vs 28.20 &#xb1; 0.73 for ND1, 32.52 &#xb1; 0.56 vs 27.60 &#xb1; 0.79 for ND6, and 32.85 &#xb1; 0.75 vs 27.86 &#xb1; 1.27 for D-Loop). Patients with above-median mtDNA DAMP levels had a significantly elevated relative risk for mortality. Four patients died secondary to severe MODS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings comprise the first observational evidence that plasma mtDNA DAMPs is associated with the evolution of SIRS, MODS, and mortality in severely injured human subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Departments of *Surgery &#x2020;Center for Lung Biology &#x2021;Pharmacology, University of South Alabama College of Medicine, Mobile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yann-Leei</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Mulekar</LastName><ForeName>Sujata</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kuck</LastName><ForeName>Jamie L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Brevard</LastName><ForeName>Sidney B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Gillespie</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>William O</ForeName><Initials>WO</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01812941</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL058234</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL113614</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL076125</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051545">Cyclooxygenase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="C496511">PTGS1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C507225">MT-ND6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="D009245">NADH Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C515075">NADH dehydrogenase subunit 1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051545" MajorTopicYN="N">Cyclooxygenase 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009245" MajorTopicYN="N">NADH Dehydrogenase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23979273</ArticleId><ArticleId IdType="mid">NIHMS554065</ArticleId><ArticleId IdType="pmc">PMC3935616</ArticleId><ArticleId IdType="doi">10.1097/SLA.0b013e3182a4ea46</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou Z, Daugherty WP, Sun D, et al. Protection of mitochondrial function and improvement in cognitive recovery in rats treated with hyperbaric oxygen following lateral fluid-percussion injury. J Neurosurg. 2007;106:687&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">17432723</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinbroum AA, Hochhauser E, Rudick V, et al. Multiple organ dysfunction after remote circulatory arrest: common pathway of radical oxygen species? J Trauma. 1999;47:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">10528603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Flaring U, Guillet C, et al. Muscle mitochondrial activity increases rapidly after an endotoxin challenge in human volunteers. Acta Anaesthesiol Scand. 2009;53:299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">19243315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Tjader I, Keller P, et al. Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. PLoS One. 2008;3:e3686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579334</ArticleId><ArticleId IdType="pubmed">18997871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson K, Rooyackers O. Mitochondrial function in sepsis: respiratory versus leg muscle. Crit Care Med. 2007;35:S449&#x2013;S53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17713392</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Kong RH, Zhang LM, et al. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol. 2012;167:699&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575772</ArticleId><ArticleId IdType="pubmed">23003569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843437</ArticleId><ArticleId IdType="pubmed">20203610</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko DV, Agostinis P, Krysko O, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011;32:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">21334975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Sursal T, Adibnia Y, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One. 2013;8:e59989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603956</ArticleId><ArticleId IdType="pubmed">23527291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sursal T, Stearns-Kurosawa DJ, Itagaki K, et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock. 2013;39:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537509</ArticleId><ArticleId IdType="pubmed">23247122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Itagaki K, Hauser CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock. 2010;34:55&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">19997055</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mehdi AB, Pastukh VM, Swiger BM, et al. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci Signal. 2012:5:ra47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3565837</ArticleId><ArticleId IdType="pubmed">22763339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastukh VM, Zhang L, Ruchko MV, et al. Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int J Chron Obstruct Pulmon Dis. 2011;6:209&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107697</ArticleId><ArticleId IdType="pubmed">21660298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, et al. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">1597042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94:514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19544</ArticleId><ArticleId IdType="pubmed">9012815</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishko V, Solomon M, Wilson GL, et al. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell pheno-types. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1300&#x2013;L1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">11350811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruchko MV, Gorodnya OM, Zuleta A, et al. The DNA glycosylase Ogg1 defends against oxidant-induced mtDNA damage and apoptosis in pulmonary artery endothelial cells. Free Radic Biol Med. 2011;50:1107&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033972</ArticleId><ArticleId IdType="pubmed">20969951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokolenko I, Venediktova N, Bochkareva A, et al. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37:2539&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677867</ArticleId><ArticleId IdType="pubmed">19264794</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouteau J, Gorodnya O, Ruchko M, et al. Novel fusion protein constructs targeting DNA repair enzymes to mitochondria protect against pseudomonas aeruginosa-induced acute lung injury in intact rats [Abstracts, 2011 ATS International Conference]. Am J Resp Crit Care Med. 2011;183:A3763.</Citation></Reference><Reference><Citation>Hill JK, Obiako B, Gorodnya O, et al. A positive feedback cycle involving oxidative mitochondrial (mt) DNA damage and mtDNA damage associated molecular patterns (DAMPs) contributes to bacteria-induced endothelial barrier dysfunction in isolated rat lungs. Am J Resp Crit Care Med. 2013;187:A4978.</Citation></Reference><Reference><Citation>Gill R, Ruan X, Menzel CL, et al. Systemic inflammation and liver injury following hemorrhagic shock and peripheral tissue trauma involve functional TLR9 signaling on bone marrow-derived cells and parenchymal cells. Shock. 2011;35:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000874</ArticleId><ArticleId IdType="pubmed">20577143</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds RD, Vodovotz Y, Lagoa C, et al. Transcriptomic response of murine liver to severe injury and hemorrhagic shock: a dual-platform microarray analysis. Physiol Genomics. 2011;43(20):1170&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3217328</ArticleId><ArticleId IdType="pubmed">21828244</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer R, Kobbe P, Darwiche SS, et al. Role of hemorrhage in the induction of systemic inflammation and remote organ damage: analysis of combined pseudo-fracture and hemorrhagic shock. J Orthop Res. 2011;29:270&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20690183</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587220</ArticleId><ArticleId IdType="pubmed">23401516</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczor CA, Snyder JW, Shokolenko IN, et al. Targeting repair proteins to the mitochondria of mammalian cells through stable transfection, transient transfection, viral transduction, and TAT-mediated protein transduction. Methods Mol Biol. 2009;554:233&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">19513678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson AW, Grishko V, LeDoux SP, et al. Enhanced mtDNA repair capacity protects pulmonary artery endothelial cells from oxidant-mediated death. Am J Physiol Lung Cell Mol Physiol. 2002;283:L205&#x2013;L210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12060578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachek LI, Thornley NP, Grishko VI, et al. Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes. 2006;55:1022&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567524</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczor CA, Shokolenko IN, Boyd AK, et al. Mitochondrial DNA damage initiates a cell cycle arrest by a Chk2-associated mechanism in mammalian cells. J Biol Chem. 2009;284:36191&#x2013;36201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794735</ArticleId><ArticleId IdType="pubmed">19840931</ArticleId></ArticleIdList></Reference><Reference><Citation>Druzhyna NM, Hollensworth SB, Kelley MR, et al. Targeting human 8-oxoguanine glycosylase to mitochondria of oligodendrocytes protects against menadione-induced oxidative stress. Glia. 2003;42:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730957</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachek LI, Grishko VI, Ledoux SP, et al. Role of nitric oxide-induced mtDNA damage in mitochondrial dysfunction and apoptosis. Free Radic Biol Med. 2006;40:754&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">16520228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouteau JM, Obiako B, Gorodnya OM, et al. Mitochondrial DNA integrity may be a determinant of endothelial barrier properties in oxidant-challenged rat lungs. Am J Physiol Lung Cell Mol Physiol. 2011;301:L892&#x2013;L898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233824</ArticleId><ArticleId IdType="pubmed">21890512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume M, Mouner M, Chouteau JM, et al. Mitochondrial-targeted DNA repair enzyme 8-oxoguanine DNA glycosylase 1 protects against ventilator-induced lung injury in intact mice. Am J Physiol Lung Cell Mol Physiol. 2013;304:L287&#x2013;L297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567361</ArticleId><ArticleId IdType="pubmed">23241530</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebb SA, Decoux A, Waggoner A, et al. Mitochondrial DNA damage mediates hyperoxic dysmorphogenesis in rat fetal lung explants. Neonatology. 2012;103:91&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568246</ArticleId><ArticleId IdType="pubmed">23154780</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia N, Chavez E. Mitochondrial DNA fragments released through the permeability transition pore correspond to specific gene size. Life Sci. 2007;81:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17870132</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40778219</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2364-7485</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Innovative surgical sciences</Title><ISOAbbreviation>Innov Surg Sci</ISOAbbreviation></Journal><ArticleTitle>Impact of different parameters on the outcome of vv-ECMO therapy in burn patients&#xa0;- a retrospective cohort study from a burn and high output ECMO center.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>80</EndPage><MedlinePgn>73-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/iss-2024-0024</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The treatment of acute respiratory distress syndrome (ARDS) in burn patients remains a major challenge. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) is a standard treatment for severe ARDS today. But reports on survival outcome in burn patients remain variable in the literature. The aim of this study is to identify factors that may influence survival and therapy outcomes in this distinct patient population.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A single-center retrospective study was conducted in the burn intensive care unit (BICU). Inclusion criteria were the use of vv-ECMO for ARDS after burn injuries. The data analyzed included general medical data and various parameters from the BICU.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Between January 2012 and December 2022, 21 consecutive adult patients were identified who underwent vv-ECMO treatment. Five patients (24&#x202f;%) survived the therapy and could be discharged, and 16 patients (76&#x202f;%) succumbed to their disease. A higher TBSA affected, lower pH in arterial blood gas analysis after 24 and 36&#x202f;h, multiorgan dysfunction syndrome (MODS), renal insufficiency, and renal replacement therapy were significantly associated with a lethal outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The data from the present study showed an overall mortality rate of 76&#x202f;%, which is unsatisfactory compared to the literature. This could be explained by complicating factors such as MODS, renal failure, and renal replacement therapy. However, the indication for vv-ECMO must be adapted to the individual situation of the respective patient. Due to the additional higher risk for complications, the utilization of ECMO therapy should be reserved for specialized burn centers with an interdisciplinary setting.</AbstractText><CopyrightInformation>&#xa9; 2024 the author(s), published by De Gruyter, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bingoel</LastName><ForeName>Alperen S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-4057-0318</Identifier><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Plastic Surgery, Department of Trauma, Orthopedic and Plastic Surgery, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation><Identifier Source="RINGGOLD">9177</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlottmann</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1423-3086</Identifier><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plinke</LastName><ForeName>Clarissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dastagir</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obed</LastName><ForeName>Doha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enechukwu</LastName><ForeName>Anieto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieck</LastName><ForeName>Thorben</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wellkamp</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanke</LastName><ForeName>Jasmin Sarah</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;hn</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhparwar</LastName><ForeName>Arjang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krezdorn</LastName><ForeName>Nicco</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Plastic and Breast Surgery, Sjaelland University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Innov Surg Sci</MedlineTA><NlmUniqueID>101708165</NlmUniqueID><ISSNLinking>2364-7485</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute inhalation injury</Keyword><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">burn surgery</Keyword><Keyword MajorTopicYN="N">burns</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">vv-ECMO</Keyword></KeywordList><CoiStatement>Competing interests: The authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40778219</ArticleId><ArticleId IdType="pmc">PMC12327721</ArticleId><ArticleId IdType="doi">10.1515/iss-2024-0024</ArticleId><ArticleId IdType="pii">iss-2024-0024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gu&#xe9;rin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159&#x2013;68. doi: 10.1056/nejmoa1214103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1214103</ArticleId><ArticleId IdType="pubmed">23688302</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107&#x2013;16. doi: 10.1056/nejmoa1005372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1005372</ArticleId><ArticleId IdType="pubmed">20843245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. J&#xa0;Am Med Assoc. 2016;315:788&#x2013;800. doi: 10.1001/jama.2016.0291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0291</ArticleId><ArticleId IdType="pubmed">26903337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam NN, Hung TD, Hung DK. Acute respiratory distress syndrome among severe burn patients in a developing country: application result of the berlin definition. Ann Burns Fire Disasters. 2018;31:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6116651</ArticleId><ArticleId IdType="pubmed">30174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva L, Garcia L, Oliveira B, Tanita M, Festti J, Cardoso L, et al. Acute respiratory distress syndrome in burn patients: incidence and risk factor analysis. Ann Burns Fire Disasters. 2016;29:178&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5266233</ArticleId><ArticleId IdType="pubmed">28149245</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng JY, Chien JY, Kao KC, Tsai CL, Hung FM, Lin FM, et al. Predictors of early onset multiple organ dysfunction in major burn patients with ventilator support: experience from a mass casualty explosion. Sci Rep. 2018;8:10939. doi: 10.1038/s41598-018-29158-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29158-3</ArticleId><ArticleId IdType="pmc">PMC6053465</ArticleId><ArticleId IdType="pubmed">30026512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004;202:145&#x2013;56. doi: 10.1002/path.1491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1491</ArticleId><ArticleId IdType="pubmed">14743496</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374:1351&#x2013;63. doi: 10.1016/s0140-6736(09)61069-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(09)61069-2</ArticleId><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Supady A, Taccone FS, Lepper PM, Ziegeler S, Staudacher DL, Supady A, et al. Survival after extracorporeal membrane oxygenation in severe COVID-19 ARDS: results from an International Multicenter Registry. Crit Care. 2021;25:90. doi: 10.1186/s13054-021-03486-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03486-9</ArticleId><ArticleId IdType="pmc">PMC7919616</ArticleId><ArticleId IdType="pubmed">33648538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossong H, Debreuil S, Yan W, Hiebert BM, Singal RK, Arora RC, et al. Long-term survival and quality of life after extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2022 doi: 10.1016/j.jtcvs.2021.10.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2021.10.077</ArticleId><ArticleId IdType="pubmed">35346489</ArticleId></ArticleIdList></Reference><Reference><Citation>Soussi S, Gallais P, Kachatryan L, Benyamina M, Ferry A, Cupaciu A, et al. Extracorporeal membrane oxygenation in burn patients with refractory acute respiratory distress syndrome leads to 28% 90-day survival. Intensive Care Med. 2016;42:1826&#x2013;7. doi: 10.1007/s00134-016-4464-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4464-7</ArticleId><ArticleId IdType="pubmed">27502609</ArticleId></ArticleIdList></Reference><Reference><Citation>Szentgyorgyi L, Shepherd C, Dunn KW, Fawcett P, Barker JM, Exton P, et al. Extracorporeal membrane oxygenation in severe respiratory failure resulting from burns and smoke inhalation injury. Burns. 2018;44:1091&#x2013;9. doi: 10.1016/j.burns.2018.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.01.022</ArticleId><ArticleId IdType="pubmed">29500117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu YJ, Ma H, Liao WC, Shih YC, Chen MC, Shih CC, et al. Extracorporeal membrane oxygenation support may be a lifesaving modality in patients with burn and severe acute respiratory distress syndrome: experience of Formosa Water Park dust explosion disaster in Taiwan. Burns. 2018;44:118&#x2013;23. doi: 10.1016/j.burns.2017.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.06.013</ArticleId><ArticleId IdType="pubmed">28756973</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HS, Yuan ZQ, Song HP, Luo QZ, Xiang F, Ma SY, et al. Clinical application of extracorporeal membrane oxygenation in the treatment of burn patients with acute respiratory distress syndrome: a retrospective analysis and systematic review. Zhonghua Shaoshang Zazhi. 2021;37:911&#x2013;20. doi: 10.3760/cma.j.cn501120-20210803-00266.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn501120-20210803-00266</ArticleId><ArticleId IdType="pmc">PMC11917227</ArticleId><ArticleId IdType="pubmed">34689460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosanov LB, McLawhorn MM, Vigiola Cruz M, Chen JH, Shupp JW. A national perspective on ECMO utilization use in patients with burn injury. J Burn Care Res. 2017;39:10&#x2013;4. doi: 10.1097/BCR.0000000000000555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000555</ArticleId><ArticleId IdType="pubmed">28368919</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant AA, Ghodsizad A, Ingram W. ECMO in the burn patient: the time has come. Curr Trauma Rep. 2019;5:154&#x2013;9. doi: 10.1007/s40719-019-00168-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40719-019-00168-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert S, Erdogan M, Green RS, Rasmussen J. The use of extracorporeal membrane oxygenation in severely burned patients: a survey of North American Burn Centers. J Burn Care Res. 2022;43:462&#x2013;7. doi: 10.1093/jbcr/irab103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/irab103</ArticleId><ArticleId IdType="pubmed">34091669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann Emerg Med. 1982;11:260&#x2013;2. doi: 10.1016/s0196-0644(82)80096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0196-0644(82)80096-6</ArticleId><ArticleId IdType="pubmed">7073049</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42:889&#x2013;96. doi: 10.1007/s00134-016-4273-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-016-4273-z</ArticleId><ArticleId IdType="pubmed">26942446</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Hajage D, Capellier G, Demoule A, Lavou&#xe9; S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute&#xa0;respiratory distress syndrome. N Engl J Med. 2018;378:1965&#x2013;75. doi: 10.1056/nejmoa1800385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1800385</ArticleId><ArticleId IdType="pubmed">29791822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Chenru W, Jiang Y, Hu L, Fang H, Zhu F, et al. Incidence and mortality of acute respiratory distress syndrome in patients with burns: a systematic review and meta-analysis. Front Med. 2021;8:709642. doi: 10.3389/fmed.2021.709642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.709642</ArticleId><ArticleId IdType="pmc">PMC8634659</ArticleId><ArticleId IdType="pubmed">34869410</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care. 2016;20:387. doi: 10.1186/s13054-016-1570-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1570-4</ArticleId><ArticleId IdType="pmc">PMC5125043</ArticleId><ArticleId IdType="pubmed">27890016</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Yuan Z, Peng Y, Luo G. Extracorporeal membrane oxygenation combined with continuous renal replacement therapy for the treatment of severe burns: current status and challenges. Burns Trauma. 2021;9:tkab017. doi: 10.1093/burnst/tkab017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/burnst/tkab017</ArticleId><ArticleId IdType="pmc">PMC8240511</ArticleId><ArticleId IdType="pubmed">34212063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball RL, Keyloun JW, Brummel-Ziedins K, Orfeo T, Palmieri TL, Johnson LS, et al. Burn-induced coagulopathies: a comprehensive review. Shock. 2020;54:154&#x2013;67. doi: 10.1097/shk.0000000000001484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/shk.0000000000001484</ArticleId><ArticleId IdType="pmc">PMC7439938</ArticleId><ArticleId IdType="pubmed">31804296</ArticleId></ArticleIdList></Reference><Reference><Citation>Gacto-Sanchez P. Surgical treatment and management of the severely burn patient: review and update. Med Intensiva. 2017;41:356&#x2013;64. doi: 10.1016/j.medin.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2017.02.008</ArticleId><ArticleId IdType="pubmed">28456441</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakupu A, Zhang J, Dong W, Song F, Dong J, Lu S. The epidemiological characteristic and trends of burns globally. BMC Publ Health. 2022;22:1596. doi: 10.1186/s12889-022-13887-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-13887-2</ArticleId><ArticleId IdType="pmc">PMC9396832</ArticleId><ArticleId IdType="pubmed">35996116</ArticleId></ArticleIdList></Reference><Reference><Citation>James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study. Inj Prev. 2020;26:i36&#x2013;45. doi: 10.1136/injuryprev-2019-043299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/injuryprev-2019-043299</ArticleId><ArticleId IdType="pmc">PMC7571358</ArticleId><ArticleId IdType="pubmed">31857422</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke CR, Chan T, McMullan DM. Extracorporeal life support use in adult burn patients. J Burn Care Res. 2017;38:174&#x2013;8. doi: 10.1097/bcr.0000000000000436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/bcr.0000000000000436</ArticleId><ArticleId IdType="pubmed">27606550</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkestad T, Brurberg KG, Nordhuus KM, Tveiten CK, Guttormsen AB, Os I, et al. Acute kidney injury in burn patients admitted to the intensive care unit: a systematic review and meta-analysis. Crit Care. 2020;24:2. doi: 10.1186/s13054-019-2710-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2710-4</ArticleId><ArticleId IdType="pmc">PMC6941386</ArticleId><ArticleId IdType="pubmed">31898523</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldredge RS, Zhai Y, Cochran A. Effectiveness of ECMO for burn-related acute respiratory distress syndrome. Burns. 2019;45:317&#x2013;21. doi: 10.1016/j.burns.2018.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.10.012</ArticleId><ArticleId IdType="pubmed">30429074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth CR, Dellavolpe J, Chung KK, Cancio LC, Mason P. Revisiting extracorporeal membrane oxygenation for ARDS in burns: a case series and review of the literature. Burns. 2018;44:1433&#x2013;8. doi: 10.1016/j.burns.2018.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.05.008</ArticleId><ArticleId IdType="pubmed">29903600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras M, Wagner JM, Wallner C, Huber J, Buchwald D, Strauch J, et al. Extracorporeal membrane oxygenation for acute respiratory distress syndrome in burn patients: a case series and literature update. Burns Trauma. 2019;7:28. doi: 10.1186/s41038-019-0166-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-019-0166-z</ArticleId><ArticleId IdType="pmc">PMC6824128</ArticleId><ArticleId IdType="pubmed">31696126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouch&#xe9; TW, Vrouwe SQ, Gottlieb LJ, Song TH, Mehta S, Tung A, et al. Extracorporeal membrane oxygenation utilization in burn patients with severe acute respiratory distress syndrome. Burns. 2023;49:244&#x2013;6. doi: 10.1016/j.burns.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9646255</ArticleId><ArticleId IdType="pubmed">36357253</ArticleId></ArticleIdList></Reference><Reference><Citation>Asmussen S, Maybauer DM, Fraser JF, Jennings K, George S, Keiralla A, et al. Extracorporeal membrane oxygenation in burn and smoke inhalation injury. Burns. 2013;39:429&#x2013;35. doi: 10.1016/j.burns.2012.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.08.006</ArticleId><ArticleId IdType="pubmed">23062623</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu YJ, Huang YC, Chen TW, King YA, Ma H. A systematic review and meta-analysis of extracorporeal membrane oxygenation in patients with burns. Plast Reconstr Surg. 2022;149:1181e&#x2013;90e. doi: 10.1097/prs.0000000000009149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/prs.0000000000009149</ArticleId><ArticleId IdType="pmc">PMC9150852</ArticleId><ArticleId IdType="pubmed">35426867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18789145</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Analysis of N-terminal pro-B-type natriuretic peptide and cardiac index in multiple injured patients: a prospective cohort study.</ArticleTitle><Pagination><StartPage>R118</StartPage><MedlinePgn>R118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc7013</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Increased serum B-type natriuretic peptide (BNP) has been identified for diagnosis and prognosis of impaired cardiac function in patients suffering from congestive heart failure, ischemic heart disease, and sepsis. However, the prognostic value of BNP in multiple injured patients developing multiple organ dysfunction syndrome (MODS) remains undetermined. Therefore, the aims of this study were to assess N-terminal pro-BNP (NT-proBNP) in multiple injured patients and to correlate the results with invasively assessed cardiac output and clinical signs of MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-six multiple injured patients presenting a New Injury Severity Score of greater than 16 points were included. The MODS score was calculated on admission as well as 24, 48, and 72 hours after injury. Patients were subdivided into groups: group A showed minor signs of organ dysfunction (MODS score less than or equal to 4 points) and group B suffered from major organ dysfunction (MODS score of greater than 4 points). Venous blood (5 mL) was collected after admission and 6, 12, 24, 48, and 72 hours after injury. NT-proBNP was determined using the Elecsys proBNP(R) assay. The hemodynamic monitoring of cardiac index (CI) was performed using transpulmonary thermodilution.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum NT-proBNP levels were elevated in all 26 patients. At admission, the serum NT-proBNP values were 116 +/- 21 pg/mL in group A versus 209 +/- 93 pg/mL in group B. NT-proBNP was significantly lower at all subsequent time points in group A in comparison with group B (P &lt; 0.001). In contrast, the CI in group A was significantly higher than in group B at all time points (P &lt; 0.001). Concerning MODS score and CI at 24, 48, and 72 hours after injury, an inverse correlation was found (r = -0.664, P &lt; 0.001). Furthermore, a correlation was found comparing MODS score and serum NT-proBNP levels (r = 0.75, P &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Serum NT-proBNP levels significantly correlate with clinical signs of MODS 24 hours after multiple injury. Furthermore, a distinct correlation of serum NT-proBNP and decreased CI was found. The data of this pilot study may indicate a potential value of NT-proBNP in the diagnosis of post-traumatic cardiac impairment. However, further studies are needed to elucidate this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Chlodwig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Sports Surgery, Klinikum Rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, D-81675 Munich, Germany. chlodwig.kirchhoff@mac.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leidel</LastName><ForeName>Bernd A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bogner</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Kreimeier</LastName><ForeName>Uwe</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Mutschler</LastName><ForeName>Wolf</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002302" MajorTopicYN="N">Cardiac Output</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002306" MajorTopicYN="N">Cardiac Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="Y">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18789145</ArticleId><ArticleId IdType="pmc">PMC2592747</ArticleId><ArticleId IdType="doi">10.1186/cc7013</ArticleId><ArticleId IdType="pii">cc7013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res. 2004;95:1140&#x2013;1153. doi: 10.1161/01.RES.0000150734.79804.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000150734.79804.92</ArticleId><ArticleId IdType="pubmed">15591236</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews L, Singh RK. Cardiac output monitoring. Ann Card Anaesth. 2008;11:56&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182765</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart D, Waxman K, Brown CA, Schuster R, Schuster L, Hvingelby EM, Kam K, Becerra S. B-type natriuretic peptide levels may be elevated in the critically injured trauma patient without congestive heart failure. J Trauma. 2007;63:747&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090000</ArticleId></ArticleIdList></Reference><Reference><Citation>Friese RS, Dineen S, Jennings A, Pruitt J, McBride D, Shafi S, Frankel H, Gentilello LM. Serum B-type natriuretic peptide: a marker of fluid resuscitation after injury? J Trauma. 2007;62:1346&#x2013;1350. discussion 1350&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">17563646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavoie A, Moore L, LeSage N, Liberman M, Sampalis JS. The Injury Severity Score or the New Injury Severity Score for predicting intensive care unit admission and hospital length of stay? Injury. 2005;36:477&#x2013;483. doi: 10.1016/j.injury.2004.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.09.039</ArticleId><ArticleId IdType="pubmed">15755427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Stegmaier J, Bogner V, Buhmann S, Mussack T, Kreimeier U, Mutschler W, Biberthaler P. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma. 2006;23:943&#x2013;949. doi: 10.1089/neu.2006.23.943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2006.23.943</ArticleId><ArticleId IdType="pubmed">16774478</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Peres Bota D, Melot C, Lopes Ferreira F, Nguyen Ba V, Vincent JL. The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med. 2002;28:1619&#x2013;1624. doi: 10.1007/s00134-002-1491-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-002-1491-3</ArticleId><ArticleId IdType="pubmed">12415450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakka SG, Meier-Hellmann A. Cardiac output measurements. J Cardiothorac Vasc Anesth. 1999;13:515&#x2013;517. doi: 10.1016/S1053-0770(99)90254-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1053-0770(99)90254-9</ArticleId><ArticleId IdType="pubmed">10468279</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, Hosoda K, Shirakami G, Suga S, Minamino N, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158:360&#x2013;368. doi: 10.1016/S0006-291X(89)80056-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(89)80056-7</ArticleId><ArticleId IdType="pubmed">2521788</ArticleId></ArticleIdList></Reference><Reference><Citation>James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275&#x2013;281. doi: 10.1161/01.CIR.0000079170.10579.DC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000079170.10579.DC</ArticleId><ArticleId IdType="pubmed">12847065</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161&#x2013;167. doi: 10.1056/NEJMoa020233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa020233</ArticleId><ArticleId IdType="pubmed">12124404</ArticleId></ArticleIdList></Reference><Reference><Citation>Boomsma F, Meiracker AH van den. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001;51:442&#x2013;449. doi: 10.1016/S0008-6363(01)00195-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-6363(01)00195-X</ArticleId><ArticleId IdType="pubmed">11476734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia M, Cooley A, Rimmer G, MacDonald T, Barber K, Manion P, Shapiro B, Socey J, Iddings D. The efficacy of B-type natriuretic peptide for early identification of blood loss in traumatic injury. Am J Surg. 2006;191:353&#x2013;357. doi: 10.1016/j.amjsurg.2005.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2005.10.033</ArticleId><ArticleId IdType="pubmed">16490546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996;40:501&#x2013;510. discussion 510&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614027</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30:1705&#x2013;1711. doi: 10.1097/00003246-200208000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200208000-00005</ArticleId><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertel W, Keel M, Marty D, Hoop R, Safret A, Stocker R, Trentz O. [Significance of systemic inflammation in 1,278 trauma patients] Unfallchirurg. 1998;101:520&#x2013;526. doi: 10.1007/s001130050304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001130050304</ArticleId><ArticleId IdType="pubmed">9739215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandil E, Burack J, Sawas A, Bibawy H, Schwartzman A, Zenilman ME, Bluth MH. B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg. 2008;143:242&#x2013;246. doi: 10.1001/archsurg.2007.69. discussion 246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2007.69</ArticleId><ArticleId IdType="pubmed">18347270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerbaul F, Giorgi R, Oddoze C, Collart F, Guidon C, Lejeune PJ, Villacorta J, Gouin F. High concentrations of N-BNP are related to non-infectious severe SIRS associated with cardiovascular dysfunction occurring after off-pump coronary artery surgery. Br J Anaesth. 2004;93:639&#x2013;644. doi: 10.1093/bja/aeh246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeh246</ArticleId><ArticleId IdType="pubmed">15347604</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8025996</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40549182</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Change in resuscitation influenced development and severity of inflammatory complications in severely injured.</ArticleTitle><Pagination><StartPage>232</StartPage><MedlinePgn>232</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">232</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-025-02905-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Resuscitation strategies for severely injured patients have shifted toward reduced crystalloids and increased balanced blood product resuscitation, including Fresh Frozen Plasma (FFP) to reduce organ failure and mortality. However, FFP is associated with higher infection and sepsis risks. This study investigated the impact of resuscitation changes on inflammatory complications and mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This 11-year cohort study included severely injured patients (&gt;&#x2009;15 years) admitted to a Level-1 Trauma Center ICU. Exclusions included isolated head injuries, drowning, asphyxiation, burns, and deaths&#x2009;&lt;&#x2009;48&#xa0;h. Data on demographics, resuscitation, inflammatory complications (MODS, ARDS, infections, thromboembolism), and mortality were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 585 patients (median age 46,72% male, ISS 29, 94% blunt injuries), 18% developed MODS, 3% ARDS, 45% infections, 9% thromboembolism, and 14% died. Over time, crystalloids&#x2009;&#x2264;&#x2009;24&#xa0;h decreased while FFP&#x2009;&#x2264;&#x2009;24&#xa0;h increased, correlating with reduced ARDS but increased thromboembolic events. Crystalloids&#x2009;&#x2264;&#x2009;24&#xa0;h independently predicted MODS, infections, and mortality, while FFP&#x2009;&#x2264;&#x2009;24&#xa0;h was linked to MODS and thromboembolism. Causes of death other than neurological included MODS (5%), sepsis (3%), and ARDS (1%), with no deaths from thromboembolic complications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Resuscitation evolved toward less crystalloids and more FFP&#x2009;&#x2264;&#x2009;24&#xa0;h, likely reducing ARDS but increasing thromboembolic complications, while other outcomes remained comparable. Low mortality from inflammatory complications suggests these complications were mild. The anti-inflammatory, immune-modulating effect of FFP might have played a role in the attenuation of these complications, supporting current resuscitation strategies. However, improved identification of patients who require FFPs may help reduce thromboembolism. In the future, optimal FFP dosage should be determined to balance coagulopathy correction, blood volume restoration, and management of the inflammatory response following trauma.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJP</Initials><Identifier Source="ORCID">0000-0002-1166-0990</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Suite G04.232, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. kwessem@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benders</LastName><ForeName>Kim E M</ForeName><Initials>KEM</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Suite G04.232, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LPH</Initials><Identifier Source="ORCID">0000-0001-8385-1801</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Suite G04.232, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hietbrink</LastName><ForeName>Falco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1462-6840</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Center Utrecht, Suite G04.232, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077324">Crystalloid Solutions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="Y">Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077324" MajorTopicYN="N">Crystalloid Solutions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="Y">Wounds and Injuries</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="Y">Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crystalloids</Keyword><Keyword MajorTopicYN="N">FFP</Keyword><Keyword MajorTopicYN="N">Inflammatory complications</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">Resuscitation</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent: This prospective observational study was approved by the local ethics committee (reference number WAG/mb/16/026664). Publication consent: Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40549182</ArticleId><ArticleId IdType="pmc">PMC12185553</ArticleId><ArticleId IdType="doi">10.1007/s00068-025-02905-8</ArticleId><ArticleId IdType="pii">10.1007/s00068-025-02905-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cotton BA, Reddy N, Hatch QM, LeFebvre E, Wade CE, Kozar RA, Gill BS, Albarado R, McNutt MK, Holcomb JB. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Ann Surg. 2011;254(4):598&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816774</ArticleId><ArticleId IdType="pubmed">21918426</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Benders KEM, Leenen LPH, Hietbrink F. TBI related death has become the new epidemic in polytrauma: a 10-year prospective cohort analysis in severely injured patients. Eur J Trauma Emerg Surg. 2024;50(6):3083&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11666694</ArticleId><ArticleId IdType="pubmed">39287678</ArticleId></ArticleIdList></Reference><Reference><Citation>LaGrone LN, Stein D, Cribari C, Kaups K, Harris C, Miller A, Smith Brian, Dutton R, Bulger E, Napolitano L. American Association for the Surgery of Trauma/American College of Surgeons Committee on trauma: clinical protocol for damage-control resuscitation for the adult trauma patient. J Trauma Acute Care Surg. 2024;96(3):510&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">37697470</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Weaver A, Gall L, West A, Nevin D, Tallach R, O&#x2019;Neill B, Lahiri S, Allard S, Tai N, Davenport R, Green L, Brohi K. A decade of damage control resuscitation: new transfusion practice, new survivors, new directions. Ann Surg. 2021;273(6):1215&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">31651535</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Attenuation of MODS-related and ARDS-related mortality makes infectious complications a remaining challenge in the severely injured. Trauma Surg Acute Care Open. 2020;5(1):e000398. 10.1136/tsaco-2019-000398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046953</ArticleId><ArticleId IdType="pubmed">32154377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning AC, Lansink KWW, van Wessem KJP, Balogh ZJ, Rivara FP, Maier RV, et al. Demographic patterns and outcomes of patients in level-1 trauma centers in three international trauma systems. World J Surg. 2015;39(11):2677&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4591196</ArticleId><ArticleId IdType="pubmed">26183375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, Tarrant SM, King KL, Balogh ZJ. Changes in the epidemiology and prediction of multiple-organ failure after injury. J Trauma Acute Care Surg. 2013;74(3):774&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23425734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DC, White A, Attia J, Tarrant SM, King KL, Balogh ZJ. Comparison of postinjury multiple-organ failure scoring systems: Denver versus sequential organ failure assessment. J Trauma Acute Care Surg. 2014;77:624&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25250605</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLS Advanced Trauma Life Support&#xae;. Student Course Manual. Tenth edition 2018. American College of Surgeons. ISBN:78-0-9968262-3-5.</Citation></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, et al. ARDS definition task force. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute setting. Am J Infect Control. 2008;36(5):309&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">18538699</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Surgeons. Guide for the prevention of surgical site infection. Bull Am Coll Surg. 2000;85(7):23&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11349547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole E, Davenport R, Willet K, Brohi K. The burden of infection in severely injured trauma patients and the relationship with admission shock severity. J Trauma Acute Care Surg. 2014;76:730&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24487318</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, McFadyen I, Scarborough M, et al. Fracture-related infection: a consensus on definition from an international expert group. Injury. 2018;49:505&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28867644</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM. /ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31(4):1250-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasotakis G, Sideris A, Yang Y, de Moya M, Alam H, King DR, et al. Inflammation and host response to injury investigators. Aggressive early crystalloid resuscitation adversely affects outcomes in adult blunt trauma patients: an analysis of the glue grant database. J Trauma Acute Care Surg. 2013;74(5):1215&#x2013;21. discussion 1221-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984883</ArticleId><ArticleId IdType="pubmed">23609270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mica L, Simmen H, Werner CM, Plecko M, Keller C, Wirth SH, Sprengel K. Fresh frozen plasma is permissive for systemic inflammatory response syndrome, infection, and sepsis in multiple-injured patients. Am J Emerg Med. 2016;34(8):1480&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27260556</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaba K, Branco BC, Rhee P, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg. 2010;210(6):957&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20510805</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, Cuschieri J, Maier RV, Billiar TR, Peitzman AB. Inflammation and host response to injury investigators. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma. 2009;67(2):221&#x2013;7. discussion 228&#x2013;&#x2009;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">19667872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozar RA, Peng Z, Zhang R, Holcomb JB, Pati S, Park P, Ko TC, Paredes A. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. Anesth Analg. 2011;112:1289&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102787</ArticleId><ArticleId IdType="pubmed">21346161</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Z, Pati S, Potter D, Brown R, Holcomb JB, Grill R, et al. Fresh frozen plasma lessens pulmonary endothelial inflammation and hyperpermeability after hemorrhagic shock and is associated with loss of syndecan 1. Shock. 2013;40:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3764452</ArticleId><ArticleId IdType="pubmed">23807246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Kamp VM, Pennings M, Oudijk EJ, Leenen LP, Ulfman LH, et al. Acute-phase concentrations of soluble fibrinogen inhibit neutrophil adhesion under flow conditions in vitro through interactions with ICAM-1 and MAC-1 (CD11b/CD18). J Thromb Haemost. 2013;11(6):1172&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23581432</ArticleId></ArticleIdList></Reference><Reference><Citation>Abt R, Lustenberger T, Stover JF, Benninger E, Lenzlinger PM, Stocker R, et al. Base excess determined within one hour of admission predicts mortality in patients with severe pelvic fractures and severe hemorrhagic shock. Eur J Trauma Emerg Surg. 2009;35(5):429.</Citation><ArticleIdList><ArticleId IdType="pubmed">26815208</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton LM, Arnow K, Trickey AW, Sauaia A, Knudson MM. Does Tranexamic acid increase venous thromboembolism risk among trauma patients? A prospective multicenter analysis across 17 level I trauma centers. Injury. 2023;54(11):111008. 10.1016/j.injury.2023.111008.</Citation><ArticleIdList><ArticleId IdType="pubmed">37669883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas L, Estroff J, Sparks A, Nahmias J, Allen R, Smith SR, Kutcher M, Carter K, Grigorian A, Albertson S, Turay D, Quispe JC, Luo-Owen X, Vella M, Pascual J, Tororello G, Quattrone M, Bernard A, Ratnasekera A, Lee A, Tamburrini D, Rodriguez C, Harrell K, Jeyamurugan K, Bugaev N, Warner A, Weinberger J, Hazelton JP, Selevany M, Wright F, Kovar A, Urban S, Hamrick A, Mount M, Carrick M, Cullinane DC, Chang G, Jain G, Spalding C, Sarani B. The incidence of venous thromboembolic events in trauma patients after Tranexamic acid administration: an EAST multicenter study. Blood Coagul Fibrinolysis. 2021;32(1):37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">33196508</ArticleId></ArticleIdList></Reference><Reference><Citation>Karl V, Thorn S, Mathes T, Hess S, Maegele M. Association of tranexamic acid administration with mortality and thromboembolic events in patients with traumatic injury: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(3):e220625. 10.1001/jamanetworkopen.2022.0625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889461</ArticleId><ArticleId IdType="pubmed">35230436</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers SP, Kutcher ME, Rosengart MR, Sperry JL, Peitzman AB, Brown JB, Neal MD. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019;86(1):20&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30239375</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg. 2004;240(3):490&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356439</ArticleId><ArticleId IdType="pubmed">15319720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichte P, Kobbe P, Almahmoud K, Pfeifer R, Andruszkow H, Hildebrand F, et al. Trauma register DGU. Post-traumatic thrombo-embolic complications in polytrauma patients. Int Orthop. 2015;39(5):947&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">25690923</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers SP, Brown JB, Leeper CM, Kutcher ME, Chen X, Wade CE, et al. PROPPR study group. Early versus late venous thromboembolism: a secondary analysis of data from the PROPPR trial. Surgery. 2019;166(3):416&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">31230842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zander AL, Olson EJ, Van Gent JM, Bandle J, Calvo RY, Shackford SR, et al. Does resuscitation with plasma increase the risk of venous thromboembolism? J Trauma Acute Care Surg. 2015;78(1):39&#x2013;43. discussion 43&#x2013;&#x2009;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25539201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jehan F, Zangbar B, Rafieezadeh A, Shnaydman I, Klein J, Con J, et al. Is there a need for fresh frozen plasma and platelet transfusion in trauma patients receiving submassive transfusion? Trauma Surg Acute Care Open. 2024;9(1):e001310. 10.1136/tsaco-2023-001310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11086383</ArticleId><ArticleId IdType="pubmed">38737815</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wessem KJP, Hietbrink F, Leenen LPH. Dilemma of crystalloid resuscitation in non-exsanguinating polytrauma: what is too much? Trauma Surg Acute Care Open. 2020;5(1):e000593. 10.1136/tsaco-2020-000593</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594544</ArticleId><ArticleId IdType="pubmed">33178897</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber K, Kornblith L, Cuschieri J. Balanced resuscitation: the role during non-massive hemorrhage. Trauma Surg Acute Care Open. 2024;9:e001486. 10.1136/tsaco-2024-001486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11110600</ArticleId><ArticleId IdType="pubmed">38779366</ArticleId></ArticleIdList></Reference><Reference><Citation>de Fraiture EJ, Bongers SH, Jukema BN, Koenderman L, Vrisekoop N, van Wessem KJP, Leenen LPH, Hietbrink F. Visualization of the inflammatory response to injury by neutrophil phenotype categories: neutrophil phenotypes after trauma. Eur J Trauma Emerg Surg. 2023;49(2):1023&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10175373</ArticleId><ArticleId IdType="pubmed">36348032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wafaisade A, Lefering R, Bouillon B, Sakka SG, Thamm OC, Paffrath T, Neugebauer E, Maegele M. Trauma registry of the German Society for Trauma Surgery. Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the trauma registry of the German Society for Trauma Surgery. Crit Care Med. 2011;39(4):621&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21242798</ArticleId></ArticleIdList></Reference><Reference><Citation>Spain DA, Richardson JD, Polk JC, et al. Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma. 1997;42:463&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095114</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18468416</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-2361</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie</Title><ISOAbbreviation>S Afr J Surg</ISOAbbreviation></Journal><ArticleTitle>Gastric trauma: a straightforward injury, but no room for complacency.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>13</EndPage><MedlinePgn>10-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Injuries to the stomach are common following abdominal trauma, and there are few management controversies. This study was undertaken to document experience with the management of gastric injuries in a single surgical ward in a tertiary institution.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This prospective study was of a cohort of all patients found at laparotomy to have gastric injuries, over a 7-year period (1998-2004). Demographic data, clinical presentation, findings at laparotomy, and outcomes were documented. Prophylactic antibiotics were given at induction of anaesthesia. All patients found to have gastric injuries were given antifungal therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 488 patients undergoing laparotomy for abdominal trauma over this period, 99 (20%) were found to have gastric injuries, of whom 6 were female (M:F ratio 14:1). The mean age (+/- standard deviation (SD)) was 28.9 +/- 11.1 years. Mean delay before surgery was 7.6 +/- 5.2 hours. Seventeen patients presented in shock. Injury mechanisms were firearms (52), stabbing (43) and blunt trauma (4). The mean injury severity score (ISS) was 13.6 +/- 7.4. Forty-two patients required management in the intensive care unit (ICU), with a mean ICU stay of 4.7 +/- 4.6 hours. Twenty-nine patients developed complications, and 14 died. There was only 1 gastric injury-related complication. Causes of death were multiple organ dysfunction syndrome (MODS) (8) and hypovolaemic shock (4), septic shock (1) and renal failure (1). Patients presenting in shock had a significantly higher mortality than those without shock (p&lt;0.0001). Delay before laparotomy did not influence outcome. There were 20 patients with isolated gastric injuries, none of whom died. Mean hospital stay was 8.8 +/- 7.7 days.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We reaffirm that stomach injuries are common following abdominal trauma. Isolated gastric injuries are uncommon. Complications specific to gastric injuries are uncommon but devastating. Mortality is related to associated injuries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madiba</LastName><ForeName>T E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of KwaZulu-Natal and King Edward VIII Hospital, Durban.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hlophe</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>South Africa</Country><MedlineTA>S Afr J Surg</MedlineTA><NlmUniqueID>2984854R</NlmUniqueID><ISSNLinking>0038-2361</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013270" MajorTopicYN="N">Stomach</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18468416</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33180830</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany.</ArticleTitle><Pagination><StartPage>e0242127</StartPage><MedlinePgn>e0242127</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0242127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0242127</ELocationID><Abstract><AbstractText Label="BACKGROUND">Reported mortality of hospitalised Coronavirus Disease-2019 (COVID-19) patients varies substantially, particularly in critically ill patients. So far COVID-19 in-hospital mortality and modes of death under state of the art care have not been systematically studied.</AbstractText><AbstractText Label="METHODS">This retrospective observational monocenter cohort study was performed after implementation of a non-restricted, dynamic tertiary care model at the University Medical Center Freiburg, an experienced acute respiratory distress syndrome (ARDS) and extracorporeal membrane-oxygenation (ECMO) referral center. All hospitalised patients with PCR-confirmed SARS-CoV-2 infection were included. The primary endpoint was in-hospital mortality, secondary endpoints included major complications and modes of death. A multistate analysis and a Cox regression analysis for competing risk models were performed. Modes of death were determined by two independent reviewers.</AbstractText><AbstractText Label="RESULTS">Between February 25, and May 8, 213 patients were included in the analysis. The median age was 65 years, 129 patients (61%) were male. 70 patients (33%) were admitted to the intensive care unit (ICU), of which 57 patients (81%) received mechanical ventilation and 23 patients (33%) ECMO support. Using multistate methodology, the estimated probability to die within 90 days after COVID-19 onset was 24% in the whole cohort. If the levels of care at time of study entry were accounted for, the probabilities to die were 16% if the patient was initially on a regular ward, 47% if in the intensive care unit (ICU) and 57% if mechanical ventilation was required at study entry. Age &#x2265;65 years and male sex were predictors for in-hospital death. Predominant complications-as judged by two independent reviewers-determining modes of death were multi-organ failure, septic shock and thromboembolic and hemorrhagic complications.</AbstractText><AbstractText Label="CONCLUSION">In a dynamic care model COVID-19-related in-hospital mortality remained very high. In the absence of potent antiviral agents, strategies to alleviate or prevent the identified complications should be investigated. In this context, multistate analyses enable comparison of models-of-care and treatment strategies and allow estimation and allocation of health care resources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rieg</LastName><ForeName>Siegbert</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7493-7080</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Cube</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalbhenn</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utzolino</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pernice</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Heart Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechet</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baur</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Corinna N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolkewitz</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Winfried V</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biever</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Angiology I, Heart Center Freiburg University, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID UKF Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063128" MajorTopicYN="N">Tertiary Healthcare</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>12</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33180830</ArticleId><ArticleId IdType="pmc">PMC7660518</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0242127</ArticleId><ArticleId IdType="pii">PONE-D-20-25207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020. March 28;395(10229):1054&#x2013;62. 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020. June;20(6):669&#x2013;77. 10.1016/S1473-3099(20)30243-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30243-7</ArticleId><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020. May 22;369:m1985 10.1136/bmj.m1985</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020. May 22;369:m1966 10.1136/bmj.m1966</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020. April 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld S, Caridi-Scheible M, Blum JM, Robichaux CJ, Kraft CS, Jacob JT et al. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv 2020. April 26 10.1101/2020.04.23.20076737</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.23.20076737</ArticleId><ArticleId IdType="pmc">PMC7255393</ArticleId><ArticleId IdType="pubmed">32452888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK et al. Covid-19 in Critically Ill Patients in the Seattle Region&#x2014;Case Series. N Engl J Med 2020. May 21;382(21):2012&#x2013;22. 10.1056/NEJMoa2004500</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2004500</ArticleId><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020. June 6;395(10239):1763&#x2013;70. 10.1016/S0140-6736(20)31189-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31189-2</ArticleId><ArticleId IdType="pmc">PMC7237188</ArticleId><ArticleId IdType="pubmed">32442528</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020. April 6 10.1001/jama.2020.5394</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020. May;8(5):475&#x2013;81. 10.1016/S2213-2600(20)30079-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012. June 20;307(23):2526&#x2013;33. 10.1001/jama.2012.5669</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L et al. Extracorporeal Life Support Organization COVID-19 Interim Guidelines. ASAIO J 2020. April 29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228451</ArticleId><ArticleId IdType="pubmed">32604322</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002. April;11(2):91&#x2013;115. 10.1191/0962280202SM276ra</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0962280202SM276ra</ArticleId><ArticleId IdType="pubmed">12040698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazard D, Kaier K, von CM, Grodd M, Bugiera L, Lambert J et al. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. BMC Med Res Methodol 2020. August 11;20(1):206 10.1186/s12874-020-01082-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-01082-z</ArticleId><ArticleId IdType="pmc">PMC7507941</ArticleId><ArticleId IdType="pubmed">32781984</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Taccone FS. Understanding pathways to death in patients with COVID-19. Lancet Respir Med 2020. May;8(5):430&#x2013;2. 10.1016/S2213-2600(20)30165-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30165-X</ArticleId><ArticleId IdType="pmc">PMC7270480</ArticleId><ArticleId IdType="pubmed">32272081</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020. May 2;395(10234):1417&#x2013;8. 10.1016/S0140-6736(20)30937-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020. June;46(6):1105&#x2013;8. 10.1007/s00134-020-06059-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06059-6</ArticleId><ArticleId IdType="pmc">PMC7186535</ArticleId><ArticleId IdType="pubmed">32347323</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020. April 22 10.1111/jth.14869</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14869</ArticleId><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med 2020. May 6 10.7326/M20-2003</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-2003</ArticleId><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M, Benjamin L, Singh B, et al. Neurological Associations of COVID-19. The Lancet Neurology 2020. 10.2139/ssrn.3589350</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3589350</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Severac F, Merdji H, Angles-Cano E, Meziani F. Prothrombotic phenotype in COVID-19 severe patients. Intensive Care Med 2020. May 20 10.1007/s00134-020-06082-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06082-7</ArticleId><ArticleId IdType="pmc">PMC7237619</ArticleId><ArticleId IdType="pubmed">32435823</ArticleId></ArticleIdList></Reference><Reference><Citation>London AJ, Kimmelman J. Against pandemic research exceptionalism. Science 2020. May 1;368(6490):476&#x2013;7. 10.1126/science.abc1731</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1731</ArticleId><ArticleId IdType="pubmed">32327600</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha GS, Paneru HR, Vincent JL. Precision medicine for COVID-19: a call for better clinical trials. Crit Care 2020. June 2;24(1):282 10.1186/s13054-020-03002-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03002-5</ArticleId><ArticleId IdType="pmc">PMC7266425</ArticleId><ArticleId IdType="pubmed">32487260</ArticleId></ArticleIdList></Reference><Reference><Citation>von Cube M, Grodd M, Wolkewitz M, Hazard D, Lambert J. Harmonizing heterogeneous endpoints in COVID-19 trials without loss of information&#x2014;an essential step to facilitate decision making. medRxiv 2020. January 1;2020.</Citation></Reference><Reference><Citation>Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. The Lancet Infectious Diseases 2020. 10.1016/S1473-3099(20)30483-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med 2020. May 21;382(21):2049&#x2013;55. 10.1056/NEJMsb2005114</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2005114</ArticleId><ArticleId IdType="pubmed">32202722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40314767</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Absolute lymphocyte count trajectory predicts clinical outcome in severely injured patients.</ArticleTitle><Pagination><StartPage>190</StartPage><MedlinePgn>190</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-025-02864-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Lymphopenia is associated with adverse clinical outcome in trauma, but no immunomonitoring method is established to identify patients at risk. Absolute lymphocyte count (ALC) represents a promising biomarker and may support clinical decision-making in the intensive care unit (ICU). This study examined the temporal patterns of ALC in severely injured patients and their correlation with clinical outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">38 severely injured patients with an Injury Severity Score (ISS) of 18 and greater were enrolled. Blood samples were collected on admission and after 8, 24 and 48&#xa0;h and 5 and 10 days. 38 healthy volunteers served as controls. Patients were classified into four groups after 48&#xa0;h based on their dynamic ALC: persistent lymphopenia (PL), rapidly decreasing (RD), slowly rising (SR) and normal fluctuation (NF). The groups were compared regarding physical performative outcome - defined as unfavorable when patients died or new functional disability necessitated long term care, in-hospital mortality, ICU length of stay (LOS), and incidence of multi-organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A significant reduction in ALC was observed in all patients over 10 days when compared to healthy volunteers, with all patients trending towards a recovery of their ALC after 10 days. PL and RD were associated with an unfavorable physical performative outcome, increased in-hospital mortality, ICU LOS and incidence of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The dynamic course of ALC represents a cheap and clinically implementable approach for immunomonitoring within 48&#xa0;h in severely injured patients. The ALC dynamic may early identify severely injured patients at risk, thus facilitating more informed clinical decision-making.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Reichardt</LastName><ForeName>Lena-Marie</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0009-0005-6957-5173</Identifier><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hindelang</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0007-0274-5443</Identifier><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xfc;berkr&#xfc;b</LastName><ForeName>L&#xf6;nna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamberger</LastName><ForeName>Kim Lena</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graw</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-6920-8868</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuetze</LastName><ForeName>Konrad</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6607-2539</Identifier><AffiliationInfo><Affiliation>Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zechendorf</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3662-9102</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care and Intermediate Care, University Hospital of the Rheinisch-Westf&#xe4;lische Technische Hochschule Aachen, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mannes</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halbgebauer</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8060-2076</Identifier><AffiliationInfo><Affiliation>Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wohlgemuth</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1968-9007</Identifier><AffiliationInfo><Affiliation>Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebhard</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0000-3279-8633</Identifier><AffiliationInfo><Affiliation>Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber-Lang</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2359-6516</Identifier><AffiliationInfo><Affiliation>Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relja</LastName><ForeName>Borna</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5625-8823</Identifier><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Christian B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-4390-4248</Identifier><AffiliationInfo><Affiliation>Translational and Experimental Trauma Research, Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany. christian.bergmann@uniklinik-ulm.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany. christian.bergmann@uniklinik-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="Y">Lymphopenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="Y">Wounds and Injuries</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunomonitoring</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Lymphocyte count</Keyword><Keyword MajorTopicYN="N">Lymphopenia</Keyword><Keyword MajorTopicYN="N">Severely injured patients</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>2</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>2</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>2</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40314767</ArticleId><ArticleId IdType="pmc">PMC12048453</ArticleId><ArticleId IdType="doi">10.1007/s00068-025-02864-0</ArticleId><ArticleId IdType="pii">10.1007/s00068-025-02864-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, regional, and National Cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted life-Years for 29 Cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749&#x2013;68. 10.1001/jamaoncol.2019.2996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6777271</ArticleId><ArticleId IdType="pubmed">31560378</ArticleId></ArticleIdList></Reference><Reference><Citation>Venet F, Textoris J, Blein S, et al. Immune profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury. Crit Care Med. 2022;50(4):565&#x2013;75. 10.1097/CCM.0000000000005270.</Citation><ArticleIdList><ArticleId IdType="pubmed">34534131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Schmieg RE, Swanson PE, et al. Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. Crit Care Med. 2000;28(9):3207&#x2013;17. 10.1097/00003246-200009000-00016.</Citation><ArticleIdList><ArticleId IdType="pubmed">11008984</ArticleId></ArticleIdList></Reference><Reference><Citation>Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLOS Med. 2018;15(11):e1002685. 10.1371/journal.pmed.1002685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211632</ArticleId><ArticleId IdType="pubmed">30383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulliamy PE, Perkins ZB, Brohi K, Manson J. Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients. Eur J Trauma Emerg Surg Off Publ Eur Trauma Soc. 2016;42(6):755&#x2013;60. 10.1007/s00068-015-0585-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">26501197</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardot T, Rimmel&#xe9; T, Venet F, Monneret G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis Int J Program Cell Death. 2017;22(2):295&#x2013;305. 10.1007/s10495-016-1325-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27812767</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell B, Budreau D, Williams-Perez S, Chakravarty S, Galet C, McGonagill P. Admission lymphopenia predicts infectious complications and mortality in traumatic brain injury victims. Shock. 2022;57(2):189&#x2013;98. 10.1097/SHK.0000000000001872.</Citation><ArticleIdList><ArticleId IdType="pubmed">34618726</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Cole E, De&#x2019;Ath HD, et al. Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Crit Care Lond Engl. 2016;20(1):176. 10.1186/s13054-016-1341-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4895987</ArticleId><ArticleId IdType="pubmed">27268230</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock Augusta Ga. 2014;42(5):383&#x2013;91. 10.1097/SHK.0000000000000234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362626</ArticleId><ArticleId IdType="pubmed">25051284</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffernan DS, Monaghan SF, Thakkar RK, Machan JT, Cioffi WG, Ayala A. Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern. Crit Care. 2012;16(1):R12. 10.1186/cc11157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396248</ArticleId><ArticleId IdType="pubmed">22264310</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei F, Song W, Wang L, et al. Lymphocyte trajectories are associated with prognosis in critically ill patients: A convenient way to monitor immune status. Front Med. 2022;9. 10.3389/fmed.2022.953103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9386077</ArticleId><ArticleId IdType="pubmed">35991659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Wang C, Liu X, Bai X, Li Z. The trajectory of alterations in Immune-Cell counts in Severe-Trauma patients is related to the later occurrence of Sepsis and mortality: retrospective study of 917 cases. Front Immunol. 2021;11:603353. 10.3389/fimmu.2020.603353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820769</ArticleId><ArticleId IdType="pubmed">33488604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini JD, De AK, Kodys K, Puyana JC, Furse RK, Miller-Graziano C. Relationships between T lymphocyte apoptosis and anergy following trauma. J Surg Res. 2000;88(2):200&#x2013;6. 10.1006/jsre.1999.5797.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644489</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang TD, Chen D, Luo JL, et al. The different paradigms of NK cell death in patients with severe trauma. Cell Death Dis. 2024;15(8):1&#x2013;14. 10.1038/s41419-024-06992-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11339281</ArticleId><ArticleId IdType="pubmed">39168979</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermans K, Kox M, Vaneker M, et al. Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med. 2016;42(4):551&#x2013;61. 10.1007/s00134-015-4205-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5413532</ArticleId><ArticleId IdType="pubmed">26912315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and damps: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249(1):158&#x2013;75. 10.1111/j.1600-065X.2012.01146.x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662247</ArticleId><ArticleId IdType="pubmed">22889221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao F, He R, Huang Y et al. Changes of the blood lymphocytes on severe trauma patients in early time: A Retrospective Cohort Study.</Citation></Reference><Reference><Citation>Li M, Yao D, Zeng X, et al. Age related human T cell subset evolution and senescence. Immun Ageing. 2019;16(1):24. 10.1186/s12979-019-0165-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739976</ArticleId><ArticleId IdType="pubmed">31528179</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin GD. The injured brain: TBI, mTBI, the immune system, and infection: connecting the Dots. Mil Med. 2011;176(4):364&#x2013;8. 10.7205/MILMED-D-10-00021.</Citation><ArticleIdList><ArticleId IdType="pubmed">21539156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JW, Li JP, Song YL, Zhao QH. Humoral and cellular immunity changed after traumatic brain injury in human patients. 2017;47(1).</Citation><ArticleIdList><ArticleId IdType="pubmed">28249910</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher NE, D&#x2019;Este C, Balogh ZJ. The quest for a universal definition of polytrauma: a trauma registry-based validation study. J Trauma Acute Care Surg. 2014;77(4):620&#x2013;3. 10.1097/TA.0000000000000404.</Citation><ArticleIdList><ArticleId IdType="pubmed">25250604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nienaber U. TraumaRegister_DGU TR-DGU-Jahresbericht_2023. Published online 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19448210</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-7598</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Anesthesia and analgesia</Title><ISOAbbreviation>Anesth Analg</ISOAbbreviation></Journal><ArticleTitle>Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis.</ArticleTitle><Pagination><StartPage>1841</StartPage><EndPage>1847</EndPage><MedlinePgn>1841-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1213/ane.0b013e318195e11d</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although detailed analyses of the postmortem findings of various critically ill patient groups have been published, no such study has been performed in patients with sepsis. In this retrospective cohort study, we reviewed macroscopic postmortem examinations of surgical intensive care unit (ICU) patients who died from sepsis or septic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between 1997 and 2006, the ICU database and autopsy register were reviewed for patients who were admitted to the ICU because of sepsis/septic shock, or who developed sepsis/septic shock at a later stage during their ICU stay and subsequently died from of sepsis/septic shock. Clinical data and postmortem findings were documented in all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Postmortem results of 235 patients (84.8%) were available for statistical analysis. The main causes of death as reported in the patient history were refractory multiple organ dysfunction syndrome (51.5%) and uncontrollable cardiovascular failure (35.3%). Pathologies were detected in the lungs (89.8%), kidneys/urinary tract (60%), gastrointestinal tract (54%), cardiovascular system (53.6%), liver (47.7%), spleen (33.2%), central nervous system (18.7%), and pancreas (8.5%). In 180 patients (76.6%), the autopsy revealed a continuous septic focus. The most common continuous foci were pneumonia (41.3%), tracheobronchitis (28.9%), peritonitis (23.4%), uterine/ovarial necrosis (9.8% of female patients), intraabdominal abscesses (9.1%), and pyelonephritis (6%). A continuous septic focus was observed in 63 of the 71 patients (88.7%) who were admitted to the ICU because of sepsis/septic shock and treated for longer than 7 days.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Relevant postmortem findings explaining death in surgical ICU patients who died because of sepsis/septic shock were a continuous septic focus in approximately 80% and cardiac pathologies in 50%. The most frequently affected organs were the lungs, abdomen, and urogenital tract. More diagnostic, therapeutic and scientific efforts should be launched to identify and control the infectious focus in patients with sepsis and septic shock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torgersen</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. christian.torgersen@i-med.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Luckner</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mayr</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Jochberger</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hasibeder</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>D&#xfc;nser</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesth Analg</MedlineTA><NlmUniqueID>1310650</NlmUniqueID><ISSNLinking>0003-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anesth Analg. 2009 Jun;108(6):1731-3. doi: 10.1213/ane.0b013e3181a16554.</RefSource><PMID Version="1">19448193</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="Y">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014551" MajorTopicYN="N">Urinary Tract</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19448210</ArticleId><ArticleId IdType="doi">10.1213/ane.0b013e318195e11d</ArticleId><ArticleId IdType="pii">108/6/1841</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19054512</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Elevated systemic IL-18 and neopterin levels are associated with posttraumatic complications among patients with multiple injuries: a prospective cohort study.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>534</EndPage><MedlinePgn>528-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2008.08.007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Posttraumatic systemic inflammatory response syndrome (SIRS), sepsis and their subsequent complication, the multiple-organ dysfunction syndrome (MODS), remain major complications following polytrauma. This prospective clinical study aimed at evaluating the association between these and plasma interleukin-18 (IL-18) and neopterin levels.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Inclusion in the series required an Injury Severity Score (ISS) &gt;16, age 16-65 years, admission within 6 h of the accident and survival &gt;48 h; 55 patients were enrolled. Over 14 days, plasma neopterin and IL-18 levels and the clinical course regarding MODS, SIRS and sepsis were recorded daily using the Marshall Score for MODS and the ACCP/SCCM criteria for SIRS and sepsis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neopterin and IL-18 plasma levels were increased in +MODS cases as compared with -MODS cases over almost the entire observation period. IL-18 concentrations over days 3-6 were significantly increased among participants with sepsis. These increases were all apparent 2-3 days before the clinical diagnosis of sepsis or MODS was made. In contrast, no significant differences in neopterin and IL-18 plasma levels were observed between participants with and without SIRS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Determinations of neopterin and IL-18 concentrations might represent early markers for posttraumatic complications such as MODS and sepsis. They might help to differentiate between SIRS and sepsis and thereby guide the timing of the surgery for polytrauma. Neopterin and IL-18 levels should be used together with the clinical status and other inflammatory markers (IL-6, IL-8, etc.) for prediction of posttraumatic complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mommsen</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trauma Department, Hanover Medical School, Carl-Neuberg-Strasse 1, 30625 Hanover, Germany. mommsen.philipp@mh-hannover.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frink</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gaulke</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020382" MajorTopicYN="N">Interleukin-18</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19054512</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2008.08.007</ArticleId><ArticleId IdType="pii">S0020-1383(08)00386-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20819508</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin Med J (Engl)</ISOAbbreviation></Journal><ArticleTitle>Effects of traditional Chinese medicine on intestinal mucosal permeability in early phase of severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>1537</StartPage><EndPage>1542</EndPage><MedlinePgn>1537-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional Chinese medicine has been used widely for many years in China to treat acute pancreatitis. We have investigated the effects of Dachengqi decoction on intestinal mucosal permeability and outcome in patients with severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty patients with sustained SAP that required admission to the surgical intensive care unit were enrolled prospectively in the study. All of these patients were divided randomly into the Dachengqi decoction group (n = 20) and control group (n = 20) on admission. Intestinal permeability was assessed by measuring absorption of two metabolically inert markers, lactulose (L) and mannitol (M), which were administered orally. Serum concentrations of endotoxin (lipopolysaccharide, LPS) and the ratio of lactulose to mannitol in urine (L/M) were detected in all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with those in the control group, urinary L/M ratio decreased significantly in the Dachengqi decoction group on the 7th day after admission (P = 0.001). Also, serum concentrations of LPS were reduced on the 5th and 7th day after admission (P = 0.006, P = 0.008, respectively). Incidence of multiple organ dysfunction syndrome (MODS) and pancreatic infection was significantly lower in the Dachengqi decoction group compared with those in the control group (P = 0.038,P = 0.025, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dachengqi decoction may promote the recovery of intestinal mucosal permeability and decrease the incidence of MODS and pancreatic infection in patients with SAP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuan Wu Hospital of Capital Medical University, Beijing 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Jian-guo</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Diao</LastName><ForeName>Yong-peng</ForeName><Initials>YP</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zong-xin</ForeName><Initials>ZX</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jia-bang</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20819508</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19741387</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Preinjury statin use is associated with a higher risk of multiple organ failure after injury: a propensity score adjusted analysis.</ArticleTitle><Pagination><StartPage>476</StartPage><EndPage>484</EndPage><MedlinePgn>476-82; discussion 482-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e3181ad66bb</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies suggest that statin use may improve outcome in critically ill patients. This has been attributed to the pleiomorphic effect and modulation of inflammatory mediators that occurs with statin use. We sought to determine whether preinjury statin (PIS) use was associated with improved outcome in severely injured blunt trauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were obtained from a multicenter prospective cohort study evaluating outcomes in blunt injured adults with hemorrhagic shock. Patients aged 55 years and older were analyzed. Those with isolated traumatic brain injury, cervical cord injury, and those who survived &lt;24 hours were excluded. A propensity score predicting statin use was created using logistic regression. Cox proportional hazard regression was then used to evaluate the effects of PIS use on mortality and the development of multiple organ failure (MOF, multiple organ dysfunction syndrome &gt;5) and nosocomial infection (NI) after adjusting for important injury characteristics and the propensity of taking PISs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall mortality and MOF rates for the study cohort (n = 295) were 21% and 50%, respectively. Over 24% of patients (n = 71) reported PIS use. Kaplan-Meier analysis revealed no difference in NI or mortality over time but did show a significant higher incidence of MOF in those with PIS use (p = 0.04). Regression analysis verified PIS was independently associated with an 80% higher risk of MOF (hazard ratio: 1.8; 95% confidence interval, 1.1-2.9) and was found to be one of the strongest independent risk factors for the development of MOF.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PIS use was independently associated with a higher risk of MOF postinjury. These results are contrary to previous analyses. The protective effect of statins may be lost in the severely injured, and modulation of the inflammatory response may result in higher morbidity. Further studies are required to better understand the impact and potential therapeutic utility of this commonly prescribed medication both before and after injury.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cushieri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rosengart</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Alarcon</LastName><ForeName>Louis H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ernest E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Ronald V</ForeName><Initials>RV</Initials></Author><Author ValidYN="Y"><LastName>Minei</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Peitzman</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Sperry</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><CollectiveName>Inflammation and Host Response to Injury Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR024154</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM062119</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM062119-1</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024154-03</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19741387</ArticleId><ArticleId IdType="mid">NIHMS568470</ArticleId><ArticleId IdType="pmc">PMC4004067</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e3181ad66bb</ArticleId><ArticleId IdType="pii">00005373-200909000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med. 2006;260:305&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">16961668</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TM, Harken AH. Statins for surgical patients. Ann Surg. 2008;247:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18156920</ArticleId></ArticleIdList></Reference><Reference><Citation>Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006;32:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">16283159</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger PS. Statins: the next anti-endotoxin. Crit Care Resusc. 2006;8:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">16930109</ArticleId></ArticleIdList></Reference><Reference><Citation>Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;33:1352&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11565076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005;6:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199623</ArticleId><ArticleId IdType="pubmed">16042797</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34:1080&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">16484926</ArticleId></ArticleIdList></Reference><Reference><Citation>Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis. 2006;6:242&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554249</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumerie G, Fleisher LA. Perioperative beta-blocker and statin therapy. Curr Opin Anaesthesiol. 2008;21:60&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195612</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333:999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635620</ArticleId><ArticleId IdType="pubmed">17060337</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron DT, Sorock G, Haut ER, et al. Preinjury statin use is associated with improved in-hospital survival in elderly trauma patients. J Trauma. 2008;64:66&#x2013;73. discussion 73-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18188101</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier RV, Bankey P, McKinley B, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core&#x2014;standard operating procedures for clinical care. Fore-ward. J Trauma. 2005;59:762&#x2013;763.</Citation></Reference><Reference><Citation>Moore FA, McKinley BA, Moore EE, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core&#x2014;standard operating procedures for clinical care. III. Guidelines for shock resuscitation. J Trauma. 2006;61:82&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832253</ArticleId></ArticleIdList></Reference><Reference><Citation>Minei JP, Nathens AB, West M, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. J Trauma. 2006;60:1106&#x2013;1113. discussion 1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">16688078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathens AB, Johnson JL, Minei JP, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma patient. J Trauma. 2005;59:764&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361929</ArticleId></ArticleIdList></Reference><Reference><Citation>West MA, Shapiro MB, Nathens AB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care. IV. Guidelines for transfusion in the trauma patient. J Trauma. 2006;61:436&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917462</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbrecht BG, Minei JP, Shapiro MB, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-orientedresearch core-standard operating procedures for clinical care. VI. Blood glucose control in the critically ill trauma patient. J Trauma. 2007;63:703&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Freeman B, O&#x2019;Keefe G, et al. Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. Guidelines for venous thromboembolism prophylaxis in the trauma patient. J Trauma. 2008;65:944&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004057</ArticleId><ArticleId IdType="pubmed">18849816</ArticleId></ArticleIdList></Reference><Reference><Citation>The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841303</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt CA, Deshpande AM, Lu C, et al. TrialDB: a web-based Clinical Study Data Management System. AMIA Annu Symp Proc. 2003:794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480035</ArticleId><ArticleId IdType="pubmed">14728299</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple-organ-failure syndrome. Arch Surg. 1986;121:196&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">3484944</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC. Organ dysfunction as an outcome measure in clinical trials. Eur J Surg Suppl. 1999;584:62&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">10890236</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbabi S, Campion EM, Hemmila MR, et al. Beta-blocker use is associated with improved outcomes in adult trauma patients. J Trauma. 2007;62:56&#x2013;61. discussion 61-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215733</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton BA, Snodgrass KB, Fleming SB, et al. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma. 2007;62:26&#x2013;33. discussion 33-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy DM, Cipolle MD, Pasquale MD, Wasser T. Impact of preinjury warfarin use in elderly trauma patients. J Trauma. 2000;48:451&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina AA, Bair HA, Howells GA, Bendick PJ. Complications of preinjury warfarin use in the trauma patient. J Trauma. 2003;54:842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">12777897</ArticleId></ArticleIdList></Reference><Reference><Citation>Neideen T, Lam M, Brasel KJ. Preinjury beta blockers are associated with increased mortality in geriatric trauma patients. J Trauma. 2008;65:1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">19001968</ArticleId></ArticleIdList></Reference><Reference><Citation>Riordan WP, Jr, Cotton BA, Norris PR, Waitman LR, Jenkins JM, Morris JA., Jr Beta-blocker exposure in patients with severe traumatic brain injury (TBI) and cardiac uncoupling. J Trauma. 2007;63:503&#x2013;510. discussion 510-501.</Citation><ArticleIdList><ArticleId IdType="pubmed">18073593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH. Reducing cardiac risk in noncardiac surgery. N Engl J Med. 1999;341:1838&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100:1043&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollis S, Lecky F, Yates DW, Woodford M. The effect of pre-existing medical conditions and age on mortality after injury. J Trauma. 2006;61:1255&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099538</ArticleId></ArticleIdList></Reference><Reference><Citation>McGwin G, Jr, MacLennan PA, Fife JB, Davis GG, Rue LW., III Preexisting conditions and mortality in older trauma patients. J Trauma. 2004;56:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211139</ArticleId></ArticleIdList></Reference><Reference><Citation>Milzman DP, Boulanger BR, Rodriguez A, Soderstrom CA, Mitchell KA, Magnant CM. Pre-existing disease in trauma patients: a predictor of fate independent of age and injury severity score. J Trauma. 1992;32:236&#x2013;243. discussion 243-244.</Citation><ArticleIdList><ArticleId IdType="pubmed">1740808</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JA, Jr, MacKenzie EJ, Damiano AM, Bass SM. Mortality in trauma patients: the interaction between host factors and severity. J Trauma. 1990;30:1476&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">2258958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JA, Jr, MacKenzie EJ, Edelstein SL. The effect of preexisting conditions on mortality in trauma patients. JAMA. 1990;263:1942&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pubmed">2313871</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson J. When the trauma patient is elderly. J Perianesth Nurs. 2004;19:392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">15801348</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914253</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007;104:1326&#x2013;1333. table of contents.</Citation><ArticleIdList><ArticleId IdType="pubmed">17513620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007;100:316&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17631090</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140:857&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385495</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation. 1998;98:1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751677</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054840</ArticleId></ArticleIdList></Reference><Reference><Citation>Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol. 1997;44:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042800</ArticleId><ArticleId IdType="pubmed">9241100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97:1671&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">9738637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004;291:2092&#x2013;2099.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126437</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JJ, Li YS, Chen J, Yang JQ. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses. 2006;66:1199&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413682</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JJ, Li YS, Chu JM, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta. 2006;366:269&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">16343471</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal S, Abletshauser C, Luley C. Fluvastatin treatment and withdrawal: effects on endothelial function. Angiology. 2008;59:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19748210</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1615-5947</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of vascular surgery</Title><ISOAbbreviation>Ann Vasc Surg</ISOAbbreviation></Journal><ArticleTitle>Retroperitoneal approach to abdominal aortic aneurysm repair preserves splanchnic perfusion as measured by gastric tonometry.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>327</EndPage><MedlinePgn>321-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.avsg.2009.06.003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We investigated if minimizing bowel manipulation and mesenteric traction using the retroperitoneal approach in open abdominal aortic aneurysm (AAA) repair preserves splanchnic perfusion, as measured by gastric tonometry, and reduces the systemic inflammatory response and dysfunction of the various organs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients undergoing elective AAA repair were randomized into three groups. Group I had repair via the retroperitoneal approach, while groups II and III were repaired via the transperitoneal approach with the bowel packed within the peritoneal cavity or exteriorized in a bowel bag, respectively. A tonometer was used to measure gastric intramucosal pH (pHi), as an indicator of splanchnic perfusion, just prior to aortic clamping, during clamping, and at 0.5, 1, 2, 4, 6, and 12 hr after clamp release. Multiorgan dysfunction syndrome (MODS) and systemic inflammatory response syndrome (SIRS) scores were calculated and systemic interleukins (IL-6 and IL-10) measured at predetermined intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-four patients were successfully randomized. The gastric pHi was significantly lower in group II (n=12) and group III (n=11) compared to group I (n=11) during aortic clamping and immediately after clamp release (p&lt;0.05). The aortic clamp time, blood loss, MODS and SIRS scores, and systemic cytokine response were similar in all three groups. When the three groups were combined, there were significant positive correlations between the operation time, aortic clamp time, and amount of blood lost and transfused with plasma IL-6 levels and MODS score on the first postoperative day.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The retroperitoneal approach for open AAA repair is associated with gastric tonometric evidence of better splanchnic perfusion compared to the transperitoneal approach.</AbstractText><CopyrightInformation>Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arya</LastName><ForeName>Nityanand</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vascular and Endovascular Unit, Belfast City Hospital, and Department of Medicine, Queen's University, Belfast, UK. nityaarya@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Muhammad Anees</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Luk Louis</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hannon</LastName><ForeName>Raymond J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Ian S</ForeName><Initials>IS</Initials></Author><Author ValidYN="Y"><LastName>Soong</LastName><ForeName>Chee Voon</ForeName><Initials>CV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Vasc Surg</MedlineTA><NlmUniqueID>8703941</NlmUniqueID><ISSNLinking>0890-5096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019917" MajorTopicYN="N">Blood Vessel Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005745" MajorTopicYN="Y">Gastric Acidity Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005753" MajorTopicYN="N">Gastric Mucosa</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008365" MajorTopicYN="Y">Manometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012187" MajorTopicYN="N">Retroperitoneal Space</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013152" MajorTopicYN="Y">Splanchnic Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748210</ArticleId><ArticleId IdType="doi">10.1016/j.avsg.2009.06.003</ArticleId><ArticleId IdType="pii">S0890-5096(09)00128-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18477075</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-6576</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta anaesthesiologica Scandinavica</Title><ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation></Journal><ArticleTitle>Arterial thermodilution in burn patients suggests a more rapid fluid administration during early resuscitation.</ArticleTitle><Pagination><StartPage>742</StartPage><EndPage>749</EndPage><MedlinePgn>742-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-6576.2008.01658.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A number of target points have been used for fluid replacement in severely burned patients. The aim of our prospective randomized study was to compare the effect of two different types of fluid resuscitation regimes on the multiple organ dysfunction score (MODS) and central venous oxygen saturation (ScvO(2)) in the first 3 days after injury.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four patients admitted to the critical care unit of a university hospital with the presence of burn injury affecting more than 15% of the body surface area and in-hospital fluid resuscitation started within 3 h after burn injury were included. Patients were randomized into two groups. Fluid resuscitation was guided by the hourly urine output (HUO Group, n=12) or by the intrathoracic blood volume index (ITBVI Group, n=12). Invasive transpulmonary hemodynamic measurements utilizing pulse contour analysis with a single dilution technique and continuous ScvO(2) measurements were performed in both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean ScvO(2) was significantly lower in the HUO Group than in the ITBVI Group (P=0.024) for the first 24 h. MODS was significantly higher in the HUO Group than in the ITBVI group 48 h (P=0.024) and 72 h after injury (P=0.014). The two main outcome parameters, i.e., MODS calculated at 48 and 72 h after injury and ScvO(2) were negatively correlated on day 1 (r=-0.684, P=0.004, r=-0.677, P=0.003). There were no statistical differences in clinical outcome parameters.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data suggest that ITBVI may be a better target parameter than HOU in the fluid resuscitation of severely burned patients after injury.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Csontos</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Intensive Care, Faculty of Medicine, University of P&#xe9;cs, Hungary. csaba.csontos@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foldi</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bogar</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Anaesthesiol Scand</MedlineTA><NlmUniqueID>0370270</NlmUniqueID><ISSNLinking>0001-5172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Anaesthesiol Scand. 2008 Jul;52(6):725-6. doi: 10.1111/j.1399-6576.2008.01679.x.</RefSource><PMID Version="1">18582301</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001810" MajorTopicYN="N">Blood Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013815" MajorTopicYN="N">Thermodilution</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18477075</ArticleId><ArticleId IdType="doi">10.1111/j.1399-6576.2008.01658.x</ArticleId><ArticleId IdType="pii">AAS1658</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21307724</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Body adipose content is independently associated with a higher risk of organ failure and nosocomial infection in the nonobese patient postinjury.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>298</EndPage><MedlinePgn>292-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e31820b5f69</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Obesity defined by a body mass index (BMI) &gt;30 kg/m is associated with increased morbidity and mortality following trauma. Evidence suggests that obesity represents a state of chronic inflammation and that the adipose tissue content may affect the intensity and resolution of inflammatory response. We sought to avoid the confounding effects attributable to obesity and determine the association of BMI and outcomes following injury in nonobese patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were obtained from a multicenter prospective cohort study evaluating outcomes in blunt-injured adults with hemorrhagic shock. Only patients with a BMI&#x2265;18.5 and&lt;30 were analyzed. Those with isolated traumatic brain injury and cervical cord injury and those who survived&lt;24 hours were excluded. Logistic regression was used to evaluate the effects of BMI on mortality, multiple organ failure (MOF, multiple organs dysfunction score [MODS]&gt;5), and nosocomial infection (NI) after adjusting for differences in demographics, injury severity, early resuscitation needs, shock parameters, and comorbidities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall mortality, MOF, and NI rates for the study cohort (n=820) were 13%, 37%, and 46%, respectively. Median Injury Severity Score was 33 (interquartile range, 22-41). Median BMI for the study cohort was 25 (interquartile range, 23-27). As BMI increased, maximum organ dysfunction scores also significantly increased for cardiac, respiratory, and renal systems. Logistic regression revealed no significant association with mortality (odds ratio [OR]=0.95; 95% confidence interval [CI], 0.9-1.0); however, BMI was independently associated with a higher risk of MOF (OR=1.09; 95% CI, 1.02-1.06) and NI (OR=1.07; 95% CI, 1.01-1.13). For every single-point increase in BMI, the risk of MOF and NI increase by 9% and 7%, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The risk of MOF and NI increases as BMI increases in the nonobese injured patient. These results suggest that body adipose content may be associated with the magnitude of or extent of the inflammatory response postinjury. Further studies are needed to elucidate the mechanism responsible for this association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edmonds</LastName><ForeName>Rebecca D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuschieri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Minei</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Rosengart</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Ronald V</ForeName><Initials>RV</Initials></Author><Author ValidYN="Y"><LastName>Harbrecht</LastName><ForeName>Brian G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Peitzman</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ernest E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Sperry</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><CollectiveName>Inflammation the Host Response to Injury Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR024154</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM062119-1</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21307724</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31820b5f69</ArticleId><ArticleId IdType="pii">00005373-201102000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38220371</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-4577</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical nutrition ESPEN</Title><ISOAbbreviation>Clin Nutr ESPEN</ISOAbbreviation></Journal><ArticleTitle>The impact of high versus standard enteral protein provision on functional recovery following intensive care admission: Protocol for a pre-planned secondary Bayesian analysis of the PRECISe trial.</ArticleTitle><Pagination><StartPage>162</StartPage><EndPage>170</EndPage><MedlinePgn>162-170</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnesp.2023.10.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2405-4577(23)02202-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">The PRECISe trial is a pragmatic, multicenter randomized controlled trial that evaluates the effect of high versus standard enteral protein provision on functional recovery in adult, mechanically ventilated critically ill patients. The current protocol presents the rationale and analysis plan for an evaluation of the primary and secondary outcomes under the Bayesian framework, with an emphasis on clinically important effect sizes.</AbstractText><AbstractText Label="METHODS">This protocol was drafted in agreement with the ROBUST-statement, and is submitted for publication before database lock and primary data analysis. The primary outcome is health-related quality of life as measured by the EQ-5D-5L health utility score and is longitudinally assessed. Secondary outcomes comprise the 6-min walking test and handgrip strength over the entire follow-up period (longitudinal analyses), and 60-day mortality, duration of mechanical ventilation, and EQ-5D-5L health utility scores at 30, 90 and 180 days (cross-sectional). All analyses will primarily be performed under weakly informative priors. When available, informative priors elicited from contemporary literature will also be incorporated under alternative scenarios. In all other cases, objectively formulated skeptical and enthusiastic priors will be defined to assess the robustness of our results. Relevant identified subgroups were: patients with acute kidney injury, severe multi-organ failure and patients with or without sepsis. Results will be presented as absolute risk differences, mean differences, and odds ratios, with accompanying 95% credible intervals. Posterior probabilities will be estimated for clinically important benefit and harm.</AbstractText><AbstractText Label="DISCUSSION">The proposed secondary, pre-planned Bayesian analysis of the PRECISe trial will provide additional information on the effects of high protein on functional and clinical outcomes in critically ill patients, such as probabilistic interpretation, probabilities of clinically important effect sizes, and the integration of prior evidence. As such, it will complement the interpretation of the primary outcome as well as several secondary and subgroup analyses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heuts</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Heer</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabrio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Methodology and Statistics, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bels</LastName><ForeName>Julia L M</ForeName><Initials>JLM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Zheng-Yii</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia; Department of Cardiac Anesthesiology &amp; Intensive Care Medicine, Charit&#xe9; Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stoppe</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiac Anesthesiology &amp; Intensive Care Medicine, Charit&#xe9; Berlin, Germany; University Hospital W&#xfc;rzburg, Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Kuijk</LastName><ForeName>Sander</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center+, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beishuizen</LastName><ForeName>Albertus</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Care Center, Medisch Spectrum Twente, Enschede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bie-Dekker</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Catharina Ziekenhuis Eindhoven, Eindhoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraipont</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Citadelle Hospital, Li&#xe8;ge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamote</LastName><ForeName>Stoffel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Academisch Ziekenhuis Groeninge, Kortijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledoux</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sensation and Perception Research Group, GIGA Consciousness, University of Li&#xe8;ge, Li&#xe8;ge, Belgium; Intensive Care Units, University Hospital of Li&#xe8;ge, Li&#xe8;ge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheeren</LastName><ForeName>Clarissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Zuyderland Medisch Centrum, Heerlen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Waele</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Universitair Ziekenhuis Brussel, Jette, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zanten</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Gelderse Vallei Ziekenhuis, Ede, the Netherlands; Division of Human Nutrition &amp; Health, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesotten</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, UHasselt, Diepenbeek, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Poll</LastName><ForeName>Marcel C G</ForeName><Initials>MCG</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands; School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands; Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands. Electronic address: marcel.vande.poll@mumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PRECISe investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr ESPEN</MedlineTA><NlmUniqueID>101654592</NlmUniqueID><ISSNLinking>2405-4577</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bayesian</Keyword><Keyword MajorTopicYN="N">Critical illness</Keyword><Keyword MajorTopicYN="N">Functional outcomes</Keyword><Keyword MajorTopicYN="N">Nutrition</Keyword><Keyword MajorTopicYN="N">Protein</Keyword></KeywordList><CoiStatement>Declaration of competing interest MvdP received travel and speaker fees from Nutricia and research funding from Nestle Health Science and Fresenius-Kabi, not related to this research. EDW received research grants, travel and speakers fees from the Belgian Government Health, KCE (Belgian Health Care), Baxter Healthcare, Fresenius, Nestl&#xe9; and Art Medical.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>14</Day><Hour>21</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38220371</ArticleId><ArticleId IdType="doi">10.1016/j.clnesp.2023.10.040</ArticleId><ArticleId IdType="pii">S2405-4577(23)02202-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21988742</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2011</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>223</StartPage><MedlinePgn>223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1745-6215-12-223</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic inflammation in response to a femur fracture and the additional fixation is associated with inflammatory complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome. The injury itself, but also the additional procedure of femoral fixation induces a release of pro-inflammatory cytokines such as interleukin-6. This results in an aggravation of the initial systemic inflammatory response, and can cause an increased risk for the development of inflammatory complications. Recent studies have shown that administration of the serum protein C1-esterase inhibitor can significantly reduce the release of circulating pro-inflammatory cytokines in response to acute systemic inflammation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Attenuation of the surgery-induced additional systemic inflammatory response by perioperative treatment with C1-esterase inhibitor of trauma patients with a femur fracture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study is designed as a double-blind randomized placebo-controlled trial. Trauma patients with a femur fracture, Injury Severity Score &#x2265; 18 and age 18-80 years are included after obtaining informed consent. They are randomized for administration of 200 U/kg C1-esterase inhibitor intravenously or placebo (saline 0.9%) just before the start of the procedure of femoral fixation. The primary endpoint of the study is &#x394; interleukin-6, measured at t = 0, just before start of the femur fixation surgery and administration of C1-esterase inhibitor, and t = 6, 6 hours after administration of C1-esterase inhibitor and the femur fixation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study intents to identify C1-esterase inhibitor as a safe and potent anti-inflammatory agent, that is capable of suppressing systemic inflammation in trauma patients. This might facilitate early total care procedures by lowering the risk of inflammation in response to the surgical intervention. This could result in increased functional outcomes and reduced health care related costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heeres</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands. M.Heeres-2@umcutrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Tjaakje</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Koenderman</LastName><ForeName>Anky H L</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Strengers</LastName><ForeName>Paul F W</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Koenderman</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01275976</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050718">Complement C1 Inhibitor Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050718" MajorTopicYN="N">Complement C1 Inhibitor Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005264" MajorTopicYN="N">Femoral Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21988742</ArticleId><ArticleId IdType="pmc">PMC3198691</ArticleId><ArticleId IdType="doi">10.1186/1745-6215-12-223</ArticleId><ArticleId IdType="pii">1745-6215-12-223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hietbrink F, Koenderman L, Rijkers G, Leenen L. Trauma: the role of the innate immune system. World J Emerg Surg. 2006;1:15. doi: 10.1186/1749-7922-1-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-7922-1-15</ArticleId><ArticleId IdType="pmc">PMC1481567</ArticleId><ArticleId IdType="pubmed">16759367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Oudijk EJ, Braams R, Koenderman L, Leenen L. Aberrant regulation of polymorphonuclear phagocyte responsiveness in multitrauma patients. Shock. 2006;26(6):558&#x2013;564. doi: 10.1097/01.shk.0000233196.40989.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000233196.40989.78</ArticleId><ArticleId IdType="pubmed">17117129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Hietbrink F, Koenderman L, Leenen LP. The systemic inflammatory response induced by trauma is reflected by multiple phenotypes of blood neutrophils. Injury. 2007;38(12):1365&#x2013;1372. doi: 10.1016/j.injury.2007.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.016</ArticleId><ArticleId IdType="pubmed">18061190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulvik A, Kvale R, Wentzel-Larsen T, Flaatten H. Multiple organ failure after trauma affects even long-term survival and functional status. Crit Care. 2007;11(5):R95..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556737</ArticleId><ArticleId IdType="pubmed">17784940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38(12):1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79(2):161&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2167805</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Smith RM, Bellamy MC, Morrison JF, Dickson RA, Guillou PJ. Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit. J Bone Joint Surg Br. 1999;81(2):356&#x2013;361. doi: 10.1302/0301-620X.81B2.8988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.81B2.8988</ArticleId><ArticleId IdType="pubmed">10204951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135(3):291&#x2013;295. doi: 10.1001/archsurg.135.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.135.3.291</ArticleId><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65(3):646&#x2013;652. doi: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181820d48</ArticleId><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobbe P, Vodovotz Y, Kaczorowski DJ, Mollen KP, Billiar TR, Pape HC. Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock. 2008;30(1):43&#x2013;47. doi: 10.1097/SHK.0b013e31815d190b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31815d190b</ArticleId><ArticleId IdType="pubmed">18562923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Griensven MV, Hildebrand FF, Tzioupis CT, Sommer KL, Krettek CC, Giannoudis PV. Systemic inflammatory response after extremity or truncal fracture operations. J Trauma. 2008;65(6):1379&#x2013;1384. doi: 10.1097/TA.0b013e31818c8e8c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31818c8e8c</ArticleId><ArticleId IdType="pubmed">19077630</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JR, Smith RM, Pape HC, MacDonald DA, Trejdosiewitz LK, Giannoudis PV. Stimulation of the local femoral inflammatory response to fracture and intramedullary reaming: a preliminary study of the source of the second hit phenomenon. J Bone Joint Surg Br. 2008;90(3):393&#x2013;399. doi: 10.1302/0301-620X.90B3.19688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.90B3.19688</ArticleId><ArticleId IdType="pubmed">18310768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Van Griensven M, Rice J, Gansslen A, Hildebrand F, Zech S, Winny M, Lichtinghagen R, Krettek C. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma. 2001;50(6):989&#x2013;1000. doi: 10.1097/00005373-200106000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200106000-00004</ArticleId><ArticleId IdType="pubmed">11426112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschoeke SK, Hellmuth M, Hostmann A, Ertel W, Oberholzer A. The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma. 2007;62(6):1396&#x2013;1403. doi: 10.1097/TA.0b013e318047b7f0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318047b7f0</ArticleId><ArticleId IdType="pubmed">17563655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Giannoudis P, Krettek C. The timing of fracture treatment in polytrauma patients: relevance of damage control orthopedic surgery. Am J Surg. 2002;183(6):622&#x2013;629. doi: 10.1016/S0002-9610(02)00865-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(02)00865-6</ArticleId><ArticleId IdType="pubmed">12095590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC. Effects of changing strategies of fracture fixation on immunologic changes and systemic complications after multiple trauma: damage control orthopedic surgery. J Orthop Res. 2008;26(11):1478&#x2013;1484. doi: 10.1002/jor.20697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jor.20697</ArticleId><ArticleId IdType="pubmed">18524013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Grimme K, Van Griensven M, Sott AH, Giannoudis P, Morley J, Roise O, Ellingsen E, Hildebrand F, Wiebe B, Krettek C. Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group. J Trauma. 2003;55(1):7&#x2013;13. doi: 10.1097/01.TA.0000075787.69695.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000075787.69695.4E</ArticleId><ArticleId IdType="pubmed">12855874</ArticleId></ArticleIdList></Reference><Reference><Citation>Morshed S, Miclau T III, Bembom O, Cohen M, Knudson MM, Colford JM Jr. Delayed internal fixation of femoral shaft fracture reduces mortality among patients with multisystem trauma. J Bone Joint Surg Am. 2009;91(1):3&#x2013;13. doi: 10.2106/JBJS.H.00338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.00338</ArticleId><ArticleId IdType="pmc">PMC2663326</ArticleId><ArticleId IdType="pubmed">19122073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Hildebrand F, Pertschy S, Zelle B, Garapati R, Grimme K, Krettek C, Reed RL. Changes in the management of femoral shaft fractures in polytrauma patients: from early total care to damage control orthopedic surgery. J Trauma. 2002;53(3):452&#x2013;461. doi: 10.1097/00005373-200209000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200209000-00010</ArticleId><ArticleId IdType="pubmed">12352480</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Tsukamoto T, Kobbe P, Tarkin I, Katsoulis S, Peitzman A. Assessment of the clinical course with inflammatory parameters. Injury. 2007;38(12):1358&#x2013;1364. doi: 10.1016/j.injury.2007.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.026</ArticleId><ArticleId IdType="pubmed">18048038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorresteijn MJ, Visser T, Cox LA, Bouw MP, Pillay J, Koenderman AH, Strengers PF, Leenen LP, van der Hoeven JG, Koenderman L, Pickkers P. C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med. 2010;38(11):2139&#x2013;2145. doi: 10.1097/CCM.0b013e3181f17be4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181f17be4</ArticleId><ArticleId IdType="pubmed">20693886</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10699156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE, Wuillemin WA. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol. 2003;10(4):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164269</ArticleId><ArticleId IdType="pubmed">12853381</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE III. C1 inhibitor-mediated protection from sepsis. J Immunol. 2007;179(6):3966&#x2013;3972.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahador M, Cross AS. From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J Endotoxin Res. 2007;13(5):251&#x2013;279. doi: 10.1177/0968051907085986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0968051907085986</ArticleId><ArticleId IdType="pubmed">17986486</ArticleId></ArticleIdList></Reference><Reference><Citation>The Declaration of Helsinki.  (September 20th 2011) [ http://www.wma.net/en/30publications/10policies/b3/]</Citation></Reference><Reference><Citation>The Good Clinical Practice Guidelines.  (September 20th 2011) [ http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf]</Citation></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644&#x2013;1655. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800. doi: 10.1097/00003246-199811000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199811000-00016</ArticleId><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28(6):668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Stensballe J, Christiansen M, Tonnesen E, Espersen K, Lippert FK, Rasmussen LS. The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. Acta Anaesthesiol Scand. 2009;53(4):515&#x2013;521. doi: 10.1111/j.1399-6576.2008.01801.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2008.01801.x</ArticleId><ArticleId IdType="pubmed">19317866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull K, Spiegelhalter DJ. Survival analysis in observational studies. Stat Med. 1997;16(9):1041&#x2013;1074. doi: 10.1002/(SICI)1097-0258(19970515)16:9&lt;1041::AID-SIM506&gt;3.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970515)16:9&lt;1041::AID-SIM506&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">9160498</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549&#x2013;556. doi: 10.2307/2530245.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2530245</ArticleId><ArticleId IdType="pubmed">497341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol. 1999;36(4-5):225&#x2013;232. doi: 10.1016/S0161-5890(99)00048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-5890(99)00048-6</ArticleId><ArticleId IdType="pubmed">10403475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 2008;8(8):1225&#x2013;1240. doi: 10.1517/14712598.8.8.1225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.8.8.1225</ArticleId><ArticleId IdType="pubmed">18613773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschfink M, Mollnes TE. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother. 2001;2(7):1073&#x2013;1083. doi: 10.1517/14656566.2.7.1073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2.7.1073</ArticleId><ArticleId IdType="pubmed">11583058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE. Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest. 1989;84(2):443&#x2013;450. doi: 10.1172/JCI114185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI114185</ArticleId><ArticleId IdType="pmc">PMC548902</ArticleId><ArticleId IdType="pubmed">2668333</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23(21):1670&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pubmed">12398824</ArticleId></ArticleIdList></Reference><Reference><Citation>Struber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med. 1999;25(11):1315&#x2013;1318. doi: 10.1007/s001340051065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340051065</ArticleId><ArticleId IdType="pubmed">10654221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16784546</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>The distinct clinical profile of chronically critically ill patients: a cohort study.</ArticleTitle><Pagination><StartPage>R89</StartPage><MedlinePgn>R89</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Our goal was to describe the epidemiology, clinical profiles, outcomes, and factors that might predict progression of critically ill patients to chronically critically ill (CCI) patients, a still poorly characterized subgroup.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We prospectively studied all patients admitted to a university-affiliated hospital intensive care unit (ICU) between 1 July 2002 and 30 June 2005. On admission, we recorded epidemiological data, the presence of organ failure (multiorgan dysfunction syndrome (MODS)), underlying diseases (McCabe score), acute respiratory distress syndrome (ARDS) and shock. Daily, we recorded MODS, ARDS, shock, mechanical ventilation use, lengths of ICU and hospital stay (LOS), and outcome. CCI patients were defined as those having a tracheotomy placed for continued ventilation. Clinical complications and time to tracheal decannulation were registered. Predictors of progression to CCI were identified by logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-five patients (12%) fulfilled the CCI definition and, compared with the remaining 690 patients, these CCI patients were sicker (APACHE II, 21 +/- 7 versus 18 +/- 9 for non-CCI patients, p = 0.005); had more organ dysfunctions (SOFA 7 +/- 3 versus 6 +/- 4, p &lt; 0.003); received more interventions (TISS 32 +/- 10 versus 26 +/- 8, p &lt; 0.0001); and had less underlying diseases and had undergone emergency surgery more frequently (43 versus 24%, p = 0.001). ARDS and shock were present in 84% and 83% of CCI patients, respectively, versus 44% and 48% in the other patients (p &lt; 0.0001 for both). CCI patients had higher expected mortality (38% versus 32%, p = 0.003), but observed mortality was similar (32% versus 35%, p = 0.59). Independent predictors of progression to CCI were ARDS on admission, APACHE II and McCabe scores (odds ratio (OR) 2.26, p &lt; 0.001; OR 1.03, p &lt; 0.01; and OR 0.34, p &lt; 0.0001, respectively). Lengths of mechanical ventilation, ICU and hospital stay were 33 (24 to 50), 39 (29 to 55) and 55 (37 to 84) days, respectively. Tracheal decannulation was achieved at 40 +/- 19 days.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CCI patients were a severely ill population, in which ARDS, shock, and MODS were frequent on admission, and who suffered recurrent complications during their stay. However, their prognosis was equivalent to that of the other ICU patients. ARDS, APACHE II and McCabe scores were independent predictors of evolution to chronicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Estenssoro</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Terapia Intensiva, Hospital Interzonal General San Mart&#xed;n, La Plata, Buenos Aires, Argentina. elisaestenssoro@speedy.com.ar</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Canales</LastName><ForeName>H&#xe9;ctor S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Saenz</LastName><ForeName>Mar&#xed;a Gabriela</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Francisco E</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Aprea</LastName><ForeName>Mar&#xed;a M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Laffaire</LastName><ForeName>Enrique</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gola</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dubin</LastName><ForeName>Arnaldo</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="Y">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16784546</ArticleId><ArticleId IdType="pmc">PMC1550940</ArticleId><ArticleId IdType="doi">10.1186/cc4941</ArticleId><ArticleId IdType="pii">cc4941</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nierman DM. A structure of care for the chronically critically ill. Crit Care Clin. 2002;18:477&#x2013;491. doi: 10.1016/S0749-0704(02)00010-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(02)00010-6</ArticleId><ArticleId IdType="pubmed">12140909</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinhorn DJ, Stearn-Hassenpflug M. Provision of long-term mechanical ventilation. Crit Care Clin. 1998;14:819&#x2013;832. doi: 10.1016/S0749-0704(05)70032-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(05)70032-4</ArticleId><ArticleId IdType="pubmed">9891639</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368&#x2013;1377. doi: 10.1056/NEJMoa010307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa010307</ArticleId><ArticleId IdType="pubmed">11794169</ArticleId></ArticleIdList></Reference><Reference><Citation>The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301&#x2013;1308. doi: 10.1056/NEJM200005043421801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200005043421801</ArticleId><ArticleId IdType="pubmed">10793162</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1301&#x2013;1308. doi: 10.1056/NEJMoa011300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699&#x2013;709. doi: 10.1056/NEJM200103083441001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200103083441001</ArticleId><ArticleId IdType="pubmed">11236773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalb TH, Lorin S. Infection in the chronically critically ill: Unique risk profile in a newly defined population. Crit Care Clin. 2002;18:529&#x2013;552. doi: 10.1016/S0749-0704(02)00009-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(02)00009-X</ArticleId><ArticleId IdType="pubmed">12140912</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson SS, Bach PB. The epidemiology and costs of chronic critical illness. Crit Care Clin. 2002;18:461&#x2013;476. doi: 10.1016/S0749-0704(02)00015-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(02)00015-5</ArticleId><ArticleId IdType="pubmed">12140908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierman DM, Nelson JE. Chronic critical illness. Preface. Crit Care Clin. 2002;18:xi&#x2013;xii. doi: 10.1016/S0749-0704(02)00010-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(02)00010-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Malstam J, Lind L. Therapeutic intervention scoring system (TISS) &#x2013; a method for measuring workload and calculating costs in the ICU. Acta Anaesthesiol Scand. 1992;36:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">1466209</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, Moreno R, Takkala J, Suter PM, Sprung Ch, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ disfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998;26:1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Estenssoro E, Gonzalez F, Laffaire E, Canales H, Saenz G, Reina R, Dubin A. Shock on admission day is the best predictor of prolonged mechanical ventilation in the ICU. Chest. 2005;127:598&#x2013;603. doi: 10.1378/chest.127.2.598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.127.2.598</ArticleId><ArticleId IdType="pubmed">15706002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Cabe WR, Jackson GG. Gram-negative bacteriemia. I. Etiology and Ecology. Arch Int Med. 1962;110:845&#x2013;847.</Citation></Reference><Reference><Citation>Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Falestiny MN, Rogers P, Reed MJ, Pularski J, Norris R, Yu VL. Pulmonary infiltrates in the surgical ICU: prospective assessment of predictors of etiology and mortality. Chest. 1998;114:1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT, Johnson MM, Browder RW, Bowton DL, Haponik EF. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med. 1996;335:1864&#x2013;1866. doi: 10.1056/NEJM199612193352502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199612193352502</ArticleId><ArticleId IdType="pubmed">8948561</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins PM, Mion LC, Mendelson W, Palmer RM, Slomka J, Franko T. Characteristics and outcomes of patients who self-extubate from ventilatory support: a case-control study. Chest. 1997;112:1317&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9367475</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinhorn DJ, Chao DC, Stearn-Hassenpflug MA. Liberation from prolonged mechanical ventilation. Crit Care Clin. 2002;18:569&#x2013;595. doi: 10.1016/S0749-0704(02)00016-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(02)00016-7</ArticleId><ArticleId IdType="pubmed">12140914</ArticleId></ArticleIdList></Reference><Reference><Citation>The management of the agitated ICU patient. Crit Care Med. 2002;30(Suppl):S97&#x2013;123. doi: 10.1097/00003246-200201002-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200201002-00001</ArticleId><ArticleId IdType="pubmed">11852874</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest. 1992;102(Suppl):557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">1424930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollef MH, Bock KR, Richards RD, Hearns ML. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med. 1995;122:743&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">7717596</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres A, el-Ebiary M, Padro L, Gonz&#xe1;lez J, de la Bellacasa JP, Ram&#xed;rez J, Xaubet A, Ferrer M, Rodr&#xed;guez-Roisin R. Validation of different techniques for the diagnosis of ventilator-associated pneumonia: comparison with immediate postmortem pulmonary biopsy. Am J Respir Crit Care Med. 1994;149:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">8306025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermel LA, Farr BM, Sheretz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249&#x2013;1272. doi: 10.1086/320001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/320001</ArticleId><ArticleId IdType="pubmed">11303260</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN, editor. Infection Control and Applied Epidemiology: Principles and Practice. St Louis: Mosby; 1996. pp. 1&#x2013;20.</Citation></Reference><Reference><Citation>Carlet J, Thijs LG, Antonelli M, Cassell J, Cox P, Hill N, Hinds C, Pimentel JM, Reinhart K, Thompson BT. Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med. 2004;30:770&#x2013;784. doi: 10.1007/s00134-004-2241-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-004-2241-5</ArticleId><ArticleId IdType="pubmed">15098087</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinhorn DJ, Chao DC, Stearn-Hassenpflug M, LaBree LD, Heltsley DJ. Post-ICU mechanical ventilation: treatment of 1,123 patients at a regional weaning center. Chest. 1997;111:1654&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennef MG, Wagner DP, Thompson D. The impact of long-term acute-care facilities on the outcome and cost for patients undergoing prolonged mechanical ventilation. Crit Care Med. 2000;28:342&#x2013;350. doi: 10.1097/00003246-200002000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200002000-00009</ArticleId><ArticleId IdType="pubmed">10708164</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson SS, Bach PB, Brzozowski L, Leff A. Outcomes after long-term acute care. An analysis of 133 mechanically ventilated patients. Am J Respir Crit Care Med. 1999;159:1568&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">10228128</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicher JE, White DP. Outcome and function following prolonged mechanical ventilation. Arch Intern Med. 1987;147:421&#x2013;425. doi: 10.1001/archinte.147.3.421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.147.3.421</ArticleId><ArticleId IdType="pubmed">3827415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracey DR, Naessens JM, Viggiano RW, Koenig GE, Silverstein MD, Hubmayr RD. Outcome of patients cared for in a ventilator-dependent unit in a general hospital. Chest. 1995;107:494&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">7842783</ArticleId></ArticleIdList></Reference><Reference><Citation>Laupland KB, Kirkpatrick AW, Kortbeek JB, Zuege DJ. Long-term mortality outcome associated with prolonged admission to the ICU. Chest. 2006;129:954&#x2013;959. doi: 10.1378/chest.129.4.954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.129.4.954</ArticleId><ArticleId IdType="pubmed">16608944</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Costa MA, Trouillet JL, Baudot J, Mokhtari M, Gibert C, Chastre J. Morbidity, mortality, and quality-of-life outcomes of patients requiring &#x2265;14 days of mechanical ventilation. Crit Care Med. 2003;31:1373&#x2013;1381. doi: 10.1097/01.CCM.0000065188.87029.C3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000065188.87029.C3</ArticleId><ArticleId IdType="pubmed">12771605</ArticleId></ArticleIdList></Reference><Reference><Citation>Frutos-Vivar F, Esteban A, Apezteguia C, Anzueto A, Nightingale P, Gonzalez M, Soto L, Rodrigo C, Raad J, David CM, Matamis D, D' Empaire G, International Mechanical Ventilation Study Group Outcome of mechanically ventilated patients who require a tracheostomy. Crit Care Med. 2005;33:290&#x2013;298. doi: 10.1097/01.CCM.0000150026.85210.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000150026.85210.13</ArticleId><ArticleId IdType="pubmed">15699830</ArticleId></ArticleIdList></Reference><Reference><Citation>Seneff MG, Zimmerman JE, Knaus WA, Wagner DP, Draper EA. Predicting the duration of mechanical ventilation: the importance of disease and patients characteristics. Chest. 1996;110:469&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">8697853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapijaszko MJ, Brant R, Sandham D, Berthiaume Y. Nonrespiratory predictor of mechanical ventilation dependency in intensive care units patients. Crit Care Med. 1996;24:601&#x2013;607. doi: 10.1097/00003246-199604000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199604000-00009</ArticleId><ArticleId IdType="pubmed">8612410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emori TG, Banerjee S, Tolson J, Henderson T, Gaynes R. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med. 1991;91(3B):185S&#x2013;191S. doi: 10.1016/0002-9343(91)90367-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(91)90367-7</ArticleId><ArticleId IdType="pubmed">1928163</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinhorn DJ, Chao DC, Stearn-Hassenpflug M. Approach to patients with long-term weaning failure. Respir Care Clin N Am. 2000;6:437&#x2013;461, vi. doi: 10.1016/S1078-5337(05)70080-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1078-5337(05)70080-0</ArticleId><ArticleId IdType="pubmed">10899265</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein SK, Ciubotaru RL. Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation. Am J Respir Crit Care Med. 1998;158:489&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med. 1996;24:1408&#x2013;1416. doi: 10.1097/00003246-199608000-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199608000-00022</ArticleId><ArticleId IdType="pubmed">8706499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001;119:1222&#x2013;1241. doi: 10.1378/chest.119.4.1222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.119.4.1222</ArticleId><ArticleId IdType="pubmed">11296191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med. 1999;27:2812&#x2013;2817. doi: 10.1097/00003246-199912000-00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199912000-00034</ArticleId><ArticleId IdType="pubmed">10628631</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe B, Appere-De-Vechi C, Fournier M, Tran B, Merrer J, Melchior JC, Outin A prospective survey of nutritional support practices in intensive care unit patients: what is prescribed? What is delivered? Crit Care Med. 2001;29:8&#x2013;12. doi: 10.1097/00003246-200101000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200101000-00002</ArticleId><ArticleId IdType="pubmed">11176150</ArticleId></ArticleIdList></Reference><Reference><Citation>American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388&#x2013;416. doi: 10.1164/rccm.200405-644ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200405-644ST</ArticleId><ArticleId IdType="pubmed">15699079</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of the outcome of adequate empirical antibiotherapy in patients admitted to the ICU for sepsis. Crit Care Med. 2003;31:2742&#x2013;2751. doi: 10.1097/01.CCM.0000098031.24329.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000098031.24329.10</ArticleId><ArticleId IdType="pubmed">14668610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17381399</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>82</EndPage><MedlinePgn>73-82</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of inhaled tobramycin (TOBI) in the treatment of ventilator-associated pneumonia (VAP) in a randomized, double-blind pilot study.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Ten patients from a cohort of 108 mechanically ventilated patients with documented clinical and bacteriological evidence of VAP caused by Pseudomonas aeruginosa or Acinetobacter spp. in the surgical and trauma intensive care units of a university teaching hospital were randomized to receive either TOBI (n = 5) or intravenous tobramycin (TOBRA; n = 5). The two groups were similar in their Acute Physiology and Chronic Health Evaluation (APACHE) score, Clinical Pulmonary Infection Score (CPIS), and Multiple Organ Dysfunction Score (MODS) prior to randomization. The primary outcome measure was resolution of pneumonia. The CPIS and MODS were used as objective indicators of clinical progress.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All TOBI patients had clinical resolution of VAP. Two TOBRA patients were considered failures. One had deterioration in MODS, and the other had doubling of his serum creatinine concentration. The patients treated with TOBI may have had more ventilator-free days than those receiving TOBRA, but the difference was not statistically significant owing to the small sample size (24 +/- 3 vs. 14 +/- 13 days; p = 0.12).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Aerosolized tobramycin for the treatment of VAP appeared safe and effective in this pilot study. A larger study is warranted to determine if aerosolized tobramycin will lead to better outcomes than intravenous tobramycin when used for the treatment of VAP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hallal</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ryder Trauma Center, Department of Surgery and Division of Infectious Diseases, Jackson Memorial Hospital, University of Miami School of Medicine, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Namias</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Habib</LastName><ForeName>Fahim</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Baracco</LastName><ForeName>Gio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Manning</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Crookes</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schulman</LastName><ForeName>Carl I</ForeName><Initials>CI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VZ8RRZ51VK</RegistryNumber><NameOfSubstance UI="D014031">Tobramycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000150" MajorTopicYN="N">Acinetobacter</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000151" MajorTopicYN="N">Acinetobacter Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053717" MajorTopicYN="N">Pneumonia, Ventilator-Associated</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011552" MajorTopicYN="N">Pseudomonas Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014031" MajorTopicYN="N">Tobramycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17381399</ArticleId><ArticleId IdType="doi">10.1089/sur.2006.051</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20219387</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2011</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Prediction of mortality in intensive care unit cardiac surgical patients.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>109</EndPage><MedlinePgn>104-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejcts.2010.01.053</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to develop a specific postoperative score in intensive care unit (ICU) cardiac surgical patients for the assessment of organ dysfunction and survival. To prove the reliability of the new scoring system, we compared its performance to existing ICU scores.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study consisted of all consecutive adult patients admitted after cardiac surgery to our ICU over a period of 5.5 years. Variables were evaluated using the patients of the first year who stayed in ICU for at least 24h. The reproducibility was then tested in two validation sets using all patients. Performance was assessed with the Hosmer-Lemeshow (HL) goodness-of-fit test and receiver operating characteristic (ROC) curves and compared with the Acute Physiology and Chronic Health Evaluation (APACHE II) and Multiple Organ Dysfunction Score (MODS). The outcome measure was defined as 30-day mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 6007 patients were admitted to the ICU after cardiac surgery. Mean HL values for the new score were 5.8 (APACHE II, 11.3; MODS, 9.7) for the construction set, 7.2 (APACHE II, 8.0; MODS, 4.5) for the validation set I and 4.9 for the validation set II. The mean area under the ROC curve was 0.91 (APACHE II, 0.86; MODS, 0.84) for the new score in the construction set, 0.88 (APACHE II, 0.84; MODS, 0.84) in the validation set I and 0.92 in the validation set II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most of general ICU scoring systems use extensive data collection and focus on the first day of ICU stay. Despite this fact, general scores do not perform well in the prediction of outcome in cardiac surgical patients. Our new 10-variable risk index performs very well, with calibration and discrimination very high, better than general severity systems, and it is an appropriate tool for daily risk stratification in ICU cardiac surgery patients. Thus, it may serve as an expert system for diagnosing organ failure and predicting mortality in ICU cardiac surgical patients.</AbstractText><CopyrightInformation>Copyright 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hekmat</LastName><ForeName>Khosro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University, Jena, Germany. hekmat@med.uni-jena.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kroener</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heldwein</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bossert</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Badreldin</LastName><ForeName>Akmal M A</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lichtenberg</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Cardiothorac Surg. 2011 May;39(5):797; author reply 797-8. doi: 10.1016/j.ejcts.2010.09.004.</RefSource><PMID Version="1">20940100</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20219387</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2010.01.053</ArticleId><ArticleId IdType="pii">S1010-7940(10)00117-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24379596</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>46</Issue><PubDate><Year>2013</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Perirenal space blocking restores gastrointestinal function in patients with severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>8752</StartPage><EndPage>8757</EndPage><MedlinePgn>8752-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v19.i46.8752</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate effects of perirenal space blocking (PSB) on gastrointestinal function in patients with severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty patients with SAP were randomly allocated to receive PSB or no PSB (NPSB). All the SAP patients received specialized medical therapy (SMT). Patients in the PSB group received PSB + SMT when hospitalized and after diagnosis, whereas patients in the NPSB group only received SMT. A modi&#xfb01;ed gastrointestinal failure (GIF) scoring system was used to assess the gastrointestinal function in SAP patients after admission. Pain severity (visual analog scale, 0 to 100) was monitored every 24 h for 72 h.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Modified GIF score decreased in both groups during the 10-d study period. The median score decrease was initially significantly greater in the PSB group than in the NPSB group after PSB was performed. During the 72-h study period, pain intensity decreased in both groups. The median pain decrease was significantly greater in the PSB group than in the NPSB group at single time points. Patients in the PSB group had significantly lower incidences of hospital mortality, multiple organ dysfunction syndrome, systemic inflammatory response syndrome, and pancreatic infection, and stayed in the intensive care unit for a shorter duration. However, no difference in terms of operation incidence was found between the two groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PSB could ameliorate gastrointestinal dysfunction or failure during the early stage of SAP. Moreover, PSB administration could improve prognosis and decrease the mortality of SAP patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jun-Jun</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Zhi-Jie</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei-Feng</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Shi-Fang</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yan-Hui</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Peng-Lei</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Hui</ForeName><Initials>XH</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wen-Sheng</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Jun-Jun Sun, Zhi-Jie Chu, Wei-Feng Liu, Shi-Fang Qi, Yan-Hui Yang, Peng-Lei Ge, Xiao-Hui Zhang, Wen-Sheng Li, Cheng Yang, Yu-Ming Zhang, Department of General Surgery, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance></Chemical><Chemical><RegistryNumber>98PI200987</RegistryNumber><NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000779" MajorTopicYN="N">Anesthetics, Local</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002447" MajorTopicYN="N">Celiac Plexus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="Y">Gastrointestinal Motility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008012" MajorTopicYN="N">Lidocaine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009407" MajorTopicYN="N">Nerve Block</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gastrointestinal function</Keyword><Keyword MajorTopicYN="N">Perirenal space blocking</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Severe acute pancreatitis</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24379596</ArticleId><ArticleId IdType="pmc">PMC3870524</ArticleId><ArticleId IdType="doi">10.3748/wjg.v19.i46.8752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKay CJ, Buter A. Natural history of organ failure in acute pancreatitis. Pancreatology. 2003;3:111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748419</ArticleId></ArticleIdList></Reference><Reference><Citation>De Campos T, Braga CF, Kuryura L, Hebara D, Assef JC, Rasslan S. Changes in the management of patients with severe acute pancreatitis. Arq Gastroenterol. 2008;45:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">18852942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloor B, M&#xfc;ller CA, Worni M, Stahel PF, Redaelli C, Uhl W, B&#xfc;chler MW. Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. Arch Surg. 2001;136:592&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">11343553</ArticleId></ArticleIdList></Reference><Reference><Citation>Runkel NS, Moody FG, Smith GS, Rodriguez LF, LaRocco MT, Miller TA. The role of the gut in the development of sepsis in acute pancreatitis. J Surg Res. 1991;51:18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">2067354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz S, Hackert T, Hartwig W, Rossmanith F, Strobel O, Schneider L, Will-Schweiger K, Kommerell M, B&#xfc;chler MW, Werner J. Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon. Am J Surg. 2010;200:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">20637344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228:188&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1191459</ArticleId><ArticleId IdType="pubmed">9712563</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Mofleh IA. Severe acute pancreatitis: pathogenetic aspects and prognostic factors. World J Gastroenterol. 2008;14:675&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683992</ArticleId><ArticleId IdType="pubmed">18205255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JK, Mu XW, Li WQ, Tong ZH, Li J, Zheng SY. Effects of early enteral nutrition on immune function of severe acute pancreatitis patients. World J Gastroenterol. 2013;19:917&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574890</ArticleId><ArticleId IdType="pubmed">23431120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ol&#xe1;h A, Romics L. Early enteral nutrition in acute pancreatitis--benefits and limitations. Langenbecks Arch Surg. 2008;393:261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">18266002</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirag A, Pastor CM, Morel P, Jean-Christophe C, Sielenk&#xe4;mper AW, G&#xfc;vener N, Mai G, Berney T, Frossard JL, B&#xfc;hler LH. Epidural anaesthesia restores pancreatic microcirculation and decreases the severity of acute pancreatitis. World J Gastroenterol. 2006;12:915&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066157</ArticleId><ArticleId IdType="pubmed">16521220</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbrook RA. Epidural anesthesia and gastrointestinal motility. Anesth Analg. 1998;86:837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539611</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortel&#xe9; KJ, Mergo PJ, Taylor HM, Ernst MD, Ros PR. Renal and perirenal space involvement in acute pancreatitis: spiral CT findings. Abdom Imaging. 2000;25:272&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823450</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XH, Zhang XM, Ji YF, Jing ZL, Huang XH, Yang L, Zhai ZH. Renal and perirenal space involvement in acute pancreatitis: An MRI study. Eur J Radiol. 2012;81:e880&#x2013;e887.</Citation><ArticleIdList><ArticleId IdType="pubmed">22613509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993;128:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">8489394</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisinda G, Vanella S, Crocco A, Mazzari A, Tomaiuolo P, Santullo F, Grossi U, Crucitti A. Severe acute pancreatitis: advances and insights in assessment of severity and management. Eur J Gastroenterol Hepatol. 2011;23:541&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">21659951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JK, Li WQ, Ni HB, Ke L, Tong ZH, Li N, Li JS. Modified gastrointestinal failure score for patients with severe acute pancreatitis. Surg Today. 2013;43:506&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">23361596</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009;37:1649&#x2013;1654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703722</ArticleId><ArticleId IdType="pubmed">19325482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombeau JL, Takala J. Summary of round table conference: gut dysfunction in critical illness. Intensive Care Med. 1997;23:476&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142592</ArticleId></ArticleIdList></Reference><Reference><Citation>Balthazar EJ, Freeny PC, vanSonnenberg E. Imaging and intervention in acute pancreatitis. Radiology. 1994;193:297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">7972730</ArticleId></ArticleIdList></Reference><Reference><Citation>Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, De Waele J, Balogh Z, Lepp&#xe4;niemi A, Olvera C, Ivatury R, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med. 2006;32:1722&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967294</ArticleId></ArticleIdList></Reference><Reference><Citation>Layer P, Bronisch HJ, Henniges UM, Koop I, Kahl M, Dignass A, Ell C, Freitag M, Keller J. Effects of systemic administration of a local anesthetic on pain in acute pancreatitis: a randomized clinical trial. Pancreas. 2011;40:673&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke L, Ni HB, Tong ZH, Li WQ, Li N, Li JS. Intra-abdominal pressure and abdominal perfusion pressure: which is a better marker of severity in patients with severe acute pancreatitis. J Gastrointest Surg. 2011;15:1426&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">21557012</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Bahrani AZ, Abid GH, Sahgal E, O&#x2019;shea S, Lee S, Ammori BJ. A prospective evaluation of CT features predictive of intra-abdominal hypertension and abdominal compartment syndrome in critically ill surgical patients. Clin Radiol. 2007;62:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556037</ArticleId></ArticleIdList></Reference><Reference><Citation>Siewert B, Raptopoulos V. CT of the acute abdomen: findings and impact on diagnosis and treatment. AJR Am J Roentgenol. 1994;163:1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">7992721</ArticleId></ArticleIdList></Reference><Reference><Citation>Reintam A, Parm P, Redlich U, Tooding LM, Starkopf J, K&#xf6;hler F, Spies C, Kern H. Gastrointestinal failure in intensive care: a retrospective clinical study in three different intensive care units in Germany and Estonia. BMC Gastroenterol. 2006;6:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513588</ArticleId><ArticleId IdType="pubmed">16792799</ArticleId></ArticleIdList></Reference><Reference><Citation>Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12:R90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575570</ArticleId><ArticleId IdType="pubmed">18625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhan O, Ozmen MN, Basgun N, Akinci D, Oguz O, Koroglu M, Karcaaltincaba M. Long-term results of celiac Ganglia block: correlation of grade of tumoral invasion and pain relief. AJR Am J Roentgenol. 2004;182:891&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039160</ArticleId></ArticleIdList></Reference><Reference><Citation>Borley NR. Abdominal oesophagus and stomach. In: Standring S, ed , editors. Gray&#x2019;s Anatomy. 39th ed. Edinburgh, UK: Elsevier Churchill Livingstone; 2005. p. 1150.</Citation></Reference><Reference><Citation>Lee JM. CT-guided celiac plexus block for intractable abdominal pain. J Korean Med Sci. 2000;15:173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3054618</ArticleId><ArticleId IdType="pubmed">10803693</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton FJ, Kandiah SS, Monkhouse WS, Lee MJ. Helical CT evaluation of the perirenal space and its boundaries: a cadaveric study. Radiology. 2001;218:659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230636</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik PE, Zaloga GP. Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. BMJ. 2004;328:1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC421778</ArticleId><ArticleId IdType="pubmed">15175229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sielenk&#xe4;mper AW, Eicker K, Van Aken H. Thoracic epidural anesthesia increases mucosal perfusion in ileum of rats. Anesthesiology. 2000;93:844&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">10969320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19939284</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies.</ArticleTitle><Pagination><StartPage>R188</StartPage><MedlinePgn>R188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc8182</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">An excessive inflammatory response is thought to account for the pathogenesis of sepsis and multiple organ dysfunction syndrome (MODS) after severe trauma. The interleukin-10 (IL-10) is a potent anti-inflammatory cytokine. The objectives of this prospective study were to investigate the distribution of IL-10 promoter polymorphisms in a cohort of 308 Chinese Han patients with major trauma, and to identify associations of IL-10 promoter polymorphisms with IL-10 production and incidence of sepsis and MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 308 patients with major trauma were included in this study. The genotypes of polymorphisms -1082, -819 and -592 were determined by polymerase chain reaction-restriction fragment length polymorphism. The IL-10 levels in the supernatants were determined with enzyme-linked immunoabsorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The -1082A and -592A alleles were significantly associated with lower lipopolysaccharide-induced IL-10 production in an allele-dose dependent fashion. There was no significant difference for the -819 polymorphism. Except for the -1082 polymorphism, the -819 and -592 polymorphisms were not significantly associated with sepsis morbidity rate and MOD scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results further confirm the functionality of the IL-10 promoter single nucleotide polymorphisms in relation to IL-10 production. They also suggest that individual difference in IL-10 production in trauma patients might be at least in part related to genetic variations in the IL-10 promoter region.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Yuzhong District, Chongqing, 400042, PR China. zengling_1025@126.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kehong</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Dongpo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lianyang</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Dingyuan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Suna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2010;14(1):119. doi: 10.1186/cc8839.</RefSource><PMID Version="1">20236506</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19939284</ArticleId><ArticleId IdType="pmc">PMC2811917</ArticleId><ArticleId IdType="doi">10.1186/cc8182</ArticleId><ArticleId IdType="pii">cc8182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang ZG, Jiang JX. An overview of research advances in road traffic trauma in China. Traffic Injury Prevention. 2003;4:9&#x2013;16. doi: 10.1080/15389580309860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15389580309860</ArticleId><ArticleId IdType="pubmed">14522656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JX. Posttraumatic stress and immune dissonance. Chin J Traumatol. 2008;11:203&#x2013;208. doi: 10.1016/S1008-1275(08)60044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1008-1275(08)60044-9</ArticleId><ArticleId IdType="pubmed">18667117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Ausevic ML, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JX. Genomic polymorphisms and sepsis. Chin J Traumatol. 2005;21:45&#x2013;49.</Citation></Reference><Reference><Citation>Gu W, Du DY, Huang J, Zhang LY, Liu Q, Zhu PF, Wang ZG, Jiang JX. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg. 2007;246:151&#x2013;158. doi: 10.1097/01.sla.0000262788.67171.3f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000262788.67171.3f</ArticleId><ArticleId IdType="pmc">PMC1899213</ArticleId><ArticleId IdType="pubmed">17592304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann TR. Properties and functions of interleukin-10. Adv Immunol. 1994;56:1&#x2013;26. full_text.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073945</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205&#x2013;218. doi: 10.1111/j.1600-065X.2008.00706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00706.x</ArticleId><ArticleId IdType="pmc">PMC2724982</ArticleId><ArticleId IdType="pubmed">19161426</ArticleId></ArticleIdList></Reference><Reference><Citation>Welborn Mr, Moldawer LL, Seeger JM, Minter RM, Huber TS. Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion. Shock. 2003;20:35&#x2013;40. doi: 10.1097/01.SHK.0000071062.67193.b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.SHK.0000071062.67193.b6</ArticleId><ArticleId IdType="pubmed">12813366</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidhardt R, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, Ertel W. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma. 1997;42:863&#x2013;871. doi: 10.1097/00005373-199705000-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199705000-00017</ArticleId><ArticleId IdType="pubmed">9191668</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel DO, Hamilton J, Brock M, May W, Calcote L, Tee LY, Vick L, Newman DB, Vick K, Harrison S, Timberlake G, Toevs C. Molecular analysis of inflammatory markers in trauma patients at risk of postinjury complications. J Trauma. 2007;63:147&#x2013;157. doi: 10.1097/TA.0b013e31806bf0ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31806bf0ab</ArticleId><ArticleId IdType="pubmed">17622883</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170&#x2013;173. doi: 10.1016/S0140-6736(96)06413-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)06413-6</ArticleId><ArticleId IdType="pubmed">9111542</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart D, Fulton WB, Wilson C, Monitto CL, Paidas CN, Reeves RH, De Maio A. Genetic contribution to the septic response in a mouse model. Shock. 2002;18:342&#x2013;347. doi: 10.1097/00024382-200210000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200210000-00009</ArticleId><ArticleId IdType="pubmed">12392278</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D, Templeton D, Radford-Smith GL. TNF alpha and IL10 SNPs act together to predict disease behavior in Crohn's disease. J Med Genet. 2005;42:523&#x2013;528. doi: 10.1136/jmg.2004.027425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2004.027425</ArticleId><ArticleId IdType="pmc">PMC1736076</ArticleId><ArticleId IdType="pubmed">15937090</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, Zhang J, Li XW, Chen WY, Pan YX, Yang FP, Gu NF, Feng GY, Yang SL, He JY, Liu BX, Peng YW, Liu J, He L. Interleukin-10-1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci Lett. 2006;394:1&#x2013;4. doi: 10.1016/j.neulet.2005.06.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.06.054</ArticleId><ArticleId IdType="pubmed">16378687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ni H, Chen L, Song WQ. Interleukin-10 promoter polymorphism in patients with hepatitis B virus infection or hepatocellular carcinomain Chinese Han ethnic population. Hepatobiliary Pancreat Dis Int. 2005;5:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Hei P, Deng L, Lin J. Interleukin-10 gene promoter polymorphisms and their protein production in peritoneal fluid in patients with endometriosis. Mol Hum Reprod. 2007;13:135&#x2013;140. doi: 10.1093/molehr/gal106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gal106</ArticleId><ArticleId IdType="pubmed">17178764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging. 2005;26:1005&#x2013;1010. doi: 10.1016/j.neurobiolaging.2004.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.08.010</ArticleId><ArticleId IdType="pubmed">15748779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, Pothier L, Christiani DC. Interleukin-10 polymorphism in position - 1082 and acute respiratory distress syndrome. Eur Respir J. 2006;27:674&#x2013;681. doi: 10.1183/09031936.06.00046405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.06.00046405</ArticleId><ArticleId IdType="pmc">PMC3090261</ArticleId><ArticleId IdType="pubmed">16585075</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med. 2006;32:260&#x2013;266. doi: 10.1007/s00134-005-0022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-005-0022-4</ArticleId><ArticleId IdType="pubmed">16435103</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder O, Laun RA, Held B, Ekkernkamp A, Schulte KM. Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock. 2004;21:306&#x2013;310. doi: 10.1097/00024382-200404000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200404000-00003</ArticleId><ArticleId IdType="pubmed">15179129</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero JM, Lopez PS, Cozar JM, Carretero R, Canton J, Vazquez F, Concha A, Tallada M, Garrido F, Ruiz-Cabello F. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009;70:60&#x2013;64. doi: 10.1016/j.humimm.2008.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.10.020</ArticleId><ArticleId IdType="pubmed">19027043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Qu YB, Tang YX, Cao DZ, Sun P, Xia ZL. Lack of association between cytokine gene polymorphisms and silicosis and pulmonary tuberculosis in Chinese iron miners. J Occup Health. 2008;50:445&#x2013;454. doi: 10.1539/joh.L8006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1539/joh.L8006</ArticleId><ArticleId IdType="pubmed">18931463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder O, Schulte KM, Schroeder J, Ekkernkamp A, Laun RA. The -1082 interleukin-10 polymorphism is associated with acute respiratory failure after major trauma: a prospective cohort study. Surgery. 2008;143:233&#x2013;242. doi: 10.1016/j.surg.2007.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2007.07.040</ArticleId><ArticleId IdType="pubmed">18242340</ArticleId></ArticleIdList></Reference><Reference><Citation>The Abbreviated Injury Scale. Barrington. Illinois: Association for the Advancement of Automotive Medicine. 2005.</Citation></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Power and Sample Size Program. http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize</Citation></Reference><Reference><Citation>Chung BS, Lee JK, Choi MH, Park MH, Choi D, Hong ST. Single nucleotide polymorphisms of cytokine genes are associated with fibrosis of the intrahepatic bile duct wall in human clonorchiasis. Korean J Parasitol. 2009;47:145&#x2013;151. doi: 10.3347/kjp.2009.47.2.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3347/kjp.2009.47.2.145</ArticleId><ArticleId IdType="pmc">PMC2688796</ArticleId><ArticleId IdType="pubmed">19488421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng LH, Storer B, Petersdorf E, Lin MT, Chien JW, Grogan BM, Malkki M, Chen PJ, Zhao LP, Martin PJ, Hansen JA. IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation. 2009;87:704&#x2013;710. doi: 10.1097/TP.0b013e318195c474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e318195c474</ArticleId><ArticleId IdType="pmc">PMC3019105</ArticleId><ArticleId IdType="pubmed">19295315</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez M, Romero-Gomez M, Madrazo A, Duran JA, De Dios AM, Borraz Y, Navarro JM, Andrade RJ. Analysis of IL-10, IL-4 and TNF-a polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008;49:107&#x2013;114. doi: 10.1016/j.jhep.2008.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2008.03.017</ArticleId><ArticleId IdType="pubmed">18485518</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865&#x2013;872. doi: 10.1016/S0140-6736(03)12715-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)12715-8</ArticleId><ArticleId IdType="pubmed">12642066</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendrop RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence of cytokine production and fatal meningococcal disease. Lancet. 1997;349:170&#x2013;173. doi: 10.1016/S0140-6736(96)06413-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)06413-6</ArticleId><ArticleId IdType="pubmed">9111542</ArticleId></ArticleIdList></Reference><Reference><Citation>MOTIF Search. http://motif.genome.jp</Citation></Reference><Reference><Citation>Keijsers V, Verweij CL, Westendorp RGJ, Breedveld FC, Huizinga TWJ. IL10 polymorphisms in relation to production and rheumatoid arthritis. Arthritis Rheum. 1997;40:179&#x2013;185. doi: 10.1002/art.1780400123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400123</ArticleId><ArticleId IdType="pubmed">9008614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine gene polymorphism influence mucosal cytokine expression, gastric inflammation and host specific colonization during Helicobacter pylori infection. Gut. 2004;53:1082&#x2013;1089. doi: 10.1136/gut.2003.029736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.029736</ArticleId><ArticleId IdType="pmc">PMC1774164</ArticleId><ArticleId IdType="pubmed">15247172</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid CL, Perrey C, Pravica V, Hutchinson IV, Campbell IT. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med. 2003;30:2216&#x2013;2221. doi: 10.1097/00003246-200210000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200210000-00007</ArticleId><ArticleId IdType="pubmed">12394947</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, van Griensven M, Tsiridis E, Pape HC. The genetic predisposition to adverse outcome after trauma. J Bone Joint Surg Br. 2007;89:1273&#x2013;1279. doi: 10.1302/0301-620X.89B10.19022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.89B10.19022</ArticleId><ArticleId IdType="pubmed">17957062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen AQ, Wang J, Feng K, Zhu PF, Wang ZG, Jiang JX. Effects of haplotypes in the interleukin 1 beta promoter on lipopolysacchride-induced interleukin 1 beta expression. Shock. 2006;26:25&#x2013;30. doi: 10.1097/01.shk.0000223125.56888.c7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000223125.56888.c7</ArticleId><ArticleId IdType="pubmed">16783194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand F, Pape HC, van Griensven M, Meier S, Hasenkamp S, Krettek C, Stuhrmann M. Genentic predisposition for a compromised immune system after multiple trauma. Shock. 2005;24:518&#x2013;522. doi: 10.1097/01.shk.0000184212.97488.4e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000184212.97488.4e</ArticleId><ArticleId IdType="pubmed">16317381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23582344</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2165</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</Title><ISOAbbreviation>Eur J Vasc Endovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Perioperative haemorrhage in endovascular abdominal aneurysm repair affects outcome.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>92</EndPage><MedlinePgn>87-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejvs.2013.02.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1078-5884(13)00133-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to evaluate the outcome and predisposing factors related to perioperative bleeding in patients treated with endovascular aneurysm repair (EVAR) for ruptured and non-ruptured abdominal aortic aneurysm (AAA).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a retrospective cohort study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 525 consecutive patients (73% elective) with AAA underwent EVAR at two vascular centres from 2008 to 2011. From registry data perioperative bleeding was analysed in relation to outcome and preoperative data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 453 (86%) patients presented with a perioperative bleeding &lt;1000 ml, 42 (8%) patients 1000-1999 ml, 19 (4%) patients 2000-5000 ml and 11 (2%) &gt;5000 ml. Other than ruptured AAA (n = 90), no preoperative risk factors for increased perioperative bleeding were found. Open femoral artery access (n = 101), branched (n = 18) and uni-iliacal endografts (n = 18) and introducer size were associated with increased perioperative bleeding (P &lt; 0.001). In multivariable logistic regression only rupture and perioperative bleeding &gt;2000 ml were significantly related to 30-day mortality (odds ratio 10.6 (range 3.8-29.6) and 13.4 (range 4.8-37.4), respectively). Postoperative renal failure, multi-organ failure, &gt;5 days at intensive care unit, bowel ischaemia and abdominal compartments syndrome were significantly related to perioperative bleeding &gt;2000 ml (P &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Large perioperative bleeding during EVAR is a clinical problem that affects outcome. About 10% of elective AAA patients and 34% of patients with ruptured AAA, undergoing EVAR, present a perioperative blood loss exceeding 1 l. In our study, a perioperative blood loss exceeding 2 l was independently associated with increased mortality and morbidity in both acute and elective AAA patients. Open femoral access, branched EVAR and larger diameter introducers were associated with increased perioperative blood loss. ETHICAL APPLICATION: 2011/664-31/3 (approved).</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mont&#xe1;n</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center of Molecular Medicine and Surgery, Department of Vascular Surgery, Karolinska Institute, Karolinska University Hospital, Stockholm SE-171 76, Sweden. carl.montan@karolinska.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wannberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Holst</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wahlgren</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Vasc Endovasc Surg</MedlineTA><NlmUniqueID>9512728</NlmUniqueID><ISSNLinking>1078-5884</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057510" MajorTopicYN="Y">Endovascular Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23582344</ArticleId><ArticleId IdType="doi">10.1016/j.ejvs.2013.02.011</ArticleId><ArticleId IdType="pii">S1078-5884(13)00133-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38926003</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8422</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of cardiothoracic and vascular anesthesia</Title><ISOAbbreviation>J Cardiothorac Vasc Anesth</ISOAbbreviation></Journal><ArticleTitle>Trends in the Utilization of Multiorgan Support Among Adults Undergoing High-risk Cardiac Surgery in the United States.</ArticleTitle><Pagination><StartPage>1987</StartPage><EndPage>1995</EndPage><MedlinePgn>1987-1995</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.jvca.2024.04.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1053-0770(24)00296-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine trends in the prevalence of multiorgan dysfunction (MODS), utilization of multi-organ support (MOS), and mortality among patients undergoing cardiac surgery with MODS who received MOS in the United States.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">183 hospitals in the Premier Healthcare Database.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adults &#x2265;18 years old undergoing high-risk elective or non-elective cardiac surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">none.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">The exposure was time (consecutive calendar quarters) January 2008 and June 2018. We analyzed hospital data using day-stamped hospital billing codes and diagnosis and procedure codes to assess MODS prevalence, MOS utilization, and mortality. Among 129,102 elective and 136,190 non-elective high-risk cardiac surgical cases across 183 hospitals, 10,001 (7.7%) and 21,556 (15.8%) of patients developed MODS, respectively. Among patients who experienced MODS, 2,181 (22%) of elective and 5,425 (25%) of non-elective cardiac surgical cases utilized MOS. From 2008-2018, MODS increased in both high-risk elective and non-elective cardiac surgical cases. Similarly, MOS increased in both high-risk elective and non-elective cardiac surgical cases. As a component of MOS, mechanical circulatory support (MCS) increased over time. Over the study period, risk-adjusted mortality, in patients who developed MODS receiving MOS, increased in high-risk non-elective cardiac surgery and decreased in high-risk elective cardiac surgery, despite increasing MODS prevalence and MOS utilization (p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among patients undergoing high-risk cardiac surgery in the United States, MODS prevalence and MOS utilization (including MCS) increased over time. Risk-adjusted mortality trends differed in elective and non-elective cardiac surgery. Further research is necessary to optimize outcomes among patients undergoing high-risk cardiac surgery.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cobert</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anesthesia Service, San Francisco VA Health Care System, San Francisco, CA; Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University Medical Center, Durham, NC. Electronic address: Julien.Cobert@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frere</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Yale University. Department of Statistics. New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wongsripuemtet</LastName><ForeName>Pattrapun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University Medical Center, Durham, NC; Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnuma</LastName><ForeName>Tetsu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Department of Anesthesiology, Duke University, Durham, NC; Department of Population Health Sciences, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>Allyson C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Palliative Medicine, Department of Internal Medicine, University of California San Francisco, San Francisco, CA; Department of Surgery, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaport</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghadimi</LastName><ForeName>Kamrouz</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California San Francisco, San Francisco, CA; Department of Anesthesiology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartz</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Brigham and Women's Hospital, Harvard University. Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghunathan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Critical Care and Perioperative Population Health Research (CAPER) Unit, Department of Anesthesiology, Duke University Medical Center, Durham, NC; Department of Anesthesiology, Duke University, Durham, NC; Department of Population Health Sciences, Duke University, Durham, NC; Anesthesia Service, Durham VA Healthcare System. Durham, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiothorac Vasc Anesth</MedlineTA><NlmUniqueID>9110208</NlmUniqueID><ISSNLinking>1053-0770</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult cardiac surgery</Keyword><Keyword MajorTopicYN="N">mechanical circulatory support</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">multiorgan failure</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JC reports consulting fees from Teleflex, but there are no other conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>21</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38926003</ArticleId><ArticleId IdType="doi">10.1053/j.jvca.2024.04.038</ArticleId><ArticleId IdType="pii">S1053-0770(24)00296-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15179129</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1073-2322</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study.</ArticleTitle><Pagination><StartPage>306</StartPage><EndPage>310</EndPage><MedlinePgn>306-10</MedlinePgn></Pagination><Abstract><AbstractText>A dysbalanced immune response is thought to account for a substantial part of the morbidity and mortality after severe trauma. The cytokine interleukin-10 (IL-10) suppresses the transcription of proinflammatory cytokines, mainly in macrophages and monocytes. The objectives of this prospective study in a level I trauma center in Germany were to examine the distribution of IL-10 promoter polymorphisms in a cohort of severely injured patients, to measure IL-10 cytokine levels and relate these to the genotype, and to identify associations of IL-10 polymorphisms with the incidence of severe multiple organ dysfunction syndrome (MODS). The genotypes of polymorphisms -592 and -1082 were determined by polymerase chain reaction (PCR) and restriction cleavage with Rsa 1 or Mnl I, respectively. We analyzed 119 severely injured trauma patients [mean Injury Severity Score (ISS) 38.0 +/- 13.2]. The frequency of the -1082A allele was 0.542, and that of the -592C allele was 0.807. IL-10 polymorphisms were not significantly associated with mean systemic IL-10 cytokine levels 6, 12, and 18 h after admission to the ICU. Carriers of the genotype -592AC had significantly higher overall MOD scores than non-AC carriers (P = 0.018; P(corr) = 0.036). The genotypes of the IL-10 SNP -1082 were not significantly associated with MOD scores. A multivariate Cox hazard regression analysis including important factors of the patients' anatomic and physiological trauma impact revealed only the shock index, the severity of the head injury, and the IL-10 -592 genotype AC as significant independent risk factors for the development of MODS. In this multivariate analysis, carriers of the genotype -592AC displayed a 3.3-fold increase in the relative risk of developing a MODS (P = 0.008, hazard ratio 3.29, 95% CI 1.36-7.97). Our data suggest a possible link between the AC genotype of the -592 single nucleotide polymorphism and significantly higher mean MOD scores. The AC genotype was associated in multivariate analysis with a higher relative risk of MODS in multiply injured patients. Further investigations in larger cohorts need to focus on the potential diagnostic and therapeutic options of this SNP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Ove</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Ernst-Moritz-Arndt-University of Greifswald, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laun</LastName><ForeName>Reinhold Alexander</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ekkernkamp</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Klaus-Martin</ForeName><Initials>KM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15179129</ArticleId><ArticleId IdType="doi">10.1097/00024382-200404000-00003</ArticleId><ArticleId IdType="pii">00024382-200404000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16698594</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1499-3872</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Hepatobiliary &amp; pancreatic diseases international : HBPD INT</Title><ISOAbbreviation>Hepatobiliary Pancreat Dis Int</ISOAbbreviation></Journal><ArticleTitle>Is there a role for serum endothelin in predicting the severity of acute pancreatitis?</ArticleTitle><Pagination><StartPage>290</StartPage><EndPage>293</EndPage><MedlinePgn>290-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute pancreatitis remains a common presentation to acute surgical units and carries significant morbidity and mortality. The progression of the disease to necrotizing pancreatitis and multi-organ dysfunction syndrome (MODS) is associated with a very poor clinical outcome, and persistently high mortality. Increases in serum endothelin (ET) have been seen in animal models of acute pancreatitis and this study aims to investigate whether there is a change in serum ET-1 in patients with acute pancreatitis and whether any such change is linked to disease severity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All patients admitted with acute pancreatitis were prospectively recruited from the emergency admissions at the Norfolk and Norwich University Hospital. Serum ET levels were determined on admission, at 24 hours and 5 days post admission. Healthy adult controls were recruited from dermatology outpatients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 21 patients joined the trial after giving informed consent. There were 3 men and 18 women with a median age of 65 years (range 26-87 years). Serum ET levels were significantly higher in acute pancreatitis patients than in normal controls (P&lt;0.05). An association was seen between persistently raised serum ET levels and progression to MODS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study does demonstrate a correlation between the circulating levels of ET and acute pancreatitis in humans, although it does not elicit its involvement in the pathogenesis of the disease. The observation that a persistently high level of circulating ET-1 is associated with progression to MODS may indicate a role for ET in the monitoring of acute pancreatitis patients for recovery or progression to MODS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Norfolk, England. jj@doctors.org.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Balakrishnan</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rhodes</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Hepatobiliary Pancreat Dis Int</MedlineTA><NlmUniqueID>101151457</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016232">Endothelins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016232" MajorTopicYN="N">Endothelins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010186" MajorTopicYN="N">Pancreatic Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16698594</ArticleId><ArticleId IdType="pii">836</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21443081</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0172-6390</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>104</Issue><PubDate><Year>2010</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Hepato-gastroenterology</Title><ISOAbbreviation>Hepatogastroenterology</ISOAbbreviation></Journal><ArticleTitle>Surgical treatment of Klatskin tumor: liver resection versus transplantation.</ArticleTitle><Pagination><StartPage>1337</StartPage><EndPage>1340</EndPage><MedlinePgn>1337-40</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Our objective was to evaluate liver transplantation as a treatment option for Klatskin tumor. Results for transplanted patients suffering from hilar cholangiocarcinoma were therefore compared to patients after hemihepatectomy.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">In a retrospective case-control study, seven patients transplanted for hilar cholangiocarcinoma were matched in terms of UICC stage with seven patients who underwent resection of the hilar bifurcation combined with a hemihepatectomy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median survival was 22 months (range 1-55 months) for patients after liver resection and 64 months (range 1-138 months) for patients after liver transplantation. One and three year overall survival was 71% and 43% after liver resection versus 71% and 57% after liver transplantation. One patient from each group died within one month after surgery. Fatal cerebral bleeding and post-resection liver failure leading to multi-organ failure and sepsis were the causes of early mortality. Three patients are currently alive: one with 64 months after transplantation and two patients with 42 and 55 months after liver resection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on our findings and recently published promising results using liver transplantation for Klatskin tumor, it seems worthwhile to reconsider its potential use in the light of multimodal tumor treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Gernot M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of General, visceral, and Transplantation Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany gernot.kaiser@uk-essen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotiropoulos</LastName><ForeName>Georgios C</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Sgourakis</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bleck</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Hideo Andreas</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Beckebaumr</LastName><ForeName>Susanne n</ForeName><Initials>Sn</Initials></Author><Author ValidYN="Y"><LastName>Gerken</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Trarbach</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Hepatogastroenterology</MedlineTA><NlmUniqueID>8007849</NlmUniqueID><ISSNLinking>0172-6390</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001650" MajorTopicYN="N">Bile Duct Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006498" MajorTopicYN="N">Hepatectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006500" MajorTopicYN="Y">Hepatic Duct, Common</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018285" MajorTopicYN="N">Klatskin Tumor</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21443081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19595327</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Is dopexamine superior to dopamine in the treatment of multiple trauma patients--a prospective, double-blind, randomised study.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>505</EndPage><MedlinePgn>499-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2009.06.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The goal of this prospective, randomised, double-blind clinical trial study was to assess the effects of dopexamine hydrochloride on organ failure, inflammatory mediators and splanchnic oxygenation in blunt multiple trauma patients at high risk of multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a prospective randomised controlled trial on 30 consecutive blunt multiple trauma patients with ISS&gt;or=16, age 18-60 years and initial blood pressure &gt;or=120 mmHg initially admitted to our level I trauma centre. Patients were randomised to treatment with dopamine (n=15) or dopexamine (n=15) for 48 h after admission. Outcome in terms of mortality, MODS, splanchnic perfusion, complications, duration of stay was statistically analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The indication to use dopexamine hydrochloride appears questionable. In the absence of an antiinflammatory effect, dopexamine demonstrated a disadvantageous ICU course in regards to the organ function and the duration of treatment. In addition, a decreased pHi and MEGX formation suggested a deterioration of splanchnic oxygenation.</AbstractText><CopyrightInformation>(c) 2009 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Hannover Medical School, 30623 Hannover, Germany. probst.christian@mh-hannover.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baur</LastName><ForeName>Hellmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mahlke</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>Hans-Christoph</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Grotz</LastName><ForeName>Martin Rolf Wolfgang</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>398E7Z7JB5</RegistryNumber><NameOfSubstance UI="C046318">dopexamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>98PI200987</RegistryNumber><NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>D8Q99HC770</RegistryNumber><NameOfSubstance UI="C001173">monoethylglycinexylidide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005753" MajorTopicYN="N">Gastric Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008012" MajorTopicYN="N">Lidocaine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013152" MajorTopicYN="N">Splanchnic Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014781" MajorTopicYN="N">Viscera</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19595327</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2009.06.018</ArticleId><ArticleId IdType="pii">S0020-1383(09)00310-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18212641</PMID><DateCompleted><Year>2008</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2008</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>What happened to total parenteral nutrition? The disappearance of its use in a trauma intensive care unit.</ArticleTitle><Pagination><StartPage>1215</StartPage><EndPage>1222</EndPage><MedlinePgn>1215-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e31815b83e9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total parenteral nutrition (TPN) is associated with known costs, including the use of invasive procedures, which may be necessary to optimize care. Our purpose was to document TPN use in trauma patients over time as well as concurrent changes in TPN-associated complications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective analysis of all consecutive trauma patients admitted to the surgical intensive care unit during a period of 6 years from a Level I trauma center. Comparative cohorts and the matched case-control approaches were used to analyze the difference in outcomes between patients with and without TPN during hospitalization. Logistic regression model was used to compare the outcomes of the two groups of patients adjusting for significant risk factors. The McNemar's test was used to assess the differences in outcomes between the cases and their matched controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 2,964 patients admitted to the surgical intensive care unit during the 6-year period and 464 patients received TPN during their hospital course. TPN use decreased significantly from 26% in the year 2000 to 3% in 2005 (p &lt; 0.0001). Excluding those who died in the first 72 hours, the mortality rate was significantly lower (5.4% no TPN vs. 10.2% TPN, p = 0.001) in patients who were managed without TPN. Complication rates (wound infection, dehiscence, line sepsis, bacteremia, sepsis, pneumonia, renal failure, acute respiratory distress syndrome, multiple organ dysfunction syndrome, deep venous thrombosis, pulmonary embolism) were significantly higher in patients that were managed with TPN. Multivariate analysis adjusting for abbreviated injury score, injury severity score, mechanism, admission year, dialysis, ventilator use, hollow viscous injury, and solid organ injury found that TPN use was still an independent risk factor for increased complications but not death. The matched case-control approach confirmed this finding. TPN use was also associated with increase intensive care unit and hospital length of stay.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The rate of TPN use has declined significantly from 26% to 3% during the 6-year period. The change in practice of minimizing TPN was concurrent with decreased complications and less hospital resource utilization without negatively impacting mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trauma Division, University of Arizona, Phoenix, Arizona, USA. prhee@surgery.arizona.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjizacharia</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Trankiem</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Salim</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Inaba</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Jenifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Demetriades</LastName><ForeName>Demetrios</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010289" MajorTopicYN="N">Parenteral Nutrition, Total</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014193" MajorTopicYN="N">Trauma Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18212641</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31815b83e9</ArticleId><ArticleId IdType="pii">00005373-200712000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15998424</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1478-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Liver international : official journal of the International Association for the Study of the Liver</Title><ISOAbbreviation>Liver Int</ISOAbbreviation></Journal><ArticleTitle>Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation -- a pilot study.</ArticleTitle><Pagination><StartPage>740</StartPage><EndPage>745</EndPage><MedlinePgn>740-5</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this prospective study was to evaluate the effectiveness of preconditioning molecular adsorbent recirculating system (MARS) treatment on patients with acute-on-chronic liver failure (AoCLF), who were awaiting living donor liver transplantation (LDLT).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between January and December 2001, 10 consecutive AoCLF patients (with progressive hyperbilirubinemia (&gt;20 mg/dl) and hepatic encephalopathy grade &gt; or =2) were studied. MARS was used in eight of these patients who were evaluated for LDLT during 2001. Three AoCLF patients who received LDLT before clinical use of MARS were used as historical controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Because of a shortage of donors, only five out of 10 patients considered for LDLT could receive transplants. Three patients were treated with MARS for 8 h the day before receiving LDLT, and all three survived. The remaining two patients who received transplants, and who were not pretreated with MARS, died from sepsis and multi-organ failure within 2 weeks. Four of the patients who did not receive transplants because of donor shortage died despite 1 or 3 MARS treatments, however bilirubin levels and grade of encephalopathy were significantly reduced in these patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results of this small pilot study suggest that MARS, by reducing the severity of jaundice and encephalopathy, might be effective as a bridging option in AoCLF patients awaiting LDLT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jong Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. jychoi@cmc.cuk.ac.kr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Si Hyun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seung Kew</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Se Hyun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jin Mo</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Joon Yeol</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Byung Min</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kyu Won</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hee Sik</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong Goo</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Liver Int</MedlineTA><NlmUniqueID>101160857</NlmUniqueID><ISSNLinking>1478-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017093" MajorTopicYN="N">Liver Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019164" MajorTopicYN="Y">Liver, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019520" MajorTopicYN="N">Living Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015990" MajorTopicYN="N">Placebo Effect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016060" MajorTopicYN="N">Sorption Detoxification</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="Y">Transplantation Conditioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15998424</ArticleId><ArticleId IdType="doi">10.1111/j.1478-3231.2005.01074.x</ArticleId><ArticleId IdType="pii">LIV1074</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20118780</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>251</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Red blood cell transfusion threshold in postsurgical pediatric intensive care patients: a randomized clinical trial.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>427</EndPage><MedlinePgn>421-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0b013e3181c5dc2e</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal transfusion threshold after surgery in children is unknown. We analyzed the general surgery subgroup of the TRIPICU (Transfusion Requirements in Pediatric Intensive Care Units) study to determine the impact of a restrictive versus a liberal transfusion strategy on new or progressive multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The TRIPICU study, a prospective randomized controlled trial conducted in 17 centers, enrolled a total of 648 critically ill children with a hemoglobin equal to or below 9.5 g/dL within 7 days of pediatric intensive care unit (PICU) admission to receive prestorage leukocyte-reduced red-cell transfusion if their hemoglobin dropped below either 7.0 g/dL (restrictive) or 9.5 g/dL (liberal). A subgroup of 124 postoperative patients (60 randomized to restrictive and 64 to the liberal group) were analyzed. This study was registered at http://www.controlled-trials.com and carries the following ID ISRCTN37246456.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants in the restrictive and liberal groups were similar at randomization in age (restrictive vs. liberal: 53.5 +/- 51.8 vs. 73.7 +/- 61.8 months), severity of illness (pediatric risk of mortality [PRISM] score: 3.5 +/- 4.0 vs. 4.4 +/- 4.0), MODS (35% vs. 29%), need for mechanical ventilation (77% vs. 74%), and hemoglobin level (7.7 +/- 1.1 vs. 7.9 +/- 1.0 g/dL). The mean hemoglobin level remained 2.3 g/dL lower in the restrictive group after randomization. No significant differences were found for new or progressive MODS (8% vs. 9%; P = 0.83) or for 28-day mortality (2% vs. 2%; P = 0.96) in the restrictive versus liberal group. However, there was a statistically significant difference between groups for PICU length of stay (7.7 +/- 6.6 days for the restrictive group vs. 11.6 +/- 10.2 days for the liberal group; P = 0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this subgroup analysis of pediatric general surgery patients, we found no conclusive evidence that a restrictive red-cell transfusion strategy, as compared with a liberal one, increased the rate of new or progressive MODS or mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rouette</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Critical Care Unit, Sainte-Justine Hospital, Universit&#xe9; de Montr&#xe9;al, Montreal, QC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trottier</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Beaunoyer</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Canadian Critical Care Trials Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PALISI Network</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN37246456</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>130770</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>84300</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20118780</ArticleId><ArticleId IdType="doi">10.1097/SLA.0b013e3181c5dc2e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40899696</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0488</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of burn care &amp; research : official publication of the American Burn Association</Title><ISOAbbreviation>J Burn Care Res</ISOAbbreviation></Journal><ArticleTitle>Early Dysregulation of Angiopoietin-1 and -2 as a Predictor of Mortality in Critically Ill Burn Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">iraf172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jbcr/iraf172</ELocationID><Abstract><AbstractText>Shock-induced endothelial dysfunction plays a critical role in burn pathophysiology, with endothelial glycocalyx layer (EGL) degradation promoting systemic inflammation, vascular instability, and multi-organ failure. The Angiopoietin-TIE2 axis, particularly the Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) balance, regulates endothelial function; elevated Ang-2 and a high Ang-2/1 ratio are linked to worse outcomes in critical illness. While well-documented in sepsis and trauma, effects of burn-induced Angiopoietin dysregulation remains unclear. This study evaluates Ang-1, Ang-2, and the Ang-2/1 ratio as biomarkers of endothelial dysfunction and predictors of 30-day mortality in burn patients. In this prospective study, 62 adult burn patients were enrolled (January 2021-November 2024), with serum Ang-1 and Ang-2 measured via ELISA on post-burn day 1 (PBD1). Of 62 patients, 52 were analyzed; 78.05% of survivors and 90.91% of non-survivors were male. Median age was 45 (survivors) vs. 54 years (non-survivors, p = 0.139). Non-survivors trended toward burns &gt;20% TBSA (72.73% vs. 41.46%, p = 0.093). Ang-1 was lower in non-survivors (3.96 vs. 7.97 ng/mL, p&lt;0.001), predicting early mortality (AUROC 0.82) with a cut-off of 4.825 ng/mL and decreased mortality risk (OR 0.63, 95% CI 0.40-0.87, p = 0.017). Ang-2 was higher (6.07 vs. 1.99 ng/mL, p&lt;0.001; AUROC 0.95), with a cut-off of 3.554 ng/mL. The Ang-2/1 ratio was elevated (1.59 vs. 0.23, p&lt;0.001; AUROC 0.93), with a cut-off of 0.504 and increased mortality risk (OR 2.17, 95% CI 1.10-5.12, p = 0.038). Early Ang-1, Ang-2, and Ang-2/1 ratio levels correlate with 30-day mortality and may guide early prognostication.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-1809-6023</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Loyola University Medical Center, Maywood, IL, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plum</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galicia</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Surgery, Loyola University Medical Center, Maywood, IL, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helenowski</LastName><ForeName>Irena B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipp</LastName><ForeName>Madison D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Mary Grace</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Loyola University Medical Center, Maywood, IL, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhry</LastName><ForeName>Mashkoor A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubasiak</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Loyola University Medical Center, Maywood, IL, US.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burn and Shock Trauma Research Institute, Loyola University Chicago, Maywood, IL, US.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Burn Care Res</MedlineTA><NlmUniqueID>101262774</NlmUniqueID><ISSNLinking>1559-047X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiopoietin</Keyword><Keyword MajorTopicYN="N">Burn injury</Keyword><Keyword MajorTopicYN="N">Endothelial glycocalyx</Keyword><Keyword MajorTopicYN="N">Endotheliopathy</Keyword><Keyword MajorTopicYN="N">Prognostic Biomarkers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40899696</ArticleId><ArticleId IdType="doi">10.1093/jbcr/iraf172</ArticleId><ArticleId IdType="pii">8246627</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26068807</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1877-0568</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Orthopaedics &amp; traumatology, surgery &amp; research : OTSR</Title><ISOAbbreviation>Orthop Traumatol Surg Res</ISOAbbreviation></Journal><ArticleTitle>Early inflammatory response in polytraumatized patients: Cytokines and heat shock proteins. A pilot study.</ArticleTitle><Pagination><StartPage>607</StartPage><EndPage>611</EndPage><MedlinePgn>607-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.otsr.2015.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1877-0568(15)00107-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In the initial phases after polytrauma there is an hyperinflammatory state that sometimes leads to multiple organ dysfunction syndrome (MODS) and death, and that appears to be responsible for posttraumatic immunosuppression; among the trigger endogenous stimuli, heat shock proteins (HSPs) have been proposed. The objectives of this study were to analyze if some inflammatory mediators can be considered prognostic biomarkers of outcome, and the possible role of HSPA1A in posttraumatic immunosuppression.</AbstractText><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Cytokines and HSPs could be early prognostic biomarkers of inflammatory and immune response in polytrauma patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospective observational descriptive pilot study was carried out, evaluating the early inflammatory and stress response of 18 polytraumatized patients (ISS&gt;16) on hospital admission, at 12hours, 24hours, and 48hours posttrauma. Variable means were compared using non-parametric tests; qualitative and quantitative variables were analyzed using a Spearman's correlation test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven patients met criteria for MODS. Statistically significant changes were recorded in leukocyte count, C-reactive-protein (CRP), IL-6, TNF-&#x3b1;, and IL-1&#xdf; concentrations. HSPA1A levels were significantly higher immediately after the accident followed by gradual lowering. Anti-Hsp70 antibodies showed a significant reduction in all the studied time-points. MODS did not influence either plasma levels of leukocytes, fibrinogen, RCP or anti-Hsp70, but patients with MODS had higher plasma levels of IL-6 and TNF-&#x3b1; and a slower decrease of HSPA1A concentrations.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The higher serum concentrations of TNF-&#x3b1; and IL-6 found in patients with MODS, suggests a possible role as potential early predictive markers for systemic inflammatory response and clinical complications. The higher levels of HSPA1A in patients with MODS, allows proposing HSPA1A as a useful prognostic trauma biomarker early after severe injury and to consider a "damage control surgery". The significant reduction in the levels of anti-Hsp70 antibodies could reflect a part of posttraumatic immunosuppression and hydrocortisone treatment might be suggested.</AbstractText><AbstractText Label="LEVEL III" NlmCategory="METHODS">case-control study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guisasola</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medicina y Cirug&#xed;a Experimental, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Dr. Esquerdo 46, 28007 Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain. Electronic address: mguisasola@mce.hggm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chana</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaquero</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Orthop Traumatol Surg Res</MedlineTA><NlmUniqueID>101494830</NlmUniqueID><ISSNLinking>1877-0568</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490786">HSPA1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Heat shock proteins</Keyword><Keyword MajorTopicYN="N">Inflammatory response</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">Posttraumatic immunosuppresion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26068807</ArticleId><ArticleId IdType="doi">10.1016/j.otsr.2015.03.014</ArticleId><ArticleId IdType="pii">S1877-0568(15)00107-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21924400</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1883</ISSN><JournalIssue CitedMedium="Internet"><Volume>203</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>American journal of surgery</Title><ISOAbbreviation>Am J Surg</ISOAbbreviation></Journal><ArticleTitle>Prestorage leukoreduction abrogates the detrimental effect of aging on packed red cells transfused after trauma: a prospective cohort study.</ArticleTitle><Pagination><StartPage>198</StartPage><EndPage>204</EndPage><MedlinePgn>198-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjsurg.2011.05.012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to prospectively duplicate previous retrospective findings showing that prestorage leukoreduction blunts the detrimental effect of aging on banked packed red blood cells transfused after injury.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Over 19 months, trauma patients transfused with &#x2265;4 U of packed red blood cells and surviving &#x2265;24 hours were followed. The age of each unit was collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort consisted of 153 patients. All models showed no association between advancing blood age and the likelihood of developing multiple-organ dysfunction syndrome or infections, regardless of whether the mean age of blood was analyzed as a continuous variable, as a percentage of blood received that was &lt;14 days old, or as a dichotomized value &gt;14 or &lt;14 days old.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This prospective study duplicates previous retrospective findings of an abrogation of the detrimental effects of advancing mean packed red blood cell age on outcomes after trauma by performing prestorage leukoreduction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phelan</LastName><ForeName>Herb A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Burns/Trauma/Critical Care, University of Texas Southwestern Medical School, Dallas, USA. herb.phelan@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eastman</LastName><ForeName>Alexander L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Aldy</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Nakonezny</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Jan</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>Jessi L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixiao</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Friese</LastName><ForeName>Randall S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Minei</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR024983</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Surg</MedlineTA><NlmUniqueID>0370473</NlmUniqueID><ISSNLinking>0002-9610</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001771" MajorTopicYN="N">Blood Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001800" MajorTopicYN="Y">Blood Specimen Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004905" MajorTopicYN="N">Erythrocyte Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047589" MajorTopicYN="Y">Leukocyte Reduction Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21924400</ArticleId><ArticleId IdType="mid">NIHMS315099</ArticleId><ArticleId IdType="pmc">PMC3243822</ArticleId><ArticleId IdType="doi">10.1016/j.amjsurg.2011.05.012</ArticleId><ArticleId IdType="pii">S0002-9610(11)00441-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Opelz G, Sengar DP, Mickey MR, Teraski PI. Effect of blood transfusions on subsequent kidney transplants. Transplantation Proceedings. 1973;5:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">4572098</ArticleId></ArticleIdList></Reference><Reference><Citation>Opelz G, Teraski J. Improvement of kidney-graft survival with increased numbers of blood transfusions. NEJM. 1978;299:799&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">357971</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster RS, Jr, Costanza MC, Foster JC, et al. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer. 1985;55:1195&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">3971293</ArticleId></ArticleIdList></Reference><Reference><Citation>Creasy TS, Veitch PS, Bell PR. A relationship between perioperative blood transfusion and recurrence of carcinoma of the sigmoid colon following potentially curative surgery. Ann of Royal Coll Surg of England. 1987;69:100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2498481</ArticleId><ArticleId IdType="pubmed">3605994</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg N, Heal J, Chuang C, et al. Further evidence supporting a cause and effect relationship between blood transfusion and earlier cancer recurrence. Ann Surg. 1988;207:410&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1493418</ArticleId><ArticleId IdType="pubmed">3355265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. BJS. 1993;80:427&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8192723</ArticleId></ArticleIdList></Reference><Reference><Citation>Edna TH, Bjerkeset T. Association between transfusion of stored blood and infective bacterial complications after resection for colorectal cancer. European J Surg. 1998;164:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">9696446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarugi M, Buccianti P, Disarli M, et al. Effect of blood transfusions on disease-free interval after rectal cancer surgery. Hepato-Gastroenterology. 2000;47:1002&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020864</ArticleId></ArticleIdList></Reference><Reference><Citation>Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. Canadian J Anesthesia. 1997;44:1256&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pubmed">9429042</ArticleId></ArticleIdList></Reference><Reference><Citation>Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg. 1999;178:570&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670874</ArticleId></ArticleIdList></Reference><Reference><Citation>Offner PJ, Moore EE, Biffl WL, et al. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002;137:711&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">12049543</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen HJ, Reimert CM, Pedersen AN, et al. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood. Transfusion. 1996;36:960&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">8937404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansson M, Soop M, Saraste L, Sundqvist KG. Cytokines in stored red blood cell concentrates: promoters of systemic inflammation and simulators of acute transfusion reactions? Acta Anaesthesiologica Scandinavica. 1996;40:496&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738697</ArticleId></ArticleIdList></Reference><Reference><Citation>Silliman CC, Clay KL, Thurman GW, et al. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med. 1994;124:684&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451958</ArticleId><ArticleId IdType="pubmed">7964126</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Carroll CL, Staff I, et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Critical Care (London, England) 1999;13(5):R151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784373</ArticleId><ArticleId IdType="pubmed">19772604</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan HA, Sperry JL, Friese RS. Leukoreduction before red cell transfusion has no impact on mortality in trauma patients. Journal of Surgical Research. 2007;138:32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathens AB, Nester TA, Rubenfeld GD, et al. The effects of leukoreduced blood transfusion on infection risk following injury: A randomized controlled trial. Shock. 2006;26:342&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980879</ArticleId></ArticleIdList></Reference><Reference><Citation>Friese RS, Sperry JL, Phelan HA, et al. The use of leukoreduced red cell products is associated with fewer infectious complications in trauma patients. Am J Surg. 2008;196(1):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513694</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan HA, Gonzalez RP, Patel H, et al. Prestorage leukoreduction ameliorates the detrimental effects of age on stored blood. J Trauma. 2010;69(2):330&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153987</ArticleId><ArticleId IdType="pubmed">20699741</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg JA, McGwin G, Jr, Griffin RL, et al. Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma. 2008;65:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695462</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26988541</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2016</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1221-9118</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Chirurgia (Bucharest, Romania : 1990)</Title><ISOAbbreviation>Chirurgia (Bucur)</ISOAbbreviation></Journal><ArticleTitle>To Study the Aetiological Factors and Outcomes of Urgent Re-Laparotomy in Himalayan Hospital.</ArticleTitle><Pagination><StartPage>58</StartPage><EndPage>63</EndPage><MedlinePgn>58-63</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment of a number of complications that occur after abdominal surgeries may require that Urgent Relaparotomy (UR), the life-saving and obligatory operations, are performed. The objectives of this study were to evaluate the reasons for performing URs, their outcomes and factors that affect mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Observational, Prospective Study. The study included all the patients who underwent urgent re-laparotomy following laparotomy (emergency, elective) in Himalayan Hospital from 01.01.2013 to 01.06.2014 and excluded those who underwent laparotomy outside.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">UR was performed for 40 out of 1050 patients (4.2%), of which males were 25 and females 15. The average time interval between the index laparotomy and urgent re-exploration was 6.4 days. The most common reason for mortality was multi organ failure with septic shock. The most common criteria for re-exploration were anastomotic leak (n=13), followed by pyoperitoneum (n=11) and persistent peritonitis (n=6). Comparing the index surgery, lower gastro-intestinal procedures were most usually involved (n=21, 47.7%), followed by hepato-pancreato-biliary surgeries (n=8, 18.2%). There were 6 cases of upper gastro-intestinal surgeries that reexplored (13.6%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">UR that is performed following complicated abdominal surgeries has high mortality rates. In particular, they have higher mortality rates following GIS surgeries or when infectious complications occur.</AbstractText><CopyrightInformation>Celsius.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Arunav</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sahu</LastName><ForeName>Shantanu Kumar</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Nautiyal</LastName><ForeName>Mayank</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Navneet</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><CollectiveName>-</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Chirurgia (Bucur)</MedlineTA><NlmUniqueID>9213031</NlmUniqueID><ISSNLinking>1221-9118</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000006" MajorTopicYN="N">Abdomen, Acute</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004630" MajorTopicYN="N">Emergencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007410" MajorTopicYN="N">Intestinal Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009390" MajorTopicYN="N" Type="Geographic">Nepal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26988541</ArticleId><ArticleId IdType="pii">8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31279260</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-8673</ISSN><JournalIssue CitedMedium="Internet"><Volume>244</Volume><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of surgical research</Title><ISOAbbreviation>J Surg Res</ISOAbbreviation></Journal><ArticleTitle>Elevations in Circulating sST2 Levels Are Associated With In-Hospital Mortality and Adverse Clinical Outcomes After Blunt Trauma.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>33</EndPage><MedlinePgn>23-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jss.2019.05.057</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-4804(19)30386-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Soluble suppression of tumorigenicity 2 (sST2), a decoy receptor for interleukin (IL)-33, has emerged as a novel biomarker in various disease processes. Recent studies have elucidated the role of the sST2/IL-33 complex in modulating the balance of Th1/Th2 immune responses after tissue stress. However, the role of sST2 as a biomarker after traumatic injury remains unclear. To address this, we evaluated serum sST2 correlations with mortality and in-hospital adverse outcomes as endpoints in blunt trauma patients.</AbstractText><AbstractText Label="METHODS">We retrospectively analyzed clinical and biobank data of 493 blunt trauma victims 472 survivors (mean age: 48.4&#xa0;&#xb1;&#xa0;0.87; injury severity score [ISS]: 19.6&#xa0;&#xb1;&#xa0;0.48) and 19 nonsurvivors (mean age: 58.8&#xa0;&#xb1;&#xa0;4.5; ISS: 23.3&#xa0;&#xb1;&#xa0;2.1) admitted to the intensive care unit. Given the confounding impact of age on the inflammatory response, we derived a propensity-matched survivor subgroup (n&#xa0;=&#xa0;19; mean age: 59&#xa0;&#xb1;&#xa0;3; ISS: 23.4&#xa0;&#xb1;&#xa0;2) using an IBM SPSS case-control matching algorithm. Serial blood samples were obtained from all patients (3 samples within the first 24&#xa0;h and then once daily from day [D] 1 to D5 after injury). sST2 and twenty-nine inflammatory biomarkers were assayed using enzyme-linked immunosorbent assay and Luminex, respectively. Two-way analysis of variance on ranks was used to compare groups (P&#xa0;&lt;&#xa0;0.05). Spearman rank correlation was performed to determine the association of circulating sST2 levels with biomarker levels and in-hospital clinical outcomes.</AbstractText><AbstractText Label="RESULTS">Circulating sST2 levels of the nonsurvivor cohort were statistically significantly elevated at 12&#xa0;h after injury and remained elevated up to D5 when compared either to the overall 472 survivor cohort or a matched 19 survivor subcohort. Admission sST2 levels obtained from the first blood draw after injury in the survivor cohort correlated positively with admission base deficit (correlation coefficient [CC]&#xa0;=&#xa0;0.1; P&#xa0;=&#xa0;0.02), international normalized ratio (CC&#xa0;=&#xa0;0.1, P&#xa0;=&#xa0;0.03), ISS (CC&#xa0;=&#xa0;0.1, P&#xa0;=&#xa0;0.008), and the average Marshall multiple organ dysfunction score between D2 and D5 (CC&#xa0;=&#xa0;0.1, P&#xa0;=&#xa0;0.04). Correlations with ISS revealed a positive correlation of ISS with plasma sST2 levels across the mild ISS (CC&#xa0;=&#xa0;0.47, P&#xa0;&lt;&#xa0;0.001), moderate ISS (CC&#xa0;=&#xa0;0.58, P&#xa0;&lt;&#xa0;0.001), and severe ISS groups (CC&#xa0;=&#xa0;0.63, P&#xa0;&lt;&#xa0;0.001). Analysis of biomarker correlations in the matched survivor group over the initial 24&#xa0;h after injury showed that sST2 correlates strongly and positively with IL-4 (CC&#xa0;=&#xa0;0.65, P&#xa0;=&#xa0;0.002), IL-5 (CC&#xa0;=&#xa0;0.57, P&#xa0;=&#xa0;0.01), IL-21 (CC&#xa0;=&#xa0;0.52, P&#xa0;=&#xa0;0.02), IL-2 (CC&#xa0;=&#xa0;0.51, P&#xa0;=&#xa0;0.02), soluble IL-2 receptor-&#x3b1; (CC&#xa0;=&#xa0;0.5, P&#xa0;=&#xa0;0.02), IL-13 (CC&#xa0;=&#xa0;0.49, P&#xa0;=&#xa0;0.02), and IL-17A (CC&#xa0;=&#xa0;0.48, P&#xa0;=&#xa0;0.03). This was not seen in the matched nonsurvivor group. sST2/IL-33 ratios were significantly elevated in nonsurvivors and patients with severe injury based on ISS &#x2265;&#xa0;25.</AbstractText><AbstractText Label="CONCLUSIONS">Elevations in serum sST2 levels are associated with poor clinical trajectories and mortality after blunt trauma. High sST2 coupled with low IL-33 associates with severe injury, mortality, and worse clinical outcomes. These findings suggest that sST2 could serve as an early prognostic biomarker in trauma patients and that sustained elevations of sST2 could contribute to a detrimental suppression of IL-33 bioavailability in patients with high injury severity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Isabel M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guardado</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Malak</LastName><ForeName>Othman</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodovotz</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative, Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative, Medicine, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namas</LastName><ForeName>Rami A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative, Medicine, Pittsburgh, Pennsylvania. Electronic address: namasra2@upmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 GM053789</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Surg Res</MedlineTA><NlmUniqueID>0376340</NlmUniqueID><ISSNLinking>0022-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079241">IL1RL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506536">IL33 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072179">Interleukin-1 Receptor-Like 1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067596">Interleukin-33</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072179" MajorTopicYN="N">Interleukin-1 Receptor-Like 1 Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067596" MajorTopicYN="N">Interleukin-33</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute inflammation</Keyword><Keyword MajorTopicYN="N">Base deficit</Keyword><Keyword MajorTopicYN="N">Blunt trauma</Keyword><Keyword MajorTopicYN="N">Clinical outcomes</Keyword><Keyword MajorTopicYN="N">Coagulopathy</Keyword><Keyword MajorTopicYN="N">Inflammatory biomarkers</Keyword><Keyword MajorTopicYN="N">Injury severity</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Soluble suppression of tumorigenicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31279260</ArticleId><ArticleId IdType="mid">NIHMS1531219</ArticleId><ArticleId IdType="pmc">PMC6815699</ArticleId><ArticleId IdType="doi">10.1016/j.jss.2019.05.057</ArticleId><ArticleId IdType="pii">S0022-4804(19)30386-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, Morozoff C, Kutz MJ, Huynh C, Barber RM, Shackelford KA, Mackenbach JP, van Lenthe FJ et al.: US County-Level Trends in Mortality Rates for Major Causes of Death, 1980&#x2013;2014. JAMA 2016, 316(22):2385&#x2013;2401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576343</ArticleId><ArticleId IdType="pubmed">27959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Vodovotz Y, Almahmoud K, Abdul-Malak O, Zaaqoq A, Namas R, Mi Q, Barclay D, Zuckerbraun B, Peitzman AB et al.: Temporal Patterns of Circulating Inflammation Biomarker Networks Differentiate Susceptibility to Nosocomial Infection Following Blunt Trauma in Humans. Ann Surg 2016, 263(1):191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136774</ArticleId><ArticleId IdType="pubmed">25371118</ArticleId></ArticleIdList></Reference><Reference><Citation>von Ruden C, Woltmann A, Rose M, Wurm S, Ruger M, Hierholzer C, Buhren V: Outcome after severe multiple trauma: a retrospective analysis. J Trauma Manag Outcomes 2013, 7(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698044</ArticleId><ArticleId IdType="pubmed">23675931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschoeke SK, Ertel W: Immunoparalysis after multiple trauma. Injury 2007, 38(12):1346&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048039</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Mi Q, Namas R, Almahmoud K, Zaaqoq AM, Abdul-Malak O, Azhar N, Day J, Abboud A, Zamora R et al.: Insights into the Role of Chemokines, Damage-Associated Molecular Patterns, and Lymphocyte-Derived Mediators from Computational Models of Trauma-Induced Inflammation. Antioxidants &amp; redox signaling 2015, 23(17):1370&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685502</ArticleId><ArticleId IdType="pubmed">26560096</ArticleId></ArticleIdList></Reference><Reference><Citation>Glance LG, Osler TM, Mukamel DB, Dick AW: Outcomes of adult trauma patients admitted to trauma centers in Pennsylvania, 2000&#x2013;2009. Archives of surgery 2012, 147(8):732&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">22911068</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP et al.: A genomic storm in critically injured humans. J Exp Med 2011, 208(13):2581&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal MD, Moore FA: Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. J Adv Nutr Hum Metab 2015, 1(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467914</ArticleId><ArticleId IdType="pubmed">26086042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingraham AM, Xiong W, Hemmila MR, Shafi S, Goble S, Neal ML, Nathens AB: The attributable mortality and length of stay of trauma-related complications: a matched cohort study. Ann Surg 2010, 252(2):358&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">20622658</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV: Current concepts of the inflammatory response after major trauma: an update. Injury 2003, 34(6):397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG: Systemic inflammation after trauma. Injury 2007, 38(12):1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Almahmoud K, Mi Q, Ghuma A, Namas R, Zaaqoq A, Zhu X, Abdul-Malak O, Sperry J, Zamora R et al.: Individual-specific principal component analysis of circulating inflammatory mediators predicts early organ dysfunction in trauma patients. Journal of critical care 2016, 36:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5097026</ArticleId><ArticleId IdType="pubmed">27546764</ArticleId></ArticleIdList></Reference><Reference><Citation>Roumen RM, Hendriks T, van der Ven-Jongekrijg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, Goris RJ: Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993, 218(6):769&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1243073</ArticleId><ArticleId IdType="pubmed">8257227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O&#x2019;Keefe G, Sperry J et al.: Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock 2010, 34(4):346&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud A, Namas RA, Ramadan M, Mi Q, Almahmoud K, Abdul-Malak O, Azhar N, Zaaqoq A, Namas R, Barclay DA et al.: Computational Analysis Supports an Early, Type 17 Cell-Associated Divergence of Blunt Trauma Survival and Mortality. Crit Care Med 2016, 44(11):e1074&#x2013;e1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201164</ArticleId><ArticleId IdType="pubmed">27513538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera CP, Manson J, Shepherd JM, Torrance HD, Watson D, Longhi MP, Hoti M, Patel MB, O&#x2019;Dwyer M, Nourshargh S et al.: Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: A prospective cohort study. PLoS medicine 2017, 14(7):e1002352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5513400</ArticleId><ArticleId IdType="pubmed">28715416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeldine J, Naumann DN, Toman E, Davies D, Bishop JRB, Su Z, Hampson P, Dinsdale RJ, Crombie N, Duggal NA et al.: Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study. PLoS medicine 2017, 14(7):e1002338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5515405</ArticleId><ArticleId IdType="pubmed">28719602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker AB, Krijnen P, Schipper IB: Predictive value of cytokines for developing complications after polytrauma. World journal of critical care medicine 2016, 5(3):187&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986547</ArticleId><ArticleId IdType="pubmed">27652210</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuchowski MF, Welch K, Siddiqui J, Remick DG: Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. Journal of immunology 2006, 177(3):1967&#x2013;1974.</Citation><ArticleIdList><ArticleId IdType="pubmed">16849510</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I: Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007, 28(6):668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamparello AJ, Namas RA, Constantine G, Vodovotz Y, Billiar TR: A Conceptual Time Window-Based Model for the Early Stratification of Trauma Patients. Journal of Internal Medicine 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30623510</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Guardado J, Hoffman R, Xu H, Namas R, Vodovotz Y, Xu L, Ramadan M, Brown J, Turnquist HR et al.: IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS medicine 2017, 14(7):e1002365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526517</ArticleId><ArticleId IdType="pubmed">28742815</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew FY, Girard JP, Turnquist HR: Interleukin-33 in health and disease. Nature reviews Immunology 2016, 16(11):676&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">27640624</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Turnquist HR, Hoffman R, Billiar TR: Role of the IL-33-ST2 axis in sepsis. Military Medical Research 2017, 4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288881</ArticleId><ArticleId IdType="pubmed">28168040</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RV, Januzzi JL Jr.: ST2: a novel remodeling biomarker in acute and chronic heart failure. Current heart failure reports 2010, 7(1):9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20425491</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y: ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochemical and biophysical research communications 2002, 299(1):18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435383</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109(18):2186&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pubmed">15117853</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA: Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflammatory bowel diseases 2010, 16(7):1097&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">20014018</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, Ebe K, Tanaka K, Sugiura H, Nakashima K et al.: Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Human molecular genetics 2005, 14(19):2919&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16118232</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sugiyama Y: Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. American journal of respiratory and critical care medicine 2001, 164(2):277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11463601</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, Graham GJ, Kurowska-Stolarska M, Liew FY, McSharry C et al.: IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. The Journal of allergy and clinical immunology 2014, 134(6):1422&#x2013;1432 e1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258609</ArticleId><ArticleId IdType="pubmed">24985397</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE, Gabay C: Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis and rheumatism 2009, 60(3):738&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">19248109</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML: Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. International journal of cancer 2014, 134(7):1669&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pubmed">24105680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013, 62(16):e147&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">23747642</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieplinger B, Mueller T: Soluble ST2 in heart failure. Clinica chimica acta; international journal of clinical chemistry 2015, 443:57&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">25269091</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YC, Chu PH: Soluble ST2: A Novel Prognostic Biomarker of Heart Failure. Acta Cardiologica Sinica 2014, 30(5):501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4834966</ArticleId><ArticleId IdType="pubmed">27122827</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5):721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T: Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive care medicine 2010, 36(4):630&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837188</ArticleId><ArticleId IdType="pubmed">20151106</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur M, Kim H, Kim HJ, Yang HS, Magrini L, Marino R, Cardelli P, Di Somma S, Network G: Soluble ST2 has a prognostic role in patients with suspected sepsis. Annals of laboratory medicine 2015, 35(6):570&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4579100</ArticleId><ArticleId IdType="pubmed">26354344</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ: Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23(10):1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa H, Hayakawa M, Kume A, Tominaga S: Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. The Journal of biological chemistry 2007, 282(36):26369&#x2013;26380.</Citation><ArticleIdList><ArticleId IdType="pubmed">17623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamparello AJ, Namas RA, Abdul-Malak O, Vodovotz Y, Billiar TR: Young and Aged Blunt Trauma Patients Display Major Differences in Circulating Inflammatory Mediator Profiles after Severe Injury. Journal of the American College of Surgeons 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7768550</ArticleId><ArticleId IdType="pubmed">30448299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperry JL, Vodovotz Y, Ferrell RE, Namas R, Chai YM, Feng QM, Jia WP, Forsythe RM, Peitzman AB, Billiar TR: Racial disparities and sex-based outcomes differences after severe injury. Journal of the American College of Surgeons 2012, 214(6):973&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360838</ArticleId><ArticleId IdType="pubmed">22521668</ArticleId></ArticleIdList></Reference><Reference><Citation>Almahmoud K, Namas RA, Abdul-Malak O, Zaaqoq AM, Zamora R, Zuckerbraun BS, Sperry J, Peitzman AB, Billiar TR, Vodovotz Y: Impact of Injury Severity on Dynamic Inflammation Networks Following Blunt Trauma. Shock 2015, 44(2):101&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504837</ArticleId><ArticleId IdType="pubmed">26009819</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr., Long WB: The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. The Journal of trauma 1974, 14(3):187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone RE, Santanello SA, Schulz MA, Monk J, Satiani B, Carey LC: Correlation of metabolic acidosis with outcome following injury and its value as a scoring tool. World journal of surgery 1993, 17(5):575&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">8273377</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunham CM, Siegel JH, Weireter L, Fabian M, Goodarzi S, Guadalupi P, Gettings L, Linberg SE, Vary TC: Oxygen debt and metabolic acidemia as quantitative predictors of mortality and the severity of the ischemic insult in hemorrhagic shock. Crit Care Med 1991, 19(2):231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">1989759</ArticleId></ArticleIdList></Reference><Reference><Citation>Maegele M: Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. World journal of emergency medicine 2010, 1(1):12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129771</ArticleId><ArticleId IdType="pubmed">25214935</ArticleId></ArticleIdList></Reference><Reference><Citation>Frith D, Davenport R, Brohi K: Acute traumatic coagulopathy. Current opinion in anaesthesiology 2012, 25(2):229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">22270921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ: Acute traumatic coagulopathy: clinical characterization and mechanistic investigation. Thrombosis research 2014, 133 Suppl 1:S25&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">24759135</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Malak O, Vodovotz Y, Zaaqoq A, Guardado J, Almahmoud K, Yin J, Zuckerbraun B, Peitzman AB, Sperry J, Billiar TR et al.: Elevated Admission Base s sDeficit Is Associated with a Complex Dynamic Network of Systemic Inflammation Which Drives Clinical Trajectories in Blunt Trauma Patients. Mediators of inflammation 2016, 2016:7950374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126463</ArticleId><ArticleId IdType="pubmed">27974867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E, Spittler A, Sautner T, Bonaros N, Wolner E et al.: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive care medicine 2004, 30(7):1468&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacker S, Lambers C, Pollreisz A, Hoetzenecker K, Lichtenauer M, Mangold A, Niederpold T, Hacker A, Lang G, Dworschak M et al.: Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. Journal of clinical laboratory analysis 2009, 23(6):372&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6649135</ArticleId><ArticleId IdType="pubmed">19927353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagenaar JF, Gasem MH, Goris MG, Leeflang M, Hartskeerl RA, van der Poll T, van &#x2018;t Veer C, van Gorp EC: Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS neglected tropical diseases 2009, 3(6):e453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684584</ArticleId><ArticleId IdType="pubmed">19488407</ArticleId></ArticleIdList></Reference><Reference><Citation>Younas M, Psomas C, Mehraj V, Cezar R, Portales P, Tuaillon E, Guigues A, Reynes J, Corbeau P, Routy JP: Plasma Level of Soluble ST2 in Chronically Infected HIV-1 Patients with Suppressed Viremia. The open AIDS journal 2017, 11:32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427803</ArticleId><ArticleId IdType="pubmed">28553430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Z, Mo Z, Zhu J, Pang X, Zheng X, Wu Z, Wang K, Li X, Xie D, Gao Z: Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure. Mediators of inflammation 2015, 2015:535938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393901</ArticleId><ArticleId IdType="pubmed">25892854</ArticleId></ArticleIdList></Reference><Reference><Citation>Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I: Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008, 41(2):114&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276732</ArticleId><ArticleId IdType="pubmed">18226917</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandara G, Beaven MA, Olivera A, Gilfillan AM, Metcalfe DD: Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. European journal of immunology 2015, 45(11):3034&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4813659</ArticleId><ArticleId IdType="pubmed">26256265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I et al.: ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Science translational medicine 2015, 7(308):308ra160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699312</ArticleId><ArticleId IdType="pubmed">26446957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, Nickl S, Dome B, Tschachler E, Ankersmit HJ: Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovascular research 2010, 87(4):769&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">20363761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A et al.: ST2 as a marker for risk of therapy-resistant graft-versushost disease and death. The New England journal of medicine 2013, 369(6):529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943357</ArticleId><ArticleId IdType="pubmed">23924003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH: High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. Translational oncology 2013, 6(3):311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660800</ArticleId><ArticleId IdType="pubmed">23730411</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature reviews Immunology 2010, 10(2):103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">20081870</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Fuente M, MacDonald TT, Hermoso MA: The IL-33/ST2 axis: Role in health and disease. Cytokine &amp; growth factor reviews 2015, 26(6):615&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">26271893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar R, Lee RT: The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature reviews Drug discovery 2008, 7(10):827&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277436</ArticleId><ArticleId IdType="pubmed">18827826</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5):479&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D: IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proceedings of the National Academy of Sciences of the United States of America 2015, 112(34):10762&#x2013;10767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4553775</ArticleId><ArticleId IdType="pubmed">26243875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirchandani AS, Salmond RJ, Liew FY: Interleukin-33 and the function of innate lymphoid cells. Trends in immunology 2012, 33(8):389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609147</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta BM, Reichenbach DK, Zhang X, Mathews L, Koehn BH, Dwyer GK, Lott JM, Uhl FM, Pfeifer D, Feser CJ et al.: Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 2016, 128(3):427439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957164</ArticleId><ArticleId IdType="pubmed">27222477</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, Turnquist HR: IL33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. Journal of immunology 2014, 193(8):4010&#x2013;4020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185240</ArticleId><ArticleId IdType="pubmed">25217167</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr., Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ et al.: Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nature medicine 2010, 16(6):708&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">20473304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, Graham GJ, Liew FY, Miller AM, McInnes IB: IL-33 induces skin inflammation with mast cell and neutrophil activation. European journal of immunology 2011, 41(8):2229&#x2013;2237.</Citation><ArticleIdList><ArticleId IdType="pubmed">21674479</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Xu J, Xu L, Jin S, Turnquist HR, Hoffman R, Loughran P, Billiar TR, Deng M: Interleukin-33 contributes to ILC2 activation and early inflammation-associated lung injury during abdominal sepsis. Immunology and cell biology 2018, 96(9):935947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10116412</ArticleId><ArticleId IdType="pubmed">29672927</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31621674</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">0974-5181</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Annals of cardiac anaesthesia</Title><ISOAbbreviation>Ann Card Anaesth</ISOAbbreviation></Journal><ArticleTitle>Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>393</EndPage><MedlinePgn>388-393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/aca.ACA_108_18</ELocationID><Abstract><AbstractText Label="BACKGROUND">Excessive bleeding and surgical reexploration are common complications that increase the risk of multi-organ failure and prolonged hospitalization after cardiac surgery. Off-label use of recombinant activated factor VII (rFVIIa) is a recommended treatment for refractory bleeding.</AbstractText><AbstractText Label="OBJECTIVE">The objective of the study is to determine if the adequacy of hemostatic resuscitation enhances the efficacy of rFVIIa.</AbstractText><AbstractText Label="METHODS">This retrospective, observational, cohort study included patients who received rFVIIa for refractory postoperative bleeding after cardiac surgery. Patients were divided into two groups based on the presence or absence of adequate coagulation resuscitation before rFVIIa administration, defined as international ratio (INR) &#x2264;1.5, platelet count &#x2265;100 K/mL, and fibrinogen &#x2265;200 mg/dL. The failure of rFVIIa treatment was defined as surgical reexploration within 24 h, thoracostomy drainage &gt;400 mL/h within 6 h or transfusion of additional blood products or another rFVIIa dose within 6 h after initial rFVIIa dose.</AbstractText><AbstractText Label="RESULTS">Of the 3833 patients, screened who underwent cardiothoracic surgery procedures, 58 patients received rFVIIa for refractory postoperative bleeding. Successful hemostasis with rFVIIa was more likely in patients who were adequately resuscitated compared with those who were not (20 [71.4%] vs. 10 [33.3%], respectively; P = 0.0046). Multiple logistic regression analysis indicated that patients who were adequately resuscitated before rFVIIa were less likely to fail treatment (odds ratio, 0.16; 95% confidence interval [0.04-0.62]; P = 0.007).</AbstractText><AbstractText Label="CONCLUSIONS">The therapeutic efficacy of rFVIIa is dependent on the adequacy of hemostatic resuscitation; restoration of normal serum fibrinogen, INR, and platelet counts &gt;100 K/mL may provide an adequate substrate for rFVIIa to be effective in managing refractory postoperative cardiac surgical bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feih</LastName><ForeName>Joel T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Froedtert and the Medical College of Wisconsin; Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juul</LastName><ForeName>Janelle J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G Rinka</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee; Department of Pharmacy Practice, Concordia University Wisconsin School of Pharmacy, Mequon, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann Kreuziger</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin; The Blood Center of Wisconsin, Blood Research Institute, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagel</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Medical College of Wisconsin; Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tawil</LastName><ForeName>Justin N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Ann Card Anaesth</MedlineTA><NlmUniqueID>9815987</NlmUniqueID><ISSNLinking>0971-9784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006490">Hemostatics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>AC71R787OV</RegistryNumber><NameOfSubstance UI="C103587">recombinant FVIIa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.21</RegistryNumber><NameOfSubstance UI="D015942">Factor VIIa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="Y">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015942" MajorTopicYN="N">Factor VIIa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006487" MajorTopicYN="Y">Hemostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006490" MajorTopicYN="N">Hemostatics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">coagulopathy</Keyword><Keyword MajorTopicYN="N">hemostasis</Keyword><Keyword MajorTopicYN="N">postoperative bleeding</Keyword><Keyword MajorTopicYN="N">recombinant activated factor VII</Keyword><Keyword MajorTopicYN="N">transfusion</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31621674</ArticleId><ArticleId IdType="pmc">PMC6813715</ArticleId><ArticleId IdType="doi">10.4103/aca.ACA_108_18</ArticleId><ArticleId IdType="pii">AnnCardAnaesth_2019_22_4_388_268545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996;111:1037&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">8622301</ArticleId></ArticleIdList></Reference><Reference><Citation>American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology. 2015;122:241&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">25545654</ArticleId></ArticleIdList></Reference><Reference><Citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21353044</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047223</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponschab M, Landoni G, Biondi-Zoccai G, Bignami E, Frati E, Nicolotti D, et al. Recombinant activated factor VII increases stroke in cardiac surgery: A meta-analysis. J Cardiothorac Vasc Anesth. 2011;25:804&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21596585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasowicz M, Meineri M, McCluskey SM, Mitsakakis N, Karkouti K. The utility of thromboelastography for guiding recombinant activated factor VII therapy for refractory hemorrhage after cardiac surgery. J Cardiothorac Vasc Anesth. 2009;23:828&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19467888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatta A, Mcquilten Z, Kandane-Rathnayake R, Isbister J, Dunkley S, Mcneil J, et al. The Australian and New Zealand Haemostasis Registry: Ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus. 2015;13:86&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317095</ArticleId><ArticleId IdType="pubmed">24960661</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein DM, Dutton RP, O'Connor J, Alexander M, Scalea TM. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma. 2005;59:609&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall K, Forrest P, Sawyer C. The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration. Anaesth Intensive Care. 2007;35:494&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18020065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, et al. Recombinant activated factor VII (NovoSeven): Addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang. 2004;87:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260820</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandsborg S, S&#xf8;rensen B, Poulsen LH, Ingerslev J. Recombinant activated factor VIIa in uncontrolled bleeding: A haemostasis laboratory study in non-haemophilia patients. Blood Coagul Fibrinolysis. 2006;17:241&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651865</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18606914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost. 1985;11:281&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">4048952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, Baryshnikova E, Ciotti E, Ranucci M, Silvetti S Surgical and Clinical Outcome REsearch (SCORE) Group. Hemodilution on cardiopulmonary bypass: Thromboelastography patterns and coagulation-related outcomes. J Cardiothorac Vasc Anesth. 2017;31:1588&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">28778772</ArticleId></ArticleIdList></Reference><Reference><Citation>Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95:596&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120:21&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19546387</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis. 2000;11(Suppl 1):S121&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850577</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen ND, Bhattacharya SD, Williams JB, Fosbol EL, Lockhart EL, Patel MB, et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg. 2012;93:1921&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718882</ArticleId><ArticleId IdType="pubmed">22551846</ArticleId></ArticleIdList></Reference><Reference><Citation>Brase J, Finger B, He J, Wirtz K, Stun L, McMillen R, et al. Analysis of outcomes using low-dose and early administration of recombinant activated factor VII in cardiac surgery. Ann Thorac Surg. 2016;102:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26874365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Bill&#xe8; G, et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): A propensity score analysis. Eur J Cardiothorac Surg. 2008;33:64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17996457</ArticleId></ArticleIdList></Reference><Reference><Citation>Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L, Rostagno C, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg. 2006;102:1320&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632803</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Garde EM, Bras LJ, Heijmen RH, Knibbe CA, van Dongen EP, Wiltink EH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth. 2006;20:573&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16884993</ArticleId></ArticleIdList></Reference><Reference><Citation>von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16:615&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12407617</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis C, Bird R, Mullany D, Cameron P, Phillips L. Use of rFVIIa for critical bleeding in cardiac surgery: Dose variation and patient outcomes. Vox Sang. 2010;98:531&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19878495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17523274</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0172-6390</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>74</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Hepato-gastroenterology</Title><ISOAbbreviation>Hepatogastroenterology</ISOAbbreviation></Journal><ArticleTitle>Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?</ArticleTitle><Pagination><StartPage>359</StartPage><EndPage>363</EndPage><MedlinePgn>359-63</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">In surgical sepsis, the rapid identification of source of infection at an early stage after surgery or serious trauma is crucial for favorable outcome. The discrimination between local and generalized infection is critical for correct treatment.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">In a randomized, controlled, single-centre study we investigated 72 patients with severe sepsis after major abdominal surgery or surgery for multiple trauma. Patients were divided in 2 groups: in the first group (PCT, n=38), more important role in the treatment decision was given to PCT level (severe sepsis with PCT &gt;2 ng/mL signalled bacteremia and pushed us to change antibiotics and intravascular devices, severe sepsis with PCT &lt; or =2 ng/mL prompted use of ultrasonography and/or CT, followed by repeated surgery in patients with localized infection). The control group (CON, n=34) was treated by standard evaluation of all parameters by consultant surgeon. We investigated 28-day all-cause mortality, sepsis-related complications, the duration of stay in the intensive care unit, and ventilated days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The hospital mortality was in PCT group 26% and 38% in control group (p = 0.28). Average SOFA score was 7.9 +/- 2.8 in PCT group vs. 9.3 +/- 3.3 (p = 0.06). The decline of ICU days (16.1 +/- 6.9 vs. 19.4 +/- 8.9; p = 0.09) and ventilated days (10.3 +/- 7.8 vs. 13.9 +/- 9.4; p = 0.08) in PCT group was observed, but the difference was not significant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed a clear tendency to decrease extent of multiple organ dysfunction syndrome in patients, in which therapeutic decision was made earlier using procalcitonin as an additional marker separating local infection from generalized one.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Svoboda</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Traumatological Hospital Brno, Research Center for Traumatology and Surgery, Brno. p.svoboda@unbr.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantorov&#xe1;</LastName><ForeName>Iona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Scheer</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Radvanova</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Radvan</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Hepatogastroenterology</MedlineTA><NlmUniqueID>8007849</NlmUniqueID><ISSNLinking>0172-6390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606589">CALCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>JHB2QIZ69Z</RegistryNumber><NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="N">Abdomen</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015740" MajorTopicYN="N">Calcitonin Gene-Related Peptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17523274</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17184516</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.</ArticleTitle><Pagination><StartPage>R178</StartPage><MedlinePgn>R178</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with severe trauma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Blunt and penetrating trauma patients were randomly assigned to rFVIIa (200 + 100 + 100 microg/kg) at 0, 1, and 3 hours after transfusion of 8 units of red blood cells (RBCs) or to placebo. Subjects were monitored for 48 hours post-dosing and followed for 30 days. Coagulopathy was retrospectively defined as transfusion of fresh frozen plasma (FFP) (&gt;1 unit of FFP per 4 units of RBCs), FFP in addition to whole blood, and transfusion of platelets and/or cryoprecipitate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty rFVIIa-treated and 76 placebo subjects were retrospectively identified as being coagulopathic. No significant differences were noted in baseline characteristics. The rFVIIa-treated coagulopathic subgroup consumed significantly less blood product: RBC transfusion decreased by 2.6 units for the whole study population (P = 0.02) and by 3.5 units among patients surviving more than 48 hours (P &lt; 0.001). Transfusion of FFP (1,400 versus 660 ml, P &lt; 0.01), platelet (300 versus 100 ml, P = 0.01), and massive transfusions (29% versus 6%, P &lt; 0.01) also dropped significantly. rFVIIa reduced multi-organ failure and/or acute respiratory distress syndrome in the coagulopathic patients (3% versus 20%, P = 0.004), whereas thromboembolic events were equally present in both groups (3% versus 4%, P = 1.00).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Coagulopathic trauma patients appear to derive particular benefit from early adjunctive rFVIIa therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizoli</LastName><ForeName>Sandro B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada. sandro.rizoli@sw.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boffard</LastName><ForeName>Kenneth D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Riou</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Iau</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kluger</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rossaint</LastName><ForeName>Rolf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tillinger</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>NovoSeven Trauma Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.21</RegistryNumber><NameOfSubstance UI="D015942">Factor VIIa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015942" MajorTopicYN="N">Factor VIIa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17184516</ArticleId><ArticleId IdType="pmc">PMC1794494</ArticleId><ArticleId IdType="doi">10.1186/cc5133</ArticleId><ArticleId IdType="pii">cc5133</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol. 2004;41(1 Suppl 1):40&#x2013;43. doi: 10.1053/j.seminhematol.2003.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2003.11.009</ArticleId><ArticleId IdType="pubmed">14872420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">7869433</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269&#x2013;1276. doi: 10.1016/S0140-6736(96)07493-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)07493-4</ArticleId><ArticleId IdType="pubmed">9142060</ArticleId></ArticleIdList></Reference><Reference><Citation>Peden M, McGee K, Sharma G. The Injury Chart Book: A Graphical Overview of the Global Burden of Injuries. Geneva: World Health Organization; 2002.</Citation></Reference><Reference><Citation>WHO report 2003: The World Health Report 2003 'Shaping the Future' </Citation></Reference><Reference><Citation>Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">12813333</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855879</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehling IC, Task Force Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732&#x2013;747. doi: 10.1097/00000542-199603000-00032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199603000-00032</ArticleId><ArticleId IdType="pubmed">8659805</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">15514523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma. 1997;42:857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang. 2004;87:34&#x2013;40. doi: 10.1111/j.1423-0410.2004.00533.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2004.00533.x</ArticleId><ArticleId IdType="pubmed">15260820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JF, De Moerloose P, Samama M, Groupe d'interet en Hemostase Perioperatoire Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth. 2004;51:293&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15064258</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542&#x2013;547. doi: 10.1046/j.1365-2141.1997.4463256.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.1997.4463256.x</ArticleId><ArticleId IdType="pubmed">9401063</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 1998;9 Suppl 1():S15&#x2013;S20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9819024</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinowitz U, Michaelson M, The Israeli Multidisciplinary rFVIIa Task Force Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640&#x2013;648. doi: 10.1111/j.1538-7836.2005.01203.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01203.x</ArticleId><ArticleId IdType="pubmed">15842347</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta JF, Ahrens CL, Tyburski JG, Wilson RF. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma. 2005;58:646&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15761369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth. 2005;94:592&#x2013;595. doi: 10.1093/bja/aei094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aei094</ArticleId><ArticleId IdType="pubmed">15708871</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal S, Shemesh IY, Blumental R, Yoffe B, Laufer N, Mankuta D, Mazor M, Zohar S, Schiff E, Martinovitz U. The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 2004;83:771&#x2013;772. doi: 10.1111/j.0001-6349.2004.00501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0001-6349.2004.00501.x</ArticleId><ArticleId IdType="pubmed">15255852</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg. 2005;28:254&#x2013;258. doi: 10.1016/j.ejcts.2005.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcts.2005.04.021</ArticleId><ArticleId IdType="pubmed">15935687</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66&#x2013;71. doi: 10.1016/j.athoracsur.2005.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2005.02.044</ArticleId><ArticleId IdType="pubmed">15975342</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey SA, Ghannam M, Sutton D, van Rensburg A, Karski J. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26&#x2013;34. doi: 10.1111/j.1537-2995.2005.04216.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2005.04216.x</ArticleId><ArticleId IdType="pubmed">15647015</ArticleId></ArticleIdList></Reference><Reference><Citation>Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, NovoSeven Trauma Study Group Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096533</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SC, Young GS, Talucci RC, Greenbaum BH, Ross SE. Delayed brain injury after head trauma: significance of coagulopathy. Neurosurgery. 1992;30:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">1545882</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou B, Landais P, Vivien B, Stell P, Labbene I, Carli P. Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients. Anesthesiology. 2001;95:56&#x2013;63. doi: 10.1097/00000542-200107000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200107000-00014</ArticleId><ArticleId IdType="pubmed">11465584</ArticleId></ArticleIdList></Reference><Reference><Citation>Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594&#x2013;596. doi: 10.1136/bmj.330.7491.594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.330.7491.594</ArticleId><ArticleId IdType="pmc">PMC554039</ArticleId><ArticleId IdType="pubmed">15761002</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Manach Y, Perel A, Coriat P, Godet G, Bertrand M, Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology. 2005;102:885&#x2013;891. doi: 10.1097/00000542-200505000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200505000-00004</ArticleId><ArticleId IdType="pubmed">15851872</ArticleId></ArticleIdList></Reference><Reference><Citation>Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Reviews. 2003;17:S11&#x2013;S21. doi: 10.1016/S0268-960X(03)90002-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0268-960X(03)90002-6</ArticleId><ArticleId IdType="pubmed">14697209</ArticleId></ArticleIdList></Reference><Reference><Citation>Spivey M, Parr MJ. Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol. 2005;71:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886589</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber MA. Damage control surgery. Crit Care Clin. 2004;20:101&#x2013;118. doi: 10.1016/S0749-0704(03)00095-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-0704(03)00095-2</ArticleId><ArticleId IdType="pubmed">14979332</ArticleId></ArticleIdList></Reference><Reference><Citation>ASA Transfusion Practice 3rd edition: Questions and Answers About Transfusion Practices. Third </Citation></Reference><Reference><Citation>Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med. 2002;28 Suppl 2():S241&#x2013;S247. doi: 10.1007/s00134-002-1471-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-002-1471-7</ArticleId><ArticleId IdType="pubmed">12404093</ArticleId></ArticleIdList></Reference><Reference><Citation>Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci. 2002;27:83&#x2013;92. doi: 10.1016/S1473-0502(02)00029-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-0502(02)00029-0</ArticleId><ArticleId IdType="pubmed">12201474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth. 2000;85:487&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11103199</ArticleId></ArticleIdList></Reference><Reference><Citation>Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion. 2004;44:809&#x2013;813. doi: 10.1111/j.1537-2995.2004.03409.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2004.03409.x</ArticleId><ArticleId IdType="pubmed">15157244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med. 2005;33:1191&#x2013;1198. doi: 10.1097/01.CCM.0000165566.82925.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000165566.82925.14</ArticleId><ArticleId IdType="pubmed">15942330</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325&#x2013;1331. doi: 10.1111/j.1537-2995.2004.04052.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2004.04052.x</ArticleId><ArticleId IdType="pubmed">15318856</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaslef SN, Knudsen NW, Neligan PJ, Sebastian MW. Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma. 2002;53:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22777113</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Resuscitation of traumatic hemorrhagic shock patients with hypertonic saline-without dextran-inhibits neutrophil and endothelial cell activation.</ArticleTitle><Pagination><StartPage>341</StartPage><EndPage>350</EndPage><MedlinePgn>341-50</MedlinePgn></Pagination><Abstract><AbstractText>Posttraumatic inflammation and excessive neutrophil activation cause multiple organ dysfunction syndrome (MODS), a major cause of death among hemorrhagic shock patients. Traditional resuscitation strategies may exacerbate inflammation; thus, novel fluid treatments are needed to reduce such posttraumatic complications. Hypertonic resuscitation fluids inhibit inflammation and reduce MODS in animal models. Here we studied the anti-inflammatory efficacy of hypertonic fluids in a controlled clinical trial. Trauma patients in hypovolemic shock were resuscitated in a prehospital setting with 250 mL of either 7.5% hypertonic saline (HS; n = 9), 7.5% hypertonic saline + 6% dextran 70 (HSD; n = 8), or 0.9% normal saline (NS; n = 17). Blood samples were collected on hospital admission and 12 and 24 h after resuscitation. Multicolor flow cytometry was used to quantify neutrophil expression of cell-surface activation/adhesion (CD11b, CD62L, CD64) and degranulation (CD63, CD66b, CD35) markers as well as oxidative burst activity. Circulating concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVACM-1), P- and E-selectins, myeloperoxidase (MPO), and matrix metalloproteinase 9 (MMP-9) were assessed by immunoassay. Multiple organ dysfunction syndrome, leukocytosis, and mortality were lower in the HS and HSD groups than in the NS group. However, these differences were not statistically significant. Hypertonic saline prevented priming and activation and neutrophil oxidative burst and CD11b and CD66b expression. Hypertonic saline also reduced circulating markers of neutrophil degranulation (MPO and MMP-9) and endothelial cell activation (sICAM-1, sVCAM-1, soluble E-selectin, and soluble P-selectin). Hypertonic saline + 6% dextran 70 was less capable than HS of suppressing the upregulation of most of these activation markers. This study demonstrates that initial resuscitation with HS, but neither NS nor HSD, can attenuate posttraumatic neutrophil and endothelial cell activation in hemorrhagic shock patients. These data suggest that hypertonic resuscitation without dextran may inhibit posttraumatic inflammation. However, despite this effect, neither HS nor HSD reduced MODS in trauma patients with hemorrhagic shock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Junger</LastName><ForeName>Wolfgang G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria. wjunger@bidmc.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhind</LastName><ForeName>Shawn G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Rizoli</LastName><ForeName>Sandro B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Cuschieri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shiu</LastName><ForeName>Maria Y</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Linglin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shek</LastName><ForeName>Pang N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Hoyt</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Bulger</LastName><ForeName>Eileen M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL077866</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PR043034</GrantID><Acronym>PR</Acronym><Agency>OCPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM060475</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077867</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM076101</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL073233</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM051477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 GM051477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI-080582</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI072287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077873</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077871</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077881</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077908</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077887</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077885</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U01 HL077865</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077863</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077908</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077872</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U01HL077863</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077873</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM-51477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077866</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077887</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM-60475</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI-072287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077881</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI080582</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077867</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077885</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077865</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077872</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012462">Saline Solution, Hypertonic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020896" MajorTopicYN="N">Hypovolemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018375" MajorTopicYN="N">Neutrophil Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="Y">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012462" MajorTopicYN="N">Saline Solution, Hypertonic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22777113</ArticleId><ArticleId IdType="mid">NIHMS392121</ArticleId><ArticleId IdType="pmc">PMC3455119</ArticleId><ArticleId IdType="doi">10.1097/SHK.0b013e3182635aca</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duchesne JC, Barbeau JM, Islam TM, Wahl G, Greiffenstein P, et al. Damage control resuscitation: from emergency department to the operating room. Am Surg. 2011;77:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">21337881</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, et al. Long-term survival of adult trauma patients. JAMA. 2011;305:1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">21386078</ArticleId></ArticleIdList></Reference><Reference><Citation>Angele MK, Schneider CP, Chaudry IH. Bench-to-bedside review: latest results in hemorrhagic shock. Crit Care. 2008;12:218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575549</ArticleId><ArticleId IdType="pubmed">18638356</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattstrom O, Granath F, Rossi P, Oldner A. Early predictors of morbidity and mortality in trauma patients treated in the intensive care unit. Acta Anaesthesiol Scand. 2010;54:1007&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury. 2010;41:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19729158</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med. 1995;3:277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790621</ArticleId></ArticleIdList></Reference><Reference><Citation>Angle N, Cabello-Passini R, Hoyt DB, Loomis WH, Shreve A, et al. Hypertonic saline infusion: can it regulate human neutrophil function? Shock. 2000;14:503&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11092681</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG, Hoyt DB, Davis RE, Herdon-Remelius C, Namiki S, et al. Hypertonicity regulates the function of human neutrophils by modulating chemoattractant receptor signaling and activating mitogen-activated protein kinase p38. J Clin Invest. 1998;101:2768&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508868</ArticleId><ArticleId IdType="pubmed">9637711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Shukla A, Namiki S, Insel PA, Junger WG. A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors. J Leukoc Biol. 2004;76:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15107462</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpelini S, Rhind SG, Tien H, Spencer Netto AC, et al. Effects of hypertonic saline on the development of acute lung injury following traumatic shock. J Organ Dysfunction. 2008;4:99&#x2013;105.</Citation></Reference><Reference><Citation>Angle N, Hoyt DB, Cabello-Passini R, Herdon-Remelius C, Loomis W, et al. Hypertonic saline resuscitation reduces neutrophil margination by suppressing neutrophil L selectin expression. J Trauma. 1998;45:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9680004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Kapus A, Fan J, Li YH, Marshall JC, et al. Immunomodulatory effects of hypertonic resuscitation on the development of lung inflammation following hemorrhagic shock. J Immunol. 1998;161:6288&#x2013;6296.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotstein OD. Novel strategies for immunomodulation after trauma: revisiting hypertonic saline as a resuscitation strategy for hemorrhagic shock. J Trauma. 2000;49:580&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">11038073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla A, Hashiguchi N, Chen Y, Coimbra R, Hoyt DB, Junger WG. Osmotic regulation of cell function and possible clinical applications. Shock. 2004;21:391&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Rhind SG, Shek PN, Inaba K, Filips D, et al. The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial. Ann Surg. 2006;243:47&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449974</ArticleId><ArticleId IdType="pubmed">16371736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, Cuschieri J, Warner K, Maier RV. Hypertonic resuscitation modulates the inflammatory response in patients with traumatic hemorrhagic shock. Ann Surg. 2007;245:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877049</ArticleId><ArticleId IdType="pubmed">17414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Donaldson K, Loftus CM, Jallo J. Hypertonic saline: a clinical review. Neurosurg Rev. 2007;30:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hashiguchi N, Yip L, Junger WG. Hypertonic saline enhances neutrophil elastase release through activation of P2 and A3 receptors. Am J Physiol Cell Physiol. 2006;290:C1051&#x2013;C1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282197</ArticleId></ArticleIdList></Reference><Reference><Citation>Murao Y, Hoyt DB, Loomis W, Namiki S, Patel N, et al. Does the timing of hypertonic saline resuscitation affect its potential to prevent lung damage? Shock. 2000;14:18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10909888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchin V, Alam HB, Rhee P, Kirkpatrick JR, Koustova E. cDNA profiling in leukocytes exposed to hypertonic resuscitation fluids. J Am Coll Surg. 2003;197:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253:431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232054</ArticleId><ArticleId IdType="pubmed">21178763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and disease. J Intern Med. 2010;268:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497300</ArticleId></ArticleIdList></Reference><Reference><Citation>Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, et al. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine. 2007;36:283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TC, Li CY, Tsai CS, Ku CH, Wu CT, et al. Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg. 2005;100:1554&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920174</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldt J, Muller M, Kuhn D, Linke LC, Hempelmann G. Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients. Intensive Care Med. 1996;22:122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM. 7.5% saline and 7.5% saline/6% dextran for hypovolemic shock. J Trauma. 2011;70 (5 Suppl):S27&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111047</ArticleId><ArticleId IdType="pubmed">21666775</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Chen Y, Pauzenberger R, Hirsh MI, Junger WG. Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis. Crit Care Med. 2008;36:2569&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643471</ArticleId><ArticleId IdType="pubmed">18679117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubick MA, Bruttig SP, Wade CE. Issues of concern regarding the use of hypertonic/hyperoncotic fluid resuscitation of hemorrhagic hypotension. Shock. 2006;25:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">16670632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee P, Wang D, Ruff P, Austin B, DeBraux S, et al. Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med. 2000;28:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungstr&#xf6;m KG. Safety of dextran in relation to other colloids - Ten years experience with hapten inhibition. Infusionsther Transfusionsmed. 1993;20:206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7508309</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis WH, Namiki S, Ostrom RS, Insel PA, Junger WG. Hypertonic stress increases T cell interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38 MAPK activation. J Biol Chem. 2003;278:4590&#x2013;4596.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip L, Cheung CW, Corriden R, Chen Y, Insel PA, et al. Hypertonic stress regulates T-cell function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock. 2007;27:242&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17304104</ArticleId></ArticleIdList></Reference><Reference><Citation>Woehrle T, Yip L, Manohar M, Sumi Y, Yao Y, et al. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptors. J Leukoc Biol. 2010;88:1181&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996895</ArticleId><ArticleId IdType="pubmed">20884646</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209705</ArticleId><ArticleId IdType="pubmed">21331080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, Tower CM, Warner KJ, Garland T, Cuschieri J, et al. Increased neutrophil adenosine a3 receptor expression is associated with hemorrhagic shock and injury severity in trauma patients. Shock. 2011;36:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204900</ArticleId><ArticleId IdType="pubmed">21841534</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Tanaka H, Sumi Y, Woehrle T, Chen Y, et al. A3 adenosine receptor inhibition improves the efficacy of hypertonic saline resuscitation. Shock. 2011;35:178&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038630</ArticleId><ArticleId IdType="pubmed">20661181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16875458</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Serum lipopolysaccharide-binding protein concentrations in trauma victims.</ArticleTitle><Pagination><StartPage>251</StartPage><EndPage>261</EndPage><MedlinePgn>251-61</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In low concentrations, lipopolysaccharide-binding protein (LBP), an acute-phase protein recognizing lipopolysaccharide (LPS), catalyzes its transfer to the cellular receptor consisting of CD14 and Toll-like receptor-4. Previous studies have documented increased serum LBP concentrations in patients with sepsis, systemic inflammatory response syndrome (SIRS), or acute pancreatitis and after cardiopulmonary bypass. No prior studies have examined LBP expression in trauma victims. We hypothesized that admission LBP plasma concentrations are predictive of outcome (mortality) in trauma. This study assessed time-dependent changes in serum LBP concentrations in trauma patients soon after injury.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective, single-institution, observational cohort study of 121 adult trauma patients (age &gt; or =17 years) with moderate to severe injury who required hospitalization. The trauma patients were male in 79.6% of the cases and had a mean age of 43.0 +/- 20.6 years. The mean injury severity score (ISS) was 23 +/- 12, and the crystalloid resuscitation volume given in the first 24 h averaged 6,640 +/- 3,729 mL. Informed consent was obtained on admission, and blood samples were drawn on admission and at 24 h postadmission. Prospective data were collected for daily SIRS score, multiple organ dysfunction score (MODS), and sequential organ failure assessment (SOFA) score, complications, and outcomes. Plasma concentrations of LBP were measured by enzyme-linked immunosorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty patients (48.8% of the study cohort) required emergency surgical intervention and sustained a substantial intraoperative blood loss (mean 1,404 +/- 2,757 mL). The hospital mortality rate was 16.3% (20 patients). The mean intensive care unit stay was 8.9 +/- 16.4 days, and the hospital stay was 14.8 +/- 19.6 days. The patients had a significantly higher serum concentrations of LBP on admission (mean 28.0 +/- 25.3 mg/L; range 2-100 mg/L) than did control subjects (mean 6.2 +/- 2.1 mg/L; range 1.3-12.8 mg/L; p &lt; 0.01), similar to the plasma concentrations previously reported in septic patients. A significant increase in LBP concentration was noted at 24 h (mean 72.3 +/- 45.7 mg/L; range 8-210 mg/L; p &lt; 0.05). The admission LBP concentration was significantly greater in nonsurvivors than in survivors. However, after controlling for age and ISS, the admission LBP concentration did not predict death.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Debra L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Bochicchio</LastName><ForeName>Grant V</ForeName><Initials>GV</Initials></Author><Author ValidYN="Y"><LastName>Genuit</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Keledjian</LastName><ForeName>Kaspar</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>J Kathleen</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Napolitano</LastName><ForeName>Lena M</ForeName><Initials>LM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000209">Acute-Phase Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C061257">lipopolysaccharide-binding protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000209" MajorTopicYN="N">Acute-Phase Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16875458</ArticleId><ArticleId IdType="doi">10.1089/sur.2006.7.251</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32221070</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>13</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Effect of sub-hypothermia blood purification technique in cardiac shock after valvular disease surgery.</ArticleTitle><Pagination><StartPage>e19476</StartPage><MedlinePgn>e19476</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e19476</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000019476</ELocationID><Abstract><AbstractText>To observe the effect of sub-hypothermia (HT) blood purification technique in the treatment of cardiac shock after heart valve disease.The patients were randomly divided into normothermic (NT) continuous blood purification (CBP) group (NT group) and HT CBP group (HT group). Observe the cardiac index (CI), the oxygen delivery (DO2) and oxygen consumption (VO2) ratio, Acute Physiology and Chronic Health Evaluation III(APACHE III) score, multiple organ dysfunction syndrome (MODS) score, dynamic monitoring of electrocardiograph, blood loss with or without muscle tremors, intensive care unit stay, mechanical ventilation time, CBP time, and the cases of infection and mortality at 0 day, 1 day, 2 day, 3 day; all above indicators were compared between 2 groups.Ninety-five patients were randomly assigned into HT group (48 cases) and NT group (47 cases); there were no significant differences between the 2 groups for age, gender, pre-operative cardiac function, cardiothoracic ratio, and type of valve replacement (P&#x200a;&gt;&#x200a;.05). There were no significant differences among the 1 day, 2 day, 3 day after recruited for CI, DO2/VO2 ratio, APACHE III score, MODS score (P&#x200a;&gt;&#x200a;.05). But in HT group, DO2/VO2 ratio had been significantly improved after treatment for 1 day (2.5&#x200a;&#xb1;&#x200a;0.7 vs 1.8&#x200a;&#xb1;&#x200a;0.4, P&#x200a;=&#x200a;.024), and CI (3.0&#x200a;&#xb1;&#x200a;0.5 vs 1.9&#x200a;&#xb1;&#x200a;0.7, P&#x200a;=&#x200a;.004), APACHE III score (50.6&#x200a;&#xb1;&#x200a;6.2 vs 77.5&#x200a;&#xb1;&#x200a;5.5 P&#x200a;=&#x200a;.022), MODS score (6.0&#x200a;&#xb1;&#x200a;1.5 vs 9.3&#x200a;&#xb1;&#x200a;3.4, P&#x200a;=&#x200a;.013) also had been significantly improved after treatment for 3 days. In clinical outcomes, there were no significant differences between 2 groups for blood loss (617.0&#x200a;&#xb1;&#x200a;60.7&#x200a;ml vs 550.9&#x200a;&#xb1;&#x200a;85.2&#x200a;ml, P&#x200a;=&#x200a;.203), infection ratio (54.17% vs 53.19%, P&#x200a;=&#x200a;.341), the incidence of ventricular arrhythmia (31.25% vs 36.17%, P&#x200a;=&#x200a;.237), and muscle tremors (14.58% vs 8.51%, P&#x200a;=&#x200a;.346), while there were significant differences between 2 groups for intensive care unit stay (6.9&#x200a;&#xb1;&#x200a;3.4 days vs 12.5&#x200a;&#xb1;&#x200a;3.5 days, P&#x200a;=&#x200a;.017,), mechanical ventilation time (4.2&#x200a;&#xb1;&#x200a;1.3 days vs 7.5&#x200a;&#xb1;&#x200a;2.7 days, P&#x200a;=&#x200a;.034,), CBP time (4.6&#x200a;&#xb1;&#x200a;1.4 days vs 10.5&#x200a;&#xb1;&#x200a;4.0 days, P&#x200a;=&#x200a;.019), mortality (12.50% vs 23.40%, P&#x200a;=&#x200a;.024). But the incidence of bradycardia in HT group was much higher than the NT group (29.16% vs 14.89%, P&#x200a;=&#x200a;.029).HT blood purification is a safer and more effective treatment than NT blood purification for patients who suffered from cardiac shock after valve surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Jihui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Wuhan Asia Heart Hospital, Wuhan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Wuhan Asia Heart Hospital, Wuhan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Urinary Surgery, Dongfeng Maojian Hospital, Shiyan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wuhan Asia Heart Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Laichun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Hongyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Asia Heart Hospital, Wuhan University of Science and Technology, Hankou District, Wuhan, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058385" MajorTopicYN="N">Cardiac Valve Annuloplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003080" MajorTopicYN="Y">Cold Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006349" MajorTopicYN="N">Heart Valve Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012770" MajorTopicYN="N">Shock, Cardiogenic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32221070</ArticleId><ArticleId IdType="pmc">PMC7220519</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000019476</ArticleId><ArticleId IdType="pii">00005792-202003270-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nesrallah GE, Mustafa RA, Macrae J, et al. Canadian society of nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis. Am J Kidney Dis 2013;62:187&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23566638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarraf N, Thalib L, Hughes A, et al. Cross-clamp time is an independent predictor of monality and morbidity in low- and high-risk cardiac patients. Int J Surg 2011;9:104&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965288</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005;294:448&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichter-Konecki U, Nadkarni V, Moudgil A, et al. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acid emias. Mol Genet Metab 2013;109:354&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23791307</ArticleId></ArticleIdList></Reference><Reference><Citation>Laky D, Parascan L, Candea V. Myocardial stunning. Morphological studies in acute experimental ischemia and intraoperatory myocardial biopsies. Rom J Morphol Embryol 2008;49:153&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18516320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrichs ES, Kondrative T, Tveita T. Milrinone ameliorates cardiac mechanical dysfunction after hypothermia in an intact rat model. Cryobiology 2014;69:361&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25224046</ArticleId></ArticleIdList></Reference><Reference><Citation>Field JM, Hazinski MF, Sayre MR, et al. 2010 American Heart Association guideline for CPR and ECC. Part 12: Postresuscitation support. Circulation 2010;122:s640&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20956217</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BW, Kilgannon JH, Chansky ME, et al. Therapeutic hypothermia and vasopressor dependency after cardiac arrest. Resuscitation 2013;84:331&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22885092</ArticleId></ArticleIdList></Reference><Reference><Citation>Skulec R, Kovarnik T, Dostalova G, et al. Induction of mild hypothermia in cardiac arrest survivors presenting with cardiogenic shock syndrome. Acta Anaesthesiol Scand 2008;52:188&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005380</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz BG, Kloner RA, Thomas JL, et al. Therapeutic hypothermia for acute myocardial infarction and cardiac arrest. Am J Cardiol 2012;110:461&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22541421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamamoto H, Sakamoto H, Leshnower BG, et al. Very mild hypothermia during ischaemia and reperfusion improves post infarction ventricular remodeling. Ann Thorac Surg 2009;87:172&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021243</ArticleId><ArticleId IdType="pubmed">19101292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo JS, Kim JB, Jung SH, et al. Surgical repair of descending thoracic and thoracoabdominal aortic aneurysm involving the distal arch: open proximal anastomosis under deep hypothermia versus arch clamping technique. J Thorac Cardiovasc Surg 2014;148:2101&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131174</ArticleId></ArticleIdList></Reference><Reference><Citation>Raza S, Ali Baig M, Chang C, et al. A prospective study on red blood cell transfusion related hyperkalemia in critically ill patients. J Clin Med Res 2015;7:417&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394913</ArticleId><ArticleId IdType="pubmed">25883703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard SA, Buist M. Induced hypothermia in critical care medicine: a review. Crit Care Med 2003;31:2041&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-de-Sa E, Rey JR, Armada E, et al. Hypothermia in comatose survivors from out-of-hospital cardiac arrest: pilot trial comparing 2 levels of target temperature. Circulation 2012;126:2826&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">23136160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22196238</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2482</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2011</Year><Month>Dec</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC surgery</Title><ISOAbbreviation>BMC Surg</ISOAbbreviation></Journal><ArticleTitle>Failure of available scoring systems to predict ongoing infection in patients with abdominal sepsis after their initial emergency laparotomy.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2482-11-38</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To examine commonly used scoring systems, designed to predict overall outcome in critically ill patients, for their ability to select patients with an abdominal sepsis that have ongoing infection needing relaparotomy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from a RCT comparing two surgical strategies was used. The study population consisted of 221 patients at risk for ongoing abdominal infection. The following scoring systems were evaluated with logistic regression analysis for their ability to select patients requiring a relaparotomy: APACHE-II score, SAPS-II, Mannheim Peritonitis Index (MPI), MODS, SOFA score, and the acute part of the APACHE-II score (APS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The proportion of patients requiring a relaparotomy was 32% (71/221). Only 2 scores had a discriminatory ability in identifying patients with ongoing infection needing relaparotomy above chance: the APS on day 1 (AUC 0.61; 95%CI 0.52-0.69) and the SOFA score on day 2 (AUC 0.60; 95%CI 0.52-0.69). However, to correctly identify 90% of all patients needing a relaparotomy would require such a low cut-off value that around 80% of all patients identified by these scoring systems would have negative findings at relaparotomy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">None of the widely-used scoring systems to predict overall outcome in critically ill patients are of clinical value for the identification of patients with ongoing infection needing relaparotomy. There is a need to develop more specific tools to assist physicians in their daily monitoring and selection of these patients after the initial emergency laparotomy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Ruler</LastName><ForeName>Oddeke</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiewiet</LastName><ForeName>Jordy J S</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Boer</LastName><ForeName>Kimberley R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Lamme</LastName><ForeName>Bas</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gouma</LastName><ForeName>Dirk J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Boermeester</LastName><ForeName>Marja A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reitsma</LastName><ForeName>Johannes B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN51729393</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Surg</MedlineTA><NlmUniqueID>100968567</NlmUniqueID><ISSNLinking>1471-2482</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="Y">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010538" MajorTopicYN="N">Peritonitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22196238</ArticleId><ArticleId IdType="pmc">PMC3268736</ArticleId><ArticleId IdType="doi">10.1186/1471-2482-11-38</ArticleId><ArticleId IdType="pii">1471-2482-11-38</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Ruler O, Mahler CW, Boer KR, Reuland EA, Gooszen HG, Opmeer BC, de Graaf PW, Lamme B, Gerhards MF, Steller EP, van Till JW, de Borgie CJ, Gouma DJ, Reitsma JB, Boermeester MA. Dutch Peritonitis Study Group. Comparison of on-demand versus planned relaparotomy strategy in patients with severe peritonitis. A randomized trial. JAMA. 2007;298:865&#x2013;873. doi: 10.1001/jama.298.8.865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.298.8.865</ArticleId><ArticleId IdType="pubmed">17712070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818&#x2013;829. doi: 10.1097/00003246-198510000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198510000-00009</ArticleId><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall Jr, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957&#x2013;2963. doi: 10.1001/jama.1993.03510240069035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1993.03510240069035</ArticleId><ArticleId IdType="pubmed">8254858</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder MM, Wacha H, Feldmann U, Wesch G, Streifensand RA, Gundlach E. The Mannheim peritonitis index. An instrument for the intraoperative prognosis of peritonitis. Chirurg. 1987;58:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacha H, Linder MM, Feldmann U, Wesch G, Gundlach E, Steifensand RA. Mannheim Peritonitis Index - prediction of risk of death from peritonitis: construction of a statistical and validation of an emperically based index. Theor Surg. 1987. pp. 169&#x2013;177.</Citation></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8:3&#x2013;15. doi: 10.1191/096228099671525676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096228099671525676</ArticleId><ArticleId IdType="pubmed">10347857</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. Multiple imputation after 18+ years. Journal of the American Statistical Association. 1996;91:473&#x2013;489. doi: 10.2307/2291635.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2291635</ArticleId></ArticleIdList></Reference><Reference><Citation>Timsit JF, Fosse JP, Troche G, De Lassence A, Alberti C, Garrouste-Orgeas M, Bornstain C, Adrie C, Cheval C, Chevret S. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med. 2002;30:2003&#x2013;2013. doi: 10.1097/00003246-200209000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200209000-00009</ArticleId><ArticleId IdType="pubmed">12352033</ArticleId></ArticleIdList></Reference><Reference><Citation>Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59:1087&#x2013;1091. doi: 10.1016/j.jclinepi.2006.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2006.01.014</ArticleId><ArticleId IdType="pubmed">16980149</ArticleId></ArticleIdList></Reference><Reference><Citation>Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research--part 2: multiple imputation. Acad Emerg Med. 2007;14:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">17595237</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJA, Rubin DB. Statistical analysis with missing data. New York, NY: Wiley;</Citation></Reference><Reference><Citation>van Ruler O, Lamme B, Gouma DJ, Reitsma JB, Boermeester MA. Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Crit Care Med. 2007;35:468&#x2013;476. doi: 10.1097/01.CCM.0000253399.03545.2D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000253399.03545.2D</ArticleId><ArticleId IdType="pubmed">17205025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg. 1999;384:24&#x2013;32. doi: 10.1007/s004230050169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004230050169</ArticleId><ArticleId IdType="pubmed">10367626</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;gel NP, Kox M, Lichtwark-Aschoff M, Gippner-Steppert C, Jochum M. Predictive relevance of clinical scores and inflammatory parameters in secondary peritonitis. Bull Soc Sci Med Grand Duche Luxemb. 2011;1:41&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">21634221</ArticleId></ArticleIdList></Reference><Reference><Citation>Torer N, Yorganci K, Elker D, Sayek I. Prognostic factors of the mortality of postoperative intraabdominal infections. Infection. 2010;38:255&#x2013;260. doi: 10.1007/s15010-010-0021-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-010-0021-4</ArticleId><ArticleId IdType="pubmed">20393782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan KK, Bang SL, Sim R. Surgery for small bowel perforation in an Asian population: predictors of morbidity and mortality. J Gastrointest Surg. 2010;14:493&#x2013;499. doi: 10.1007/s11605-009-1097-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-009-1097-y</ArticleId><ArticleId IdType="pubmed">19997984</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan KK, Hong CC, Zhang J, Liu JZ, Sim R. Predictors of outcome following surgery in colonic perforation: an institution's experience over 6 years. J Gastrointest Surg. 2011;15:277&#x2013;284. doi: 10.1007/s11605-010-1330-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-010-1330-8</ArticleId><ArticleId IdType="pubmed">20824374</ArticleId></ArticleIdList></Reference><Reference><Citation>Schein M. Surgical management of intra-abdominal infection: is there any evidence? Langenbecks Arch Surg. 2002;387:1&#x2013;7. doi: 10.1007/s00423-002-0276-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-002-0276-z</ArticleId><ArticleId IdType="pubmed">11981677</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;gel N, Siebeck M, Geissler B, Lichtwark-Aschoff M, Gippner-Steppert C, Witte J, Jochum M. Circulating mediators and organ function in patients undergoing planned relaparotomy vs conventional surgical therapy in severe secondary peritonitis. Arch Surg. 2002;137:590&#x2013;599. doi: 10.1001/archsurg.137.5.590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.137.5.590</ArticleId><ArticleId IdType="pubmed">11982474</ArticleId></ArticleIdList></Reference><Reference><Citation>Go HL, Baarslag HJ, Vermeulen H, Lameris JS, Legemate DA. A comparative study to validate the use of ultrasonography and computed tomography in patients with post-operative intra-abdominal sepsis. Eur J Radiol. 2005;54:383&#x2013;387. doi: 10.1016/j.ejrad.2004.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2004.08.004</ArticleId><ArticleId IdType="pubmed">15899340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18426347</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>160</EndPage><MedlinePgn>153-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/sur.2007.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gram-negative bacilli, including multi-drug-resistant (MDR) Pseudomonas aeruginosa, are responsible for severe intensive care unit (ICU)-acquired infections, mainly pneumonia and bacteremia. The aim of this study was to determine the incidence of MDR strains of Pseudomonas in patients undergoing cardiac surgery, to elucidate the effectiveness of treating these patients with colistin, and to assess the safety of the drug.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study was conducted among 1,452 patients who underwent surgery for a variety of cardiac lesions over a one-year period, and who spent a portion of the recovery period in the surgical ICU. Their case histories were analyzed to identify infectious complications. Diagnosis of infection was based on clinical data, and the pathogen was tested with respect to its susceptibility to colistin (polymyxin E). The clinical response to the antibiotic was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over the 12-month period, among 115 infected patients, 15 were affected by strains of P. aeruginosa. In 10 patients, this pathogen proved resistant to all potentially active antibiotics except colistin. All of the affected patients were being ventilated mechanically, and eight of them presented with ventilator-associated pneumonia (VAP), whereas one patient suffered a deep incisional surgical site infection and bacteremia and the remaining patient had a superficial infection of a lower-extremity vein graft donor site. The MDR pathogen was introduced to the hospital by three patients transferred from three institutions. All patients were treated with intravenous colistin. In cases of VAP, aerosolized colistin was added. Deterioration of renal function occurred in three patients (30%), all of whom had a history of renal insufficiency. Cure or clinical improvement was observed in seven patients (70%), whereas four patients, including one who improved initially, developed sepsis and died with multiple organ dysfunction syndrome (mortality rate 40%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The increasing prevalence of MDR P. aeruginosa in ICU patients has rekindled interest in polymyxins, which had been abandoned because of toxic side effects. Colistin retained significant in vitro activity against this virulent organism, had an acceptable safety profile, and should be considered as a treatment option in critically ill patients with infection caused by MDR gram-negative bacilli. Aerosolized colistin may merit further consideration as a therapeutic intervention for patients with refractory pulmonary infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mastoraki</LastName><ForeName>Aikaterini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit, Onassis Cardiac Surgery Center, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douka</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kriaras</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Stravopodis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Manoli</LastName><ForeName>Heleni</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Geroulanos</LastName><ForeName>Stefanos</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z67X93HJG1</RegistryNumber><NameOfSubstance UI="D003091">Colistin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003091" MajorTopicYN="N">Colistin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024901" MajorTopicYN="N">Drug Resistance, Multiple, Bacterial</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011552" MajorTopicYN="N">Pseudomonas Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18426347</ArticleId><ArticleId IdType="doi">10.1089/sur.2007.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30717728</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2482</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>BMC surgery</Title><ISOAbbreviation>BMC Surg</ISOAbbreviation></Journal><ArticleTitle>Effect of restrictive fluid therapy with hydroxyethyl starch during esophagectomy on postoperative outcomes: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>15</StartPage><MedlinePgn>15</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12893-019-0482-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To improve prognosis after esophageal surgery, intraoperative fluid optimization is important. Herein, we hypothesized that hydroxyethyl starch administration during esophagectomy reduce the total amount of fluid infused and it could have a positive effect on postoperative complication occurrence and mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All consecutive adult patients who underwent elective esophageal surgery for cancer were studied. The primary outcome was the development of composite complications including death, cardio-cerebrovascular complications, respiratory complications, renal complications, gastrointestinal complications, sepsis, empyema or abscess, and multi-organ failure. The relationship between perioperative variables and composite complication was evaluated using multivariable logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 892 patients analyzed, composite complications developed in 271 (30.4%). The higher hydroxyethyl starch ratio in total fluid had a negative relationship with the total fluid infusion amount (r&#x2009;=&#x2009;-&#x2009;0.256, P&#x2009;&lt;&#x2009;&#xa0;0.001). In multivariable analysis, intraoperatively administered total fluid per weight per hour (odds ratio, 1.248; 95% CI, 1.153-1.351; P&#x2009;&lt;&#x2009;&#xa0;0.001) and HES-to-crystalloid ratio (odds ratio, 2.125; 95% CI, 1.521-2.969; P&#x2009;&lt;&#x2009;&#xa0;0.001) were associated with increased risks of postoperative composite outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although hydroxyethyl starch administration reduces the total fluid infusion amount during esophageal surgery for cancer, intravenous hydroxyethyl starch infusion is associated with an increasing risk of postoperative composite complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Jun-Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Wook-Jong</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Dae-Kee</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeong Ryul</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun-Ho</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0002-6369-7429</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. leho@naver.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In-Cheol</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Laboratory for Perioperative Outcomes Analysis and Research, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2016-7023</GrantID><Agency>Asan Institute for Life Sciences, Asan Medical Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Surg</MedlineTA><NlmUniqueID>100968567</NlmUniqueID><ISSNLinking>1471-2482</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077324">Crystalloid Solutions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006895">Hydroxyethyl Starch Derivatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010952">Plasma Substitutes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077324" MajorTopicYN="N">Crystalloid Solutions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016629" MajorTopicYN="Y">Esophagectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005440" MajorTopicYN="N">Fluid Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006895" MajorTopicYN="N">Hydroxyethyl Starch Derivatives</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007432" MajorTopicYN="N">Intraoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010952" MajorTopicYN="N">Plasma Substitutes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Esophageal surgery</Keyword><Keyword MajorTopicYN="N">Intraoperative management</Keyword><Keyword MajorTopicYN="N">Intravenous fluid</Keyword><Keyword MajorTopicYN="N">Postoperative outcome</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30717728</ArticleId><ArticleId IdType="pmc">PMC6360773</ArticleId><ArticleId IdType="doi">10.1186/s12893-019-0482-z</ArticleId><ArticleId IdType="pii">10.1186/s12893-019-0482-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Connors RC, Reuben BC, Neumayer LA, Bull DA. Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17,395 patients. J Am Coll Surg. 2007;205(6):735&#x2013;740. doi: 10.1016/j.jamcollsurg.2007.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2007.07.001</ArticleId><ArticleId IdType="pubmed">18035255</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg. 2008;85(2):424&#x2013;429. doi: 10.1016/j.athoracsur.2007.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2007.10.007</ArticleId><ArticleId IdType="pubmed">18222237</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond DP, Seder CW, Wright CD, Magee MJ, Kosinski AS, Cassivi SD, Grogan EL, Blackmon SH, Allen MS, Park BJ. Predictors of major morbidity or mortality after resection for esophageal cancer: a society of thoracic surgeons general thoracic surgery database risk adjustment model. Ann Thorac Surg. 2016;102(1):207&#x2013;214. doi: 10.1016/j.athoracsur.2016.04.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.04.055</ArticleId><ArticleId IdType="pmc">PMC5016796</ArticleId><ArticleId IdType="pubmed">27240449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng JM. Update on anesthetic management for esophagectomy. Current Opinion in Anesthesiology. 2011;24(1):37&#x2013;43. doi: 10.1097/ACO.0b013e32834141f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0b013e32834141f7</ArticleId><ArticleId IdType="pubmed">21102314</ArticleId></ArticleIdList></Reference><Reference><Citation>Casado D, L&#xf3;pez F, Marti R. Perioperative fluid management and major respiratory complications in patients undergoing esophagectomy. Dis Esophagus. 2010;23(7):523&#x2013;528. doi: 10.1111/j.1442-2050.2010.01057.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-2050.2010.01057.x</ArticleId><ArticleId IdType="pubmed">20459444</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi GP. Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery. Anesth Analg. 2005;101(2):601&#x2013;605. doi: 10.1213/01.ANE.0000159171.26521.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000159171.26521.31</ArticleId><ArticleId IdType="pubmed">16037184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S, Tian J, Song X, Chen Y. Association of perioperative fluid balance and adverse surgical outcomes in esophageal cancer and esophagogastric junction cancer. Ann Thorac Surg. 2008;86(1):266&#x2013;272. doi: 10.1016/j.athoracsur.2008.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2008.03.017</ArticleId><ArticleId IdType="pubmed">18573435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. Jama. 2013;309(7):678&#x2013;688. doi: 10.1001/jama.2013.430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.430</ArticleId><ArticleId IdType="pubmed">23423413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortelmans YJ, Vermaut G, Verbruggen AM, Arnout JM, Vermylen J, Van Aken H, Mortelmans LA. Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg. 1995;81(6):1235&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">7486110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EH, Kim HR, Baek SH, Kim KM, Chin JH, Choi DK, Kim WJ, Choi IC. Risk factors of postoperative acute kidney injury in patients undergoing esophageal cancer surgery. J Cardiothorac Vasc Anesth. 2014;28(4):936&#x2013;942. doi: 10.1053/j.jvca.2013.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2013.12.006</ArticleId><ArticleId IdType="pubmed">24680132</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjanovic G, Villain C, Timme S, Zur Hausen A, Hoeppner J, Makowiec F, Holzner P, Hopt UT, Obermaier R. Colloid vs. crystalloid infusions in gastrointestinal surgery and their different impact on the healing of intestinal anastomoses. Int J Color Dis. 2010;25(4):491&#x2013;498. doi: 10.1007/s00384-009-0854-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-009-0854-4</ArticleId><ArticleId IdType="pubmed">19943164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundgaard-Nielsen M, Holte K, Secher N, Kehlet H. Monitoring of peri-operative fluid administration by individualized goal-directed therapy. Acta Anaesthesiol Scand. 2007;51(3):331&#x2013;340. doi: 10.1111/j.1399-6576.2006.01221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2006.01221.x</ArticleId><ArticleId IdType="pubmed">17390421</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, Von Elm E, Altman DG, G&#xf8;tzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative S. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi: 10.1371/journal.pmed.0040297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040297</ArticleId><ArticleId IdType="pmc">PMC2020496</ArticleId><ArticleId IdType="pubmed">17941715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EH, Chin JH, Choi DK, Hwang BY, Choo SJ, Song JG, Kim TY, Choi IC. Postoperative hypoalbuminemia is associated with outcome in patients undergoing off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011;25(3):462&#x2013;468. doi: 10.1053/j.jvca.2010.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2010.09.008</ArticleId><ArticleId IdType="pubmed">21093290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, Leva B, Rhodes A, Hoeft A, Walder B. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European perioperative clinical outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. European Journal of Anaesthesiology (EJA) 2015;32(2):88&#x2013;105. doi: 10.1097/EJA.0000000000000118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000118</ArticleId><ArticleId IdType="pubmed">25058504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau EHL, Slinger P. Seminars in cardiothoracic and vascular anesthesia: 2014: SAGE publications Sage CA: Los Angeles, CA. 2014. Perioperative fluid management for pulmonary resection surgery and esophagectomy; pp. 36&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23719773</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatz T, Kulemann B, Marjanovic G, Bregenzer S, Makowiec F, Hoeppner J. Postoperative fluid overload is a risk factor for adverse surgical outcome in patients undergoing esophagectomy for esophageal cancer: a retrospective study in 335 patients. BMC Surg. 2017;17(1):6. doi: 10.1186/s12893-016-0203-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-016-0203-9</ArticleId><ArticleId IdType="pmc">PMC5237209</ArticleId><ArticleId IdType="pubmed">28086855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s DO, Barros TG, Njimi H, Vincent JL. Crystalloids versus colloids: exploring differences in fluid requirements by systematic review and meta-regression. Anesth Analg. 2015;120(2):389&#x2013;402. doi: 10.1213/ANE.0000000000000564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000000564</ArticleId><ArticleId IdType="pubmed">25565318</ArticleId></ArticleIdList></Reference><Reference><Citation>Durkin C, Schisler T, Lohser J. Current trends in anesthesia for esophagectomy. Current Opinion in Anesthesiology. 2017;30(1):30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">27764049</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, &#xc5;neman A, Madsen KR, M&#xf8;ller MH, Elkj&#xe6;r JM, Poulsen LM. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124&#x2013;134. doi: 10.1056/NEJMoa1204242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1204242</ArticleId><ArticleId IdType="pubmed">22738085</ArticleId></ArticleIdList></Reference><Reference><Citation>Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901&#x2013;1911. doi: 10.1056/NEJMoa1209759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1209759</ArticleId><ArticleId IdType="pubmed">23075127</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125&#x2013;139. doi: 10.1056/NEJMoa070716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa070716</ArticleId><ArticleId IdType="pubmed">18184958</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies M, Habicher M, Jhanji S, Sander M, Mythen M, Hamilton M, Pearse R. Incidence of postoperative death and acute kidney injury associated with iv 6% hydroxyethyl starch use: systematic review and meta-analysis. Br J Anaesth. 2013;112(1):25&#x2013;34. doi: 10.1093/bja/aet303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aet303</ArticleId><ArticleId IdType="pubmed">24046292</ArticleId></ArticleIdList></Reference><Reference><Citation>Min JJ, Cho HS, Jeon S, Lee JH, Lee JJ, Lee YT. Effects of 6% hydroxyethyl starch 130/0.4 on postoperative blood loss and kidney injury in off-pump coronary arterial bypass grafting: a retrospective study. Medicine. 2017;96(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419925</ArticleId><ArticleId IdType="pubmed">28471979</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 2001;59(4):1510&#x2013;1519. doi: 10.1046/j.1523-1755.2001.0590041510.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.2001.0590041510.x</ArticleId><ArticleId IdType="pubmed">11260415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew SQ, Borum ML, Ing TS. Gastrointestinal complications of acute kidney injury. In: Management of Acute Kidney Problems. Edn: Springer; 2010. p. 209&#x2013;20.</Citation></Reference><Reference><Citation>Vandijck D, Reynvoet E, Blot S, Vandecasteele E, Hoste E. Severe infection, sepsis and acute kidney injury. Acta Clin Belg. 2007;62(sup2):332&#x2013;336. doi: 10.1179/acb.2007.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/acb.2007.075</ArticleId><ArticleId IdType="pubmed">18283994</ArticleId></ArticleIdList></Reference><Reference><Citation>Fares KM, Mohamed SA, Hamza HM, Sayed DM, Hetta DF. Effect of thoracic epidural analgesia on pro-inflammatory cytokines in patients subjected to protective lung ventilation during Ivor Lewis esophagectomy. Pain Physician. 2014;17(4):305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">25054390</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Li Y, Huang Q, Ye S, Rong T. Short and long-term outcomes of epidural or intravenous analgesia after esophagectomy: a propensity-matched cohort study. PLoS One. 2016;11(4):e0154380. doi: 10.1371/journal.pone.0154380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154380</ArticleId><ArticleId IdType="pmc">PMC4844138</ArticleId><ArticleId IdType="pubmed">27110939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli U, Melis A, Balazova J, Lascari V, Morenghi E, Rosati R. Intra-operative hypotensive episodes may be associated with post-operative esophageal anastomotic leak. Updat Surg. 2016;68(2):185&#x2013;190. doi: 10.1007/s13304-016-0369-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13304-016-0369-9</ArticleId><ArticleId IdType="pubmed">27146868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15854666</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-4804</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of surgical research</Title><ISOAbbreviation>J Surg Res</ISOAbbreviation></Journal><ArticleTitle>Clinical evaluation of circulating interleukin-6 and interleukin-10 levels after surgery-induced inflammation.</ArticleTitle><Pagination><StartPage>144</StartPage><EndPage>150</EndPage><MedlinePgn>144-50</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It was previously reported that both pro- and anti-inflammatory cytokines are elevated in systemic inflammatory response syndrome (SIRS). Cytokine-mediated systemic neutrophil activation is a direct consequence of SIRS, and can lead to multiple organ dysfunction syndrome (MODS). This prospective study assessed the risk of SIRS and MODS after orthognathic surgery by measuring the circulating levels of inflammatory cytokines such as IL-6 and IL-10 as well as the neutrophil functions as a marker of organ failure.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Blood samples for the measurement of IL-6, IL-10, CRP, neutrophil counts, and neutrophil function were drawn from 21 patients with mandibular prognathism at 2 days before, and at 1 and 3 days after orthognathic surgery. The neutrophil function was estimated by superoxide production and elastase release under the stimulation of FMLP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight of the 21 patients were applicable to SIRS criteria 1 day postoperatively, and all of the subjects were excluded from SIRS criteria 3 days postoperatively. Although IL-6 and IL-10 levels were raised 1 day postoperatively, increased cytokine concentrations were decreased in most patients at 3 days postoperatively. The IL-6 concentration and the ratio of IL-6 to IL-10 were higher in the SIRS-matched group compared with the non-SIRS-matched group. Neutrophil priming for superoxide production and elastase release was discovered 1 day after orthognathic surgery, and differences in those values could not be distinguished between the groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest that a few patients in whom high levels of circulating inflammatory cytokine and neutrophil-derived toxic factor continue may have a possibility of contracting severe diseases such as SIRS and MODS after orthognathic surgery. We conclude that the ratio of IL-6 to IL-10 may be a predictive factor in SIRS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyaoka</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Surgery, Showa University School of Dentistry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Masayasu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Rikako</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Gen</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nagumo</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Surg Res</MedlineTA><NlmUniqueID>0376340</NlmUniqueID><ISSNLinking>0022-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>11062-77-4</RegistryNumber><NameOfSubstance UI="D013481">Superoxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.36</RegistryNumber><NameOfSubstance UI="D010196">Pancreatic Elastase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010196" MajorTopicYN="N">Pancreatic Elastase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011378" MajorTopicYN="N">Prognathism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013481" MajorTopicYN="N">Superoxides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15854666</ArticleId><ArticleId IdType="doi">10.1016/j.jss.2004.12.001</ArticleId><ArticleId IdType="pii">S0022-4804(04)00706-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19864941</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Effects of allogeneic leukocytes in blood transfusions during cardiac surgery on inflammatory mediators and postoperative complications.</ArticleTitle><Pagination><StartPage>546</StartPage><EndPage>552</EndPage><MedlinePgn>546-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3181c0de7b</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether the higher prevalence of postoperative complications in cardiac surgery after transfusion of leukocyte-containing red blood cells can be related to inflammatory mediators.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Analysis of inflammatory markers interleukin-6, interleukin-10, interleukin-12, and procalcitonin in patients participating in a randomized trial comparing leukocyte-depleted with leukocyte-containing, buffy-coat-depleted red blood cells.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Two university-affiliated hospitals in the Netherlands.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">A total of 346 patients undergoing cardiac valve surgery with a complete series of pre- and postoperative blood samples.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">There were no differences in the cytokines and procalcitonin concentrations between both study arms when the patients arrived in the intensive care unit. In subgroups, patients who received zero to three red blood cell transfusions showed similar cytokine concentrations in both study arms, whereas patients with &gt; or = 4 red blood cell transfusions had significantly higher interleukin-6 concentrations in the leukocyte-containing, buffy-coat-depleted red blood cell group. Patients who developed postoperative infections and multiple organ dysfunction syndrome showed, respectively, increased concentrations of interleukin-6 and interleukin-12 in the leukocyte-containing, buffy-coat-depleted, red blood cell group. The interaction tests in these subgroups showed significantly different reaction patterns in the leukocyte-containing, buffy-coat-depleted red blood cell group compared with leukocyte-depleted red blood cell group for interleukin-6 and interleukin-12. Multivariate analysis showed a high interleukin-6 concentration with multiple organ dysfunction syndrome and both high interleukin-6 and interleukin-10 concentrations with hospital mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Allogeneic leukocyte-containing blood transfusions compared with leukocyte-depleted blood transfusions induce dose-dependent significantly higher concentrations of proinflammatory mediators in the immediate postoperative period after cardiac surgery. High concentrations of interleukin-6 are strong predictors for development of multiple organ dysfunction syndrome, whereas both interleukin-6 and interleukin-10 are associated with hospital mortality. These findings suggest that leukocyte-containing red blood cells interfere with the balance between postoperative proinflammatory response, which may further affect the development of complications after cardiac surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Yavuz M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Sanquin Blood Bank Southwest Region, Leiden, Netherlands. bilginyavuz@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>Leo M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Versteegh</LastName><ForeName>Michel I M</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>van Oers</LastName><ForeName>Marinus H J</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Anneke</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606589">CALCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>187348-17-0</RegistryNumber><NameOfSubstance UI="D018664">Interleukin-12</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-12-9</RegistryNumber><NameOfSubstance UI="D002116">Calcitonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>JHB2QIZ69Z</RegistryNumber><NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care Med. 2010 Feb;38(2):720-1. doi: 10.1097/CCM.0b013e3181c5867f.</RefSource><PMID Version="1">20083944</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002116" MajorTopicYN="N">Calcitonin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015740" MajorTopicYN="N">Calcitonin Gene-Related Peptide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018664" MajorTopicYN="N">Interleukin-12</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017708" MajorTopicYN="N">Leukocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065227" MajorTopicYN="Y">Transfusion Reaction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19864941</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3181c0de7b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34261391</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-9116</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Vascular and endovascular surgery</Title><ISOAbbreviation>Vasc Endovascular Surg</ISOAbbreviation></Journal><ArticleTitle>The Minimally Invasive Treatment of Visceral Artery Pseudoaneurysms: A Retrospective Observational Single Centre Cohort Study on Glue Embolization.</ArticleTitle><Pagination><StartPage>831</StartPage><EndPage>837</EndPage><MedlinePgn>831-837</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/15385744211028730</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective is to report a single centre experience in the embolization of visceral artery pseudoaneurysms with N-butyl-cyanoacrylate-methacryloxy sulfolane (NBCA-MS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective observational cohort study was conducted on data about all consecutive patients treated for visceral artery pseudoaneurysms in the Interventional Radiology Unit of SS Annunziata Hospital, in Taranto (Italy) between January 2016 and July 2020. Only patients treated with NBCA-MS embolization were included. Clinical and technical outcomes were evaluated during in-hospital stay and at 3-month follow-up by computed angiotomography (CTA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 89 patients undergoing treatment for visceral artery pseudoaneurysm, a total of 58 (65.2%) patients (n = 32, 55.2% men; median age 45.8 years, range: 35-81) treated with NBCA-MS only were enrolled. Pseudoaneurysms were located in the renal artery (n = 18 cases, 31%), in the splenic artery (n = 27, 46.6%), in the intra-parenchymal hepatic artery (n = 3, 5.2%), in the common hepatic artery (n = 4, 6.9%) or in the pancreatic artery (n = 6, 10.3%). N-butyl-cyanoacrylate was diluted 1:1 with Lipiodol ultra-fluid, and mean volume injected was 0.6 &#xb1; 0.3&#xa0;mL (range: 0.2-2.8&#xa0;mL). Embolization was technically and clinically successful in all patients (n = 58, 100%) with an immediate total thrombosis of the pseudoaneurysm at the completion angiography. No systemic complications were noted in all cases. Five cases (8.6%) of non-target vessel embolization occurred without any clinical complication. No pseudoaneurysm recurrence was detected at the CTA control 1 day postoperatively. In one case (1.7%), a recurrence was detected 4&#xa0;days after the initial treatment and successfully managed by a repeated NBCA-MS embolization. During the hospital stay, 56 patients recovered well but 2 (3.4%) died from multi-organ failure not related to the embolization. No recurrences were detected at the 3-month postoperative CTA in the remaining patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In properly selected patients affected with visceral artery pseudoaneurysms, NBCA-MS represents a definitive and safe embolization agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borghese</LastName><ForeName>Ottavia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2422-5517</Identifier><AffiliationInfo><Affiliation>Department of Vascular and Endovascular Surgery, 55183Nord Laennec Hospital, Saint-Herblain, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>9311University Sapienza of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganimede</LastName><ForeName>Maria Porzia</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Interventional Radiology Unit, 170131SS Annunziata Hospital, Taranto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briatico Vangosa</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Interventional Radiology Unit, 170131SS Annunziata Hospital, Taranto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisani</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, 47165Pinata Grande Hospital, Castel Volturno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidali</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5982-4387</Identifier><AffiliationInfo><Affiliation>9318University Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Stasi</LastName><ForeName>Carmine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Interventional Radiology Unit, 170131SS Annunziata Hospital, Taranto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burdi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Interventional Radiology Unit, 170131SS Annunziata Hospital, Taranto, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semeraro</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Interventional Radiology Unit, 170131SS Annunziata Hospital, Taranto, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vasc Endovascular Surg</MedlineTA><NlmUniqueID>101136421</NlmUniqueID><ISSNLinking>1538-5744</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>F8CEP82QNP</RegistryNumber><NameOfSubstance UI="D004659">Enbucrilate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017541" MajorTopicYN="Y">Aneurysm, False</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="Y">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004659" MajorTopicYN="Y">Enbucrilate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012077" MajorTopicYN="N">Renal Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">embolic agent</Keyword><Keyword MajorTopicYN="N">endovascular embolization</Keyword><Keyword MajorTopicYN="N">interventional radiology</Keyword><Keyword MajorTopicYN="N">pseudoaneurysm</Keyword><Keyword MajorTopicYN="N">visceral artery aneurysms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34261391</ArticleId><ArticleId IdType="doi">10.1177/15385744211028730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38470396</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2501-062X</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Romanian journal of internal medicine = Revue roumaine de medecine interne</Title><ISOAbbreviation>Rom J Intern Med</ISOAbbreviation></Journal><ArticleTitle>A tagging polymorphism in fat mass and obesity-associated (<i>FTO</i>) gene is associated with sepsis status in children.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>285</EndPage><MedlinePgn>279-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2478/rjim-2024-0008</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sepsis is one of the most common causes of death in patients admitted to intensive care units (ICUs). The development of sepsis is significantly influenced by genetic predisposition. In this study, we highlight a potential association between a variant of the fat mass and obesity-associated (<i>FTO</i>) gene and risk of sepsis in children and adolescents.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated a first-intron tagging <i>FTO</i> polymorphism (rs17817449) by comparing a severe condition (SC) group, comprising 598 paediatric patients (ages 0-19 years) admitted to an ICU with fever, systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, or multiple organ dysfunction syndrome (MODS), with a control group consisting of 616 healthy young adults.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed a lower prevalence (<i>p</i> &lt; 0.01; OR = 0.59, 95% CI = 0.39-0.87) of the <i>FTO</i> TT genotype in febrile and SIRS patients compared to patients with severe illness. There was a borderline trend towards a lower prevalence of the <i>FTO</i> TT genotype in the control group compared to the SC group (<i>p</i> &lt; 0.09, OR = 0.81, 95% CI = 0.62-1.06).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that rs17817449, a common <i>FTO</i> polymorphism, may be a predictor of sepsis in paediatric patients, and that higher body weight is protective against this clinical complication.</AbstractText><CopyrightInformation>&#xa9; 2024 Petr Jabandziev et al., published by Sciendo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jabandziev</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Central European Institute of Technology, &#x17d;erot&#xed;novo n&#xe1;m. 617/9, 601 77, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubacek</LastName><ForeName>Jaroslav Alois</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>4Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, V&#xed;de&#x148;sk&#xe1; 1958/9, 140 21, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>5Third Department of Internal Medicine, First Faculty of Medicine, Charles University, U Nemocnice 1, 121 08, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>6Department of Quantitative Methods, University of Defence, Kounicova 156/65, 662 10, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouza</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papez</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pecl</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaba</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaby</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Central European Institute of Technology, &#x17d;erot&#xed;novo n&#xe1;m. 617/9, 601 77, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urik</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aulicka</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunovsky</LastName><ForeName>Lumir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>7Department of Gastroenterology and Internal Medicine, University Hospital Brno, Jihlavsk&#xe1; 340, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>8Department of Surgery, University Hospital Brno, Jihlavsk&#xe1; 340, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>9Cellthera Ltd., V&#xed;de&#x148;sk&#xe1; 119, 619 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominik</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kratochvil</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klucka</LastName><ForeName>Jozef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stourac</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rom J Intern Med</MedlineTA><NlmUniqueID>9304507</NlmUniqueID><ISSNLinking>1220-4749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="D000071516">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="C526492">FTO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071516" MajorTopicYN="Y">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">child</Keyword><Keyword MajorTopicYN="N">genetic predisposition to the disease</Keyword><Keyword MajorTopicYN="N">genotype</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>2</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38470396</ArticleId><ArticleId IdType="doi">10.2478/rjim-2024-0008</ArticleId><ArticleId IdType="pii">rjim-2024-0008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BONE R.C., BALK R.A., CERRA F.B., DELLINGER R.P., FEIN A.M., KNAUS W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101 :1644-55.</Citation></Reference><Reference><Citation>RELLO J., VALENZUELA-S&#xc1;NCHEZ F., RUIZ-RODRIGUEZ M., MOYANO S. Sepsis: A review of advances in management. Adv Ther. 2017; 34 :2393-411.</Citation></Reference><Reference><Citation>KAWASAKI T. Update on pediatric sepsis: a review. J Intensive Care. 2017; 5 :47.</Citation></Reference><Reference><Citation>SINGER M., DEUTSCHMAN C.S., SEYMOUR C.W., SHANKAR-HARI M., ANNANE D., BAUER M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 :801-10.</Citation></Reference><Reference><Citation>MENON K., SCHLAPBACH L.J., AKECH S., ARGENT A., BIBAN P., CARROL E.D., et al. Pediatric Sepsis Definition Taskforce of the Society of Critical Care Medicine. Criteria for pediatric sepsis-a systematic review and meta-analysis by the pediatric sepsis definition taskforce . Crit Care Med. 2022; 50 :21-36.</Citation></Reference><Reference><Citation>CARDOSO T., TEIXEIRA-PINTO A., RODRIGUES P.P., ARAG&#xc3;O I., COSTA-PEREIRA A., SARMENTO A.E. Predisposition, insult/infection, response and organ dysfunction (PIRO): a pilot clinical staging system for hospital mortality in patients with infection. PLoS One. 2013; 8 :e70806.</Citation></Reference><Reference><Citation>FONT M.D., THYAGARAJAN B., KHANNA A.K. Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making. Med Clin North Am. 2020; 104 :573-585.</Citation></Reference><Reference><Citation>LU H., WEN D., WANG X., GAN L., DU J., SUN J., et al. Host genetic variants in sepsis risk: a field synopsis and meta-analysis . Crit Care 2019; 23 :26.</Citation></Reference><Reference><Citation>JABANDZIEV P., SMEREK M., MICHALEK J., FEDORA M., KOSINOVA L., HUBACEK J.A., et al. Multiple gene-to-gene interactions in children with sepsis: a combination of five gene variants predicts outcome of life-threatening sepsis. Crit Care 2014; 18 :R1.</Citation></Reference><Reference><Citation>RAUTANEN A., MILLS T.C., GORDON A.C., HUTTON P., STEFFENS M., NUAMAH R., et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2015; 3 :53-60.</Citation></Reference><Reference><Citation>SCHERAG A., SCH&#xd6;NEWECK F., KESSELMEIER M., TAUDIEN S., PLATZER M., FELDER M., et al. Genetic factors of the disease course after sepsis: A genome-wide study for 28day mortality . EBioMedicine. 2016; 12 :239-46.</Citation></Reference><Reference><Citation>KUPERMAN E.F., SHOWALTER J.W., LEHMAN E.B., LEIB A.E., KRASCHNEWSKI J.L. The impact of obesity on sepsis mortality: a retrospective review . BMC Infect Dis 2013; 13 :377.</Citation></Reference><Reference><Citation>TRIVEDI V., BAVISHI C., JEAN R. Impact of obesity on sepsis mortality: A systematic review. J Crit Care 2015; 30 :518-24.</Citation></Reference><Reference><Citation>DINA C., MEYRE D., GALLINA S., DURAND E., K&#xd6;RNER A., JACOBSON P., et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nature Genet. 2007; 39 :724-6.</Citation></Reference><Reference><Citation>DAY F.R., LOOS R.J. Developments in obesity genetics in the era of genome-wide association studies . J Nutrigenet Nutrigenomics. 2011; 4 :222-38.</Citation></Reference><Reference><Citation>GERKEN T., GIRARD C.A., TUNG Y.C., WEBBY C.J., SAUDEK V., HEWITSON K.S., et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase . Science. 2017; 318 :1469-72.</Citation></Reference><Reference><Citation>MICHALEK J., SVETLIKOVA P., FEDORA M., KLIMOVIC M., KLAPACOVA L., BARTOSOVA D., et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med. 2007; 33 :2158-64.</Citation></Reference><Reference><Citation>MICHALEK J, SVETLIKOVA P, FEDORA M, KLIMOVIC M, KLAPACOVA L, BARTOSOVA D, et al. Interleukin-6 gene variants and the risk of sepsis development in children . Hum Immunol. 2007;68:756-60.</Citation></Reference><Reference><Citation>LEVY M.M., FINK M.P., MARSHALL J.C., ABRAHAM E., ANGUS D., COOK D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference . Crit Care Med. 2003; 31 :1250-6.</Citation></Reference><Reference><Citation>HUBACEK J.A., STANEK V., GEBAUEROV&#xc1; M., PILIPCINCOV&#xc1; A., DLOUH&#xc1; D., POLEDNE R., et al. A FTO variant and risk of acute coronary syndrome. Clin Chim Acta. 2010; 411 :1069-72.</Citation></Reference><Reference><Citation>C&#xcd;FKOV&#xc1; R., SKODOV&#xc1; Z., BRUTHANS J., AD&#xc1;MKOV&#xc1; V., JOZ&#xcd;FOV&#xc1; M., GALOVCOV&#xc1; M., et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010; 211 :676-81.</Citation></Reference><Reference><Citation>KOBZOV&#xc1; J., VIGNEROV&#xc1; J., BL&#xc1;HA P., KREJCOVSK&#xdd; L., RIEDLOV&#xc1; J. The 6th nationwide anthropological survey of children and adolescents in the Czech Republic in 2001. Centr Eur J Public Health. 2004; 12 :126-130.</Citation></Reference><Reference><Citation>AGRESTI A. Categorical Data Analysis. 3rd ed. Hoboken, 2013; NJ: Wiley. ISBN: 978-0-470-46363-5.</Citation></Reference><Reference><Citation>S&#xd8;RENSEN T.I., NIELSEN G.G., ANDERSEN P.K., TEASDALE T.W. Genetic and environmental influences on premature death in adult adoptees . N Engl J Med. 1988; 318 :727-32.</Citation></Reference><Reference><Citation>DAVID V.L., ERCISLI M.F., ROGOBETE A.F., BOIA E.S., HORHAT R., NITU R., et al. Early prediction of sepsis incidence in critically ill patients using specific genetic polymorphisms . Biochem Genet. 2017; 55 :193-203.</Citation></Reference><Reference><Citation>SRINIVASAN L., PAGE G., KIRPALANI H., MURRAY J.C., DAS A., HIGGINS R.D., et al. Genome-wide association study of sepsis in extremely premature infants . Arch Dis Child Fetal Neonatal Ed. 2017; 102 :F439-45.</Citation></Reference><Reference><Citation>FENG Y., WANG F., PAN H., QIU S., L&#xdc; J., WU L., et al. Obesity-associated gene FTO rs9939609 polymorphism in relation to the risk of tuberculosis . BMC Infect Dis. 2014; 14 :592.</Citation></Reference><Reference><Citation>CRONIN R.M., FIELD J.R., BRADFORD Y., SHAFFER C.M., CARROLL R.J., MOSLEY J.D., et al. Phenome-wide association studies demonstrating pleiotropy of genetic variants within FTO with and without adjustment for body mass index . Front Genet 2014; 5 :250.</Citation></Reference><Reference><Citation>LUO J., WANG F., SUN F., YUE T., ZHOU Q., YANG C., et al. Targeted inhibition of FTO demethylase protects mice against LPS-induced septic shock by suppressing NLRP3 inflammasome . Front Immunol. 2021; 12 :663295.</Citation></Reference><Reference><Citation>WANG H., WANG Q., CHEN J., CHEN C. Association among the gut microbiome, the serum metabolomic profile and RNA m6A methylation in sepsis-associated encephalopathy. Front Genet. 2022; 13 :859727.</Citation></Reference><Reference><Citation>DUBEY P.K., PATIL M., SINGH S., DUBEY S., AHUJA P., VERMA S.K., et al. Increased m6A-RNA methylation and FTO suppression is associated with myocardial inflammation and dysfunction during endotoxemia in mice. Mol Cell Biochem. 2022; 477 :129-41.</Citation></Reference><Reference><Citation>WANG W., ZHANG T.N., YANG N., WEN R., WANG Y.J., ZHANG B.L., et al. Transcriptome-wide identification of altered RNA m6A profiles in cardiac tissue of rats with LPS-induced myocardial injury. Front Immunol. 2023; 14 :1122317.</Citation></Reference><Reference><Citation>TUERDIMAIMAITI D., ABUDUAINI B., KANG S., JIAO J., LI M., MADENIYATI W., TUERDI B., et al. Genome-wide identification and functional analysis of dysregulated alternative splicing profiles in sepsis. J Inflamm (Lond). 2023; 20 :31.</Citation></Reference><Reference><Citation>ZHANG Q, BAO X, CUI M, WANG C, JI J, JING J, et al. Identification and validation of key biomarkers based on RNA methylation genes in sepsis. Front Immunol. 2023; 14 :1231898.</Citation></Reference><Reference><Citation>CROSS D., DRURY R., HIL J., POLLARD A.J. Epigenetics in sepsis: Understanding its role in endothelial dysfunction, immunosuppression, and potential therapeutics. Front Immunol. 2019; 10 :1363.</Citation></Reference><Reference><Citation>HERTEL J.K., JOHANSSON S., SONESTEDT E., JONSSON A., LIE R.T., PLATOU C.G., et al. FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes. 2011; 60 :1637-44.</Citation></Reference><Reference><Citation>HUBACEK J.A., DLOUHA D., KLEMENTOVA M., LANSKA V., NESKUDLA T., PELIKANOVA T. The FTO variant is associated with chronic complications of diabetes mellitus in Czech population . Gene. 2018; 642 :220-4.</Citation></Reference><Reference><Citation>HUANG X., ZHAO J., YANG M., LI M., ZHENG J. Association between FTO gene polymorphism (rs9939609 T/A) and cancer risk: a meta-analysis. Eur J Cancer Care. 2017; 26(5).</Citation></Reference><Reference><Citation>HUBACEK J.A., VIKLICKY O., DLOUHA D., BLOUDICKOVA S., KUBINOVA R., PEASEY A., et al. The FTO gene polymorphism is associated with end-stage renal disease: two large independent case-control studies in a general population. Nephrol Dial Transplant. 2012; 27 :1030-5.</Citation></Reference><Reference><Citation>ZIMMERMANN E., KRING S.I., BERENTZEN T.L., HOLST C., PERS T.H., HANSEN T., et al. Fatness-associated FTO gene variant increases mortality independent of fatness - in cohorts of Danish men. PLoS One. 2009; 4 :e4428.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26643240</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection.</ArticleTitle><Pagination><StartPage>147</StartPage><EndPage>149</EndPage><MedlinePgn>147-9</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare the effects and side-effects of fondaparinux sodium and low molecular weight heparin in patients with hypercoagulability accompanied with traumatic infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-six patients with post-traumatic infections in our hospital intensive care center were diagnosed with hypercoagulability from February 2012 to February 2013. These patients were randomly divided into 2 groups. In group F (18 patients), the patients were treated with fondaparinux sodium, 2.5 mg, 1/d for 11 d. In group L (18 patients), the patients were treated with low molecular weight heparin, 4100 U, 1/12 h for 11 d. The incidence of deep vein thrombosis, bleeding events and multiple organ dysfunction syndrome (MODS) and mortality of two groups after anticoagulation therapy were analyzed. Fibrinogen, D-dimer level and activity of antithrombin III were measured by the coagulation analyzer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of deep vein thrombosis, MODS incidence and mortality were not significantly different between the two groups. The rate of bleeding evens in group F was lower than group L (p &lt; 0.05). Antithrombin III got an upward trend after anticoagulant therapy, in which it was higher in group F than in group L on the 5th d and 11th d (p&lt;0.05). Fibrinogen levels were gradually increased, and there was no significant difference between two groups (p&gt;0.05). D-dimer was significantly decreased after anticoagulant therapy for 5 d (p&lt;0.01), and there were significant differences between two groups on the 5th d and 7th d (p&lt;0.05). It showed no significant difference on the 11th d (p&gt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Fondaparinux sodium and low molecular weight heparin can effectively improve coagulopathy in patients with traumatic infection. Compared with low molecular weight heparin, fondaparinux sodium may reduce the risk of bleeding events in patients with hypercoagulability accompanied by traumatic infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Baiqiang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kang</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Haichen</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>J177FOW5JL</RegistryNumber><NameOfSubstance UI="D000077425">Fondaparinux</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077425" MajorTopicYN="N">Fondaparinux</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26643240</ArticleId><ArticleId IdType="pii">S1008-1275(15)00074-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15239238</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0172-6390</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>58</Issue><PubDate><Year>2004</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Hepato-gastroenterology</Title><ISOAbbreviation>Hepatogastroenterology</ISOAbbreviation></Journal><ArticleTitle>Ultraflex stent--benefits and risks in ultimate palliation of advanced, malignant stenosis in the esophagus.</ArticleTitle><Pagination><StartPage>1021</StartPage><EndPage>1026</EndPage><MedlinePgn>1021-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Sophisticated endoscopical palliation in end-stage malignant stenosis of the esophagus and gastroesophageal-junction must be weighed against associated morbidity and mortality. In a prospective study we investigated benefits and risks of one type of coated, self-expandable stent in ultimate palliation of esophageal neoplasms focusing on factors that might predispose patients to develop complications.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">33 men (70.2%) and 14 women (29.8%), (mean age 68.3 years, range from 38 to 90 years), suffering from nonresectable malignant stenosis of the esophagus due to advanced tumor stage and/or functional inoperability were treated by using a covered, self-expandable stent (covered ULTRAFLEX esophageal stent system, Microinvasive, Boston Scientific Corporation, Boston, MA). Stenting was indicated because of severe dysphagia for liquids and saliva in 41 (87.2%) patients, tracheoesophageal fistula in 5 (10.6%) patients and in one case of tumor bleeding (2.1%). 32 out of 47 patients had had one or other multiple treatment modalities before stenting. In 15 patients stenting was the first and only therapeutic option.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients experienced an improvement of dysphagia immediately after stenting. Eight out of 47 patients (17.1%) developed major stent-associated complications: Early complications within 4 days after implantation evolved in two cases, with one patient dying from stent-induced perforation with consecutive mediastinitis and multi-organ failure. Late complications (20 to 180 days after stent implantation) occurred in 6 cases: Three esophagotracheal fistulae (two with tracheal compression) induced by stent expansion, one stent-induced bleeding and two stent dislocations. After appropriate complication management all but two patients were able to be discharged after a mean of 2.6 days. Multivariate analysis did not show any factors that might have predicted the development of major stent-associated complications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Implantation of the self-expandable Ultraflex-stent will efficiently palliate dysphagia, bleeding and fistulae. The 17% risk of major complications seems acceptable regarding the inherent problems of alternative treatment options, like gastrostomy, PEG, nasogastric tube or long-term parenteral feeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomaselli</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Thoracic and Hyperbaric Surgery, University Medical School, Graz, Austria. florian.tomaselli@kfunigraz.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Alfred</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sankin</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Pinter</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Smolle</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Smolle-J&#xfc;ttner</LastName><ForeName>Freyja Maria</ForeName><Initials>FM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Hepatogastroenterology</MedlineTA><NlmUniqueID>8007849</NlmUniqueID><ISSNLinking>0172-6390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020099">Coated Materials, Biocompatible</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020099" MajorTopicYN="N">Coated Materials, Biocompatible</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="N">Deglutition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004940" MajorTopicYN="N">Esophageal Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004945" MajorTopicYN="N">Esophagoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005471" MajorTopicYN="N">Fluoroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="Y">Palliative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15239238</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18376164</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-8809</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>2 Suppl</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients.</ArticleTitle><Pagination><StartPage>S188</StartPage><EndPage>S194</EndPage><MedlinePgn>S188-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/TA.0b013e318160a5a3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">After injury, there is a synergistic response between inflammation and coagulation systems. We hypothesized that combining markers of these processes and standard clinical indices would improve early prediction of in- hospital mortality in burned and nonburned trauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients admitted to the surgical or burn intensive care unit within 24 hours of injury with an anticipated stay &gt;or=3 days were enrolled during a one year period. Upon admission, blood was drawn for thromboelastography, plasma-based clotting assays, and cytokine levels. Clinical indices and multiple organ dysfunction syndrome (MODS) scores were recorded. Candidate variables evaluated included age, percentage third degree burns, inhalation injury, percentage total body surface area burns, interleukin-6, tumor necrosis factor alpha, interleukin-8, prothrombin time, partial thromboplastin time (PTT), maximal amplitude reflective of clot strength, group (burn or nonburn) and admission MODS. Multiple logistic regression with stepwise selection and likelihood ratio test was performed to identify predictors for mortality. A receiver operating characteristic (ROC) curve was constructed to assess the diagnostic performance of identified predictors. Validation of the model with an additional cohort was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For model development, we enrolled 25 burned and 33 nonburned trauma patients (20 blunt and 13 penetrating injuries). Fifteen deaths occurred. Multiple logistic regression analysis identified six independent risk factors for death: age, percentage third degree burns, inhalation injury, tumor necrosis factor alpha level, maximal amplitude, and MODS score with an area under ROC curve of 0.961 (95% confidence interval: 0.891, 1.000, p &lt; 0.05). The area under the ROC curve for the validation cohort (n = 66) was 0.936 (95% confidence interval: 0.875, 0.997, p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our model improves prediction of in-hospital mortality in comparison to previous methods for burn and nonburn trauma patients. Furthermore, our model is equally applicable to all patients regardless of type of traumatic injury (nonburn or burn). This improvement is because of the inclusion of patient's early coagulation and inflammatory status in addition to standard clinical indices. These data provide a baseline within which to measure incremental improvements in care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Myung S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>US Army Institute of Surgical Research, Fort Sam Houston, TX 78234, USA. myung.park@amedd.army.mil</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>Charles E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Pusateri</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Gerald A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Holcomb</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001779">Blood Coagulation Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001779" MajorTopicYN="N">Blood Coagulation Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013916" MajorTopicYN="N">Thrombelastography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18376164</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e318160a5a3</ArticleId><ArticleId IdType="pii">00005373-200802001-00028</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20655807</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1473-0502</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</Title><ISOAbbreviation>Transfus Apher Sci</ISOAbbreviation></Journal><ArticleTitle>Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7).</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>116</EndPage><MedlinePgn>107-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transci.2010.05.014</ELocationID><Abstract><AbstractText>The question of whether storage of red blood cells (RBCs) alters their capacity to deliver oxygen and affects patient outcomes remains in a state of clinical equipoise. Studies of the changes which occur while RBCs are stored have led to several physiologically plausible hypotheses that these changes impair RBC function when the units are transfused. Although there is some evidence of this effect in vivo from animal model experiments, the results of several largely retrospective patient studies have not been consistent. Some studies have shown an association between worse clinical outcomes and transfusion of RBC which have been stored for longer periods of time, while others have found no effect. Three multicenter, randomized, controlled trials have been developed to address this important, but currently unanswered, question. Two clinical trials, one in low birth weight neonates and the other in intensive care unit patients, are enrolling subjects in Canada (the Age of Red Blood Cells in Premature Infants; the Age of Blood Study). The third trial, which is being developed in the United States, is the Red Cell Storage Duration Study (RECESS). This is a multicenter, randomized, controlled trial in which patients undergoing complex cardiac surgical procedures who are likely to require RBC transfusion will be randomized to receive RBC units stored for either 10 or fewer days or 21 or more days. Randomization will only occur if the blood bank has enough units of RBC of both storage times to meet the crossmatch request; hence, subjects randomized to the 21 day arm will receive RBC of the same storage time as they would have following standard inventory practice of "oldest units out first". The primary outcome is the change in the Multiple Organ Dysfunction Score (MODS), a composite measure of multiorgan dysfunction, by day 7. Secondary outcomes include the change in the MODS by day 28, all-cause mortality, and several composite and single measures of specific organ system function. The estimated total sample size required will be 1434 evaluable subjects (717 per arm).</AbstractText><CopyrightInformation>(c) 2010. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology, University of Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assmann</LastName><ForeName>S F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pulkrabek</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00991341</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL072346</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072289</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072291</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072290</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072274</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072331</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072359</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072248</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072191</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072033</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072196</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072268</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072305</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072028</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072283</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072299</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072355</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072072</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transfus Apher Sci</MedlineTA><NlmUniqueID>101095653</NlmUniqueID><ISSNLinking>1473-0502</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20655807</ArticleId><ArticleId IdType="mid">NIHMS208949</ArticleId><ArticleId IdType="pmc">PMC2918709</ArticleId><ArticleId IdType="doi">10.1016/j.transci.2010.05.014</ArticleId><ArticleId IdType="pii">S1473-0502(10)00097-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steiner M, Stowell C. Does red blood cell storage affect clinical outcome? When in doubt, do the experiment. Transfusion. 2009;49:1286&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19602209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess J. Red cell changes during storage. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20558107</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani A, Hebbell R. The microcirculation and RBC transfusion. Transfus Aph Sci. 2010;43</Citation></Reference><Reference><Citation>Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery as targets for blood transfusion: the experimental evidence. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918661</ArticleId><ArticleId IdType="pubmed">20646963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y. Techniques to assess tissue oxygenation in the clinical setting. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20692624</ArticleId></ArticleIdList></Reference><Reference><Citation>Triulzi D, Yazer M. Clinical Studies of the effect of blood storage on patient outcomes. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Chin-Yee I, Fergusson D, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005;100:1433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Stafford-Smith M, Waweru PM, Bredehoeft SJ, Campbell ML, Haley NR, Phillips-Bute B, Newman MF, Bandarenko N. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion. 2009;49:1375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of &#x201c;old&#x201d; (versus &#x201c;fresh&#x201d;) red blood cells: are we at equipoise? Transfusion. 2010;50:600&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D, Hutton B, Hogan DL, et al. The age of red blood cells in premature infants (ARIPI) randomized, controlled trial: study design. Transfus Med Rev. 2009;23:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056034</ArticleId></ArticleIdList></Reference><Reference><Citation>The Age of Blood (ABLE) Study.  [2/2/10].   http://www.controlled-trials.com/ISRCTN44878718/</Citation></Reference><Reference><Citation>Transfusion Medicine and Hemostasis Clinical Trials Network (TMHCTN)  [2/2/10].   http://www.tmhnetwork.org/</Citation></Reference><Reference><Citation>New England Research Institutes.  [2/2/10].   http://neriscience.com/</Citation></Reference><Reference><Citation>Elahi MM, Yii M, Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2008;22:455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503942</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg. 1992;104:307&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">1495291</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Cristou NV, et al. Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. NEJM. 2008;358:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thoracic Surg. 2008;86:554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CK, Trethewey D, Sadek I. Comprehensive survey of red blood cell unit life cycle at a large teaching institution in eastern Canada. Transfusion. 2010;50:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19761550</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8874456</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:62&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974;27:365&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4612056</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Wells G, Blachman MJ, Marshall J, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med. 1999;340:409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9971864</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Wagner DP. Multiple system organ failure: epidemiology and prognosis. Crit Care Med. 1989;5:221&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2650815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriani R, Mazzoni M, Bortone F, Gandini S, et al. Application of the sequential organ failure assessment score to cardiac surgical patients. Chest. 2003;123:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">12684316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekmat K, Kroener A, Stuetzer H, Schwinger RH, et al. Daily assessment of organ dysfunction and survival in intensive care unit cardiac surgical patients. Annals Thorac Surg. 2005;79:1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15854933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin YM, van de Watering L, Eijsman L, Versteegh MIM, et al. Double-blind randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004;109:2755&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148271</ArticleId></ArticleIdList></Reference><Reference><Citation>Patila T, Kukkonen S, Vento A, et al. Relation of the sequential organ failue assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg. 2006;82:2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni M, De Maria M, Bortone F, et al. Long term outcome of survivors of prolonged intensive care treatment after cardiac surgery. Ann Thorac Surg. 2006;82:2080&#x2013;2088.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, et al. Outcome of pediatric patients with multiple organ system failure. Crit Care Med. 1986;14:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, et al. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109:1033&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttiman UE. PRISM III: an updated Pediatric Risk of Mortality Score. Crit Care Med. 1996;24:743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33:1484&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational multicentre study. Lancet. 2003;362:192&#x2013;197.38.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Hutchison JS, Hume HA, et al. Transfusion strategies for patients in pediatric intensive care units. New Engl J Med. 2007;356:1609&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shime N, Kageyama K, Ashida H, Tanaka Y. Application of modified sequential organ failure assessment score in children after cardiac surgery. J Cardiothorac Vasc Anesthesia. 2001;15:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">11505351</ArticleId></ArticleIdList></Reference><Reference><Citation>Slichter SJ, Kaufman RM, Assmann SF, McCullough J, et al. Dose of prophylactic platelet pransfusions and prevention of hemorrhage. New Eng J Med. 2010;362:600&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951321</ArticleId><ArticleId IdType="pubmed">20164484</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier AC, Kalish LA, Busch MP, Gernsheimer T, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: The Viral Activation Transfusion Study: a randomized controlled trial. J Amer Med Assoc. 2001;285:1592&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MT, Piomelli S, Granger S, Miller ST, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): Extended follow-up and final results. Blood. 2006;108:847&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895848</ArticleId><ArticleId IdType="pubmed">16861341</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New Engl J Med. 2005;353:2769&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16045576</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1120-8694</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus</Title><ISOAbbreviation>Dis Esophagus</ISOAbbreviation></Journal><ArticleTitle>Does transthoracic compared to transhiatal resection alter the early postoperative course of oesophagectomy?</ArticleTitle><Pagination><StartPage>155</StartPage><EndPage>159</EndPage><MedlinePgn>155-9</MedlinePgn></Pagination><Abstract><AbstractText>Several techniques for esophageal resections have been reported. However, clear clinical evidence is still lacking whether any of the procedures is superior to the others regarding morbidity and mortality in the early postoperative period. Two operative approaches for esophageal carcinoma, transhiatal and transthoracic, were compared with respect to operative morbidity, mortality and systemic inflammatory response. In our prospective study between 2000 and 2002 83 patients were investigated. In a retrospective post hoc analysis patients were divided into two groups due to the performed operational procedure, transhiatal (TH) or transthoracic (TT). Multiple Organ Dysfunction Score (MODS) was monitored daily (t1,t2,t3). Serum procalcitonin (PCT) levels were determined on admission to the ICU (t0), then 24 hourly (t24,t48,t72). Microalbuminuria (M:Cr) was measured before (tp), and after surgery (t0,t6,t24,t48,t72). For statistical analysis Wilcoxon rank sum test, Mann-Whitney U-test and chi-square test were used as appropriate. We examined 52 patients in the TH group, and 31 patients in the TT group. There was no significant difference between the two groups regarding age, male/female ratio, and SAPS II scores. Operations lasted significantly longer in the TT group: 375 (300-480) min compared to the TH group 240 375 (180-319) min, P &lt; 0.001. ICU mortality was similar in both groups (TH: 46 survivors/6 non-survivors; TT: 27 survivors/4 non-survivors; P = 0.607, respectively). Daily MODS did not differ significantly between the two groups. The observed inflammatory markers (PCT and M:Cr) followed the pattern we described earlier, without significant difference. In this study there was no difference in the clinical and biochemical variables of the patients between the transthoracic and transhiatal groups. The observed early postoperative morbidity and mortality may indicate, that both procedures can be considered as procedures with similar postoperative risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xe1;rton</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, University of P&#xe9;cs, P&#xe9;cs, Hungary. smarton11@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szakm&#xe1;ny</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cseke</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Horv&#xe1;th</LastName><ForeName>P O</ForeName><Initials>PO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Esophagus</MedlineTA><NlmUniqueID>8809160</NlmUniqueID><ISSNLinking>1120-8694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016629" MajorTopicYN="Y">Esophagectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="Y">Laparotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013908" MajorTopicYN="Y">Thoracotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16045576</ArticleId><ArticleId IdType="doi">10.1111/j.1442-2050.2005.00479.x</ArticleId><ArticleId IdType="pii">DES479</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21232130</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis.</ArticleTitle><Pagination><StartPage>R20</StartPage><MedlinePgn>R20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc9965</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Deregulated apoptosis and overshooting neutrophil functions contribute to immune and organ dysfunction in sepsis and multiple organ failure (MOF). In the present study, we determined the role of soluble Fas (sFas) in the regulation of posttraumatic neutrophil extrinsic apoptosis and the development of sepsis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-seven major trauma patients, 18 with and 29 without sepsis development during the first 10 days after trauma, were enrolled in this prospective study. Seventeen healthy volunteers served as controls. Blood samples from severely injured patients were analyzed at day 1, day 5 and day 9 after major trauma. sFas levels, plasma levels of neutrophil elastase (PMNE) and levels of interleukin (IL)-6 were quantified by enzyme-linked immunosorbent assay and related to patients' Sequential Organ Failure Assessment (SOFA) score and Multiple Organ Dysfunction Score (MODS). Neutrophil apoptosis was determined by propidium iodide staining of fragmented DNA and flow cytometry. sFas-mediated effects on neutrophil apoptosis were investigated in cells cultured with agonistic anti-Fas antibodies in the presence of recombinant sFas, sFas-depleted serum or untreated serum from septic patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum levels of sFas in patients who later developed sepsis were significantly increased at day 5 (P &lt; 0.01) and day 9 (P &lt; 0.05) after trauma compared with patients with uneventful recovery. Apoptosis of patient neutrophils was significantly decreased during the observation period compared with control cells. Moreover, Fas-mediated apoptosis of control neutrophils was efficiently inhibited by recombinant sFas and serum from septic patients. Depletion of sFas from septic patient sera diminished the antiapoptotic effects. In septic patients, sFas levels were positively correlated with SOFA at day 1 (r = 0.7, P &lt; 0.001), day 5 (r = 0.62, P &lt; 0.01) and day 9 (r = 0.58, P &lt; 0.01) and with PMNE and leukocyte counts (r = 0.49, P &lt; 0.05 for both) as well as MODS at day 5 (r = 0.56, P &lt; 0.01) after trauma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased sFas in patients with sepsis development impairs neutrophil extrinsic apoptosis and shows a positive correlation with the organ dysfunction scores and PMNE. Therefore, sFas might be a therapeutic target to prevent posttrauma hyperinflammation and sepsis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paunel-G&#xf6;rg&#xfc;l&#xfc;</LastName><ForeName>Adnana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Trauma and Hand Surgery, University Hospital D&#xfc;sseldorf, Moorenstrasse 5, D-40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floh&#xe9;</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Windolf</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>L&#xf6;gters</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21232130</ArticleId><ArticleId IdType="pmc">PMC3222054</ArticleId><ArticleId IdType="doi">10.1186/cc9965</ArticleId><ArticleId IdType="pii">cc9965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest. 1989;83:865&#x2013;875. doi: 10.1172/JCI113970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI113970</ArticleId><ArticleId IdType="pmc">PMC303760</ArticleId><ArticleId IdType="pubmed">2921324</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C. Points of control in inflammation. Nature. 2002;420:846&#x2013;852. doi: 10.1038/nature01320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01320</ArticleId><ArticleId IdType="pubmed">12490957</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195&#x2013;S199. doi: 10.1097/01.CCM.0000057843.47705.E8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000057843.47705.E8</ArticleId><ArticleId IdType="pubmed">12682440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol. 2007;35:757&#x2013;766. doi: 10.1080/01926230701584163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230701584163</ArticleId><ArticleId IdType="pubmed">17943649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuligowski M, Kitching A, Hickey M. Leukocyte recruitment to the inflamed glomerulus: A critical role for platelet-derived P-selectin in the absence of rolling. J Immunol. 2006;176:6991&#x2013;6999.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709860</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368:157&#x2013;169. doi: 10.1016/S0140-6736(06)69005-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69005-3</ArticleId><ArticleId IdType="pubmed">16829300</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ, Little K, Haslett C. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151:1428&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">7735596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia R, Dent C, Topley N, Pallister I. Neutrophil priming for elastase release in adult blunt trauma patients. J Trauma. 2006;60:590&#x2013;596. doi: 10.1097/01.ta.0000205614.51885.ff.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ta.0000205614.51885.ff</ArticleId><ArticleId IdType="pubmed">16531859</ArticleId></ArticleIdList></Reference><Reference><Citation>Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol. 1997;61:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">9103222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 1995;16:569&#x2013;574. doi: 10.1016/0167-5699(95)80079-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(95)80079-4</ArticleId><ArticleId IdType="pubmed">8579749</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469&#x2013;474. doi: 10.1038/82712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/82712</ArticleId><ArticleId IdType="pubmed">11101867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29&#x2013;55. doi: 10.1146/annurev.genet.33.1.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genet.33.1.29</ArticleId><ArticleId IdType="pubmed">10690403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759&#x2013;1762. doi: 10.1126/science.7510905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7510905</ArticleId><ArticleId IdType="pubmed">7510905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777&#x2013;1783. doi: 10.1084/jem.182.6.1777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.182.6.1777</ArticleId><ArticleId IdType="pmc">PMC2192231</ArticleId><ArticleId IdType="pubmed">7500022</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001;85:1047&#x2013;1054. doi: 10.1054/bjoc.2001.2042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2001.2042</ArticleId><ArticleId IdType="pmc">PMC2375090</ArticleId><ArticleId IdType="pubmed">11592778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806&#x2013;809. doi: 10.1038/364806a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364806a0</ArticleId><ArticleId IdType="pubmed">7689176</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, Jonas M, Martin TR. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS) J Immunol. 1999;163:2217&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438964</ArticleId></ArticleIdList></Reference><Reference><Citation>Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996;184:429&#x2013;440. doi: 10.1084/jem.184.2.429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.2.429</ArticleId><ArticleId IdType="pmc">PMC2192712</ArticleId><ArticleId IdType="pubmed">8760796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg. 1997;132:1263&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitnis D, Dickerson C, Munster AM, Winchurch RA. Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. J Leukoc Biol. 1996;59:835&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">8691068</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenspan L, McLellan BA, Greig H. Abbreviated Injury Scale and Injury Severity Score: a scoring chart. J Trauma. 1985;25:60&#x2013;64. doi: 10.1097/00005373-198501000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198501000-00010</ArticleId><ArticleId IdType="pubmed">3965737</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538&#x2013;1548. doi: 10.1097/01.CCM.0000168253.91200.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple Organ Dysfunction Score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Maianski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood. 2002;99:672&#x2013;679. doi: 10.1182/blood.V99.2.672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.2.672</ArticleId><ArticleId IdType="pubmed">11781253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271&#x2013;279. doi: 10.1016/0022-1759(91)90198-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(91)90198-O</ArticleId><ArticleId IdType="pubmed">1710634</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837&#x2013;845. doi: 10.2307/2531595.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Paunel-G&#xf6;rg&#xfc;l&#xfc; A, Z&#xf6;rnig M, L&#xf6;gters T, Altrichter J, Rabenhorst U, Cinatl J, Windolf J, Scholz M. Mcl-1-mediated Impairment of the intrinsic apoptosis pathway in circulating neutrophils from critically ill patients can be overcome by Fas stimulation. J Immunol. 2009;183:6198&#x2013;6206.</Citation><ArticleIdList><ArticleId IdType="pubmed">19841168</ArticleId></ArticleIdList></Reference><Reference><Citation>Maianski NA, Maianski AN, Kujpers TW, Roos D. Apoptosis of neutrophils. Acta Haematol. 2004;111:56&#x2013;66. doi: 10.1159/000074486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000074486</ArticleId><ArticleId IdType="pubmed">14646345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilton B, Andjelkovic M, Didichenko SA, Hemmings BA, Thelen M. G-Protein-coupled receptors and Fc&#x3b3;-receptors mediate activation of Akt/protein kinase B in human phagocytes. J Biol Chem. 1997;272:28096&#x2013;28101. doi: 10.1074/jbc.272.44.28096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.44.28096</ArticleId><ArticleId IdType="pubmed">9346964</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, Johnson GL. Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-&#x3b1; and GM-CSF. J Leukoc Biol. 1998;64:537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">9766635</ArticleId></ArticleIdList></Reference><Reference><Citation>Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem. 2004;279:26915&#x2013;26921. doi: 10.1074/jbc.M313875200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313875200</ArticleId><ArticleId IdType="pubmed">15078892</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanassoglou ED, Moynihan JA, Vermillion DL, McDermott MP, Ackerman MH. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Shock. 2000;14:107&#x2013;112. doi: 10.1097/00024382-200014020-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200014020-00005</ArticleId><ArticleId IdType="pubmed">10947151</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsik C, Halama T, Cardona F, Wlassits W, Mayr F, Pleiner J, Jilma B. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock. 2003;20:493&#x2013;496. doi: 10.1097/01.shk.0000097248.97298.ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000097248.97298.ea</ArticleId><ArticleId IdType="pubmed">14625471</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre D, Tambini R, Manfredi M, Mangani V, Livi P, Maldifassi V, Campi P, Speranza F. Circulating levels of FAS/APO-1 in patients with the systemic inflammatory response syndrome. Diagn Microbiol Infect Dis. 2003;45:233&#x2013;236. doi: 10.1016/S0732-8893(02)00550-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0732-8893(02)00550-3</ArticleId><ArticleId IdType="pubmed">12729991</ArticleId></ArticleIdList></Reference><Reference><Citation>De Freitas I, Fernandez-Somoza M, Essenfeld-Sekler, Cardier JE. Serum levels of the apoptosis-associated molecules, tumor necrosis factor-&#x3b1;/tumor necrosis factor type-I receptor and Fas/FasL, in sepsis. Chest. 2004;125:2238&#x2013;2246. doi: 10.1378/chest.125.6.2238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.125.6.2238</ArticleId><ArticleId IdType="pubmed">15189947</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani K, Nishioka Y, Yamabe K, Ogawa H, Miki T, Yanagawa H, Sone S. Soluble Fas in malignant pleural effusion and its expression in lung cancer cells. Cancer Sci. 2003;94:302&#x2013;307. doi: 10.1111/j.1349-7006.2003.tb01437.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2003.tb01437.x</ArticleId><ArticleId IdType="pmc">PMC11160079</ArticleId><ArticleId IdType="pubmed">12824926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KS, Choi YH, Kim YS, Baik SH, Oh YJ, Sheen SS, Park JH, Hwang SC, Park KJ. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Respir Med. 2008;102:464&#x2013;469. doi: 10.1016/j.rmed.2007.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2007.10.001</ArticleId><ArticleId IdType="pubmed">17988850</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwase M, Kondo G, Watanabe H, Takaoka S, Uchida M, Ohashi M, Nagumo M. Regulation of Fas-mediated apoptosis in neutrophils after surgery-induced acute inflammation. J Surg Res. 2006;134:114&#x2013;123. doi: 10.1016/j.jss.2005.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.10.013</ArticleId><ArticleId IdType="pubmed">16376940</ArticleId></ArticleIdList></Reference><Reference><Citation>Liacos C, Katsaragakis S, Konstadoulakis MM, Messaris EG, Papanicolaou M, Georgiadis GG, Menenakos E, Vasiliadi-Chioti A, Androulakis G. Apoptosis in cells of bronchoalveolar lavage: a cellular reaction in patients who die with sepsis and respiratory failure. Crit Care Med. 2001;29:2310&#x2013;2317. doi: 10.1097/00003246-200112000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200112000-00013</ArticleId><ArticleId IdType="pubmed">11801832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialkow L, Fochesatto Filho L, Bozzetti MC, Milani AR, Rodrigues Filho EM, Ladniuk RM, Pierozan P, de Moura RM, Prolla JC, Vachon E, Downey GP. Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit Care. 2006;10:R155. doi: 10.1186/cc5090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc5090</ArticleId><ArticleId IdType="pmc">PMC1794458</ArticleId><ArticleId IdType="pubmed">17092345</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus. 2003;12:8&#x2013;14. doi: 10.1191/0961203303lu250oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu250oa</ArticleId><ArticleId IdType="pubmed">12587820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Ye F, Lv W, Cheng Q, Chen H, Xie X. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma. Eur J Obstet Gynaecol Reprod Biol. 2008;138:204&#x2013;211. doi: 10.1016/j.ejogrb.2007.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2007.06.025</ArticleId><ArticleId IdType="pubmed">17826886</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry MA, Ahmad S, Thompson KD, Sayeed MM. T-lymphocyte Ca2+ signalling and proliferative responses during sepsis. Shock. 1994;1:466&#x2013;471. doi: 10.1097/00024382-199406000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-199406000-00012</ArticleId><ArticleId IdType="pubmed">7735977</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth G, Moser B, Krenn C, Brunner M, Haisjackl M, Almer G, Gerlitz S, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem Biophys Res Commun. 2003;308:840&#x2013;846. doi: 10.1016/S0006-291X(03)01482-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(03)01482-7</ArticleId><ArticleId IdType="pubmed">12927795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol. 2005;174:6672&#x2013;6676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15905506</ArticleId></ArticleIdList></Reference><Reference><Citation>Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, Ho AD. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108:1627&#x2013;1634. doi: 10.1182/blood-2006-11-010389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-11-010389</ArticleId><ArticleId IdType="pubmed">16709924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, K&#xfc;bler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270&#x2013;8278. doi: 10.1158/1078-0432.CCR-08-0165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0165</ArticleId><ArticleId IdType="pubmed">19088044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15778773</PMID><DateCompleted><Year>2005</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners</Title><ISOAbbreviation>Cardiovasc J S Afr</ISOAbbreviation></Journal><ArticleTitle>Endovascular aortic aneurysm repair by a multidisciplinary team: lessons learned and six-year clinical update.</ArticleTitle><Pagination><StartPage>36</StartPage><EndPage>47</EndPage><MedlinePgn>36-47</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endovascular aneurysm repair (EVAR) (using an Federal Drug Association-approved AneuRx device) compared to conventional surgical repair of abdominal aortic aneurysm (AAA) previously rendered favourable outcomes regarding post-operative pain, avoidance of laparotomy, and rapid rehabilitation and hospital discharge in high-risk patients, including octagenarians.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the safety, reduction in aneurysm-related deaths, and interim survival data up to 72 months after AAA exclusion by endoluminal endografts (EVAR).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We carried out an open, controlled, prospective, multidisciplinary EVAR study for the period 1998 to 2003 (six years). In the earlier part of the study, EVAR was compared with previously published results of conventional open aneurysmectomy surgery.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Heart Unit, Panorama Medi-Clinic, Parow, South Africa.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">We recruited adult male and female patients presenting with AAA and fulfilling the inclusion criteria for endovascular repair, as recommended by the consensus 2003 meeting of the Vascular Association of South Africa (VASSA). All patients were offered open surgery as an alternative and were entered into the VASSA EVAR trial registry. Pre-operatively, AAA anatomy was assessed by spiral-computed tomography (CT), and selectively with conventional angiography and intravascular ultrasound (IVUS). Informed consent was obtained in accordance with the recommendations of the Senate of Surgery Paper 2, Ethical Guidelines, Great Britain and Ireland. Patients underwent EVAR by a multidisciplinary interventional team.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Two hundred and seven adult patients with AAA were assessed. Forty-four of the 207 (21.2%) were excluded from EVAR because of irreversible comorbid factors and complex aneurysm morphology. One hundred and sixty-three patients (78%), with a mean age of 70.7 years (range 60-91 years), underwent EVAR (1998-2003). Five patients were lost to follow-up (3%). Median AAA diameter was 56.9 mm and ASA ratings were I, 1.2%; II, 15.9%; III, 57%; IV, 22.6%; and V, 2.4%. EVAR was performed in high- and low-risk categories of both sexes. Most patients were in ASA groups III and IV. DEVICES DEPLOYED: EVAR was performed using a selection of endografts over 72 months- AneuRx (Medtronic) 47; Talent (Medtronic) 49; Vanguard three; Zenith (Cook) one; Powerlink (Endologix) 62; and other, one.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-day outcome: successful deployment 99%, primary stent patency 97%, surgical conversion 0.6%, procedural or intra-operative mortality 1.2%, 30-day mortality 4.3%, endoleaks 1.84%, and secondary intraprocedural endovascular interventions 24.5%. Perioperative mortality was 3.1% (one aneurysm related). One patient had suspected endograft infection. Late mortality was 21.4% (35 patients due to co-morbidities, and one was aneurysm related). Follow-up was a median of 28.3 months (range 1-69 months). In 163 patients, two persisting endoleaks (1.2%) were detected. Endotension was detected in 3/163 (1.8%) with average sac increase of 0.8 cm. Conversion to open surgery was needed in one patient (0.6%). Co-morbidities that contributed to late mortality included multi-organ failure, ischaemic heart disease (IHD), cardiomyopathy, renal failure, stroke and cancer. One procedural rupture was fatal (0.6%). Two late ruptures occurred; one was successfully endostented and the other patient died after a failed surgical intervention (0.6%). Endovascular repair of AAA is more expensive than conventional surgery. Introduction of the Endologix stent has reduced operative time from 120 to 60 minutes in un complicated patients. Newer-generation aortic stents allow better control of negative remodeling and stent migration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A multidisciplinary team can safely perform EVAR, with a low 30-day mortality rate in selected patients graded ASA II-IV and with favourable aortic aneurysm morphology. About 22% of patients with AAA are not suited for EVAR. Persisting late endoleaks occurred in 1.2% of the cohort study and were not device specific. Life-long follow-up post EVAR is a prerequisite to detect late device failure, endoleaks and aneurysm-sac enlargement, and to assure the durability of these midterm results. Short-term aneurysm rupture prevention is a predictable outcome in high-risk groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du Toit</LastName><ForeName>D F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>School of Basic and Applied Sciences, Faculty of Health Sciences, University of Stellenbosch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saaiman</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Geldenhuys</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>South Africa</Country><MedlineTA>Cardiovasc J S Afr</MedlineTA><NlmUniqueID>100964061</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017544" MajorTopicYN="N">Aortic Aneurysm, Abdominal</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001807" MajorTopicYN="N">Blood Vessel Prosthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019917" MajorTopicYN="Y">Blood Vessel Prosthesis Implantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="N">Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15778773</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19408487</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-5423</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Acta chirurgiae plasticae</Title><ISOAbbreviation>Acta Chir Plast</ISOAbbreviation></Journal><ArticleTitle>Hemocoagulation disorders in extensively burned patients: pilot study for scoring of the DIC.</ArticleTitle><Pagination><StartPage>115</StartPage><EndPage>118</EndPage><MedlinePgn>115-8</MedlinePgn></Pagination><Abstract><AbstractText Label="GOAL OF THE STUDY" NlmCategory="OBJECTIVE">To apply results of the hemocoagulation parameters to the DIC (disseminated intravascular coagulation) score system. Compare parameters of the DIC score in patients with extensive burn trauma (hospitalized at the Intensive Care Unit, ICU) and patients with lesser extent of burn injury (hospitalized at the standard unit). To use these data within the evidence based medicine for the prediction of organ damage and multi-organ failure.</AbstractText><AbstractText Label="TYPE OF STUDY" NlmCategory="METHODS">Prospective study.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">We have included total of 36 patients in the group within four months. Twelve patients were hospitalized at the ICU, 24 patients were hospitalized at the intermedial care and standard unit. Repeatedly, we have taken blood from patients to evaluate the hemocoagulation parameters. In patients hospitalized at the ICU, the blood was taken from the central vein (prior to the drawn, the access was flushed with 100 ml of F1/1, the blood was taken from different access than from the one administering heparin), in patients hospitalized at the standard unit the blood was taken from a peripheral vein. The results were then put into the tables established according to the ISTH (International Society on Thrombosis and Hemostasis). Next, the DIC score was calculated to predict severity of hemocoagulation balance disorders in burn trauma, or occurrence of complications during the treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Part 1: We have evaluated 12 patients (4 females) hospitalized at the ICU. At the day of injury the overt DIC score reached 1.25 (0-3), fifth day after the injury the average value of overt DIC score was 1.83 (0-3), one day after the autotransplantation it was 2.08 (0-3) and at the day of discharge from the hospital 0. In the deceased patient the DIC score reached value of 2. Part 2: We evaluated 24 patients (10 females) hospitalized at the standard unit. The extent of their burn injury was 5.9% TBSA (0.5-12% TBSA), age 49.13 years (17-94 years). At the day of injury the overt DIC score reached 0.25 (0-2). Fifth day after the injury the average value of overt DIC score was 1.66 (0-2). Day after the autotransplantation it was 1.83 (0-3) and at the day of discharge 0.02 (0-2).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During the treatment of the patients with various extent of burn injury, none of the patients' scores reached values that would mean occurrence of obvious "overt" DIC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipov&#xfd;</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Burns and Reconstructive Surgery, Medical Faculty, Masaryk University Brno, Czech Republic. B.Lipovy@seznam.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaloudov&#xe1;</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mat&#xfd;skov&#xe1;</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Penka</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rihov&#xe1;</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Brychta</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Acta Chir Plast</MedlineTA><NlmUniqueID>0370301</NlmUniqueID><ISSNLinking>0001-5423</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004211" MajorTopicYN="N">Disseminated Intravascular Coagulation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19408487</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21573031</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The potential influence of common viral infections diagnosed during hospitalization among critically ill patients in the United States.</ArticleTitle><Pagination><StartPage>e18890</StartPage><MedlinePgn>e18890</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e18890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0018890</ELocationID><Abstract><AbstractText>Viruses are the most common source of infection among immunocompetent individuals, yet they are not considered a clinically meaningful risk factor among the critically ill. This work examines the association of viral infections diagnosed during the hospital stay or not documented as present on admission to the outcomes of ICU patients with no evidence of immunosuppression on admission. This is a population-based retrospective cohort study of University HealthSystem Consortium (UHC) academic centers in the U.S. from the years 2006 to 2009. The UHC is an alliance of over 90% of the non-profit academic medical centers in the U.S. A total of 209,695 critically ill patients were used in this analysis. Eight hospital complications were examined. Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission. Viral infections diagnosed during hospitalization significantly increased the risk of all complications. There was also a seasonal pattern for viral infections. Specific viruses associated with poor outcomes included influenza, RSV, CMV, and HSV. Patients who had both viral and bacterial infections during the same hospitalization had the greatest risk of mortality RR 6.58, 95% CI (5.47, 7.91); multi-organ failure RR 8.25, 95% CI (7.50, 9.07); and septic shock RR 271.2, 95% CI (188.0, 391.3). Viral infections may play a significant yet unrecognized role in the outcomes of ICU patients. They may serve as biological markers or play an active role in the development of certain adverse complications by interacting with coincident bacterial infection.</AbstractText><CopyrightInformation>&#xa9; 2011 Miggins et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miggins</LastName><ForeName>Makesha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Anjum</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hohmann</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Southwick</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Casella</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schain</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huazhi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bihorac</LastName><ForeName>Azra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moldawer</LastName><ForeName>Lyle</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Efron</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ang</LastName><ForeName>Darwin</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 GM087709</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA106493</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21573031</ArticleId><ArticleId IdType="pmc">PMC3091021</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0018890</ArticleId><ArticleId IdType="pii">PONE-D-10-05834</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiche L, Forel JM, Roch A, Guervilly C, Pauly V, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37:1850&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pubmed">19384219</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CH, Martin LC, Yenchar JK, Lahm MC, McGuinness B, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med. 2003;31:1923&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CH, Yenchar JK, Kraner TO, Davies EA, Ferguson RM. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg. 1998;176:357&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817255</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102:2&#x2013;9; discussion 25-26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7124320</ArticleId><ArticleId IdType="pubmed">10868136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaber S, Chanques G, Borry J, Souche B, Verdier R, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest. 2005;127:233&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med. 2009;37:2350&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pubmed">19531944</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. Jama. 2008;300:413&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774501</ArticleId><ArticleId IdType="pubmed">18647984</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med. 2007;175:935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">17234903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med. 2008;36:3145&#x2013;3150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18936696</ArticleId></ArticleIdList></Reference><Reference><Citation>Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, et al. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med. 2001;29:541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">11373417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ. Causes. Am J Epidemiol. 1976;104:587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">998606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlbom A, Alfredsson L. Interaction: A word with two meanings creates confusion. Eur J Epidemiol. 2005;20:563&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">16119427</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20:575&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">16119429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruynseels P, Jorens PG, Demey HE, Goossens H, Pattyn SR, et al. Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet. 2003;362:1536&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, et al. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med. 2006;32:1022&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080063</ArticleId><ArticleId IdType="pubmed">16791664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong GM, Lowry K, Mahajan S, Wyatt DE, Simpson C, et al. Herpes simplex type 1 shedding is associated with reduced hospital survival in patients receiving assisted ventilation in a tertiary referral intensive care unit. J Med Virol. 2004;72:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">14635019</ArticleId></ArticleIdList></Reference><Reference><Citation>Porteous C, Bradley JA, Hamilton DN, Ledingham IM, Clements GB, et al. Herpes simplex virus reactivation in surgical patients. Crit Care Med. 1984;12:626&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">6086234</ArticleId></ArticleIdList></Reference><Reference><Citation>Stollenwerk N, Harper RW, Sandrock CE. Bench-to-bedside review: rare and common viral infections in the intensive care unit&#x2014;linking pathophysiology to clinical presentation. Crit Care. 2008;12:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575602</ArticleId><ArticleId IdType="pubmed">18671826</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazian L, Fraisse A, Garbe L, Zandotti C, Thomas P, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology. 1996;84:280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602657</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Viral infections in the ICU. Current Opinion in Critical Care. 2008;14:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">18787457</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Brink JW, Simoons-Smit AM, Beishuizen A, Girbes AR, Strack van Schijndel RJ, et al. Respiratory herpes simplex virus type 1 infection/colonisation in the critically ill: marker or mediator? J Clin Virol. 2004;30:68&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15072757</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical. Atlanta: Center for Disease Control and Prevention; 2010. Cytomegalovirus (CMV) and Congenital CMV Infection.</Citation></Reference><Reference><Citation>Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Jama. 2006;296:964&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">16926356</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva AR, Park M, Boas LSV, Machado CM. Respiratory syncytial virus rhinosinusitis in intensive care unit patients. Brazilian Journal of Infectious Diseases. 2007;11:163&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hament JM, Kimpen JL, Fleer A, Wolfs TF. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol. 1999;26:189&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">10575129</ArticleId></ArticleIdList></Reference><Reference><Citation>Beadling C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis. 2004;17:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15166819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18503956</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation></Journal><ArticleTitle>Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>596</EndPage><MedlinePgn>589-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2008.02.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this study we analyzed putative biomarkers for myocardial remodeling in plasma from 55 endstage heart failure patients with the need for mechanical circulatory support (MCS). We compared our data to 40 healthy controls and examined if MCS by either ventricular assist devices or total artificial hearts has an impact on plasma concentrations of remodeling biomarkers.</AbstractText><AbstractText Label="METHODS &amp; RESULTS" NlmCategory="RESULTS">Plasma biomarkers were analysed pre and 30 days post implantation of a MCS device using commercially available enzyme linked immunosorbent assays (ELISA). We observed that the plasma concentrations of remodeling biomarkers: tissue inhibitor of metalloproteinase 1 (TIMP1), tenascin C (TNC), galectin 3 (LGALS3), osteopontin (OPN) and of neurohumoral biomarker brain natriuretic peptide (BNP), are significantly elevated in patients with terminal heart failure compared to healthy controls. We did not find elevated plasma concentrations for matrix metalloproteinase 2 (MMP2) and procollagen I C-terminal peptide (PCIP). However, only BNP plasma levels were reduced by MCS, whereas the concentrations of remodeling biomarkers remained elevated or even increased further 30 days after MCS. LGALS3 plasma concentrations at device implantation were significantly higher in patients who did not survive MCS due to multi organ failure (MOF).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings indicate that mechanical unloading in endstage heart failure is not reflected by a rapid reduction of remodeling plasma biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milting</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Herz- und Diabeteszentrum NRW, Erich und Hanna Klessmann Institut f&#xfc;r Kardiovaskul&#xe4;re Forschung und Entwicklung, Bad Oeynhausen, Germany. hmilting@hdz-nrw.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellinghaus</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Seewald</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cakar</LastName><ForeName>Hamdin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bohms</LastName><ForeName>Birte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kassner</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>K&#xf6;rfer</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kruska</LastName><ForeName>Lothar</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>El Banayosy</LastName><ForeName>Aly</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019063">Tenascin</NameOfSubstance></Chemical><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.7</RegistryNumber><NameOfSubstance UI="D020781">Matrix Metalloproteinase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004719" MajorTopicYN="N">Endomyocardial Fibrosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020781" MajorTopicYN="N">Matrix Metalloproteinase 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019063" MajorTopicYN="N">Tenascin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="Y">Ventricular Remodeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18503956</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2008.02.018</ArticleId><ArticleId IdType="pii">S1053-2498(08)00187-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17680957</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0958-7578</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Transfusion medicine (Oxford, England)</Title><ISOAbbreviation>Transfus Med</ISOAbbreviation></Journal><ArticleTitle>Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis.</ArticleTitle><Pagination><StartPage>304</StartPage><EndPage>311</EndPage><MedlinePgn>304-11</MedlinePgn></Pagination><Abstract><AbstractText>In two randomized trials in cardiac surgery we observed that leukoreduced allogeneic red blood cell (RBC) transfusions (LR) compared with standard buffy-coat-depleted RBC transfusions (BCD) resulted in lower rates of post-operative infections and mortality. To unravel whether this comprises two independent side effects or could be related complications of allogeneic leukocytes, we performed a re-analysis on the patients of these two trials. For all analyses, homogeneity tests were shown not to be significant. Data on characteristics of post-operative infections, nature of microorganisms, number of transfusions and causes of death in both studies were subjected to an integrated analysis. In both studies combined, 1085 patients had been assigned to prestorage leukoreduced RBCs (LR, n= 542) or standard buffy-coat-depleted RBCs (BCD, n= 543). Post-operative infections were significantly higher in the BCD group [BCD: 34.2% vs. LR: 24.0%, common odds ratios (COR): 1.65, 95% confidence interval (CI): 1.27-2.15], whereas the species of cultured microorganisms and the type of the infections were similar in both randomization arms. Mortality with infections was significantly higher in patients receiving BCD compared with LR (BCD: 5.5% vs. LR: 2.2%, COR: 2.59, 95% CI: 1.31-5.14), whereas mortality without infections was similar in both arms (BCD: 3.9% vs. LR: 3.1%, COR: 1.24, 95% CI: 0.65-2.38). The only cause of death that differed significantly between BCD and LR was the combination of multiple organ dysfunction syndrome with infections. This re-analysis shows that transfusion of leukocytes containing RBCs during cardiac surgery may be associated with more infections with fatal outcome. This should be confirmed in a larger extended analysis or a prospective study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Y M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Hematology, Academical Medical Center, Amsterdam, The Netherlands. bilginyavuz@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>L M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Eijsman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Versteegh</LastName><ForeName>M I M</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>van Oers</LastName><ForeName>M H J</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transfus Med</MedlineTA><NlmUniqueID>9301182</NlmUniqueID><ISSNLinking>0958-7578</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17680957</ArticleId><ArticleId IdType="doi">10.1111/j.1365-3148.2007.00746.x</ArticleId><ArticleId IdType="pii">TME746</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16148869</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1341-1098</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia</Title><ISOAbbreviation>Ann Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Systemic inflammatory response syndrome (SIRS) in serious chest injuries: is a pharmacological blockade effective?</ArticleTitle><Pagination><StartPage>232</StartPage><EndPage>237</EndPage><MedlinePgn>232-7</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">There has been an ongoing increase in the frequency and severity of blunt chest injuries. Their rather high lethality is caused by the injury alone as well as by the following systemic inflammatory response. The aim of the study is to verify the efficacy of the pharmacological blockade of the systemic inflammatory response syndrome (SIRS) in serious blunt chest injuries, and to identify whether the administration of indomethacin as a cyclooxygenase inhibitor could prevent a multiorgan dysfunction (MODS) and a multiorgan failure (MOF).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were divided into 4 Groups according to trauma severity--injury severity score (ISS) and into two subgroups--an indomethacin subgroup where patients received indomethacin together with standard therapy, and a non-indomethacin subgroup.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty-four patients were included in the study and 33 patients were given indomethacin. In Groups III and IV there was a later increase in inflammatory markers in patients treated with indomethacin. The elevation of inflammatory markers and the period of mechanical ventilation support in patients treated with indomethacin were shorter in Groups II and III. Seven (8.3%) patients died. Six of the seven dead patients were from the non-indomethacin subgroup. MOF was the cause of death in two patients in the non-indomethacin subgroup and in one patient in the indomethacin subgroup.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results obtained during the first 20 months of the study imply that a certain number of patients with serious blunt chest trauma could benefit from indomethacin administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Havl&#xed;cek</LastName><ForeName>Karel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Institute of Medical Studies, The University of Pardubice, and Department of Surgery, Pardubice General Hospital, Pardubice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motycka</LastName><ForeName>Vladim&#xed;r</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Siller</LastName><ForeName>Jir&#xed;</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cervinka</LastName><ForeName>Vladim&#xed;r</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Ann Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>9703158</NlmUniqueID><ISSNLinking>1341-1098</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>XXE1CET956</RegistryNumber><NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013898" MajorTopicYN="N">Thoracic Injuries</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16148869</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17644265</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0305-4179</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Snapshot assessment of RNA-expression in severely burned patients using the PAXgene Blood RNA system: a pilot study.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>204</EndPage><MedlinePgn>197-204</MedlinePgn></Pagination><Abstract><AbstractText>Severe burn induces destabilization of the immune system and the likelihood of multiple organ dysfunction syndrome. Current studies focus on RNA-expression analyses of immune system cells, however, the present methods of analysis are complex, potentially altered by artefacts and therefore not feasible for routine analyses. The new PAXgene Blood RNA System provides "snapshot" analysis of RNA by immediate cell lysis and prevention of RNA-degradation. Using this system the aim of this study was to analyse intracellular cytokine RNA-expression under clinical conditions. Whole blood samples (PAXgene tubes) of nine severely burned patients were drawn at admission and 6, 12, 24, 48 and 72h after trauma during routine treatment. Four healthy individuals served as control. Analysis of RNA-expression of TNF-alpha as pro-inflammatory and IL-10 as anti-inflammatory mediator was performed by RT-PCR. The RNA-expression of TNF-alpha was increased at 72h after burn. The increase occurred mainly in surviving patients. In contrast, RNA-expression of IL-10 was elevated already at 24h and the difference between surviving and deceased patients occurred earlier. We demonstrate for the first time a "snapshot" analysis of cytokine RNA-expression in severely burned patients under routine conditions. The results correspond well to current hypothesis of posttraumatic MODS development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landes</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Traumatology and Orthopaedic Surgery, Ludwig-Maximilians-University of Munich, Nussbaumstrasse 20, D-80336 Munich, Germany. juergen.landes@med.uni-muechen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schuetz</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Joneidi-Jafari</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Stegmaier</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mutschler</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001800" MajorTopicYN="N">Blood Specimen Collection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17644265</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2007.02.008</ArticleId><ArticleId IdType="pii">S0305-4179(07)00062-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39210684</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-2995</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Life-threatening hemorrhage as defined by the critical administration threshold in nontraumatic critical bleeding: A descriptive observational study.</ArticleTitle><Pagination><StartPage>1841</StartPage><EndPage>1850</EndPage><MedlinePgn>1841-1850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/trf.17996</ELocationID><Abstract><AbstractText Label="BACKGROUND">Evaluations of critical bleeding and massive transfusion have focused on traumatic hemorrhage. However, most critical bleeding in hospitalized patients occurs outside trauma. The purpose of this study was to provide an in-depth description examining the critical administration threshold (CAT; &#x2265;3&#x2009;units red blood cells (RBCs) in a 1-h period) occurrences in nontraumatic hemorrhage. This will assist in establishing the framework for future investigations in nontraumatic hemorrhage.</AbstractText><AbstractText Label="METHODS">This is an observational cohort study of adults experiencing critical bleeding defined as being CAT+ during hospitalization from 2016 to 2021 at a single academic institution. A CAT episode started with administration of the first qualifying RBC unit and ended at the time of completion of the last allogeneic unit prior to a &#x2265;4-h gap without subsequent transfusion. The primary goal was to describe demographic, clinical and transfusion characteristics of participants with nontraumatic critical bleeding.</AbstractText><AbstractText Label="RESULTS">2433 patients suffered critical bleeding, most often occurring in the operating room (71.1%) followed by the intensive care unit (20.8%). 57% occurred on the initial day of hospitalization, with a median duration of 138 (36, 303) minutes. The median number of RBCs transfused during the episode was 5 (4, 8), with median total allogeneic units of 9 (4, 9). Hospital mortality was 19.2%. The most common cause of death was multi-organ failure (50.3%), however death within 24&#x2009;h was due to exsanguination (72.7%).</AbstractText><AbstractText Label="DISCUSSION">The critical administration threshold may be employed to identify critical bleeding in non-trauma settings of life-threatening hemorrhage, with a mortality rate of approximately 20%.</AbstractText><CopyrightInformation>&#xa9; 2024 AABB.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matzek</LastName><ForeName>Luke J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0001-7515-3739</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Division of Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Phillip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cureton</LastName><ForeName>Kimberly D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kor</LastName><ForeName>Daryl J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-6625-8755</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Patient Blood Management Program, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL153310</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR002377</GrantID><Agency>Center for Clinical and Translational Science, Mayo Clinic</Agency><Country/></Grant><Grant><GrantID>KL2 TR002379</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="Y">Hemorrhage</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">critical administration threshold</Keyword><Keyword MajorTopicYN="N">critical bleeding</Keyword><Keyword MajorTopicYN="N">massive transfusion</Keyword><Keyword MajorTopicYN="N">nontraumatic hemorrhage</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>30</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39210684</ArticleId><ArticleId IdType="mid">NIHMS2017626</ArticleId><ArticleId IdType="pmc">PMC11493504</ArticleId><ArticleId IdType="doi">10.1111/trf.17996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phillips T SG, Wilson R. Outcome of Massive Transfusion Exceeding Two Blood Volumes in Trauma and Emergency Surgery. Journal of Trauma. 1987;27(8):903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">3612868</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber-Wagner S, Qvick M, Mussack T, et al. Massive blood transfusion and outcome in polytrauma patients: a prospective study based on Trauma Registry of the German Trauma Society. Vox Sang. 2007;92(1):69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">17181593</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Postpartum Haemorrhage (PPH) Summit. Organization WH. 2022.</Citation></Reference><Reference><Citation>Lauzier F AD, Rabbat C, Heels-Ansdell D, et al. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Medicine. 2013;39(12):2435&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23942857</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D DJ, Meade M, Guyatt G, et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Critical Care. 2008;12(2):R32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447552</ArticleId><ArticleId IdType="pubmed">18315876</ArticleId></ArticleIdList></Reference><Reference><Citation>Subat YW, Rayes H, Hanson AC, et al. Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. Journal of Critical Care. 2020/August/01/ 2020;58:34&#x2013;40. doi:10.1016/j.jcrc.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7321912</ArticleId><ArticleId IdType="pubmed">32335493</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgman M, Spinella P, Perkins J, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cap AP, Spinella PC, Borgman MA, et al. Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. The Journal of Trauma and Acute Care Surgery. 2012;73(2 Suppl 1):S89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22847102</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb J, Wade C, Michalek J, et al. Increased Plasma and Platelet to Red Blood Cell Ratios Improves Outcome in 466 Massively Transfused Civilian Trauma Patients. Ann Surg. 2008;248:447&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">18791365</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb J, del Junco D, Fox E, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study: Comparative Effectiveness of a Time-varying Treatment with Competeing Risks. JAMA Surg. 2013;148:127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740072</ArticleId><ArticleId IdType="pubmed">23560283</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb J, Tilley BC, Baraniuk S, et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: the PROPPR randomized clinical trail. JAMA. 2015;313:471&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374744</ArticleId><ArticleId IdType="pubmed">25647203</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer D, Cotton B, Fox E, et al. A Comparison of Resuscitation Intensity and Critical Administration Threshold in Predicting Early Mortality Among Bleeding Patients: A Multicenter Validation in 680 Major Transfusion Patients. J Trauma Acute Care Surg. 2018;85:691&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158088</ArticleId><ArticleId IdType="pubmed">29985236</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage S, Zarzaur B, Croce M, Fabian T. Redefining Massive Transfusion When Every Second Counts. J Trauma Acute Care Surg. 2013;74:2396&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">23354230</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage S, Sumislawski J, Zarzaur B, et al. The New Metric to Define Large-Volume Hemorrhage: Results of a Prospective Study of the Critical Adminstration Threshold. J Trauma Acute Care Surg. 2015;78:224&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25757105</ArticleId></ArticleIdList></Reference><Reference><Citation>Etchill E, Myers S, McDaniel L, et al. Should All Massively Transfused Patients Be Treated Equally? An Analysis of Massive Transfusion Ratios in the Nontrauma Setting. Critical Care Medicine. 2017;45:1311&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pubmed">28537938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbano D, Chica J, Orlas C, et al. Performance of Multiple Massive Transfusion Definitions in Trauma Patients. Panamerican Journal of Trauma. 2020;9(1):61&#x2013;66.</Citation></Reference><Reference><Citation>Wong HS, Curry NS, Davenport RA, Yu LM, Stanworth S. A Delphi study to establish consensus on a definition of major bleeding in adult trauma. Transfusion. 2020;60:3028&#x2013;3038.</Citation><ArticleIdList><ArticleId IdType="pubmed">32984985</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesar T, Larentzakis A, Dzik W, et al. Association Between Ratio of Fresh Frozen Plasam to Red Blood Cells During Massive Transfusion and Survival Among Patients Without Traumatic Injury. JAMA Surg. 2017;152:574&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831422</ArticleId><ArticleId IdType="pubmed">28273299</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik WS ZA, Cohn C, Pai M, et al. Survival after ultramassive transfusion: a review of 1360 cases. Transfusion. 2016;56(3):558&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26450364</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzek LJ, Kurian EB, Frank RD, et al. Plasma, platelet, and red blood cell transfusion ratios for life-threatening non-traumatic haemorrhage in medical and post-surgical patients: An observational study. Vox Sanguinis. 2022;117(3):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8803985</ArticleId><ArticleId IdType="pubmed">34337749</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman D, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. J Clin Epidemiol. 2008;61:344&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute C, Beck S, Fisk T, Mohr D. The Enterprise Data Trust at Mayo Clinic: A Semantically Integrated Warehouse of Biomedical Data. J Am Med Inform Assoc. 2010;17:131&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000789</ArticleId><ArticleId IdType="pubmed">20190054</ArticleId></ArticleIdList></Reference><Reference><Citation>Herasevich V, Kor D, Li M, Pickering B. ICU Data Mart: A non-IT Approach. A Team of Clinicians, Researchers and Informatics Personnel at the Mayo Clinic Have Taken a Homegrown Approach to Building an ICU Data Mart. Healthc Inform. 2011;42:44&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22121570</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner M, Jia Q, Clifford L, et al. Preoperative platelet transfusions and perioperative red blood cell requirements in patients with thrombocytopenia undergoing noncardiac surgery. Transfusion. 2016;56:682&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4857703</ArticleId><ArticleId IdType="pubmed">26559936</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner M, Frank R, Weister T, et al. Ratios of Plasma and Platelets to Red Blood Cells in Surgical Patients With Acute Intraoperative Hemorrhage. Anesthesia and Analgesia. 2019;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580504</ArticleId><ArticleId IdType="pubmed">31880628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang WS, Shin IS, Pyo J, et al. Prognostic Accuracy of Massive Transfusion, Critical Administration Threshold, and Resuscitation Intensity in Assessing Mortality in Traumatic Patients with Severe Hemorrhage: a Meta-Analysis. J Korean Med Sci. 2019;34(50):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935555</ArticleId><ArticleId IdType="pubmed">31880415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15142422</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1096-2964</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Surgical infections</Title><ISOAbbreviation>Surg Infect (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>49</EndPage><MedlinePgn>39-49</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Decreased concentrations of total cholesterol, lipoproteins, and lipoprotein cholesterols occur early in the course of critical illness. Low cholesterol concentrations correlate with high concentrations of cytokines such as interleukin (IL)-6 and IL-10, and may be due to decreased synthesis or increased catabolism of cholesterol. Low cholesterol concentrations have been associated clinically with several adverse outcomes, including the development of nosocomial infections. The study was performed to test the hypothesis that a low cholesterol concentration predicts mortality and secondarily predicts the development of organ dysfunction in critical surgical illness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective study was undertaken of 215 patients admitted to a university surgical ICU with systemic inflammatory response syndrome (SIRS). Serial blood samples were collected within 24 h of admission, as well as on the morning of days 2, 4, and 7 of the ICU stay for as long as the patients were in the ICU. Demographic data and predetermined outcomes were noted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred nine patients had at least two samples drawn and form the population for analysis. Sixty-two of the patients had three samples obtained, whereas 42 patients had four samples obtained. By univariate analysis, non-survivors were more severely ill on admission (APACHE III), more likely to have been admitted to the ICU as an emergency, more likely to develop a nosocomial infection, and more likely to develop severe organ dysfunction (MODS) (all, p &lt; 0.05). Death was associated on day 1 with increased concentrations of sIL2R, IL-6, IL-10, and sTNFR-p75 (all, p &lt; 0.01), but there were initially no differences in serum lipid concentrations. However, by day 2, concentrations of IL-6, IL-10, and cholesterol had decreased significantly (all, p &lt; 0.05) from day 1 in non-survivors but not in survivors; the difference in serum cholesterol concentration persisted to day 7 (p &lt; 0.05). Persistently elevated concentrations of IL-6 and IL-10 were observed in patients who developed severe MODS. By logistic regression, increased APACHE III score, development of a nosocomial infection, and decreased cholesterol concentration were independently associated with mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Decreased serum cholesterol concentration is an independent predictor of mortality in critically ill surgical patients. Repletion of serum lipids is a feasible therapeutic approach for the management of critical illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonville</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Medical College of Cornell University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Bruce R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Hydo</LastName><ForeName>Lynn J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Eachempati</LastName><ForeName>Soumitra R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Barie</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Infect (Larchmt)</MedlineTA><NlmUniqueID>9815642</NlmUniqueID><ISSNLinking>1096-2964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018806" MajorTopicYN="N">APACHE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15142422</ArticleId><ArticleId IdType="doi">10.1089/109629604773860291</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19932032</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions.</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>858</EndPage><MedlinePgn>853-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejcts.2009.10.010</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies have highlighted the possible influence of chemokines and cytokines on several types of pulmonary arterial hypertension (PAH). Increasing interest has also been focussed on their role as a cause of post-cardiopulmonary bypass (CPB) organ dysfunction.</AbstractText><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Chemokines and cytokines are involved in the pathobiology of rheumatic PAH.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum levels of the chemokine, regulated upon activation, normal T-cell expressed and secreted (RANTES) and the cytokine interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA) in 35 patients with rheumatic mitral valve disease and 10 matched healthy subjects (control group). Eleven patients (31.4%) had severe pulmonary hypertension. Subsequently, 23 patients underwent mitral valve replacement. The relation of RANTES and IL-6 circulating level with postoperative organ dysfunction was analysed through multiple organ dysfunction score (MODS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with severe PAH have a significantly higher mean serum level of RANTES compared with other patients (6138.6+/-3543.8 pg/ml vs 1818.2+/-475.2 pg/ml, p=0.0003). The serum level of IL-6 in the patients was statistically different from that of the control (378+/-50.8 pg/ml vs 262+/-90.5 pg/ml, respectively, p=0.002). Patients who required postoperative inotropes had higher preoperative and post-CPB levels of both RANTES and IL-6. While patients with postoperative lung dysfunction had higher levels of IL-6 preoperatively and post-CPB and lower levels of RANTES post-CPB.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RANTES and IL-6 should be investigated as potential therapeutic targets in the control of rheumatic PAH. Improved understanding of the contribution of RANTES and IL-6 to adverse postoperative complications can lead to improved patient outcome.</AbstractText><CopyrightInformation>Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serag</LastName><ForeName>Amany R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Menoufyia University, Shebin El-Kom, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hazaa</LastName><ForeName>Sahar M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Afifi</LastName><ForeName>Ibtesam K</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Ghoname</LastName><ForeName>Naglaa F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Serag</LastName><ForeName>Amro R</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C483024">CCL5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018946" MajorTopicYN="N">Chemokine CCL5</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="N">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008946" MajorTopicYN="N">Mitral Valve Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012214" MajorTopicYN="N">Rheumatic Heart Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19932032</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2009.10.010</ArticleId><ArticleId IdType="pii">S1010-7940(09)00987-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15718917</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1073-2322</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>215</EndPage><MedlinePgn>209-15</MedlinePgn></Pagination><Abstract><AbstractText>Decreased lymphocyte proliferation, lymphopenia, immunodepression, and opportunistic infections are common after major trauma. Early alimentation in these patients corrects lymphopenia, enhances immunity, and reduces the incidence of infections, but the underlying mechanisms are poorly understood. Tryptophan is essential for the production and function of rapidly proliferating cells such as lymphocytes. Tryptophan is enzymatically degraded by indoleamine 2,3-dioxygenase (IDO), whose activity is solely dependent on expression of interferon-gamma (IFN-gamma). Because increased expression of IFN-gamma has been reported in trauma patients, we investigated whether enhanced IDO-mediated tryptophan degradation is associated with lymphopenia and poor outcomes after major trauma. The incidence of bacteremic sepsis (BS), adult respiratory distress syndrome (ARDS), multiple organ dysfunction/failure syndromes (MODS/MOF), and death was prospectively documented in 22 trauma patients with a mean ISS of 24.9 +/- 2.2. Sequential blood samples were obtained from admission through postinjury day 10. Five patients developed BS, three of whom developed ARDS; two of the three ARDS patients developed MOF and died on day 10. Trauma patients had significantly lower tryptophan levels (days 1-10), higher kynurenine:tryptophan ratios (days 1-2), and fewer lymphocytes (days 1-4) than healthy volunteers (P &lt; 0.05). Although patients with poor outcomes (i.e., BS, ARDS, MOF, and death) had significantly lower tryptophan levels and greater lymphopenia on several days after injury, the sample size was too small to draw any definitive conclusions. These data indicate that decreased plasma tryptophan levels and lymphopenia typically occur after major trauma. A concomitant increase in kynurenine suggests that the observed tryptophan deficiency is caused, in part, by IDO-mediated tryptophan degradation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pellegrin</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, M. L. King, Jr./Drew Medical Center, Los Angeles, California, USA. kathpellegrin@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neurauter</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wirleitner</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Verlyn M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.11</RegistryNumber><NameOfSubstance UI="D014366">Tryptophan Oxygenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016470" MajorTopicYN="N">Bacteremia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014366" MajorTopicYN="N">Tryptophan Oxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15718917</ArticleId><ArticleId IdType="pii">00024382-200503000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15817428</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0949-2321</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Hemofiltration does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo.</ArticleTitle><Pagination><StartPage>81</StartPage><EndPage>87</EndPage><MedlinePgn>81-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prognosis in patients with hyperdynamic septic shock correlates with the presence and the severity of septic encephalopathy. However, the neurological evaluation is considerably influenced by the use of analgesia sedation during mechanical ventilation. An early concentration peak of the neuroprotein S-100B in serum reflects both cellular damage at an increased permeability of the blood-brain-barrier and a delayed renal elimination. Thus, the objective of this study was to analyze the effect of continuous veno-venous hemofiltration (CVVH) on early S-100B serum levels in septic shock patients, who were treated with either stress doses of hydrocortisone or placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four consecutive patients, who met the ACCP / SCCM criteria for septic shock, were enrolled in this prospective, randomised, double-blind, single-center trial. The severity of illness at recruitment was graded using the APACHE II and SAPS II scoring systems; the MODS was described by the SOFA score. All patients were prospectively randomised to receive either stress doses of hydrocortisone or placebo. Hydrocortisone was started in 12 patients with a loading dose of 100 mg and followed by a continuous infusion of 0.18 mg/kg/h for 6 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median S-100B serum levels of the hydrocortisone group decreased from 0.32 ng/ml (0.19-3.60) at study entry to 0.07 ng/ml (0.04 - 0.32) 6 days later without significant differences compared to the placebo group. Patients undergoing CVVH showed significantly higher S-100B serum values compared to patients without CVVH (p&lt;0.001). However, initial median S-100B serum levels of the CVVH group even increased from 0.92 ng/ml (0.16 - 4.63) to 2.33 ng/ml (0.59 - 2.44) 30 hours after study entry, reaching data ranges already known in patients with out-of-hospital cardiac arrest or severe traumatic brain injury.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Early S-100B serum levels in septic shock patients receiving either stress doses of hydrocortisone or placebo were not influenced by CVVH. For the first time, we observed a similar extent of S-100B serum increase in CVVH patients, who had significantly higher S-100B serum values compared to those without CVVH, as reported for out-of-hospital cardiac arrest or severe traumatic brain injury. Hypercortisolemia induced by the infusion of stress doses of hydrocortisone did not significantly reduce early S-100B serum concentrations with time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mussack</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery Innenstadt, Klinikum der Universit&#xe4;t M&#xfc;nchen, Germany. Thomas.Mussack@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briegel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schelling</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Jochum</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="Y">Hemofiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15817428</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15737948</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0949-2321</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Hemofiltrastion does not influence early S-100B serum levels in septic shock patients receiving stress doses of hydrocortisone or placebo.</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>17</EndPage><MedlinePgn>11-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prognosis in patients with hyperdynamic septic shock correlates with the presence and the severity of septic encephalopathy. However, the neurological evaluation is considerably influenced by the use of analgesia sedation during mechanical ventilation. An early concentration peak of the neuroprotein S-100B in serum reflects both cellular damage at an increased permeability of the blood-brain-barrier and a delayed renal elimination. Thus, the objective of this study was to analyze the effect of continuous veno-venous hemofiltration (CVVH) on early S-100B serum levels in septic shock patients, who were treated with either stress doses of hydrocortisone or placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four consecutive patients, who met the ACCP / SCCM criteria for septic shock, were enrolled in this prospective, randomised, double-blind, single-center trial. The severity of illness at recruitment was graded using the APACHE II and SAPS II scoring systems; the MODS was described by the SOFA score. All patients were prospectively randomised to receive either stress doses of hydrocortisone or placebo. Hydrocortisone was started in 12 patients with a loading dose of 100 mg and followed by a continuous infusion of 0.18 mg/kg/h for 6 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median S-100B serum levels of the hydrocortisone group decreased from 0.32 ng/ml (0.19-.60) at study entry to 0.07 ng/ml (0.04-0.32) 6 days later without significant differences compared to the placebo group. Patients undergoing CVVH showed significantly higher S-100B serum values compared to patients without CVVH (p&gt;0.001). However, initial median S-100B serum levels of the CVVH group even increased from 0.92 ng/ml (0.16 - 4.63) to 2.33 ng/ml (0.59-2.44) 30 hours after study entry, reaching data ranges already known in patients with out-of-hospital cardiac arrest or severe traumatic brain injury.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Early S-100B serum levels in septic shock patients receiving either stress doses of hydrocortisone or placebo were not influenced by CVVH. For the first time, we observed a similar extent of S-100B serum increase in CVVH patients, who had significantly higher S-100B serum values compared to those without CVVH, as reported for out-of-hospital cardiac arrest or severe traumatic brain injury. Hypercortisolemia induced by the infusion of stress doses of hydrocortisone did not significantly reduce early S-100B serum concentrations with time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mussack</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery Innenstadt, Klinikum der Universit&#xe4;t M&#xfc;nchen, Nussbaumstr. 20, D-80336 M&#xfc;nchen, Germany. Thomas.Mussack@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briegel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schelling</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Jochum</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15737948</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>